0001193125-18-290169.txt : 20181002 0001193125-18-290169.hdr.sgml : 20181002 20181002060821 ACCESSION NUMBER: 0001193125-18-290169 CONFORMED SUBMISSION TYPE: S-1/A PUBLIC DOCUMENT COUNT: 29 FILED AS OF DATE: 20181002 DATE AS OF CHANGE: 20181002 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Equillium, Inc. CENTRAL INDEX KEY: 0001746466 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821554746 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1/A SEC ACT: 1933 Act SEC FILE NUMBER: 333-227387 FILM NUMBER: 181099275 BUSINESS ADDRESS: STREET 1: 2223 AVENIDA DE LA PLAYA STREET 2: SUITE 108 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 412-5302 MAIL ADDRESS: STREET 1: 2223 AVENIDA DE LA PLAYA STREET 2: SUITE 108 CITY: LA JOLLA STATE: CA ZIP: 92037 S-1/A 1 d582934ds1a.htm S-1/A S-1/A
Table of Contents

As filed with the Securities and Exchange Commission on October 2, 2018

Registration No. 333-227387

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Amendment No. 2

TO

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Equillium, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   2834   20-3828755

(State or Other Jurisdiction of

Incorporation or Organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

2223 Avenida de la Playa, Suite 108

La Jolla, CA 92037

858-412-5302

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

 

Daniel M. Bradbury

Chief Executive Officer

Equillium, Inc.

2223 Avenida de la Playa, Suite 108

La Jolla, CA 92037

858-412-5302

(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)

 

 

Copies to:

Thomas A. Coll, Esq.

Karen E. Anderson, Esq.

Wade W. Andrews, Esq.

Cooley LLP

4401 Eastgate Mall

San Diego, California 92121

(858) 550-6000

 

Cheston J. Larson, Esq.

Matthew T. Bush, Esq.

Anthony A. Gostanian, Esq.

Latham & Watkins LLP

12670 High Bluff Drive

San Diego, California 92130

(858) 523-5400

Approximate date of commencement of proposed sale to the public:

As soon as practicable after the effective date of this registration statement.

 

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.  

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has not elected to use the extended transition period for complying with any new or revised financial accounting standards provided in Section 7(a)(2)(B) of the Securities Act.  

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of each class of

securities to be registered

 

Proposed

maximum

aggregate

        offering price (1)    

      

Amount of

registration fee (2)

Common Stock, $0.0001 par value per share

  $85,928,000       $10,415(3)

 

 

 

(1) 

Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(o) under the Securities Act. Includes the offering price of shares that the underwriters have the option to purchase.

(2) 

Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum offering price.

(3) 

Previously paid.

 

 

The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

 

 

 


Table of Contents

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.

 

SUBJECT TO COMPLETION, DATED OCTOBER 2, 2018

 

PRELIMINARY PROSPECTUS

4,670,000 Shares

 

LOGO

Common Stock

This is the initial public offering of Equillium, Inc. We are offering 4,670,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. We estimate that the initial public offering price of our common stock will be between $14.00 and $16.00 per share.

We have applied to list our common stock on The Nasdaq Global Market under the symbol “EQ.”

We are an “emerging growth company” as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings.

Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page 11.

 

 

 

     PER SHARE      TOTAL  

Initial Public Offering Price

   $                    $                

Underwriting Discounts and Commissions (1)

   $        $    

Proceeds to Equillium (before expenses)

   $        $    

 

 

(1)    We have agreed to reimburse the underwriters for certain expenses. See “Underwriting.”

We have granted the underwriters a 30-day option to purchase up to a total of 700,500 additional shares of common stock from us at the initial public offering price less the underwriting discounts and commissions.

The underwriters expect to deliver the shares of common stock to purchasers on or about                 , 2018 through the book-entry facilities of The Depository Trust Company.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

Joint Book-Running Managers

 

Jefferies   Leerink Partners   Stifel

The date of this prospectus is                , 2018


Table of Contents

TABLE OF CONTENTS

 

 

 

     PAGE  

PROSPECTUS SUMMARY

     1  

RISK FACTORS

     11  

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

     57  

USE OF PROCEEDS

     59  

DIVIDEND POLICY

     60  

CAPITALIZATION

     61  

DILUTION

     63  

SELECTED FINANCIAL DATA

     66  

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

     68  

BUSINESS

     79  

MANAGEMENT

     116  

EXECUTIVE AND DIRECTOR COMPENSATION

     124  

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

     138  

PRINCIPAL STOCKHOLDERS

     140  

DESCRIPTION OF CAPITAL STOCK

     142  

SHARES ELIGIBLE FOR FUTURE SALE

     146  

MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON STOCK

     148  

UNDERWRITING

     152  

LEGAL MATTERS

     160  

EXPERTS

     160  

WHERE YOU CAN FIND ADDITIONAL INFORMATION

     161  

INDEX TO FINANCIAL STATEMENTS

     F-1  

 

 

We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date.

Through and including                , 2018 (25 days after the commencement of this offering), all dealers that buy, sell or trade shares of our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers’ obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

This prospectus includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.

For investors outside the United States: we have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States.


Table of Contents

PROSPECTUS SUMMARY

This summary highlights information contained in other parts of this prospectus. Because it is only a summary, it does not contain all of the information that you should consider before investing in shares of our common stock and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. You should read the entire prospectus carefully, especially “Risk Factors” and our financial statements and the related notes, before deciding to buy shares of our common stock. Unless the context requires otherwise, references in this prospectus to “Equillium,” “the Company,” “we,” “us” and “our” refer to Equillium, Inc.

OVERVIEW

We are a biotechnology company leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Our initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cells, or Teff cells. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. Therefore, we believe EQ001 may have broad therapeutic utility in treating a large and diverse set of severe immuno-inflammatory diseases.

 

LOGO

 

*

We are focusing our initial development efforts on EQ001 for the treatment of the diseases underlined in bold and are evaluating additional T cell driven indications for future development.

Our pipeline is focused on developing EQ001 as a potentially best-in-class, disease modifying treatment for multiple severe immuno-inflammatory disorders. We plan to initiate a Phase 1b/2 clinical trial of EQ001 for the treatment of acute graft-versus-host disease, or aGVHD, in early 2019, and expect top-line data from the Phase 1b part of this trial within 12 months of initiation. Our Investigational New Drug application, or IND, with the U.S. Food and Drug Administration, or FDA, for aGVHD was accepted in July 2018. Additionally, in the first half of 2019, we plan to commence a Phase 2 clinical trial of EQ001 for the treatment of chronic graft-versus-host disease, or cGVHD, initiate a proof-of-concept clinical trial for the treatment of severe asthma and select one or more additional indications for future development. The following chart summarizes our initial development plans for EQ001.



 

1


Table of Contents

LOGO

*

The Phase 1 clinical trial was conducted by Biocon, our collaboration partner, in Australia.

We have an ongoing translational biology program to assess the therapeutic utility of EQ001 in additional indications where the CD6 pathway and activated Teff cells play an important role in the pathogenesis of T cell mediated diseases. Our selection of additional indications is driven by our analysis of the scientific, translational, clinical and commercial rationale for advancing EQ001 into further development.

We acquired U.S. and Canadian rights to itolizumab in May 2017, pursuant to a collaboration and license agreement with Biocon SA (subsequently assigned to Biocon Limited, or together, Biocon). Following completion of a Phase 3 clinical trial conducted outside of North America, itolizumab was approved in India for the treatment of moderate to severe plaque psoriasis and is marketed by Biocon as ALZUMAb. Today, India is the only jurisdiction where ALZUMAb is approved or marketed. EQ001 has been evaluated in one Phase 1 clinical trial to date, conducted by Biocon, and is not approved for commercial sale in the United States or Canada. Our partnership with Biocon includes an exclusive supply agreement for clinical and commercial drug product of EQ001. Biocon currently manufactures EQ001 at commercial scale in a facility regulated by the FDA.

We have assembled an accomplished team that includes veterans in drug discovery, development and commercialization. Notably, our Chief Executive Officer is Daniel Bradbury, who has over 30 years of experience bringing novel medicines to market. Mr. Bradbury was the President, Chief Executive Officer and Director of Amylin Pharmaceuticals, Inc., where during his 18 year tenure he oversaw the development and launch of three first-in-class medicines, which ultimately led to the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb.

Understanding the Basis of Our Approach: The Role of CD6 in Autoimmunity

The role of the immune system is to defend the body against foreign organisms and cells, including cancerous cells, and in doing so must distinguish accurately between self- and non-self entities, a process called tolerance. Autoimmunity is an immune response directed against the body’s own healthy cells and tissues, and is the underlying process in many inflammatory diseases. Autoimmunity results from a loss of tolerance caused in part by an imbalance in the relationship between regulatory T cells, or Treg cells, and Teff cells.

CD6 is a novel, tightly-regulated, co-stimulatory receptor that plays an integral role in modulating T cell activation, proliferation, differentiation and trafficking. CD6 serves as a key checkpoint in regulating Teff cells that are central to autoimmune responses. Preclinical and clinical studies have shown that blockade of CD6 co-stimulation leads to selective inhibition of pathogenic Teff cell activity and trafficking, while preserving the important regulatory function of Treg cells. Such studies and new insights into the underlying biology highlight CD6 as a resurgent target for the treatment of multiple immuno-inflammatory diseases.

Modulation of Teff Cell Activity with EQ001

EQ001 is a humanized antibody that selectively binds to human CD6 and inhibits the interaction of CD6 with its ligand ALCAM, preventing co-stimulation, and thereby reducing Teff cell activity and trafficking. Preclinical



 

2


Table of Contents

studies of EQ001 have shown that blockade of CD6 leads to a reduction in Teff cell proliferation and downregulation of several important intracellular pathways that contribute to Teff cell development. Critically, CD6 blockade leads to the downregulation of important cellular pathways that control inflammation, including STAT3 and RORgt. The downregulation of these pathways is accompanied by decreased secretion of the pro-inflammatory Teff cytokines IFN-g, TNF-a, IL-6 and IL-17. Additionally, inhibiting the binding of ALCAM to CD6, either by anti-CD6 monoclonal antibodies or by deletion of the gene expressing CD6, modulates lymphocyte trafficking and results in reduced Teff cell infiltration into inflamed tissues. Based on its broad multi-modal mechanism, we believe EQ001 has the potential to treat multiple immuno-inflammatory diseases including those that are resistant or refractory to existing therapies.

Our Planned Initial Clinical Indications

We plan to initially develop EQ001 for the treatment of aGVHD, cGVHD, severe asthma and at least one additional indication. We expect to initiate a Phase 1b/2 clinical trial of EQ001 in patients with aGVHD in early 2019 and a Phase 2 clinical trial of EQ001 in patients with cGVHD in the first half of 2019. We also plan to initiate a proof-of-concept clinical trial in severe asthma in the first half of 2019. We continue to evaluate additional indications for future development and plan to select a fourth indication in the first half of 2019.

Recent Developments

In July 2018, we received a “study may proceed” letter from the FDA in response to our initial IND submission related to the conduct of clinical trials of EQ001 in the indication of aGVHD.

In August 2018, we hired Dr. Krishna Polu to serve as our Chief Medical Officer and, in September 2018, we added three experienced independent members to our board of directors.

In September 2018, we submitted a request to the U.S. Department of the Treasury’s Office of Foreign Assets Control, or OFAC, seeking guidance on the application of a general license permitting the import, development and commercialization of EQ001, a product that is derived from intellectual property of Cuban origin (see “Business—Government Regulation and Product Approval—Governmental Regulations Related to Economic Sanctions” for additional background).

Strategy

Our goal is to become a leading, fully-integrated biotechnology company focused on therapies for severe immuno-inflammatory disorders. To achieve our goal, we intend to:

 

   

Advance EQ001 through clinical development for aGVHD and cGVHD. Based on our deep and proprietary understanding of the CD6 pathway, our translational research and prior clinical studies targeting CD6, we are initially focused on aGVHD and cGVHD as our initial indications for the clinical development of EQ001. We plan to initiate a Phase 1b/2 clinical trial of EQ001 as a front-line therapy concomitant with steroids in patients with aGVHD in early 2019 and expect top-line data from the Phase 1b part of this trial within 12 months of initiation. In this trial we will assess safety, overall response rate, survival, steroid taper and incidence of cGVHD. In addition, we plan to initiate a Phase 2 clinical trial of EQ001 in patients with cGVHD in the first half of 2019.

 

   

Develop EQ001 for the treatment of severe asthma. We believe that the unique mechanism of action of EQ001 has the potential to treat severe asthma patients characterized by an immunophenotype of low Th2 and high Th17 and who consequently have a poor response to high dose inhaled and/or oral steroids. There are a sizeable number of these patients who are underserved by currently available therapies and for which there are no FDA-approved biologic or other targeted treatments. We plan to initiate a proof-of-concept clinical trial of EQ001 in patients with severe asthma in the first half of 2019.

 

   

Expand clinical development of EQ001 into additional indications based on our translational biology program. We will continue to conduct studies in animal models and human tissue, as well as EQ001



 

3


Table of Contents
 

clinical trials, to help inform the selection of additional indications for further development. In the first half of 2019, we intend to select a fourth indication for future EQ001 development.

 

   

Opportunistically expand our pipeline of product candidates. We will leverage the collective talent within our organization to opportunistically acquire or in-license other high-value therapeutic programs that may complement our core strategy or have the potential for synergistic therapeutic benefit in combination with EQ001.

 

   

Build a commercial infrastructure. If approved, we intend to commercialize EQ001 ourselves in indications that can be efficiently targeted using a specialty sales force, such as aGVHD and cGVHD. For other indications, we intend to commercialize EQ001 either independently or through collaborations with other parties.

RISKS ASSOCIATED WITH OUR BUSINESS

Our business and our ability to implement our business strategy are subject to numerous risks, as more fully described in the section entitled “Risk Factors” immediately following this prospectus summary. You should read these risks before you invest in our common stock. We may be unable, for many reasons, including those that are beyond our control, to implement our business strategy. In particular, risks associated with our business include:

 

   

We have a very limited operating history and have never generated any revenues. We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability.

 

   

We are highly dependent on the success of our product candidate, EQ001, which is in early stage clinical development, and we may not be able to successfully obtain regulatory or marketing approval for, or successfully commercialize, this product candidate in any of the indications for which we plan to develop it.

 

   

If we fail to comply with U.S. export control and economic sanctions, our business, financial condition and prospects may be materially and adversely affected.

 

   

EQ001 is a monoclonal antibody that selectively targets CD6, a target for which there are no FDA-approved therapies. This makes it difficult to predict the timing and costs of clinical development for EQ001. We do not know whether our approach in targeting CD6 will allow us to develop any products of commercial value.

 

   

Even if this offering is successful, we will need to obtain substantial additional funding to complete the development and any commercialization of EQ001. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our research and development programs or other operations.

 

   

We are very early in our development efforts. We have not yet begun our first clinical trial to evaluate EQ001 in patients and, as a company, we have limited experience in this area.

 

   

We have licensed EQ001 from Biocon pursuant to an exclusive license agreement which rights are conditioned upon us meeting certain development and commercialization milestones and on making significant milestone payments in connection with regulatory approval and commercial milestones as well as royalty payments.

 

   

The development and commercialization of biopharmaceutical products are subject to extensive regulation, and we may not obtain regulatory approvals for EQ001 in any of the indications for which we plan to develop it, or any future product candidates, on a timely basis or at all.

 

   

Any delays in the commencement or completion, or termination or suspension, of our planned or future clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.

 

   

Adverse side effects or other safety risks associated with EQ001 could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon further development, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.



 

4


Table of Contents
   

The manufacture of biologics is complex and Biocon, our third-party manufacturer, may encounter difficulties in production. If Biocon encounters such difficulties, our ability to provide supply of EQ001 for clinical trials, our ability to obtain marketing approval, or our ability to obtain commercial supply of our products, if approved, could be delayed or stopped.

 

   

We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies, and these third parties may not perform satisfactorily.

 

   

We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated.

 

   

If we are unable to obtain or protect intellectual property rights covering our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and we may not be able to compete effectively in our market.

 

   

There has been no prior public market for our common stock, the stock price of our common stock may be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the initial public offering price.

CORPORATE AND OTHER INFORMATION

We were originally incorporated as Attenuate Biopharmaceuticals, Inc. in Delaware in March 2017 and subsequently changed our name to Equillium, Inc. in May 2017. Our principal executive offices are located at 2223 Avenida de la Playa, Suite 108, La Jolla, CA 92037, and our telephone number is 858-412-5302. Our corporate website address is www.equilliumbio.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.

This prospectus contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

IMPLICATIONS OF BEING AN EMERGING GROWTH COMPANY

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act, as amended, or JOBS Act, enacted in April 2012. An “emerging growth company” may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to:

 

   

being permitted to present only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations in this prospectus;

 

   

not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or Sarbanes-Oxley;

 

   

reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and

 

   

exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved.

We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenue of at least



 

5


Table of Contents

$1.07 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests.

The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with the adoption of new or revised accounting standards. We have elected to avail ourselves of this exemption. Therefore, we may not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult.



 

6


Table of Contents

THE OFFERING

 

Common stock offered by us

4,670,000 shares

 

Common stock to be outstanding after this offering

16,696,662 shares

 

Option to purchase additional shares

The underwriters have a 30-day option to purchase up to a total of 700,500 additional shares of common stock.

 

Use of proceeds

We intend to use the net proceeds from this offering to fund research and development of EQ001 and for working capital and other general corporate purposes, including costs and expenses associated with being a public company. See “Use of Proceeds.”

 

Risk factors

You should read the “Risk Factors” section of this prospectus for a discussion of certain of the factors to consider carefully before deciding to purchase any shares of our common stock.

 

Proposed Nasdaq Global Market symbol

“EQ”

The number of shares of our common stock to be outstanding after this offering is based on 12,026,662 shares of common stock outstanding as of June 30, 2018, including 267,690 shares of restricted common stock which are subject to a right of repurchase by us as of June 30, 2018 and after giving effect to (i) the conversion of $9.4 million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the completion of this offering into an aggregate of 808,661 shares of our common stock based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on September 30, 2018 and (ii) the issuance by us of 242,237 shares of common stock upon completion of this offering to Biocon, pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and excludes:

 

   

107,084 shares of common stock issuable upon the exercise of outstanding stock options as of June 30, 2018, each at an exercise price of $0.05 per share;

 

   

2,229,773 shares of common stock reserved for future issuance under our 2018 equity incentive plan, or the 2018 Plan, which will become effective in connection with the execution and delivery of the underwriting agreement for this offering (including 1,040,000 new shares plus the number of shares (not to exceed 1,189,773 shares) (i) that remain available for grant of future awards under our 2017 equity incentive plan, or the 2017 Plan, which shares will be added to the shares reserved under the 2018 Plan upon its effectiveness and (ii) any shares underlying outstanding stock awards granted under our 2017 Plan that expire, or are forfeited, cancelled, withheld or reacquired, as more fully described under the terms of the 2018 Plan described in the section titled “Executive Compensation—Equity Benefit Plans”); and

 

   

343,275 shares of common stock reserved for future issuance under our 2018 employee stock purchase plan, or the ESPP, which will become effective in connection with the execution and delivery of the underwriting agreement for this offering.

Unless otherwise indicated, all information contained in this prospectus assumes or gives effect to:

 

   

the conversion of $9.4 million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the completion of this offering into an aggregate of 808,661 shares of our common stock based on an assumed initial public offering



 

7


Table of Contents
 

price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on September 30, 2018;

 

   

the issuance by us of 242,237 shares of common stock upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus);

 

   

no exercise by the underwriters of their option to purchase up to a total of 700,500 additional shares of our common stock;

 

   

the filing of our amended and restated certificate of incorporation and the adoption of our amended and restated bylaws immediately prior to the completion of this offering; and

 

   

a one-for-8.62 stock split of our common stock effected on October 1, 2018.

A $1.00 increase in the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus) would decrease the number of shares of our common stock issued on conversion of our convertible promissory notes and issued to Biocon (and therefore the number of shares to be outstanding after this offering) by 65,851 shares. A $1.00 decrease in the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase the number of shares of our common stock issued on conversion of our convertible promissory notes and issued to Biocon (and therefore the number of shares to be outstanding after this offering) by 74,919 shares. Because the closing date of this offering will occur after September 30, 2018, the convertible promissory notes will continue to accrue interest at a rate of 6% per annum and additional shares of our common stock will be issued upon conversion of this additional accrued interest.



 

8


Table of Contents

SUMMARY FINANCIAL DATA

The following summary statement of operations data for the period March 16, 2017 (inception) through December 31, 2017 is derived from our audited financial statements appearing elsewhere in this prospectus. The summary statements of operations data for the period March 16, 2017 (inception) through June 30, 2017 and the six months ended June 30, 2018 and the balance sheet data as of June 30, 2018 are derived from our unaudited interim financial statements included elsewhere in this prospectus. In our opinion, these unaudited financial statements have been prepared on a basis consistent with our audited financial statements and contain all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of such financial data. You should read these data together with our financial statements and related notes appearing elsewhere in this prospectus and the information in “Selected Financial Data” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Our historical results are not necessarily indicative of the results to be expected in the future, and our operating results for the interim periods are not necessarily indicative of the results that may be expected for any other interim periods or any future year.

 

     PERIOD
MARCH 16,
2017
(INCEPTION)
THROUGH
DECEMBER 31,
2017
    PERIOD
MARCH 16,
2017
(INCEPTION)
THROUGH
JUNE 30,
2017
    SIX MONTHS
ENDED
JUNE 30,
2018
 
           (unaudited)  

Statement of Operations Data:

      

Operating expenses:

      

Research and development

   $ 1,333,721     $ 801,364     $ 1,202,917  

General and administrative

     378,328       187,173       958,691  
  

 

 

   

 

 

   

 

 

 

Total operating expenses

     1,712,049       988,537       2,161,608  
  

 

 

   

 

 

   

 

 

 

Loss from operations

     (1,712,049     (988,537     (2,161,608

Interest expense

     379,385       7,069       1,108,197  

Interest income

                 (29,926

Change in fair value of Biocon anti-dilution right

     170,440       18,887       102,280  
  

 

 

   

 

 

   

 

 

 

Net loss and comprehensive loss

   $ (2,261,874   $ (1,014,493   $ (3,342,159
  

 

 

   

 

 

   

 

 

 

Net loss per share, basic and diluted (1)

   $ (0.28   $ (0.19   $ (0.31
  

 

 

   

 

 

   

 

 

 

Weighted average shares of common stock outstanding, basic and diluted (1)

     8,030,029       5,307,596       10,711,788  
  

 

 

   

 

 

   

 

 

 

Pro forma net loss per share, basic and diluted (unaudited) (1)

   $ (0.21     $ (0.18
  

 

 

     

 

 

 

Pro forma weighted average shares of common stock outstanding, basic and diluted (unaudited) (1)

     8,300,749         11,644,175  
  

 

 

     

 

 

 

 

(1)    See Note 2 to our financial statements appearing elsewhere in this prospectus for an explanation of the method used to calculate the basic and diluted net loss per common share, unaudited pro forma basic and diluted net loss per share and the number of shares used in the computation of the per share amounts.


 

9


Table of Contents
     AS OF JUNE 30, 2018  
     ACTUAL     PRO FORMA (1)     PRO FORMA AS
ADJUSTED (2)(3)
 
     (unaudited)  

Balance Sheet Data:

      

Cash and cash equivalents

   $ 6,626,443     $ 6,626,443     $ 69,672,943  

Working capital

     5,788,958       6,125,507       69,172,007  

Total assets

     6,728,134       6,728,134       69,774,634  

Convertible promissory notes, including related party

     10,517,896       —         —    

Accumulated deficit

     (5,604,033     (5,604,033     (5,604,033

Total stockholders’ (deficit) equity

     (5,593,501     6,139,067       69,185,567  

 

(1)    Pro forma amounts reflect (i) the conversion of $9.4 million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the completion of this offering into an aggregate of 808,661 shares of our common stock based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on September 30, 2018 and (ii) the issuance by us of 242,237 shares of common stock upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus).

 

(2)    Pro forma as adjusted amounts reflect the pro forma adjustments described in footnote (1) above, as well as the sale of 4,670,000 shares of our common stock in this offering based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

(3)    A $1.00 increase (decrease) in the assumed initial public offering price would increase (decrease) each of cash and cash equivalents, working capital, total assets and total stockholders’ equity by $4.3 million, assuming the number of shares offered by us as stated on the cover page of this prospectus remain unchanged and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, a one million share increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) each of cash and cash equivalents, working capital, total assets and total stockholders’ equity by $13.9 million, assuming the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus) remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.


 

10


Table of Contents

RISK FACTORS

Investing in our common stock is speculative and involves a high degree of risk. Before investing in our common stock, you should consider carefully the risks described below, together with the other information contained in this prospectus, including our financial statements and the related notes appearing at the end of this prospectus. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described below. See “Information Regarding Forward-Looking Statements.”

Risks Related to Our Business and to the Development and Regulatory Approval of EQ001

We have a very limited operating history and have never generated any revenues.

We are an early-stage biotechnology company with a very limited operating history that may make it difficult to evaluate the success of our business to date and to assess our future viability. We were incorporated in March 2017 and our operations, to date, have been limited to organizing and staffing our company, business planning, raising capital, in-licensing rights to EQ001, conducting preclinical research, filing our initial IND and preparing to commence clinical development of EQ001. We have not yet demonstrated an ability to successfully complete any clinical trials and have never completed the development of any product candidate, and we have never generated any revenue from product sales or otherwise. Consequently, we have no meaningful operations upon which to evaluate our business, and predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing biopharmaceutical products.

We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability.

Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable. We have never generated any revenues, and we cannot estimate with precision the extent of our future losses. For the period March 16, 2017 (inception) through December 31, 2017 and six months ended June 30, 2018, our net losses were $2.3 million and $3.3 million, respectively. As of December 31, 2017, and June 30, 2018, we had an accumulated deficit of $2.3 million and $5.6 million, respectively. We expect to incur increasing levels of operating losses for the foreseeable future as we execute our plan to continue our research and development activities, including the planned clinical development of EQ001, and as we incur the additional costs of operating as a public company. In addition, if we obtain regulatory approval for EQ001, we expect to incur increased sales and marketing expenses. As a result, we expect to continue to incur significant and increasing operating losses and negative cash flows for the foreseeable future. These losses have had and will continue to have an adverse effect on our financial position and working capital.

To become and remain profitable, we must develop and eventually commercialize a product with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of EQ001, obtaining marketing approval for EQ001, manufacturing, marketing and selling EQ001 if we obtain marketing approval, and satisfying post-marketing requirements, if any. We may never succeed in these activities and, even if we succeed in obtaining approval for and commercializing EQ001, we may never generate revenues that are significant enough to achieve profitability. In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. Furthermore, because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we may continue to incur substantial research and development and other expenditures to develop and market additional product candidates. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.

 

11


Table of Contents

Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.

Our auditors have issued a going concern opinion on our financial statements as of December 31, 2017 and for the period from March 16, 2017 (inception) to December 31, 2017, expressing substantial doubt that we can continue as an ongoing business due to insufficient capital for us to fund our operations. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. If we are unable to successfully complete this offering, we will need to create and implement alternate financing or operational plans to continue as a going concern, and investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all.

We are highly dependent on the success of our product candidate, EQ001, which is in early stage clinical development, and we may not be able to successfully obtain regulatory or marketing approval for, or successfully commercialize, this product candidate in any of the indications for which we plan to develop it.

Our future success will depend almost entirely on our ability to successfully develop, obtain regulatory approval for and then successfully commercialize EQ001, in any of the indications for which we initially plan to develop it, including aGVHD, cGVHD and severe asthma, which may never occur. We have no product candidates in our pipeline other than EQ001. We currently generate no revenues from sales of any biopharmaceutical products or otherwise, and we may never be able to develop or commercialize a marketable biopharmaceutical product.

Before we can market and sell EQ001 in the United States, we will need to manage research and development activities, commence and complete clinical trials, obtain necessary regulatory approvals from the FDA and build a commercial organization or enter into a marketing collaboration with a third party, among other things. We cannot assure you that we will be able to successfully complete the necessary clinical trials and/or obtain regulatory approval and develop sufficient commercial capabilities for EQ001. We have not submitted a Biologics License Application, or BLA, to the FDA for any product candidate. Further, EQ001 may not receive regulatory approval even if it is successful in clinical trials. If we do not receive regulatory approvals, our business, prospects, financial condition and results of operations will be adversely affected. Even if we obtain regulatory approval, we may never generate significant revenues from any commercial sales of EQ001. If EQ001 is approved and we fail to successfully commercialize it, we may be unable to generate sufficient revenues to sustain and grow our business, and our business, prospects, financial condition and results of operations will be adversely affected.

If we fail to comply with U.S. export control and economic sanctions, our business, financial condition and prospects may be materially and adversely affected.

Our business and our products are subject to U.S. export control laws and regulations, including the U.S. Export Administration Regulations and economic and trade sanctions regulations administered by OFAC. See “Business—Government Regulation and Product Approval—Governmental Regulations Related to Economic Sanctions.” Our company must comply with these laws and regulations. The antibody sequence for both EQ001 and ALZUMAb is derived from Cuban-origin intellectual property and thus we believe this to be a pharmaceutical of Cuban origin which would make the import, development and commercialization of EQ001 subject to these laws, sanctions and regulations. We currently rely on a general license issued by OFAC under the Cuban Assets Control Regulations, or CACR, relating to Cuban-origin pharmaceuticals to import and conduct clinical trials relating to EQ001. Although we believe our activities for EQ001 qualify for, and are authorized under, the OFAC general license and we have maintained compliance with the general license requirements, there is some question regarding such applicability given that we have licensed EQ001 from Biocon and OFAC has not confirmed the applicability of the general license to EQ001 or products not wholly developed in or exported from Cuba. In the absence of the OFAC general license, all of our development and potential commercialization activities for EQ001 would be prohibited under the CACR, and we would be required to request a specific license from OFAC authorizing such activities, which OFAC could deny. We have submitted to OFAC a request for interpretive guidance confirming the applicability of the general license to EQ001, or in its absence, a specific license authorization from OFAC. We have simultaneously requested that OFAC treat our submission as a voluntary disclosure if OFAC concludes that our determination that the general license applies to EQ001 was in error. Even if OFAC concludes that the general license applies to EQ001, there can be no assurance that the general license will not be revoked or modified by OFAC in the future, or that we will remain in compliance with these or other export laws and regulations. If OFAC determines that the general license

 

12


Table of Contents

does not apply, and OFAC then denies our request for a specific license, we will be unable to deal in, or otherwise commercialize, EQ001. In that case, we would be required to cease operations related to EQ001 which would materially and adversely affect our financial condition and business prospects. In addition, in the absence of the general or specific license, the transfer, sale and/or purchase of our securities could be prohibited, and the ownership or possession of our securities could be subject to an affirmative OFAC reporting requirement relating to blocked property. We and certain of our employees could also be subject to substantial civil or criminal penalties.

EQ001 is a monoclonal antibody that selectively targets CD6, a target for which there are no FDA-approved therapies. This makes it difficult to predict the timing and costs of clinical development for EQ001. We do not know whether our approach in targeting CD6 will allow us to develop any products of commercial value.

We have concentrated our research and development approach on targeting CD6, and our future success depends on the successful development of this therapeutic approach to the diseases we are targeting for treatment. To date, there are no FDA-approved drugs that target CD6, and while there are a number of independent studies clinically validating CD6 as a target, other than our partner Biocon, CD6 has not traditionally been a pathway targeted by other biopharmaceutical companies. The regulatory approval process for novel product candidates such as EQ001 can be more expensive and take longer than for other, better known or extensively studied therapeutic approaches. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring EQ001 to market could decrease our ability to generate sufficient revenue to maintain our business.

Even if this offering is successful, we will need to obtain substantial additional funding to complete the development and any commercialization of EQ001. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our research and development programs or other operations.

We expect our expenses to increase substantially during the next few years. The development of biotechnology product candidates is capital intensive. As EQ001 enters and advances through preclinical studies and clinical trials, we will need substantial additional funds to expand our clinical, regulatory and quality capabilities. In addition, if we obtain marketing approval for EQ001, we expect to incur significant commercialization expenses for marketing, sales, manufacturing and distribution. Furthermore, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company.

As of June 30, 2018, we had $6.6 million in cash and cash equivalents. Based on our current operating plan, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operations for at least the next 24 months. In particular, we expect that the net proceeds from this offering will allow us to fund a Phase 1b/2 clinical trial of EQ001 for aGVHD, a Phase 2 clinical trial of EQ001 for cGVHD and a proof-of-concept clinical trial of EQ001 for severe asthma. However, changing circumstances or inaccurate estimates by us may cause us to use capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. For example, our planned clinical trials for EQ001 may encounter technical, enrollment or other issues that could cause our development costs to increase more than we expect. Even with the expected net proceeds from this offering, we will not have sufficient funds to complete the clinical development of EQ001 through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of EQ001.

Our future capital requirements will depend on many factors, including:

 

   

the initiation, progress, timing, costs and results of our planned clinical trials for EQ001;

 

   

the number and scope of indications we decide to pursue for EQ001 development;

 

   

the cost, timing and outcome of regulatory review of any BLA we may submit for EQ001;

 

   

the costs and timing of manufacturing for EQOO1, if approved;

 

   

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;

 

   

our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of EQ001;

 

   

the costs associated with being a public company;

 

   

the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;

 

13


Table of Contents
   

the extent to which we acquire or in-license other product candidates and technologies; and

 

   

the cost associated with commercializing EQ001, if approved for commercial sale.

Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for sale for at least the next several years, if ever. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or other operations.

We are very early in our development efforts. We have not yet begun our first clinical trial to evaluate EQ001 in patients and, as a company, we have limited experience in this area.

While Biocon has evaluated EQ001 in a Phase 1 clinical trial, we expect to initiate our first clinical trial of EQ001 in patients with aGVHD in early 2019. We have one active IND with the FDA for EQ001 in the aGVHD indication. Because of our limited interaction with the FDA, we may not learn of certain information or data that the FDA may request until future interactions. In part because of our limited infrastructure, experience conducting clinical trials as a company and regulatory interactions, we cannot be certain that our clinical trials will be initiated on time, that our planned clinical trials will be completed on time, if at all, or that our planned development programs would be acceptable to the FDA.

Adverse safety and toxicology findings may emerge as we conduct clinical trials. In addition, success in early clinical trials does not mean that later clinical trials will be successful, because later-stage clinical trials may be conducted in broader patient populations and involve different study designs. For example, although EQ001 and ALZUMAb share the same primary monoclonal antibody sequence, they are manufactured in different cell lines and thus could be considered different biopharmaceutical products. Therefore, results seen in clinical trials of ALZUMAb conducted by Biocon may not be predictive of the results of our clinical trials of EQ001. Furthermore, our future clinical trials will need to demonstrate sufficient safety and efficacy in larger patient populations for approval by the FDA. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results, and we cannot be certain that we will not face similar setbacks. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. In addition, only a small percentage of biologics under development result in the submission of a BLA to the FDA and even fewer are approved for commercialization.

Our ability to generate product revenues, which we do not expect will occur for at least the next several years, if ever, will depend heavily on our ability to successfully complete the above activities and any other activities required for the successful development and eventual commercialization of EQ001. The success of EQ001 will further depend on factors such as:

 

   

completion of our planned clinical trials and preclinical studies with favorable results;

 

   

acceptance of INDs by the FDA for our future clinical trials in additional indications such as cGVHD and asthma, as applicable;

 

   

timely and successful enrollment in, and completion of, clinical trials with favorable results;

 

   

demonstrating safety, efficacy and acceptable risk-benefit profile of EQ001 to the satisfaction of the FDA;

 

   

receipt of marketing approvals from the FDA;

 

   

maintaining arrangements with Biocon, our third-party manufacturer, for cell lines and drug product clinical supply and, if and when approved, for commercial supply of EQ001;

 

   

establishing sales, marketing and distribution capabilities and launching commercial sale of EQ001, if and when approved in one or more indications;

 

   

acceptance of EQ001, if and when approved, by patients, the medical community and third-party payors;

 

   

effectively competing with other therapies;

 

14


Table of Contents
   

obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for EQ001; and

 

   

maintaining a continued acceptable safety profile of EQ001, following approval.

If we do not achieve one or more of these factors in a timely manner, we could experience significant delays or an inability to successfully obtain marketing approval and commercialize EQ001, which would materially harm our business.

We have licensed EQ001 from Biocon pursuant to an exclusive license agreement, which rights are conditioned upon us meeting certain development and commercialization milestones and on making significant milestone payments in connection with regulatory approval and commercial milestones as well as royalty payments.

We are party to an exclusive license agreement with Biocon, pursuant to which we acquired an exclusive license in the United States and Canada to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit EQ001 and any pharmaceutical composition or preparation containing or comprising EQ001. We are obligated, under this agreement, to use commercially reasonable efforts to achieve certain development, regulatory, commercialization and funding milestones within specified timeframes in order to retain all of the licensed rights. Certain of such milestones are largely outside of our control. Further, we are obligated to make certain cash milestone payments to Biocon upon completion of certain development and commercial milestones and are required to make certain cash royalty payments upon our achievement of target levels of revenue from sales of EQ001, if approved. Though we believe that the royalty rates and milestone payments are reasonable in light of our business plan, we will require large amounts of capital to satisfy these obligations. We may become obligated to make a milestone payment when we do not have the cash on hand to make such payment, which could require us to delay our clinical trials, curtail our operations, scale back our commercialization and marketing efforts or seek funds to meet these obligations on terms unfavorable to us. In addition, if we are unable to make any payment when due or, if we fail to use commercially reasonable efforts to achieve the development, regulatory, commercial and funding milestones within the timeframes required by the license agreement, Biocon may have the right to limit the scope of our license or terminate the agreement and all of our rights to develop and commercialize EQ001.

We have only licensed the rights to EQ001 in the United States and Canada. Any adverse developments that occur during any clinical trials conducted by third parties in other jurisdictions may affect our ability to obtain regulatory approval or commercialize EQ001.

Biocon and its partner, over which we have no control, have the rights to develop and commercialize itolizumab in geographies outside of the United States and Canada. Itolizumab is approved in India for the treatment of moderate to severe plaque psoriasis and is marketed by Biocon as ALZUMAb. In addition, a conditional approval for itolizumab was granted to Centro de Immunologia Molecular, Cuba in May 2014. This approval is subject to completion of a Phase 3 clinical trial in Cuban patients. Two clinical trials are currently open in Cuba. If serious adverse events occur with patients using ALZUMAb or during any clinical trials of itolizumab conducted by third parties, the FDA may delay, limit or deny approval of EQ001 or require us to conduct additional clinical trials as a condition to marketing approval, which would increase our costs. If we receive FDA approval for EQ001 and a new and serious safety issue is identified in connection with use of ALZUMAb or in clinical trials of itolizumab conducted by third parties, the FDA may withdraw their approval of the product or otherwise restrict our ability to market and sell EQ001. In addition, treating physicians may be less willing to administer our product due to concerns over such adverse events, which would limit our ability to commercialize EQ001.

The development and commercialization of biopharmaceutical products are subject to extensive regulation, and we may not obtain regulatory approvals for EQ001 in any of the indications for which we plan to develop it, or any future product candidates, on a timely basis or at all.

The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing, distribution, adverse event reporting, including the submission of safety and other post-marketing information and reports, and other possible activities relating to EQ001, currently our only product candidate, as well as any other product candidate that we may develop in the future, are subject to extensive regulation. Marketing approval of biologics in the United States requires the submission of a BLA to the FDA and we

 

15


Table of Contents

are not permitted to market any product candidate in the United States until we obtain approval from the FDA of the BLA for that product. A BLA must be supported by extensive clinical and preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing and controls.

FDA approval of a BLA is not guaranteed, and the review and approval process is an expensive and uncertain process that may take several years. The FDA also has substantial discretion in the approval process. The number and types of preclinical studies and clinical trials that will be required for BLA approval varies depending on the product candidate, the disease or the condition that the product candidate is designed to treat and the regulations applicable to any particular product candidate. Despite the time and expense associated with preclinical studies and clinical trials, failure can occur at any stage. The results of preclinical and early clinical trials of EQ001 or any future product candidates may not be predictive of the results of our later-stage clinical trials.

Clinical trial failure may result from a multitude of factors including flaws in trial design, dose selection, placebo effect, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits, and failure in clinical trials can occur at any stage. Companies in the biopharmaceutical industry frequently suffer setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from clinical trials are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may further delay, limit or prevent marketing approval.

The FDA could delay, limit or deny approval of a product candidate for many reasons, including because they:

 

   

may not deem our product candidate to be adequately safe and effective;

 

   

may not agree that the data collected from clinical trials are acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval, and may impose requirements for additional preclinical studies or clinical trials;

 

   

may determine that adverse events experienced by participants in our clinical trials represents an unacceptable level of risk;

 

   

may determine that population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;

 

   

may not accept clinical data from trials, which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;

 

   

may disagree regarding the formulation, labeling and/or the specifications;

 

   

may not approve the manufacturing processes or facilities associated with our product candidate;

 

   

may change approval policies or adopt new regulations; or

 

   

may not accept a submission due to, among other reasons, the content or formatting of the submission.

Generally, public concern regarding the safety of biopharmaceutical products could delay or limit our ability to obtain regulatory approval, result in the inclusion of unfavorable information in our labeling, or require us to undertake other activities that may entail additional costs. We have not obtained FDA approval for any product. This lack of experience may impede our ability to obtain FDA approval in a timely manner, if at all, for EQ001.

If we experience delays in obtaining approval or if we fail to obtain approval of EQ001, our commercial prospects will be harmed and our ability to generate revenues will be materially impaired which would adversely affect our business, prospects, financial condition and results of operations.

Any delays in the commencement or completion, or termination or suspension, of our planned or future clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.

Any delays in the commencement or completion, or termination or suspension, of our planned or future clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects. Before we can initiate clinical trials of EQ001 in any distinct indication, we must submit the

 

16


Table of Contents

results of preclinical studies to the FDA along with other information, including information about EQ001 chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND or similar regulatory filing.

Before obtaining marketing approval from the FDA for the sale of EQ001 in any indication, we must conduct extensive clinical studies to demonstrate the safety and efficacy of EQ001. Clinical testing is expensive, time consuming and uncertain as to outcome. In addition, we expect to rely in part on preclinical, clinical and quality data generated by our partner, Biocon, as well as contract research organizations, or CROs, and other third parties for regulatory submissions for EQ001. While we have or will have agreements governing these third parties’ services, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase. To date, we have only submitted an IND for clinical trials of EQ001 for the treatment of aGVHD, and we will need to submit an IND for acceptance by the FDA prior to initiating any clinical trials in the United States in other indications.

The FDA may require us to conduct additional preclinical studies for EQ001 or any future product candidate before it allows us to initiate clinical trials under any IND, which may lead to additional delays and increase the costs of our preclinical development programs. Any such delays in the commencement or completion of our planned or future clinical trials could significantly affect our product development costs. We do not know whether our planned trials will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:

 

   

the FDA disagreeing as to the design or implementation of our clinical studies;

 

   

obtaining FDA authorizations to commence a trial or reaching a consensus with the FDA on trial design;

 

   

any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

 

   

obtaining approval from one or more institutional review boards, or IRBs;

 

   

IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;

 

   

changes to clinical trial protocol;

 

   

clinical sites deviating from trial protocol or dropping out of a trial;

 

   

manufacturing sufficient quantities of product candidate or obtaining sufficient quantities of combination therapies for use in clinical trials;

 

   

subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment follow-up;

 

   

subjects choosing an alternative treatment, or participating in competing clinical trials;

 

   

lack of adequate funding to continue the clinical trial;

 

   

subjects experiencing severe or unexpected drug-related adverse effects;

 

   

occurrence of serious adverse events in trials of the same class of agents conducted by other companies;

 

   

selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;

 

   

a facility manufacturing our product candidates or any of their components being ordered by the FDA to temporarily or permanently shut down due to violations of current good manufacturing practice, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;

 

   

any changes to our manufacturing process that may be necessary or desired;

 

   

third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements;

 

   

us, or our third-party contractors not performing data collection or analysis in a timely or accurate manner or improperly disclosing data prematurely or otherwise in violation of a clinical trial protocol; or

 

17


Table of Contents
   

third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.

We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a pharmaceutical, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.

Certain of our scientific advisors or consultants who receive compensation from us are likely to be investigators for our future clinical trials. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of EQ001 in one or more indications. If we experience delays in the completion of, or termination of, any clinical trial of EQ001, the commercial prospects of EQ001 will be harmed, and our ability to generate product revenues will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our development and approval process and jeopardize our ability to commence product sales and generate revenues which may harm our business, financial condition, results of operations and prospects significantly.

If we experience delays or difficulties in enrolling patients in our planned clinical trials, our receipt of necessary regulatory approval could be delayed or prevented.

We may not be able to initiate or continue our planned clinical trials for EQ001 if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA. The first indication that we are pursuing, aGVHD, is an acute and life threatening condition which may make it difficult to enroll patients in clinical trials. In addition, some of our competitors may have ongoing clinical trials for product candidates that would treat the same indications as EQ001, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors’ product candidates. This is acutely relevant for our development of EQ001 for the treatment of patients with severe asthma, a disease for which there is significant competition for clinical trial subjects. Patient enrollment is also affected by other factors, including:

 

   

severity of the disease under investigation;

 

   

our ability to recruit clinical trial investigators of appropriate competencies and experience;

 

   

invasive procedures required to obtain evidence of the product candidate’s performance during the clinical trial;

 

   

availability and efficacy of approved medications for the disease under investigation;

 

   

eligibility criteria defined in the protocol for the trial in question;

 

   

the size of the patient population required for analysis of the trial’s primary endpoints;

 

   

perceived risks and benefits;

 

   

efforts to facilitate timely enrollment in clinical trials;

 

   

reluctance of physicians to encourage patient participation in clinical trials;

 

   

the ability to monitor patients adequately during and after treatment;

 

   

our ability to obtain and maintain patient consents; and

 

   

proximity and availability of clinical trial sites for prospective patients.

 

18


Table of Contents

Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs, which would cause the value of our company to decline and limit our ability to obtain additional financing.

Adverse side effects or other safety risks associated with EQ001 could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon further development, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.

As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with EQ001 in our planned clinical trials. In the Phase 1 clinical trial of EQ001 conducted by Biocon in healthy subjects, there were no serious adverse events, dose limiting toxicities, or study drug discontinuations reported.

Biocon has completed three clinical studies of ALZUMAb in India in patients with rheumatoid arthritis and chronic plaque psoriasis, with a total of 333 patients exposed to ALZUMAb to date at dose levels ranging from 0.2 mg/kg to 1.6 mg/kg. An additional 35 patients have received itolizumab in clinical trials conducted in Cuba. In Biocon’s Phase 3 clinical trial, infusion-related reactions and related events were the main adverse events attributed to itolizumab. There were five serious adverse events reported including exfoliative dermatitis (widespread redness and peeling of the skin), erythrodermic (severe) psoriasis, infusion-related reaction, adjustment disorder with anxiety, and bacterial arthritis. There has been limited market experience of ALZUMAb in patients since the date of market authorization in India in December 2012. Since the date of market authorization and as of the current cut-off date of August 10, 2017 for the most recent Periodic Safety Update Report, ALZUMAb has accrued approximately 275 patient-years of use. Post-market safety surveillance has demonstrated 27 adverse event reports in that time period, of which four have been noted as serious, including infusion reaction, type 1 hypersensitivity, diarrhea and urticaria (hives). The majority of reactions have involved the dermatologic standard of care and include rash, acne, urticaria, increased pruritus (itching) and increased psoriasis. Although EQ001 and ALZUMAb share the same primary monoclonal antibody sequence, they are manufactured in different cell lines and thus could be considered different biopharmaceutical products. Therefore, clinical results seen with ALZUMAb may have no bearing on results, including adverse events, that may be seen with EQ001.

Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by EQ001 could result in the delay, suspension or termination of clinical trials by us or the FDA for a number of reasons. Additionally, a material percentage of patients in our GVHD clinical trials will die from GVHD, possibly as a result of EQ001, which could impact development of EQ001. If we elect or are required to delay, suspend or terminate any clinical trial, the commercial prospects of EQ001 will be harmed and our ability to generate product revenues from this product candidate will be delayed or eliminated. Serious adverse events observed in clinical trials could hinder or prevent market acceptance of EQ001. Any of these occurrences may harm our business, prospects, financial condition and results of operations significantly.

Moreover, if EQ001 is associated with undesirable side effects in clinical trials or has characteristics that are unexpected, we may elect to abandon or limit its development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for EQ001, if approved. We may also be required to modify our study plans based on findings in our clinical trials. Many biologics that initially showed promise in early stage testing have later been found to cause side effects that prevented further development. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.

It is possible that as we test EQ001 in larger, longer and more extensive clinical trials, including with different dosing regimens, or as the use of EQ001 becomes more widespread following any regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition, results of operations and prospects significantly.

 

19


Table of Contents

In addition, if EQ001 receives marketing approval, and we or others later identify undesirable side effects caused by EQ001, a number of potentially significant negative consequences could result, including:

 

   

regulatory authorities may withdraw approval of EQ001;

 

   

we may be required to recall a product or change the way EQ001 is administered to patients;

 

   

regulatory authorities may require additional warnings on the label, such as a “black box” warning or a contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;

 

   

we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;

 

   

additional restrictions may be imposed on the marketing or promotion of the particular product or the manufacturing processes for the product or any component thereof;

 

   

we could be sued and held liable for harm caused to patients;

 

   

EQ001 could become less competitive; and

 

   

our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of EQ001, if approved, and could significantly harm our business, financial condition, results of operations and prospects.

Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publicly disclose preliminary or topline data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock after this offering. See the description of risks under the heading “Risks Related to our Common Stock and this Offering” for more disclosure related to the risks of volatility in our stock price.

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses, or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular biopharmaceutical product, biopharmaceutical product candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, EQ001 or any future product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.

 

20


Table of Contents

A Phase 1 clinical trial for EQ001 was recently conducted by Biocon in Australia, and we may conduct additional clinical trials of EQ001 outside of the United States. However, the FDA may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.

In the fourth quarter of 2017, Biocon completed a Phase 1 clinical trial of EQ001 in healthy subjects in Australia to assess the safety and tolerability of the subcutaneous version of EQ001. The trial also included a separate stage to compare the pharmacokinetics of the intravenous administration of EQ001 to ALZUMAb and determine the absolute bioavailability of subcutaneous EQ001 SC, but this stage was terminated early due to the occurrence of an initial decrease in lymphocyte counts and the occurrence of transient lymphopenia in the healthy subjects. We submitted this data to the FDA as part of our IND submission for the conduct of clinical trials for the treatment of aGVHD. However, it is possible that the FDA will not authorize us to proceed with clinical studies in connection with any future IND submissions in other indications that have different patient populations, and we may be required to conduct additional Phase 1 clinical trials, which would be costly and time consuming, and delay aspects of our development plan, which could harm our business.

Although the FDA may accept data from clinical trials conducted entirely outside the United States and not under an IND, acceptance of such study data is generally subject to certain conditions. For example, the FDA requires the clinical trial to have been conducted in accordance with GCPs, and the FDA must be able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary. In addition, when studies are conducted only at sites outside of the United States, the FDA generally does not provide advance comment on the clinical protocols for the studies, and therefore there is an additional potential risk that the FDA could determine that the study design or protocol for a non-U.S. clinical trial was inadequate, which would likely require us to conduct additional clinical trials. Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with:

 

   

additional foreign regulatory requirements;

 

   

foreign exchange fluctuations;

 

   

compliance with foreign manufacturing, customs, shipment and storage requirements;

 

   

cultural differences in medical practice and clinical research; and

 

   

diminished protection of intellectual property in some countries.

We may not be successful in our efforts to expand our pipeline by identifying additional indications for which to test EQ001 in the future. We may expend our limited resources to pursue a particular indication for EQ001 and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Our translational biology program may initially show promise in identifying additional indications for which EQ001 may have therapeutic benefit, yet this may fail to yield additional clinical development opportunities for EQ001 for a number of reasons, including, EQ001 may, on further study, be shown to have harmful side effects, limited to no efficacy or other characteristics that indicate that it is unlikely to receive marketing approval and achieve market acceptance in such additional indications. Research programs to identify additional indications for EQ001 require substantial technical, financial and human resources.

Because we have limited financial and managerial resources, we must prioritize our research programs and will need to focus EQ001 development on the potential treatment of certain indications. As a result, we may forego or delay pursuit of opportunities with other indications or for any future product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on EQ001 for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for EQ001 or any future product candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.

 

21


Table of Contents

Even if we receive regulatory approval for EQ001 or any future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, EQ001 and any future product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.

Any regulatory approvals that we receive for EQ001 or any future product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. In addition, if the FDA approves any product candidate, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and record keeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs, for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, undesirable side effects caused by the product, problems encountered by our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, either before or after product approval, may result in, among other things:

 

   

restrictions on the marketing or manufacturing of the product;

 

   

requirements to include additional warnings on the label;

 

   

requirements to create a medication guide outlining the risks to patients;

 

   

withdrawal of the product from the market;

 

   

voluntary or mandatory product recalls;

 

   

requirements to change the way the product is administered or for us to conduct additional clinical trials;

 

   

fines, warning letters or holds on clinical trials;

 

   

refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic partners, or suspension or revocation of product license approvals;

 

   

product seizure or detention, or refusal to permit the import or export of products;

 

   

injunctions or the imposition of civil or criminal penalties; and

 

   

harm to our reputation.

Additionally if any product candidate receives marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits of the therapy outweigh its risks, which may include, among other things, a medication guide outlining the risks for distribution to patients and a communication plan to health care practitioners. Any of these events could prevent us from achieving or maintaining market acceptance of the product or the particular product candidate at issue and could significantly harm our business, prospects, financial condition and results of operations.

In addition, if we have any product candidate approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about biopharmaceutical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product’s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.

The FDA’s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of EQ001 or any future product candidates. We cannot predict the likelihood, nature or

 

22


Table of Contents

extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.

Even if EQ001 receives marketing approval in any indication, it may fail to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, healthcare payors and others in the medical community necessary for commercial success.

If EQ001 receives marketing approval in any one or more indication, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. If EQ001 does not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of EQ001, if approved for commercial sale in any indication, will depend on a number of factors, including:

 

   

efficacy and potential advantages compared to alternative treatments;

 

   

our ability to offer EQ001 for sale at competitive prices;

 

   

convenience and ease of administration compared to alternative treatments;

 

   

the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;

 

   

the strength of marketing and distribution support;

 

   

potential product liability claims;

 

   

the timing of market introduction of EQ001 as well as competitive biopharmaceutical products;

 

   

the effectiveness of our or any of our potential future sales and marketing strategies;

 

   

unfavorable publicity relating to EQ001;

 

   

sufficient third-party payor coverage and adequate reimbursement;

 

   

the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement; and

 

   

the prevalence and severity of any side effects.

We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell EQ001, we may not be able to generate product revenue.

We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If EQ001 ultimately receives regulatory approval, we may not be able to effectively market and distribute it. We may have to seek collaborators or invest significant amounts of financial and management resources to develop internal sales, distribution and marketing capabilities, some of which will be committed prior to any confirmation that EQ001 will be approved, if at all. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute EQ001 ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market EQ001 effectively. Even if we determine to perform sales, marketing and distribution functions ourselves, we could face a number of additional related risks, including:

 

   

we may not be able to attract and build an effective marketing department or sales force;

 

   

the cost of establishing a marketing department or sales force may exceed our available financial resources and the revenue generated by EQ001; and

 

   

our direct sales and marketing efforts may not be successful.

 

23


Table of Contents

We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated.

The development and commercialization of new products is highly competitive. We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop drugs and biologics for the treatment of immuno-inflammatory diseases. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop, or that would render any products that we may develop obsolete or non-competitive. Our competitors also may obtain marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.

Other products in the same class as EQ001 have already been approved or are further along in development. Currently-marketed treatments for cGVHD include AbbVie Inc.’s Imbruvica (ibrutinib), a BTK inhibitor previously approved for the treatment of chronic lymphocytic leukemia and other cancers. Further, we are aware of both private and public companies with development programs in GVHD, including AbbVie Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, CSL Behring LLC, Incyte Corporation, Jazz Pharmaceuticals plc, Kadmon Holdings, Inc., Kalytera Therapeutics, Inc., Kamada Ltd., Mesoblast Limited, Novartis AG, Prometheus Laboratories Inc. and Xenikos B.V. Major, currently marketed asthma therapies include several biologic therapies that specifically target IgE or Th2-associated cytokines including products developed by AbbVie Inc., Amgen Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Roche Holding AG and Teva Pharmaceutical Industries Limited, and we are aware of several companies with development programs in this indication including, AbbVie Inc., Amgen Inc., AnaptysBio, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Novartis AG, Regeneron Pharmaceuticals, Inc., Roche Holding AG and Sanofi-Aventis U.S. LLC.

Many of our competitors, such as large pharmaceutical and biotechnology companies like Amgen Inc. and Bristol-Myers Squibb Company have longer operating histories and significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. In addition, these larger companies may be able to use their greater market power to obtain more favorable distribution and sales-related agreements with third parties, which could give them a competitive advantage over us.

Further, as more product candidates within a particular class of biopharmaceutical products proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Consequently, the results of our clinical trials for product candidates in those classes will likely need to show a risk benefit profile that is competitive with or more favorable than those products and product candidates in order to obtain marketing approval or, if approved, a product label that is favorable for commercialization. If the risk benefit profile is not competitive with those products or product candidates, we may have developed a product that is not commercially viable, that we are not able to sell profitably or that is unable to achieve favorable pricing or reimbursement. In such circumstances, our future product revenues and financial condition would be materially and adversely affected.

Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and subject enrollment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, EQ001 or any future programs.

The key competitive factors affecting the success of EQ001 are likely to be its efficacy, safety, convenience and availability of reimbursement. If we are not successful in developing, commercializing and achieving higher levels of reimbursement than our competitors, we will not be able to compete against them and our business would be materially harmed.

 

24


Table of Contents

EQ001 and any future product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.

The Patient Protection and Affordable Care Act, or Affordable Care Act, signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.

We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

If the U.S. market opportunities for EQ001 are smaller than we believe they are, our revenue may be adversely affected and our business may suffer.

We only have the rights to EQ001 for the United States and Canada and we are focused on the development of EQ001 for immuno-inflammatory diseases, with an initial intention to develop it for the treatment of aGVHD, cGVHD and severe asthma. Our projections of addressable patient populations in the United States and Canada that have the potential to benefit from treatment with EQ001 are based on estimates and may prove to be incorrect. If any of our estimates are inaccurate, the market opportunities for EQ001 could be significantly diminished and have an adverse material impact on our business.

We may be unsuccessful in our efforts to obtain orphan drug designations from the FDA for EQ001 or may not ultimately realize the potential benefits of orphan drug designation.

We intend to seek orphan drug designation for EQ001 in eligible indications. The FDA grants orphan designation to drugs that are intended to treat rare diseases with fewer than 200,000 patients in the United States or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug. Orphan drugs do not require prescription drug user fees with a marketing application, may qualify the drug development sponsor for certain tax credits, and may be eligible for a market exclusivity period of seven years (with certain exceptions). However, orphan drug designation neither shortens the development time nor regulatory review time of a product candidate nor gives the candidate any advantage in the regulatory review or approval process. If we are unable to secure orphan drug designation in eligible indications, our regulatory and commercial prospects may be negatively impacted.

Even if we obtain orphan drug designations and are awarded marketing exclusivity, the FDA can still approve another drug containing the same active ingredient and used for the same orphan indication if it determines that a subsequent drug is safer, more effective or makes a major contribution to patient care, and orphan exclusivity can be lost if the orphan drug manufacturer is unable to assure that a sufficient quantity of the orphan drug is available to meet the needs of patients with the rare disease or condition. Orphan drug exclusivity may also be lost if the FDA later determines that the initial request for designation was materially defective. In addition, orphan drug exclusivity

 

25


Table of Contents

does not prevent the FDA from approving competing drugs for the same or similar indication containing a different active ingredient. If orphan drug exclusivity is lost and we were unable to successfully enforce any remaining patents covering our eligible product candidates, we could be subject to biosimilar competition earlier than we anticipate. In addition, if a subsequent drug is approved for marketing for the same or a similar indication as EQ001, we may face increased competition and lose market share regardless of orphan drug exclusivity.

Risks Related to Manufacturing and Our Reliance on Third Parties

The manufacture of biologics is complex and Biocon, our third-party manufacturer, may encounter difficulties in production. If Biocon encounters such difficulties, our ability to provide supply of EQ001 for clinical trials, our ability to obtain marketing approval, or our ability to obtain commercial supply of our products, if approved, could be delayed or stopped.

We have no experience in biologic manufacturing and do not own or operate, and we do not expect to own or operate, facilities for product manufacturing, storage and distribution, or testing. We are completely dependent on Biocon to fulfill our clinical and commercial supply of EQ001. In May 2017, we entered into an exclusive clinical supply agreement with Biocon and have agreed to enter into an exclusive commercial supply agreement with Biocon in the future. Biocon manufactures EQ001 at its FDA regulated facility in Bangalore, India. However the process of manufacturing biologics is complex, highly-regulated and subject to multiple risks. Manufacturing biologics is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions and higher costs. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials, result in higher costs of drug product and adversely harm our business. Moreover, if the FDA determines that our manufacturer is not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may deny BLA approval until the deficiencies are corrected or we replace the manufacturer in our BLA with a manufacturer that is in compliance.

In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with cGMPs, lot consistency and timely availability of raw materials. Even if we obtain regulatory approval for EQ001 or any future product candidates, there is no assurance that Biocon or other potential manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.

Scaling up a biologic manufacturing process is a difficult and uncertain task, and Biocon may not have the necessary capabilities to complete the implementation and development process of further scaling up production, transferring production to other sites, or managing its production capacity to timely meet product demand. If Biocon is unable to meet our manufacturing requirements, it has the discretion to outsource manufacturing to a third party and the joint steering committee may determine to shift manufacturing to a third party. However, transfer of the manufacturing of biologic products to a new contract manufacturer can be lengthy and involve significant additional costs. Even if we are able to adequately validate and scale-up the manufacturing process for EQ001 with a contract manufacturer, we will still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to us, if at all. In addition, Biocon has certain rights to reacquire exclusive manufacturing rights for EQ001, even after a third party has been engaged following shortfalls by Biocon, which will may make it difficult and expensive to engage any third party manufacturer for EQ001 other than Biocon.

 

26


Table of Contents

We rely, and intend to continue to rely, on third parties to conduct our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, our development programs may be delayed or subject to increased costs or we may be unable to obtain regulatory approval, each of which may have an adverse effect on our business, financial condition, results of operations and prospects.

We do not have the ability to independently conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we will be dependent on third parties to conduct our planned clinical trials of EQ001 and preclinical studies, and any future preclinical studies and clinical trials of any other product candidates. The timing of the initiation and completion of these trials will therefore be partially controlled by such third parties and may result in delays to our development programs. Specifically, we expect CROs, clinical investigators and consultants to play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, we will not be able to control all aspects of their activities. Nevertheless, we are responsible for ensuring that each clinical trial is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, for product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites fail to comply with applicable GCP requirements, the data generated in our clinical trials may be deemed unreliable, and the FDA may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing approval process.

There is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise performs in a substandard manner, or terminates its engagement with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If our clinical trial site terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in such clinical trial unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. In addition, clinical trial investigators for our clinical trial may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit by the FDA. Any such delay or rejection could prevent us from commercializing EQ001 or any future product candidates.

Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors for whom they may also be conducting clinical trials or other biopharmaceutical product development activities that could harm our competitive position. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for EQ001 or any future product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our products.

Even if we receive marketing approval, we may not be able to successfully commercialize EQ001 due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell EQ001 or any future product candidates profitably.

Obtaining coverage and adequate reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of EQ001 or other future products to the payor. There may be significant delays in

 

27


Table of Contents

obtaining such coverage and reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA. Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors, by any future laws limiting pharmaceutical prices and by any future relaxation of laws that presently restrict imports of product from countries where they may be sold at lower prices than in the United States.

There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. One payor’s determination to provide coverage for a drug does not assure that other payors will also provide coverage and adequate reimbursement for the drug. Additionally, a third-party payor’s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy.

Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor’s determination that use of a product is:

 

   

a covered benefit under its health plan;

 

   

safe, effective and medically necessary;

 

   

appropriate for the specific patient;

 

   

cost-effective; and

 

   

neither experimental nor investigational.

We cannot be sure that coverage or reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement will be. Obtaining adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with branded therapeutics and therapeutics administered under the supervision of a physician. Similarly, because our product candidates are physician-administered injectables, separate reimbursement for the product itself may or may not be available. Instead, the administering physician may be reimbursed for providing the treatment or procedure in which our product is used. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.

Reimbursement may impact the demand for, and the price of, any product for which we obtain marketing approval. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy and on what tier of its list of covered drugs, or formulary, it will be placed. The position on a payor’s formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and

 

28


Table of Contents

economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available.

We expect to experience pricing pressures in connection with the sale of EQ001 or any future product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the successful commercialization of new products. Further, the adoption and implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for any approved product.

Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Because we rely on third parties to research and develop and to manufacture EQ001, we must share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.

In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with will likely expect to be granted rights to publish data arising out of such collaboration and any joint research and development programs may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor’s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.

We may wish to acquire rights to future assets through in-licensing or may attempt to form collaborations in the future with respect to future product candidates, but may not be able to do so, which may cause us to alter or delay our development and commercialization plans.

The development and potential commercialization of EQ001 and any future product candidates will require substantial additional capital to fund expenses. We may, in the future, decide to collaborate with biotechnology companies for the development and potential commercialization of product candidates. We will face significant competition in seeking appropriate collaborators. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for any product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view such product candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the following:

 

   

the design or results of clinical trials;

 

   

the likelihood of approval by the FDA or comparable foreign regulatory authorities;

 

29


Table of Contents
   

the potential market for the product candidate;

 

   

the costs and complexities of manufacturing and delivering such product candidate to patients;

 

   

the potential of competing products;

 

   

the existence of uncertainty with respect to our ownership of technology or other rights, which can exist if there is a challenge to such ownership without regard to the merits of the challenge; and

 

   

industry and market conditions generally.

The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our future product candidates or bring them to market and generate product revenue. Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development approval of a product candidate is delayed, the safety of a product candidate is questioned or sales of an approved product candidate are unsatisfactory.

Risks Related to Intellectual Property

If we are unable to obtain or protect intellectual property rights covering our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and we may not be able to compete effectively in our market.

Our success depends in significant part on our and Biocon’s ability to establish, maintain and protect patents and other intellectual property rights with respect to our proprietary technologies, research programs, and product candidates, including EQ001 and operate without infringing the intellectual property rights of others. The patent prosecution process is expensive and time-consuming, and we and our current or future licensors, licensees or partners may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our current and future licensors, licensees or partners will fail to identify patentable aspects of our research or inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Although we enter into confidentiality agreements with parties who have access to patentable aspects of our research and development programs, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, independent contractors, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection on technology relating to our research programs. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors, licensees or partners. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. If our current or future licensors, licensees or partners fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors, licensees or partners are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. There may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent

 

30


Table of Contents

protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns.

The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, that have increased uncertainties as to the ability to enforce patent rights in the future. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, allowing foreign competitors a better opportunity to create, develop and market competing product candidates, or vice versa. We cannot be certain that the claims in our pending patent applications directed to our product candidates such as EQ001 and others, as well as technologies relating to our research programs, will be considered patentable by the United States Patent and Trademark Office, or USPTO, or by patent offices in foreign countries. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors’, licensees’ or partners’ patent rights are highly uncertain. Our and our licensors’, licensees’ or partners’ pending and future patent applications may not result in patents being issued, which protect our technology or products, in whole or in part, or their intended uses, methods of manufacture or formulations, or which effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our licensors, licensees or partners to narrow the scope of the claims of our or our licensors’, licensees’ or partners’ pending and future patent applications, which may limit the scope of patent protection that may be obtained. In the past, we have not always been able to obtain the full scope of patent protection we have initially sought in our patent applications, and as described above and as is typical for most biotechnology patent prosecution, we have been required to narrow or eliminate patent claims as part of the patent prosecution process. In addition, some patent applications that we or our licensors have filed have not resulted in issued patents because we or our licensors have abandoned those patent applications as changes in business and/or legal strategies dictated.

We cannot assure you that all of the potentially relevant prior art—information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention—relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application, and we may be subject to a third party pre-issuance submission of prior art to the USPTO. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may an initiate litigation or opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated, may allow third parties to commercialize our product candidates and compete directly with us, without payment to us, or limit the duration of the patent protection of our technology and products. The legal threshold for initiating such proceedings may be low, so that even proceedings with a low probability of success might be initiated. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Our and our licensors’, licensees’ or partners’ patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology.

Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to our research programs and product candidates such as EQ001. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. In addition, patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar or generic medications.

 

31


Table of Contents

If we are not able to obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for EQ001 or any other product candidates that we may identify, our business may be materially harmed.

Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms where these are available in any countries where we are prosecuting patents. This includes in the United States under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Act, which permits a patent term extension of up to five years beyond the expiration of the patent. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA-approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However the applicable authorities, including the FDA and USPTO, in the United States, and any equivalent foreign regulatory authority, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.

The degree of future protection for our proprietary rights is uncertain, and we cannot predict:

 

   

if and when patents may issue based on our patent applications;

 

   

the scope of protection of any patent issuing based on our patent applications;

 

   

whether the claims of any patent issuing based on our patent applications will provide protection against competitors;

 

   

whether any of the patents we own or license will be found to ultimately be valid and enforceable;

 

   

whether or not third parties will find ways to invalidate or circumvent our patent rights;

 

   

whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications;

 

   

whether the patents of others will not have an adverse effect on our business;

 

   

whether we will develop additional proprietary technologies or products that are separately patentable

 

   

whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose; and/or

 

   

whether the patent applications that we own or in-license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries.

We depend on intellectual property licensed from Biocon and termination of our license could result in the loss of significant rights, which would harm our business.

We currently in-license certain intellectual property that is important to our business from Biocon and, in the future, we may enter into additional agreements that provide us with licenses to valuable intellectual property or technology. We rely to some extent on Biocon to file patent applications and to otherwise protect the intellectual property we license from them. We have limited control over these activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by Biocon have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which Biocon initiates an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us. It is possible that our licensor’s infringement proceeding or defense activities may be less vigorous than had we conducted them ourselves.

 

32


Table of Contents

Furthermore, in-licensed patents may be subject to a reservation of rights by one or more third parties. Further, our existing license with Biocon imposes, and future agreements may also impose, various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, we may be required to pay damages and our licensor may have the right to terminate the license, in which event we would not be able to develop or market the products covered by such licensed intellectual property and our competitors or other third parties might be able to gain access to technologies and products that are identical to ours. Our business would suffer if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any current or future licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor’s rights. Disputes may also arise between us and our licensor regarding intellectual property subject to a license agreement, including those relating to:

 

   

the scope of rights granted under the license agreement and other interpretation-related issues;

 

   

whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement;

 

   

our right to sublicense patent and other rights to third parties under collaborative development relationships;

 

   

whether we are complying with our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates; and

 

   

the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us and our partners.

In addition, intellectual property or technology license agreements, including our existing agreements, are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described below. If we or our licensor fail to adequately protect this intellectual property, our ability to commercialize products could suffer.

Because our programs may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.

In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.

 

33


Table of Contents

In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.

From time to time we may be required to license technologies relating to our therapeutic research programs from additional third parties to further develop or commercialize our product candidates such as EQ001 and/or others. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our product candidates, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations.

Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products.

Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that:

 

   

collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;

 

   

collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;

 

   

collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;

 

   

a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;

 

   

we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;

 

   

collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;

 

   

disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our current or future products or that results in costly litigation or arbitration that diverts management attention and resources;

 

   

collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable current or future products;

 

   

collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and

 

   

a collaborator’s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.

We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third party patent, which might adversely affect our ability to develop and market our products.

We cannot assure you that our operations do not, or will not in the future, infringe existing or future patents. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third party patent and pending application in the United States and abroad that is relevant to our therapeutic research programs or necessary for the commercialization of our product candidates such as EQ001 and/or others in any jurisdiction.

 

34


Table of Contents

Numerous U.S. and foreign patents and pending patent applications exist in our market that are owned by third parties, and there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of EQ001 that we may identify. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our products. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. Patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the United States can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products. As such, there may be applications of others now pending or recently revived patents of which we are unaware, potentially relating to our research programs and product candidates such as EQ001 and others, or their intended uses. These applications may later result in issued patents, or the revival of previously abandoned patents, that will prevent, limit or otherwise interfere with our ability to make, use or sell our products.

The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third party patent or may incorrectly predict whether a third party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.

We cannot provide any assurances that third party patents do not exist which might be enforced against our current technology, including our research programs, product candidates, which include EQ001 and others, their respective methods of use, manufacture and formulations thereof, and could result in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.

If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.

Our commercial success depends, in part, on our ability to develop, manufacture, market and sell EQ001 and other potential future product candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed or misappropriated their intellectual property. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. We cannot assure you that our operations do not, or will not in the future, infringe existing or future patents.

 

35


Table of Contents

There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our products candidates. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. Third parties may assert infringement claims against us based on existing or future intellectual property rights. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure.

If we are found to infringe a third party’s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, and could divert the time and attention of our technical personnel and management, cause development delays, and/or require us to develop non-infringing technology, which may not be possible on a cost-effective basis, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.

We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.

Competitors may infringe our patents, trademarks, copyrights or other intellectual property that relate to our current and future product candidates, including EQ001 and others, their respective methods of use, manufacture and formulations thereof. To counter infringement or unauthorized use, we or our licensor may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we or our licensor assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and the outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent that we own or have licensed is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent’s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products.

 

36


Table of Contents

Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. For example, an unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring EQ001 or other product candidates that we may identify to market. Any of these occurrences could adversely affect our competitive business position, results of operations business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.

Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.

Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.

Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent relating to our research programs and product candidates, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.

We employ individuals who previously worked with other companies, including our competitors or potential competitors. We could in the future be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of current or former employers or competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may become subject to claims that we caused an individual to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a current or former employer or competitor.

While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management and other employees. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, including EQ001, if such technologies or features are found to

 

37


Table of Contents

incorporate or be derived from the trade secrets or other proprietary information of the current or former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition.

Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.

As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents relating to our research programs and product candidates. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or USPTO rules and regulations could increase the uncertainties and costs. Recent patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act), signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, our ability to obtain future patents, and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending all current and future patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. For example, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, some countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our

 

38


Table of Contents

patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our research programs and product candidates such as EQ001 and others as well as their respective methods of use, manufacture and formulations thereof, our competitive position would be adversely affected, as, for example, competitors might be able to enter the market earlier than would otherwise have been the case.

We may rely on trade secret and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patents for some of our technology and product candidates, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position with respect to our research programs and product candidates. Elements of our product candidates, including processes for their preparation and manufacture, may involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market.

Trade secrets and know-how can be difficult to protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We and any third parties with whom we share facilities enter into written agreements that include confidentiality and intellectual property obligations to protect each party’s property, potential trade secrets, proprietary know-how, and information. We further seek to protect our potential trade secrets, proprietary know-how, and information in part, by entering into non-disclosure and confidentiality agreements with parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Moreover, despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain

 

39


Table of Contents

aspects of our products that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.

Trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. Trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. Though our agreements with third parties typically restrict the ability of our advisors, employees, collaborators, licensors, suppliers, third-party contractors and consultants to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. Because from time to time we expect to rely on third parties in the development, manufacture, and distribution of our products and provision of our services, we must, at times, share trade secrets with them. Despite employing the contractual and other security precautions described above, the need to share trade secrets increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed.

We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We or our licensor may be subject to claims that former employees, consultants, independent contractors, collaborators or other third parties have an interest in our patents or other intellectual property as an owner, co-owner, inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

Patent rights are of limited duration. In the United States, the natural expiration of a patent is generally 20 years after its first effective non-provisional filing date. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. A patent term extension based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially.

 

40


Table of Contents

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

We currently do not own any registered trademarks. Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

 

   

others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed;

 

   

we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;

 

   

we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;

 

   

others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;

 

   

it is possible that our pending patent applications will not lead to issued patents;

 

   

issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;

 

   

our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;

 

   

we may not develop additional proprietary technologies that are patentable; and

 

   

the patents of others may have an adverse effect on our business.

Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.

Risks Related to Employee Matters and Managing Growth and Other Risks Related to Our Business

We are highly dependent on the services of our key personnel.

We are highly dependent on the services of our key personnel, Daniel M. Bradbury, who serves as our Chief Executive Officer, Bruce D. Steel, who serves as our President and Chief Business Officer, Krishna R. Polu, M.D., who serves as our Chief Medical Officer, and Stephen Connelly, Ph.D., who serves as our Chief Scientific Officer. Although we have entered into agreements with them regarding their employment, they are not for a specific term and each of them may terminate their employment with us at any time, though we are not aware of any present intention of either of these individuals to leave us.

 

41


Table of Contents

We expect to expand our development, regulatory and operational capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

As of June 30, 2018, we had seven full-time employees. As we advance EQ001 into clinical development, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, quality, regulatory affairs and, if EQ001 or any future product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must:

 

   

identify, recruit integrate, maintain and motivate additional qualified personnel;

 

   

identify and lease additional facilities;

 

   

manage our development efforts effectively, including the initiation and conduct of clinical trials for EQ001 and any future product candidates; and

 

   

improve our operational, financial and management controls, reporting systems and procedures.

Our future financial performance and our ability to develop, manufacture and commercialize EQ001 and any future product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time, to managing these growth activities.

We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain third party contract organizations, advisors and consultants to provide certain services, including assuming substantial responsibilities for the conduct of our planned clinical trials and the manufacture of EQ001 and any future product candidates. We cannot assure you that the services of such third party contract organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by our vendors or consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of our product candidates or otherwise advance our business. We cannot assure you that we will be able to properly manage our existing vendors or consultants or find other competent outside vendors and consultants on economically reasonable terms, or at all.

If we are not able to effectively expand our organization by leasing additional facilities, hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize EQ001 and any future product candidates and, accordingly, may not achieve our research, development and commercialization goals.

Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.

Our industry has experienced a high rate of turnover in recent years. Our ability to compete in the highly competitive biopharmaceuticals industry depends upon our ability to attract, retain and motivate highly skilled and experienced personnel with scientific, medical, regulatory, manufacturing and management skills and experience. We conduct our operations in the Greater San Diego Area and the San Francisco Bay Area, regions that are home to many other biopharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel. We may not be able to attract or retain qualified personnel in the future due to the intense competition for a limited number of qualified personnel among biopharmaceutical companies. Many of the other biopharmaceutical companies against which we compete have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Our competitors may provide higher compensation, more diverse opportunities and/or better opportunities for career advancement. Any or all of these competing factors may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize EQ001 or any future product candidates and to grow our business and operations as currently contemplated.

 

42


Table of Contents

Our employees, clinical trial investigators, CROs, consultants, vendors and any potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of fraud or other misconduct by our employees, clinical trial investigators, CROs, consultants, vendors and any potential commercial partners. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i) FDA laws and regulations or those of comparable foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information, (ii) manufacturing standards, (iii) federal and state health and data privacy, security, fraud and abuse, government price reporting, transparency reporting requirements, and other healthcare laws and regulations in the United States and abroad, (iv) sexual harassment and other workplace misconduct, or (v) laws that require the true, complete and accurate reporting of financial information or data. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We intend to adopt a code of conduct applicable to all of our employees prior to completion of this offering, as well as a disclosure program and other applicable policies and procedures, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional integrity reporting and oversight obligations, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

Our internal information technology systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data and other disruptions, which could result in a material disruption of our development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.

We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third party contractors who have access to our confidential information.

Despite the implementation of security measures, given their size and complexity and the increasing amounts of confidential information that they maintain, our internal information technology systems and those of our third-party CROs and other contractors and consultants are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure or lead to data leakage. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and reputational damage and the further development and commercialization of EQ001 or any future product candidates could be delayed.

While we have not experienced any such system failure, accident or security breach to date, we cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause

 

43


Table of Contents

interruptions in our operations, it could result in a material disruption of our programs and the development of EQ001 or any future product candidates could be delayed. In addition, the loss of clinical trial data for EQ001 or any future product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.

Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.

We and any potential collaborators may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.

As of May 25, 2018, the General Data Protection Regulation, or GDPR, has replaced the Data Protection Directive with respect to the processing of personal data in the European Union. The GDPR imposes several stringent requirements for controllers and processors of personal data, including, for example, higher standards for obtaining consent from individuals to process their personal data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention and secondary use of information, increased requirements pertaining to health data and pseudonymised (i.e., key-coded) data and additional obligations when we contract third party processors in connection with the processing of the personal data. The GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs could increase, and harm our business and financial condition. Failure to comply with the requirements of GDPR and the applicable national data protection laws of the European Union member states may result in fines of up to 20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. To comply with the new data protection rules imposed by GDPR we may be required to put in place additional mechanisms ensuring compliance. This may be onerous and adversely affect our business, financial condition, results of operations and prospects.

European data protection law also imposes strict rules on the transfer of personal data out of the European Union, including to the United States. These obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other requirements or our practices. In addition, these rules are constantly under scrutiny. For example, following a decision of the Court of Justice of the European Union in October 2015, transferring personal data to U.S. companies that had certified as members of the U.S. Safe Harbor Scheme was declared invalid. In July 2016 the European Commission adopted the U.S.-EU Privacy Shield Framework which replaces the Safe Harbor Scheme. However, this Framework is under review and there is currently

 

44


Table of Contents

litigation challenging other E.U. mechanisms for adequate data transfers (i.e., the standard contractual clauses). It is uncertain whether the Privacy Shield Framework and/or the standard contractual clauses will be similarly invalidated by the European courts. We rely on a mixture of mechanisms to transfer personal data from our E.U. business to the United States, and could be impacted by changes in law as a result of a future review of these transfer mechanisms by European regulators under the GDPR, as well as current challenges to these mechanisms in the European courts.

Further, the United Kingdom’s vote in favor of exiting the European Union, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear whether the United Kingdom will enact data protection legislation equivalent to the GDPR and how data transfers to and from the United Kingdom will be regulated.

Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals’ privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.

We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Our headquarters and main research facility are located in the Greater San Diego Area, which in the past has experienced severe earthquakes and fires. If these earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevented us from using all or a significant portion of our headquarters or research facility, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or third party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our ability to conduct our clinical trials, our development plans and business.

U.S. federal income tax reform could adversely affect us.

On December 22, 2017, President Trump signed into law new legislation that significantly revises the Internal Revenue Code of 1986, as amended. The newly enacted federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses generated after December 31, 2017 to 80% of current year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. We do not expect this tax legislation to have a material impact to our current projection of minimal cash taxes for the near future. However, we continue to examine the impact that this tax legislation may have on our business in the longer term. Accordingly, notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the newly enacted federal tax law. The impact of this

 

45


Table of Contents

tax legislation on holders of our common stock is also uncertain and could be adverse. We urge prospective investors to consult with their legal and tax advisors with respect to this legislation and the potential tax consequences of investing in or holding our common stock.

Product liability lawsuits against us could cause us to incur substantial liabilities and could limit our commercialization of any product candidates that we may develop.

We face an inherent risk of product liability exposure related to the testing of EQ001 and any future product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that EQ001 or any future product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in:

 

   

delay or termination of clinical trials;

 

   

decreased demand for any product candidates or products that we may develop;

 

   

injury to our reputation and significant negative media attention;

 

   

withdrawal of clinical trial subjects;

 

   

initiation of investigations by regulators;

 

   

significant costs to defend the related litigation and diversion of management’s time and our resources;

 

   

substantial monetary awards to study subjects or patients;

 

   

product recalls, withdrawals or labeling, or marketing or promotional restrictions;

 

   

loss of revenue; and

 

   

the inability to commercialize any products that we may develop.

We do not currently have product liability insurance but intend to obtain it before we initiate our first clinical trials. However, the amount of insurance that we obtain may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as EQ001 and any future product candidates advance through clinical trials and if we successfully commercialize any products. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.

Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict and may have a significant adverse effect on our business and results of operations.

There have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Among policy makers and payors in the United States there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access and the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.

The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the Affordable Care Act, substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The Affordable Care Act, among other things: (i) introduced a new average manufacturer price definition for drugs and biologics that are inhaled, infused, instilled, implanted or injected and not generally dispensed through retail community pharmacies; (ii) increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and expanded rebate liability from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as well; (iii) established a branded prescription drug fee that pharmaceutical manufacturers of branded prescription drugs must pay to the federal government; (iv) expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to the program; (v) established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts (which

 

46


Table of Contents

through subsequent legislative amendments, will be increased to 70% from 50% starting in 2019) off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D; (vi) extended manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; (vii) expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals, including individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers’ Medicaid rebate liability; (viii) created a licensure framework for follow-on biologic products; and (ix) established a Center for Medicare and Medicaid Innovation at the Centers for Medicare and Medicaid Services (CMS) to test innovative payment and service delivery models to lower Medicare and Medicaid spending.

Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the Affordable Care Act. For example, the Tax Cuts and Jobs Act of 2017 was enacted, which includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate.” Since the enactment of the Tax Cuts and Jobs Act of 2017, there have been additional amendments to certain provisions of the Affordable Care Act, and we expect the current Trump administration and Congress will likely continue to seek to modify, repeal or otherwise invalidate all, or certain provisions of, the Affordable Care Act. It is uncertain the extent to which any such changes may impact our business or financial condition. Congress may consider other legislation to repeal and replace elements of the Affordable Care Act. We continue to evaluate the effect that the Affordable Care Act and its possible repeal and replacement has on our business. It is uncertain the extent to which any such changes may impact our business or financial condition.

Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011 and subsequent laws, which began in 2013 and will remain in effect through 2027, unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. New laws may result in additional reductions in Medicare and other healthcare funding, which may materially adversely affect customer demand and affordability for our products and, accordingly, the results of our financial operations. Also, there has been heightened governmental scrutiny recently over the manner in which pharmaceutical companies set prices for their marketed products, which have resulted in several Congressional inquiries and proposed federal legislation, as well as state efforts, designed to, among other things, bring more transparency to product pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration’s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further, the Trump administration released a “Blueprint,” or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services, or HHS, has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. While some proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Most recently, the Trump administration released a “Blueprint,” or plan, to reduce the cost of drugs. The Trump administration’s Blueprint contains certain measures that the U.S. Department of Health and Human Services is already working to implement. At the state level, individual states in the United States are increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing,

 

47


Table of Contents

including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs, once marketing approval is obtained.

We will be subject to applicable foreign, federal and state fraud and abuse, transparency, government price reporting, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.

Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any future product candidates for which we obtain marketing approval. Our arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may affect the business or financial arrangements and relationships through which we would market, sell and distribute our products. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients’ rights are and will be applicable to our business. The laws that may affect our ability to operate include, but are not limited to:

 

   

the federal Anti-Kickback Statute, which prohibits, among other things, any person or entity from knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term “remuneration” has been broadly interpreted to include anything of value. The Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. Additionally, the intent standard under the Anti-Kickback Statute was amended by the Affordable Care Act such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or FCA;

 

   

federal civil and criminal false claims laws and civil monetary penalty laws, such as the FCA, which imposes significant penalties and can be enforced by private citizens through civil qui tam actions, prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment or approval by the federal government, including federal health care programs, such as Medicare and Medicaid, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes “any request or demand” for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims. Criminal prosecution is also possible for making or presenting a false, fictitious or fraudulent claim to the federal government. Government enforcement agencies and private whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA for a variety of alleged promotional and marketing activities, such as providing free product to customers with the expectation that

 

48


Table of Contents
 

the customers would bill federal programs for the product, providing consulting fees and other benefits to physicians to induce them to prescribe products, engaging in promotion for “off-label” uses, and submitting inflated best price information to the Medicaid Rebate Program;

 

   

HIPAA, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, the Affordable Care Act amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

 

   

HIPAA, as amended by HITECH and its implementing regulations, which imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers and their respective business associates that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions;

 

   

the U.S. federal Food, Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;

 

   

the Public Health Service Act, which prohibits, among other things, the introduction of a biological product into interstate commerce without an approved BLA;

 

   

federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;

 

   

the federal transparency requirements under the Physician Payments Sunshine Act, created under the Affordable Care Act, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children’s Health Insurance Program to annually report to HHS information related to payments and other transfers of value provided to physicians and teaching hospitals and physician ownership and investment interests, including such ownership and investment interests held by a physician’s immediate family members;

 

   

state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by any non-governmental third-party payors, including private insurers; and

 

   

state and foreign laws that require pharmaceutical companies to implement compliance programs and comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; track and report gifts, compensation and other remuneration provided to physicians, other health care providers, and certain health care entities; and/or ensure the registration and compliance of sales and medical personnel. In addition, we may be subject to federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.

We have entered into consulting and scientific advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of EQ001 and any future product candidates, if approved. Because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with

 

49


Table of Contents

providers who may influence the ordering of and use of EQ001 or any future product candidates, if approved, to be in violation of applicable laws.

The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies, healthcare providers and other third parties, including charitable foundations, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities may conclude that our business practices, including our consulting arrangements with physicians, some of whom receive stock options as compensation for services provided, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. Responding to investigations can be time and resource-consuming and can divert management’s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.

Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. If our operations are found to be in violation of any of these laws or any other current or future governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.

We are subject to certain U.S. and certain foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.

U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, collectively, Trade Laws, prohibit, among other things, companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving, directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies, and clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.

Requirements associated with being a public company will increase our costs significantly, as well as divert significant company resources and management attention.

After the completion of this offering, we will be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or the other rules and regulations of the Securities and Exchange Commission, or the SEC, or any securities exchange relating to public companies. Sarbanes-Oxley, as well as rules subsequently adopted by the SEC, and The Nasdaq Global Market to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and

 

50


Table of Contents

regulations in these areas, such as mandatory “say on pay” voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Compliance with the various reporting and other requirements applicable to public companies requires considerable time and attention of management. We cannot assure you that we will satisfy our obligations as a public company on a timely basis.

We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. In addition, as a public company, it may be more difficult or more costly for us to obtain certain types of insurance, including directors’ and officers’ liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified personnel to serve on our board of directors, our board committees or as executive officers.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We, and the third parties with whom we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with whom we share our facilities, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

Risks Related to our Common Stock and this Offering

There has been no prior public market for our common stock, the stock price of our common stock may be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the initial public offering price.

There has been no public market for our common stock prior to this offering. The initial public offering price for our common stock will be determined through negotiations between the underwriters and us and may vary from the market price of our common stock following this offering. If you purchase shares of our common stock in this offering, you may not be able to resell those shares at or above the initial public offering price. An active or liquid market in our common stock may not develop upon the completion of this offering or, if it does develop, it may not be sustainable. The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:

 

   

our operating performance and the performance of other similar companies;

 

51


Table of Contents
   

our ability to enroll subjects in our ongoing and planned clinical trials;

 

   

results from our planned clinical trials and future clinical trials with our current and future product candidates or of our competitors;

 

   

changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock;

 

   

regulatory or legal developments in the United States and other countries;

 

   

the level of expenses related to future product candidates or clinical development programs;

 

   

our ability to achieve product development goals in the timeframe we announce;

 

   

announcements of clinical trial results, regulatory developments, acquisitions, strategic alliances or significant agreements by us or by our competitors;

 

   

the success or failure of our efforts to acquire, license or develop additional product candidates;

 

   

recruitment or departure of key personnel;

 

   

the economy as a whole and market conditions in our industry;

 

   

trading activity by a limited number of stockholders who together beneficially own a majority of our outstanding common stock;

 

   

the expiration of market standoff or contractual lock-up agreements;

 

   

the size of our market float; and

 

   

any other factors discussed in this prospectus.

In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many life sciences companies. Stock prices of many biopharmaceutical companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business.

Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaboration and license agreements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

If we raise funds through collaboration and license agreements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Substantial amounts of our outstanding shares may be sold into the market when lock-up or market standoff periods end. If there are substantial sales of shares of our common stock, the price of our common stock could decline.

The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our directors, executive officers and significant stockholders, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur. After this offering, we will have 16,696,662 outstanding shares of our common stock, based on the number of shares outstanding as of June 30, 2018. All of the shares of common stock sold in this offering will be available for sale in the public market. All of our outstanding shares of common stock are currently restricted from resale as a result of market standoff and

 

52


Table of Contents

“lock-up” agreements, as more fully described in “Shares Eligible for Future Sale.” These shares will become available to be sold 181 days after the date of this prospectus. Shares held by directors, executive officers and other affiliates will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended, or the Securities Act, and various vesting agreements.

After our initial public offering, certain of our stockholders will have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our stockholders, subject to market standoff and lockup agreements. We also intend to register shares of common stock that we have issued and may issue under our employee equity incentive plans. Once we register these shares, they will be able to be sold freely in the public market upon issuance, subject to existing market standoff or lock-up agreements. Jefferies LLC and Leerink Partners LLC may, in their discretion, permit our stockholders to sell shares prior to the expiration of the restrictive provisions contained in those lock-up agreements.

The market price of the shares of our common stock could decline as a result of the sale of a substantial number of our shares of common stock in the public market or the perception in the market that the holders of a large number of shares intend to sell their shares.

If you purchase shares of our common stock in this offering, you will experience substantial and immediate dilution.

If you purchase shares of our common stock in this offering, you will experience substantial and immediate dilution in the pro forma net tangible book value per share of $13.85 per share as of June 30, 2018, based on an assumed initial public offering price of our common stock of $15.00 per share (the midpoint of the price range on the cover page of this prospectus) because the price that you pay will be substantially greater than the pro forma net tangible book value per share of the common stock that you acquire. This dilution is due in large part to the fact that our earlier investors paid substantially less than the initial public offering price when they purchased their shares of our capital stock. You will experience additional dilution upon exercise of options to purchase common stock under our equity incentive plans, upon vesting of options to purchase common stock under our equity incentive plans, if we issue restricted stock to our employees under our equity incentive plans or if we otherwise issue additional shares of our common stock.

We will have broad discretion in the use of the net proceeds of this offering and may not use them effectively or in ways that increase the value of our share price.

We cannot specify with any certainty the particular uses of the net proceeds that we will receive from this offering, but we currently expect such uses will include funding research and development of EQ001 and working capital and other general corporate purposes, including the additional costs associated with being a public company. We will have broad discretion in the application of the net proceeds, including working capital and other general corporate purposes, and you and other stockholders may disagree with how we spend or invest these proceeds. The failure by our management to apply these funds effectively could adversely affect our business and financial condition. Pending their use, we may invest the net proceeds from our initial public offering in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our investors.

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no or only very few securities analysts commence coverage of us, or if industry analysts cease coverage of us, the trading price for our common stock would be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline.

 

53


Table of Contents

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

Upon the completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. In addition, we do not have a risk management program or processes or procedures for identifying and addressing risks to our business in other areas.

We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.

We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:

 

   

being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;

 

   

not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;

 

   

not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;

 

   

reduced disclosure obligations regarding executive compensation; and

 

   

not being required to hold a non-binding advisory vote on executive compensation or obtain stockholder approval of any golden parachute payments not previously approved.

In addition, as an “emerging growth company” the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. We have elected to use this extended transition period under the JOBS Act.

We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenue of at least $1.07 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

We do not intend to pay dividends for the foreseeable future.

We have never declared nor paid cash dividends on our capital stock. We currently intend to retain any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any

 

54


Table of Contents

dividends in the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. Consequently, stockholders must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investment.

The concentration of our stock ownership will likely limit your ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval.

Based upon shares outstanding as of June 30, 2018, our executive officers, directors and the holders of more than 5% of our outstanding common stock, in the aggregate, beneficially owned approximately 98.2% of our common stock, and upon the completion of this offering, that same group, in the aggregate, will beneficially own approximately 66.7% of our common stock, assuming that these holders do not purchase any shares in this offering, no exercise by the underwriters of their option to purchase additional shares, no exercise of outstanding options or warrants and after giving effect to the issuance of shares in this offering. As a result, these stockholders, acting together, will have significant influence over all matters that require approval by our stockholders, including the election of directors and approval of significant corporate transactions. Corporate actions might be taken even if other stockholders, including those who purchase shares in this offering, oppose them. This concentration of ownership might also have the effect of delaying or preventing a change of control of our company that other stockholders may view as beneficial.

Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect at the completion of this offering could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.

Provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the completion of this offering, respectively, may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of incorporation and amended and restated bylaws:

 

   

permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our control);

 

   

provide that the authorized number of directors may be changed only by resolution of the board of directors;

 

   

provide that the board of directors or any individual director may only be removed with cause and the affirmative vote of the holders of at least 66-2/3% of the voting power of all of our then outstanding common stock;

 

   

provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;

 

   

divide our board of directors into three classes;

 

   

require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;

 

   

provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder’s notice;

 

   

do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose);

 

   

provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and

 

   

provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a

 

55


Table of Contents
 

fiduciary duty owed by any of our directors or officers to us or our stockholders, (iii) any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or bylaws, or (iv) any action asserting a claim against us governed by the internal affairs doctrine.

The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 66-2/3% of our then-outstanding common stock.

In addition, as a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision.

These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction.

For information regarding these and other provisions, see “Description of Capital Stock.”

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation will provide that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or amended and restated bylaws or any action asserting a claim against us that is governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, our amended and restated certificate of incorporation will also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. These choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.

We could be subject to securities class action litigation.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

 

56


Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains forward-looking statements. The forward-looking statements are contained principally in the sections entitled “Prospectus Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business.” These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

 

   

our plans to research, develop and commercialize EQ001 and any future product candidates;

 

   

our ability to obtain and maintain regulatory approval of EQ001 in any of the indications for which we plan to develop it;

 

   

our ability to obtain funding for our operations, including funding necessary to commence and complete the clinical trials of EQ001;

 

   

the success, cost, and timing of our product development activities, including our planned clinical trials of EQ001;

 

   

the size of the markets for our product candidates, and our ability to serve those markets;

 

   

our ability to successfully commercialize EQ001;

 

   

the rate and degree of market acceptance of EQ001;

 

   

our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future collaborators;

 

   

regulatory developments in the United States;

 

   

the performance of our third-party service providers, including Biocon and other suppliers and manufacturers;

 

   

the safety, efficacy and market success of competing therapies that are or become available;

 

   

our ability to attract and retain key scientific or management personnel;

 

   

our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;

 

   

our ability to attract and retain collaborators with development, regulatory and commercialization expertise;

 

   

our use of the proceeds from this offering;

 

   

the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and

 

   

our expectations regarding our ability to obtain and maintain intellectual property protection for EQ001 and our ability to operate our business without infringing on the intellectual property rights of others.

In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expects,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. These forward-looking statements reflect our management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this prospectus and are subject to risks and uncertainties. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. We discuss many of the risks associated with the forward-looking statements in this prospectus in greater detail under the heading “Risk Factors.” Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

 

57


Table of Contents

You should carefully read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements.

Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise.

 

58


Table of Contents

USE OF PROCEEDS

We estimate that we will receive net proceeds of approximately $63.0 million (or approximately $72.8 million if the underwriters’ option to purchase additional shares is exercised in full) from the sale of the shares of common stock offered by us in this offering, based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.

A $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase (decrease) the net proceeds to us from this offering by approximately $4.3 million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, a one million share increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us by $13.9 million, assuming the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus) remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

The principal purposes of this offering are to obtain additional capital to support our operations, to create a public market for our common stock and to facilitate our future access to the public equity markets. We anticipate that we will use the net proceeds of this offering as follows:

 

   

approximately $50.0 million to fund research and development of EQ001; and

 

   

the remainder for working capital and other general corporate purposes, including the additional costs associated with being a public company.

We may also use a portion of the net proceeds from this offering to in-license, acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current plans, commitments or obligations to do so.

We believe that the net proceeds from this offering and our existing cash and cash equivalents, together with interest thereon, will be sufficient to fund our currently planned operations for at least the next 24 months, although there can be no assurance in that regard. In particular, we expect that the net proceeds from this offering will allow us to fund a Phase 1b/2 clinical trial of EQ001 for aGVHD, a Phase 2 clinical trial of EQ001 for cGVHD and a proof-of-concept clinical trial of EQ001 for severe asthma.

Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering, or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual use of the net proceeds will vary depending on numerous factors, including the progress, cost and results of our preclinical and clinical development programs, our ability to obtain additional financing, and other factors described under “Risk Factors” in this prospectus, as well as the amount of cash used in our operations and any unforeseen cash needs. We may find it necessary or advisable to use the net proceeds for other purposes, and our management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds from this offering.

Pending their use, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.

 

59


Table of Contents

DIVIDEND POLICY

We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant, and subject to the restrictions contained in any future financing instruments.

 

60


Table of Contents

CAPITALIZATION

The following table sets forth our cash and cash equivalents and our capitalization as of June 30, 2018 as follows:

 

   

on an actual basis;

 

   

on a pro forma basis to reflect (1) the conversion of $9.4 million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the completion of this offering into an aggregate of 808,661 shares of our common stock based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on September 30, 2018, (2) the issuance by us of 242,237 shares of common stock upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and (3) the filing of our amended and restated certificate of incorporation immediately prior to the completion of this offering; and

 

   

on a pro forma as adjusted basis to give further effect to our issuance and sale of 4,670,000 shares of common stock in this offering based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.

The pro forma and pro forma as adjusted information below is illustrative only, and our cash and cash equivalents and capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in conjunction with our financial statements and the related notes included in this prospectus and the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section and other financial information contained in this prospectus.

 

     AS OF JUNE 30, 2018
(unaudited)
 
     ACTUAL     PRO FORMA     PRO
FORMA
AS
ADJUSTED(1)
 

Cash and cash equivalents

   $ 6,626,443       6,626,443       69,672,943  
  

 

 

   

 

 

   

 

 

 

Convertible promissory notes, including related party

     10,517,896              

Stockholders’ (deficit) equity:

      

Common stock, $0.0001 par value; 43,100,000 shares authorized at June 30, 2018 (unaudited);

      

10,975,764 shares issued and outstanding as of June 30, 2018, which includes 267,690 shares of restricted common stock subject to a right of repurchase

     127       231       698  

Additional paid-in capital

     10,405       11,742,869       74,788,902  

Accumulated deficit

     (5,604,033     (5,604,033     (5,604,033
  

 

 

   

 

 

   

 

 

 

Total stockholders’ (deficit) equity

     (5,593,501     6,139,067       69,185,567  

Total capitalization

   $ 4,924,395       6,139,067       69,185,567  
  

 

 

   

 

 

   

 

 

 

 

(1)    Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, additional paid-in capital, total stockholders’ equity and total capitalization by approximately $4.3 million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of one million shares in the number of shares offered by us at the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase (decrease) each of cash and cash equivalents, additional paid-in capital, total stockholders’ equity and total capitalization by approximately $13.9 million, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

61


Table of Contents

A $1.00 increase in the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus) would decrease the number of shares of our common stock issued on conversion of our convertible promissory notes and issued to Biocon (and therefore the number of shares to be outstanding after this offering) by 65,851 shares. A $1.00 decrease in the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase the number of shares of our common stock issued on conversion of our convertible promissory notes and issued to Biocon (and therefore the number of shares to be outstanding after this offering) by 74,919 shares. Because the closing date of this offering will occur after September 30, 2018, the convertible promissory notes will continue to accrue interest at a rate of 6% per annum and additional shares of our common stock will be issued upon conversion of this additional accrued interest.

The number of shares in the table above excludes, as of June 30, 2018:

 

   

107,084 shares of common stock issuable upon the exercise of outstanding options as of June 30, 2018, each at an exercise price of $0.05 per share;

 

   

2,229,773 shares of common stock reserved for future issuance under our 2018 Plan which will become effective in connection with the execution and delivery of the underwriting agreement for this offering (including 1,040,000 new shares plus the number of shares (not to exceed 1,189,773 shares) (i) that remain available for grant of future awards under our 2017 Plan which shares will be added to the shares reserved under the 2018 Plan upon its effectiveness and (ii) any shares underlying outstanding stock awards granted under our 2017 Plan that expire, or are forfeited, cancelled, withheld or reacquired, as more fully described under the terms of the 2018 Plan described in the section titled “Executive Compensation—Equity Benefit Plans”); and

 

   

343,275 shares of common stock reserved for issuance under the ESPP, which will become effective in connection with the execution and delivery of the underwriting agreement for this offering.

 

62


Table of Contents

DILUTION

If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering.

As of June 30, 2018, we had a historical net tangible book deficit of $(5.6) million, or $(0.51) per share of common stock. Our historical net tangible book deficit per share represents the amount of our total tangible assets less total liabilities, divided by the total number of shares of common stock outstanding (including 267,690 shares of restricted common stock which are subject to a right of repurchase by us as of June 30, 2018) at June 30, 2018.

After giving effect to the (i) conversion of $9.4 million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the completion of this offering into an aggregate of 808,661 shares of our common stock based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on September 30, 2018, and (ii) the issuance by us of 242,237 shares of common stock upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), our pro forma net tangible book value as of June 30, 2018 is $6.14 million, or $0.31 per share of our common stock.

After giving further effect to the sale of 4,670,000 shares of common stock that we are offering at the initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June 30, 2018 is $69.2 million, or approximately $1.15 per share. This amount represents an immediate increase in pro forma net tangible book value of $0.84 per share to our existing stockholders and an immediate dilution in pro forma net tangible book value of approximately $13.85 per share to new investors participating in this offering.

Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution:

 

 

 

Assumed initial public offering price per share

     $ 15.00  

Historical net tangible book deficit per share at June 30, 2018, before giving effect to this offering

   $ (0.51  

Pro forma increase in historical net tangible book value per share attributable to conversion of convertible promissory notes and issuance of shares of common stock pursuant to anti-dilution rights

     0.82    
  

 

 

   

Pro forma net tangible book value per share at June 30, 2018, before giving effect to this offering

     0.31    

Increase in pro forma net tangible book value per share attributable to investors participating in this offering

     0.84    
  

 

 

   

Pro forma as adjusted net tangible book value per share after this offering

       1.15  
    

 

 

 

Dilution per share to new investors participating in this offering

     $ 13.85  
    

 

 

 

 

 

Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase (decrease) the pro forma as adjusted net tangible book value per share after this offering by approximately $0.07, and dilution in pro forma net tangible book value per share to new investors by approximately $0.93, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us.

 

63


Table of Contents

An increase of one million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase our pro forma as adjusted net tangible book value per share after this offering by approximately $0.06 and decrease the dilution to investors participating in this offering by approximately $(0.06) per share, assuming that the assumed initial public offering price remains the same, and after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. Similarly, a decrease of one million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease the pro forma as adjusted net tangible book value per share after this offering by approximately $(0.08) and increase the dilution to investors participating in this offering by approximately $0.08 per share, assuming that the assumed initial public offering price remains the same, and after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us.

If the underwriters exercise their option to purchase additional shares of our common stock in full in this offering, the pro forma as adjusted net tangible book value after the offering would be $1.20 per share, the increase in pro forma as adjusted net tangible book value per share to existing stockholders would be $0.05 per share and the dilution per share to new investors would be $(0.05) per share, in each case assuming an initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus).

The following table summarizes on a pro forma as adjusted basis as of June 30, 2018, the number of shares of common stock purchased or to be purchased from us, the total consideration paid or to be paid to us in cash and the average price per share paid by existing stockholders for shares issued prior to this offering and the price to be paid by new investors in this offering. The calculation below is based on the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. As the table below shows, investors participating in this offering will pay an average price per share substantially higher than our existing stockholders paid.

 

 

 

     SHARES PURCHASED     TOTAL CONSIDERATION     AVERAGE
PRICE PER
SHARE
 
     NUMBER      PERCENT     AMOUNT      PERCENT  

Existing stockholders

     12,026,662        72.0   $ 9,897,265        12.4   $ 0.82  

Investors participating in this offering

     4,670,000        28.0       70,050,000        87.6       15.00  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total

     16,696,662        100.0   $ 79,947,265        100.0   $ 4.79  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

 

 

Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus) would increase (decrease) total consideration paid by new investors, total consideration paid by all stockholders and the average price per share paid by all stockholders by $4.7 million, $4.7 million and $0.28, respectively, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.

Similarly, a one million share increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by investors participating in this offering, total consideration paid by all stockholders and the average price per share paid by all stockholders by approximately $15 million, $15 million and $0.58, respectively, assuming the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus) remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.

The foregoing tables and calculations exclude:

 

   

107,084 shares of common stock issuable upon the exercise of outstanding options as of June 30, 2018, each at an exercise price of $0.05 per share;

 

64


Table of Contents
   

2,229,773 shares of common stock reserved for future issuance under our 2018 Plan which will become effective in connection with the execution and delivery of the underwriting agreement for this offering (including 1,040,000 new shares plus the number of shares (not to exceed 1,189,773 shares) (i) that remain available for grant of future awards under our 2017 Plan which shares will be added to the shares reserved under the 2018 Plan upon its effectiveness and (ii) any shares that underlying outstanding stock awards granted under our 2017 Plan that expire, or are forfeited, cancelled, withheld or reacquired, as more fully described under the terms of the 2018 Plan described in the section titled “Executive Compensation—Equity Benefit Plans”); and

 

   

343,275 shares of common stock reserved for issuance under the ESPP, which will become effective in connection with the execution and delivery of the underwriting agreement for this offering.

We may choose to raise additional capital through the sale of equity or convertible debt securities due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent we issue additional shares of common stock or other equity or convertible debt securities in the future, there will be further dilution to investors participating in this offering.

 

65


Table of Contents

SELECTED FINANCIAL DATA

The following selected statement of operations data for the period March 16, 2017 (inception) through December 31, 2017 and the balance sheet data as of December 31, 2017 are derived from our audited financial statements appearing elsewhere in this prospectus. The selected statement of operations data for the period March 16, 2017 (inception) through June 30, 2017 and the six months ended June 30, 2018 and the balance sheet data as of June 30, 2018 have been derived from our unaudited financial statements included elsewhere in this prospectus. In our opinion, these unaudited financial statements have been prepared on a basis consistent with our audited financial statements and contain all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of such financial data. You should read these data together with our financial statements and related notes appearing elsewhere in this prospectus and the information in “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Our historical results are not necessarily indicative of the results to be expected in the future, and our operating results for the interim periods are not necessarily indicative of the results that may be expected for any other interim periods or any future year.

 

     PERIOD
MARCH 16,
2017
(INCEPTION)
THROUGH

DECEMBER 31,
2017
    PERIOD
MARCH 16,
2017
(INCEPTION)
THROUGH

JUNE 30,
2017
    SIX MONTHS
ENDED

JUNE 30,
2018
 
 
           (unaudited)  

Statement of Operations Data:

      

Operating expenses:

      

Research and development

   $ 1,333,721     $ 801,364     $ 1,202,917  

General and administrative

     378,328       187,173       958,691  
  

 

 

   

 

 

   

 

 

 

Total operating expenses

     1,712,049       988,537       2,161,608  
  

 

 

   

 

 

   

 

 

 

Loss from operations

     (1,712,049     (988,537     (2,161,608

Interest expense

     379,385       7,069       1,108,197  

Interest income

                 (29,926

Change in fair value of Biocon anti-dilution right

     170,440       18,887       102,280  
  

 

 

   

 

 

   

 

 

 

Net loss and comprehensive loss

   $ (2,261,874   $ (1,014,493   $ (3,342,159
  

 

 

   

 

 

   

 

 

 

Net loss per share, basic and diluted (1)

   $ (0.28   $ (0.19   $ (0.31
  

 

 

   

 

 

   

 

 

 

Weighted average shares of common stock outstanding, basic and diluted (1)

     8,030,029       5,307,596       10,711,788  
  

 

 

   

 

 

   

 

 

 

Pro forma net loss per share, basic and diluted (unaudited) (1)

   $ (0.21     $ (0.18
  

 

 

     

 

 

 

Pro forma weighted average shares of common stock outstanding, basic and diluted (unaudited) (1)

     8,300,749         11,644,175  
  

 

 

     

 

 

 

 

(1)    See Note 2 to our financial statements appearing elsewhere in this prospectus for an explanation of the method used to calculate the basic and diluted net loss per common share, unaudited proforma basic and diluted net loss per share and the number of shares used in the computation of the per share amounts.

 

66


Table of Contents

 

 

     AS OF
DECEMBER 31,

2017
    AS OF
JUNE 30,

2018
 
 
           (unaudited)  

Balance Sheet Data:

    

Cash and cash equivalents

   $ 7,103,553     $ 6,626,443  

Working capital

     6,580,546       5,788,958  

Total assets

     7,151,443       6,728,134  

Convertible promissory notes, including related party

     8,058,866       10,517,896  

Accumulated deficit

     (2,261,874     (5,604,033

Total stockholders’ deficit

   $ (2,252,085   $ (5,593,501

 

 

 

67


Table of Contents

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with “Selected Financial Data” and our financial statements and related notes included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under “Risk Factors” and elsewhere in this prospectus. You should carefully read the “Risk Factors” section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled “Special Note Regarding Forward-Looking Statements.”

Overview

We are a biotechnology company leveraging deep understanding of immunobiology to develop products for severe immuno-inflammatory disorders with high unmet medical need. Our initial product candidate, EQ001, is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of Teff cells. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. Therefore, we believe EQ001 may have broad therapeutic utility in treating a large and diverse set of severe immuno-inflammatory diseases.

Our pipeline is focused on developing EQ001 as a potentially best-in-class, disease modifying treatment for multiple severe immuno-inflammatory disorders. We plan to initiate a Phase 1b/2 clinical trial of EQ001 for the treatment of aGVHD in early 2019, and expect top-line data from the Phase 1b part of this trial within 12 months of initiation. Our IND with the FDA for aGVHD was accepted in July 2018. Additionally, in the first half of 2019, we plan to commence a Phase 2 clinical trial of EQ001 for the treatment of cGVHD, initiate a proof-of-concept clinical trial for the treatment of severe asthma and select one or more additional indications for future development. In May 2017, we acquired U.S. and Canadian rights to itolizumab from Biocon. Itolizumab is approved in India for the treatment of moderate to severe plaque psoriasis and is marketed by Biocon as ALZUMAb.

Since our inception, substantially all of our efforts have been focused on organizing and staffing our company, business planning, raising capital, in-licensing rights to EQ001, conducting preclinical research, filing our initial IND and preparing to commence clinical development of EQ001. We have not generated any revenue from product sales or otherwise. From inception through June 30, 2018, we have raised gross proceeds of $9.4 million from the issuance of convertible promissory notes to fund our operations. We have incurred losses since our inception. Our net losses were $2.3 million for the period March 16, 2017 (inception) through December 31, 2017, and $1.0 million and $3.3 million for the period March 16, 2017 (inception) through June 30, 2017 and the six months ended June 30, 2018, respectively. As of December 31, 2017 and June 30, 2018, we had an accumulated deficit of $2.3 million and $5.6 million, respectively. Substantially all of our operating losses resulted from expenses incurred in connection with our research and preclinical activities and general and administrative costs associated with our operations.

We expect to continue to incur significant expenses and increasing losses into the foreseeable future. We anticipate our expenses will increase substantially as we continue our research and development activities, including the planned clinical development of EQ001, seek regulatory approval for and potentially commercialize any approved product candidates, hire additional personnel, protect our intellectual property, and incur additional costs associated with being a public company.

We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for EQ001 or any future product candidate, which will not be for at least the next several years, if ever. Accordingly, until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through a combination of equity offerings, debt financings, and collaboration and license agreements. However, we may not be able to secure additional financing or enter into such other arrangements in a timely manner or on favorable terms, if at all. Our failure to raise capital or

 

68


Table of Contents

enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, reduce or terminate our research and development programs or other operations, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Financial Overview

Revenue

We currently have no products approved for sale, and we have not generated any revenues to date. In the future, we may generate revenue from collaboration or license agreements we may enter into with respect to our product candidates, as well as product sales from any approved product, which approval we do not expect to occur for at least the next several years, if ever. Our ability to generate product revenues will depend on the successful development and eventual commercialization of EQ001 and any future product candidates. If we fail to complete the development of EQ001 or any future product candidates in a timely manner, or to obtain regulatory approval for our product candidates, our ability to generate future revenue and our results of operations and financial position would be materially adversely affected.

Research and Development Expenses

Research and development expenses primarily consist of costs associated with our research and preclinical activities, and clinical development of EQ001. Our research and development expenses include:

 

   

salaries and related overhead expenses, which include stock-based compensation and benefits, for personnel in research and development functions;

 

   

external research and development expenses incurred under arrangements with third parties, such as consultants and advisors for research and development;

 

   

costs related to in-licensing rights to EQ001 from Biocon;

 

   

costs of services performed by third parties, such as contract research organizations, or CROs, that conduct research and development and preclinical activities on our behalf; and

 

   

costs related to preparing and filing an IND with the FDA.

We expense research and development costs as incurred. From our inception through June 30, 2018, we have incurred $2.5 million in research and development expenses. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received.

Our direct research and development expenses consist principally of external costs, such as fees paid to CROs and consultants in connection with our preclinical and clinical development.

We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of EQ001 and potentially expand the number of indications for which we are developing EQ001. The successful development of EQ001 is highly uncertain. At this time, due to the inherently unpredictable nature of preclinical and clinical development, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of EQ001 or the period, if any, in which material net cash inflows from EQ001 may commence. Clinical development timelines, the probability of success, and development costs can differ materially from expectations.

Completion of clinical trials may take several years or more, and the length of time generally varies according to the type, complexity, novelty, and intended use of a product candidate. The cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others:

 

   

per patient clinical trial costs;

 

   

the number of clinical trials required for approval;

 

   

the number of sites included in our clinical trials;

 

   

the length of time required to enroll suitable patients;

 

69


Table of Contents
   

the number of doses that patients receive;

 

   

the number of patients that participate in our clinical trials;

 

   

the drop-out or discontinuation rates of patients in our clinical trials;

 

   

the duration of patient follow-up;

 

   

potential additional safety monitoring or other studies requested by regulatory agencies;

 

   

the number and complexity of procedures, analyses and tests performed during our clinical trials;

 

   

the costs of procuring drug product for our clinical trials;

 

   

the phase of development of the product candidate; and

 

   

the efficacy and safety profile of the product candidate.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation and benefits, and consulting fees for executive, finance, and accounting functions. Other significant costs include legal fees relating to patent and corporate matters, insurance, travel and facility costs.

We anticipate that our general and administrative expenses will increase in future periods, reflecting an expanding infrastructure and increased professional fees associated with being a public company. In addition, if we obtain regulatory approval for any product candidate, we expect to incur expenses associated with building the infrastructure to commercialize such product. However, we do not expect to receive any such regulatory approval for at least the next several years, if ever.

Interest Expense

Interest expense consists of interest on our convertible promissory notes.

Change in Fair Value of Biocon Anti-Dilution Right

We have committed to issue to Biocon additional shares of common stock to maintain Biocon’s ownership interest at 19.5% of our fully-diluted capitalization until we have received aggregate cumulative gross proceeds from sales of equity securities of $15 million, or the Biocon Anti-Dilution Right. The Biocon Anti-Dilution Right has been classified as a liability in the accompanying balance sheet. The Biocon Anti-Dilution Right is recorded at fair value using the Precedent Transaction Method. The fair value of the Biocon Anti-Dilution Right is re-measured at each financial reporting period with any changes in fair value being recognized as a component of other income (expense). The Biocon Anti-Dilution Right will be satisfied in full upon the issuance of additional shares of common stock to Biocon in connection with the completion of this initial public offering.

Results of Operations

Comparison of the Period March 16, 2017 (Inception) Through June 30, 2017 and the Six Months Ended June 30, 2018

The following table sets forth our results of operations for the period March 16, 2017 (inception) through June 30, 2017 and the six months ended June 30, 2018:

 

     FOR THE PERIOD
MARCH 16, 2017
(INCEPTION)
THROUGH
JUNE 30,

2017
     SIX MONTHS
ENDED
JUNE 30,

2018
     PERIOD-TO-PERIOD
CHANGE
 
     (unaudited)         

Research and development

   $ 801,364      $ 1,202,917      $ 401,553  

General and administrative

     187,173        958,691        771,518  

Interest expense

     7,069        1,108,197        1,101,128  

Change in fair value of Biocon anti-dilution right

     18,887        102,280        83,393  

 

70


Table of Contents

Research and Development Expenses

Research and development expenses were $0.8 million and $1.2 million for the period ended June 30, 2017 and the six months ended June 30, 2018, respectively. The $0.4 million increase in research and development expenses during this period was primarily due to an increase in costs related to our translational research and the filing of our IND. The increase in research and development expense included consulting expenses of $0.5 million, $0.4 million of expenses related to preclinical research, salary expenses of $0.3 million, and other expenses of $0.1 million, offset by a decrease in license expense of $0.9 million under our collaboration and license agreement with Biocon, or the Biocon License.

General and Administrative Expenses

General and administrative expenses were $0.2 million and $1.0 million for the period ended June 30, 2017 and the six months ended June 30, 2018, respectively. The $0.8 million increase in general and administrative expenses during this period was related to a $0.4 million increase in salary expenses, a $0.3 million increase in consulting expenses, and a $0.1 million increase in other general and administrative expenses.

Interest Expense

Interest expense was $7,069 for the period ended June 30, 2017 compared to $1.1 million for the six months ended June 30, 2018. Interest expense consisted of non-cash interest expense, including accretion of debt premium and issuance costs in relation to our outstanding convertible promissory notes.

Change in Fair Value of Biocon Anti-Dilution Right

Change in fair value of the Biocon Anti-Dilution Right was $18,887 and $0.1 million for the period ended June 30, 2017 and the six months ended June 30, 2018, respectively. The increase in change in fair value of the Biocon Anti-Dilution Right primarily reflects the increase in the likelihood that the right will be settled.

Period March 16, 2017 (Inception) Through December 31, 2017

The following table sets forth our results of operations for the period March 16, 2017 (inception) through December 31, 2017:

 

     FOR THE PERIOD
MARCH 16, 2017
(INCEPTION)
THROUGH
DECEMBER 31,
2017
 

Operating expenses:

  

Research and development

   $ 1,333,721  

General and administrative

     378,328  

Other expense:

  

Interest expense

     379,385  

Change in fair value of Biocon anti-dilution right

     170,440  

Research and Development Expenses

Research and development expenses were $1.3 million for the period ended December 31, 2017. Research and development expenses included $0.8 million to acquire the rights under the Biocon License, $0.3 million in salary and consulting expenses and $0.2 million related to translational research activities.

General and Administrative Expenses

General and administrative expenses were $0.4 million for the period ended December 31, 2017. General and administrative expenses included $0.2 million in legal fees, $0.1 million in consulting expenses, and $0.1 million in overhead and other expenses.

 

71


Table of Contents

Interest Expense

Interest expense was $0.4 million for the period ended December 31, 2017. Interest expense consisted of non-cash interest expense, including accretion of debt premium and issuance costs in relation to our convertible promissory notes.

Change in Fair Value of Biocon Anti-Dilution Right

Change in fair value of the Biocon Anti-Dilution Right was $0.2 million for the period ended December 31, 2017. The change in fair value of the Biocon Anti-Dilution Right primarily reflects the increase in the likelihood that the right will be settled.

Liquidity and Capital Resources

Sources of Liquidity

From inception through June 30, 2018, we have raised gross proceeds of $9.4 million from the issuance of convertible promissory notes to fund our operations. The convertible promissory notes accrue interest at a rate of 6% per year, mature two years from their issuance and automatically convert into equity securities sold pursuant to a qualified financing transaction from which we receive total gross proceeds of not less than $15.0 million at a conversion price equal to 90% of the per share price paid by investors for such securities if the closing of the financing occurs on or prior to the six month anniversary of the issuance of convertible promissory notes, or at a conversion price equal to 80% of the per share price paid by investors for such securities if the closing of the financing occurs after the six month anniversary of the issuance of convertible promissory notes. If we consummate a change in control prior to the conversion or repayment in full of the convertible promissory notes, we shall pay each holder in cash in an amount equal to the outstanding principal amount of the convertible promissory note plus any unpaid accrued interest on the original principal plus 1.0 times the outstanding principal amount of the note.

As of June 30, 2018, we had $6.6 million in cash and cash equivalents.

Funding Requirements

We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance clinical development of EQ001. In addition, we expect to incur additional costs associated with operating as a public company following the completion of this offering. We expect that our primary uses of capital will be third-party clinical research and development services, manufacturing, clinical trial costs, legal and other regulatory compliance expenses, compensation and related expenses, and general overhead costs.

We expect that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our currently planned operations for at least the next 24 months. In particular, we expect that the net proceeds from this offering will allow us to fund a Phase 1b/2 clinical trial of EQ001 for aGVHD, a Phase 2 clinical trial of EQ001 for cGVHD and a proof-of-concept clinical trial of EQ001 for severe asthma. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Furthermore, our operating plans may change, and we may need additional funds sooner than planned. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress in these trials is uncertain. Because the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of EQ001 or whether, or when, we may achieve profitability.

Our future capital requirements will depend on many factors, including:

 

   

the initiation, progress, timing, costs and results of our planned clinical trials for EQ001;

 

   

the number and scope of indications we decide to pursue for EQ001 development;

 

   

the cost, timing and outcome of regulatory review of any BLA we may submit for EQ001;

 

   

the costs and timing of manufacturing for EQOO1, if approved;

 

   

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;

 

72


Table of Contents
   

our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of EQ001;

 

   

the costs associated with being a public company;

 

   

the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;

 

   

the extent to which we acquire or in-license other product candidates and technologies; and

 

   

the cost associated with commercializing EQ001, if approved for commercial sale.

Until such time as we can generate substantial product revenues, if ever, we expect to finance our cash needs through a combination of equity offerings, debt financings, and collaboration and license agreements. The sale of additional equity or convertible debt could result in additional dilution to our stockholders and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. The incurrence of debt financing would result in debt service obligations and the governing documents would likely include operating and financing covenants that would restrict our operations. If we raise additional funds through collaboration or license agreements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or other operations. Any of these actions could have a material effect on our business, financial condition and results of operations. We have experienced net losses and negative cash flows from operating activities since our inception and expect to continue to incur net losses into the foreseeable future. We had an accumulated deficit of $2.3 million and $5.6 million at December 31, 2017 and June 30, 2018, respectively. We expect operating losses and negative cash flows to continue for at least the next several years as we continue to incur costs related to the development of EQ001. We have prepared cash flow forecasts which indicate that based on our expected operating losses and negative cash flows, there is substantial doubt about our ability to continue as a going concern without raising additional capital within 12 months after the date that the financial statements for the six months ended June 30, 2018, are issued.

The following table sets forth the cash flow from operating, investing and financing activities for the period March 16, 2017 (inception) through December 31, 2017 and the period March 16, 2017 (inception) through June 30, 2017 and the six months ended June 30, 2018:

 

     FOR THE PERIOD
MARCH 16, 2017
(INCEPTION)
THROUGH
DECEMBER 31,
2017
    FOR THE PERIOD
MARCH 16, 2017
(INCEPTION)
THROUGH
JUNE 30,

2017
    SIX MONTHS
ENDED
JUNE 30,
2018
 
           (unaudited)  

Net cash used in operating activities

   $ (662,201   $ (183,541   $ (2,057,681

Net cash used in investing activities

     (2,199           (21,823

Net cash provided by financing activities

     7,767,953       1,000,000       1,602,394  
  

 

 

   

 

 

   

 

 

 

Net (decrease) increase in cash and cash equivalents

   $ 7,103,553     $ 816,459     $ (477,110
  

 

 

   

 

 

   

 

 

 

Comparison of the Period March 16, 2017 (Inception) Through June 30, 2017 and the Six Months Ended June 30, 2018

Operating Activities

Net cash used in operating activities was $0.2 million during the period ended June 30, 2017 as compared to $2.1 million during the six months ended June 30, 2018. The increase in cash used in operating activities of $1.9 million was primarily the result of the increase in operating expenses in 2018.

 

73


Table of Contents

Investing Activities

Net cash used in investing activities was $0 and $21,823 during the period ended June 30, 2017 and the six months ended June 30, 2018, respectively. The increase in cash used in investing activities of $21,823 was the result of the purchase of property and equipment.

Financing Activities

Net cash provided by financing activities was $1.0 million during the period ended June 30, 2017 as compared to $1.6 million during the six months ended June 30, 2018. The increase in cash provided by financing activities of $0.6 million was the result of an increase in convertible promissory notes issued in 2018.

Period March 16, 2017 (Inception) Through December 31, 2017

Operating Activities

Net cash used in operating activities was $0.7 million during the period ended December 31, 2017. The cash used in operating activities was primarily the result of wages, consulting fees, legal fees, and preclinical research expenses.

Investing Activities

Net cash used in investing activities was $2,199 during the period ended December 31, 2017. The cash used in investing activities was the result of the purchase of property and equipment.

Financing Activities

Net cash provided by financing activities was $7.8 million during the period ended December 31, 2017. The cash provided by financing activities was the result of the issuance of convertible promissory notes.

Contractual Obligations

The following summarizes our significant contractual obligations as of June 30, 2018:

 

 

 

     PAYMENT DUE BY PERIOD  

CONTRACTUAL OBLIGATIONS

   TOTAL      LESS THAN 1
YEAR
     1-3 YEARS      3-5
YEARS
     AFTER 5
YEARS
 

Operating leases

   $ 214,255      $ 57,522      $ 156,733      $      $  

Principal under convertible notes payable, excluding accrued interest

     9,407,474               9,407,474                

Interest payable on convertible promissory notes

     336,550               336,550        
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
   $ 9,958,279      $ 57,522      $ 9,900,757      $      $  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

 

In addition, we have payment obligations under the Biocon License that are contingent upon future events such as our achievement of specified development and commercial milestones and are required to make certain cash royalty payments upon our achievement of target levels of revenue from sales of EQ001, if approved. As of June 30, 2018, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales and, therefore, any related payments are not included in the table above. For additional information regarding the Biocon License, including our payment obligations thereunder, see Note 5 to our financial statements appearing elsewhere in this prospectus.

We enter into agreements in the normal course of business with vendors for research studies and other services and products for operating purposes. We have not included these payments in the table of contractual obligations above since the contracts are cancelable at any time by us, generally upon written notice to the vendor, and therefore we believe that our non-cancelable obligations under these agreements are not material.

 

74


Table of Contents

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules, and similarly did not and do not have any holdings in variable interest entities.

Critical Accounting Policies and Significant Judgement and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in Note 2 to our financial statements appearing elsewhere in this prospectus, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.

Accrued Research and Development Expense

We are required to estimate our expenses resulting from obligations under contracts with vendors, consultants and CROs, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. We reflect research and development expenses in our financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of the preclinical or clinical study as measured by the timing of various aspects of the study or related activities. We determine accrual estimates through review of the underlying contracts along with preparation of financial models taking into account discussions with research and other key personnel as to the progress of studies, or other services being conducted. During the course of a study, we adjust our rate of expense recognition if actual results differ from our estimates.

Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.

Stock-Based Compensation Expense

Stock-based compensation expense represents the cost of the grant date fair value of employee and non-employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. We estimate the fair value of stock option grants using the Black-Scholes option-pricing model.

The Black-Scholes option-pricing model requires the use of subjective assumptions, including the risk- free interest rate, the expected stock price volatility, the expected term of stock options, the expected dividend yield and the fair value of the underlying common stock on the date of grant. See Note 7 to our financial statements included elsewhere in this prospectus for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted during the six months ended June 30, 2018. No stock options were granted during the period ended December 31, 2017. Total employee and non-employee stock-based compensation expense related to unvested stock option grants not yet recognized as of December 31, 2017 and June 30, 2018 was $0 and $10,343, respectively, and the weighted-average period over which these grants are expected to vest is 0.0 and 3.73 years, respectively.

 

75


Table of Contents

Determination of the Fair Value of Common Stock

We are required to estimate the fair value of the common stock underlying our stock-based awards when performing the fair value calculations using the Black-Scholes option pricing model. Because our common stock is not currently publicly traded, the fair value of the common stock underlying our stock-based awards has been determined on each grant date by our board of directors, with input from management, considering our most recently available third-party valuation of common shares. All options to purchase shares of our common stock are intended to be granted with an exercise price per share no less than the fair value per share of our common stock underlying those options on the date of grant, based on the information known to us on the date of grant.

Our determination of the value of our common stock was performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants, or AICPA, Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation, or the AICPA Practice Aid. In addition, our board of directors considered various objective and subjective factors to determine the fair value of our common stock, including:

 

   

valuations of our common stock performed by independent third-party valuation specialists;

 

   

the anticipated capital structure that will directly impact the value of the currently outstanding securities;

 

   

our results of operations and financial position;

 

   

the status of our research and development efforts;

 

   

the composition of, and changes to, our management team and board of directors;

 

   

the lack of liquidity of our common stock as a private company;

 

   

our stage of development and business strategy and the material risks related to our business and industry;

 

   

external market conditions affecting the life sciences and biotechnology industry sectors;

 

   

U.S. and global economic conditions;

 

   

the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public offering, or IPO, or a sale of our company, given prevailing market conditions; and

 

   

the market value and volatility of comparable companies.

The AICPA Practice Aid prescribes several valuation approaches for setting the value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an enterprise to its common stock. The cost approach establishes the value of an enterprise based on the cost of reproducing or replacing the property less depreciation and functional or economic obsolescence, if present. The income approach establishes the value of an enterprise based on the present value of future cash flows that are reasonably reflective of our company’s future operations, discounting to the present value with an appropriate risk adjusted discount rate or capitalization rate. The market approach is based on the assumption that the value of an asset is equal to the value of a substitute asset with the same characteristics.

In accordance with the AICPA Practice Aid, we considered the various methods for allocating the enterprise value to determine the fair value of our common stock at the valuation date. Under the option pricing method, or OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The value of the common stock is inferred by analyzing these options. The PWERM is a scenario-based analysis that estimates the value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class.

To date, we have utilized the precedent transaction method to value our common stock which derives the implied equity value for one type of equity security from a contemporaneous transaction involving another type of equity security. We determined the precedent transaction method was the most appropriate method given the early stage of our company. The OPM was then used to allocate the enterprise value to our common stock as it was determined to be the most reliable given the expectation of various potential liquidity outcomes and the difficulty of selecting and supporting appropriate exit values given our stage of development and financial position.

 

76


Table of Contents

There are significant judgments and estimates inherent in the determination of the fair value of our common stock. These judgments and estimates include assumptions regarding our future operating performance, the time to completing an IPO or other liquidity event and the determination of the appropriate valuation methods. If we had made different assumptions, our stock-based compensation expense, net loss and net loss per common share could have been significantly different.

Following the closing of this offering, the fair value of our common stock will be equal to the closing price of our common stock as reported on the date of the grant.

Based on the assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), the intrinsic value of stock options outstanding as of June 30, 2018 would have been $1.6 million, of which $0.0 million and $1.6 million would relate to stock options that were vested and unvested, respectively, at that date.

We intend to perform a retrospective reassessment to determine the stock-based compensation expense related to stock options granted in the third quarter of 2018.

Biocon Anti-Dilution Right

We classify the Biocon Anti-Dilution Right as a liability on our balance sheets, as an obligation exists to issue a variable number of shares and that obligation is not indexed to our own stock. The Biocon Anti-Dilution Right was initially recorded at fair value on date of grant and is subsequently remeasured to fair value at each balance sheet date. The Biocon Anti-Dilution Right is estimated at fair value using the Precedent Transaction Method. The Precedent Transaction Method was applied to solve for our enterprise value under two scenarios: with the Biocon Anti-Dilution Right and without the Biocon Anti-Dilution Right. The resulting difference in the enterprise value under these two scenarios is the estimated fair value of the Biocon Anti-Dilution Right. The estimates used to determine our enterprise value are based, in part, on subjective assumptions and could differ materially in the future. Fluctuations in the fair value of the Biocon Anti-Dilution Right are impacted by unobservable inputs, most significantly our estimated fair value and probability of achieving different financing scenarios. If we do not receive proceeds from an equity financing, the fair value of the Biocon Anti-Dilution Right would be zero. Alternatively, if an equity financing results in gross proceeds of $15.0 million or greater, the fair value of the Biocon Anti-Dilution Right could be as high as $3.6 million. Changes in our estimated fair value and the probability of achieving different financing scenarios can have a significant impact on the fair value of the Biocon Anti-Dilution Right. Changes in fair value of the Biocon Anti-Dilution Right are reported in Other expense (income) in the statement of operations and comprehensive loss.

Other Information

Net Operating Loss and Research and Development Tax Credit Carryforwards

As of December 31, 2017, we had federal and California tax net operating loss carryforwards of $0.9 million and $0.9 million, respectively, which begin to expire in 2037 and 2037, respectively, unless previously utilized. As of December 31, 2017, we also had federal and California research and development tax credit carryforwards of $23,355 and $14,344, respectively. The federal research and development tax credit carryforwards will begin to expire in 2037. The California research and development tax credit carryforwards are available indefinitely.

Utilization of the net operating losses and credits may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code of 1986, as amended. The annual limitation may result in the expiration of our net operating losses and credits before we can use them. We have recorded a valuation allowance on all of our deferred tax assets, including our deferred tax assets related to our net operating loss and research and development tax credit carryforwards.

In December 2017, the Tax Cuts and Jobs Act, or the 2017 Tax Act, was enacted. The 2017 Tax Act includes a number of changes to existing U.S. tax laws that impact us, most notably a reduction of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017. The 2017 Tax Act also provides for the acceleration of depreciation for certain assets placed in service after September 27, 2017 as well as prospective

 

77


Table of Contents

changes beginning in 2018, including limitations on the deductibility of interest and capitalization of research and development expenditures. We measure deferred tax assets and liabilities using enacted tax rates that will apply in the years in which the temporary differences are expected to be recovered or paid. Accordingly, our deferred tax assets and liabilities were remeasured to reflect the reduction in the U.S. corporate income tax rate from 35% to 21%, resulting in a $198,687 increase in tax expense for the period ended December 31, 2017 and a corresponding $198,687 decrease in net deferred tax assets as of December 31, 2017. The impact was offset by our valuation allowance.

Recent Accounting Pronouncements

See Note 2 to our financial statements included elsewhere in this prospectus for information concerning recent accounting pronouncements.

Quantitative and Qualitative Disclosures About Market Risk

Our cash and cash equivalents and short-term investments as of June 30, 2018 consisted of cash and money market funds. We are exposed to market risk related to fluctuations in interest rates and market prices. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the short-term nature of the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our financial condition and/or results of operation.

Our convertible promissory notes bear interest at a fixed rate and therefore have minimal exposure to changes in interest rates.

Internal Control Over Financial Reporting

Pursuant to Section 404(a) of the Sarbanes-Oxley Act of 2002, as amended, commencing the year following our first annual report required to be filed with the SEC, our management will be required to report on the effectiveness of our internal control over financial reporting. To comply with the requirements of being a reporting company under the Securities Exchange Act of 1934, as amended, we will need to implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff, as well as potentially upgrade our information technology systems.

 

78


Table of Contents

BUSINESS

Overview

We are a biotechnology company leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Our initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cells, or Teff cells. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. Therefore, we believe EQ001 may have broad therapeutic utility in treating a large and diverse set of severe immuno-inflammatory diseases.

 

LOGO

 

*

We are focusing our initial development efforts on EQ001 for the treatment of the diseases underlined in bold and are evaluating additional T cell driven indications for future development.

Our pipeline is focused on developing EQ001 as a potentially best-in-class, disease modifying treatment for multiple severe immuno-inflammatory disorders. We plan to initiate a Phase 1b/2 clinical trial of EQ001 for the treatment of acute graft-versus-host disease, or aGVHD, in early 2019, and expect top-line data from the Phase 1b part of this trial within 12 months of initiation. Our Investigational New Drug application, or IND, with the U.S. Food and Drug Administration, or FDA, for aGVHD was accepted in July 2018. Additionally, in the first half of 2019, we plan to commence a Phase 2 clinical trial of EQ001 for the treatment of chronic graft-versus-host disease, or cGVHD, initiate a proof-of-concept clinical trial for the treatment of severe asthma and select one or more additional indications for future development. The following chart summarizes our initial development plans for EQ001.

 

LOGO

 

*

The Phase 1 clinical trial was conducted by Biocon, our collaboration partner, in Australia.

 

79


Table of Contents

We have an ongoing translational biology program to assess the therapeutic utility of EQ001 in additional indications where the CD6 pathway and activated Teff cells play an important role in the pathogenesis of T cell mediated diseases. Our selection of additional indications is driven by our analysis of the scientific, translational, clinical and commercial rationale for advancing EQ001 into further development.

We acquired U.S. and Canadian rights to itolizumab in May 2017, pursuant to a collaboration and license agreement with Biocon SA (subsequently assigned to Biocon Limited, or together, Biocon). Following completion of a Phase 3 clinical trial conducted outside of North America, itolizumab was approved in India for the treatment of moderate to severe plaque psoriasis and is marketed by Biocon as ALZUMAb. Today, India is the only jurisdiction where ALZUMAb is approved or marketed. EQ001 has been evaluated in one Phase 1 clinical trial to date, conducted by Biocon, and is not approved for commercial sale in the United States or Canada. Our partnership with Biocon includes an exclusive supply agreement for clinical and commercial drug product of EQ001. Biocon currently manufactures EQ001 at commercial scale in a facility regulated by the FDA.

We have assembled an accomplished team that includes veterans in drug discovery, development and commercialization. Notably, our Chief Executive Officer is Daniel Bradbury, who has over 30 years of experience bringing novel medicines to market. Mr. Bradbury was the President, Chief Executive Officer and Director of Amylin Pharmaceuticals, Inc., where during his 18 year tenure he oversaw the development and launch of three first-in-class medicines, which ultimately led to the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb.

Strategy

Our goal is to become a leading, fully-integrated biotechnology company focused on therapies for severe immuno-inflammatory disorders. To achieve our goal, we intend to:

 

   

Advance EQ001 through clinical development for aGVHD and cGVHD. Based on our deep and proprietary understanding of the CD6 pathway, our translational research, and prior clinical studies targeting CD6, we are initially focused on aGVHD and cGVHD as our initial indications for the clinical development of EQ001. We plan to initiate a Phase 1b/2 clinical trial of EQ001 as a front-line therapy concomitant with steroids in patients with aGVHD in early 2019 and expect top-line data from the Phase 1b part of this trial within 12 months of initiation. In this trial we will assess safety, overall response rate, survival, steroid taper and incidence of cGVHD. In addition, we plan to initiate a Phase 2 clinical trial of EQ001 in patients with cGVHD in the first half of 2019.

 

   

Develop EQ001 for the treatment of severe asthma. We believe that the unique mechanism of action of EQ001 has the potential to treat severe asthma patients characterized by an immunophenotype of low Th2 and high Th17 and who consequently have a poor response to high dose inhaled and/or oral steroids. There are a sizeable number of these patients who are underserved by currently available therapies and for which there are no FDA-approved biologic or other targeted treatments. We plan to initiate a proof-of-concept clinical trial of EQ001 in patients with severe asthma in the first half of 2019.

 

   

Expand clinical development of EQ001 into additional indications based on our translational biology program. We will continue to conduct studies in animal models and human tissue, as well as EQ001 clinical trials, to help inform the selection of additional indications for further development. In the first half of 2019, we intend to select a fourth indication for future EQ001 development.

 

   

Opportunistically expand our pipeline of product candidates. We will leverage the collective talent within our organization to opportunistically acquire or in-license other high-value therapeutic programs that may complement our core strategy or have the potential for synergistic therapeutic benefit in combination with EQ001.

 

   

Build a commercial infrastructure. If approved, we intend to commercialize EQ001 ourselves in indications that can be efficiently targeted using a specialty sales force, such as aGVHD and cGVHD. For other indications, we intend to commercialize EQ001 either independently or through collaborations with other parties.

 

80


Table of Contents

Understanding the Basis of Our Approach: The Role of CD6 in Autoimmunity

The role of the immune system is to defend the body against foreign organisms and cells, including cancerous cells, and in doing so must distinguish accurately between self- and non-self entities, a process called tolerance. Autoimmunity is an immune response directed against the body’s own healthy cells and tissues, and is the underlying process in many inflammatory diseases. Autoimmunity results from a loss of tolerance caused in part by an imbalance in the relationship between Teff and regulatory T cells, or Treg cells, see Figure 1.

 

LOGO

Figure 1: Autoimmunity is a balancing act. Treg cells play an important role in preventing Teff cells targeting of self-antigens that can lead to autoimmunity and tissue destruction.

Immune checkpoints are critical regulators of immune activation pathways and can be either co-stimulatory (activating) or co-inhibitory (inhibiting). These pathways are crucial for maintaining immune balance and preventing autoimmunity. Immune checkpoints have been targeted for the treatment of cancers, where blockade of co-inhibitory signals results in an increased immune response against tumor cells, and such approaches have resulted in the approval of several novel therapeutics. We believe co-stimulatory checkpoints are attractive drug targets for the treatment of immuno-inflammatory diseases and more recently they have become a focus of development in immuno-inflammation. However, identifying checkpoints that allow for the selective modulation of Teff cell activity while preserving Treg cell activity in order to promote tolerance has proven challenging.

CD6 is a novel, tightly-regulated, co-stimulatory receptor that plays an integral role in modulating T cell activation, proliferation, differentiation and trafficking. CD6 serves as a key checkpoint in regulating Teff cells that are central to autoimmune responses. Preclinical and clinical studies have shown that blockade of CD6 co-stimulation leads to selective inhibition of pathogenic Teff cell activity and trafficking, while preserving the important regulatory function of Treg cells. Such studies and new insights into the underlying biology highlight CD6 as a resurgent target for the treatment of multiple immuno-inflammatory diseases.

CD6 is predominantly expressed on T helper cells, or Th cells, and regulates T cell responses. Once activated, naïve Th cells become Teff cells and carry out specialized immune functions depending on their specific phenotype such as Th1, Th2 and Th17 cells. The expression levels of CD6 are increased on Teff cells and are associated with autoreactivity in cells, leading to autoimmunity. Conversely, the lack of expression of CD6 on Treg cells suggests that CD6 is not required for their regulatory function. See Figure 2.

 

81


Table of Contents

LOGO

Figure 2: CD6, a novel, tightly-regulated, co-stimulatory checkpoint central to autoimmunity. The expression levels of CD6 are increased on Teff cells such as Th1, Th2 and Th17 cells and are associated with autoreactivity. Conversely, the lack of expression of CD6 on Treg cells suggests that CD6 is not required for their regulatory function.

Activated leukocyte cell adhesion molecule, or ALCAM, is a ligand of CD6 that is expressed on hematopoietic tissues such as antigen-presenting cells, where it is important for immune synapse formation and optimal co-stimulation. Binding of ALCAM to domain-3 of CD6 leads to the downstream activation of several mitogen activated protein kinase, or MAPK, pathways related to T cell activation, proliferation, differentiation and survival. See Figure 3.

Studies have shown that co-stimulation of CD6 by ALCAM enhances T cell activation and resulted in a five-fold increase in IL-2 receptor mediated Teff cell proliferation. Moreover, CD6 co-stimulation promotes a preferentially pro-inflammatory response and increased secretion of Teff cytokines IFN-g, TNF-a and IL-6 . Additionally, CD6 co-stimulation leads to increased expression and activation of validated targets for the treatment of immuno-inflammatory disease, including signal transducer and activator of transcription 3, or STAT3, and retinoid acid-related orphan receptor, or RORgt, the master transcriptional regulator of Th17 cells. This results in increased expression of IL-23R and high levels of IL-17, both markers of pathogenic Th17 cell activity and resistance to steroid treatment, which is a first-line therapy in many immuno-inflammatory diseases. Th17 cells play an especially important role in autoimmunity: Th17 and Treg cells are reciprocally regulated and thus an increase in Th17 cells and associated cytokines leads to suppression of Treg cell activity and loss of tolerance. Studies have shown that co-stimulation through CD6 is superior to CD28 co-stimulation in driving Th17 cell development and thus represents an attractive target for the treatment of immuno-inflammatory diseases, especially those resistant or refractory to steroid treatment.

ALCAM is also expressed on non-hematopoietic tissues such as the vascular endothelium, blood-brain barrier, skin, lung and gut, where it selectively facilitates the trafficking of T cells expressing CD6. Studies have shown that, in the presence of the pro-inflammatory cytokine IFN-g, the expression of ALCAM is increased on a number of cell types, suggesting an important dual role for CD6 and ALCAM in autoimmune responses.

 

82


Table of Contents

LOGO

Figure 3: CD6 co-stimulation drives pathogenic T cell development and activity. (1) Co-stimulation occurs through the binding of ALCAM to domain-3 of CD6, (2) leading to synergistic activation resulting in a five-fold increase in IL-2 receptor mediated Teff cell proliferation. (3) Co-stimulation through CD6 promotes a pro-inflammatory response including the activation of pSTAT3 and RORgt resulting in increased expression of IL-23R and pathogenic secretion of several pro-inflammatory cytokines. (4) ALCAM expressed on tissues such as the skin, lung and gut, selectively facilitates the trafficking of T cells expressing CD6. (5) Th17 cells and associated cytokines suppress Treg cell activity leading to a high Th17:Treg ratio.

Modulation of Teff Cell Activity with EQ001

EQ001 is a humanized antibody that selectively binds to human CD6 and inhibits the interaction of CD6 with its ligand ALCAM, preventing co-stimulation, and thereby reducing Teff cell activity and trafficking. Preclinical studies of EQ001 have shown that blockade of CD6 leads to a reduction in Teff cell proliferation and downregulation of several important pathways that contribute to Teff cell development. Critically, CD6 blockade leads to the downregulation of important cellular pathways that control inflammation, including STAT3 and RORgt. The downregulation of these pathways is accompanied by decreased secretion of the pro-inflammatory Teff cytokines IFN-g, TNF-a, IL-6 and IL-17. See Figure 4.

 

LOGO

Figure 4: Blockade of CD6 reduces T cell activation, proliferation and differentiation. (A-C) Human peripheral blood mononuclear cells, or PBMC, were stimulated in Th17 polarizing conditions in the presence of EQ001 or a control antibody. On Day 3 post-stimulation, EQ001 reduced the percentage of activated T cells, shown in panel A, and the percentage of proliferating T cells, shown

 

83


Table of Contents

in panel B. EQ001 also reduced levels of pSTAT3, a Th17 signature transcription factor, shown in panel C. (D and E) PBMC cells were re-stimulated with PMA-Ionomycin for five hours and analyzed for expression of intracellular cytokine IL-17A and another Th17 signature transcription factor RORgt. Day 6 representative histogram of RORgt is shown in panel D and the corresponding dot plots of RORgt and IL-17A gated on lymphocyte scatter and CD3 expressing T cells are shown in panel E. (F) Splenocytes were isolated from mice treated with anti-CD6D1, a mouse surrogate anti-CD6 antibody, or a control antibody and stimulated ex vivo. Anti-CD6D1 treatment resulted in a substantially reduced response to stimulation and the splenocytes secreted lower levels of pro-inflammatory T cell cytokines IL-17A, IL-6, IFN-g and TNF-a, shown in panel F. *p<0.05.

Additionally, inhibiting the binding of ALCAM to CD6, either by anti-CD6 monoclonal antibodies or by deletion of the gene expressing CD6, modulates lymphocyte trafficking and results in reduced Teff cell infiltration into inflamed tissues. Based on its broad multi-modal mechanism, we believe EQ001 has the potential to treat multiple immuno-inflammatory diseases including those that are resistant or refractory to existing therapies. See Figure 5.

 

LOGO

Figure 5: Blockade of CD6 by EQ001 inhibits Teff cell activation, proliferation, differentiation and trafficking. (1) EQ001 selectively binds to domain-1 of CD6 and inhibits the interaction of ALCAM, preventing co-stimulation (2) and thereby reducing Teff cell proliferation. (3) Blockade of CD6 downregulates pSTAT and RORgt resulting in reduced expression of IL-23R and secretion of pro-inflammatory Teff cytokines IFN-g, TNF-a, IL-6 and IL-17. (4) Additionally, inhibiting the binding of ALCAM to CD6, reduces lymphocyte trafficking into inflamed tissues. (5) Reduction of Treg cells inhibiting Th17 cells restores immune balance and promotes tolerance.

Experimental Evidence for Targeting CD6 in Immuno-Inflammation

We are leveraging our deep understanding of immunobiology and translational biology program to assess the importance of CD6 in disease pathogenesis and therapeutic utility of CD6 blockade using well-characterized model systems and human tissues. As a leader in the field of CD6 immunobiology, our objective is to inform selection of indications in specific disease areas that are likely to respond to CD6 targeting by EQ001.

The role of CD6 in pathogenic Teff cell development has been independently validated in vivo both genetically and pharmacologically in experimental models of immuno-inflammation, as summarized in Table 1.

 

84


Table of Contents

Table 1: Published, independent studies supporting the role of CD6 in immuno-inflammatory diseases.

 

 

 

ANIMAL MODEL/INDICATIONS

 

METHOD

 

RESULTS & CONCLUSIONS

Experimental Autoimmune Uveitis

 

Zhang et al. 2018

 

Journal of Autoimmunity

  CD6-/- mouse†  

 

  Decreased retinal inflammation (80% reduction in the mean histopathological scores)*

 

  Decreased autoreactive T cell responses (>70% reduction in Th1 and Th17 cytokine production)*

 

  Mouse anti-CD6D1**  

 

  Decreased retinal inflammation (80% reduction in the mean histopathological scores)*

 

  Decreased T cell infiltration in the eyes (79% reduction in infiltrating T cell numbers)*

 

 

Experimental OVA-induced Asthma

 

Kim et al. 2018

 

The Journal of Translational Immunology

 

  ALCAM-/- mouse†  

 

  Decreased pro-inflammatory Th2 cell responses*

 

  Decreased T cell trafficking into the lung

 

 

 

Mouse anti-CD6D1**

 

 

 

  Decreased T cell proliferation*

 

 

Experimental Autoimmune Encephalomyelitis

 

Multiple Sclerosis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis

 

Li et al. 2017

 

Proceedings of the National Academy of Sciences

 

  CD6-/- mouse†  

 

  Decreased clinical disease scores*

 

  Decreased pathogenic T cell responses (significant reduction in Th1 and Th17 cytokine production)*

 

  Blocked pathogenic T cell infiltration into the CNS

 

  Mouse anti-CD6D1**  

 

  Decreased clinical disease scores*

 

  Decreased Th1 and Th17 cell responses*

 

  Decreased inflammation and demyelination in the CNS

 

 

Imiquimod-induced Psoriasis

 

Consuegra-Fernandez et al. 2017

 

Cellular and Molecular Immunology

 

 

 

CD6-/- mouse†

 

 

 

  Decreased skin inflammation (epidermal thickness)*

 

  Decreased pro-inflammatory cytokines*

 

  Decreased Th17 cell differentiation in vitro*

 

 

Experimental OVA-induced Allergy

 

Kim et al., 2018

 

Clinical & Experimental Immunology

 

 

ALCAM-/-

 

 

 

  Decreased pro-inflammatory Th2 cell responses*

 

  Decreased disturbance of intestinal tissue

 

  Decreased Th2 cytokines (IL-4, IL-5 and IL-13)

 

 

 

anti-mouse CD6

 

 

 

  Decreased T cell proliferation*

 

 

 

 

CD6-/- is a mouse with a homozygous null gene deletion of CD6. ALCAM -/- is a mouse with a homozygous null gene deletion of ALCAM.

*

Represents a statistically significant result (p<0.05).

**

Mouse surrogate anti-CD6 antibody.

In addition to these published studies, we have demonstrated the activity of EQ001 (or anti-CD6D1, its mouse surrogate anti-CD6 antibody) in a number of disease models. Described below are findings from studies in models of several key immuno-inflammatory disease areas, including GVHD, inflammatory bowel disease and neuroinflammation, which illustrate blockade of CD6 inhibiting pathogenic T cell activity. We believe the results of these published studies and our internal translational program support our approach in targeting CD6 in the treatment of immuno-inflammation.

 

85


Table of Contents

Treatment with EQ001 Attenuates GVHD

GVHD is a multisystem disease commonly associated with hematopoietic stem cell transplants in which transplanted donor lymphocytes attack host tissues. GVHD is predominantly driven by T cells that express high levels of CD6. Prior clinical studies have implicated cells expressing CD6 in the development of GVHD, suggesting that CD6 is a highly relevant target to this disease.

The Hu-PBMC-NSG model is a humanized xenograft mouse model of GVHD generated by injection of human peripheral blood mononuclear cells, or Hu-PBMC, into an NSG mouse, which is an immunodeficient mouse. In this well-characterized, gold standard model, disease is aggressively driven by a human T cell response against host tissue. The severity of disease is assessed by survival, weight loss, prevalence of human cells in peripheral blood and trafficking of human cells into tissues. EQ001 can be assessed in this model because human T cells are present. In the model, we tested a high dose of EQ001 (300μg/dose), a low dose of EQ001 (60μg), and as comparator controls, two CTLA4-Ig based modulators of CD28 co-stimulation, Nulojix (belatacept) and Orencia (abatacept), which are both FDA-approved drugs that also target activated Teff cells.

Treatment with both high and low dose EQ001 resulted in no deaths by Day 35 compared to the 90% mortality seen in vehicle treated control animals. See Figure 6. This is a direct result of inhibition of human T cell proliferation and infiltration into tissues. Animals treated with EQ001 demonstrated a profound reduction in human T cells at Days 10 and 35 with a prevalence of 0.2% (both days), whereas vehicle treated animals exhibit a prevalence of 17.5% human T cells by Day 10. The ability of EQ001 to prevent T cell establishment compared highly favorably to both Nulojix and Orencia.

 

86


Table of Contents

LOGO

Figure 6: Treatment with EQ001 attenuates GVHD. (A) Kaplan-Meier survival curve of mice treated with either EQ001, Nulojix, Orencia or vehicle prior to injection with human PBMCs. Mice treated with EQ001 experienced 100% survival. (B and C) Proportion of human T cells detected in the periphery was statistically significantly lower in Hu-NSG-PBMC mice treated with EQ001 vs. vehicle control at Day 10 (B) and remains low at Day 35 (C). (E and F) CD3 staining in lung tissue shows infiltration of T cells. No statistically significant presence of T cells was detected in the lungs of mice treated with EQ001. ****p<0.0001 and **p<0.01.

Treatment with Anti-CD6 Antibody Inhibits Inflammatory Bowel Disease

Inflammatory bowel disease, or IBD, such as Crohn’s disease and ulcerative colitis, is characterized by chronic inflammation resulting from persistent activation of immune cells in the gut. Activated Teff cells, such as Th17, which express CD6, are associated with IBD and its severity. Data from human genetic studies have demonstrated an association between CD6 and the development and severity of IBD. Inhibition of Teff cells, such as Th17 cells, have been shown to reduce IBD disease severity and progression, confirming the relevance of the CD6 pathway in this disease.

The 2,4,6-trinitrobenzenesulfonic acid, or TNBS, model is a standard model of IBD that is driven by Th1 and Th17 cell responses. Exposure to TNBS leads to inflammation, diarrhea, tissue destruction and shortening of the colon. In

 

87


Table of Contents

this model, we tested blockade of CD6 using anti-CD6D1, which binds to the same CD6 domain-1 in mice that EQ001 binds on human CD6. As comparator controls, separate groups of mice were treated with either anti-IL-12p40 (a therapeutic mechanism of action similar to Stelara, an FDA-approved therapy for Crohn’s disease), dexamethasone or vehicle. Blockade of CD6 inhibits the TNBS-induced immune response as exhibited by decreases in serum and tissue pro-inflammatory cytokines, see Figure 7. This is accompanied by statistically significant decreases in inflammation-mediated colon shrinkage, histological measures of necrosis, edema and mucosal inflammation, and diarrhea/loose stool. The results of anti-CD6D1 treatment were comparable to high dose anti-IL-12p40 treatment, another inhibitor of the Th1 and Th17 cell pathways. Results of this model are relevant not only to IBD but also other immuno-inflammatory gut conditions, including GVHD.

 

LOGO

Figure 7: Treatment with anti-CD6D1 inhibits inflammatory bowel disease. (A and B) Anti-CD6D1 treatment decreased disease scores as measured by (A) a reduction in body weight loss and (B) the statistically significant reduction of colon weight to length ratio compared to vehicle control. (C) CD6 blockade decreased serum pro-inflammatory cytokines. (D and E) Tissue pathology scores were statistically significantly improved by anti-CD6D1 treatment. Red line denotes width of colon mucosa, delineating mucosal hyperplasia (tissue thickening). Hyperplasia was greatest in vehicle animals and was reduced in anti-CD6D1, anti-IL-12p40 and dexamethasone treated animals. (F and G) Anti-CD6D1 treatment reduced trafficking of T cells into the colon, as demonstrated by CD3, a pan T cell marker. ****p<0.0001, ***p<0.001, **p<0.01 and *p<0.05.

 

88


Table of Contents

Treatment with Anti-CD6 Antibody Reduces Neuroinflammation

CD6 is overexpressed on activated Th17 cells isolated from multiple sclerosis patients and has been implicated in the pathogenesis of neuroinflammation. On the vascular endothelium of the blood-brain-barrier, ALCAM is upregulated by IFN-g, providing a potential mechanism for the entry of T cells expressing CD6 into the central nervous system, or CNS. Increased levels of CD6 are correlated to increased infiltration of Teff cells into the CNS and the development of neuroinflammation.

Experimental autoimmune encephalomyelitis, or EAE, is a well-established mouse model of neuroinflammation that is commonly used to study disorders such as multiple sclerosis and neuromyelitis optica. In this model, an autoimmune response leads to T cell infiltration across the blood-brain barrier and into the tissues of the CNS (including spinal cord and optic nerve). Mice with EAE exhibit muscle weakness progressing to paralysis due to increasing neuronal damage. Blockade of CD6 by anti-CD6D1 results in reduced disease severity as demonstrated by statistically significant improvements in disease model scores (i.e., less weakness and paralysis), decreased autoimmune T cell activity and decreased T cell trafficking, resulting in decreased demyelination of the spinal cord, see Figure 8.

 

LOGO

Figure 8: Treatment with anti-CD6D1 attenuates neuroinflammation. (A) Antagonism of the CD6 pathway during EAE induction results in statistically significant decreases in disease model scores. (B) Isolated T cells stimulated ex vivo exhibit a substantially reduced response to stimulation, secreting lower levels of important T cell cytokines IL-17A, IL-6, IFN-g, and TNF-a. (C) Amelioration of EAE

 

89


Table of Contents

is supported by decreased cellular trafficking into the spinal cord and reduced demyelination. Anti-CD6D1 treated animals appear similar to normal, disease-free animals. *p<0.01.

Itolizumab: Clinically Validated in the Treatment of Immuno-Inflammatory Diseases

Itolizumab has shown activity in clinical trials in patients with rheumatoid arthritis and psoriasis. Itolizumab has been approved for the treatment of moderate to severe plaque psoriasis in India and is marketed by Biocon under the brand name ALZUMAb.

Psoriasis is a chronic immuno-inflammatory disease characterized by inflammation and aberrant hyperproliferation of keratinocytes. The pathogenesis of psoriasis is complex and numerous components of the immune system play a role, including Th17 cells and associated cytokines, most notably IL-17.

Biocon has completed three clinical studies of ALZUMAb in India in patients with rheumatoid arthritis and chronic plaque psoriasis, with a total of 333 patients exposed to ALZUMAb at dose levels ranging from 0.2 mg/kg to 1.6 mg/kg. An overview of these clinical studies is presented in Table 2.

Table 2: Overview of the Biocon clinical development program of itolizumab

 

 

 

PHASE

  

STUDY NUMBER

   NUMBER OF
PATIENTS
  

DOSE LEVELS
(MG/KG)

   DURATION
(WEEKS)
  

INDICATION

2

   CLG007/BIO004/
RA/CD6/2006
   70    0.2, 0.4, and 0.8    12    Rheumatoid arthritis

2

   T1hAb-CT1-001-07    40    0.4, 0.8, and 1.6    8    Chronic plaque psoriasis

3

   T1hAb-CT3-002-09 (TREAT-PLAQ)    223    0.4 and 1.6    52    Chronic plaque psoriasis

 

 

In addition to the clinical trials described above, 35 patients have received itolizumab in prior clinical trials conducted in Cuba for the treatment of rheumatoid arthritis.

The Phase 3 TREAT-PLAQ trial was a randomized, double-blind, placebo controlled, multi-arm, multi-dose, one-way crossover design studying 223 psoriasis patients. Results from this trial demonstrated that ALZUMAb had a favorable safety and tolerability profile and durable efficacy as measured by psoriasis area and severity index, or PASI. The primary end point was the proportion of patients with at least 75% improvement in PASI score, or PASI 75, at Week 12.

 

90


Table of Contents

In Arm A patients received ALZUMAb at 0.4 mg/kg weekly for the first four weeks, then 1.6 mg/kg every two weeks until Week 12; in Arm B patients received ALZUMAb at 1.6 mg/kg every two weeks until Week 12. At Week 12 only 2.3% of patients receiving placebo achieved PASI 75 compared to 27.0% and 36.4% of patients achieving PASI 75 by Week 12 in Arms A (p value = 0.0172) and B (p value = 0.0043), respectively. At Week 12, patients in the placebo arm crossed over to treatment with ALZUMAb. Following Week 28, patients that responded to ALZUMAb (those that reached PASI 75) were re-randomized to one of two groups, either cessation of drug (n =40) or maintenance therapy (n = 39, with 1.6mg/kg of drug given every 3 weeks). Prior ALZUMAb treatment produced a durable effect in patients that were no longer given drug, with 53% of patients maintaining PASI 75 and 75% at PASI 50. 67% of patients that continued ALZUMAb treatment had maintained PASI 75 scores, while 85% maintained PASI 50. Histologically, skin biopsy data show that treatment with ALZUMAb statistically significantly reduces the trafficking of T cells in to the dermis and this is consistent with observed reduced severity of disease and therapeutic mechanism. See Figure 9.

 

LOGO

Figure 9: ALZUMAb, an approved treatment for psoriasis in India. (A) The proportion of patients who achieved a PASI 75 response at each visit until Week 28. (B) Treatment with ALZUMAb statistically significantly reduces the trafficking of T cells into the dermis. Compared to Visit 1, at Visit 16 there were statistically significantly fewer T cells in the dermis, as shown by CD3 labeling, a pan T cell marker. (C) Histogram shows the mean T cell count in the dermis was statistically significantly reduced in Week 12 and Week 28, compared to Week 0, which was consistent with the observed reduced severity of disease. ****p<0.0001.

The underlying pathophysiology of different immuno-inflammatory diseases can vary substantially, and therefore drugs that operate by different mechanisms can demonstrate diverging levels of efficacy in each condition. For example, the PASI 75 scores achieved at three months by subjects treated with ALZUMAb (36%) in its pivotal trial

 

91


Table of Contents

in psoriasis were in line with Enbrel (46-47%), an effective psoriasis drug, but they were less than the newly approved anti-IL-17 agents such as Cosentyx (66-82%). We believe the explanation for this result is that while Th17 cells play a role in psoriasis, there are also non-T cell mediators that contribute to disease pathogenesis, suggesting that psoriasis may not be an ideal indication for this therapeutic approach. Based on published clinical trial data from multiple studies that were not conducted on a head-to-head basis, it appears that ALZUMAb has demonstrated superior PASI 75 scores in psoriasis compared to modulation of CD28 co-stimulation using Orencia (16.4%), which is approved for the treatment of psoriatic and rheumatoid arthritis. Also, a recent meta-analysis comparing efficacy across trials indicated that Orencia demonstrated superior efficacy in ACR 50 scores, a common clinical test for determining improvement in a person’s rheumatoid arthritis, than Cosentyx in certain populations of psoriatic arthritis patients. These observations illustrate the importance of matching disease pathology and therapeutic mechanism in order to optimize therapeutic benefit.

ALZUMAb was well tolerated by the patients in the Phase 3 TREAT-PLAQ trial, with infusion reactions and related events, which are expected for an antibody infusion, as the main adverse events, or AEs, attributed to ALZUMAb. The incidence of infusion reactions dropped sharply after the first few infusions. ALZUMAb did not appear to increase the rate of infections compared to placebo, and the incidence of severe adverse events, or SAEs, was low (a total of five SAEs were reported). SAEs included exfoliative dermatitis (widespread redness and peeling of the skin), erythrodermic (severe) psoriasis, infusion-related reaction, adjustment disorder with anxiety, and bacterial arthritis. No SAEs led to discontinuation or reduction of drug dosage. See Table 3 for a summary of adverse events seen during the Phase 3 trial.

Table 3. Adverse events that occurred in >5% of subjects in either ALZUMAb treatment arm, placebo arm, or overall in the trial.

 

 

 

Weeks 1-12

 

ALZUMAb

(n = 180)

n(%)

 

Placebo

(n = 43)

n(%)

Any Adverse Event   72 (40.0%)   20 (46.5%)
Infusion Reaction (acute)   33 (18.3%)   1 (2.3%)
Infection   6 (3.3%)   4 (9.3%)
Pruritus (itching)   5 (2.8%)   3 (7.0%)

Weeks 13-52

 

ALZUMAb

(n = 223)

n(%)

Any Adverse Event   111 (49.8%)
Infusion Reaction (acute)   38 (17.0%)
Pyrexia (fever)   19 (8.5%)
Infection   17 (7.6%)
Pruritus   12 (5.4%)

 

 

An examination of lymphocyte counts in the study noted a mild decrease in the mean absolute lymphocyte count, or ALC, in the two ALZUMAb treatment arms at the initiation of treatment during the placebo controlled portion of the study (weeks 1-12). No further decrease was observed after the first dose. See Figure 10. These observed changes were not associated with an increase in secondary infection.

 

92


Table of Contents

LOGO

Figure 10: Lymphocyte counts in the peripheral blood of psoriasis patients during treatment with ALZUMAb. Graphs depict mean ALC (+/- standard deviation) of each treatment group during the first 12 weeks following initiation of treatment. The treatment regimen of each group is specified beneath the respective graph. Groups A and B, which received ALZUMAb, exhibited a modest decrease in ALC after the first dose but not subsequent doses.

Since approval and as of the current cut-off date of August 10, 2017 for the most recent Periodic Safety Update Report, ALZUMAb has accrued approximately 275 patient-years of use. Post-market safety surveillance has demonstrated 27 AE reports in that time period, of which four have been noted as serious, including infusion reaction, type 1 hypersensitivity, diarrhea and urticaria. The overall safety profile is favorable and has remained largely unchanged from the time of approval.

EQ001 Product Development

ALZUMAb is produced in an NS0 cell line and is currently available only in an intravenous, or IV, formulation. EQ001 contains the identical monoclonal antibody sequence produced in a Chinese hamster ovary, or CHO, cell line and is available in IV and subcutaneous injection, or SC, formulations. CHO cell lines are the industry-standard antibody therapeutic production system. EQ001 is manufactured by Biocon at commercial scale in an FDA regulated manufacturing facility. We have received a “study may proceed” letter from the FDA in response to our IND submission, which contained data from Biocon demonstrating biocomparability of EQ001 and ALZUMAb using industry-standard physico-chemical and biofunctional characterization methods.

 

LOGO

 

93


Table of Contents

EQ001 Phase 1 Clinical Trial in Healthy Subjects

Biocon conducted a Phase 1 clinical trial of EQ001 in 37 healthy subjects that was completed in Australia in the fourth quarter of 2017. The study was conducted in two stages, with the first stage designed to assess the safety, tolerability, pharmacokinetics, or PK, pharmacodynamics, or PD, and immunogenicity of ascending single doses of EQ001 SC, and the second stage designed to compare the PK of EQ001 IV to ALZUMAb and determine the absolute bioavailability of EQ001 SC.

Stage 1 was a randomized, double-blind, placebo controlled, ascending single dose evaluation of EQ001 SC. Thirty-two subjects completed Stage 1: 24 subjects (six per cohort) were administered EQ001 SC in single doses of 0.8 mg/kg, 1.6mg/kg, 2.4 mg/kg, or 3.2 mg/kg, and eight subjects were administered placebo. Serum concentrations of EQ001 were measurable at Day 57, and the mean half-life ranged from 532 hours to 616 hours across dose cohorts. The PK for exposure following EQ001 SC administration were dose proportional, with the peak serum concentration generally achieved within 168 hours after dosing for most subjects. Saturation of CD6 receptors by EQ001 was seen at all dose levels. During Stage 1, a transient decrease in T cells expressing CD4, and to a lesser extent CD8, here observed, as well as a two- to three-times increase in the proportion of Treg cells.

The administration of single doses of EQ001 SC in Stage 1 was found to be well tolerated, with a low incidence (2/24) of low titer anti-drug antibodies. There were no SAEs, dose limiting toxicities, or DLTs, or study drug discontinuations reported. No clinically meaningful changes in physical examinations or vital signs was observed, whereas transient decreases in lymphocyte counts without clinical consequences were seen in 11/24 (46%) subjects. There were five subjects who experienced grade 3 treatment emergent adverse events, or TEAEs, of lymphocyte count decreases (two subjects each in the 1.6 mg/kg and 3.2 mg/kg dose cohorts and one subject in the 2.4 mg/kg dose cohort). Mild to moderate injection site reactions were observed in 15/24 (63%) of the patients. The other most common TEAEs with EQ001 SC were headache in 7/24 (29%), urticaria (hives) in 4/24 (17%), and pyrexia (fever) in 3/24 (13%) of the subjects. In general, observed AEs were transient, mild to moderate in severity, were not dose dependent, and most were consistent with those observed in prior clinical experience with ALZUMAb.

Stage 2 was a comparability study of the PK of EQ001 IV, and ALZUMAb, and the absolute bioavailability of EQ001 SC. The trial featured a randomized, single-blind, parallel group design for the comparability component, and an open-label design for the absolute bioavailability component. Seven subjects enrolled in the study and received single doses of 0.4 mg/kg (one subject each EQ001 SC, EQ001 IV, ALZUMAb, and placebo) and 0.8 mg/kg (one subject each EQ001 SC, EQ001 IV, and ALZUMAb); five subjects completed the study, and one subject each that received EQ001 IV and ALZUMAb in the 0.8 mg/kg group discontinued dosing early due to AEs (one subject experienced persistent cough and dizziness; one subject experienced nausea). The infusion of single doses of both EQ001 IV and ALZUMAb was associated with the development of transient, reversible, grade 2 to 3 decreases in lymphocyte counts in the healthy subjects. As a result, Stage 2 of the trial was terminated early following the enrollment of seven subjects, yielding limited overall safety data and insufficient PK data for evaluation. There were no SAEs reported. No other clinically meaningful abnormalities or trends were noted in clinical chemistry, hematology, and urinalysis parameters. Similar to Stage 1, a transient decrease in T cells expressing CD4, and to a lesser extent CD8, a two- to three-times increase in the proportion of Treg cells, and saturation of CD6 receptors were observed across EQ001 and ALZUMAb cohorts.

While similar decreases in lymphocyte counts have not been reported with ALZUMAb previously, the timing of hematologic assessments in prior clinical studies may not have occurred at sufficiently early time-points to detect this transient response. Additionally, ALZUMAb had previously only been dosed in patients with active autoimmune disease and not healthy subjects. Importantly, the magnitude and kinetics of lymphocyte decreases were similar for EQ001 IV and ALZUMAb in Stage 2, while administration of EQ001 SC demonstrated milder decreases in lymphocyte counts, which would be expected based on the different PK properties of SC versus IV formulations. Furthermore, ALZUMAb had been well tolerated with demonstrated safety and clinical activity in three clinical studies in India in patients with rheumatoid arthritis and chronic plaque psoriasis, with a total of 333 patients exposed to ALZUMAb to date in clinical trials at doses ranging from 0.2 mg/kg to 1.6 mg/kg over a period of four years. Therefore, we believe the transient decreases in lymphocyte counts seen in the Phase 1 clinical trial in healthy subjects represents a PD property of both EQ001 and ALZUMAb that will be monitored going forward, and the results of the Phase 1 clinical trial support the advancement of EQ001 SC and IV into further clinical development in patients with immuno-inflammatory disease.

 

94


Table of Contents

Our Planned Initial Clinical Indications

We plan to initially develop EQ001 for the treatment of aGVHD, cGVHD, severe asthma and at least one additional indication. We expect to initiate a Phase 1b/2 clinical trial of EQ001 in patients with aGVHD in early 2019 and a Phase 2 clinical trial of EQ001 in patients with cGVHD in the first half of 2019. We also plan to initiate a proof-of-concept clinical trial in severe asthma in the first half of 2019. We continue to evaluate additional indications for future development and plan to select a fourth indication in the first half of 2019.

Graft-Versus-Host Disease Market Overview

aGVHD and cGVHD are multisystem disorders that are common complications of allogeneic hematopoietic stem cell transplants, or allo-HSCT, caused by the transplanted immune system recognizing and attacking the recipient’s body. GVHD is the leading cause of non-relapse mortality in patients receiving an allo-HSCT. The risk of GVHD limits the number and type of patients receiving HSCT and we believe that a therapy that can attenuate GVHD risk could significantly expand the patient population eligible for allo-HSCT.

According to the Center for International Blood & Marrow Transplant Research, there were more than 8,500 allo-HSCT’s performed in the United States in 2016 and the number of procedures has grown at an average annual growth rate of approximately 4% since 2007. Approximately 50% of HSCT recipients develop GVHD. HSCT recipients are at risk of developing either or both aGVHD and cGVHD with approximately 30-70% of HSCT recipients developing aGVHD, 50% of which will get cGVHD, and another 30-70% developing cGVHD independent of aGVHD. Five year survival for patients that respond to first-line treatment with corticosteroids has been reported to be as low as 53% while steroid refractory aGVHD mortality has been reported to be as high as 95%. Additionally, cGVHD is the leading cause of non-relapse mortality in patients surviving more than two years. We estimate that the incidence of aGVHD in 2018 is up to 5,000 patients and the total prevalence of GVHD could be up to 25,000 patients. We estimate that by the year 2025, the annual incidence of aGVHD will be up to 6,000 patients and the total prevalence of GVHD could be up to 35,000 patients.

Rationale for EQ001 for the Treatment of GVHD

Third-party clinical experience with targeting CD6 in GVHD

Clinical evidence to support the rationale of treating GVHD with EQ001 comes from previously-reported third-party clinical experience with CD6 expressing T cell depletion in patients receiving bone marrow transplants for hematologic malignancies where it has been demonstrated that using an anti-CD6 monoclonal antibody to deplete T cells from donor bone marrow or lymphocyte infusions has the potential to prevent aGVHD. In a study evaluating the clinical effects of selective in vitro CD6 expressing T cell depletion of donor allogeneic bone marrow using a monoclonal antibody to CD6 and rabbit complement, Soiffer et al. reported that in vitro T cell depletion with an anti-CD6 monoclonal antibody effectively reduced the incidence of both acute and chronic GVHD after allogeneic bone marrow transplant without compromising engraftment.

Subsequent studies further confirmed the feasibility of CD6 expressing T cell depletion in patients undergoing allogeneic bone marrow transplantation from human leukocyte antigen identical related and unrelated donors. In these studies, CD6 expressing depletion of the donor stem cell product was the sole method for GVHD prophylaxis. The low incidence of aGVHD reported in patients receiving allogeneic bone marrow treated with anti-CD6 monoclonal antibodies was attributed to the early appearance of a population of peripheral CD3 expressing T lymphocytes with a CD6-negative phenotype, which showed diminished reactivity to allogeneic stimulation in mixed lymphocyte reaction assays. Although the above described approach is one of ex vivo CD6 expressing T cell depletion, we believe that it further supports the role of CD6 expressing T cells in aGVHD pathogenesis and validates CD6 as a potentially important target for modulation for the treatment of GVHD.

EQ001 selectively targets GVHD pathogenesis

There is a high unmet medical need for a safe, effective and targeted treatment in GVHD. We believe EQ001 has the potential to be a best-in-class treatment for both aGVHD and cGVHD based on its ability to target the underlying biology of GVHD in a highly selective way.

 

95


Table of Contents

It is well established that Th17 cells, driven by pSTAT3 signaling, play a role in the pathogenesis of both aGVHD and cGVHD, and studies have shown that pSTAT3 was significantly increased in T cells of GVHD patients. In aGVHD, additional studies have reported that Th17 cells and IL-17 serum levels were significantly elevated in patients at onset compared with HSCT patients without aGVHD. As the disease progresses, Th17 cells traffic from the peripheral blood into GVHD target tissues where they trigger damage. Furthermore, the expansion of Th17 cells in the early phase of aGVHD plays a role in the transition to cGVHD. In GVHD patients, studies have shown a high Th17:Treg ratio suggesting a loss of tolerance. Notably the increased number of circulating Th17 cells was accompanied by a decrease in Treg cells, suggesting a loss of Teff cell regulation. Such regulatory mechanisms are crucial for eliminating alloreactive T cell activity, thus preventing sustained autoimmune responses and tissue destruction in GVHD.

We believe EQ001 can selectively target elements of the underlying pathogenesis of both aGVHD and cGVHD by: a) inhibiting Teff cells proliferation; b) downregulating the STAT3 pathway associated with development of pathogenic Th17 cells driving GVHD pathogenesis; c) inhibiting trafficking of Teff cells into GVHD target tissues preventing further inflammation and organ damage; and d) reducing the Th17:Treg ratio associated with the development of GVHD and thereby promoting tolerance.

Development Plan in GVHD

We plan to initiate a Phase 1b/2 multicenter clinical trial in approximately 84 patients in order to evaluate the safety, tolerability, PK and clinical activity of EQ001 IV in newly diagnosed aGVHD patients in early 2019 and expect top-line data from the Phase 1b part of the trial within 12 months of initiation. All patients will be administered EQ001 as a front-line therapy concomitant with steroid use upon first presentation of aGVHD.

The Phase 1b part of the trial will be an open-label, cohort based, dose escalation study that will enroll up to 24 adult patients in successive cohorts of three to six patients treated with multiple doses of EQ001 IV. The primary objective of this part of the trial will be to assess the safety and tolerability of EQ001 and to determine the optimal dose. Secondary objectives include assessing pharmacological activity of EQ001. Once an optimal dose is determined, and if the observed safety, tolerability, and pharmacological activity of EQ001 warrants, we will commence the Phase 2 part of the trial.

The Phase 2 part of the trial will be a randomized, double-blind, placebo-controlled study that will enroll up to 60 additional patients, randomized in a 2:1 ratio with 40 patients on active treatment of EQ001 and 20 patients on placebo. The primary objective of the Phase 2 part of the trial will be to assess the clinical activity of EQ001 and secondary objectives include further characterizing safety and tolerability.

We also plan to initiate a Phase 2 clinical trial of EQ001 for the treatment of cGVHD in the first half of 2019 under our existing IND.

Severe Asthma Market Overview

Asthma is a heterogeneous disease characterized by both allergic (Th2 driven) and autoimmune mechanisms (Th17 driven), leading to chronic airway inflammation. Asthma is now recognized as a disease with two predominant subtypes categorized by the degree of Th2-associated inflammation present in the airways. One subtype of asthma, often characterized as allergic asthma, includes patients with high levels of Th2-associated inflammation, or Th2-high, in the airways, often accompanied by high levels of eosinophils, and production of immunoglobulin E, or IgE. We estimate that 40-50% of the poorly controlled severe asthma population fall within the Th2-high subtype. These Th2-high patients often respond to treatment with steroids and recently approved biologic therapies which target IgE or Th2-cytokines.

Another subtype of asthma is characterized by low levels of Th2-associated inflammation, or Th2-low, in the airways. These Th2-low patients typically do not respond to treatment with corticosteroids or recently approved biologic therapies, have more severe disease, and have low levels of eosinophils. We estimate that 50–60% of the poorly controlled severe asthma population fall within the Th2-low subtype. A portion of Th2-low patients have airway inflammation caused by Th17 cytokines such as IL-17.

Based on publicly available sources, we estimate that asthma impacts approximately 26 million individuals. Of these, 5–10%, or approximately 1.3–2.6 million individuals, suffer from severe disease, and approximately half of

 

96


Table of Contents

these patients are poorly controlled with the current standard of care. We estimate that 325,000 to 650,000 of poorly controlled patients do not respond to therapies targeting Th2-driven disease. Notably, these patients account for most asthma-related treatment costs and economic burden.

Rationale for EQ001 for Severe Asthma

Current therapies for severe asthma and their limitations

Patients with mild-to-moderate asthma accompanied by Th2-high inflammation respond well to currently available treatments, including inhaled corticosteroids, or ICS, and long-acting beta agonists. Patients with Th2-low or severe disease are often not adequately controlled by these therapies, resulting in a large unmet need.

Recently, several biologic therapies that specifically target IgE or Th2-associated cytokines have been approved by the FDA for the treatment of moderate to severe asthma. While these therapies have proven effective for Th2-high inflammation they have had a minimal impact in patients with Th2-low inflammation. Genentech Inc.’s Xolair, or omalizumab, is an anti-IgE approved for the treatment of moderate to severe persistent allergic asthma that is not controlled by ICS. Other recently approved biologic therapies that are directed against IL-5 or the IL-5 receptor, which together mediate eosinophil development and inflammation of the airways, include mepolizumab (marketed under the name Nucala by GlaxoSmithKline plc), reslizumab (marketed under the name CINQAIR by Teva Pharmaceutical Industries Limited) and benralizumab (marketed under the name Fasenra by AstraZeneca plc).

In addition, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC have filed a BLA for the approval of Dupixent (dupilimab), an anti-IL-4 receptor antibody, for the treatment of moderate to severe asthma.

EQ001 for Th2-low inflammation in asthma pathogenesis

There is a high unmet medical need for a safe, effective and targeted treatment for patients with severe asthma. We believe that the unique mechanism of action of EQ001 has the potential to treat severe asthma patients characterized by an immunophenotype of low Th2 and high Th17 and who consequently have a poor response to high dose inhaled and/or oral steroids. There are a sizeable number of these patients who are underserved by currently available therapies and for which there are no FDA-approved biologic or other targeted treatments. Studies have shown that Th2 and Th17 cells are reciprocally regulated. More specifically, Th2 cytokines can negatively regulate Th17 cytokine expression which means that Th2-high patients cannot also be Th17-high patients. As a result, if a drug only downregulates Th2 associated inflammation, then a Th2-high patient may experience increased inflammation caused by Th17 cells, and vice versa. We believe that targeting both Th2 cytokines and Th17 cytokines, such as IL-17, may maximize therapeutic efficacy for Th2-low patients with inflammation caused by Th17 cytokines by avoiding a potential increase in inflammation caused by Th17 cells. By selectively targeting elements of the underlying pathogenesis of severe asthma by inhibiting proliferation of both Th2 and Th17 cells and associated cytokines driving Th2-low inflammation, EQ001 has the potential opportunity to provide a meaningful benefit to severe asthma patients. See Figure 11.

 

 

LOGO

Figure 11: Th17 cells expressing CD6 drive severe refractory asthma. Current approved therapeutic approaches target downstream signaling of Th2-associated inflammation and are largely ineffective in patients with low levels of eosinophils. We believe the upstream mechanism of EQ001 can uniquely address both the Th2 and Th17 inflammation driving severe refractory asthma pathogenesis.

 

97


Table of Contents

Translational research program supporting EQ001 in severe asthma

To further validate the use of EQ001 in severe asthma, we have an ongoing translational research program assessing the role of CD6 in severe asthma, specifically in Th2-low asthma. Preliminary findings derived from analysis of gene expression datasets support the presence of increased CD6, CD4 T cells, and ALCAM in the lungs of severe asthma patients. Gene expression in cells collected from the lungs of non-asthma, steroid-sensitive moderate asthma, and steroid-insensitive severe asthma patients, suggest that CD6 is significantly elevated in severe asthma, likely due to increases in CD4 T cells as supported by higher CD4 gene expression. In a separate set of patients, analysis of gene expression in lung tissue suggests higher expression of the CD6 ligand ALCAM within the airway of patients who have died from asthma. See Figure 12.

 

 

LOGO

Figure 12: CD6 is upregulated in cells collected from lungs of severe asthma patients. (A and B) Analysis of gene expression in cells collected from lungs of healthy non-asthma, moderate asthma and severe asthma patients as part of two multi-center prospective observational studies (Study of the Mechanisms of Asthma (MAST; NCT00595153); Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) study) shows higher levels of (A) CD4 expression and (B) CD6 expression in severe asthma, indicating the presence of CD6 in severe asthma and the presence of CD4 T cells. (C) Gene expression in smooth airway muscle from lung tissue of fatal asthmatic patients suggest elevation of ALCAM. ***p<0.001, *p<0.05.

Development Plan in Asthma

We plan to file an IND and initiate a proof-of-concept clinical trial of EQ001 for the treatment of severe asthma in the first half of 2019. The initial proof-of-concept study will focus on the treatment of non-eosinophilic severe asthma refractory to steroids with EQ001 administered subcutaneously. The study objectives will include an assessment of safety, pharmacokinetic/pharmacodynamic markers, dose finding and efficacy.

Partnerships

Collaboration and License Agreement with Biocon

In May 2017, we entered into a collaboration and license agreement with Biocon, as amended in September 2018, or the Biocon License, pursuant to which Biocon granted us an exclusive license in the United States and Canada, or the Equillium Territory, to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit EQ001 and any pharmaceutical composition or preparation containing or comprising EQ001, or collectively, a Biocon Product, that uses Biocon technology or Biocon know-how. However, unless we achieve certain regulatory and development milestones within a specific time period, the licensed rights, other than development rights, are limited to the fields of orphan indications and the treatment of asthmatic conditions. We also have the right to sublicense through multiple tiers to third parties, provided such sublicenses comply with the terms of the Biocon License and we provide Biocon a copy of each sublicense agreement within 30 days of execution. Under the Biocon License, we granted back to Biocon a license to use our technology and know-how related to EQ001 and Biocon Products in certain countries outside of the Equillium Territory.

In consideration of the rights granted to us by Biocon, we issued Biocon shares of our common stock equal to 19.5% of our outstanding shares at the time of the execution of the Biocon License. Biocon also has certain anti-dilution

 

98


Table of Contents

rights which are described in “Description of Capital Stock — Anti-Dilution Rights.” In addition, we are obligated to pay Biocon up to an aggregate of $30 million in regulatory milestone payments upon the achievement of certain regulatory approvals and up to an aggregate of $565 million in sales milestone payments upon the achievement of first commercial sale of product and specified levels of product sales. We are also required to pay quarterly tiered royalties based on a percentage from the mid-single digits to sub-teen double digits of net sales of Biocon Products, subject to adjustments in certain circumstances. Biocon is also required to pay us royalties at comparable percentages for sales of EQ001 outside of the Equillium Territory if the approvals in such geographies included or referenced our data, including data from certain of our clinical trials, subject to adjustments in certain circumstances. Under the Biocon License, net sales are calculated on a country-by-country basis and are subject to adjustments, including whether the Biocon Product is sold in the form of a combination product.

The Biocon License will continue until the expiration of all royalty obligations, unless terminated earlier. Our royalty obligations expire on a product-by-product and country-by-country basis upon the later of ten years from the first commercial sale of such Biocon Product in such country, the expiration of regulatory exclusivity, and the expiration of the last-to-expire Biocon patent covering such Biocon Product in such country. We may terminate the Biocon License unilaterally, with or without reason, upon 120 days’ prior written notice and either party may terminate the Biocon License in the event of the other party’s material breach of the Biocon License that remains uncured for 90 days after receipt of notice from the non-breaching party. Upon termination by us unilaterally or by Biocon for our material breach, Biocon will retain its license to use our intellectual property related to EQ001 and Biocon Products in certain countries outside the Equillium Territory, and we also will grant Biocon a non-exclusive license, and a right of first negotiation to an exclusive license, to use our intellectual property related to EQ001 and Biocon Products in the Equillium Territory. Further, we are subject to certain diligence obligations related to development, commercialization and funding activities and if we fail to comply with these obligations Biocon may, in certain circumstances, terminate the Biocon License and, in certain other circumstances, such failure may result in the permitted fields of use for licensed Biocon Products being limited to orphan indications and the treatment of asthmatic conditions.

Clinical Supply Agreement with Biocon

In May 2017, in connection with the Biocon License, we entered into a clinical supply agreement, or the Biocon Supply Agreement, with Biocon, pursuant to which Biocon agreed to be our exclusive supplier of EQ001 clinical drug product for up to three concurrent orphan drug clinical indications at no cost until our first U.S. regulatory approval and all other clinical drug product at cost. The Biocon Supply Agreement will remain in effect until the expiration or termination of the Biocon License.

Intellectual Property

Our intellectual property is critical to our business and we strive to protect it, including by obtaining and maintaining patent protection in the United States and internationally for our product candidate, novel biological discoveries, epitopes, new therapeutic approaches and potential indications, and other inventions that are important to our business. For our product candidates, generally we initially pursue patent protection covering compositions of matter, antibody sequence diversity, epitopes, functional activity and methods of use. Throughout the development of our product candidates, we will seek to identify additional means of obtaining patent protection that would potentially enhance commercial success, including through additional methods of use and biomarker and companion diagnostic related claims.

As of June 30, 2018, our patent portfolio related to EQ001 included patents and patent applications exclusively licensed from Biocon in the United States and Canada, as well as a pending U.S. provisional patent application that we own. The terms of the Biocon License are discussed above in “Business—Partnerships—Collaboration and License Agreement with Biocon and Clinical Supply Agreement with Biocon.”

Specifically, as of June 30, 2018, our licensed rights from Biocon related to EQ001 include four issued patents in the United States, two issued patents in Canada, three pending patent applications in the United States, one pending patent application in Canada, and two pending international applications filed under the Patent Cooperation Treaty, or PCT. Our issued U.S. patents are expected to expire in 2028 (absent any patent term extension for regulatory delays) and include claims directed to the antibody sequence of EQ001 and methods of formulating and

 

99


Table of Contents

using EQ001 alone or in combination with other agents to treat various T cell mediated diseases and disorders including GVHD and transplant rejection. Our issued Canadian patents are expected to expire between 2027 and 2030. Patents that may issue from our pending in-licensed patent applications are expected to expire between 2027 and 2037, absent any patent term adjustments or extensions.

Additionally, Equillium owns one pending U.S. provisional patent application related to methods of using EQ001 to treat severe asthma. If granted, this patent is expected to expire in 2039, absent any patent term adjustments or extensions. Provisional applications for patents were designed to provide a lower-cost first patent filing in the United States. Corresponding non-provisional patent applications must be filed not later than 12 months after the provisional application filing date. The corresponding non-provisional application benefits in that the priority date(s) of the patent application is/are the earlier provisional application filing date(s), and the patent term of the finally issued patent is calculated from the later non-provisional application filing date. This system allows us to obtain an early priority date, add material to the patent application(s) during the priority year, obtain a later start to the patent term and to delay prosecution costs, which may be useful in the event that we decide not to pursue examination in an application.

We file U.S. non-provisional applications and PCT applications that claim the benefit of the priority date of earlier filed provisional applications, when applicable. The PCT system allows a single application to be filed within 12 months of the original priority date of the patent application, and to designate all of the 152 PCT member states in which national patent applications can later be pursued based on the international patent application filed under the PCT. The PCT searching authority performs a patentability search and issues a non-binding patentability opinion which can be used to evaluate the chances of success for the national applications in foreign countries prior to having to incur the filing fees. Although a PCT application does not issue as a patent, it allows the applicant to seek protection in any of the member states through national-phase applications. At the end of the period of 2 1/2 years from the first priority date of the patent application, separate patent applications can be pursued in any of the PCT member states either by direct national filing or, in some cases by filing through a regional patent organization, such as the European Patent Organization. The PCT system delays expenses, allows a limited evaluation of the chances of success for national/regional patent applications and enables substantial savings where applications are abandoned within the first 2 1/2 years of filing.

We intend to prosecute the pending applications that we own and in-license and to pursue patent issuance and protection in key commercial markets where we expect significant product sales may occur.

With the enactment of the Biologics Price Competition and Innovation Act of 2009, or BPCIA, an abbreviated pathway for the approval of biosimilar and interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as interchangeable based on its similarity to an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product is approved under a BLA.

The patent positions of biotechnology companies like ours are generally uncertain and involve complex legal, scientific and factual questions. We recognize that the ability to obtain patent protection and the degree of such protection depends on a number of factors, including the extent of the prior art, the novelty and non-obviousness of the invention, and the ability to satisfy the enablement requirement of the patent laws. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our product candidates. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.

Our commercial success will also depend in part on not infringing the proprietary rights of third parties. In addition, we have licensed rights under proprietary technologies of third parties to develop, manufacture and commercialize specific aspects of our products and services. It is uncertain whether the issuance of any third party patent would require us to alter our development or commercial strategies, alter our processes, obtain licenses or cease certain activities. The expiration of patents or patent applications licensed from third parties or our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our

 

100


Table of Contents

future technology may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the United States Patent and Trademark Office, or USPTO, to determine priority of invention. For a more comprehensive discussion of the risks related to our intellectual property, please see “Risk Factors—Risks Related to Our Intellectual Property.”

The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non- provisional patent application related to the patent. A U.S. patent also may be accorded a PTA under certain circumstances to compensate for delays in obtaining the patent from the USPTO. In some instances, such a PTA may result in a U.S. patent term extending beyond 20 years from the earliest date of filing a non-provisional patent application related to the U.S. patent. In addition, in the United States, the term of a U.S. patent that covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.

We also rely on trade secrets relating to product candidates and seek to protect and maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets, including through breaches of such agreements with our employees and consultants. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific partners, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual’s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or from the employee’s use of our confidential information are our exclusive property.

Competition

The biotechnology and pharmaceutical industries are characterized by continuing technological advancement and significant competition. While we believe that our product candidates, technology, knowledge, experience and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. The level of generic competition and the availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.

Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be

 

101


Table of Contents

significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

Specifically, there are several companies developing or marketing treatments that may be approved for the same indications and/or diseases as our lead product candidate EQ001.

Graft-Versus-Host Disease

Corticosteroids, or steroids, remain the first-line of therapy for both aGVHD and cGVHD. There are currently no FDA-approved therapies for the treatment of aGVHD, and second-line therapy consists of off-label immunosuppressives for which the therapeutic benefit has not been established. Additionally, there is only one approved therapy for cGVHD, Imbruvica (ibrutinib), approved for cGVHD after failure of one or more lines of therapy.

In addition, we are aware of a number of companies with development programs in aGVHD and cGVHD, including AbbVie Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, CSL Behring LLC, Jazz Pharmaceuticals plc, Kadmon Holdings, Inc., Kalytera Therapeutics, Inc., Kamada Ltd., Mesoblast Limited, Novartis AG, Prometheus Laboratories Inc. and Xenikos B.V. Incyte Corporation is developing both Jakafi (ruxolitinib), for steroid-refractory aGVHD as well as cGVHD, and itacitinib, a JAK1 inhibitor, for first-line treatment of aGVHD, currently in Phase 3 clinical development.

Severe Asthma

Several biologic therapies that specifically target IgE or Th2-associated cytokines have been approved by the FDA for the treatment of asthma including products developed by AbbVie Inc., Amgen Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Roche Holding AG and Teva Pharmaceutical Industries Limited.

In addition, Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC have filed a BLA for the approval of Dupixent (dupilimab), an anti-IL-4 receptor antibody, for the treatment of moderate to severe asthma. We are also aware of several companies with development programs in this indication including, AbbVie Inc., Amgen Inc., AnaptysBio, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Novartis AG, Regeneron Pharmaceuticals, Inc., Roche Holding AG and Sanofi-Aventis U.S. LLC.

Sales and Marketing

Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We intend to build a commercial infrastructure to support sales of EQ001 in the United States. We expect to manage sales, marketing and distribution through internal resources and third-party relationships. While we may commit significant financial and management resources to commercial activities, we will also consider collaborating with one or more pharmaceutical companies to enhance our commercial capabilities.

Manufacturing

We do not own or operate manufacturing facilities for the production of EQ001 or any future product candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on Biocon, our third-party contract manufacturer, pursuant to the Biocon License and Biocon Supply Agreement, for all our required raw materials, drug substance and drug product needs for preclinical research, clinical trials and commercial supply of EQ001. If EQ001 is approved, we have agreed to enter into a separate exclusive supply agreement with Biocon in the future. Biocon currently manufactures EQ001 at its FDA regulated facility in Bangalore, India.

With respect to any future product candidates, we expect to rely on third-party contract manufacturers for all our required raw materials, drug substance and drug product needs for preclinical research, clinical trials and commercial supply.

 

102


Table of Contents

Government Regulation and Product Approval

The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.

In the United States, the FDA regulates biologics under both the Federal Food, Drug and Cosmetic Act, or FDCA, and the Public Health Services Act, or PHSA, and their implementing regulations. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:

 

   

completion of preclinical laboratory tests and animal studies performed in accordance with the FDA’s current Good Laboratory Practices, or GLP, regulations;

 

   

submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;

 

   

approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is commenced;

 

   

performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;

 

   

preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials that includes substantial evidence of safety, purity and potency from results of nonclinical testing and clinical trials;

 

   

satisfactory completion of an FDA Advisory Committee review, if applicable;

 

   

a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;

 

   

satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product’s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with Good Clinical Practices, or GCP; and

 

   

FDA review and approval, or licensure, of the BLA to permit commercial marketing of the product for particular indications for use in the United States.

Preclinical and Clinical Development

Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product candidate; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.

Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an

 

103


Table of Contents

independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.

For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.

 

   

Phase 1—The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism, distribution and elimination of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.

 

   

Phase 2—The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.

 

   

Phase 3—The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.

In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so- called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

BLA Submission, Review and Approval

Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s chemistry, manufacturing, controls, and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to FDA, unless a waiver or exemption applies.

Once a BLA has been submitted, the FDA’s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held

 

104


Table of Contents

meets standards designed to assure the product’s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.

After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.

If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.

Expedited Development and Review Programs

Any marketing application for a biologic submitted to the FDA for approval may be eligible for FDA programs intended to expedite the FDA review and approval process, such as priority review, fast track designation, breakthrough therapy and accelerated approval.

A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular entities, priority review designation means the FDA’s goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under standard review).

To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides opportunities for frequent interactions with the FDA review team to expedite development and review of the product. The FDA may also review sections of the BLA for a fast track product on a rolling basis before the complete application is

 

105


Table of Contents

submitted, if the sponsor and FDA agree on a schedule for the submission of the application sections, and the sponsor pays any required user fees upon submission of the first section of the BLA.

In addition, under the provisions of the Food and Drug Administration Safety and Innovation Act, or FDASIA, passed in July 2012, a sponsor can request designation of a product candidate as a “breakthrough therapy.” A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs or biologics designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.

Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.

Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review and approval will not be shortened. Furthermore, priority review, fast track designation, breakthrough therapy designation, and accelerated approval do not change the standards for approval but may expedite the development or approval process.

Orphan Drug Designation

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan designation must be requested before submitting a BLA. After the FDA grants orphan designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.

If a product that has orphan designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity . Orphan exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee.

A designated orphan product may not receive orphan exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.

Post-Approval Requirements

Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to quality control and quality assurance,

 

106


Table of Contents

record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.

The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

 

   

restrictions on the marketing or manufacturing of a product, mandated modification of promotional materials or issuance of corrective information, issuance by FDA or other regulatory authorities of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product, or complete withdrawal of the product from the market or product recalls;

 

   

fines, warning or untitled letters or holds on post-approval clinical studies;

 

   

refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;

 

   

product seizure or detention, or refusal of the FDA to permit the import or export of products; or

 

   

injunctions, consent decrees or the imposition of civil or criminal penalties.

The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer’s communications on the subject of off-label use of their products.

Biosimilars and Reference Product Exclusivity

The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. To date, a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents outlining its approach to the review and approval of biosimilars.

Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal

 

107


Table of Contents

studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.

Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed “interchangeable” by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.

The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.

Other U.S. Healthcare Laws and Compliance Requirements

In the United States, our current and future operations are subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, or HHS (such as the Office of Inspector General, Office for Civil Rights and the Health Resources and Service Administration), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, our clinical research, sales, marketing and scientific/educational grant programs may have to comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as amended, as applicable.

The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between therapeutic product manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.

Additionally, the intent standard under the Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or Affordable Care Act, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act codified case

 

108


Table of Contents

law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or FCA (discussed below).

The federal false claims and civil monetary penalty laws, including the FCA, which imposes significant penalties and can be enforced by private citizens through civil qui tam actions, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by, the federal government, including federal healthcare programs, such as Medicare and Medicaid, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. A claim includes “any request or demand” for money or property presented to the U.S. government. For instance, historically, pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies’ marketing of the product for unapproved, off-label, and thus generally non-reimbursable, uses.

HIPAA created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, the Affordable Care Act amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.

Also, many states have similar, and typically more prohibitive, fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.

We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA’s privacy and security standards directly applicable to business associates, independent contractors, or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys’ fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways, are often not pre-empted by HIPAA, and may have a more prohibitive effect than HIPAA, thus complicating compliance efforts.

We may develop products that, once approved, may be administered by a physician. Under currently applicable U.S. law, certain products not usually self-administered (including injectable drugs) may be eligible for coverage under Medicare through Medicare Part B. Medicare Part B is part of original Medicare, the federal health care program that provides health care benefits to the aged and disabled, and covers outpatient services and supplies, including certain biopharmaceutical products, that are medically necessary to treat a beneficiary’s health condition. As a condition of receiving Medicare Part B reimbursement for a manufacturer’s eligible drugs, the manufacturer is required to participate in other government healthcare programs, including the Medicaid Drug Rebate Program and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of HHS as a condition for states to receive federal matching funds for the manufacturer’s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities that participate in the program.

In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such

 

109


Table of Contents

metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. It is difficult to predict how Medicare coverage and reimbursement policies will be applied to our products in the future and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program.

Additionally, the federal Physician Payments Sunshine Act, or the Sunshine Act, within the Affordable Care Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members. Failure to report accurately could result in penalties. In addition, many states also govern the reporting of payments or other transfers of value, many of which differ from each other in significant ways, are often not pre-empted, and may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts.

In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.

Ensuring business arrangements with third parties comply with applicable healthcare laws and regulations is a costly endeavor. If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other current or future governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private “qui tam” actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

Coverage, Pricing and Reimbursement

Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may obtain regulatory approval. In the United States and in foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United States, and commercial payors are critical to new product acceptance.

Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration

 

110


Table of Contents

authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which therapeutics they will pay for and establish reimbursement levels. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor’s determination that use of a therapeutic is:

 

   

a covered benefit under its health plan;

 

   

safe, effective and medically necessary;

 

   

appropriate for the specific patient;

 

   

cost-effective; and

 

   

neither experimental nor investigational.

We cannot be sure that reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement will be. Coverage may also be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Reimbursement may impact the demand for, or the price of, any product for which we obtain regulatory approval.

Third-party payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded drugs and drugs administered under the supervision of a physician. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. Obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our product on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. A payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop.

Different pricing and reimbursement schemes exist in other countries. In the European Union, governments influence the price of biopharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.

The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care, the increasing influence of health maintenance organizations, and additional legislative changes in the United States has increased, and we expect will continue to increase, the pressure on healthcare pricing. The downward pressure on the rise in healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

 

111


Table of Contents

Healthcare Reform

In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.

For example, the Affordable Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the Affordable Care Act provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above, are the following:

 

   

an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs that began in 2011;

 

   

an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January 1, 2010, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;

 

   

a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts, which through subsequent legislative amendments, will be increased to 70%, starting in 2019, off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers’ outpatient drugs to be covered under Medicare Part D;

 

   

extension of manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;

 

   

expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals beginning in 2014 and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers’ Medicaid rebate liability;

 

   

expansion of the entities eligible for discounts under the 340B Drug Discount Program;

 

   

a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;

 

   

expansion of healthcare fraud and abuse laws, including the FCA and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;

 

   

a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected;

 

   

requirements to report certain financial arrangements with physicians and teaching hospitals;

 

   

a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians;

 

   

establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending; and

 

   

a licensure framework for follow on biologic products.

Some of the provisions of the Affordable Care Act have yet to be implemented, and there have been legal and political challenges to certain aspects of the Affordable Care Act. Since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. In December 2017, Congress repealed the tax penalty for an individual’s failure to maintain Affordable Care Act-mandated health insurance as part of a tax reform bill. Further, on January 22, 2018, President

 

112


Table of Contents

Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain Affordable Care Act-mandated fees, including the so-called “Cadillac” tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. Moreover, the Bipartisan Budget Act of 2018, or the BBA, among other things, amends the Affordable Care Act, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole.” More recently, in July 2018, CMS announced that it is suspending further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk adjustment program pending the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. Congress is continuing to consider legislation that would alter other aspects of the Affordable Care Act. The ultimate content, timing or effect of any healthcare reform legislation on the U.S. healthcare industry is unclear.

We anticipate that the Affordable Care Act, if substantially maintained in its current form, will continue to result in additional downward pressure on coverage and the price that we receive for any approved product, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.

Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013 and will stay in effect through 2027 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration’s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further, the Trump administration released a “Blueprint,” or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services, or HHS, has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. While some proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control biopharmaceutical product pricing, including price or patient reimbursement constraints,

 

113


Table of Contents

discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

The Foreign Corrupt Practices Act

The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.

Additional Regulation

In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.

Government Regulations Related to Economic Sanctions

Pursuant to various laws, regulations, and executive orders, the U.S. Treasury Department’s Office of Foreign Assets Control, or OFAC, administers and enforces economic and trade sanctions that prohibit or restrict certain activities with embargoed countries, sanctioned entities, and sanctioned individuals for particular foreign policy and national security reasons. The scope of the sanctions varies significantly, but may include comprehensive restrictions on imports, exports, investment, and facilitation of foreign transactions involving a sanctioned jurisdiction, entity or person, as well as non-sanctioned persons and entities acting on behalf of sanctioned jurisdictions, entities or people.

One such set of regulations is the Cuban Assets Control Regulations, or CACR. The CACR prohibits U.S. persons from engaging in virtually all transactions involving property of the government of Cuba or Cuban nationals, or property in which the government of Cuba or any Cuban national has at any time on or since July 8, 1963 had any interest of any nature whatsoever, direct or indirect. Where activity is prohibited by the CACR, engagement in such activity must be authorized by a general or specific license granted by OFAC. The antibody sequence for both EQ001 and ALZUMAb was developed exclusively by Cuban nationals. We currently rely on a general license issued by OFAC under CACR, relating to Cuban-origin pharmaceuticals to import and conduct clinical trials relating to EQ001. Although we believe our current and planned activities related to EQ001 qualify for, and are authorized under, the OFAC general license and we have maintained compliance with the general license requirements, OFAC has not confirmed the applicability of the general license to EQ001. We have submitted to OFAC a request for interpretive guidance confirming the applicability of the general license, or in its absence, a specific license authorization from OFAC. We have simultaneously requested that OFAC treat our submission as a voluntary disclosure if OFAC concludes that our determination that the general license applies to EQ001 was in error.

Other Regulations

We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now or in the future.

 

114


Table of Contents

Employees

As of June 30, 2018, we employed seven employees, all of whom are full-time and engaged in research and development activities, operations, finance, business development and administration. Two of our employees hold doctorate degrees (Ph.D., M.D. or PharmD.).

Research and Development

We have invested $1.3 million and $1.2 million in research and development for the period March 16, 2017 (inception) through December 31, 2017 and the six months ended June 30, 2018, respectively.

Property and Facilities

We lease approximately 1,750 square feet of space for our current headquarters in La Jolla, California under an agreement that expires in February 2022. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.

Legal Proceedings

From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this prospectus, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

 

115


Table of Contents

MANAGEMENT

The following table sets forth information about our executive officers and directors as of August 30, 2018.

 

 

 

NAME

   AGE     

POSITION(S)

Executive Officers

     

Daniel M. Bradbury

     57     

Chief Executive Officer and Chairman of the Board of Directors

Bruce D. Steel

     51     

President, Chief Business Officer and Director

Stephen Connelly, Ph.D.

     37     

Chief Scientific Officer and Director

Jason A. Keyes

     47     

Chief Financial Officer

Krishna R. Polu, M.D.

     45     

Chief Medical Officer

Non-Employee Directors

     

Martha J. Demski (1)(2)

     66     

Director

Bala S. Manian, Ph.D. (1)(2)

     73     

Director

Charles McDermott (1)(3)

     46     

Director

Mark Pruzanski, M.D. (3)

     50     

Director

 

 

 

(1)   Member of the audit committee.
(2)   Member of the compensation committee.
(3)   Member of the nominating and corporate governance committee.

Executive Officers

Daniel M. Bradbury has served as our Chief Executive Officer since June 2018 and as a member and the chairman of our board of directors since March 2017. Mr. Bradbury is a co-founder of Equillium and served as our President from March 2017 until June 2018. Mr. Bradbury is the founder and has served as the managing member of BioBrit, LLC, a life sciences consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from March 2007 until Amylin’s acquisition by Bristol-Myers Squibb Company in August 2012. Prior to Amylin, Mr. Bradbury worked in marketing and sales for 10 years at SmithKline Beecham Pharmaceuticals, a privately-held pharmaceutical company. Mr. Bradbury serves on the board of directors of numerous private companies and the following publicly-held companies: Biocon Limited, Corcept Therapeutics Incorporated, Geron Corporation and Intercept Pharmaceuticals, Inc. Mr. Bradbury previously served on the board of directors of BioMed Realty Trust, Inc., a publicly-held real estate investment trust company, from 2013 to 2016; Illumina, Inc., a publicly-held biotechnology company, from 2004 to 2017; and Syngene International Ltd., a publicly-held science research company, from 2015 to 2016. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.

Our board of directors believes that Mr. Bradbury’s experience as our Chief Executive Officer and his other executive and board experience qualify him to serve on our board of directors.

Bruce D. Steel has served as our President and as our Chief Business Officer since June 2018 and as a member of our board of directors since March 2017. Mr. Steel is a co-founder of Equillium. Mr. Steel is the founder and has served as the Managing Director of BioMed Ventures, an investment firm owned by BioMed Realty, LP, since 2010. From 2008 to 2010, Mr. Steel served as the Chief Business Officer at Anaphore, Inc., a privately-held pharmaceutical company. Prior to that, Mr. Steel was co-founder and Chief Executive Officer of Rincon Pharmaceuticals, Inc., a genetic engineering biotechnology company, from 2005 until its acquisition in 2008. Mr. Steel also previously served as the Head of Corporate Development at Ambit Biosciences Corporation from 2002 to 2005. Mr. Steel previously served on the board of directors of Zosano Pharma Corporation, a publicly-held biopharmaceutical company, from 2012 to 2017. Mr. Steel serves on the board of directors of the following privately-held companies: Breathe Technologies, Inc. and Aegea Medical, Inc. Mr. Steel received his B.A. degree from Dartmouth College and M.B.A. degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst.

 

116


Table of Contents

Our board of directors believes that Mr. Steel’s experience in founding, managing and building companies and investment experience qualify him to serve on our board of directors.

Stephen Connelly, Ph.D. has served as our Chief Scientific Officer since January 2018 and as a member of our board of directors since March 2017. Dr. Connelly is a co-founder of Equillium and served as a consultant from March 2017 until January 2018. Dr. Connelly has served as a principal at BioMed Ventures, an investment firm owned by BioMed Realty, LP, since March 2016. From March 2014 to March 2016, Dr. Connelly served as the Director of Business Development and Therapeutic Alliances at aTyr Pharma, Inc., a publicly-held biotechnology company. Prior to that, Dr. Connelly was a Senior Scientist at The Scripps Research Institute from March 2012 to March 2014, where he worked on multiple drug discovery projects spanning different therapeutic areas. Dr. Connelly has broad experience in conducting novel and innovative research and has published over 30 original scientific papers and patents. Dr. Connelly received a B.S. in Medicinal Chemistry and a Ph.D. in Biological Chemistry from the University of Exeter, United Kingdom, and an M.B.A. from the Rady School at University of California, San Diego.

Our board of directors believes that Dr. Connelly’s scientific and research expertise qualify him to serve on our board of directors.

Jason A. Keyes has served as our Chief Financial Officer since March 2018. From January 2013 to February 2018, Mr. Keyes held positions of increasing responsibility at Orexigen Therapeutics, Inc., a publicly-held pharmaceutical company which filed a voluntary petition for Chapter 11 bankruptcy in March 2018, most recently as Executive Vice President and Chief Financial Officer. Mr. Keyes held positions of increasing responsibility at Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from August 2007 until January 2013, most recently as Senior Director of Finance. Prior to joining Amylin, Mr. Keyes held positions of increasing responsibility in finance and corporate strategy at Amgen Inc., a publicly-held biopharmaceutical company, and Baxter Healthcare Corporation, a publicly-held healthcare company. Mr. Keyes is also a licensed professional engineer and has six years of experience in the environmental engineering industry. Mr. Keyes received his B.S. and M.S. degrees in Civil Engineering from Stanford University and an M.B.A. from the Anderson School at the University of California, Los Angeles.

Krishna R. Polu, M.D. has served as our Chief Medical Officer since August 2018. From February 2018 to August 2018, Dr. Polu served as Interim Chief Executive Officer of Scout Bio, Inc., a privately-held biotechnology company. Dr. Polu founded Expedition Therapeutics, Inc., a privately-held search company, in June 2017 and served as its Chief Executive Officer from June 2017 until August 2018. Dr. Polu also served as an Entrepreneur-in-Residence at Frazier Healthcare Partners, an investment firm, from February 2017 until August 2018. Prior to that, Dr. Polu served as the Chief Medical Officer of Raptor Pharmaceutical Corp., a publicly-held biopharmaceutical company, from January 2015 to December 2016. Dr. Polu also previously served as the Chief Medical Officer of CytomX Therapeutics, Inc., a privately-held biotechnology company, from March 2013 to June 2014. From July 2009 to March 2013, Dr. Polu served as Vice President of Clinical Development at Affymax, Inc., a publicly-held biopharmaceutical company. Prior to Affymax, Inc., Dr. Polu served as the Executive Director, Global Development of Amgen Inc., a publicly-held biotechnology company, from November 2007 to July 2009. Dr. Polu holds a B.A. in Human Biology from Stanford University and a M.D. from University of Texas Health Science Center, San Antonio. Dr. Polu also completed an internal medicine internship and residency at the University of Colorado as well as clinical and research fellowships in nephrology and transplant at Harvard Medical School in a joint program with Brigham and Women’s Hospital and Massachusetts General Hospital.

Non-Employee Directors

Martha J. Demski has served as a member of our board of directors since September 2018. From August 2011 to May 2017, Ms. Demski served as Senior Vice President and Chief Financial Officer of Ajinomoto Althea, Inc. (formerly Althea Technologies, Inc.), a privately-held fully-integrated contract development and manufacturing organization. From July 2008 to December 2010, Ms. Demski served as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center, a non-profit corporation that was engaged in biomedical research prior to voluntarily filing for Chapter 11 bankruptcy in 2009. Previously, Ms. Demski served as Vice President and Chief Financial Officer of Vical Incorporated, a publicly-held biopharmaceutical company, from

 

117


Table of Contents

December 1988 to June 2004. Ms. Demski currently serves as the chair of the board of directors of Chimerix, Inc., a publicly-held biopharmaceutical company, and on the board of directors, as the chair of the audit committee and as a member of the compensation and finance committees, of Adamas Pharmaceuticals, Inc., a publicly-held biotechnology company. Prior to 2018, Ms. Demski was a member of the board of directors, chair of the audit committee and member of the compensation committee, nominating and governance committee, and operating committee of Neothetics, Inc., a publicly-held biotechnology company. Ms. Demski is a National Association of Corporate Directors Board Governance Fellow. In 2017, she received the Director of the Year in Corporate Governance award by the Corporate Directors Forum. Additionally, Ms. Demski has over 13 years of banking experience with Bank of America and U.S. Trust. Ms. Demski earned a B.A. from Michigan State University and M.B.A. from The University of Chicago Booth School of Business with concentrations in accounting and finance.

Our board of directors believes that Ms. Demski’s more than 30 years’ experience in the fields of finance and biotechnology as well as her experience as a member of various boards of directors qualify her to serve on our board of directors.

Bala S. Manian, Ph.D. has served as a member of our board of directors since May 2017. Dr. Manian has served on the board of directors of Syngene International Ltd., a publicly-held contract research and manufacturing organization based in India, since June 2015. Dr. Manian has served as Chief Executive Officer and chairman of the board of directors of ReaMatrix, Inc., a privately-held biotechnology company, since 2004. Dr. Manian has served as Executive Chairman of LeukoDx Inc., a privately-held biotechnology company, since May 2017. Dr. Manian founded and served as chairman of the board of directors of Lumisys Incorporated, a publicly-held medical systems company, from 1987 to 1994, of Molecular Dynamics, Inc., a publicly-held genetic discovery and analysis company, from 1987 to 1994, and of Biometric Imaging, Inc., a privately-held biotechnology company, from 1993 to 1998. Dr. Manian also co-founded Quantum Dot Corporation and SurroMed Inc. Dr. Manian received a B.S. in Physics from Loyola College, Chennai, a postgraduate level Diploma in Instrumentation from the Madras Institute of Technology, Chennai, an M.S. in Applied Optics from the University of Rochester, and a Ph.D. in Mechanical Engineering from Purdue University.

Our board of directors believes that Dr. Manian’s experience in founding, managing and building companies and scientific and research experience qualify him to serve on our board of directors.

Charles McDermott has served as a member of our board of directors since September 2018. From September 2017 to May 2018, Mr. McDermott served as President and Chief Business Officer of Impact Biomedicines, Inc., a privately-held biotechnology company. Prior to that, Mr. McDermott served as President and Chief Business Officer of Kala Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from June 2015 to August 2017. Previously, he served as Interim President and Chief Business Officer of Kala from October 2014 to June 2015 and as Executive Vice President of Business Development of Kala from June 2013 to October 2014. Prior to joining Kala, Mr. McDermott served first as Director and then Vice President of Business Development, Eye Care and Drug Delivery at Allergan plc, a publicly-held global pharmaceutical company, where he worked from April 2005 to May 2013. Prior to joining Allergan, Mr. McDermott held a variety of business development positions at deCODE Genetics, Inc. (now DGI Resolutions, Inc.), a privately-held biopharmaceutical company, from January 2001 to March 2005. Prior to deCODE Genetics, Mr. McDermott was a research scientist in the angiogenesis pharmacology group at Agouron Pharmaceuticals, Inc. Mr. McDermott currently serves on the board of directors of Primmune Therapeutics, Inc., a privately-held biotechnology company. Mr. McDermott holds an M.B.A. from the University of San Diego, an M.A. in Molecular, Cellular and Developmental Biology from the University of California at Santa Barbara, a B.S. in Biochemistry and Molecular Biology from the University of California Santa Cruz and a Certificate in Clinical Trial Design and Management from the University of California San Diego Extension.

Our board of directors believes that Mr. McDermott’s biopharmaceutical and executive experience qualify him to serve on our board of directors.

Mark Pruzanski, M.D. has served as a member of our board of directors since September 2018. Dr. Pruzanski is a co-founder and has served as President and Chief Executive Officer and as a member of the board of directors of Intercept Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, since 2002. Dr. Pruzanski has over 20 years of experience in life sciences company management, venture capital and strategic consulting. Prior to co-founding Intercept, Dr. Pruzanski was a venture partner at Apple Tree Partners, an early stage life sciences venture

 

118


Table of Contents

capital firm that he co-founded, and an entrepreneur-in-residence at Oak Investment Partners, a venture capital firm. Dr. Pruzanski is a co-author of a number of scientific publications and is named as an inventor on several patents. Dr. Pruzanski currently serves on the boards of the Emerging Companies Section of the Biotechnology Innovation Organization, a biotechnology-focused trade association, and the Foundation for Defense of Democracies, a non-profit policy institute focusing on foreign policy and national security. Dr. Pruzanski received his M.D. from McMaster University in Hamilton, Canada, a M.A. degree in International Affairs from the Johns Hopkins University School of Advanced International Studies in Bologna, Italy and Washington, D.C., and a bachelor’s degree from McGill University in Montreal, Canada.

Our board of directors believes that Dr. Pruzanski’s experience in founding, managing and building life sciences companies as well as his venture capital experience qualify him to serve on our board of directors.

Board Composition

Our business and affairs are organized under the direction of our board of directors, which currently consists of seven members. The primary responsibilities of our board of directors are to provide oversight, strategic guidance, counseling and direction to our management. Our board of directors meets on a regular basis and on an ad hoc basis as required.

Our board of directors has determined that all of our directors, other than Mr. Bradbury, Dr. Connelly and Mr. Steel, are independent directors, as defined by Rule 5605(a)(2) of The Nasdaq Listing Rules.

In accordance with the terms of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the completion of this offering, respectively, we will divide our board of directors into three classes, as follows:

 

   

Class I, which will consist of Dr. Connelly and Dr. Manian, whose terms will expire at our annual meeting of stockholders to be held in 2019;

 

   

Class II, which will consist of Mr. McDermott and Mr. Steel, whose terms will expire at our annual meeting of stockholders to be held in 2020; and

 

   

Class III, which will consist of Mr. Bradbury, Ms. Demski and Dr. Pruzanski, whose terms will expire at our annual meeting of stockholders to be held in 2021.

At each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms then expire will serve until the third annual meeting following their election and until their successors are duly elected and qualified. The authorized size of our board of directors is currently seven members. The authorized number of directors may be changed only by resolution of our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed between the three classes so that, as nearly as possible, each class will consist of one-third of the directors. This classification of our board of directors may have the effect of delaying or preventing changes in our control or management. Our directors may be removed for cause by the affirmative vote of the holders of at least 66-2/3% of our voting stock.

Board Leadership Structure

Our board of directors is currently chaired by Mr. Bradbury who has authority, among other things, to call and preside over board of directors meetings, to set meeting agendas and to determine materials to be distributed to the board of directors. Accordingly, the Chairman has substantial ability to shape the work of the board of directors. We have a separate chair for each committee of our board of directors. The chair of each committee is expected to report annually to our board of directors on the activities of their committee in fulfilling their responsibilities as detailed in their respective charters or specify any shortcomings should that be the case.

Role of the Board in Risk Oversight

The audit committee of our board of directors is primarily responsible for overseeing our risk management processes on behalf of our board of directors. Going forward, we expect that the audit committee will receive reports from management at least quarterly regarding our assessment of risks. In addition, the audit committee reports regularly to our board of directors, which also considers our risk profile. The audit committee and our board of directors focus on the most significant risks we face and our general risk management strategies. While our board of directors

 

119


Table of Contents

oversees our risk management, management is responsible for day-to-day risk management processes. Our board of directors expects management to consider risk and risk management in each business decision, to proactively develop and monitor risk management strategies and processes for day-to-day activities and to effectively implement risk management strategies adopted by the audit committee and our board of directors. We believe this division of responsibilities is the most effective approach for addressing the risks we face and that our board of directors’ leadership structure, which also emphasizes the independence of our board of directors in its oversight of its business and affairs, supports this approach.

Board Committees

Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee.

Audit Committee

Our audit committee consists of Ms. Demski, Dr. Manian and Mr. McDermott. Our board of directors has determined that each of the members of our audit committee satisfies The Nasdaq Stock Market and SEC independence requirements. Ms. Demski serves as the chair of our audit committee. The functions of this committee include, among other things:

 

   

evaluating the performance, independence and qualifications of our independent auditors and determining whether to retain our existing independent auditors or engage new independent auditors;

 

   

reviewing and approving the engagement of our independent auditors to perform audit services and any permissible non-audit services;

 

   

monitoring the rotation of partners of our independent auditors on our engagement team as required by law;

 

   

prior to engagement of any independent auditor, and at least annually thereafter, reviewing relationships that may reasonably be thought to bear on their independence, and assessing and otherwise taking the appropriate action to oversee the independence of our independent auditor;

 

   

reviewing our annual and quarterly financial statements and reports, including the disclosures contained under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and discussing the statements and reports with our independent auditors and management;

 

   

reviewing, with our independent auditors and management, significant issues that arise regarding accounting principles and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls;

 

   

reviewing with management and our independent auditors any earnings announcements and other public announcements regarding material developments;

 

   

establishing procedures for the receipt, retention and treatment of complaints received by us regarding financial controls, accounting or auditing matters and other matters;

 

   

preparing the report that the SEC requires in our annual proxy statement;

 

   

reviewing and providing oversight of any related-person transactions in accordance with our related person transaction policy and reviewing and monitoring compliance with legal and regulatory responsibilities, including our code of business conduct and ethics;

 

   

reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management are implemented;

 

   

reviewing on a periodic basis our investment policy; and

 

   

reviewing and evaluating on an annual basis the performance of the audit committee and the audit committee charter.

Our board of directors has determined that Ms. Demski qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of the Nasdaq Listing Rules. In making this determination, our board has considered Ms. Demski’s prior experience, business acumen and independence. Both our independent registered public accounting firm and management periodically meet privately with our audit committee.

 

120


Table of Contents

We believe that the composition and functioning of our audit committee complies with all applicable requirements of Sarbanes-Oxley, and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us.

Compensation Committee

Our compensation committee consists of Ms. Demski and Dr. Manian. Dr. Manian serves as the chair of our compensation committee. Our board of directors has determined that each of the members of our compensation committee is a non-employee director, as defined in Rule 16b-3 promulgated under the Exchange Act, and satisfies The Nasdaq Stock Market independence requirements. The functions of this committee include, among other things:

 

   

reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) our overall compensation strategy and policies;

 

   

reviewing and making recommendations to the full board of directors regarding the compensation and other terms of employment of our executive officers;

 

   

reviewing and approving (or if it deems it appropriate, making recommendations to the full board of directors regarding) performance goals and objectives relevant to the compensation of our executive officers and assessing their performance against these goals and objectives;

 

   

reviewing and approving (or if it deems it appropriate, making recommendations to the full board of directors regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs;

 

   

evaluating risks associated with our compensation policies and practices and assessing whether risks arising from our compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us;

 

   

reviewing and making recommendations to the full board of directors regarding the type and amount of compensation to be paid or awarded to our non-employee board members;

 

   

establishing policies with respect to votes by our stockholders to approve executive compensation as required by Section 14A of the Exchange Act and determining our recommendations regarding the frequency of advisory votes on executive compensation, to the extent required by law;

 

   

reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as required by Section 10C of the Exchange Act;

 

   

administering our equity incentive plans;

 

   

establishing policies with respect to equity compensation arrangements;

 

   

reviewing the competitiveness of our executive compensation programs and evaluating the effectiveness of our compensation policy and strategy in achieving expected benefits to us;

 

   

reviewing and making recommendations to the full board of directors regarding the terms of any employment agreements, severance arrangements, change in control protections and any other compensatory arrangements for our executive officers;

 

   

reviewing with management and approving our disclosures under the caption “Compensation Discussion and Analysis” in our periodic reports or proxy statements to be filed with the SEC, to the extent such caption is included in any such report or proxy statement;

 

   

preparing the report that the SEC requires in our annual proxy statement; and

 

   

reviewing and assessing on an annual basis the performance of the compensation committee and the compensation committee charter.

We believe that the composition and functioning of our compensation committee complies with all applicable requirements of Sarbanes-Oxley, and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us.

Nominating and Corporate Governance Committee

Our nominating and corporate governance committee consists of Mr. McDermott and Dr. Pruzanski. Mr. McDermott serves as the chair of our nominating and corporate governance committee. Our board of directors has determined

 

121


Table of Contents

that each of the members of this committee satisfies the Nasdaq Stock Market independence requirements. The functions of this committee include, among other things:

 

   

identifying, reviewing and evaluating candidates to serve on our board of directors consistent with criteria approved by our board of directors;

 

   

determining the minimum qualifications for service on our board of directors;

 

   

evaluating director performance on the board and applicable committees of the board and determining whether continued service on our board is appropriate;

 

   

evaluating, nominating and recommending individuals for membership on our board of directors;

 

   

evaluating nominations by stockholders of candidates for election to our board of directors;

 

   

considering and assessing the independence of members of our board of directors;

 

   

developing a set of corporate governance policies and principles, including a code of business conduct and ethics, periodically reviewing and assessing these policies and principles and their application and recommending to our board of directors any changes to such policies and principles;

 

   

considering questions of possible conflicts of interest of directors as such questions arise; and

 

   

reviewing and assessing on an annual basis the performance of the nominating and corporate governance committee and the nominating and corporate governance committee charter.

We believe that the composition and functioning of our nominating and corporate governance committee complies with all applicable requirements of Sarbanes-Oxley, and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us.

Compensation Committee Interlocks and Insider Participation

None of our current or former executive officers serve as a member of the compensation committee. None of our officers serve, or have served during the last completed fiscal year, on the board of directors or compensation committee, or other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. Prior to establishing the compensation committee, our full board of directors made decisions relating to compensation of our officers. For a description of transactions between us and members of our compensation committee and affiliates of such members, please see “Certain Relationships and Related Party Transactions.”

Code of Business Conduct and Ethics

We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or person performing similar functions. Following this offering, a current copy of the code will be available on the Corporate Governance section of our website, www.equilliumbio.com.

Limitation of Liability and Indemnification

Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, limits the liability of directors to the maximum extent permitted by Delaware law. Delaware law allows a corporation to eliminate the personal liability of directors of a corporation to the corporation and its stockholders for monetary damages for breach of their fiduciary duties as directors, except for liability for any:

 

   

breach of his or her duty of loyalty to the corporation or its stockholders;

 

   

act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

 

   

unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or

 

   

transaction from which the director derived an improper personal benefit.

Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, does not eliminate a director’s duty of care and, in appropriate circumstances, equitable

 

122


Table of Contents

remedies, such as injunctive or other forms of non-monetary relief, will remain available under Delaware law. These limitations also do not affect a director’s responsibilities under any other laws, such as the federal securities laws or other state or federal laws. Our amended and restated bylaws, which will become effective upon the completion of this offering, provide that we will indemnify our directors and executive officers and may indemnify other officers, employees and other agents, to the fullest extent permitted by law. Our amended and restated bylaws, which will become effective upon the completion of this offering, also provide that we are obligated to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding and also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our amended and restated bylaws permit such indemnification. We have obtained a policy of directors’ and officers’ liability insurance.

We have entered, and intend to continue to enter, into separate indemnification agreements with our directors and executive officers, in addition to the indemnification provided for in our amended and restated bylaws. These agreements, among other things, will require us to indemnify our directors and executive officers for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.

The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. A stockholder’s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.

We believe that these provisions in our amended and restated certificate of incorporation and amended and restated bylaws and these indemnification agreements are necessary to attract and retain qualified persons as directors and officers.

Except as otherwise disclosed under the heading “Legal Proceedings” in the “Business” section of this prospectus, at present, there is no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.

 

123


Table of Contents

EXECUTIVE AND DIRECTOR COMPENSATION

Due to our limited operations in 2017, we did not have an executive or board compensation program and we did not pay any executive compensation or issue any stock-based compensation to any executive or board member in 2017. Daniel M. Bradbury, our Chief Executive Officer, was our only executive officer during 2017 and accordingly is our only named executive officer for the period March 16, 2017 (inception) through December 31, 2017. During 2017, Mr. Bradbury served as our President. Our other current executive officers commenced employment with us during 2018. We have included information in the following narrative regarding our named executive officer and other current executive officers’ 2018 compensation where it may be helpful to an understanding of our compensation program.

Summary Compensation Table

Mr. Bradbury did not receive any compensation from us for services in any capacity during the period March 16, 2017 (inception) through December 31, 2017.

Annual Base Salary

Other than with respect to Mr. Bradbury, the base salary of our executive officers is generally determined and approved in connection with the commencement of employment of the executive, by our board of directors. As of December 31, 2017, Mr. Bradbury did not receive an annual base salary. Effective June 1, 2018, in connection with his offer letter, the board of directors approved an annual base salary for Mr. Bradbury of $400,000.

Bonus Compensation

Mr. Bradbury was not entitled to and did not receive any bonus payments during 2017. Our board of directors or compensation committee may approve bonuses in the future for our executives based on individual performance, company performance or as otherwise determined appropriate.

Beginning in 2018, pursuant to his offer letter, Mr. Bradbury is entitled to an annual discretionary performance-based bonus. Mr. Bradbury’s offer letter is described under “—Agreements with Executive Officers.”

Equity-Based Incentive Awards

Our equity-based incentive awards are designed to align our interests and those of our stockholders with those of our employees and consultants, including our executive officers. The board of directors is responsible for approving equity grants. As of the date of this prospectus, we have not granted any equity awards to Mr. Bradbury.

In 2018, we granted stock options to each of Mr. Keyes and Dr. Polu, which are described in the section entitled “—Agreements with Executive Officers.” Following this offering, we expect to use stock options or other stock awards as an incentive for long-term compensation to our executive officers at such times as our board of directors determines appropriate. Other than our founders, our executive officers generally are awarded an initial grant in the form of a stock option in connection with their commencement of employment with us. Additional grants may occur periodically in order to specifically incentivize executives with respect to achieving certain corporate goals or to reward executives for exceptional performance.

Prior to this offering, we have granted all stock options pursuant to our 2017 Plan. Following this offering, we expect to grant equity incentive awards under the terms of our 2018 Plan. The terms of the 2017 Plan and the 2018 Plan are described below under “—Equity Benefit Plans.”

All options are granted with an exercise price per share that is no less than the fair market value of our common stock on the date of grant of such award. Our stock option awards generally vest over a four-year period subject to continued service and may be subject to acceleration of vesting and exercisability under certain termination and change in control events.

 

124


Table of Contents

Agreements with Executive Officers

Agreement with Mr. Bradbury

We did not maintain an agreement with Mr. Bradbury governing his services to us during 2017. In June 2018, we entered into an offer letter with Mr. Bradbury, which governs the terms of his employment with us. Under the terms of the offer letter, Mr. Bradbury is entitled to an annual base salary of $400,000 and is eligible to receive an annual performance-based bonus opportunity at a target amount of 35% of his base salary, based on the attainment of individual and corporate objectives to be determined and approved by us. The payment and amount of the annual bonus will be in our sole discretion. The offer letter also provides for severance benefits described below under “—Potential Payments and Benefits upon Termination or Change in Control.” In addition, Mr. Bradbury is eligible to participate in the employee benefit plans generally available to our employees, and is subject to customary confidentiality covenants.

Agreement with Mr. Steel

In June 2018, we entered into an offer letter with Mr. Steel, our President and Chief Business Officer, which governs the terms of his employment with us. Under the terms of the offer letter, Mr. Steel is entitled to an annual base salary of $375,000 and is eligible for an annual performance-based bonus opportunity at a target amount of 35% of his base salary, based on the attainment of individual and corporate objectives to be determined and approved by us. The payment and amount of the annual bonus will be in our sole discretion. The offer letter also provides for severance benefits described below under “—Potential Payments and Benefits upon Termination or Change in Control.” In addition, Mr. Steel is eligible to participate in the employee benefit plans generally available to our employees, and is subject to customary confidentiality covenants.

Agreement with Dr. Connelly

In January 2018, we entered into an offer letter Dr. Connelly, our Chief Scientific Officer, which governs the terms of his employment with us, and which was amended and restated in June 2018. Under the terms of his offer letter, Dr. Connelly is currently entitled to an annual base salary of $300,000 and is eligible for an annual performance-based bonus opportunity at a target amount of 35% of his base salary, based on the attainment of individual and corporate objectives to be determined and approved by us. The payment and amount of the annual bonus will be in our sole discretion. The offer letter also provides for severance benefits described below under “—Potential Payments and Benefits upon Termination or Change in Control.” In addition, Dr. Connelly is eligible to participate in the employee benefit plans generally available to our employees, and is subject to customary confidentiality covenants.

Agreement with Mr. Keyes

In March 2018, we entered into an offer letter with Mr. Keyes, our Chief Financial Officer, which governs the terms of his employment with us. Under the terms of the offer letter, Mr. Keyes is entitled to an annual base salary of $290,000 and is eligible for an annual performance-based bonus opportunity at a target amount of 30% of his base salary, based on the attainment of individual and corporate objectives to be determined and approved by us. The payment and amount of the annual bonus will be in our sole discretion. The offer letter also provides for severance benefits described below under “—Potential Payments and Benefits upon Termination or Change in Control.” In addition, Mr. Keyes is eligible to participate in the employee benefit plans generally available to our employees, and is subject to customary confidentiality covenants.

The offer letter also contemplates the grant to Mr. Keyes of a stock option, which was granted to Mr. Keyes on June 6, 2018. The option provides that Mr. Keyes may purchase up to 148,720 shares of our common stock at an exercise price of $0.05 per share, which vests as to 25% of the shares on April 1, 2019 with the balance of shares vesting in approximately equal monthly installments over the remaining 36 months, subject to Mr. Keyes’ continued service with us, subject to full acceleration of all of the shares in the event Mr. Keyes is terminated by us without cause or resigns for good reason within 12 months after a change in control. In June 2018, Mr. Keyes early exercised his option in full and we issued him 148,720 shares of common stock, all of which are restricted shares subject to the vesting schedule described above.

 

125


Table of Contents

Agreement with Dr. Polu

On August 1, 2018, we entered into an offer letter with Dr. Polu, our Chief Medical Officer, which governs the terms of his employment with us. Under the terms of the offer letter, Dr. Polu is entitled to an annual base salary of $375,000 and is eligible for an annual performance-based bonus opportunity at a target amount of 30% of his base salary, based on the attainment of individual and corporate objectives to be determined and approved by us. The payment and amount of the annual bonus will be in our sole discretion. The offer letter also provides for severance benefits described below under “—Potential Payments and Benefits upon Termination or Change in Control.” In addition, Dr. Polu is eligible to participate in the employee benefit plans generally available to our employees, and is subject to customary confidentiality covenants. The offer letter also contemplates that Dr. Polu will, at our discretion, be reimbursed for up to $50,000 per year, subject to adjustment based on our business needs, to commute to our offices in La Jolla.

The offer letter also contemplates the grant to Dr. Polu of a stock option, which was granted to Dr. Polu on August 16, 2018. The option provides that Dr. Polu may purchase up to 208,216 shares of our common stock at an exercise price of $3.30 per share, which vests as to 25% of the shares on September 1, 2019 with the balance of shares vesting in approximately equal monthly installments over the remaining 36 months, subject to Dr. Polu’s continued service with us, subject to full acceleration of all of the shares in the event Dr. Polu is terminated by us without cause or resigns for good reason within 12 months after a change in control.

Potential Payments and Benefits upon Termination or Change in Control

Each of our executive officer’s employment is at will and may be terminated by us at any time. Regardless of the manner in which an executive officer’s service terminates, such executive officer is entitled to receive any and all accrued but unpaid amounts earned during his or her term of service, including unpaid salary and unused vacation, as applicable. In addition, the offer letter agreements with each of Messrs. Bradbury, Steel, and Keyes and Drs. Connelly and Polu each provide that, if we terminate such executive’s employment without cause, the executive is entitled to receive (i) continuation of the applicable executive officer’s then-current base salary for six months and (ii) payment of the premiums for group health insurance COBRA continuance coverage for six months or, if earlier, until the date on which the executive becomes eligible to receive comparable benefits from another employer.

Additionally, if we terminate the executive’s employment without cause within one month prior to, or 12 months following, certain change of control and asset sale transactions, the executive is entitled to receive (i) continuation of the applicable executive officer’s then-current base salary for 12 months, (ii) an amount equal to the applicable executive’s target annual bonus and (iii) payment of the premiums for group health insurance COBRA continuance coverage for 12 months or, if earlier, until the date on which the executive becomes eligible to receive comparable benefits from another employer. In each case, the severance benefits are conditioned upon the execution and non-revocation of a general release of claims by the applicable executive in a form provided by us. Mr. Keyes and Dr. Polu are also entitled to vesting acceleration upon their respective terminations in connection with a change in control pursuant to the terms of their stock options granted on June 6, 2018 and August 16, 2018, respectively, as described above.

Outstanding Equity Awards at Fiscal Year-End

Mr. Bradbury does not hold any unexercised options, stock that has not vested or equity incentive plan awards that were outstanding as of December 31, 2017.

We did not engage in any repricings or other modifications or cancellations to our named executive officer’s outstanding equity awards during the period March 16, 2017 (inception) through December 31, 2017.

Perquisites, Health, Welfare and Retirement Benefits

Our named executive officer and other executive officers, during their employment with us, are eligible to participate in our employee benefit plans, including our medical, dental, group term life, disability and accidental death and dismemberment insurance plans, in each case on the same basis as all of our other employees. In addition, we provide a 401(k) plan to our employees, including our named executive officer, as discussed in the section below entitled “—401(k) Plan.”

 

126


Table of Contents

We generally do not provide perquisites or personal benefits to our named executive officer and other executive officers, except in limited circumstances. We do, however, pay the premiums for medical, dental, group term life, disability and accidental death and dismemberment insurance for all of our employees, including our named executive officer. Our board of directors may elect to adopt qualified or nonqualified benefit plans in the future if it determines that doing so is in our best interests.

401(k) Plan

We maintain a defined contribution employee retirement plan, or 401(k) plan, for our employees. Our named executive officer and other executive officers are eligible to participate in the 401(k) plan on the same basis as our other employees. The 401(k) plan is intended to qualify as a tax-qualified plan under Section 401(k) of the U.S. Internal Revenue Code of 1986, as amended, or the Code. The 401(k) plan provides that each participant may contribute up to the lesser of 100% of his or her compensation or the statutory limit, which is $18,000 and $18,500 for calendar years 2017 and 2018, respectively. Participants that are 50 years or older can also make “catch-up” contributions, which in calendar years 2017 and 2018 may be up to an additional $6,000 above the statutory limit. We currently do not make matching contributions into the 401(k) plan on behalf of participants. Participant contributions are held and invested, pursuant to the participant’s instructions, by the plan’s trustee.

Nonqualified Deferred Compensation

We do not maintain nonqualified defined contribution plans or other nonqualified deferred compensation plans. Our board of directors may elect to provide our officers and other employees with nonqualified defined contribution or other nonqualified deferred compensation benefits in the future, if it determines that doing so is in our best interests.

Equity Benefit Plans

The principal features of our equity plans are summarized below. These summaries are qualified in their entirety by reference to the actual text of the plans, which are filed as exhibits to the registration statement of which this prospectus is a part.

2018 Plan

Our board of directors adopted our 2018 Plan in October 2018 and our stockholders approved our 2018 Plan in October 2018 prior to this offering. Our 2018 Plan is a successor to and continuation of our 2017 Plan. No stock awards may be granted under the 2018 Plan until the date of the underwriting agreement related to this offering. Once the 2018 Plan is effective, no further grants will be made under the 2017 Plan.

Stock awards. Our 2018 Plan provides for the grant of incentive stock options, or ISOs, within the meaning of Section 422 of the Code, to employees, including employees of any parent or subsidiary, and for the grant of nonstatutory stock options, or NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other forms of stock awards to employees, directors and consultants, including employees and consultants of our affiliates.

Authorized shares. Initially, the maximum number of shares of our common stock that may be issued under our 2018 Plan after it becomes effective will be 2,229,773 shares, which is the sum of (1) 1,040,000 new shares, plus (2) the number of shares (not to exceed 1,189,773 shares) (i) that remain available for the grant of future awards under our 2017 Plan at the time our 2018 Plan becomes effective, and (ii) any shares subject to outstanding stock options or other stock awards that were granted under our 2017 Plan that terminate or expire prior to exercise or settlement; are forfeited because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares of our common stock reserved for issuance under our 2018 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2019 (assuming the 2018 Plan becomes effective in 2018) through January 1, 2028, in an amount equal to 5.0% of the total number of shares of our capital stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by our board of directors. The maximum number of shares of our common stock that may be issued on the exercise of ISOs under our 2018 Plan is 6,689,319.

 

127


Table of Contents

Shares subject to stock awards granted under our 2018 Plan that expire or terminate without being exercised in full or that are paid out in cash rather than in shares do not reduce the number of shares available for issuance under our 2018 Plan. If any shares of common stock issued pursuant to a stock award are forfeited back to or repurchased or reacquired by us for any reason, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the 2018 Plan. Any shares reacquired in satisfaction of tax withholding obligations or as consideration for the exercise or purchase price of a stock award will again become available for issuance under the 2018 Plan.

The maximum number of shares of common stock subject to stock awards granted under the 2018 Plan or otherwise during a single calendar year to any non-employee director, taken together with any cash fees paid by us to such non-employee director during such calendar year for service on the board of directors, will not exceed $350,000 in total value (calculating the value of any such stock awards based on the grant date fair value of such stock awards for financial reporting purposes), or, with respect to the calendar year in which a non-employee director is first appointed or elected to the board of directors, $550,000.

Plan administration. Our board of directors, or a duly authorized committee of our board of directors, will administer our 2018 Plan and is referred to as the “plan administrator” herein. Our board of directors may also delegate to one or more of our officers the authority to (1) designate employees (other than officers) to receive specified stock awards and (2) determine the number of shares subject to such stock awards. Under our 2018 Plan, our board of directors has the authority to determine award recipients, grant dates, the numbers and types of stock awards to be granted, the applicable fair market value, and the provisions of each stock award, including the period of exercisability and the vesting schedule applicable to a stock award.

Under the 2018 Plan, the board of directors also generally has the authority to effect, with the consent of any adversely affected participant, (A) the reduction of the exercise, purchase, or strike price of any outstanding award; (B) the cancellation of any outstanding award and the grant in substitution therefore of other awards, cash, or other consideration; or (C) any other action that is treated as a repricing under generally accepted accounting principles.

Stock options. ISOs and NSOs are granted under stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for stock options, within the terms and conditions of the 2018 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2018 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator.

The plan administrator determines the term of stock options granted under the 2018 Plan, up to a maximum of 10 years. Unless the terms of an optionholder’s stock option agreement provide otherwise, if an optionholder’s service relationship with us or any of our affiliates ceases for any reason other than disability, death, or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. This period may be extended in the event that exercise of the option is prohibited by applicable securities laws or our insider trading policy. If an optionholder’s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 18 months following the date of death. If an optionholder’s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of 12 months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. In no event may an option be exercised beyond the expiration of its term.

Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include (1) cash, check, bank draft or money order, (2) a broker-assisted cashless exercise, (3) the tender of shares of our common stock previously owned by the optionholder, (4) a net exercise of the option if it is an NSO, or (5) other legal consideration approved by the plan administrator.

Unless the plan administrator provides otherwise, options generally are not transferable except by will or the laws of descent and distribution. Subject to approval of the plan administrator or a duly authorized officer in each case,

 

128


Table of Contents

(i) an option may be transferred pursuant to a domestic relations order, official marital settlement agreement, or other divorce or separation instrument and (ii) an optionholder may designate a beneficiary who may exercise the option following the optionholder’s death.

Tax limitations on ISOs. The aggregate fair market value, determined at the time of grant, of our common stock with respect to ISOs that are exercisable for the first time by an award holder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our affiliates unless (1) the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant, and (2) the term of the ISO does not exceed five years from the date of grant.

Restricted stock unit awards. Restricted stock unit awards are granted under restricted stock unit award agreements adopted by the plan administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock unit awards that have not vested will be forfeited once the participant’s continuous service ends for any reason.

Restricted stock awards. Restricted stock awards are granted under restricted stock award agreements adopted by the plan administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past or future services to us, or any other form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. The plan administrator determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant’s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right.

Stock appreciation rights. Stock appreciation rights are granted under stock appreciation right agreements adopted by the plan administrator. The plan administrator determines the purchase price or strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our common stock on the date of grant. A stock appreciation right granted under the 2018 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator.

The plan administrator determines the term of stock appreciation rights granted under the 2018 Plan, up to a maximum of 10 years. If a participant’s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. This period may be further extended in the event that exercise of the stock appreciation right following such a termination of service is prohibited by applicable securities laws or our insider trading policy. If a participant’s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for cause, stock appreciation rights generally terminate immediately upon the occurrence of the event giving rise to the termination of the individual for cause. In no event may a stock appreciation right be exercised beyond the expiration of its term.

Performance awards. The 2018 Plan permits the grant of performance-based stock and cash awards. Our compensation committee may structure awards so that the stock or cash will be issued or paid only following the achievement of certain pre-established performance goals during a designated performance period.

The performance goals that may be selected include one or more of the following: (i) sales; (ii) revenues; (iii) assets; (iv) expenses; (v) market penetration or expansion; (vi) earnings from operations; (vii) earnings before or after deduction for all or any portion of interest, taxes, depreciation, amortization, incentives, service fees or extraordinary or special items, whether or not on a continuing operations or an aggregate or per share basis; (viii) net income or

 

129


Table of Contents

net income per common share (basic or diluted); (ix) return on equity, investment, capital or assets; (x) one or more operating ratios; (xi) borrowing levels, leverage ratios or credit rating; (xii) market share; (xiii) capital expenditures; (xiv) cash flow, free cash flow, cash flow return on investment, or net cash provided by operations; (xv) stock price, dividends or total stockholder return; (xvi) development of new technologies or products; (xvii) sales of particular products or services; (xviii) economic value created or added; (xix) operating margin or profit margin; (xx) customer acquisition or retention; (xxi) raising or refinancing of capital; (xxii) successful hiring of key individuals; (xxiii) resolution of significant litigation; (xxiv) acquisitions and divestitures (in whole or in part); (xxv) joint ventures and strategic alliances; (xxvi) spin-offs, split-ups and the like; (xxvii) reorganizations; (xxviii) recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings; (xxix) or strategic business criteria, consisting of one or more objectives based on the following goals: achievement of timely development, design management or enrollment, meeting specified market penetration or value added, payor acceptance, patient adherence, peer reviewed publications, issuance of new patents, establishment of or securing of licenses to intellectual property, product development or introduction (including, without limitation, any clinical trial accomplishments, regulatory or other filings, approvals or milestones, discovery of novel products, maintenance of multiple products in pipeline, product launch or other product development milestones), geographic business expansion, cost targets, cost reductions or savings, customer satisfaction, operating efficiency, acquisition or retention, employee satisfaction, information technology, corporate development (including, without limitation, licenses, innovation, research or establishment of third-party collaborations), manufacturing or process development, legal compliance or risk reduction, patent application or issuance goals, or goals relating to acquisitions, divestitures or other business combinations (in whole or in part), joint ventures or strategic alliances; and (xxx) other measures of performance selected by the board of directors.

The performance goals may be based on company-wide performance or performance of one or more business units, divisions, affiliates, or business segments, and may be either absolute or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Our board of directors is authorized at any time in its sole discretion, to adjust or modify the calculation of a performance goal for such performance period in order to prevent the dilution or enlargement of the rights of participants, (a) in the event of, or in anticipation of, any unusual or extraordinary corporate item, transaction, event or development; (b) in recognition of, or in anticipation of, any other unusual or nonrecurring events affecting us, or our financial statements in response to, or in anticipation of, changes in applicable laws, regulations, accounting principles, or business conditions; or (c) in view of the board of director’s assessment of our business strategy, performance of comparable organizations, economic and business conditions, and any other circumstances deemed relevant. Specifically, the board of directors is authorized to make adjustment in the method of calculating attainment of performance goals and objectives for a performance period as follows: (i) to exclude the dilutive effects of acquisitions or joint ventures; (ii) to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; and (iii) to exclude the effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends. In addition, the board of directors is authorized to make adjustment in the method of calculating attainment of performance goals and objectives for a performance period as follows: (i) to exclude restructuring and/or other nonrecurring charges; (ii) to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated net sales and operating earnings; (iii) to exclude the effects of changes to generally accepted accounting standards required by the Financial Accounting Standards Board; (iv) to exclude the effects of any items that are “unusual” in nature or occur “infrequently” as determined under generally accepted accounting principles; (v) to exclude the effects to any statutory adjustments to corporate tax rates; and (vi) to make other appropriate adjustments selected by the board of directors.

Other stock awards. The plan administrator may grant other awards based in whole or in part by reference to our common stock. The plan administrator will set the number of shares under the stock award and all other terms and conditions of such awards.

Changes to capital structure. In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, appropriate adjustments will be made to (1) the class and maximum

 

130


Table of Contents

number of shares reserved for issuance under the 2018 Plan, (2) the class and maximum number of shares by which the share reserve may increase automatically each year, (3) the class and maximum number of shares that may be issued on the exercise of ISOs, (4) the class(es) and maximum number of securities that may be awarded to any non-employee director, and (5) the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards.

Corporate transactions. Our 2018 Plan provides that in the event of certain specified significant corporate transactions (or a change in control, as defined below), unless otherwise provided in an award agreement or other written agreement between us and the award holder, the plan administrator may take one or more of the following actions with respect to such stock awards:

 

   

arrange for the assumption, continuation, or substitution of a stock award by a successor corporation;

 

   

arrange for the assignment of any reacquisition or repurchase rights held by us to a successor corporation;

 

   

accelerate the vesting, in whole or in part, of the stock award and provide for its termination if not exercised (if applicable) at or before the effective time of the transaction;

 

   

arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us;

 

   

cancel or arrange for the cancellation of the stock award, to the extent not vested or not exercised before the effective time of the transaction, in exchange for a cash payment, if any; or

 

   

make a payment equal to the excess, if any, of (A) the value of the property the participant would have received on exercise of the award immediately before the effective time of the transaction, over (B) any exercise price payable by the participant in connection with the exercise.

The plan administrator is not obligated to treat all stock awards or portions of stock awards in the same manner and is not obligated to take the same actions with respect to all participants.

Under the 2018 Plan, a corporate transaction is generally the consummation of: (1) a sale of all or substantially all of our assets, (2) the sale or disposition of more than 50% of our outstanding securities, (3) a merger or consolidation where we do not survive the transaction, or (4) a merger or consolidation where we do survive the transaction but the shares of our common stock outstanding immediately before such transaction are converted or exchanged into other property by virtue of the transaction.

Change in control. In the event of a change in control, the plan administrator may take any of the above-mentioned actions. Awards granted under the 2018 Plan may be subject to additional acceleration of vesting and exercisability upon or after a change in control as may be provided in the applicable stock award agreement or in any other written agreement between us or any affiliate and the participant, but in the absence of such provision, no such acceleration will automatically occur. Under the 2018 Plan, a change in control is generally (1) the acquisition by any person or company of more than 50% of the combined voting power of our then outstanding stock, (2) a merger, consolidation or similar transaction in which our stockholders immediately before the transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity) in substantially the same proportions as their ownership immediately prior to such transaction, (3) a sale, lease, exclusive license or other disposition of all or substantially all of our assets other than to an entity more than 50% of the combined voting power of which is owned by our stockholders in substantially the same proportions as their ownership of our outstanding voting securities immediately prior to such transaction, (4) a complete dissolution or liquidation of the company, or (5) when a majority of our board of directors becomes comprised of individuals who were not serving on our board of directors on the date of the underwriting agreement related to this offering, or the incumbent board, or whose nomination, appointment, or election was not approved by a majority of the incumbent board still in office.

Plan amendment or termination. Our board of directors has the authority to amend, suspend, or terminate our 2018 Plan, provided that such action does not materially impair the existing rights of any participant without such participant’s written consent. Certain material amendments also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our board of directors adopts our 2018 Plan. No stock awards may be granted under our 2018 Plan while it is suspended or after it is terminated.

 

131


Table of Contents

2017 Plan

Our board of directors and our stockholders approved our 2017 Plan in December 2017. As of June 30, 2018, there were 814,999 shares remaining available for the future grant of stock awards under our 2017 Plan. As of June 30, 2018, there were outstanding stock options covering a total of 107,084 shares of our common stock that were granted under our 2017 Plan. We expect that any shares remaining available for issuance under the 2017 will become available for issuance under the 2018 Plan in connection with this offering.

Stock awards. Our 2017 Plan provides for the grant of ISOs within the meaning of Section 422 of the Code to employees, including employees of any parent or subsidiary, and for the grant of NSOs, stock appreciation rights, restricted stock, restricted stock units and other forms of stock awards to employees, directors and consultants, including employees and consultants of our affiliates. To date, we have only granted stock options under the 2017 Plan.

Authorized shares. Subject to certain capitalization adjustments, the aggregate number of shares of common stock that may be issued pursuant to stock awards under the 2017 Plan will not exceed 1,189,773 shares. The maximum number of shares of our common stock that may be issued pursuant to the exercise of ISOs under our 2017 Plan is 3,569,319 shares.

Shares subject to stock awards granted under our 2017 Plan that expire or otherwise terminate without being exercised in full or that are settled in cash rather than in shares do not reduce or otherwise offset the number of shares available for issuance under our 2017 Plan. Additionally, if any shares issued pursuant to a stock award are forfeited back to or repurchased because of the failure to meet a contingency or condition required to vest, then the shares that are forfeited or repurchased will revert to and again become available for issuance under the 2017 Plan. This includes shares used to pay the exercise price of a stock award or to satisfy the tax withholding obligations related to a stock award.

Plan administration. Our board of directors, or a duly authorized committee of our board of directors to which the board delegates its administrative authority, will administer our 2017 Plan and is referred to as the “plan administrator” herein. The plan administrator may also delegate to one or more of our officers the authority to (1) designate employees (other than officers) to receive specified options and stock appreciation rights (and to the extent permitted by applicable law, other stock awards) and (2) determine the number of shares subject to such stock awards; provided, however, that the board resolutions regarding such delegation must specify the total number of shares that may be subject to awards granted by such officer, and provided further, that no officer may grant an award under the 2017 Plan to himself or herself. Under our 2017 Plan, the plan administrator has the authority to, among other things, determine award recipients, dates of grant, the numbers and types of stock awards to be granted, the applicable fair market value and the provisions of each stock award, including the period of their exercisability and the vesting schedule applicable to a stock award, to construe and interpret the 2017 Plan and awards granted thereunder (and to establish, amend and revoke any rules and regulations for the administration of the 2017 Plan and any such awards), or to accelerate awards.

Under the 2017 Plan, the plan administrator also generally has the authority to effect, with the consent of any adversely affected participant, (A) the reduction of the exercise, purchase, or strike price of any outstanding award; (B) the cancellation of any outstanding award and the grant in substitution therefor of other awards, cash, or other consideration; or (C) any other action that is treated as a repricing under generally accepted accounting principles.

Stock options. ISOs and NSOs are granted under stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for stock options, within the terms and conditions of the 2017 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant (or 110% of the fair market value for certain major stockholders). Options granted under the 2017 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator.

The plan administrator determines the term of stock options granted under the 2017 Plan, up to a maximum of 10 years (or five years, for certain major stockholders). If an optionholder’s service relationship with us or any of our

 

132


Table of Contents

affiliates ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of up to three months following the cessation of service. This period may be extended in the event that exercise of the option is prohibited by applicable securities laws or our insider trading policy.

If an optionholder’s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of up to 18 months following the date of death. If an optionholder’s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of up to 12 months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. In no event may an option be exercised beyond the expiration of its term.

Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include (1) cash, check, bank draft or money order payable to us, (2) a broker-assisted cashless exercise, (3) the tender of shares of our common stock previously owned by the optionholder, (4) a net exercise of the option if it is an NSO, (5) a deferred payment arrangement, or (6) other legal consideration approved by the plan administrator.

Unless the plan administrator provides otherwise, options generally are not transferable except by will or the laws of descent and distribution. Subject to approval of the plan administrator or a duly authorized officer in each case, (i) an option may be transferred pursuant to a domestic relations order, official marital settlement agreement, or other divorce or separation instrument and (ii) an optionholder may designate a beneficiary who may exercise the option following the optionholder’s death.

Tax limitations on ISOs. The aggregate fair market value, determined at the time of grant, of our common stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our affiliates unless (1) the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant, and (2) the term of the ISO does not exceed five years from the date of grant.

Restricted stock unit awards. Restricted stock unit awards are granted under restricted stock unit award agreements adopted by the plan administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. A restricted stock unit awards may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock unit awards that have not vested will be forfeited once the participant’s continuous service ends for any reason.

Restricted stock awards. Restricted stock awards are granted under restricted stock award agreements adopted by the plan administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past or future services to us, or any other form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. The plan administrator determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant’s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right.

Changes to capital structure. In the event of a “capitalization adjustment,” the board of directors, in its discretion, will make appropriate and proportionate adjustments to (1) the class and maximum number of shares reserved for issuance under the 2017 Plan, (2) the class and maximum number of shares that may be issued on the exercise of ISOs, and (3) the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards. For purposes of the 2017 Plan, “capitalization adjustment” generally means any change that is made in (or other events occurring with respect to) our common stock subject to the 2017 Plan or any award

 

133


Table of Contents

without the receipt of consideration by us through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large non-recurring cash dividend, stock split, reverse stock split, liquidating dividend, combination or exchange of shares, change in corporate structure, or other similar equity restructuring transaction (within the meaning of Statement of Financial Accounting Standards Board ASC Topic 718).

Corporate transactions. Our 2017 Plan provides that in the event of a “corporate transaction,” unless otherwise provided in an award agreement or other written agreement between us and the award holder, the plan administrator may take one or more of the following actions with respect to such stock awards:

 

   

arrange for the assumption, continuation, or substitution of a stock award by a surviving or acquiring corporation;

 

   

arrange for the assignment of any reacquisition or repurchase rights held by us to the surviving or acquiring corporation;

 

   

accelerate the vesting, in whole or in part, of the stock award and provide for its termination if not exercised (if applicable) at or before the effective time of the transaction;

 

   

arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us;

 

   

cancel or arrange for the cancellation of the stock award, to the extent not exercised before the effective time of the transaction, in exchange for a payment in such form as may be determined by our board of directors, equal to the excess, if any, of (A) the per share amount (or value of property per share) payable to holders of common stock in connection with the transaction, over (B) the per share exercise price under the stock award (if any), multiplied by the number of vested shares subject to the stock award;

 

   

make a payment equal to the excess, if any, of (A) the value of the property the participant would have received on exercise of the award immediately before the effective time of the transaction, over (B) any exercise price payable by the participant in connection with the exercise;

 

   

suspend the exercise of the stock award, prior to the effective time of the transaction, for such period as our board of directors determines is necessary to facilitate the negotiation and consummation of the transaction; and

 

   

if a stock award is eligible for “early exercise,” cancel or arrange for the cancellation of any such “early exercise” rights upon the transaction, such that following the transaction, such stock award may only be exercised to the extent vested.

The plan administrator is not obligated to treat all stock awards or portions of stock awards in the same manner and is not obligated to treat all participants in the same manner.

Under the 2017 Plan, a “corporate transaction” is generally defined as the consummation, in a single transaction or in a series of related transactions, of: (1) a sale of all or substantially all of our assets, (2) the sale or disposition of more than 50% of our outstanding securities, (3) a merger or consolidation where we do not survive the transaction, or (4) a merger or consolidation where we do survive the transaction but the shares of our common stock outstanding immediately before such transaction are converted or exchanged into other property by virtue of the transaction.

Change in control. A stock award may be subject to additional acceleration of vesting and exercisability upon or after a change in control as may be provided in an applicable award agreement or other written agreement, but in the absence of such provision, no such acceleration will occur. Under the 2017 Plan, a “change in control” is generally defined as (1) certain acquisitions by a person or company of more than 50% of the combined voting power of our then outstanding stock, (2) a merger, consolidation or similar transaction in which our stockholders immediately before the transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity) in substantially the same proportions as their ownership immediately prior to such transaction, or (3) a sale, lease, exclusive license or other disposition of all or substantially all of our consolidated assets other than to an entity more than 50% of the combined voting power of which is owned by our stockholders in substantially the same proportions as their ownership of our outstanding voting securities immediately prior to such transaction.

 

134


Table of Contents

Plan amendment or termination. Our board of directors has the authority to amend, suspend, or terminate our 2017 Plan, provided that such action does not impair the existing rights of any participant without such participant’s written consent. Certain material amendments also require the approval of our stockholders. Unless terminated sooner, the 2017 Plan will automatically terminate on December 10, 2027. No stock awards may be granted under our 2017 Plan while it is suspended or after it is terminated.

2018 Employee Stock Purchase Plan

Our board of directors adopted, and our stockholders approved, our ESPP in October 2018 prior to this offering. The ESPP will become effective immediately prior to and contingent upon the date of the underwriting agreement related to this offering. The purpose of the ESPP is to secure the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward our success and that of our affiliates. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Code for U.S. employees.

Share reserve. Following this offering, the ESPP authorizes the issuance of 343,275 shares of our common stock under purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of our common stock reserved for issuance will automatically increase on January 1 of each calendar year, beginning on January 1, 2019 (assuming the ESPP becomes effective in 2018) through January 1, 2028, by the lesser of (1) 1.0% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of the automatic increase, and (2) 343,275 shares; provided that before the date of any such increase, our board of directors may determine that such increase will be less than the amount set forth in clauses (1) and (2). As of the date hereof, no shares of our common stock have been purchased under the ESPP.

Administration. Our board of directors administers the ESPP and may delegate its authority to administer the ESPP to our compensation committee. The ESPP is implemented through a series of offerings under which eligible employees are granted purchase rights to purchase shares of our common stock on specified dates during such offerings. Under the ESPP, we may specify offerings with durations of not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. An offering under the ESPP may be terminated under certain circumstances.

Payroll deductions. Generally, all regular employees, including executive officers, employed by us or by any of our designated affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, up to 15% of their earnings (as defined in the ESPP) for the purchase of our common stock under the ESPP. Unless otherwise determined by our board of directors, common stock will be purchased for the accounts of employees participating in the ESPP at a price per share that is at least the lesser of (1) 85% of the fair market value of a share of our common stock on the first date of an offering, or (2) 85% of the fair market value of a share of our common stock on the date of purchase.

Limitations. Employees may have to satisfy one or more of the following service requirements before participating in the ESPP, as determined by our board of directors, including: (1) being customarily employed for more than 20 hours per week, (2) being customarily employed for more than five months per calendar year, or (3) continuous employment with us or one of our affiliates for a period of time (not to exceed two years). No employee may purchase shares under the ESPP at a rate in excess of $25,000 worth of our common stock based on the fair market value per share of our common stock at the beginning of an offering for each calendar year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value under Section 424(d) of the Code.

Changes to capital structure. In the event that there occurs a change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar transaction, the board of directors will make appropriate adjustments to: (1) the class(es) and maximum number of shares reserved under the ESPP, (2) the class(es) and

 

135


Table of Contents

maximum number of shares by which the share reserve may increase automatically each year, (3) the class(es) and number of shares subject to and purchase price applicable to outstanding offerings and purchase rights, and (4) the class(es) and number of shares that are subject to purchase limits under ongoing offerings.

Corporate transactions. In the event of certain significant corporate transactions, any then-outstanding rights to purchase our stock under the ESPP may be assumed, continued, or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue, or substitute for such purchase rights, then the participants’ accumulated payroll contributions will be used to purchase shares of our common stock within 10 business days before such corporate transaction, and such purchase rights will terminate immediately.

Under the ESPP, a corporate transaction is generally the consummation of: (1) a sale of all or substantially all of our assets, (2) the sale or disposition of more than 50% of our outstanding securities, (3) a merger or consolidation where we do not survive the transaction, and (4) a merger or consolidation where we do survive the transaction but the shares of our common stock outstanding immediately before such transaction are converted or exchanged into other property by virtue of the transaction.

ESPP amendment or termination. Our board of directors has the authority to amend or terminate our ESPP, provided that except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder’s consent. We will obtain stockholder approval of any amendment to our ESPP as required by applicable law or listing requirements.

Director Compensation

Historically, we have not paid or awarded any cash compensation to any of our non-employee directors for service on our board of directors. In addition, we have not paid equity compensation to our non-employee directors for service on our board of directors, except as set forth below.

During the period March 16, 2017 (inception) through December 31, 2017, we did not pay or award any compensation to any of our non-employee directors for service on our board and none of our non-employee directors were granted or held outstanding stock or option awards. The following table sets forth in summary form information concerning the compensation that we paid or awarded during the period March 16, 2017 (inception) through December 31, 2017 to each of our non-employee directors who served at any time during 2017. Ms. Demski, Mr. McDermott and Dr. Pruzanski were not members of our board of directors in 2017 and are not included in the table.

 

 

 

NAME

   ALL OTHER
COMPENSATION
($)
    TOTAL
($)
 

Stephen Connelly, Ph.D.

     30,000  (1)       30,000  

Bala S. Manian, Ph.D.

            

Bruce D. Steel

            

 

 

(1)    Represents fees paid to Dr. Connelly for his consulting services to us during 2017. Dr. Connelly provided scientific and business-related consulting services to us from October 2017 through December 2017 pursuant to a consulting agreement with us effective as of October 16, 2017, which terminated in connection with his commencement as our Chief Scientific Officer in January 2018.

On June 6, 2018, we granted Dr. Manian an option to purchase 23,799 shares of common stock at an exercise price of $0.05 per share. Dr. Manian’s option vests in 48 successive equal monthly installments beginning on June 6, 2018, subject to Dr. Manian’s continued service with us. In July 2018, Dr. Manian early exercised his option in full and we issued him 23,799 shares of common stock, which are restricted shares subject to the vesting schedule described in the preceding sentence.

On September 13, 2018, we granted each of Ms. Demski and Mr. McDermott an option to purchase 23,799 shares of common stock at an exercise price of $3.87 per share. Each such option vests in 48 successive equal monthly installments beginning on September 13, 2018, subject to Ms. Demski’s and Mr. McDermott’s respective continued

 

136


Table of Contents

service with us. In September 2018, each of Ms. Demski and Mr. McDermott early exercised their option in full and we issued 23,799 shares of common stock to each of Ms. Demski and Mr. McDermott, which are restricted shares subject to the vesting schedule described in the preceding sentence.

On September 14, 2018, we granted Dr. Pruzanski an option to purchase 23,799 shares of common stock at an exercise price of $3.87 per share. Such option vests in 48 successive equal monthly installments beginning on September 14, 2018, subject to Dr. Pruzanski’s continued service with us.

We have reimbursed and expect to continue to reimburse all of our non-employee directors for their travel, lodging and other reasonable expenses incurred in attending meetings of our board of directors and committees of our board of directors.

Non-employee Director Compensation Policy

Our board of directors adopted a new compensation policy in October 2018 that will become effective upon the execution and delivery of the underwriting agreement for this offering and will be applicable to all of our non-employee directors. This compensation policy provides that each such non-employee director will receive the following compensation for service on our board of directors:

 

   

an annual cash retainer of $40,000;

 

   

an additional cash retainer of $20,000 to the chairman of the board of directors;

 

   

an additional annual cash retainer of $7,500, $5,000 and $4,000 for service as a member of the audit committee, compensation committee and the nominating and corporate governance committee, respectively;

 

   

an additional annual cash retainer of $15,000, $10,000 and $8,000 for service as chairman of the audit committee, compensation committee and the nominating and corporate governance committee, respectively (in lieu of the additional cash retainer for committee membership);

 

   

an initial option grant for each non-employee director who first joins our board of directors after this offering, in an amount to be determined by the board or compensation committee, on the date of commencement of service on the board, vesting over a three year period following the grant date; and

 

   

an annual option grant for each non-employee director serving on the board of directors on the date of our annual stockholder meeting, in an amount to be determined by the board or compensation committee, vesting over the one year period following the grant date.

Each of the option grants described above will vest and become exercisable subject to the director’s continuous service to us, provided that each option will vest in full upon a change in control (as defined in the 2018 Plan). The term of each option will be 10 years, subject to earlier termination as provided in the 2018 Plan, except that the post-termination exercise period will be for up to 12 months from the date of termination, if such termination is other than for death, disability or cause. The options will be granted under our 2018 Plan, the terms of which are described in more detail above under “—Equity Benefit Plans—2018 Plan.”

 

137


Table of Contents

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

The following includes a summary of transactions since March 16, 2017, our inception, to which we have been a party, in which the amount involved in the transaction exceeded $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under “Executive And Director Compensation.”

Convertible Promissory Note Financing

From May 2017 to June 2018, we issued and sold to investors convertible promissory notes in the aggregate principal amount of approximately $9.4 million. The convertible promissory notes carry an interest rate of 6% per annum. The participants in this convertible promissory note financing included the following executive officers and members of our board of directors, or entities affiliated with them.

 

 

 

PARTICIPANTS

   AGGREGATE PRINCIPAL
AMOUNT OF NOTES
 

Executive Officers and Directors

  

Daniel M. Bradbury

   $ 512,165.00  (1)  

Bruce D. Steel

   $ 512,164.00  (2)  

 

 

(1)    Consists of convertible promissory notes held by (i) BioBrit, LLC, or BioBrit, in the principal amount of $409,732.00 (which convertible promissory note was originally issued in May 2017 in principal amount of $400,000.00 and was amended and restated in October 2017 in principal amount of $409,732.00, which amount includes accrued interest from May 2017 to October 2017), or the BioBrit Note, and (ii) The Bradbury Family 2009 Irrevocable Trust dated September 1, 2009, or Bradbury Trust, in the principal amount of $102,433.00 (which convertible promissory note was originally issued in May 2017 in principal amount of $100,000.00 and was amended and restated in October 2017 in principal amount of $102,433.00, which amount includes accrued interest from May 2017 to October 2017), or the Bradbury Trust Note. Mr. Bradbury, is the managing member of BioBrit.
(2)    Such convertible promissory note, or the Steel Note, was originally issued in May 2017 in principal amount of $500,000.00 and was amended and restated in October 2017 in principal amount of $512,164.00, which amount includes accrued interest from May 2017 to October 2017.

The BioBrit Note, the Bradbury Note and the Steel Note will automatically convert upon the completion of this offering into an aggregate of 36,119 shares, 9,029 shares and 45,149 shares of our common stock, respectively, each based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on September 30, 2018.

Employment Arrangements

We have entered into offer letters with Mr. Bradbury, Mr. Steel, Dr. Connelly, Mr. Keyes and Dr. Polu, each of which is described in the section titled “Executive and Director Compensation.”

Biocon Agreements

In May 2017, we entered into the Biocon License and the Biocon Supply Agreement with Biocon, one of our 5% stockholders. Such agreements are described in “Business—Partnerships—Collaboration and License Agreement with Biocon” and “Business—Partnerships—Clinical Supply Agreement with Biocon.” In connection with the Biocon License, we entered into a Common Stock Purchase Agreement with Biocon, pursuant to which we issued 2,088,074 shares of our common stock as consideration under the Biocon License.

In connection with the completion of this offering, we will issue to Biocon 242,237 shares of common stock pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus). Such anti-dilution rights are described in “Description of Capital Stock—Anti-Dilution Rights.”

 

138


Table of Contents

Investor Agreements

In May 2017, we entered into an investor rights agreement and voting agreement with Biocon and certain other of our stockholders containing, among other things, voting rights, information rights, pre-emptive rights, co-sale rights, anti-dilution rights and potential future registration rights. These rights will terminate upon the closing of this offering.

Indemnification Agreements

We have entered, and intend to continue to enter, into separate indemnification agreements with each of our directors and executive officers, as described in “Management—Limitation of Liability and Indemnification.”

Policies and Procedures for Transactions with Related Persons

We have adopted a written related-person transactions policy that sets forth our policies and procedures regarding the identification, review, consideration and oversight of “related-person transactions.” For purposes of our policy only, a “related-person transaction” is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any “related person” are participants involving an amount that exceeds $120,000. Transactions involving compensation for services provided to us as an employee, consultant or director are not considered related-person transactions under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than five percent of our common stock, including any of their immediate family members and affiliates, including entities owned or controlled by such persons.

Under the policy, where a transaction has been identified as a related-person transaction, management must present information regarding the proposed related-person transaction to our audit committee (or, where review by our audit committee would be inappropriate, to another independent body of our board of directors) for review. The presentation must include a description of, among other things, all of the parties thereto, the direct and indirect interests of the related persons, the purpose of the transaction, the material facts, the benefits of the transaction to us and whether any alternative transactions are available, an assessment of whether the terms are comparable to the terms available from unrelated third parties and management’s recommendation. To identify related-person transactions in advance, we rely on information supplied by our executive officers, directors and certain significant stockholders. In considering related-person transactions, our audit committee or another independent body of our board of directors takes into account the relevant available facts and circumstances including, but not limited to:

 

   

the risks, costs and benefits to us;

 

   

the impact on a director’s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated;

 

   

the terms of the transaction;

 

   

the availability of other sources for comparable services or products; and

 

   

the terms available to or from, as the case may be, unrelated third parties.

In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval. All of the transactions described in this section occurred prior to the adoption of this policy.

 

139


Table of Contents

PRINCIPAL STOCKHOLDERS

The following table sets forth information regarding beneficial ownership of our capital stock by:

 

   

each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;

 

   

each of our directors;

 

   

each of our named executive officers; and

 

   

all of our current executive officers and directors as a group.

The percentage ownership information under the column entitled “Before Offering” is based on 11,082,848 shares of common stock outstanding as of August 30, 2018. The percentage ownership information under the column entitled “After Offering” is based on the sale of 4,670,000 shares of common stock in this offering and takes into account (i) the conversion of $9.4 million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the completion of this offering into an aggregate of 808,661 shares of our common stock based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on September 30, 2018 and (ii) the issuance by us of 242,237 shares of common stock upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus).

Information with respect to beneficial ownership has been furnished by each director, officer or beneficial owner of more than 5% of our common stock. We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include shares of common stock issuable pursuant to the exercise of stock options or warrants that are either immediately exercisable or exercisable on or before October 29, 2018, which is 60 days after August 30, 2018. These shares are deemed to be outstanding and beneficially owned by the person holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws.

Except as otherwise noted below, the address for each person or entity listed in the table is c/o Equillium, Inc., 2223 Avenida de la Playa, Suite 108, La Jolla, CA 92037.

 

 

 

NAME AND ADDRESS OF BENEFICIAL OWNER

   NUMBER OF SHARES
BENEFICIALLY OWNED
     PERCENTAGE OF SHARES
BENEFICIALLY OWNED
 
   BEFORE
OFFERING
     AFTER
OFFERING
     BEFORE
OFFERING
    AFTER
OFFERING
 

5% or Greater Stockholders

          

Biocon SA (1)

     2,088,074        2,330,311        18.8     13.9

Directors and Named Executive Officers

          

Daniel M. Bradbury (2)

     3,663,500        3,708,648        33.1     22.1

Bruce D. Steel (3)

     3,663,500        3,708,649        33.1     22.1

Stephen Connelly, Ph.D.

     1,293,000        1,293,000        11.7     7.7

Martha J. Demski

                   *       *  

Bala S. Manian, Ph.D.

     23,799        23,799        *       *  

Charles McDermott

                   *       *  

Mark Pruzanski, M.D.

                   *       *  

All current executive officers and directors as a group (9 persons) (4)

     9,000,735        9,091,032        79.7     53.4

 

 

*   Represents beneficial ownership of less than 1%.

 

140


Table of Contents
(1)    The number of shares beneficially owned after the offering includes 242,237 shares of common stock issuable upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus). The address of Biocon SA is c/o BDO SA, Rue de l’Avenir 2, 2800 Delémont, Switzerland.
(2)    Consists of (i) 2,930,800 shares of common stock held by BioBrit, LLC, or BioBrit, of which Mr. Bradbury is the managing member, and (ii) 732,700 shares of common held by The Bradbury Family 2009 Irrevocable Trust dated September 1, 2009, or Bradbury Trust. The number of shares beneficially owned after the offering includes 45,148 shares of common stock issuable upon the conversion of a convertible promissory note in the principal amount of (a) $409,732 plus accrued interest held by BioBrit and (b) $102,433.00 plus accrued interest held by Bradbury Trust, each upon the completion of this offering based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on September 30, 2018.
(3)    Consists of (i) 3,232,500 shares of common stock held by Bruce D. Steel, as trustee of the Steel Family Revocable Trust dated June 5, 2002, and (ii) 431,000 shares of common held by Kevin N. Steel, as trustee of the Sierra Kathleen Steel Trust of January 1, 2005. The number of shares beneficially owned after the offering includes 45,149 shares of common stock issuable upon the conversion of a convertible promissory note in the principal amount of $512,164 plus accrued interest held by Bruce D. Steel upon the completion of this offering based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on September 30, 2018.
(4)    Consists of (i) the shares described in Notes (2) and (3) above and the shares held by Dr. Connelly and Dr. Manian, (ii) 148,720 shares of common stock held by The Keyes Trust Dated September 10, 2004 and beneficially owned by Jason A. Keyes, our Chief Financial Officer, all of which are subject to a right of repurchase by us as of August 30, 2018 and (iii) 208,216 shares of common stock that Krishna R. Polu, M.D., our Chief Medical Officer, has the right to acquire from us within 60 days of August 30, 2018 pursuant to the exercise of stock options.

 

141


Table of Contents

DESCRIPTION OF CAPITAL STOCK

Upon filing of our amended and restated certificate of incorporation and the completion of this offering, our authorized capital stock will consist of 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. All of our authorized preferred stock upon the completion of this offering will be undesignated. The following is a summary of the rights of our common and preferred stockholders and some of the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the completion of this offering, respectively, and of the Delaware General Corporation Law. This summary is not complete. For more detailed information, please see our amended and restated certificate of incorporation and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant provisions of the Delaware General Corporation Law. As of the date of this prospectus, we have not issued any shares of preferred stock.

Common Stock

Outstanding Shares

As of June 30, 2018, there were 10,975,764 shares of common stock issued and outstanding (including 267,690 shares of restricted common stock which are subject to a right of repurchase by us as of June 30, 2018) held of record by 12 stockholders. Based on the number of shares of common stock outstanding as of June 30, 2018, and assuming (1) the conversion of $9.4 million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the completion of this offering into an aggregate of 808,661 shares of our common stock based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on September 30, 2018, (2) the issuance by us of 242,237 shares of common stock upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and (3) the issuance by us of 4,670,000 shares of common stock in this offering, there will be 16,696,662 shares of common stock outstanding upon the completion of this offering.

As of June 30, 2018, there were 107,084 shares of common stock subject to outstanding options under our 2017 Plan.

Voting

Our common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election.

Dividends

Subject to preferences that may be applicable to any then-outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.

Liquidation

In the event of our liquidation, dissolution or winding-up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock.

Rights and Preferences

Following the closing of this offering, no holders of our common stock will have preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The

 

142


Table of Contents

rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.

Fully Paid and Nonassessable

All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering will be, fully paid and nonassessable.

Stockholder Registration Rights

The holders of our capital stock do not have the right to require us to register with the SEC any such shares of capital stock.

Anti-Dilution Rights

Pursuant to that certain Investors’ Rights Agreement, dated May 22, 2017, by and among us and certain of our stockholders listed therein, in the event we issue certain equity securities, in connection with such issuances we are obligated to issue to Biocon additional shares of our common stock in order to maintain Biocon’s ownership interest at 19.5% of our outstanding shares. Such anti-dilution rights terminate at such time we have received aggregate cumulative gross proceeds from sales of equity securities equal to $15,000,000 and will terminate in connection with this offering.

Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our Amended and Restated Bylaws and Delaware Law

Delaware Anti-Takeover Law

We are subject to Section 203 of the Delaware General Corporation Law, or Section 203. Section 203 generally prohibits a public Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years following the time that such stockholder became an interested stockholder, unless:

 

   

prior to such time the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

 

   

upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (1) by persons who are directors and also officers and (2) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

 

   

at or subsequent to such time, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66-2/3% of the outstanding voting stock which is not owned by the interested stockholder.

Section 203 defines a business combination to include:

 

   

any merger or consolidation involving the corporation and the interested stockholder;

 

   

any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;

 

   

subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

 

   

subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and

 

143


Table of Contents
   

the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.

Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws

Provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the completion of this offering, respectively, may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of incorporation and amended and restated bylaws:

 

   

permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our control);

 

   

provide that the authorized number of directors may be changed only by resolution of the board of directors;

 

   

provide that the board of directors or any individual director may only be removed with cause and the affirmative vote of the holders of at least 66-2/3% of the voting power of all of our then outstanding common stock;

 

   

provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;

 

   

divide our board of directors into three classes;

 

   

require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;

 

   

provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder’s notice;

 

   

do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); and

 

   

provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors.

In addition, our amended and restated certificate of incorporation provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to us or our stockholders, (iii) any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or amended and restated bylaws, and (iv) any action asserting a claim against us governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, our amended and restated certificate of incorporation will also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable.

 

144


Table of Contents

The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 66-2/3% of our then-outstanding common stock.

The Nasdaq Global Market Listing

We have applied for listing of our common stock on The Nasdaq Global Market under the symbol “EQ.”

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC. The transfer agent and registrar’s address is 6201 15th Avenue, Brooklyn, New York 11219.

 

145


Table of Contents

SHARES ELIGIBLE FOR FUTURE SALE

Immediately prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of common stock in the public market could adversely affect prevailing market prices. Furthermore, since only a limited number of shares will be available for sale shortly after this offering because of contractual and legal restrictions on resale described below, sales of substantial amounts of common stock in the public market after the restrictions lapse could adversely affect the prevailing market price for our common stock as well as our ability to raise equity capital in the future.

Based on the number of shares of common stock outstanding as of June 30, 2018, upon the completion of this offering and assuming (1) the 1-for-8.62 stock split of all outstanding shares of our capital stock, (2) the conversion of $9.4 million of aggregate principal amount, plus accrued interest thereon, of convertible promissory notes which will automatically convert upon the completion of this offering into an aggregate of 808,661 shares of our common stock based on an assumed initial public offering price of $15.00 per share (the midpoint of the price range set forth on the cover page of this prospectus), and assuming the occurrence of the conversion on September 30, 2018, (3) the issuance by us of 242,237 shares of common stock upon completion of this offering to Biocon pursuant to certain anti-dilution rights that will be satisfied in full upon such issuance, (4) no exercise of the underwriters’ option to purchase additional shares of common stock and (5) no exercise of outstanding options, an aggregate of 16,696,662 shares of common stock will be outstanding. All of the shares sold in this offering will be freely tradable in the public market without restriction or further registration under the Securities Act, unless held by an affiliate of ours. Except as set forth below, the remaining shares of common stock outstanding after this offering will be restricted as a result of securities laws or lock-up agreements. In addition, any shares sold in this offering to entities affiliated with our existing stockholders and directors will be subject to lock-up agreements. These remaining shares will generally become available for sale in the public market as follows:

 

   

no restricted shares will be eligible for immediate sale upon the completion of this offering;

 

   

up to 11,820,936 restricted shares will be eligible for sale under Rule 144 or Rule 701 upon expiration of lock-up agreements 180 days after the date of this offering; and

 

   

the remainder of the restricted shares will be eligible for sale from time to time thereafter upon expiration of their respective holding periods under Rule 144, as described below.

Rule 144

In general, under Rule 144 as currently in effect, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, any person who is not an affiliate of ours and has held their shares for at least six months, including the holding period of any prior owner other than one of our affiliates, may sell shares without restriction, provided current public information about us is available. In addition, under Rule 144, any person who is not an affiliate of ours and has held their shares for at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited number of shares immediately upon the completion of this offering without regard to whether current public information about us is available. Beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours and who has beneficially owned restricted securities for at least six months, including the holding period of any prior owner other than one of our affiliates, is entitled to sell a number of restricted shares within any three-month period that does not exceed the greater of:

 

   

1% of the number of shares of our common stock then outstanding, which will equal approximately 166,967 shares immediately after this offering; or

 

   

the average weekly trading volume of our common stock on The Nasdaq Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.

Sales of restricted shares under Rule 144 held by our affiliates are also subject to requirements regarding the manner of sale, notice and the availability of current public information about us. Rule 144 also provides that affiliates relying on Rule 144 to sell shares of our common stock that are not restricted shares must nonetheless comply with the same restrictions applicable to restricted shares, other than the holding period requirement.

 

146


Table of Contents

Notwithstanding the availability of Rule 144, the holders of all of our restricted shares have entered into lock-up agreements as described below and their restricted shares will become eligible for sale at the expiration of the restrictions set forth in those agreements.

Rule 701

Under Rule 701, shares of our common stock acquired upon the exercise of currently outstanding options or pursuant to other rights granted under our stock plans may be resold by:

 

   

persons other than affiliates, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, subject only to the manner-of-sale provisions of Rule 144; and

 

   

our affiliates, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, subject to the manner-of-sale and volume limitations, current public information and filing requirements of Rule 144, in each case, without compliance with the six-month holding period requirement of Rule 144.

As of June 30, 2018, options to purchase a total of 107,084 shares of common stock were outstanding, none of which were vested. Of the total number of shares of our common stock issuable under these options, all are subject to contractual lock-up agreements with us or the underwriters described below under “Underwriting” and will become eligible for sale at the expiration of those agreements unless held by an affiliate of ours.

Lock-Up Agreements

We, along with our directors, executive officers and all of our other stockholders, noteholders, and optionholders, have agreed that for a period of 180 days, after the date of this prospectus, except with the prior written consent of Jefferies LLC and Leerink Partners LLC and subject to specified exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, or enter into any swap or other arrangement that transfers to another, in whole or in part, directly or indirectly, any of the economic consequences of ownership of the common stock. Jefferies LLC and Leerink Partners LLC have advised us that it has no current intent or arrangement to release any of the shares subject to the lock-up agreements prior to the expiration of the lock-up agreements.

After this offering, certain of our employees, including our executive officers and/or directors, may enter into written trading plans that are intended to comply with Rule 10b5-1 under the Exchange Act. Sales under these trading plans would not be permitted until the expiration of the lock-up agreements relating to the offering described above.

Registration Rights

The holders of our capital stock do not have any rights with respect to the registration of their shares under the Securities Act.

Equity Incentive Plans

We intend to file with the SEC a registration statement on Form S-8 under the Securities Act covering the shares of common stock reserved for issuance under the 2017 Plan, the 2018 Plan and the ESPP. The registration statement is expected to be filed and become effective as soon as practicable after the completion of this offering. Accordingly, shares registered under the registration statement will be available for sale in the open market following its effective date, subject to Rule 144 volume limitations and the lock-up agreements described above, if applicable.

 

147


Table of Contents

MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES

TO NON-U.S. HOLDERS OF OUR COMMON STOCK

The following summary describes the material U.S. federal income tax consequences of the acquisition, ownership and disposition of our common stock acquired in this offering by Non-U.S. Holders (as defined below). This discussion does not address all aspects of U.S. federal income taxes that may be relevant to Non-U.S. Holders in light of their particular circumstances, nor does it address any state, local or non-U.S. tax consequences or U.S. federal tax consequences other than income taxes (such as U.S. federal estate or gift tax consequences). Rules different from those described below may apply to certain Non-U.S. Holders that are subject to special treatment under the Code such as financial institutions, insurance companies, tax-exempt organizations, tax-qualified retirement plans, broker-dealers and traders in securities, commodities or currencies, government organizations, certain foreign citizens or long-term residents of the United States, “controlled foreign corporations,” “passive foreign investment companies,” corporations that accumulate earnings to avoid U.S. federal income tax, persons that hold our common stock as part of a “straddle,” “hedge,” “conversion transaction,” “synthetic security,” integrated investment or other risk reduction strategy, holders deemed to sell our common stock under the constructive sale provisions of the Code, holders who hold or receive our common stock pursuant to the exercise of employee stock options or otherwise as compensation, holders who are subject to the alternative minimum tax or the federal Medicare contribution tax on net investment income, persons who have a functional currency other than the U.S. dollar, accrual method taxpayers subject to special tax accounting rules under Section 451(b) of the Code, partnerships and other pass-through entities, and investors in such pass-through entities or entities that are treated as disregarded entities for U.S. federal income tax purposes (regardless of their places of organization or formation). Such Non-U.S. Holders are urged to consult their own tax advisors to determine the U.S. federal, state, local and other tax consequences that may be relevant to them. Furthermore, the discussion below is based upon the provisions of the Code, and U.S. Treasury regulations, published administrative pronouncements, rulings and judicial decisions thereunder as of the date hereof. Such authorities may be repealed, revoked or modified, perhaps retroactively, so as to result in U.S. federal income tax consequences different from those discussed below. We have not requested a ruling from the U.S. Internal Revenue Service, or IRS, with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS will agree with such statements and conclusions. This discussion assumes that the Non-U.S. Holder holds our common stock as a “capital asset” within the meaning of Section 1221 of the Code (generally, property held for investment).

The following discussion is for general information only and is not tax advice for any Non-U.S. Holders under their particular circumstances. Persons considering the purchase of our common stock pursuant to this offering should consult their own tax advisors concerning the U.S. federal income tax and other tax consequences of acquiring, owning and disposing of our common stock in light of their particular situations as well as any consequences arising under the laws of any other taxing jurisdiction, including any state, local and non-U.S. tax consequences and any U.S. federal non-income tax consequences. In addition, significant changes in U.S. federal income tax laws were recently enacted. You should also consult with your tax advisor with respect to such changes in U.S. tax law as well as potential conforming changes in state tax laws.

For the purposes of this discussion, a “Non-U.S. Holder” is, for U.S. federal income tax purposes, a beneficial owner of common stock that is not a U.S. Holder. A “U.S. Holder” means a beneficial owner of our common stock that is for U.S. federal income tax purposes (a) an individual who is a citizen or resident of the United States, (b) a corporation or other entity treated as a corporation that is created or organized in or under the laws of the United States, any state thereof or the District of Columbia, (c) an estate the income of which is subject to U.S. federal income taxation regardless of its source or (d) a trust if it (1) is subject to the primary supervision of a court within the United States and one or more U.S. persons have the authority to control all substantial decisions of the trust or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person. Also, partnerships and their partners, or other entities that are treated as partnerships for U.S. federal income tax purposes and their equity holders (regardless of their place of organization or formation) and entities that are treated as disregarded entities for U.S. federal income tax purposes (regardless of their place of organization or formation) are not addressed by this discussion and are, therefore, not considered to be Non-U.S. Holders for the purposes of this discussion.

 

148


Table of Contents

Distributions on Our Common Stock

Subject to the discussion below regarding backup withholding and foreign accounts, distributions, if any, made on our common stock to a Non-U.S. Holder generally will constitute dividends for U.S. tax purposes to the extent made out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles) and will be subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. To obtain a reduced rate of withholding under a treaty, a Non-U.S. Holder generally will be required to provide us with a properly executed IRS Form W-8BEN (in the case of individuals) or IRS Form W-8BEN-E (in the case of entities), or other appropriate form, certifying the Non-U.S. Holder’s entitlement to benefits under that treaty. This certification must be provided to us or our paying agent prior to the payment of dividends and must be updated periodically. In the case of a Non-U.S. Holder that is an entity, U.S. Treasury regulations and the relevant tax treaty provide rules to determine whether, for purposes of determining the applicability of a tax treaty, dividends will be treated as paid to the entity or to those holding an interest in that entity. If a Non-U.S. Holder holds stock through a financial institution or other agent acting on the holder’s behalf, the holder will be required to provide appropriate documentation to such agent. The holder’s agent will then be required to provide such certification to us or our paying agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty, you should consult with your own tax advisor to determine if you are able to obtain a refund or credit if any excess amount is withheld by timely filing an appropriate claim for a refund with the IRS.

We generally are not required to withhold tax on dividends paid to a Non-U.S. Holder that are effectively connected with the Non-U.S. Holder’s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment that such holder maintains in the United States) if a properly executed IRS Form W-8ECI, certifying that the dividends are so connected, is furnished to us (or, if stock is held through a financial institution or other agent, to such agent). In general, such effectively connected dividends will be subject to U.S. federal income tax, on a net income basis at the regular graduated rates applicable to U.S. residents, unless a specific treaty exemption applies. A corporate Non-U.S. Holder receiving effectively connected dividends may also be subject to an additional “branch profits tax,” which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the corporate Non-U.S. Holder’s effectively connected earnings and profits, subject to certain adjustments. Non-U.S. Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.

To the extent distributions on our common stock, if any, exceed our current and accumulated earnings and profits, they will first reduce the Non-U.S. Holder’s adjusted basis in our common stock as a non-taxable return of capital, but not below zero, and then any excess will be treated as gain and taxed in the same manner as gain realized from a sale or other disposition of common stock as described in the next section.

Gain on Disposition of Our Common Stock

Subject to the discussion below regarding backup withholding and foreign accounts, a Non-U.S. Holder generally should not be subject to U.S. federal income tax with respect to gain realized on a sale or other disposition of our common stock unless (a) the gain is effectively connected with a trade or business of such holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment that such holder maintains in the United States), (b) the Non-U.S. Holder is a nonresident alien individual and is present in the United States or 183 or more days in the taxable year of the disposition and certain other conditions are met, or (c) we are or have been a “United States real property holding corporation,” or a USRPHC, within the meaning of Code Section 897(c)(2) at any time within the shorter of the five-year period preceding such disposition or such holder’s holding period.

If you are a Non-U.S. Holder described in clause (a) above, you will be required to pay tax on the net gain derived from the sale at regular graduated U.S. federal income tax rates, unless a specific treaty exemption applies, and corporate Non-U.S. Holders described in clause (a) above may be subject to the additional branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. If you are an individual Non-U.S. Holder described in clause (b) above, you will be required to pay a flat 30% tax on the gain derived from the sale, which gain may be offset by U.S. source capital losses (even though you are not considered a resident of

 

149


Table of Contents

the United States), provided you have timely filed U.S. federal income tax returns with respect to such losses. With respect to clause (c) above, in general, we would be a USRPHC if interests in U.S. real property constituted (by fair market value) at least half of our assets. We believe that we are not, and do not anticipate becoming, a USRPHC. However, because the determination of whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our other assets, there can be no assurance that we will not become a USRPHC in the future. Even if we are treated as a USRPHC, gain realized by a Non-U.S. Holder on a disposition of our common stock will not be subject to U.S. federal income tax so long as (1) the Non-U.S. Holder owned, directly, indirectly and constructively, no more than 5% of our common stock at all times within the shorter of (a) the five-year period preceding the disposition or (b) the holder’s holding period and (2) our common stock is regularly traded on an established securities market within the meaning of applicable U.S. Treasury regulations. There can be no assurance that our common stock will continue to qualify as regularly traded on an established securities market. If any gain on your disposition of our common stock is taxable because we are a USRPHC and your ownership of our common stock exceeds 5%, you will be taxed on such disposition generally in the manner applicable to U.S. persons and in addition, a purchaser of your common stock may be required to withhold tax with respect to that obligation.

Information Reporting Requirements and Backup Withholding

Generally, we or certain financial middlemen must report information to the IRS with respect to any dividends we pay on our common stock (even if payments are not subject to withholding) including the amount of any such dividends, the name and address of the recipient, and the amount, if any, of tax withheld. A similar report is sent to the holder to whom any such dividends are paid. Pursuant to tax treaties or certain other agreements, the IRS may make its reports available to tax authorities in the recipient’s country of residence.

Dividends paid by us (or our paying agents) to a Non-U.S. Holder may also be subject to U.S. backup withholding. U.S. backup withholding generally will not apply to a Non-U.S. Holder who provides a properly executed IRS Form W-8BEN (in the case of individuals), IRS Form W-8BEN-E (in the case of entities) or IRS Form W-8ECI, or otherwise establishes an exemption. Notwithstanding the foregoing, backup withholding may apply if the payor has actual knowledge, or reason to know, that the holder is a U.S. person who is not an exempt recipient.

Under current U.S. federal income tax law, U.S. information reporting and backup withholding requirements generally will apply to the proceeds of a disposition of our common stock effected within the United States or through certain U.S.-related brokers, unless the holder provides a properly executed IRS Form W-8BEN (in the case of individuals), IRS Form W-8BEN-E (in the case of entities) or IRS Form W-8ECI, or otherwise establishes an exemption. Generally, U.S. information reporting and backup withholding requirements will not apply to a payment of disposition proceeds to a Non-U.S. Holder where the transaction is effected outside the United States through a non-U.S. office of a non-U.S. broker. Information reporting and backup withholding requirements may, however, apply to a payment of disposition proceeds if the broker has actual knowledge, or reason to know, that the holder is, in fact, a U.S. person. For information reporting purposes, certain brokers with substantial U.S. ownership or operations will generally be treated in a manner similar to U.S. brokers.

Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or credit against a Non-U.S. Holder’s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. If backup withholding is applied to you, you should consult with your own tax advisor to determine if you are able to obtain a tax refund or credit with respect to the amount withheld.

Foreign Accounts

A U.S. federal withholding tax of 30% may apply to dividends and the gross proceeds of a disposition of our common stock paid to a foreign financial institution (as specifically defined by applicable rules), including when the foreign financial institution holds our common stock on behalf of a Non-U.S. Holder, unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which may include certain equity holders of such institution, as well as certain account holders that are foreign entities with U.S. owners). Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United

 

150


Table of Contents

States governing these withholding and reporting requirements may be subject to different rules. This U.S. federal withholding tax of 30% will also apply to dividends on and the gross proceeds of a disposition of our common stock paid to a non-financial foreign entity unless such entity provides the withholding agent with either a certification that it does not have any substantial direct or indirect U.S. owners or provides information regarding direct and indirect U.S. owners of the entity. The withholding tax described above will not apply if the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. Under certain circumstances, a Non-U.S. Holder might be eligible for refunds or credits of such taxes. Holders are encouraged to consult with their own tax advisors regarding the possible implications of these rules on their investment in our common stock.

The withholding provisions described above generally apply to payments of dividends, and will apply to payments of gross proceeds from a sale or other disposition of common stock after December 31, 2018.

EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT AND PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, NON-U.S. OR U.S. FEDERAL NON-INCOME TAX LAWS.

 

151


Table of Contents

UNDERWRITING

Subject to the terms and conditions set forth in the underwriting agreement, dated                  among us and Jefferies LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as the representatives of the underwriters named below and the joint book-running managers of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the respective number of shares of common stock shown opposite its name below:

 

 

 

UNDERWRITER

   NUMBER OF
SHARES
 

Jefferies LLC

  

Leerink Partners LLC

  

Stifel, Nicolaus & Company, Incorporated

  
  

 

 

 

Total

     4,670,000  
  

 

 

 

 

 

The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters of officers’ certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock if any of them are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities.

The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common stock as permitted by applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable.

The underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.

Commission and Expenses

The underwriters have advised us that they propose to offer the shares of common stock to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in excess of $         per share of common stock. The underwriters may allow, and certain dealers may reallow, a discount from the concession not in excess of $         per share of common stock to certain brokers and dealers. After the offering, the initial public offering price, concession and reallowance to dealers may be reduced by the representatives. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus.

The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters’ option to purchase additional shares.

 

152


Table of Contents

 

 

     PER SHARE      TOTAL  
     WITHOUT
OPTION TO
PURCHASE
ADDITIONAL
SHARES
     WITH
OPTION TO
PURCHASE
ADDITIONAL
SHARES
     WITHOUT
OPTION TO
PURCHASE
ADDITIONAL
SHARES
     WITH
OPTION TO
PURCHASE
ADDITIONAL
SHARES
 

Public offering price

   $                    $                    $                    $                

Underwriting discounts and commissions paid by us

   $        $        $        $    

Proceeds to us, before expenses

   $        $        $        $    

 

 

We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $2.1 million. We have also agreed to reimburse the underwriters for certain of their expenses in an amount up to $25,000.

Determination of Offering Price

Prior to this offering, there has not been a public market for our common stock. Consequently, the initial public offering price for our common stock will be determined by negotiations between us and the representatives. Among the factors to be considered in these negotiations will be prevailing market conditions, our financial information, market valuations of other companies that we and the underwriters believe to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant.

We offer no assurances that the initial public offering price will correspond to the price at which the common stock will trade in the public market subsequent to the offering or that an active trading market for the common stock will develop and continue after the offering.

Listing

We intend to apply to have our common stock listed on The Nasdaq Global Market under the symbol “EQ.”

Stamp Taxes

If you purchase shares of common stock offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus.

Option to Purchase Additional Shares

We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate of 700,500 shares from us at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional shares proportionate to that underwriter’s initial purchase commitment as indicated in the table above.    

No Sales of Similar Securities

We, our officers, directors and holders of all our outstanding capital stock and other securities have agreed, subject to specified exceptions, not to directly or indirectly:

 

   

sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open “put equivalent position” within the meaning of Rule 16a-1(h) under the Exchange Act, or

 

   

otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock hereafter owned either of record or beneficially, or

 

   

publicly announce an intention to do any of the foregoing for a period of 180 days after the date of this prospectus without the prior written consent of Jefferies LLC and Leerink Partners LLC.

 

153


Table of Contents

This restriction terminates after the close of trading of the common stock on and including the 180th day after the date of this prospectus.

Jefferies LLC and Leerink Partners LLC may, in their sole discretion and at any time or from time to time before the termination of the 180-day period release all or any portion of the securities subject to lock-up agreements. There are no existing agreements between the underwriters and any of our shareholders who will execute a lock-up agreement, providing consent to the sale of shares prior to the expiration of the lock-up period.

Stabilization

The underwriters have advised us that they, pursuant to Regulation M under the Exchange Act, and certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either “covered” short sales or “naked” short sales.

“Covered” short sales are sales made in an amount not greater than the underwriters’ option to purchase additional shares of our common stock in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option to purchase additional shares.

“Naked” short sales are sales in excess of the option to purchase additional shares of our common stock. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our common stock in the open market after pricing that could adversely affect investors who purchase in this offering.

A stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriter’s purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member.

Neither we, nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time.

The underwriters may also engage in passive market making transactions in our common stock on The Nasdaq Global Market in accordance with Rule 103 of Regulation M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker’s bid, that bid must then be lowered when specified purchase limits are exceeded.

Electronic Distribution

A prospectus in electronic format may be made available by e-mail or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and

 

154


Table of Contents

may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters’ web sites and any information contained in any other web site maintained by any of the underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors.

Other Activities and Relationships

The underwriter and certain of its affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriter and certain of its affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses.

In the ordinary course of their various business activities, the underwriter and certain of its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates.    If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could adversely affect future trading prices of the common stock offered hereby. The underwriters and certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.

NOTICE TO HOLDERS

Australia

This prospectus is not a disclosure document for the purposes of Australia’s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian Securities & Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia:

You confirm and warrant that you are either:

 

   

a “sophisticated investor” under section 708(8)(a) or (b) of the Corporations Act;

 

   

a “sophisticated investor” under section 708(8)(c) or (d) of the Corporations Act and that you have provided an accountant’s certificate to the Company which complies with the requirements of section 708(8)(c)(i) or (ii) of the Corporations Act and related regulations before the offer has been made;

 

   

a person associated with the Company under Section 708(12) of the Corporations Act; or

 

   

a “professional investor” within the meaning of section 708(11)(a) or (b) of the Corporations Act.

To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations Act any offer made to you under this prospectus is void and incapable of acceptance.

You warrant and agree that you will not offer any of the securities issued to you pursuant to this prospectus for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the Corporations Act.

 

155


Table of Contents

Canada

Resale Restrictions

The distribution of our shares in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private placement basis exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the shares of common stock in Canada must be made under applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the securities.

Representations of Canadian Purchasers

By purchasing our shares of common stock in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase confirmation is received that:

 

   

the purchaser is entitled under applicable provincial securities laws to purchase the shares without the benefit of a prospectus qualified under those securities laws as it is an “accredited investor” as defined under National Instrument 45-106—Prospectus Exemptions,

 

   

the purchaser is a “permitted client” as defined in National Instrument 31-103—Registration Requirements, Exemptions and Ongoing Registrant Obligations,

 

   

where required by law, the purchaser is purchasing as principal and not as agent, and

 

   

the purchaser has reviewed the text above under Resale Restrictions.

Conflicts of Interest

Canadian purchasers are hereby notified that the underwriters proposing to sell into Canada are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National Instrument 33-105—Underwriting Conflicts from having to provide certain conflict of interest disclosure in this document.

Statutory Rights of Action

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus (including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars of these rights or consult with a legal advisor.

Enforcement of Legal Rights

All of our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada.

Taxation and Eligibility for Investment

Canadian purchasers of our shares of common stock should consult their own legal and tax advisors with respect to the tax consequences of an investment in the share in their particular circumstances and about the eligibility of the shares for investment by the purchaser under relevant Canadian legislation.

European Economic Area

In relation to each member state of the European Economic Area which has implemented the Prospectus Directive, each, a Relevant Member State, an offer to the public of any common shares which are the subject of the offering

 

156


Table of Contents

contemplated by this prospectus supplement and the accompanying prospectus may not be made in that Relevant Member State except that an offer to the public in that Relevant Member State of any common shares may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State:

 

   

to any legal entity which is a “qualified investor” as defined in the Prospectus Directive;

 

   

to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the underwriters or the underwriters nominated by us for any such offer; or

 

   

in any other circumstances falling within Article 3(2) of the Prospectus Directive,

provided that no such offer of common shares shall require us or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive.

For the purposes of this provision, the expression an “offer common shares to the public” in relation to the common shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the common shares to be offered so as to enable an investor to decide to purchase or subscribe to the common shares, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State and the expression “Prospectus Directive” means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression “2010 PD Amending Directive” means Directive 2010/73/EU.

Hong Kong

No securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to “professional investors” as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong, or SFO, and any rules made under that Ordinance; or in other circumstances which do not result in the document being a “prospectus” as defined in the Companies Ordinance (Cap. 32) of Hong Kong, or CO, or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO. No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” as defined in the SFO and any rules made under that Ordinance.

This prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and that he is not acquiring, and has not been offered any securities in circumstances that contravene any such restrictions.

Israel

This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the shares is directed only at, (i) a limited number of persons in accordance with the Israeli Securities Law and (ii) investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and “qualified individuals,”

 

157


Table of Contents

each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it.

Japan

The offering has not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948 of Japan, as amended), or FIEL, and the Initial Purchaser will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and ministerial guidelines of Japan.

Singapore

This prospectus has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the securities may not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275, of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

Where the securities are subscribed or purchased under Section 275 of the SFA by a relevant person which is:

 

   

a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or

 

   

a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,

 

   

securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the notes pursuant to an offer made under Section 275 of the SFA except:

 

   

to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA;

 

   

where no consideration is or will be given for the transfer;

 

   

where the transfer is by operation of law;

 

   

as specified in Section 276(7) of the SFA; or

 

   

as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.

Switzerland

The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland.

 

158


Table of Contents

Neither this prospectus nor any other offering or marketing material relating to the offering, the Company or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities.

United Kingdom

This prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive that are also (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, and/or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order and other persons to whom it may lawfully be communicated (each such person being referred to as a “relevant person”).

This prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents.

 

159


Table of Contents

LEGAL MATTERS

The validity of the shares of common stock being offered by this prospectus will be passed upon for us by Cooley LLP, San Diego, California. The underwriters are being represented by Latham & Watkins LLP, San Diego, California.

EXPERTS

The financial statements of Equillium, Inc. as of December 31, 2017 and for the period from March 16, 2017 (inception) to December 31, 2017 have been included herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. The audit report covering the December 31, 2017 financial statements contains an explanatory paragraph that states that the Company’s recurring losses from operations and net capital deficiency raise substantial doubt about the entity’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of that uncertainty.

 

160


Table of Contents

WHERE YOU CAN FIND ADDITIONAL INFORMATION

We have filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to the shares of common stock being offered by this prospectus. This prospectus does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the common stock offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference.

You can read our SEC filings, including the registration statement, over the Internet at the SEC’s website at www.sec.gov. You may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street NE, Washington, D.C. 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing us at 2223 Avenida de la Playa, Suite 108, La Jolla, CA 92037 or telephoning us at (858) 412-5302.

Upon the completion of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for inspection and copying at the public reference room and website of the SEC referred to above. We also maintain a website at www.equilliumbio.com, at which, following the completion of this offering, you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus.

 

161


Table of Contents

EQUILLIUM, INC.

Index to Financial Statements

 

 

 

     PAGE  

Report of Independent Registered Public Accounting Firm

     F-2  

Balance Sheets

     F-3  

Statements of Operations and Comprehensive Loss

     F-4  

Statements of Stockholders’ Deficit

     F-5  

Statements of Cash Flows

     F-6  

Notes to Financial Statements

     F-7  

 

 

 

 

F-1


Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and Board of Directors

Equillium, Inc.:

Opinion on the Financial Statements

We have audited the accompanying balance sheet of Equillium, Inc. (the Company) as of December 31, 2017, the related statements of operations and comprehensive loss, stockholders’ deficit, and cash flows for the period from March 16, 2017 (inception) to December 31, 2017, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017, and the results of its operations and its cash flows for the period from inception to December 31, 2017, in conformity with U.S. generally accepted accounting principles.

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ KPMG LLP

We have served as the Company’s auditor since 2018.

San Diego, California

August 3, 2018, except for the stock split described in Note 11, as to which the date is October 1, 2018

 

F-2


Table of Contents

EQUILLIUM, INC.

Balance Sheets

 

     DECEMBER 31,
        2017        
    JUNE 30,
        2018        
    Pro Forma
JUNE 30,
        2018        
 
           (unaudited)  

Assets

      

Current assets:

 

   

Cash and cash equivalents

   $ 7,103,553     $ 6,626,443    

Prepaid expenses and other current assets

     45,813       79,704    
  

 

 

   

 

 

   

Total current assets

     7,149,366       6,706,147    

Property and equipment, net

     2,077       21,987    
  

 

 

   

 

 

   

Total assets

   $ 7,151,443     $ 6,728,134    
  

 

 

   

 

 

   

Liabilities and stockholders’ (deficit) equity

 

 

Current liabilities:

 

   

Accounts payable

   $ 243,741     $ 346,848    

Accrued expenses

     325,079       570,341       233,791  
  

 

 

   

 

 

   

Total current liabilities

     568,820       917,189    

Long-term deferred rent

           278    

Long term convertible promissory notes

     6,994,847       9,355,699        

Long-term convertible promissory notes, related party

     1,064,019       1,162,197        

Biocon anti-dilution right

     775,842       878,122        

Other non-current liabilities

           8,150    
  

 

 

   

 

 

   

Total liabilities

     9,403,528       12,321,635    

Commitments and contingencies

 

 

Stockholders’ (deficit) equity:

      

Common stock, $0.0001 par value; 43,100,000 shares authorized at December 31, 2017 and June 30, 2018 (unaudited); 10,708,074 and 10,975,764 shares issued as of December 31, 2017 and June 30, 2018 (unaudited), respectively; and 10,708,074 and 10,975,764 shares outstanding as of December 31, 2017 and June 30, 2018 (unaudited), respectively

     124       127       231  

Additional paid-in capital

     9,665       10,405       11,742,869  

Accumulated deficit

     (2,261,874     (5,604,033  
  

 

 

   

 

 

   

 

 

 

Total stockholders’ (deficit) equity

     (2,252,085     (5,593,501     6,139,067  
  

 

 

   

 

 

   

 

 

 

Total liabilities and stockholders’ (deficit) equity

   $ 7,151,443     $ 6,728,134    
  

 

 

   

 

 

   

See accompanying notes

 

F-3


Table of Contents

EQUILLIUM, INC.

Statements of Operations and Comprehensive Loss

 

     FOR THE
PERIOD
MARCH 16,
2017
(INCEPTION)
THROUGH

DECEMBER 31,
2017
    FOR THE
PERIOD
MARCH 16,
2017
(INCEPTION)
THROUGH
JUNE 30,
2017
    SIX MONTHS
ENDED

JUNE 30, 2018
 
           (unaudited)  

Operating expenses:

      

Research and development

   $ 1,333,721     $ 801,364     $ 1,202,917  

General and administrative

     378,328       187,173       958,691  
  

 

 

   

 

 

   

 

 

 

Total operating expenses

     1,712,049       988,537       2,161,608  
  

 

 

   

 

 

   

 

 

 

Loss from operations

     (1,712,049     (988,537     (2,161,608

Other expense (income):

      

Interest expense

     379,385       7,069       1,108,197  

Interest income

                 (29,926

Change in fair value of Biocon anti-dilution right

     170,440       18,887       102,280  
  

 

 

   

 

 

   

 

 

 

Total other expense (income)

     549,825       25,956       1,180,551  
  

 

 

   

 

 

   

 

 

 

Net loss and comprehensive loss

   $ (2,261,874   $ (1,014,493   $ (3,342,159
  

 

 

   

 

 

   

 

 

 

Net loss per share, basic and diluted

   $ (0.28   $ (0.19   $ (0.31
  

 

 

   

 

 

   

 

 

 

Weighted-average common shares outstanding, basic and diluted

     8,030,029       5,307,596       10,711,788  
  

 

 

   

 

 

   

 

 

 

Pro forma net loss per share, basic and diluted (unaudited)

   $ (0.21     $ (0.18
  

 

 

     

 

 

 

Pro forma weighted-average common shares outstanding, basic and diluted (unaudited)

     (8,300,749       11,644,175  
  

 

 

     

 

 

 

See accompanying notes

 

F-4


Table of Contents

EQUILLIUM, INC.

Statements of Stockholders’ Deficit

 

     COMMON STOCK      ADDITIONAL
PAID-IN

CAPITAL
     ACCUMULATED
DEFICIT
    TOTAL
STOCKHOLDERS’

DEFICIT
 
     SHARES      AMOUNT  

Balance at March 16, 2017 (inception)

          $      $      $     $  

Issuance of founders’ stock

     8,620,000        100                     100  

Issuance of common stock to Biocon at $0.005 per share for license

     2,088,074        24        9,665              9,689  

Net loss

              (2,261,874     (2,261,874
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Balance at December 31, 2017

     10,708,074      $ 124      $ 9,665      $ (2,261,874   $ (2,252,085
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Issuance of common stock, net of liability (unaudited)

     267,690      $ 3      $      $     $ 3  

Stock-based compensation expense (unaudited)

                   740              740  

Net loss (unaudited)

                          (3,342,159     (3,342,159
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Balance at June 30, 2018 (unaudited)

     10,975,764      $ 127      $ 10,405      $ (5,604,033   $ (5,593,501
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

See accompanying notes

 

 

F-5


Table of Contents

EQUILLIUM, INC.

Statements of Cash Flows

 

     FOR THE PERIOD
MARCH 16, 2017
(INCEPTION) THROUGH

DECEMBER 31,
2017
    FOR THE PERIOD
MARCH 16, 2017
(INCEPTION) THROUGH

JUNE 30,
2017
    SIX MONTHS ENDED
JUNE 30,

2018
 
           (unaudited)  

Operating activities:

      

Net loss

   $ (2,261,874   $ (1,014,493   $ (3,342,159

Adjustments to reconcile net loss to cash used in operating activities:

      

Depreciation and amortization

     122             1,913  

Stock-based compensation

                 740  

Deferred rent

                 278  

Non-cash interest expense

     379,385       7,069       1,108,197  

Change in fair value of Biocon anti-dilution right

     170,440       18,887       102,280  

Non-cash research license expense

     615,091       615,091        

Changes in operating assets and liabilities:

      

Prepaid expenses and other current assets

     (45,813     (4,497     (26,404

Accounts payable

     243,740       9,875       103,108  

Accrued expenses

     236,708       184,527       (5,634
  

 

 

   

 

 

   

 

 

 

Net cash used in operating activities

     (662,201     (183,541     (2,057,681

Investing activities:

      

Purchases of property and equipment

     (2,199           (21,823
  

 

 

   

 

 

   

 

 

 

Net cash used in investing activities

     (2,199           (21,823

Financing activities:

      

Proceeds from issuance of convertible promissory notes, net

     6,767,853             1,599,012  

Proceeds from issuance of convertible promissory notes, related party

     1,000,000       1,000,000        

Proceeds from issuance of common stock

     100              

Proceeds from issuance of unvested common stock

                 3,382  
  

 

 

   

 

 

   

 

 

 

Net cash provided by financing activities

     7,767,953       1,000,000       1,602,394  
  

 

 

   

 

 

   

 

 

 

Net decrease in cash and cash equivalents

     7,103,553       816,459       (477,110

Cash and cash equivalents at beginning of period

                 7,103,553  
  

 

 

   

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 7,103,553     $ 816,459     $ 6,626,443  
  

 

 

   

 

 

   

 

 

 

Supplemental disclosures of noncash activities

      

Issuance of common stock to Biocon for license

     9,689       9,689        
  

 

 

   

 

 

   

 

 

 
   $ 9,689     $ 9,689     $  
  

 

 

   

 

 

   

 

 

 

See accompanying notes

 

F-6


Table of Contents

1. Organization and Basis of Presentation

Description of Business

The Company was incorporated in the state of Delaware on March 16, 2017, under the name Attenuate Biopharmaceuticals, Inc. On May 18, 2017, the Company changed its name to Equillium, Inc. (the “Company”). The Company is engaged in the research and development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need.

The Company has devoted substantially all of its efforts on organizing and staffing our company, business planning, raising capital, in-licensing rights to EQ001, conducting preclinical research, filing our initial IND and preparing to commence clinical development of EQ001. In addition, the Company has a limited operating history, has not generated revenues from its principal operations, and the sales and income potential of its business is unproven. The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty.

Liquidity

The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable future. The Company had an accumulated deficit of $2.3 million and $5.6 million at December 31, 2017 and June 30, 2018 (unaudited), respectively. In 2017, the Company used $0.7 million in cash for operations. For the six month period ended June 30, 2018 (unaudited), the Company used $2.1 million in cash for operations. At December 31, 2017 and June 30, 2018 (unaudited), the Company had cash and cash equivalents of $7.1 million and $6.6 million, respectively. Management expects operating losses and negative cash flows to continue for at least the next several years as the Company continues to incur costs related to the development of EQ001. Management has prepared cash flow forecasts which indicate that based on the Company’s expected operating losses and negative cash flows, there is substantial doubt about the Company’s ability to continue as a going concern without raising additional capital within 12 months after the date that the financial statements for the period March 16, 2017 (inception) through December 31, 2017 are issued.

The Company’s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management intends to raise additional capital through a combination of equity offerings, debt financings, and collaboration and license agreements. However, the Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company’s ability to achieve the development and commercialization goals would be adversely affected.

2. Summary of Significant Accounting Policies

Use of Estimates

The Company’s financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of the Company’s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company’s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

 

F-7


Table of Contents

Unaudited Interim Financial Information

The accompanying interim balance sheet as of June 30, 2018, and the statements of operations and comprehensive loss and cash flows for the period March 16, 2017 (inception) through June 30, 2017 and the six months ended June 30, 2018 and the statement of stockholders’ deficit for the six months ended June 30, 2018 and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared in accordance with GAAP. The unaudited interim financial statements have been prepared on the same basis as the audited financial statements and reflect, in management’s opinion, all adjustments of a normal, recurring nature that are necessary for the fair statement of the Company’s financial position as of June 30, 2018 and its results of operations and cash flows for the period ended June 30, 2017 and the six months ended June 30, 2018. The results for the six months ended June 30, 2018 are not necessarily indicative of the results expected for the full fiscal year or any other period.

Unaudited Pro Forma Balance Sheet Information

The unaudited pro forma balance sheet information as of June 30, 2018 gives effect to the issuance of $9.4 million of convertible promissory notes issued in October 2017, November 2017, April 2018, and June 2018 (see Note 6) and the automatic conversion of such notes (including accrued interest thereon) into shares of common stock upon completion of this offering, assuming an initial public offering price of $15.00 per share (the midpoint of the price range listed on the cover page of this prospectus). The unaudited pro forma balance sheet assumes that the completion of the IPO had occurred as of June 30, 2018 and excludes shares of common stock issued in the offering and any related net proceeds.

Concentration of Credit Risk

Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.

Comprehensive Loss

The Company is required to report all components of comprehensive loss, including net loss, in the financial statements in the period in which they are recognized. Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on investments and foreign currency gains and losses. Comprehensive loss is the same as the net loss for the period ended December 31, 2017 and six months ended June 30, 2018 (unaudited).

Fair Value of Financial Instruments

The carrying amounts of all prepaid and other current assets, accounts payable, accrued expenses, and debt are considered to be representative of their respective fair values because of the short-term nature of those instruments.

Property and Equipment

Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally two to five years, or the remaining term of the lease).

Accrued Research and Development Expense

The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants and contract research organizations, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects research and development expenses in its financial statements by matching those

 

F-8


Table of Contents

expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical or clinical study as measured by the timing of various aspects of the study or related activities. The Company determines accrual estimates through review of the underlying contracts along with preparation of financial models taking into account discussions with research and other key personnel as to the progress of studies, or other services being conducted. During the course of a study, the Company adjusts its rate of expense recognition if actual results differ from its estimates.

Research and Development

Research and development expenses include salaries, benefits, costs to third-party contractors to perform research and development activities, and associated overhead expenses. Research and development costs are expensed as incurred.

Patent Costs

The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statement of operations.

Debt Costs

The Company capitalizes related debt issuance costs and amortizes them over the life of the loan using the effective interest method. Conversion discounts on the Company’s convertible promissory notes based on a future round of financing are recognized as additional interest expense over the life of the debt using the effective interest method.

Deferred Rent

Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the facilities the Company leases. The Company’s leases for its facilities provide for fixed increases in minimum annual rental payments. The total amount of rental payments due over the lease terms are being charged to rent expense ratably over the life of the leases.

Biocon Anti-Dilution Right

The Company has committed to issue to Biocon SA (together with Biocon Limited, “Biocon”) additional shares of common stock to maintain Biocon’s ownership interest at 19.5% of the diluted Company shares outstanding (as defined in the License Agreements (as defined below)) until the Company has received aggregate cumulative gross proceeds from sales of equity securities of $15.0 million (“Biocon Anti-Dilution Right”). As an obligation exists to issue a variable number of shares and that obligation is not indexed to the Company’s common stock, the Biocon Anti-Dilution Right has been classified as a liability in the accompanying balance sheet. The Biocon Anti-Dilution Right is recorded at fair value using the Precedent Transaction Method. The fair value of the Biocon Anti-Dilution Right is re-measured at each financial reporting period with any changes in fair value recognized as a component of other expense (income).

Stock-Based Compensation

Stock-based compensation expense represents the cost of the grant date fair value of employee and non-employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of actual forfeitures during the period. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The exercise price for all stock options granted was at the estimated fair value of the underlying common stock as determined on the date of grant by the Company’s Board of Directors.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the

 

F-9


Table of Contents

differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

As of December 31, 2017, and as of June 30, 2018, the Company maintained valuation allowances against its deferred tax assets as the Company concluded it had not met the “more likely than not” to be realized threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate.

The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities include outstanding stock options under the Company’s equity incentive plan and have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):

 

     FOR THE PERIOD
MARCH 16,
2017
(INCEPTION)
THROUGH

DECEMBER 31,
2017
     FOR THE PERIOD
MARCH 16, 2017
(INCEPTION)
THROUGH

JUNE 30,
2017
     SIX MONTHS
ENDED

JUNE 30,
2018
 
            (unaudited)  

Common stock options

                   374,774  

Biocon anti-dilution right

        
  

 

 

    

 

 

    

 

 

 

Total

                   374,774  
  

 

 

    

 

 

    

 

 

 

 

F-10


Table of Contents

Unaudited Pro Forma Net Loss Per Share

The following table summarizes the unaudited pro forma net loss per share:

 

     FOR THE PERIOD
MARCH 16, 2017
(INCEPTION)
THROUGH

DECEMBER 31, 2017
    SIX MONTHS
ENDED
JUNE 30, 2018
 
    

(unaudited)

 

Net loss attributable to common stockholders

   $ (2,261,874   $ (3,342,159

Add:

    

Interest expense on convertible promissory notes

     379,385       1,108,197  

Change in fair value of Biocon anti-dilution right

     170,440       102,280  
  

 

 

   

 

 

 

Pro forma net loss

   $ (1,712,049   $ (2,131,682
  

 

 

   

 

 

 

Weighted-average common shares outstanding, basic and diluted

     8,030,029       10,711,788  

Add:

    

Pro forma adjustments to reflect assumed conversion of convertible promissory notes and settlement of Biocon anti-dilution right into common shares

     270,720       932,387  
  

 

 

   

 

 

 

Pro forma weighted-average common shares outstanding, basic and diluted

     8,300,749       11,644,175  
  

 

 

   

 

 

 

Pro forma net loss per share attributable to common stockholders, basic and diluted

     (0.21     (0.18
  

 

 

   

 

 

 

Recent Accounting Pronouncements

In February 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2016-02, Leases (Topic 842), which amends the FASB Accounting Standards Codification and creates Topic 842, “Leases.” The new topic supersedes Topic 840, “Leases,” and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. The guidance is effective for reporting periods beginning after December 15, 2018. ASU 2016-02 mandates a modified retrospective transition method. The Company entered into a lease in 2018 and will evaluate the impact of adoption of the ASU on its financial statements.

In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice for certain cash receipts and cash payments. The standard is effective for annual reporting periods beginning after December 15, 2018 and interim periods reporting within fiscal years beginning after December 15, 2019, with early adoption permitted. The Company does not believe the adoption of this guidance will have a material impact on the financial statements.

In June 2018, the FASB issued ASU 2018-07, Improvements to Non-Employee Share-Based Payment Accounting (Topic 718). ASU 2018-07 aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance of share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date, which may lower their cost and reduce volatility in the income statement. The standard is effective in annual periods beginning after December 15, 2018 including interim periods within that fiscal year, with early adoption permitted but not before the Company adopts ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The Company early adopted this guidance as of January 1, 2018.

3. Fair Value Measurements

The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based

 

F-11


Table of Contents

measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2—Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3—Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

At December 31, 2017 and June 30, 2018, the Company did not have financial assets that are measured at fair value on a recurring basis. The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. The Company believes the fair value of its convertible promissory notes approximates its carrying value. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.

The Company estimated the fair value of its Biocon Anti-Dilution Right (see Note 5) at the time of issuance and remeasures it at each reporting date using the Precedent Transaction Method. The Precedent Transaction Method was applied to solve for the enterprise value of the Company under two scenarios: with the Biocon Anti-Dilution Right and without the Biocon Anti-Dilution Right. The resulting difference in the enterprise value under these two scenarios is the estimated fair value of the Biocon Anti-Dilution Right. The estimates used to determine the enterprise value of the Company are based, in part, on subjective assumptions and could differ materially in the future. Fluctuations in the fair value of the Biocon Anti-Dilution Right are impacted by unobservable inputs, most significantly the estimated fair value of the Company and probability of achieving different financing scenarios. If the Company does not receive proceeds from an equity financing, the fair value of the Biocon Anti-Dilution Right would be zero. Alternatively, if an equity financing results in gross proceeds of $15.0 million or greater, the fair value of the Biocon Anti-Dilution Right could be as high as $3.6 million. Changes in the estimated fair value of the Company and the probability of achieving different financing scenarios can have a significant impact on the fair value of the Biocon Anti-Dilution Right.

Financial liabilities measured at fair value on a recurring basis consist of the Biocon Anti-Dilution Right. As of December 31, 2017 and June 30, 2018 (unaudited), the carrying amount of the Biocon Anti-Dilution Right was $0.8 million and $0.9 million, respectively, which approximates fair value and was determined based upon Level 3 inputs. As of December 31, 2017 and June 30, 2018, the Company did not hold any Level 1 or Level 2 financial liabilities that are recorded at fair value on a recurring basis.

 

F-12


Table of Contents

The following table presents activity for the Biocon Anti-Dilution Right measured at fair value using Level 3 unobservable inputs as of December 31, 2017 and June 30, 2018 (unaudited):

 

     FAIR VALUE
MEASUREMENTS
AT REPORTING
DATE USING
SIGNIFICANT
UNOBSERVABLE
INPUTS (LEVEL 3)
 

Balance at March 16, 2017 (inception)

   $  
  

 

 

 

Issuance of Biocon anti-dilution right

     605,402  
  

 

 

 

Changes in fair value of Biocon anti-dilution right

     170,440  
  

 

 

 

Balance at December 31, 2017

     775,842  
  

 

 

 

Changes in fair value of Biocon anti-dilution right

     102,280  
  

 

 

 

Balance at June 30, 2018 (unaudited)

   $ 878,122  
  

 

 

 

4. Accrued Expenses

Accrued expenses consist of the following:

 

     DECEMBER 31,
2017
     JUNE 30,
2018
 
            (unaudited)  

Accrued payroll and other employee benefits

   $ 15,548      $ 137,487  

Accrued interest

     88,372        336,550  

Preclinical studies

     36,000        63,880  

Accrued taxes

     184,527         

Other accruals

     632        32,424  
  

 

 

    

 

 

 

Accrued expenses

   $ 325,079      $ 570,341  
  

 

 

    

 

 

 

5. Collaboration and License Agreement

In May 2017, the Company entered into a collaboration and license agreement, clinical supply agreement, investor rights agreement, and common stock purchase agreement (collectively “License Agreements”) with Biocon. Pursuant to the License Agreements, Biocon granted the Company an exclusive license in the United States and Canada (“Company Territory”) to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit EQ001 and any pharmaceutical composition or preparation containing or comprising EQ001 (“Biocon Product”) that uses Biocon technology or Biocon know-how. Pursuant to the License Agreements, Biocon agreed to be the Company’s exclusive supplier of EQ001 clinical drug product for up to three concurrent orphan drug clinical indications at no cost until the Company’s first U.S. regulatory approval and all other clinical drug product at cost.

In consideration of the rights granted to the Company by Biocon, the Company issued Biocon shares of its common stock equal to 19.5% of its outstanding shares at the time of the execution of the License Agreements. Biocon also has a Biocon Anti-Dilution Right (see Note 2) which is recorded at fair value using the Precedent Transaction Method (see Note 3) and was determined to be $605,402 at the time of issuance. As an obligation exists to issue a variable number of shares and such obligation is not indexed to the Company’s common stock, the Biocon Anti-Dilution Right has been classified as a liability in the accompanying balance sheet. The fair value of the Biocon Anti-Dilution Right is re-measured at each financial reporting period with any changes in fair value being recognized as a component of other expense (income). As of December 31, 2017, and June 30, 2018 (unaudited), the fair value of the Biocon Anti-Dilution Right was $775,842 and $878,122, respectively.

In addition, the Company is obligated to pay Biocon up to an aggregate of $30 million in regulatory milestone payments upon the achievement of certain regulatory approvals and up to an aggregate of $565 million in sales

 

F-13


Table of Contents

milestone payments upon the achievement of first commercial sale of product and specified levels of product sales. The Company is also required to pay quarterly tiered royalties based on a percentage from the mid-single digits to sub-teen double-digits of net sales of Biocon Products, subject to adjustments in certain circumstances. Biocon is also required to pay the Company royalties at comparable percentages for sales of EQ001 outside of the Company Territory if the approvals in such geographies included or referenced the Company’s data. To date, the Company has not made or received payments in connection with the milestones or royalties within the agreement.

6. Convertible Promissory Notes

In May 2017, the Company issued $1,000,000 in convertible promissory notes to its founders (“Founder Notes”). The Founder Notes accrued interest at a rate of 6% a year and mature one year from issuance. The Founder Notes are convertible at the option of the holder upon a Qualified Financing (as defined below).

In October 2017, November 2017, April 2018, and June 2018, the Company entered into note purchase agreements whereby the Company agreed to issue and investors (the “Noteholders”) agreed to purchase $9,407,474 in convertible promissory notes (the “Convertible Promissory Notes”). As part of the October 2017 Convertible Promissory Notes, the Founder Notes were amended and restated on terms matching the Convertible Promissory Notes and the then outstanding principal and accrued interest thereunder was included as the principal amount of each such amended and restated Convertible Promissory Note. The Convertible Promissory Notes accrue interest at a rate of 6% per year and mature two years from their issuance.

The Convertible Promissory Notes automatically convert into equity securities sold pursuant to a qualified financing (“Qualified Financing”) transaction from which the Company receives total gross proceeds of not less than $15 million at a conversion price equal to 90% of the per share price paid by investors for such securities if the closing of the financing occurs on or prior to the six month anniversary of the issuance of Convertible Promissory Notes or at a conversion price equal to 80% of the per share price paid by investors for such securities if the closing of the financing occurs after the six month anniversary of the issuance of Convertible Promissory Notes.

The Company recorded interest expense of $379,385 and $1,108,197 using the effective-interest method for the period ending December 31, 2017 and the six months ended June 30, 2018 (unaudited), respectively, in relation to stated interest and the estimated discount at which the Convertible Promissory Notes will convert.

The following is a summary of all debt obligations recorded on the balance sheet at December 31, 2017 and June 30, 2018:

 

     DECEMBER 31,
2017
     JUNE 30,
2018
 
            (unaudited)  

Convertible promissory notes (inclusive of related party)

   $ 7,807,474      $ 9,407,474  

Accrued premium

     251,392        1,110,422  
  

 

 

    

 

 

 

Total convertible promissory notes

   $ 8,058,866      $ 10,517,896  
  

 

 

    

 

 

 

7. Stockholders’ Deficit

During 2017, the Company issued 8,620,000 shares of common stock to founders at a price of $0.00001 per share and 2,088,074 shares of common stock to Biocon as partial consideration for the License Agreements (Note 5). The shares issued to Biocon were valued at $0.005 per share, resulting in $9,689 of research license expense.

Stock Options

In December 2017, the Company adopted the 2017 Equity Incentive Plan (the “Plan”). The Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards. As of December 31, 2017 and June 30, 2018 (unaudited), the number of shares reserved under the Plan was 1,189,773.

There were 1,189,773 and 814,999 shares available for grant under the Plan as of December 31, 2017 and June 30, 2018 (unaudited), respectively. Options granted under the Plan are exercisable at various dates as

 

F-14


Table of Contents

determined upon grant and will expire no more than ten years from their date of grant. The exercise price of each option shall be determined by the Board of Directors based on the estimated fair value of the Company’s stock on the date of the option grant. The exercise price shall not be less than 100% of the fair market value of the Company’s common stock at the time the option is granted. Most option grants generally vest 25% on the first anniversary of the original vesting commencement date, with the balance vesting monthly over the remaining three years and early exercise is permitted.

A summary of the Company’s stock option activity under the Plan is as follows:

 

     TOTAL
OPTIONS
    WEIGHTED-
AVERAGE
EXERCISE
PRICE PER
SHARE
     WEIGHTED-
AVERAGE
REMAINING
CONTRACT
TERM
     AGGREGATE
INTRINSIC
VALUE
 

Outstanding at December 31, 2017

         $             $  

Granted

     374,774       0.05        10.0        2,609  

Exercised

     (267,690     0.05        9.9        1,863  

Cancelled

                  
  

 

 

   

 

 

    

 

 

    

 

 

 

Outstanding at June 30, 2018 (unaudited)

     107,084     $             $  
  

 

 

   

 

 

    

 

 

    

 

 

 

Vested and expected to vest at December 31, 2017

         $             $  
  

 

 

         

 

 

 

Vested and exercisable at December 31, 2017

         $             $  
  

 

 

         

 

 

 

Vested and expected to vest at June 30, 2018 (unaudited)

     107,084     $ 0.05        9.9      $ 745  
  

 

 

         

 

 

 

Vested and exercisable at June 30, 2018 (unaudited)

     374,774     $ 0.05        9.9      $ 261  
  

 

 

         

 

 

 

For the period ended December 31, 2017 and six months ended June 30, 2018 (unaudited), the total grant date fair value of vested options was $0 and $0.03 per share, respectively.

The weighted-average grant date fair value of employee option grants during the period ended December 31, 2017 and the six months ended June 30, 2018 (unaudited) was $0 and $0.03 per share, respectively.

Liability for Early Exercise of Restricted Stock Options

Certain individuals were granted the ability to early exercise their stock options. The shares of common stock issued from the early exercise of unvested stock options are restricted and continue to vest in accordance with the original vesting schedule. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The cash received, net of par value, in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options on the accompanying balance sheets and will be transferred into additional paid-in capital as the shares vest. As of December 31, 2017 and June 30, 2018 (unaudited), there were 0 and 267,690, respectively, shares subject to repurchase by the Company. As of December 31, 2017 and June 30, 2018 (unaudited), the Company recorded $0 and $10,866, respectively, of liabilities associated with shares issued with repurchase rights.

 

F-15


Table of Contents

Stock-Based Compensation Expense

The Company recognized stock-based compensation expense of $0 for the period ended December 31, 2017 and $740 for the six months ended June 30, 2018 (unaudited).

The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee and nonemployee stock option grants were as follows:

 

     FOR THE PERIOD MARCH 16,
2017 (INCEPTION)
THROUGH DECEMBER 31,

2017
     FOR THE PERIOD
MARCH 16, 2017
(INCEPTION)
THROUGH JUNE 30,

2017
     FOR THE SIX
MONTHS ENDED
JUNE 30,

2018
 
            (unaudited)  

Risk-free rate of interest

                   2.86% - 2.88%

Expected term (years)

                   5.75 - 6.08    

Expected stock price volatility

                   85.56%  

Dividend yield

                    

Risk-free interest rate. The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company’s stock options.

Expected volatility. Due to the Company’s limited operating history and lack of company-specific historical or implied volatility as a private company, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available.

Expected term. The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.

Expected dividend yield. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends.

Forfeitures. The Company reduces stock-based compensation expense for actual forfeitures during the period.

As of December 31, 2017 and June 30, 2018 (unaudited), the unrecognized compensation cost related to outstanding employee and nonemployee options was $0 and $10,343, respectively, and is expected to be recognized as expense over approximately 0 years and 3.73 years, respectively.

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consists of the following as of December 31, 2017 and June 30, 2018:

 

     DECEMBER 31,
2017
     JUNE 30,
2018
 
            (unaudited)  

Stock options issued and outstanding

            107,084  

Authorized for future stock awards or options grants

     1,189,773        814,999  
  

 

 

    

 

 

 

Total

     1,189,773        922,083  
  

 

 

    

 

 

 

8. Income Taxes

Due to our net losses for the period ended December 31, 2017, and since we have a full valuation allowance against deferred tax assets, there was no provision or benefit for income taxes recorded There were no components of current or deferred federal, state or foreign tax provisions for the period ended December 31, 2017.

 

F-16


Table of Contents

A reconciliation of the total income tax provision tax rate to the statutory federal income tax rate of 34% for the period ended December 31, 2017 is as follows:

 

     DECEMBER 31,
2017
 

Income Taxes at Statutory Rates

     34.00

State Income Tax, Net of Federal Benefit

     0.00

Permanent Items

     -10.92

Tax Law Change—Tax Reform

     -8.78

Federal Research Credit

     0.41

Change in Federal Valuation Allowance

     -14.71
  

 

 

 
     0.00
  

 

 

 

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities as of December 31, 2017 are as follows:

 

     DECEMBER 31,
2017
 

Deferred tax assets:

  

Net operating loss carryforward

   $ 248,222  

Credits

     43,162  

Intangibles

     198,290  
  

 

 

 

Deferred tax assets

     489,674  

Deferred tax liabilities:

  

Fixed Assets

     (89
  

 

 

 

Deferred tax liabilities

     (89

Net deferred tax assets

     489,585  

Valuation allowance

     (489,585
  

 

 

 

Net deferred tax assets

   $  
  

 

 

 

The Company has established a valuation allowance against its net deferred tax assets due to the uncertainty surrounding the realization of such assets. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred assets are realizable, the valuation allowance will be reduced. The Company has recorded a full valuation allowance of $489,585 as of December 31, 2017 as it does not believe it is more likely than not that certain deferred tax assets will be realized primarily due to the generation of pre-tax book losses in its first year, no ability to carryback losses, the lack of feasible tax-planning strategies, the limited existing taxable temporary differences, and the subjective nature of forecasting future taxable income into the future.

The Company increased its valuation allowance by approximately $489,585 during the period ended December 31, 2017.

At December 31, 2017, the Company had federal and California tax loss carry forwards of approximately $884,776 and $893,787, respectively. The federal and state net operating loss carry forwards begin to expire in 2037 and 2037, respectively, if unused.

At December 31, 2017, we had federal and state tax credit carry forwards of approximately $23,355 and $14,344 respectively, after reduction for uncertain tax positions. The Company has not performed a formal research and development credit study with respect to these credits. The federal credits will begin to expire in 2037, if unused, and the state credits carry forward indefinitely.

Pursuant to the Internal Revenue Code (“IRC”) of 1986, as amended, specifically IRC §382 and IRC §383, the Company’s ability to use net operating loss and R&D tax credit carry forwards (“tax attribute carry forwards”) to

 

F-17


Table of Contents

offset future taxable income is limited if the Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes within the meaning of IRC Section 382 are identified as having occurred, the amount of remaining tax attribute carry-forwards available to offset future taxable income and income tax expense in future years may be significantly restricted or eliminated. Further, our deferred tax assets associated with such tax attributes could be significantly reduced upon realization of an ownership change within the meaning of IRC §382.

In December 2017, the Tax Cuts and Jobs Act (the “2017 Tax Act”) was enacted. The 2017 Tax Act includes a number of changes to existing U.S. tax laws that impact the Company, most notably a reduction of the U.S. corporate income tax rate from 35% to 21% for tax years beginning after December 31, 2017. The 2017 Tax Act also provides for the acceleration of depreciation for certain assets placed in service after September 27, 2017 as well as prospective changes beginning in 2018, including limitations on the deductibility of interest and capitalization of research and development expenditures. The Company measures deferred tax assets and liabilities using enacted tax rates that will apply in the years in which the temporary differences are expected to be recovered or paid. Accordingly, the Company’s deferred tax assets and liabilities were remeasured to reflect the reduction in the U.S. corporate income tax rate from 35% to 21%, resulting in a $198,687 increase in tax expense for the period ended December 31, 2017 and a corresponding $198,687 decrease in net deferred tax assets as of December 31, 2017. The impact was offset by the Company’s valuation allowance.

The following table summarizes the reconciliation of the unrecognized tax benefits activity during the years ended December 31, 2017:

 

     DECEMBER 31,
2017
 

Unrecognized Tax Benefits—Beginning

   $  

Gross increases—tax positions in prior period

      

Gross decreases—tax positions in prior period

      

Gross increase—current-period tax positions

     18,849  

Gross decrease—current-period tax positions

      

Settlements

      

Lapse of statute of limitations

      
  

 

 

 

Unrecognized Tax Benefits—Ending

   $ 18,849  
  

 

 

 

The unrecognized tax benefit amounts are reflected in the determination of the Company’s deferred tax assets. If recognized, none of these amounts would affect the Company’s effective tax rate, since it would be offset by an equal corresponding adjustment in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next 12 months.

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company’s balance sheets as of December 31, 2017 and has not recognized interest and/or penalties in the Statement of Operations for the period ended December 31, 2017.

All tax years for both federal and state purposes remain open and subject to examination by tax jurisdictions.

9. Related-Party Transactions

In May 2017, the Company entered into License Agreements with Biocon, a pharmaceutical company in which the Company’s Chief Executive Officer is on the Board of Directors.

In May 2017, the Company entered into Founder Notes with the Company’s Chief Executive Officer and Chief Business Officer in the amounts of $500,000 and $500,000, respectively. These Founder Notes were subsequently amended and restated on terms matching the Convertible Promissory Notes and the then outstanding principal and accrued interest thereunder was included as the principal amount of each such amended and restated Convertible Promissory Note.

 

F-18


Table of Contents

10. Commitments and Contingencies

Leases

The Company leases certain office space in San Diego, California under a non-cancelable operating lease, with a term through February 2022. Rent expense was $0 and $10,157 for the period ended December 31, 2017, and for the six months ended June 30, 2018 (unaudited).

The future minimum lease payments required under non-cancelable leases as of December 31, 2017, are summarized as follows:

 

Year Ending December 31,

  

2018

   $ 47,935  

2019

     57,522  

2020

     58,914  

2021

     59,193  

2022

     9,865  
  

 

 

 

Total minimum lease payments

   $ 233,429  
  

 

 

 

Litigation

As of December 31, 2017 and June 30, 2018, there was no litigation against the Company.

11. Subsequent Events

For the purposes of the financial statements as of December 31, 2017 and the year then ended, the Company has evaluated the subsequent events through August 3, 2018, the date the audited annual financial statements were issued. For the purposes of the unaudited interim condensed financial statements as of June 30, 2018 and the six month period then ended, such evaluation of subsequent events has been performed through August 3, 2018.

Forward Stock Split

On October 1, 2018, the Company amended its amended and restated certificate of incorporation to effect a one-for-8.62 forward stock split of every outstanding share of its common stock. The financial statements and accompanying footnotes have been retroactively restated to reflect the forward stock split.

 

F-19


Table of Contents

 

 

4,670,000 Shares

 

 

LOGO

Common Stock

 

 

PRELIMINARY PROSPECTUS

 

 

Joint Book-Running Managers

Jefferies

Leerink Partners

Stifel

                    , 2018

 

 

 


Table of Contents

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13. Other Expenses of Issuance and Distribution.

The following table sets forth all costs and expenses, other than underwriting discounts and commissions, payable by Equillium, Inc., or the Registrant, in connection with the sale of the common stock being registered. All amounts shown are estimates except for the Securities and Exchange Commission, or SEC, registration fee, the FINRA filing fee and The Nasdaq Global Market listing fee.

 

 

 

     AMOUNT  

SEC registration fee

     $10,415  

FINRA filing fee

     12,788  

Nasdaq Global Market listing fee

     125,000  

Printing and engraving expenses

     330,000  

Legal fees and expenses

     1,200,000  

Accounting fees and expenses

     400,000  

Transfer agent and registrar fees and expenses

     4,000  

Miscellaneous expenses

     17,797  
  

 

 

 

Total

     $2,100,000  
  

 

 

 

 

 

Item 14. Indemnification of Directors and Officers.

The Registrant is incorporated under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may indemnify any persons who were, are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation, or is or was serving at the request of such corporation as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify any persons who were, are, or are threatened to be made, a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests, except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses (including attorneys’ fees) actually and reasonably incurred.

The Registrant’s amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the completion of this offering, respectively, provide for the indemnification of its directors and officers to the fullest extent permitted under the Delaware General Corporation Law. Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability for any:

 

   

transaction from which the director derives an improper personal benefit;

 

II-1


Table of Contents
   

act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

 

   

unlawful payment of dividends or redemption of shares; or

 

   

breach of a director’s duty of loyalty to the corporation or its stockholders.

The Registrant’s amended and restated certificate of incorporation, as currently in effect, includes such a provision, and the Registrant’s amended and restated certificate of incorporation that will become effective immediately prior to the completion of this offering will include such a provision. Expenses incurred by any officer or director in defending any such action, suit or proceeding in advance of its final disposition shall be paid by the Registrant upon delivery to it of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified by the Registrant.

Section 174 of the Delaware General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the unlawful actions were approved or dissented at the time may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.

As permitted by the Delaware General Corporation Law, the Registrant has entered into indemnity agreements with each of its directors and executive officers, that require the Registrant to indemnify such persons against any and all costs and expenses (including attorneys’, witness or other professional fees) actually and reasonably incurred by such persons in connection with any action, suit or proceeding (including derivative actions), whether actual or threatened, to which any such person may be made a party by reason of the fact that such person is or was a director or officer or is or was acting or serving as an officer, director, employee or agent of the Registrant or any of its affiliated enterprises. Under these agreements, the Registrant is not required to provide indemnification for certain matters, including:

 

   

indemnification beyond that permitted by the Delaware General Corporation Law;

 

   

indemnification for any proceeding with respect to the unlawful payment of remuneration to the director or officer;

 

   

indemnification for certain proceedings involving a final judgment that the director or officer is required to disgorge profits from the purchase or sale of the Registrant’s stock;

 

   

indemnification for proceedings involving a final judgment that the director’s or officer’s conduct was in bad faith, knowingly fraudulent or deliberately dishonest or constituted willful misconduct or a breach of his or her duty of loyalty, but only to the extent of such specific determination;

 

   

indemnification for proceedings or claims brought by an officer or director against us or any of the Registrant’s directors, officers, employees or agents, except for claims to establish a right of indemnification or proceedings or claims approved by the Registrant’s board of directors or required by law;

 

   

indemnification for settlements the director or officer enters into without the Registrant’s consent; or

 

   

indemnification in violation of any undertaking required by the Securities Act of 1933, as amended, or the Securities Act, or in any registration statement filed by the Registrant.

The indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification thereunder. Except as otherwise disclosed under the heading “Legal Proceedings” in the “Business” section of the prospectus included in this registration statement, there is at present no pending litigation or proceeding involving any of the Registrant’s directors or executive officers as to which indemnification is required or permitted, and the Registrant is not aware of any threatened litigation or proceeding that may result in a claim for indemnification.

The Registrant has an insurance policy in place that covers its officers and directors with respect to certain liabilities, including liabilities arising under the Securities Act, or otherwise.

The Registrant plans to enter into an underwriting agreement which provides that the underwriters are obligated, under some circumstances, to indemnify the Registrant’s directors, officers and controlling persons against specified liabilities, including liabilities under the Securities Act.

 

II-2


Table of Contents

Item 15. Recent sales of unregistered securities.

Set forth below is information regarding securities issued and options granted by us since March 16, 2017, our inception, that were not registered under the Securities Act. Also included is the consideration, if any, received by us, for such securities and options and information relating to the Securities Act, or rule of the SEC, under which exemption from registration was claimed.

(1) In March 2017, we issued 8,620,000 shares of common stock to our founders and/or entities affiliated with them pursuant to stock purchase agreements.

(2) In May 2017, we issued 2,088,074 shares of common stock to Biocon SA pursuant to a stock purchase agreement.

(3) From May 2017 to June 2018, we issued convertible promissory notes in an aggregate principal amount of $9.4 million to investors pursuant to note purchase agreements.

(4) From June 2018 to the effective date of this registration statement, we granted stock options under our 2017 equity incentive plan, or the 2017 Plan, to purchase up to an aggregate of 856,654 shares of our common stock to our employees, directors and consultants, at a weighted-average exercise price of $2.06 per share. From June 2018 to the effective date of this registration statement, 422,372 shares of common stock were issued upon the exercise of options granted to certain employees, directors and consultants and the payment of $199,210 to us was made.

The offers, sales and issuances of the securities described in paragraphs (1) through (3) were deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) (or Regulation D promulgated thereunder) in that the issuance of securities to the accredited investors did not involve a public offering. The recipients of securities in each of these transactions acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions was an accredited investor under Rule 501 of Regulation D. No underwriters were involved in these transactions.

The offers, sales and issuances of the securities described in paragraph (4) were deemed to be exempt from registration under the Securities Act in reliance on Rule 701 in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of such securities were our employees, directors or bona fide consultants and received the securities under the 2017 Plan. Appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions had adequate access, through employment, business or other relationships, to information about us.

Item 16. Exhibits and financial statement schedules.

(a) Exhibits.

The exhibits listed below are filed as part of this registration statement.

 

 

 

EXHIBIT

NUMBER

  

DESCRIPTION OF DOCUMENT

1.1    Form of Underwriting Agreement.
3.1    Amended and Restated Certificate of Incorporation, as amended, as currently in effect.
3.2#    Form of Amended and Restated Certificate of Incorporation to become effective immediately prior to the completion of this offering.
3.3#    Bylaws, as currently in effect.
3.4#    Form of Amended and Restated Bylaws to become effective upon the completion of this offering.
4.1    Form of Common Stock Certificate of the Registrant.
5.1    Opinion of Cooley LLP.

 

 

 

 

II-3


Table of Contents

 

 

EXHIBIT
NUMBER
 

DESCRIPTION OF DOCUMENT

10.1+#   Form of Indemnity Agreement by and between the Registrant and its directors and officers.
10.2+#   Equillium, Inc. 2017 Equity Incentive Plan and Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder.
10.3+   Equillium, Inc. 2018 Equity Incentive Plan and Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder.
10.4+   Equillium, Inc. 2018 Employee Stock Purchase Plan.
10.5+   Equillium, Inc. Non-Employee Director Compensation Policy.
10.6*#   Collaboration and License Agreement, dated May  22, 2017, by and between the Registrant and Biocon SA (which was subsequently assigned to Biocon Limited effective March 2018).
10.7*#   Clinical Supply Agreement, dated May  22, 2017, by and between the Registrant and Biocon SA (which was subsequently assigned to Biocon Limited effective March 2018).
10.8#   Standard Office Lease, effective as of February 1, 2018, by and between the Registrant and La Jolla Shores Plaza, LLC.
10.9+#   Offer Letter, dated June 1, 2018, by and between the Registrant and Daniel M. Bradbury.
10.10+#   Offer Letter, dated March 19, 2018, by and between the Registrant and Jason A. Keyes.
10.11+#   Offer Letter, dated June 1, 2018, by and between the Registrant and Bruce D. Steel.
10.12+#   Amended and Restated Offer Letter, dated June 7, 2018, by and between the Registrant and Stephen Connelly, Ph.D.
10.13#   Offer Letter, dated August 1, 2018, by and between the Registrant and Krishna Polu, M.D.
10.14   First Amendment to Collaboration and License Agreement, effective as of September 28, 2018, by and between the Registrant and Biocon Limited.
23.1   Consent of Independent Registered Public Accounting Firm.
23.2   Consent of Cooley LLP. Reference is made to Exhibit 5.1.
24.1#   Power of Attorney.

 

 

+   Indicates management contract or compensatory plan.
*   Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.
#   Previously filed.

(b) Financial statement schedules.

No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or the notes thereto.

Item 17. Undertakings.

The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the Underwriting Agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the

 

II-4


Table of Contents

Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The undersigned Registrant hereby undertakes that:

 

  (a)

For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

 

  (b)

For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

II-5


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Act, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of La Jolla, State of California, on the 2nd day of October, 2018.

 

EQUILLIUM, INC.

By:

 

/s/ Daniel M. Bradbury

 

Daniel M. Bradbury

Chief Executive Officer

Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

 

 

SIGNATURE

  

TITLE

 

DATE

/s/ Daniel M. Bradbury

Daniel M. Bradbury

  

Chief Executive Officer and
Chairman of the Board of Directors

(Principal Executive Officer)

  October 2, 2018

/s/ Jason A. Keyes

Jason A. Keyes

  

Chief Financial Officer

(Principal Financial and Accounting Officer)

  October 2, 2018

/s/ Bruce D. Steel*

Bruce D. Steel

  

President, Chief Business Officer and

Member of the Board of Directors

  October 2, 2018

/s/ Stephen Connelly, Ph.D.*

Stephen Connelly, Ph.D.

  

Chief Scientific Officer and

Member of the Board of Directors

  October 2, 2018

/s/ Martha J. Demski*

Martha J. Demski

   Member of the Board of Directors  

October 2, 2018

/s/ Bala S. Manian, Ph.D.*

Bala S. Manian, Ph.D.

   Member of the Board of Directors   October 2, 2018

/s/ Charles McDermott*

Charles McDermott

   Member of the Board of Directors  

October 2, 2018

/s/ Mark Pruzanski, M.D.*

Mark Pruzanski, M.D.

   Member of the Board of Directors   October 2, 2018

 

 

 

*

Pursuant to power of attorney

 

By:   /s/ Jason A. Keyes
 

Jason Keyes

Attorney-in-fact

 

II-6

EX-1.1 2 d582934dex11.htm EX-1.1 EX-1.1

Exhibit 1.1

[] Shares

Equillium, Inc.

UNDERWRITING AGREEMENT

[●], 2018

JEFFERIES LLC

LEERINK PARTNERS LLC

STIFEL, NICOLAUS & COMPANY, INCORPORATED

As Representatives of the several Underwriters

c/o JEFFERIES LLC

520 Madison Avenue

New York, New York 10022

c/o LEERINK PARTNERS LLC

One Federal Street, 37th Floor

Boston, Massachusetts 02110

and

c/o STIFEL, NICOLAUS & COMPANY, INCORPORATED

787 Seventh Avenue, 11th Floor

New York, New York 10019

Ladies and Gentlemen:

Introductory. Equillium, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of [●] shares of its common stock, par value $0.0001 per share (the “Shares”). The [●] Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional [●] Shares as provided in Section 2. The additional [●] Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Jefferies LLC (“Jefferies”), Leerink Partners LLC (“Leerink”) and Stifel, Nicolaus & Company, Incorporated (“Stifel”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representatives” as used herein shall mean you, as Underwriters, and the term “Underwriters” shall mean either the singular or the plural, as the context requires.

The Company has prepared and filed with the Securities and Exchange Commission (the “Commission”) a registration statement on Form S-1, File No. 333-[●] which contains a form of prospectus to be used in connection with the public offering and sale of the Offered Shares. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (collectively, the “Securities Act”), including any information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430A under the Securities Act, is called


the “Registration Statement.” Any registration statement filed by the Company pursuant to Rule 462(b) under the Securities Act in connection with the offer and sale of the Offered Shares is called the “Rule 462(b) Registration Statement,” and from and after the date and time of filing of any such Rule 462(b) Registration Statement the term “Registration Statement” shall include the Rule 462(b) Registration Statement. The prospectus, in the form first used by the Underwriters to confirm sales of the Offered Shares or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act, is called the “Prospectus.” The preliminary prospectus dated [●], 2018 describing the Offered Shares and the offering thereof is called the “Preliminary Prospectus,” and the Preliminary Prospectus and any other prospectus in preliminary form that describes the Offered Shares and the offering thereof and is used prior to the filing of the Prospectus is called a “preliminary prospectus.” As used herein, “Applicable Time” is [●][a.m.][p.m.] (New York City time) on [●], 2018. As used herein, “free writing prospectus” has the meaning set forth in Rule 405 under the Securities Act, and “Time of Sale Prospectus” means the Preliminary Prospectus together with the free writing prospectuses, if any, identified in Schedule B hereto and the pricing information set forth on Schedule C hereto. As used herein, Road Show means a “road show” (as defined in Rule 433 under the Securities Act) relating to the offering of the Offered Shares contemplated hereby that is a “written communication” (as defined in Rule 405 under the Securities Act). As used herein, “Section 5(d) Written Communication” means each written communication (within the meaning of Rule 405 under the Securities Act) that is made in reliance on Section 5(d) of the Securities Act by the Company or any person authorized to act on behalf of the Company to one or more potential investors that are qualified institutional buyers (“QIBs”) and/or institutions that are accredited investors (“IAIs”), as such terms are respectively defined in Rule 144A and Rule 501(a) under the Securities Act, to determine whether such investors might have an interest in the offering of the Offered Shares; “Section 5(d) Oral Communication” means each oral communication, if any, made in reliance on Section 5(d) of the Securities Act by the Company or any person authorized to act on behalf of the Company made to one or more QIBs and/or one or more IAIs to determine whether such investors might have an interest in the offering of the Offered Shares; “Marketing Materials” means any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Offered Shares, including any roadshow or investor presentations made to investors by the Company (whether in person or electronically); and “Permitted Section 5(d) Communication” means the Section 5(d) Written Communication(s) and Marketing Materials listed on Schedule D attached hereto.

All references in this Agreement to (i) the Registration Statement, any preliminary prospectus (including the Preliminary Prospectus), or the Prospectus, or any amendments or supplements to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (“EDGAR”) and (ii) the Prospectus shall be deemed to include any “electronic Prospectus” provided for use in connection with the offering of the Offered Shares as contemplated by Section 3(o) of this Agreement.

The Company hereby confirms its agreement with the Underwriters as follows:

Section 1.    Representations and Warranties of the Company. The Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement, as of the First Closing Date (as hereinafter defined) and as of each Option Closing Date (as hereinafter defined), if any, as follows:

(a)    Compliance with Registration Requirements. The Registration Statement has become effective under the Securities Act. The Company has complied, to the Commission’s satisfaction with all requests of the Commission for additional or supplemental information, if any. No stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by the Commission.

 

2


(b)    Disclosure. Each preliminary prospectus and the Prospectus when filed complied in all material respects with the Securities Act and, if filed by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by Regulation S-T under the Securities Act) to the copy thereof delivered to the Underwriters for use in connection with the offer and sale of the Offered Shares. Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, the Time of Sale Prospectus (including any preliminary prospectus wrapper) did not, and at the First Closing Date (as defined in Section 2) and at each applicable Option Closing Date (as defined in Section 2), will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus (including any Prospectus wrapper), as of its date, did not, and at the First Closing Date and at each applicable Option Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto, or the Prospectus or the Time of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with written information relating to any Underwriter furnished to the Company in writing by the Representatives expressly for use therein, it being understood and agreed that the only such information consists of the information described in Section 9(b) below. There are no contracts or other documents required to be described in the Time of Sale Prospectus or the Prospectus or to be filed as an exhibit to the Registration Statement which have not been described or filed as required.

(c)    Free Writing Prospectuses; Road Show. As of the determination date referenced in Rule 164(h) under the Securities Act, the Company was not, is not or will not be (as applicable) an “ineligible issuer” in connection with the offering of the Offered Shares pursuant to Rules 164, 405 and 433 under the Securities Act. Each free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act, including timely filing with the Commission or retention where required and legending, and each such free writing prospectus, as of its issue date and at all subsequent times through the completion of the public offer and sale of the Offered Shares did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Prospectus or any preliminary prospectus and not superseded or modified. Except for the free writing prospectuses, if any, identified in Schedule B, and electronic road shows, if any, furnished to you before first use, the Company has not prepared, used or referred to, and will not, without your prior written consent, prepare, use or refer to, any free writing prospectus. Each Road Show, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.

(d)    Distribution of Offering Material By the Company. Prior to the later of (i) the expiration or termination of the option granted to the several Underwriters in Section 2, (ii) the completion of the Underwriters’ distribution of the Offered Shares and (iii) the expiration of 25 days after the date of the

 

3


Prospectus, the Company has not distributed and will not distribute any offering material in connection with the offering and sale of the Offered Shares other than the Registration Statement, the Preliminary Prospectus, the Time of Sale Prospectus, the Prospectus or any free writing prospectus reviewed and consented to by the Representatives, the free writing prospectuses, if any, identified on Schedule B hereto and any Permitted Section 5(d) Communications.

(e)    The Underwriting Agreement. This Agreement has been duly authorized, executed and delivered by the Company.

(f)    Authorization of the Offered Shares. The Offered Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the Offered Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Offered Shares.

(g)    No Applicable Registration or Other Similar Rights. There are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived.

(h)    No Material Adverse Change. Except as otherwise disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Prospectus: (i) there has been no material adverse change, or any development that could be expected to result in a material adverse change, in the condition, financial or otherwise, or in the earnings, business, properties, operations, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company (any such change being referred to herein as a “Material Adverse Change”); (ii) the Company has not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with its business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company, or has entered into any material transactions not in the ordinary course of business; and (iii) there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company and there has been no dividend or distribution of any kind declared, paid or made by the Company, or any repurchase or redemption by the Company of any class of its capital stock.

(i)    Independent Accountants. KPMG LLP, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is (i) an independent registered public accounting firm as required by the Securities Act, the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the “Exchange Act”), and the rules of the Public Company Accounting Oversight Board (“PCAOB”), (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn.

(j)    Financial Statements. The financial statements filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus present fairly in all material respects, the financial position of the Company as of the dates indicated and the results of its operations,

 

4


changes in stockholders’ equity and cash flows for the periods specified. Such financial statements have been prepared in conformity with generally accepted accounting principles as applied in the United States applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. No other financial statements or supporting schedules are required to be included in the Registration Statement, the Time of Sale Prospectus or the Prospectus. The financial data set forth in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus under the captions “Prospectus Summary—Summary Financial Data,” “Selected Financial Data” and “Capitalization” fairly present, in all material respects, the information set forth therein on a basis consistent with that of the audited financial statements contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus. To the Company’s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus.

(k)    Companys Accounting System. The Company makes and keeps, in all material respects, accurate books and records and maintains a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles as applied in the United States and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

(l)    Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting. The Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are designed to ensure that material information relating to the Company is made known to the Company’s principal executive officer and its principal financial officer, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; and (ii) are effective in all material respects to perform the functions for which they were established. Since the end of the Company’s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company’s internal control over financial reporting (whether or not remediated) and no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

(m)    Incorporation and Good Standing of the Company. The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of California and each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where a failure to be so qualified or in good standing would not reasonably be expected individually or in the aggregate to have a Material Adverse Effect (defined below).

(n)    Subsidiaries. The Company has no subsidiaries.

 

5


(o)    Capitalization and Other Capital Stock Matters. The authorized, issued and outstanding capital stock of the Company is as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption “Capitalization” (other than for subsequent issuances, if any, pursuant to employee benefit plans, or upon the exercise of outstanding options or warrants, in each case described in the Registration Statement, the Time of Sale Prospectus and the Prospectus). The Shares (including the Offered Shares) conform in all material respects to the description thereof contained in the Time of Sale Prospectus. All of the issued and outstanding Shares have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and state securities laws. None of the outstanding Shares was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company other than those described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. The descriptions of the Company’s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus accurately and fairly present, in all material respects, the information required to be shown with respect to such plans, arrangements, options and rights.

(p)    Stock Exchange Listing. The Offered Shares have been approved for listing on The Nasdaq Global Market (“Nasdaq”), subject only to official notice of issuance.

(q)    Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required. The Company is not in violation of its charter or by-laws, partnership agreement or operating agreement or similar organizational documents, as applicable, or in default (or, with the giving of notice or lapse of time, would be in default) (“Default”) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company is a party or by which it may be bound, or to which any of its properties or assets are subject (each, an “Existing Instrument”), except for such Defaults as would reasonably not be expected, individually or in the aggregate, to have a material adverse effect on the condition (financial or other), earnings, business, properties, operations, assets, liabilities or prospects of the Company (a “Material Adverse Effect”). The Company’s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus and the issuance and sale of the Offered Shares (including the use of proceeds from the sale of the Offered Shares as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption “Use of Proceeds”) (i) have been duly authorized by all necessary corporate action and will not result in any violation of the provisions of the charter or by-laws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company, (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to, or require the consent of any other party to, any Existing Instrument, except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and (iii) will not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company, except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company’s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus, except such as have been obtained or made by the Company and are in full force and effect under the Securities Act and such as may be required under applicable state securities or blue sky laws or FINRA.

 

6


As used herein, a “Debt Repayment Triggering Event” means any event or condition which gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company.

(r)    Compliance with Laws. The Company has been and is in compliance with all applicable laws, rules and regulations, except where failure to be so in compliance would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(s)    No Material Actions or Proceedings. There is no action, suit, proceeding, inquiry or investigation brought by or before any governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company, which would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect or materially or adversely affect the consummation of the transactions contemplated hereby or the performance by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company is a party or of which any of its properties or assets is the subject, if determined adversely to the Company, would not reasonably be expected to have a Material Adverse Effect. No material labor dispute with the employees of the Company, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the knowledge of the Company, is threatened or imminent.

(t)    Intellectual Property Rights. The Company owns, or has obtained licenses for, the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as being owned or licensed by it or, to the Company’s knowledge, which are necessary for the conduct of its business as currently conducted or as currently proposed to be conducted in the Registration Statement, the Time of Sale Prospectus and the Prospectus (collectively, “Intellectual Property”); and to the Company’s knowledge, any such licenses are valid and enforceable. To the Company’s knowledge: (i) there are no third parties who have rights to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus as licensed to the Company, and the Company has taken all reasonable steps necessary to secure its interests in the Intellectual Property from its employees and contractors; (ii) there is no infringement by third parties of any Intellectual Property; (iii) the Company is not infringing the intellectual property rights of third parties; (iv) the Company is the sole owner of the Intellectual Property owned by it; and (v) no employee of the Company is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee’s employment with the Company. There is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others: (A) challenging the Company’s rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B) challenging the validity, enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C) asserting that the Company infringes or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement, the Time of Sale Prospectus or the Prospectus as under development, infringe, misappropriate or violate, any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. The Company has complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company, and all such agreements are in full force and effect. The drug candidates described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as under development by the Company fall within the scope of the claims of one or more patents or patent applications owned by, or exclusively licensed to, the Company.

 

7


(u)    Patents and Patent Applications. All patents and patent applications owned by, or licensed to the Company, have, to the Company’s knowledge, been duly and properly filed and maintained; to the Company’s knowledge, the parties prosecuting such applications have complied with their duty of candor and disclosure to the U.S. Patent and Trademark Office (the “USPTO”) in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which would preclude the grant of a patent in connection with any such application or could form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications.

(v)    Regulatory Matters; Products and Product Candidates. Except as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company: (i) has operated and currently operates its business in compliance in all material respects with applicable provisions of the Health Care Laws (as defined below) of the Food and Drug Administration (“FDA”), the Department of Health and Human Services (“HHS”) and any comparable foreign or other regulatory authority to which they are subject (collectively, the “Applicable Regulatory Authorities”) applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, storage, import, export or disposal of any of the Company’s product candidates or any product manufactured or distributed by the Company; (ii) has not received any FDA Form 483, written notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from any court or arbitrator or governmental or regulatory authority alleging or asserting non-compliance with (A) any Health Care Laws or (B) or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Health Care Laws (“Regulatory Authorizations”); (iii) possesses all Regulatory Authorizations required to conduct its business as currently conducted and such Regulatory Authorizations are valid and in full force and effect and the Company is not in violation, in any material respect, of any term of any such Regulatory Authorizations; (iv) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the Applicable Regulatory Authorities or any other third party alleging that any product operation or activity is in material violation of any Health Care Laws or Regulatory Authorizations and has no knowledge that the Applicable Regulatory Authorities or any other third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (v) has not received notice that any of the Applicable Regulatory Authorities has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Regulatory Authorizations and has no knowledge that any of the Applicable Regulatory Authorities is considering such action; (vi) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws or Regulatory Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were materially corrected or supplemented by a subsequent submission); (vii) is not a party to or have any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any Applicable Regulatory Authority; and (viii) has not been and, to the Company’s knowledge, its employees, officers and directors, have not been excluded, suspended or debarred from participation in any government health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.

(w)    Health Care Laws Defined. The term “Health Care Laws” means Title XVIII of the Social Security Act, 42 U.S.C. §§ 1395-1395hhh (the Medicare statute); Title XIX of the Social Security

 

8


Act, 42 U.S.C. §§ 1396-1396v (the Medicaid statute); the Federal Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b); the civil False Claims Act, 31 U.S.C. §§ 3729 et seq.; the criminal False Claims Act 42 U.S.C. 1320a-7b(a); any criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287 and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. §§ 1320d et seq., (“HIPAA”); the Civil Monetary Penalties Law, 42 U.S.C. § 1320a-7a; the Physician Payments Sunshine Act, 42 U.S.C. § 1320a-7h; the Exclusion Laws, 42 U.S.C. § 1320a-7; HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, 42 U.S.C. §§ 17921 et seq.; the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301 et seq.; the Public Health Service Act, 42 U.S.C. §§ 201 et seq.; the regulations promulgated pursuant to such laws; and any similar federal, state and local laws and regulations.

(x)    Regulatory Matters: Manufacturing. To the Company’s knowledge, the manufacturing facilities and operations of its suppliers are operated in compliance in all material respects with all applicable statutes, rules, regulations and policies of the Applicable Regulatory Authorities.

(y)    Regulatory Matters: Clinical Trials. Except as disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus, none of the Company’s product candidates have received marketing approval from any Applicable Regulatory Authority. All clinical and pre-clinical studies and trials conducted by or on behalf of or sponsored by the Company, or in which the Company has participated, with respect to the Company’s product candidates, including any such studies and trials that are described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Prospectus and the Prospectus, as applicable (collectively, “Company Trials”), and to the Company’s knowledge, all clinical and pre-clinical studies and trials conducted by Biocon SA or Biocon Limited (together, “Biocon”) with respect to the Company’s product candidates which are described in the Registration Statement, the Time of Sale Prospectus and the Prospectus (collectively, “Biocon Trials”), were, and if still pending are, being conducted in all material respects in accordance with all applicable Health Care Laws of the Applicable Regulatory Authorities and current Good Clinical Practices, standard medical and scientific research procedures and any applicable rules, regulations and policies of the jurisdiction in which such trials and studies are being conducted; the descriptions in the Registration Statement, the Time of Sale Prospectus and the Prospectus of the results of any Company Trials and any Biocon Trials are accurate and complete descriptions in all material respects and fairly present the data derived therefrom; the Company has no knowledge of any other studies or trials not described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the results of which are inconsistent with or call into question the results described or referred to in the Registration Statement, the Time of Sale Prospectus and the Prospectus; the Company has operated at all times and is currently in compliance in all material respects with all applicable Health Care Laws of the Applicable Regulatory Authorities; the Company has not received, nor does the Company have knowledge after due inquiry that any of its collaboration partners have received any written notices, correspondence or other communications from the Applicable Regulatory Authorities or any other governmental entity requiring or threatening the termination, material modification or suspension of Company Trials, other than ordinary course communications with respect to modifications in connection with the design and implementation of such studies or trials, and, to the Company’s knowledge, there are no reasonable grounds for the same. No investigational new drug application or comparable submission filed by or on behalf of the Company with the FDA has been terminated or suspended by the FDA or any other Applicable Regulatory Authority. The Company has obtained (or caused to be obtained) informed consent by or on behalf of each human subject who participated in a Company Trial. In using or disclosing patient information received by the Company in connection with a Company Trial, the Company has complied in all material respects with all applicable laws and regulatory rules or requirements, including, without limitation, HIPAA and the rules and regulations thereunder. To the Company’s knowledge, none of the Company Trials involved any investigator who has been disqualified as a clinical investigator or has been found by the FDA to have engaged in scientific misconduct.

 

9


(z)    All Necessary Permits, etc. The Company possesses such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct its business as currently conducted and as described in the Registration Statement, the Time of Sale Prospectus or the Prospectus (“Permits”), except where failure to so possess would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. The Company is not in violation of, or in default under, any of the Permits and has not received any notice of proceedings relating to the revocation or modification of, or non-compliance with, any such certificate, authorization or permit, except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.

(aa)    Title to Properties. The Company has good and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section 1(j) above (or elsewhere in the Registration Statement, the Time of Sale Prospectus or the Prospectus), in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except where failure to so possess would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. The real property, improvements, equipment and personal property held under lease by the Company are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company.

(bb)    Tax Law Compliance. The Company has filed all necessary federal, state and foreign income and franchise tax returns or has properly requested extensions thereof and has paid all taxes required to be paid by it and, if due and payable, any related or similar assessment, fine or penalty levied against it except as may be being contested in good faith and by appropriate proceedings, except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. The Company has made adequate charges, accruals and reserves, in conformity with generally accepted accounting principals, in the applicable financial statements referred to in Section 1(j) above in respect of all federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the Company has not been finally determined.

(cc)    Insurance. The Company is insured by recognized, financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited to, policies covering real and personal property owned or leased by the Company against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company for product liability claims and clinical trial liability claims. The Company has no reason to believe that it will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not reasonably be expected to have a Material Adverse Effect. The Company has not been denied any insurance coverage which it has sought or for which it has applied.

(dd)    Compliance with Environmental Laws. Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect: (i) the Company is not in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release

 

10


of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”); (ii) the Company has all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements; (iii) there are no pending or, to the Company’s knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company; and (iv) to the Company’s knowledge, there are no events or circumstances that might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company relating to Hazardous Materials or any Environmental Laws.

(ee)    ERISA Compliance. The Company and any “employee benefit plan” (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, “ERISA”)) established or maintained by the Company or, to the knowledge of the Company, its “ERISA Affiliates” (as defined below) are in compliance in all material respects with ERISA. “ERISA Affiliate” means, with respect to the Company, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the “Code”) of which the Company is a member. No “reportable event” (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any “employee benefit plan” established or maintained by the Company or any of its ERISA Affiliates. No “employee benefit plan” established or maintained by the Company or any of its ERISA Affiliates, if such “employee benefit plan” were terminated, would have any “amount of unfunded benefit liabilities” (as defined under ERISA). Neither the Company nor any of its ERISA Affiliates has incurred or reasonably expects to incur any liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any “employee benefit plan” or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each employee benefit plan established or maintained by the Company or any of its ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and, to the Company’s knowledge, nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification.

(ff)    Company Not an Investment Company. The Company is not, and will not be, either after receipt of payment for the Offered Shares or after the application of the proceeds therefrom as described under “Use of Proceeds” in the Registration Statement, the Time of Sale Prospectus or the Prospectus, required to register as an “investment company” under the Investment Company Act of 1940, as amended (the Investment Company Act).

(gg)    No Price Stabilization or Manipulation; Compliance with Regulation M. The Company has not taken, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that would reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (Regulation M)) with respect to the Shares, whether to facilitate the sale or resale of the Offered Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M.

(hh)    Related-Party Transactions. There are no business relationships or related-party transactions involving the Company or any other person required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus that have not been described as required.

(ii)    FINRA Matters. All of the information provided to the Underwriters or to counsel for the Underwriters by the Company, its counsel, its officers and directors and, to the Company’s knowledge, the

 

11


holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Offered Shares is true, complete, correct in all material respects and compliant with FINRA’s rules and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct in all material respects.

(jj)    Parties to Lock-Up Agreements. The Company has furnished to the Underwriters a letter agreement in the form attached hereto as Exhibit C (the “Lock-up Agreement”) from each of its officers, directors and securityholders. If any additional persons shall become directors or officers of the Company prior to the end of the Company Lock-up Period (as defined below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election as a director or officer of the Company, to execute and deliver to the Representatives a Lock-up Agreement.

(kk)    Statistical and Market-Related Data. All statistical, demographic and market-related data included in the Registration Statement, the Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects. To the extent required, the Company has obtained the written consent to the use of such data from such sources.

(ll)    No Unlawful Contributions or Other Payments. Neither the Company nor, to the Company’s knowledge, any employee or agent of the Company, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus.

(mm)    Foreign Corrupt Practices Act. Neither the Company nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company has, in the course of its actions for, or on behalf of, the Company (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any domestic government official, “foreign official” (as defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (collectively, the “FCPA”) or employee from corporate funds; (iii) violated or is in violation of any provision of the FCPA or any applicable non-U.S. anti-bribery statute or regulation; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any domestic government official, such foreign official or employee; and the Company and, to the knowledge of the Company, the Company’s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.

(nn)    Money Laundering Laws. The operations of the Company are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

(oo)    OFAC. Neither the Company nor, to the knowledge of the Company, after due inquiry, any director, officer, agent, employee, affiliate or person acting on behalf of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC” and such sanctions, “U.S. Sanctions”); and the Company will not directly or

 

12


indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that currently is the subject to any U.S. Sanctions or in any other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of U.S. Sanctions.

(pp)    Brokers. Except pursuant to this Agreement, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this Agreement.

(qq)    Forward-Looking Statements. Each financial or operational projection or other “forward-looking statement” (as defined by Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus (i) was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii) is accompanied by meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such forward-looking statement. No such statement was made with the knowledge of an executive officer or director of the Company that is was false or misleading.

(rr)    No Outstanding Loans or Other Extensions of Credit. The Company does not have any outstanding extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by Section 13(k) of the Exchange Act.

(ss)    Emerging Growth Company Status. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).

(tt)    Communications. The Company (i) has not alone engaged in communications with potential investors in reliance on Section 5(d) of the Securities Act other than Permitted Section 5(d) Communications or Section 5(d) Oral Communications, in each case, with the consent of the Representatives with entities that are QIBs or IAIs and (ii) has not authorized anyone other than the Representatives to engage in such communications; the Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking Marketing Materials, Section 5(d) Oral Communications and Section 5(d) Written Communications; as of the Applicable Time, each Permitted Section 5(d) Communication, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Permitted Section 5(d) Communication, if any, does not, as of the date hereof, conflict with the information contained in the Registration Statement, the Preliminary Prospectus and the Prospectus; and the Company has filed publicly on EDGAR at least 15 calendar days prior to any “road show” (as defined in Rule 433 under the Securities Act), any confidentially submitted registration statement and registration statement amendments relating to the offer and sale of the Offered Shares.

(uu)    Clinical Data and Regulatory Compliance. The preclinical tests and clinical trials, and other studies (collectively, “studies”) being conducted by or for the Company that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and

 

13


scientific research procedures and all applicable laws, including, without limitation, the Federal Food, Drug, and Cosmetic Act and its implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58, and 312; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company has no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectuses or the Prospectus; the Company has made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); the Company has not received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the Company has operated and currently is in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.

(vv)    No Rights to Purchase Preferred Stock. The issuance and sale of the Shares as contemplated hereby will not cause any holder of any shares of capital stock, securities convertible into or exchangeable or exercisable for capital stock or options, warrants or other rights to purchase capital stock or any other securities of the Company to have any right to acquire any shares of preferred stock of the Company.

(ww)    No Contract Terminations. The Company has not sent or received any communication regarding termination of, or intent not to renew, any of the contracts or agreements referred to or described in any preliminary prospectus, the Prospectus or any free writing prospectus, or referred to or described in, or filed as an exhibit to, the Registration Statement, and no such termination or non-renewal has been threatened by the Company or, to the Company’s knowledge, any other party to any such contract or agreement, which threat of termination or non-renewal has not been rescinded as of the date hereof.

(xx)    No Indebtedness. Except as otherwise disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company has no outstanding indebtedness.

Any certificate signed by any officer of the Company and delivered to any Underwriter or to counsel for the Underwriters in connection with the offering, or the purchase and sale, of the Offered Shares shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby.

The Company has a reasonable basis for making each of the representations set forth in this Section 1. The Company acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to Section 6 hereof, counsel to the Company and counsel to the Underwriters, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.

Section 2.    Purchase, Sale and Delivery of the Offered Shares.

(a)    The Firm Shares. Upon the terms herein set forth, the Company agrees to issue and sell to the several Underwriters an aggregate of [●] Firm Shares. On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not jointly, to purchase from the Company the respective number of Firm Shares set forth opposite their names on Schedule A. The purchase price per Firm Share to be paid by the several Underwriters to the Company shall be $[●] per share.

 

14


(b)    The First Closing Date. Delivery of certificates for the Firm Shares to be purchased by the Underwriters and payment therefor shall be made at the offices of Latham & Watkins LLP, 12670 High Bluff Drive, San Diego, California 92130 (or such other place as may be agreed to by the Company and the Representatives) at 9:00 a.m. New York City time, on [●], 2018, or such other time and date not later than 1:30 p.m. New York City time, on [●], 2018 as the Representatives shall designate by notice to the Company (the time and date of such closing are called the “First Closing Date”). The Company hereby acknowledges that circumstances under which the Representatives may provide notice to postpone the First Closing Date as originally scheduled include, but are not limited to, any determination by the Company or the Representatives to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section 11.

(c)    The Optional Shares; Option Closing Date. In addition, on the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to an aggregate of [●] Optional Shares from the Company at the purchase price per share to be paid by the Underwriters for the Firm Shares. The option granted hereunder may be exercised at any time and from time to time in whole or in part upon notice by the Representatives to the Company, which notice may be given at any time within 30 days from the date of this Agreement. Such notice shall set forth (i) the aggregate number of Optional Shares as to which the Underwriters are exercising the option and (ii) the time, date and place at which certificates for the Optional Shares will be delivered (which time and date may be simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and date are simultaneous with the First Closing Date, the term “First Closing Date” shall refer to the time and date of delivery of the Firm Shares and such Optional Shares). Any such time and date of delivery, if subsequent to the First Closing Date, is called an “Option Closing Date,” shall be determined by the Representatives and shall not be earlier than two or later than five full business days after delivery of such notice of exercise. If any Optional Shares are to be purchased, (a) each Underwriter agrees, severally and not jointly, to purchase the number of Optional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same proportion to the total number of Optional Shares to be purchased as the number of Firm Shares set forth on Schedule A opposite the name of such Underwriter bears to the total number of Firm Shares and (b) the Company agrees to sell the number of Optional Shares set forth in the “Introductory” paragraph of this Agreement (subject to such adjustments to eliminate fractional shares as the Representatives may determine). The Representatives may cancel the option at any time prior to its expiration by giving written notice of such cancellation to the Company.

(d)    Public Offering of the Offered Shares. The Representatives hereby advise the Company that the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their respective portions of the Offered Shares as soon after this Agreement has been executed and the Registration Statement has been declared effective as the Representatives, in their sole judgment, have determined is advisable and practicable.

(e)    Payment for the Offered Shares. (i) Payment for the Firm Shares to be sold by the Company shall be made at the First Closing Date (and, if applicable, payment for the Optional Shares shall be made at the First Closing Date or at the applicable Option Closing Date, as the case may be) by wire transfer of immediately available funds to the order of the Company.

(ii)    It is understood that the Representatives have been authorized, for their own account and the accounts of the several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Firm Shares and any Optional Shares the Underwriters have agreed to purchase. Each of Jefferies, Leerink and Stifel, individually and not as the Representatives of the Underwriters, may (but shall not be obligated to) make payment for any Offered Shares to be purchased by

 

15


any Underwriter whose funds shall not have been received by the Representatives by the First Closing Date or the applicable Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement.

(f)    Delivery of the Offered Shares. The Company shall deliver, or cause to be delivered, through the facilities of the Depository Trust Company to the Representatives for the accounts of the several Underwriters certificates for the Firm Shares to be sold by it at the First Closing Date, against release of a wire transfer of immediately available funds for the amount of the purchase price therefor. The Company shall also deliver, or cause to be delivered to the Representatives for the accounts of the several Underwriters, certificates for the Optional Shares the Underwriters have agreed to purchase from it at the First Closing Date or the applicable Option Closing Date, as the case may be, against the release of a wire transfer of immediately available funds for the amount of the purchase price therefor. The certificates for the Offered Shares shall be registered in such names and denominations as the Representatives shall have requested at least two full business days prior to the First Closing Date (or the applicable Option Closing Date, as the case may be) and shall be made available for inspection on the business day preceding the First Closing Date (or the applicable Option Closing Date, as the case may be) at a location in New York City as the Representatives may designate. Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to the obligations of the Underwriters.

Section 3.    Additional Covenants of the Company. The Company further covenants and agrees with each Underwriter as follows:

(a)    Delivery of Registration Statement, Time of Sale Prospectus and Prospectus. The Company shall furnish to you in New York City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as you may reasonably request.

(b)    Representatives Review of Proposed Amendments and Supplements. During the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), the Company (i) will furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii) will not amend or supplement the Registration Statement without the Representatives’ prior written consent, which will not be unreasonably withheld, conditioned or delayed. Prior to amending or supplementing any preliminary prospectus, the Time of Sale Prospectus or the Prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement. The Company shall not file or use any such proposed amendment or supplement without the Representatives’ prior written consent, which will not be unreasonably withheld, conditioned or delayed. The Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.

(c)    Free Writing Prospectuses. The Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or on behalf of, used by, or referred to by the Company, and the Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Representatives’ prior written consent, which will not be unreasonably withheld, conditioned or delayed. The Company shall furnish to each

 

16


Underwriter, without charge, as many copies of any free writing prospectus prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request. If at any time when a prospectus is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares (but in any event if at any time through and including the First Closing Date) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case may be; provided, however, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus, and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Representatives’ prior written consent, which will not be unreasonably withheld, conditioned or delayed.

(d)    Filing of Underwriter Free Writing Prospectuses. The Company shall not take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder.

(e)    Amendments and Supplements to Time of Sale Prospectus. If the Time of Sale Prospectus is being used to solicit offers to buy the Offered Shares at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section 3(b) and Section 3(c) hereof) promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.

(f)    Certain Notifications and Required Actions. After the date of this Agreement, the Company shall promptly advise the Representatives in writing of: (i) the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii) the time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii) the time and date that any post-effective amendment to the Registration Statement becomes effective; and (iv) the issuance by the Commission of any stop order suspending the effectiveness of the Registration

 

17


Statement or any post-effective amendment thereto or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order as soon as possible. Additionally, the Company agrees that it shall comply with all applicable provisions of Rule 424(b), Rule 433 and Rule 430A under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a timely manner by the Commission.

(g)    Amendments and Supplements to the Prospectus and Other Securities Act Matters. If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading, or if in the opinion of the Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, the Company agrees (subject to Section 3(b) and Section 3(c) hereof) to promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the Representatives’ consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company’s obligations under Section 3(b) or Section 3(c).

(h)    Blue Sky Compliance. The Company shall cooperate with the Representatives and counsel for the Underwriters to qualify or register the Offered Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws (or other foreign laws) of those jurisdictions designated by the Representatives, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Offered Shares. The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or whether it would not be subject to taxation as a foreign corporation. The Company will advise the Representatives promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Offered Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment.

(i)    Use of Proceeds. The Company shall apply the net proceeds from the sale of the Offered Shares sold by it substantially in the manner described under the caption “Use of Proceeds” in the Registration Statement, the Time of Sale Prospectus and the Prospectus.

(j)    Transfer Agent. The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.

 

18


(k)    Earnings Statement. The Company will make generally available to its securityholders and to the Representatives as soon as practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company commencing after the date of this Agreement that will satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission thereunder.

(l)    Continued Compliance with Securities Laws. The Company will comply with the Securities Act and the Exchange Act so as to permit the completion of the distribution of the Offered Shares as contemplated by this Agreement, the Registration Statement, the Time of Sale Prospectus and the Prospectus. Without limiting the generality of the foregoing, the Company will, during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), file on a timely basis with the Commission and Nasdaq all reports and documents required to be filed under the Exchange Act. Additionally, the Company shall report the use of proceeds from the issuance of the Offered Shares as may be required under Rule 463 under the Securities Act.

(m)    Listing. The Company will use its best efforts to list, subject to notice of issuance, the Offered Shares on Nasdaq.

(n)    Company to Provide Copy of the Prospectus in Form That May be Downloaded from the Internet. If requested by the Representatives, the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representatives an “electronic Prospectus” to be used by the Underwriters in connection with the offering and sale of the Offered Shares. As used herein, the term “electronic Prospectus” means a form of Time of Sale Prospectus, and any amendment or supplement thereto, that meets each of the following conditions: (i) it shall be encoded in an electronic format, satisfactory to the Representatives, that may be transmitted electronically by the Representatives and the other Underwriters to offerees and purchasers of the Offered Shares; (ii) it shall disclose the same information as the paper Time of Sale Prospectus, except to the extent that graphic and image material cannot be disseminated electronically, in which case such graphic and image material shall be replaced in the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii) it shall be in or convertible into a paper format or an electronic format, satisfactory to the Representatives, that will allow investors to store and have continuously ready access to the Time of Sale Prospectus at any future time, without charge to investors (other than any fee charged for subscription to the Internet as a whole and for on-line time).

(o)    Agreement Not to Offer or Sell Additional Shares. During the period commencing on and including the date hereof and continuing through and including the 180th day following the date of the Prospectus (such period being referred to herein as the “Lock-up Period”), the Company will not, without the prior written consent of Jefferies and Leerink (which consent may be withheld in their sole discretion), directly or indirectly: (i) sell, offer to sell, contract to sell or lend any Shares or Related Securities (as defined below); (ii) effect any short sale, or establish or increase any “put equivalent position” (as defined in Rule 16a-1(h) under the Exchange Act) or liquidate or decrease any “call equivalent position” (as defined in Rule 16a-1(b) under the Exchange Act) of any Shares or Related Securities; (iii) pledge, hypothecate or grant any security interest in any Shares or Related Securities; (iv) in any other way transfer or dispose of any Shares or Related Securities; (v) enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi) announce the offering of any Shares or Related Securities (other than as contemplated by this Agreement with respect to the Offered Shares); (vii) file any registration statement under the Securities Act in respect of any Shares or Related Securities (other than as contemplated by this Agreement with respect to the Offered Shares); or (viii) publicly announce the intention to do any of the

 

19


foregoing; provided, however, that the Company may (A) effect the transactions contemplated hereby, (B) issue Shares or options to purchase Shares, or issue Shares upon exercise of options, pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration Statement, the Time of Sale Prospectus and the Prospectus but only if the holders of such Shares or options agree in writing with the Underwriters not to sell, offer, dispose of or otherwise transfer any such Shares or options during such Lock-up Period without the prior written consent of Jefferies and Leerink (which consent may be withheld in their sole discretion), (C) file one or more registration statements on Form S-8 with respect to any Shares or Related Securities issued or issuable pursuant to any stock option, stock bonus, or other stock plan or arrangement described in the Registration Statement, the Time of Sale Prospectus or the Prospectus, (D) issue Shares in connection with the acquisition by the Company of the securities, business, property or other assets of another person or business entity or pursuant to any employee benefit plan assumed by the Company in connection with any such acquisition or (E) issue Shares or Related Securities in connection with joint ventures, commercial relationships or other strategic transactions; provided that, in the case of immediately preceding clauses (D) and (E), (x) the aggregate number of Shares issued or underlying such Related Securities issued in connection with all such acquisitions and other transactions does not exceed 5% of the aggregate number of Shares outstanding immediately following the consummation of the offering of the Offered Shares pursuant to this Agreement and (y) the recipients of the Shares or Related Securities agrees in writing to be bound by the same terms described in the agreement attached hereto as Exhibit C. For purposes of the foregoing, “Related Securities” shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, Shares.

(p)    Future Reports to the Representatives. During the period of five years hereafter, the Company will furnish to the Representatives, c/o Jefferies, at 520 Madison Avenue, New York, New York 10022, Attention: Global Head of Syndicate, c/o Leerink, at One Federal Street, 37th Floor, Boston, Massachusetts 02110, and c/o Stifel, 787 Seventh Avenue, 11th Floor, New York, New York 10019: (i) as soon as practicable after the end of each fiscal year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders’ equity and cash flows for the year then ended and the opinion thereon of the Company’s independent public or certified public accountants; (ii) as soon as practicable after the filing thereof, copies of each proxy statement, Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other report filed by the Company with the Commission, FINRA or any securities exchange; and (iii) as soon as available, copies of any report or communication of the Company furnished or made available generally to holders of its capital stock; provided, however, that the requirements of this Section 3(p) shall be satisfied to the extent that such reports, statement, communications, financial statements or other documents are available on EDGAR.

(q)    Investment Limitation. The Company shall not invest or otherwise use the proceeds received by the Company from its sale of the Offered Shares in such a manner as would require the Company to register as an investment company under the Investment Company Act.

(r)    No Stabilization or Manipulation; Compliance with Regulation M. The Company will not take, and will ensure that no affiliate of the Company will take, directly or indirectly, any action designed to or that might reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares or any reference security with respect to the Shares, whether to facilitate the sale or resale of the Offered Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M.

(s)    Enforce Lock-Up Agreements. During the Lock-up Period, the Company will enforce all agreements between the Company and any of its securityholders that restrict or prohibit, expressly or in

 

20


operation, the offer, sale or transfer of Shares or Related Securities or any of the other actions restricted or prohibited under the terms of the form of Lock-up Agreement. In addition, the Company will direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such “lock-up” agreements for the duration of the periods contemplated in such agreements, including, without limitation, “lock-up” agreements entered into by the Company’s officers, directors and securityholders pursuant to Section 6(i) hereof.

(t)    Company to Provide Interim Financial Statements. Prior to the First Closing Date and each applicable Option Closing Date, the Company will furnish the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period subsequent to the period covered by the most recent financial statements appearing in the Registration Statement and the Prospectus; provided that the requirements of this Section 3(t) shall be deemed satisfied to the extent such financial statements are available on EDGAR.

(u)    Amendments and Supplements to Permitted Section 5(d) Communications. If at any time following the distribution of any Permitted Section 5(d) Communication, there occurred or occurs an event or development as a result of which such Permitted Section 5(d) Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Permitted Section 5(d) Communication to eliminate or correct such untrue statement or omission.

(v)    Emerging Growth Company Status. The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i) the time when a prospectus relating to the Offered Shares is not required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) and (ii) the expiration of the Lock-Up Period (as defined herein).

The Representatives, on behalf of the several Underwriters, may, in their sole discretion, waive in writing the performance by the Company of any one or more of the foregoing covenants or extend the time for their performance.

Section 4.    Payment of Expenses. The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i) all expenses incident to the issuance and delivery of the Offered Shares (including all printing and engraving costs), (ii) all fees and expenses of the registrar and transfer agent of the Shares, (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Offered Shares to the Underwriters, (iv) all fees and expenses of the Company’s counsel, independent public or certified public accountants and other advisors, (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf of, used by, or referred to by the Company, and each preliminary prospectus, each Permitted Section 5(d) Communication, and all amendments and supplements thereto, and this Agreement, (vi) all filing fees, attorneys’ fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Offered Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Representatives, preparing and printing a “Blue Sky Survey” or memorandum and a “Canadian wrapper”, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, up to a maximum aggregate amount of

 

21


$10,000, (vii) the costs, fees and expenses incurred by the Underwriters in connection with determining their compliance with the rules and regulations of FINRA related to the Underwriters’ participation in the offering and distribution of the Offered Shares, including any related filing fees and the legal fees of, and disbursements by, counsel to the Underwriters, up to a maximum aggregate amount of $25,000, (viii) the costs and expenses of the Company relating to investor presentations on any “road show”, any Permitted Section 5(d) Communication or any Section 5(d) Oral Communication undertaken in connection with the offering of the Offered Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and any such consultants, and the cost of any aircraft chartered in connection with the road show, provided that the cost of any such charted aircraft shall be borne 50% by the Company and 50% by the Underwriters, (ix) the fees and expenses associated with listing the Offered Shares on Nasdaq, and (x) all other fees, costs and expenses of the nature referred to in Item 13 of Part II of the Registration Statement. Except as provided in this Section 4 or in Section 7, Section 9 or Section 10 hereof, the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel.

Section 5.    Covenant of the Underwriters. Each Underwriter severally and not jointly covenants with the Company not to take any action that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the Company under Rule 433(d).

Section 6.    Conditions of the Obligations of the Underwriters. The respective obligations of the several Underwriters hereunder to purchase and pay for the Offered Shares as provided herein on the First Closing Date and, with respect to the Optional Shares, each Option Closing Date, shall be subject to the accuracy of the representations and warranties on the part of the Company set forth in Section 1 hereof as of the date hereof and as of the First Closing Date as though then made and, with respect to the Optional Shares, as of each Option Closing Date as though then made, to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions:

(a)    Comfort Letter. On the date hereof, the Representatives shall have received from KPMG LLP, independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the Representatives, containing statements and information of the type ordinarily included in accountant’s “comfort letters” to underwriters, delivered according to Statement of Auditing Standards No. 72 (or any successor bulletin), with respect to the audited and unaudited financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each free writing prospectus, if any.

(b)    Compliance with Registration Requirements; No Stop Order; No Objection from FINRA.

(i)    The Company shall have filed the Prospectus with the Commission (including the information required by Rule 430A under the Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities Act; or the Company shall have filed a post-effective amendment to the Registration Statement containing the information required by such Rule 430A, and such post-effective amendment shall have become effective;

 

22


(ii)    No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement shall be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission; and

(iii)    FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.

(c)    No Material Adverse Change or Ratings Agency Change. For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date:

(i)    in the judgment of the Representatives there shall not have occurred any Material Adverse Change; and

(ii)    there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally recognized statistical rating organization” as that term is used in Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act.

(d)    Opinion of Counsel for the Company. On each of the First Closing Date and each Option Closing Date the Representatives shall have received the opinion of Cooley LLP, counsel for the Company, dated as of such date, in the form attached hereto as Exhibit A and to such further effect as the Representatives shall reasonably request.

(e)    Opinion of Intellectual Property Counsel for the Company. On each of the First Closing Date and each Option Closing Date, the Representatives shall have received the opinion of Cooley LLP, counsel for the Company with respect to intellectual property matters, dated as of such date, in the form attached hereto as Exhibit B and to such further effect as the Representatives shall reasonably request.

(f)    Opinion of Counsel for the Underwriters. On each of the First Closing Date and each Option Closing Date the Representatives shall have received the opinion of Latham & Watkins LLP, counsel for the Underwriters in connection with the offer and sale of the Offered Shares, in form and substance satisfactory to the Representatives, dated as of such date.

(g)    Officers Certificate. On each of the First Closing Date and each Option Closing Date, the Representatives shall have received a certificate executed by the Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company, dated as of such date, to the effect set forth in Section 6(b)(ii) and further to the effect that:

(i)    for the period from and including the date of this Agreement through and including such date, there has not occurred any Material Adverse Change;

(ii)    the representations, warranties and covenants of the Company set forth in Section 1 of this Agreement are true and correct with the same force and effect as though expressly made on and as of such date; and

(iii)    the Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied hereunder at or prior to such date.

 

23


(h)    Bring-down Comfort Letter. On each of the First Closing Date and each Option Closing Date the Representatives shall have received from KPMG LLP, independent registered public accountants for the Company, a letter dated such date, in form and substance satisfactory to the Representatives, which letter shall: (i) reaffirm the statements made in the letter furnished by them pursuant to Section 6(a), except that the specified date referred to therein for the carrying out of procedures shall be no more than three business days prior to the First Closing Date or the applicable Option Closing Date, as the case may be; and (ii) cover certain financial information contained in the Prospectus.

(i)    Lock-Up Agreements. On or prior to the date hereof, the Company shall have furnished to the Representatives an agreement in the form of Exhibit C hereto from each of the Company’s officers, directors and securityholders and each such agreement shall be in full force and effect on each of the First Closing Date and each Option Closing Date.

(j)    Rule 462(b) Registration Statement. In the event that a Rule 462(b) Registration Statement is filed in connection with the offering contemplated by this Agreement, such Rule 462(b) Registration Statement shall have been filed with the Commission on the date of this Agreement and shall have become effective automatically upon such filing.

(k)    Approval of Listing. At the First Closing Date, the Offered Shares shall have been approved for listing on Nasdaq, subject only to official notice of issuance.

(l)    Additional Documents. On or before each of the First Closing Date and each Option Closing Date, the Representatives and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale of the Offered Shares as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Offered Shares as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representatives and counsel for the Underwriters.

If any condition specified in this Section 6 is not satisfied when and as required to be satisfied (unless waived by the Representatives), this Agreement may be terminated by the Representatives by notice from the Representatives to the Company at any time on or prior to the First Closing Date and, with respect to the Optional Shares, at any time on or prior to the applicable Option Closing Date, which termination shall be without liability on the part of any party to any other party, except that Section 4, Section 7, Section 9 and Section 10 shall at all times be effective and shall survive such termination.

Section 7.    Reimbursement of Underwriters Expenses. If this Agreement is terminated by the Representatives pursuant to Section 6, Section 11 or Section 12, or if the sale to the Underwriters of the Offered Shares on the First Closing Date is not consummated because of any refusal, inability or failure on the part of the Company to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters as have terminated this Agreement with respect to themselves), severally, upon demand for all documented, out-of-pocket expenses that shall have been reasonably incurred by the Representatives and the Underwriters in connection with the proposed purchase and the offering and sale of the Offered Shares, including, but not limited to, fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges.

Section 8.    Effectiveness of this Agreement. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.

 

24


Section 9.    Indemnification.

(a)    Indemnification of the Underwriters. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, including U.S. Sanctions, or the laws or regulations of foreign jurisdictions where Offered Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii) any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any Marketing Material, any Section 5(d) Written Communication or the Prospectus (or any amendment or supplement to the foregoing) or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading; or (iii) any act or failure to act or any alleged act or failure to act by any Underwriter in connection with, or relating in any manner to, the Shares or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action arising out of or based upon any matter covered by clause (i) or (ii) above; (iv) the violation of any laws or regulations of foreign jurisdictions where Offered Shares have been offered or sold with respect to the offering and sale of the Offered Shares; or (v) any violation or alleged violation of U.S. Sanctions, including by any Underwriter with respect to the offering and sale of the Offered Shares; and to reimburse each Underwriter and each such affiliate, director, officer, employee, agent and controlling person for any and all reasonable expenses (including the reasonable fees and disbursements of counsel) as such expenses are incurred by such Underwriter or such affiliate, director, officer, employee, agent or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company by the Representatives in writing expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any such free writing prospectus, any Marketing Material, any Section 5(d) Written Communication or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information consists of the information described in Section 9(b) below. The indemnity agreement set forth in this Section 9(a) shall be in addition to any liabilities that the Company may otherwise have.

(b)    Indemnification of the Company, its Directors and Officers. Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue

 

25


statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii) any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus, that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities Act, any Section 5(d) Written Communication or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, such preliminary prospectus, the Time of Sale Prospectus, such free writing prospectus, such Section 5(d) Written Communication or the Prospectus (or any such amendment or supplement), in reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing expressly for use therein; and to reimburse the Company, or any such director, officer or controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The Company hereby acknowledges that the only information that the Representatives have furnished to the Company expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any Section 5(d) Written Communication or the Prospectus (or any amendment or supplement to the foregoing) are the statements set forth in the first sentence of the third paragraph under the caption “Underwriting,” the first two sentences of the first paragraph under the caption “Underwriting—Commission and Expenses” and the first sentence of the first paragraph under the caption “Underwriting—Stabilization” in the Preliminary Prospectus and the Prospectus. The indemnity agreement set forth in this Section 9(b) shall be in addition to any liabilities that each Underwriter may otherwise have.

(c)    Notifications and Other Indemnification Procedures. Promptly after receipt by an indemnified party under this Section 9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section 9, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party to the extent the indemnifying party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account of this indemnity agreement. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party’s election so to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this Section 9 for any legal or other expenses subsequently incurred by such indemnified party in connection

 

26


with the defense thereof unless (i) the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the Representatives (in the case of counsel for the indemnified parties referred to in Section 9(a) above) or by the Company (in the case of counsel for the indemnified parties referred to in Section 9(b) above)) or (ii) the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii) the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.

(d)    Settlements. The indemnifying party under this Section 9 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by Section 9(c) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party.

Section 10.    Contribution. If the indemnification provided for in Section 9 is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Shares pursuant to this Agreement or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Offered Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Shares pursuant to this Agreement (before deducting expenses) received by the Company, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page of the Prospectus, bear to the aggregate initial public offering price of the Offered Shares as set forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a

 

27


material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other hand, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided that any liability resulting from any violation or alleged violation of U.S. Sanctions shall be wholly attributed as the sole fault of the Company.

The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in Section 9(c), any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in Section 9(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section 10; provided, however, that no additional notice shall be required with respect to any action for which notice has been given under Section 9(c) for purposes of indemnification.

The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 10 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section 10.

Notwithstanding the provisions of this Section 10, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Offered Shares underwritten by it and distributed to the public. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’ obligations to contribute pursuant to this Section 10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on Schedule A. For purposes of this Section 10, each affiliate, director, officer, employee and agent of an Underwriter and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company.

Section 11.    Default of One or More of the Several Underwriters. If, on the First Closing Date or any Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on such date, and the aggregate number of Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Shares to be purchased on such date, the Representatives may make arrangements satisfactory to the Company for the purchase of such Offered Shares by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of Firm Shares set forth opposite their respective names on Schedule A bears to the aggregate number of Firm Shares set forth opposite the names of all such non-defaulting Underwriters, or in such other proportions as may be specified by the Representatives with the consent of the non-defaulting Underwriters, to purchase the Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date. If, on the First Closing Date or any Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase Offered Shares and the aggregate number of Offered Shares with respect to which such default occurs exceeds 10% of the aggregate number of Offered Shares to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Offered Shares are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other party except that the provisions of Section 4, Section 7, Section 9 and Section 10 shall at all times be effective and shall survive such

 

28


termination. In any such case either the Representatives or the Company shall have the right to postpone the First Closing Date or the applicable Option Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected.

As used in this Agreement, the term “Underwriter” shall be deemed to include any person substituted for a defaulting Underwriter under this Section 11. Any action taken under this Section 11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement.

Section 12.    Termination of this Agreement. Prior to the purchase of the Firm Shares by the Underwriters on the First Closing Date, this Agreement may be terminated by the Representatives by notice given to the Company if at any time: (i) trading or quotation in any of the Company’s securities shall have been suspended or limited by the Commission or by Nasdaq, or trading in securities generally on either Nasdaq or The New York Stock Exchange shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges; (ii) a general banking moratorium shall have been declared by any of federal, New York, Delaware or California authorities; (iii) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States’ or international political, financial or economic conditions, as in the judgment of the Representatives is material and adverse and makes it impracticable to market the Offered Shares in the manner and on the terms described in the Time of Sale Prospectus or the Prospectus or to enforce contracts for the sale of securities; (iv) in the judgment of the Representatives there shall have occurred any Material Adverse Change; or (v) the Company shall have sustained a loss by strike, fire, flood, earthquake, accident or other calamity of such character as in the judgment of the Representatives may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant to this Section 12 shall be without liability on the part of (a) the Company to any Underwriter, except that the Company shall be obligated to reimburse the expenses of the Representatives and the Underwriters pursuant to Section 4 or Section 7 hereof or (b) any Underwriter to the Company; provided, however, that the provisions of Section 9 and Section 10 shall at all times be effective and shall survive such termination.

Section 13.    No Advisory or Fiduciary Relationship. The Company acknowledges and agrees that (a) the purchase and sale of the Offered Shares pursuant to this Agreement, including the determination of the public offering price of the Offered Shares and any related discounts and commissions, is an arm’s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b) in connection with the offering contemplated hereby and the process leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e) the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.

 

29


Section 14.    Representations and Indemnities to Survive Delivery. The respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Offered Shares sold hereunder and any termination of this Agreement.

Section 15.    Notices. All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows:

 

If to the Representatives:

  

Jefferies LLC

520 Madison Avenue

New York, New York 10022

Facsimile: (646) 619-4437

Attention: General Counsel

 

Leerink Partners LLC

One Federal Street, 37th Floor

Boston, Massachusetts 02110

 

Stifel, Nicolaus & Company, Incorporated

787 Seventh Avenue, 11th Floor

New York, New York 10019

with a copy to:

  

Latham & Watkins LLP

12670 High Bluff Drive

San Diego, CA 92130

Facsimile: (858) 523-5450

Attention: Cheston Larson

If to the Company:

  

Equillium, Inc.

2223 Avenida de la Playa, Suite 108

La Jolla, CA 92037

Attention: Chief Executive Officer

with a copy to:

  

Cooley LLP

4401 Eastgate Mall

San Diego, CA 92121

Facsimile: 858 (550)-6420

Attention: Thomas Coll

Any party hereto may change the address for receipt of communications by giving written notice to the others.

Section 16.    Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto, including any substitute Underwriters pursuant to Section 11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in Section 9 and Section 10, and in each case their respective successors, and no other person will have any right or obligation hereunder. The term “successors” shall not include any purchaser of the Offered Shares as such from any of the Underwriters merely by reason of such purchase.

 

30


Section 17.    Partial Unenforceability. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.

Section 18.    Governing Law Provisions. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (“Related Proceedings”) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court (a “Related Judgment”), as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.

Section 19.    General Provisions. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.

Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section 9 and the contribution provisions of Section 10, and is fully informed regarding said provisions. Each of the parties hereto further acknowledges that the provisions of Section 9 and Section 10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that adequate disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities Act and the Exchange Act.

 

31


If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms.

 

Very truly yours,

 

EQUILLIUM, INC.

By:    
  Name:  
  Title:  

The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives in New York, New York as of the date first above written.

 

JEFFERIES LLC

LEERINK PARTNERS LLC

STIFEL, NICOLAUS & COMPANY, INCORPORATED

Acting individually and as Representatives

of the several Underwriters named in

the attached Schedule A.

 

JEFFERIES LLC
By:    
  Name:  
  Title:  

 

LEERINK PARTNERS LLC
By:    
  Name:  
  Title:  

 

STIFEL, NICOLAUS & COMPANY, INCORPORATED
By:    
  Name:  
  Title:  

 

32


Schedule A

 

Underwriters   

Number of

Firm Shares

to be Purchased

 

Jefferies LLC

     [●]  

Leerink Partners LLC.

     [●]  

Stifel, Nicolaus & Company, Incorporated

     [●]  
  

 

 

 

Total

     [●]  
  

 

 

 


Schedule B

Free Writing Prospectuses Included in the Time of Sale Prospectus


Schedule C

Pricing Information Included in the Time of Sale Prospectus

 

Price per share to the public:

   $  [●]  

Number of shares being sold by the Company:

     [●]  

Number of shares potentially issuable pursuant to the option to purchase additional shares:

     [●]  


Schedule D

Permitted Section 5(d) Communications


Exhibit A

Form of Opinion of Company Counsel

 

A-1


Exhibit B

Form of Opinion of Cooley LLP, as intellectual property counsel

 

B-1


Exhibit C

Form of Lock-up Agreement

 

C-1

EX-3.1 3 d582934dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

OF

EQUILLIUM, INC.

(Pursuant to Sections 242 and 245 of the

General Corporation Law of the State of Delaware)

Equillium, Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware (the “Corporation”), does hereby certify that:

1.    The name of this corporation is Equillium, Inc. The corporation was originally incorporated pursuant to the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”) on March 16, 2017 under the name Attenuate Biopharmaceuticals, Inc.

2.    This Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of this Corporation’s Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law and has been duly approved by the holders of the requisite number of shares of this corporation in accordance with Section 228 of the General Corporation Law.

3.    The text of the Certificate of Incorporation is amended and restated to read as follows:

I.

The name of this Corporation is Equillium, Inc.

II.

The registered office of the Corporation in the State of Delaware shall be 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle, 19808 and the name of the registered agent of the Corporation in the State of Delaware at such address is Corporation Service Company.

III.

The purpose of this Corporation is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law.

IV.

A.    Capital Stock. The Corporation is authorized to issue only one class of stock, to be designated Common Stock. The total number of shares of Common Stock authorized is 5,000,000, each having a par value of $0.0001 per share


B.    Voting. Each holder of shares of Common Stock shall be entitled to cast the number of votes equal to the number of shares of Common Stock held by such holder as of the record date for determining stockholders entitled to vote on any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting).

C.    Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales.

1.1    Payments to Holders of Common Stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the remaining assets of the Corporation available for distribution to its stockholders shall be distributed among the holders of shares of Common Stock, pro rata based on the number of shares held by each such holder.

1.2    Deemed Liquidation Events.

1.2.1    Definition. Each of the following events shall be considered a “Deemed Liquidation Event” unless the holders of at least a majority of the outstanding shares of Common Stock elect otherwise by written notice sent to the Corporation at least five days prior to the effective date of any such event:

(a)    a merger or consolidation in which

(i) the Corporation is a constituent party or

(ii) a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such merger or consolidation,

except any such merger or consolidation involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1) the surviving or resulting corporation; or (2) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation; or

(b)    the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole (including, without limitation, the exclusive license under that certain Collaboration and License Agreement dated on or about the date hereof by and between the Corporation and Biocon SA), or the sale or disposition (whether by merger, consolidation or otherwise) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries,


except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation.

For purposes of this Section 1.2.1, “Affiliate” shall mean, with respect to any holder of shares of Common Stock, any person, entity or firm which, directly or indirectly, controls, is controlled by or is under common control with such holder, including, without limitation, any entity of which the holder is a partner or member, any partner, officer, director, member or employee of such holder and any venture capital fund now or hereafter existing of which the holder is a partner or member which is controlled by or under common control with one or more general partners of such holder or shares the same management company with such holder.

1.2.2    Effecting a Deemed Liquidation Event. The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in Subsection 1.2.1(a)(i) unless the agreement or plan of merger or consolidation for such transaction (the “Merger Agreement”) provides that the consideration payable to the stockholders of the Corporation shall be allocated among the holders of capital stock of the Corporation in accordance with Subsection 1.1.

1.2.3    Amount Deemed Paid or Distributed. The amount deemed paid or distributed to the holders of capital stock of the Corporation upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities paid or distributed to such holders by the Corporation or the acquiring person, firm or other entity.

1.2.4    Allocation of Escrow and Contingent Consideration. In the event of a Deemed Liquidation Event pursuant to Subsection 1.2.1(a)(i), if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the “Additional Consideration”), such Additional Consideration shall be allocated among, and distributed to, the holders of capital stock of the Corporation in accordance with Subsection 1.1. For the purposes of this Subsection 1.2.4, consideration placed into escrow or retained as holdback to be available for satisfaction of indemnification or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration.

V.

A.    The management of the business and the conduct of the affairs of the Corporation shall be vested in its Board of Directors. The number of directors which shall constitute the whole Board of Directors shall be fixed by the Board of Directors in the manner provided in the Bylaws.

B.    Directors shall be elected at each annual meeting of stockholders to hold office until the next annual meeting. So long as it holds shares of Common Stock, Biocon SA, voting as a separate class, shall be entitled to elect one (1) director (the “Biocon Director”) at each meeting of stockholders or pursuant to each consent of the Corporation’s stockholders for the election of directors, and to remove from office such director in accordance with applicable law and to fill any vacancy caused by the resignation, death or removal of such director. The holders of record of the shares of Common Stock and of any other class or series of voting stock, exclusively and voting together as a single class, shall be entitled to elect the balance of the total


number of directors of the Corporation, and to remove from office such directors in accordance with applicable law and to fill any vacancy caused by the resignation, death or removal of such directors. Notwithstanding the foregoing, Biocon SA’s right to elect the Biocon Director under this section shall terminate upon the earlier to occur of: (i) the closing of a firmly underwritten public offering pursuant to an effective S-1 or SB-2 registration statement under the Securities Act of 1933, as amended, covering the offer and sale of Common Stock for the account of the Company, or (ii) a Deemed Liquidation Event.

C.    No person entitled to vote at an election for directors may cumulate votes to which such person is entitled unless required by applicable law at the time of such election. During such time or times that applicable law requires cumulative voting, every stockholder entitled to vote at an election for directors may cumulate such stockholder’s votes and give one candidate a number of votes equal to the number of directors to be elected multiplied by the number of votes to which such stockholder’s shares are otherwise entitled, or distribute the stockholder’s votes on the same principle among as many candidates as such stockholder desires. No stockholder, however, shall be entitled to so cumulate such stockholder’s votes unless (i) the names of such candidate or candidates have been placed in nomination prior to the voting and (ii) the stockholder has given notice at the meeting, prior to the voting, of such stockholder’s intention to cumulate such stockholder’s votes. If any stockholder has given proper notice to cumulate votes, all stockholders may cumulate their votes for any candidates who have been properly placed in nomination. Under cumulative voting, the candidates receiving the highest number of votes, up to the number of directors to be elected, are elected.

D.    Subject to any limitations imposed by applicable law, the Board of Directors or any director may be removed from office at any time, with or without cause, by the affirmative vote of the holders of a majority of the voting power of all then-outstanding shares of capital stock of the Corporation entitled to vote generally at an election of directors; provided, however, that the Biocon Director may be removed without cause by, and only by, the affirmative vote of the holders entitled to elect such director, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.

E.    The Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the Corporation. The stockholders shall also have power to adopt, amend or repeal the Bylaws of the Corporation; provided, however, that, in addition to any vote of the holders of any class or series of stock of the Corporation required by law or by this Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the holders of at least a majority of the voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class.

F.    Unless and except to the extent that the bylaws of the Corporation shall so require, the election of directors of the Corporation need not be by written ballot.

VI.

The liability of the directors for monetary damages for breach of fiduciary duty as a director shall be eliminated to the fullest extent under applicable law.


A.    To the fullest extent permitted by applicable law, the corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the corporation (and any other persons to which applicable law permits the corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable law is amended after approval by the stockholders of this Article VI to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to the corporation shall be eliminated or limited to the fullest extent permitted by applicable law as so amended.

B.    Any repeal or modification of this Article VI shall only be prospective and shall not affect the rights or protections or increase the liability of any officer or director under this Article VI in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification.

VII.

The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon the stockholders herein are granted subject to this reservation.

VIII.

Any notice required or permitted by the provisions of this Certificate of Incorporation to be given to a holder of shares of Common Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission.

IX.

The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity. An “Excluded Opportunity” is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of (i) any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii) any holder of Common Stock or any partner, member, director, stockholder, employee or agent of any such holder, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, “Covered Persons”), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person’s capacity as a director of the Corporation.

X.

Unless the corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i) any derivative action or proceeding brought on behalf of the corporation, (ii) any action asserting a claim of breach of fiduciary duty


owed by any director, officer or other employee of the corporation to the corporation or the corporation’s stockholders, (iii) any action asserting a claim against the corporation, its directors, officers or employees arising pursuant to any provision of the Delaware General Corporation Law or the corporation’s certificate of incorporation or bylaws or (iv) any action asserting a claim against the corporation, its directors, officers or employees governed by the internal affairs doctrine, except for, as to each of (i) through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. If any provision or provisions of this Article X shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article X (including, without limitation, each portion of any sentence of this Article X containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.

*    *    *


IN WITNESS WHEREOF, this Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of this corporation on this 18th day of May, 2017.

 

By:   /s/ Daniel M. Bradbury
  Daniel M. Bradbury, President


CERTIFICATE OF AMENDMENT TO

AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION OF

EQUILLIUM, INC.

Daniel M. Bradbury hereby certifies that:

ONE:        The date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was March 16, 2017 under the name Attenuate Biopharmaceuticals, Inc.

TWO:        He is the duly elected and acting Chief Executive Officer of Equillium, Inc., a Delaware corporation (the “Company”).

THREE:        The Amended and Restated Certificate of Incorporation of the Company is hereby amended as follows:

Section A of Article IV of the Company’s Amended and Restated Certificate of Incorporation is hereby amended and restated in its entirety to read as follows:

“A.        Capital Stock. The Corporation is authorized to issue only one class of stock, to be designated Common Stock. The total number of shares of Common Stock authorized is 20,000,000, each having a par value of $0.0001 per share.

Effective at the time of filing of this Certificate of Amendment to Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, each one share of Common Stock issued and outstanding shall, automatically and without any action on the part of the respective holders thereof, be divided and converted into 8.62 shares of Common Stock without increasing or decreasing the par value of each share of Common Stock (the “Stock Split”); provided, however, that the Company shall issue no fractional shares of Common Stock as a result of the Stock Split, but shall instead pay to any stockholder who would be entitled to receive a fractional share as a result of the actions set forth herein a sum in cash equal to the fair market value of the shares constituting such fractional share as determined in good faith by the Board of Directors of the Company. The Stock Split shall occur whether or not the certificates representing such shares of Common Stock are surrendered to the Company or its transfer agent. The Stock Split shall be effected on a record holder-by-record holder basis, such that any fractional shares of Common Stock resulting from the Stock Split and held by a single record holder shall be aggregated.”

FOUR:        This Certificate of Amendment to Amended and Restated Certificate of Incorporation has been duly approved by the Board of Directors of the Company, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware (the “DGCL”).


FIVE:        This Certificate of Amendment to Amended and Restated Certificate of Incorporation was approved by the holders of the requisite number of shares of the Company in accordance with Section 228 of the DGCL. This Certificate of Amendment to Amended and Restated Certificate of Incorporation has been duly adopted in accordance with the provisions of Sections 228 and 242 of the DGCL by the stockholders of the Company.


IN WITNESS WHEREOF, EQUILLIUM, INC. has caused this Certificate of Amendment to Amended and Restated Certificate of Incorporation to be signed by its Chief Executive Officer this 1st day of October, 2018.

 

EQUILLIUM, INC.
/s/ Daniel M. Bradbury
Daniel M. Bradbury
Chief Executive Officer
EX-4.1 4 d582934dex41.htm EX-4.1 EX-4.1

Exhibit 4.1

LOGO

Exhibit 4.1 CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER AUTHORIZED SIGNATURE TRANSFER AGENT AND REGISTRAR (Brooklyn, NY) AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC BY COUNTERSIGNED AND REGISTERED: transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This certificate is not valid unless countersigned by the Transfer Agent and registered by the Registrar. WITNESS the facsimile signatures of the Corporation’s duly authorized officers. Dated: EQUILLIUM, INC. FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF SEE REVERSE FOR CERTAIN DEFINITIONS is the record holder of THIS CERTIFIES THAT INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE EQ EQUILLIUM, INC. SHARES COMMON STOCK CUSIP 29446K 10 6


LOGO

THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO S.E.C. RULE 17Ad-15. By: SIGNATURE(S) GUARANTEED: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE IN EVERY NOTICE: PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATEVER. By: Dated to transfer the said stock on the books of the within named Corporation with full power of substitution in the premises. Attorney of the Common Stock represented by this Certificate, and does hereby irrevocably constitute and appoint shares (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE For Value Received, undersigned hereby sells, assigns and transfers unto Additional abbreviations may also be used though not in the above list. UNIF GIFT MIN ACT–....................Custodian.................... (Cust) (Minor) under Uniform Gifts to Minors Act......................... (State) TEN COM TEN ENT JT TEN as tenants in common as tenants by the entireties as joint tenants with right of survivorship and not as tenants in common ––– The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations:

EX-5.1 5 d582934dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

 

LOGO

Karen E. Anderson

+1 858 550 6088

kanderson@cooley.com

October 2, 2018

Equillium, Inc.

2223 Avenida de la Playa, Suite 108

La Jolla, CA 92037

Ladies and Gentlemen:

We have represented Equillium, Inc., a Delaware corporation (the “Company”), in connection with the filing by the Company of a Registration Statement (No. 333-227387) on Form S-1 (the “Registration Statement”) with the Securities and Exchange Commission, including a related prospectus filed with the Registration Statement (the “Prospectus”), covering an underwritten public offering of up to 5,370,500 shares (the “Shares”) of the Company’s common stock, par value $0.0001, which includes up to 700,500 Shares that may be sold by the Company pursuant to the exercise of an over-allotment option granted to the underwriters.

In connection with this opinion, we have (i) examined and relied upon (a) the Registration Statement and related Prospectus, (b) the Company’s Amended and Restated Certificate of Incorporation and Bylaws, as currently in effect, (c) the Company’s Amended and Restated Certificate of Incorporation, filed as Exhibit 3.2 to the Registration Statement and the Company’s Amended and Restated Bylaws, filed as Exhibit 3.4 to the Registration Statement, each of which will be in effect upon the closing of the offering contemplated by the Registration Statement, and (d) the originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below and (ii) assumed that the Shares will be sold at a price established by the Board of Directors of the Company or a duly constituted pricing committee thereof in accordance with Section 153 of the Delaware General Corporation Law. We have undertaken no independent verification with respect to such matters.

We have assumed the genuineness and authenticity of all documents submitted to us as originals and the conformity to originals of all documents submitted to us as copies and the due execution and delivery of all documents (other than by the Company) where due execution and delivery are a prerequisite to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not sought independently to verify such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued against payment therefor as described in the Registration Statement and the Prospectus, will be validly issued, fully paid and non-assessable.

Cooley LLP    4401 Eastgate Mall    San Diego, CA    92121

t: (858) 550-6000 f: (858) 550-6420 cooley.com


LOGO

Equillium, Inc.

October 2, 2018

Page Two

We consent to the reference to our firm under the caption “Legal Matters” in the Prospectus included in the Registration Statement and to the filing of this opinion as an exhibit to the Registration Statement.

Sincerely,

COOLEY LLP

 

By:  

/s/ Karen E. Anderson

  Karen E. Anderson

Cooley LLP    4401 Eastgate Mall    San Diego, CA    92121

t: (858) 550-6000 f: (858) 550-6420 cooley.com

EX-10.3 6 d582934dex103.htm EX-10.3 EX-10.3

Exhibit 10.3

EQUILLIUM, INC.

2018 EQUITY INCENTIVE PLAN

ADOPTED BY THE BOARD OF DIRECTORS:                     

APPROVED BY THE STOCKHOLDERS:                     

IPO DATE:                    

1. GENERAL.

(a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Equillium, Inc. 2017 Equity Incentive Plan (the “Prior Plan”). From and after 12:01 a.m. Pacific Time on the IPO Date, no additional stock awards will be granted under the Prior Plan. All Awards granted on or after 12:01 a.m. Pacific Time on the IPO Date will be granted under this Plan. All stock awards granted under the Prior Plan will remain subject to the terms of the Prior Plan.

(i) Any shares that would otherwise remain available for future grants under the Prior Plan as of 12:01 a.m. Pacific Time on the IPO Date (the “Prior Plan’s Available Reserve”) will cease to be available under the Prior Plan at such time. Instead, that number of shares of Common Stock equal to the Prior Plan’s Available Reserve will be added to the Share Reserve (as further described in Section 3(a) below) and will be immediately available for grants and issuance pursuant to Stock Awards hereunder, up to the maximum number set forth in Section 3(a) below.

(ii) In addition, from and after 12:01 a.m. Pacific Time on the IPO Date, any shares subject, at such time, to outstanding stock awards granted under the Prior Plan that (i) expire or terminate for any reason prior to exercise or settlement; (ii) are forfeited because of the failure to meet a contingency or condition required to vest such shares or otherwise return to the Company; or (iii) are reacquired, withheld (or not issued) to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price of a stock award (such shares the “Returning Shares”) will immediately be added to the Share Reserve (as further described in Section 3(a) below) as and when such shares become Returning Shares, up to the maximum number set forth in Section 3(a) below.

(b) Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive Awards.

(c) Available Awards. The Plan provides for the grant of the following types of Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards.

(d) Purpose. The Plan, through the granting of Awards, is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.

2. ADMINISTRATION.

(a) Administration by Board. The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c).


(b) Powers of Board. The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:

(i) To determine (A) who will be granted Awards; (B) when and how each Award will be granted; (C) what type of Award will be granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Award; (E) the number of shares of Common Stock subject to, or the cash value of, an Award; and (F) the Fair Market Value applicable to a Stock Award.

(ii) To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement or in the written terms of a Performance Cash Award, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective.

(iii) To settle all controversies regarding the Plan and Awards granted under it.

(iv) To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or the time at which cash or shares of Common Stock may be issued in settlement thereof).

(v) To suspend or terminate the Plan at any time. Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of the Plan will not materially impair a Participant’s rights under the Participant’s then-outstanding Award without the Participant’s written consent except as provided in subsection (viii) below.

(vi) To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or bringing the Plan or Awards granted under the Plan into compliance with the requirements for Incentive Stock Options or ensuring that they are exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law. If required by applicable law or listing requirements, and except as provided in Section 9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A) materially increases the number of shares of Common Stock available for issuance under the Plan, (B) materially expands the class of individuals eligible to receive Awards under the Plan, (C) materially increases the benefits accruing to Participants under the Plan, (D) materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (E) materially extends the term of the Plan, or (F) materially expands the types of Awards available for issuance under the Plan. Except as otherwise provided in the Plan or an Award Agreement, no amendment of the Plan will materially impair a Participant’s rights under an outstanding Award without the Participant’s written consent.

(vii) To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A) Section 422 of the Code regarding incentive stock options or (B) Rule 16b-3.

(viii) To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided however, that a Participant’s rights under any Award will not be impaired by any such amendment unless (A) the Company requests the consent of the affected Participant, and (B) such Participant consents in writing. Notwithstanding the foregoing, (1) a


Participant’s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant’s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant’s consent (A) to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (B) to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (C) to clarify the manner of exemption from, or to bring the Award into compliance with, Section 409A of the Code; or (D) to comply with other applicable laws or listing requirements.

(ix) Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.

(x) To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).

(xi) To effect, with the consent of any adversely affected Participant, (A) the reduction of the exercise, purchase or strike price of any outstanding Stock Award; (B) the cancellation of any outstanding Stock Award and the grant in substitution therefor of a new (1) Option or SAR, (2) Restricted Stock Award, (3) Restricted Stock Unit Award, (4) Other Stock Award, (5) cash and/or (6) other valuable consideration determined by the Board, in its sole discretion, with any such substituted award (x) covering the same or a different number of shares of Common Stock as the cancelled Stock Award and (y) granted under the Plan or another equity or compensatory plan of the Company; or (C) any other action that is treated as a repricing under generally accepted accounting principles.

(c) Delegation to Committee.

(i) General. The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.

(ii) Rule 16b-3 Compliance. The Committee may consist solely of two or more Non-Employee Directors, in accordance with Rule 16b-3.

(d) Delegation to an Officer. The Board may delegate to one or more Officers the authority to do one or both of the following (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Awards, and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; provided, however, that the Board resolutions


regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Any such Stock Awards will be granted on the form of Stock Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section 13(w)(iii) below.

(e) Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.

3. SHARES SUBJECT TO THE PLAN.

(a) Share Reserve. Subject to Section 9(a) relating to Capitalization Adjustments, and the following sentence regarding the annual increase, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards will not exceed 2,229,773 shares (the “Share Reserve”), which number is the sum of (i) 1,040,000 new shares, plus (ii) the number of shares subject to the Prior Plan’s Available Reserve plus (iii) the number of shares that are Returning Shares, as such shares become available from time to time. In addition, the Share Reserve will automatically increase on January 1st of each year, for a period of not more than ten years, commencing on January 1st of the year following the year in which the IPO Date occurs and ending on (and including) January 1, 2028, in an amount equal to 5% of the total number of shares of Capital Stock outstanding on December 31st of the preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January 1st of a given year to provide that there will be no January 1st increase in the Share Reserve for such year or that the increase in the Share Reserve for such year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence.

For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan. Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a). Shares may be issued in connection with a merger or acquisition as permitted by Nasdaq Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.

(b) Reversion of Shares to the Share Reserve. If a Stock Award or any portion thereof (i) expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or (ii) is settled in cash (i.e., the Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or otherwise offset) the number of shares of Common Stock that may be available for issuance under the Plan. If any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased or reacquired by the Company for any reason, including because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the Plan. Any shares reacquired by the Company in satisfaction of tax withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will again become available for issuance under the Plan.


(c) Incentive Stock Option Limit. Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 6,689,319 shares of Common Stock.

(d) Limitation on Grants to Non-Employee Directors. The maximum number of shares of Common Stock subject to Stock Awards granted under the Plan or otherwise during a single calendar year to any Non-Employee Director, taken together with any cash fees paid by the Company to such Non-Employee Director during such calendar year for service on the Board, will not exceed $350,000 in total value (calculating the value of any such Stock Awards based on the grant date fair value of such Stock Awards for financial reporting purposes), or, with respect to the calendar year in which a Non-Employee Director is first appointed or elected to the Board, $550,000.

(e) Source of Shares. The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.

4. ELIGIBILITY.

(a) Eligibility for Specific Stock Awards. Incentive Stock Options may be granted only to employees of the Company or a “parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants; provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any “parent” of the Company, as such term is defined in Rule 405 of the Securities Act, unless (i) the stock underlying such Stock Awards is treated as “service recipient stock” under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction), (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from Section 409A of the Code, or (iii) the Company, in consultation with its legal counsel, has determined that such Stock Awards comply with the distribution requirements of Section 409A of the Code.

(b) Ten Percent Stockholders. A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant.

5. PROVISIONS RELATING TO OPTIONS AND STOCK APPRECIATION RIGHTS.

Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; provided, however, that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions:

(a) Term. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten (10) years from the date of its grant or such shorter period specified in the Award Agreement.


(b) Exercise Price. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a corporate transaction and in a manner consistent with the provisions of Section 409A of the Code and, if applicable, Section 424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents.

(c) Purchase Price for Options. The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board will have the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. The permitted methods of payment are as follows:

(i) by cash, check, bank draft or money order payable to the Company;

(ii) pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;

(iii) by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;

(iv) if an Option is a Nonstatutory Stock Option, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the “net exercise,” (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or

(v) in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement.

(d) Exercise and Payment of a SAR. To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR.


(e) Transferability of Options and SARs. The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs will apply:

(i) Restrictions on Transfer. An Option or SAR will not be transferable except by will or by the laws of descent and distribution (or pursuant to subsections (ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration.

(ii) Domestic Relations Orders. Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation Section 1.421-1(b)(2). If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.

(iii) Beneficiary Designation. Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, on the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant’s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.

(f) Vesting Generally. The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.

(g) Termination of Continuous Service. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the Participant’s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of (i) the date that is three (3) months following the termination of the Participant’s Continuous Service (or such longer or shorter period specified in the applicable Award Agreement, which period will not be less than thirty (30) days if necessary to comply with applicable laws unless such termination is for Cause) and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR will terminate.

(h) Extension of Termination Date. Except as otherwise provided in the applicable Award Agreement or other written agreement between the Participant and the Company, if the exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause and other than upon the Participant’s death or Disability) would be prohibited at any time solely because the


issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post termination exercise period after the termination of the Participant’s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. In addition, unless otherwise provided in a Participant’s Award Agreement, if the sale of any Common Stock received on exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause) would violate the Company’s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of a period of months (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant’s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company’s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.

(i) Disability of Participant. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates as a result of the Participant’s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date twelve (12) months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement, which period will not be less than six (6) months if necessary to comply with applicable laws) and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will terminate.

(j) Death of Participant. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if (i) a Participant’s Continuous Service terminates as a result of the Participant’s death, or (ii) the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant’s Continuous Service for a reason other than death, then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant’s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant’s death, but only within the period ending on the earlier of (i) the date eighteen (18) months following the date of death (or such longer or shorter period specified in the Award Agreement, which period will not be less than six (6) months if necessary to comply with applicable laws) and (ii) the expiration of the term of such Option or SAR as set forth in the Award Agreement. If, after the Participant’s death, the Option or SAR is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.

(k) Termination for Cause. Except as explicitly provided otherwise in a Participant’s Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant’s Continuous Service is terminated for Cause, the Option or SAR will terminate immediately upon such Participant’s termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.

(l) Non-Exempt Employees. If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six (6) months following the date of grant of the Option or SAR (although the Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or


substituted, (iii) upon a Change in Control, or (iv) upon the Participant’s retirement (as such term may be defined in the Participant’s Award Agreement, in another agreement between the Participant and the Company, or, if no such definition, in accordance with the Company’s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six (6) months following the date of grant. The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee’s regular rate of pay, the provisions of this Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements.

6. PROVISIONS OF STOCK AWARDS OTHER THAN OPTIONS AND SARS.

(a) Restricted Stock Awards. Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. To the extent consistent with the Company’s bylaws, at the Board’s election, shares of Common Stock may be (i) held in book entry form subject to the Company’s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:

(i) Consideration. A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past or future services to the Company or an Affiliate, or (C) any other form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.

(ii) Vesting. Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.

(iii) Termination of Participant’s Continuous Service. If a Participant’s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.

(iv) Transferability. Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement.

(v) Dividends. A Restricted Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate.


(b) Restricted Stock Unit Awards. Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:

(i) Consideration. At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.

(ii) Vesting. At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.

(iii) Payment. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.

(iv) Additional Restrictions. At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.

(v) Dividend Equivalents. Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate.

(vi) Termination of Participants Continuous Service. Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement or other written agreement between a Participant and the Company or an Affiliate, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant’s termination of Continuous Service.

(c) Performance Awards.

(i) Performance Stock Awards. A Performance Stock Award is a Stock Award that is payable (including that may be granted, may vest or may be exercised) contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Stock Award may, but need not, require the Participant’s completion of a specified period of Continuous Service. The length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Board or Committee, in its sole discretion. In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board or the Committee may determine that cash may be used in payment of Performance Stock Awards.


(ii) Performance Cash Awards. A Performance Cash Award is a cash award that is payable contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Cash Award may also require the completion of a specified period of Continuous Service. At the time of grant of a Performance Cash Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Board or Committee, in its sole discretion. The Board or Committee may specify the form of payment of Performance Cash Awards, which may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or such portion thereof as the Board may specify, to be paid in whole or in part in cash or other property.

(iii) Board Discretion. The Board retains the discretion to adjust or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Stock Award Agreement or the written terms of a Performance Cash Award.

(d) Other Stock Awards. Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Stock Awards provided for under Section 5 and the preceding provisions of this Section 6. Subject to the provisions of the Plan, the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.

7. COVENANTS OF THE COMPANY.

(a) Availability of Shares. The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.

(b) Securities Law Compliance. The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan, as necessary, such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Stock Awards; provided, however, that this undertaking will not require the Company to register under the Securities Act or other securities or applicable laws, the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.

(c) No Obligation to Notify or Minimize Taxes. The Company will have no duty or obligation to any Participant to advise such holder as to the tax treatment or time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.


8. MISCELLANEOUS.

(a) Use of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock pursuant to Stock Awards will constitute general funds of the Company.

(b) Corporate Action Constituting Grant of Awards. Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.

(c) Stockholder Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to such Award has been entered into the books and records of the Company.

(d) No Employment or Other Service Rights. Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state or foreign jurisdiction in which the Company or the Affiliate is domiciled or incorporated, as the case may be.

(e) Change in Time Commitment. In the event a Participant’s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.

(f) Incentive Stock Option Limitations. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).


(g) Investment Assurances. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (i) to give written assurances satisfactory to the Company as to the Participant’s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that such Participant is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant’s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.

(h) Withholding Obligations. Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award; provided, however, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Award Agreement.

(i) Electronic Delivery. Any reference herein to a “written” agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company’s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).

(j) Deferrals. To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company. The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant’s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.

(k) Clawback/Recovery. All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a


reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of an event constituting Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a right to voluntary terminate employment upon a “resignation for good reason,” or for a “constructive termination” or any similar term under any plan of or agreement with the Company.

(l) Compliance with Section 409A of the Code. Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes “deferred compensation” under Section 409A of the Code is a “specified employee” for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a “separation from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant’s “separation from service” or, if earlier, the date of the Participant’s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule.

9. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.

(a) Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities by which the share reserve is to increase automatically each year pursuant to Section 3(a), (iii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c), (iv) the class(es) and maximum number of securities that may be awarded to any Non-Employee Director pursuant to Section 3(d), and (v) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such adjustments, and its determination will be final, binding and conclusive.

(b) Dissolution. Except as otherwise provided in the Stock Award Agreement, in the event of a Dissolution of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company’s right of repurchase) will terminate immediately prior to the completion of such Dissolution, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service; provided, however, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the Dissolution is completed but contingent on its completion.

(c) Transaction. The following provisions will apply to Stock Awards in the event of a Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided


by the Board at the time of grant of a Stock Award. In the event of a Transaction, then, notwithstanding any other provision of the Plan, the Board may take one or more of the following actions with respect to Stock Awards, contingent upon the closing or completion of the Transaction:

(i) arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) to assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award to acquire the same consideration paid to the stockholders of the Company pursuant to the Transaction);

(ii) arrange for the assignment of any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company);

(iii) accelerate the vesting, in whole or in part, of the Stock Award (and, if applicable, the time at which the Stock Award may be exercised) to a date prior to the effective time of such Transaction as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective date of the Transaction), with such Stock Award terminating if not exercised (if applicable) at or prior to the effective time of the Transaction; provided, however, that the Board may require Participants to complete and deliver to the Company a notice of exercise before the effective date of a Transaction, which exercise is contingent upon the effectiveness of such Transaction;

(iv) arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the Stock Award;

(v) cancel or arrange for the cancellation of the Stock Award, to the extent not vested or not exercised prior to the effective time of the Transaction, in exchange for such cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and

(vi) make a payment, in such form as may be determined by the Board equal to the excess, if any, of (A) the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Transaction, over (B) any exercise price payable by such holder in connection with such exercise. For clarity, this payment may be $0 if the value of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company’s Common Stock in connection with the Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.

The Board need not take the same action or actions with respect to all Stock Awards or portions thereof or with respect to all Participants. The Board may take different actions with respect to the vested and unvested portions of a Stock Award.

(d) Change in Control. A Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration will automatically occur.


10. PLAN TERM; EARLIER TERMINATION OR SUSPENSION OF THE PLAN.

The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary of the earlier of (i) the date the Plan is adopted by the Board (the “Adoption Date”), or (ii) the date the Plan is approved by the stockholders of the Company. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.

11. EXISTENCE OF THE PLAN; TIMING OF FIRST GRANT OR EXERCISE.

The Plan will come into existence on the Adoption Date; provided, however, that no Stock Award may be granted prior to the IPO Date. In addition, no Stock Award will be exercised (or, in the case of a Restricted Stock Award, Restricted Stock Unit Award, Performance Share Award, or Other Stock Award, no Stock Award will be granted) and no Performance Cash Award will be settled unless and until the Plan has been approved by the stockholders of the Company, which approval will be within 12 months after the date the Plan is adopted by the Board.

12. CHOICE OF LAW.

The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state’s conflict of laws rules.

13. DEFINITIONS. As used in the Plan, the following definitions will apply to the capitalized terms indicated below:

(a)Affiliate” means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms are defined in Rule 405 of the Securities Act. The Board will have the authority to determine the time or times at which “parent” or “subsidiary” status is determined within the foregoing definition.

(b)Award” means a Stock Award or a Performance Cash Award.

(c)Award Agreement” means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.

(d)Board” means the Board of Directors of the Company.

(e)Capital Stock” means each and every class of common stock of the Company, regardless of the number of votes per share.

(f)Capitalization Adjustment” means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Adoption Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.

(g)Cause shall have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) such Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) such Participant’s attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (iii) such Participant’s intentional, material violation of


any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company; (iv) such Participant’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) such Participant’s gross misconduct. The determination that a termination of the Participant’s Continuous Service is either for Cause or without Cause shall be made by the Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant shall have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.

(h)Change in Control” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:

(i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, (C) on account of the acquisition of securities of the Company by any individual who is, on the IPO Date, either an executive officer or a Director (either, an “IPO Investor”) and/or any entity in which an IPO Investor has a direct or indirect interest (whether in the form of voting rights or participation in profits or capital contributions) of more than 50% (collectively, the “IPO Entities”) or on account of the IPO Entities continuing to hold shares that come to represent more than 50% of the combined voting power of the Company’s then outstanding securities as a result of the conversion of any class of the Company’s securities into another class of the Company’s securities having a different number of votes per share pursuant to the conversion provisions set forth in the Company’s Amended and Restated Certificate of Incorporation; or (D) solely because the level of Ownership held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control will be deemed to occur;

(ii) there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction; provided, however, that a merger, consolidation or similar transaction will not constitute a Change in Control under this prong of the definition if the outstanding voting securities representing more than 50% of the combined voting power of the surviving Entity or its parent are owned by the IPO Entities;


(iii) there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; provided, however, that a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries will not constitute a Change in Control under this prong of the definition if the outstanding voting securities representing more than 50% of the combined voting power of the acquiring Entity or its parent are owned by the IPO Entities;

(iv) the stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company will otherwise occur, except for a liquidation into a parent corporation; or

(v) individuals who, on the IPO Date, are members of the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member will, for purposes of this Plan, be considered as a member of the Incumbent Board.

Notwithstanding the foregoing definition or any other provision of the Plan, (A) the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company and (B) the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant will supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition will apply.

(i)Code” means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.

(j)Committee” means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).

(k)Common Stock” means, as of the IPO Date, the common stock of the Company, having one vote per share.

(l)Company” means Equillium, Inc., a Delaware corporation.

(m)Consultant” means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a “Consultant” for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company’s securities to such person.

(n)Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided


that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, will not terminate a Participant’s Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant’s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law.

(o)Corporate Transaction” means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:

(i) a sale or other disposition of all or substantially all, as determined by the Board, in its sole discretion, of the consolidated assets of the Company and its Subsidiaries;

(ii) a sale or other disposition of more than 50% of the outstanding securities of the Company;

(iii) a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or

(iv) a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.

(p)Director” means a member of the Board.

(q)Disability” means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.

(r)Dissolution” means when the Company, after having executed a certificate of dissolution with the State of Delaware (or other applicable state), has completely wound up its affairs. Conversion of the Company into a Limited Liability Company (or any other pass-through entity) will not be considered a “Dissolution” for purposes of the Plan.

(s)Employee” means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes of the Plan.

(t)Entity” means a corporation, partnership, limited liability company or other entity.


(u)Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

(v)Exchange Act Person means any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the IPO Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities.

(w)Fair Market Value” means, as of any date, the value of the Common Stock determined as follows:

(i) If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.

(ii) Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.

(iii) In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.

(x)Incentive Stock Option” means an option granted pursuant to Section 5 of the Plan that is intended to be, and qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code.

(y)IPO Date” means the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering.

(z)Non-Employee Director means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (“Regulation S-K”)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a “non-employee director” for purposes of Rule 16b-3.

(aa)Nonstatutory Stock Option” means any Option granted pursuant to Section 5 of the Plan that does not qualify as an Incentive Stock Option.


(bb)Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.

(cc)Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.

(dd)Option Agreement” means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan.

(ee)Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.

(ff)Other Stock Award” means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(d).

(gg)Other Stock Award Agreement means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan.

(hh)Own, Owned, Owner, Ownership means a person or Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.

(ii)Participant” means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.

(jj)Performance Cash Award” means an award of cash granted pursuant to the terms and conditions of Section 6(c)(ii).

(kk)Performance Criteria” means the one or more criteria that the Board will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Board: (i) sales; (ii) revenues; (iii) assets; (iv) expenses; (v) market penetration or expansion; (vi) earnings from operations; (vii) earnings before or after deduction for all or any portion of interest, taxes, depreciation, amortization, incentives, service fees or extraordinary or special items, whether or not on a continuing operations or an aggregate or per share basis; (viii) net income or net income per common share (basic or diluted); (ix) return on equity, investment, capital or assets; (x) one or more operating ratios; (xi) borrowing levels, leverage ratios or credit rating; (xii) market share; (xiii) capital expenditures; (xiv) cash flow, free cash flow, cash flow return on investment, or net cash provided by operations; (xv) stock price, dividends or total stockholder return; (xvi) development of new technologies or products; (xvii) sales of particular products or services; (xviii) economic value created or added; (xix) operating margin or profit margin; (xx) customer acquisition or retention; (xxi) raising or refinancing of capital; (xxii) successful hiring of key individuals; (xxiii) resolution of significant litigation; (xxiv) acquisitions and divestitures (in whole or in part); (xxv) joint ventures and strategic alliances; (xxvi) spin-offs, split-ups and the like; (xxvii) reorganizations; (xxviii) recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings; (xxix) or strategic business criteria, consisting of one or more objectives based on the following goals: achievement of timely development, design management or enrollment, meeting specified market penetration or value added, payor acceptance, patient adherence, peer


reviewed publications, issuance of new patents, establishment of or securing of licenses to intellectual property, product development or introduction (including, without limitation, any clinical trial accomplishments, regulatory or other filings, approvals or milestones, discovery of novel products, maintenance of multiple products in pipeline, product launch or other product development milestones), geographic business expansion, cost targets, cost reductions or savings, customer satisfaction, operating efficiency, acquisition or retention, employee satisfaction, information technology, corporate development (including, without limitation, licenses, innovation, research or establishment of third party collaborations), manufacturing or process development, legal compliance or risk reduction, patent application or issuance goals, or goals relating to acquisitions, divestitures or other business combinations (in whole or in part), joint ventures or strategic alliances; and (xxx) other measures of performance selected by the Board.

(ll)Performance Goals” means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. The Board is authorized at any time in its sole discretion, to adjust or modify the calculation of a Performance Goal for such Performance Period in order to prevent the dilution or enlargement of the rights of Participants, (a) in the event of, or in anticipation of, any unusual or extraordinary corporate item, transaction, event or development; (b) in recognition of, or in anticipation of, any other unusual or nonrecurring events affecting the Company, or the financial statements of the Company in response to, or in anticipation of, changes in applicable laws, regulations, accounting principles, or business conditions; or (c) in view of the Board’s assessment of the business strategy of the Company, performance of comparable organizations, economic and business conditions, and any other circumstances deemed relevant. Specifically, the Board is authorized to make adjustment in the method of calculating attainment of Performance Goals and objectives for a Performance Period as follows: (i) to exclude the dilutive effects of acquisitions or joint ventures; (ii) to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; and (iii) to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends. In addition, the Board is authorized to make adjustment in the method of calculating attainment of Performance Goals and objectives for a Performance Period as follows: (i) to exclude restructuring and/or other nonrecurring charges; (ii) to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated net sales and operating earnings; (iii) to exclude the effects of changes to generally accepted accounting standards required by the Financial Accounting Standards Board; (iv) to exclude the effects of any items that are “unusual” in nature or occur “infrequently” as determined under generally accepted accounting principles; (v) to exclude the effects to any statutory adjustments to corporate tax rates; and (vi) to make other appropriate adjustments selected by the Board.

(mm)Performance Period” means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant’s right to and the payment of a Stock Award or a Performance Cash Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board.

(nn)Performance Stock Award” means a Stock Award granted under the terms and conditions of Section 6(c)(i).

(oo)Plan” means this Equillium, Inc. 2018 Equity Incentive Plan.


(pp)Restricted Stock Award” means an award of shares of Common Stock, which is granted pursuant to the terms and conditions of Section 6(a).

(qq)Restricted Stock Award Agreement” means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.

(rr)Restricted Stock Unit Award means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).

(ss)Restricted Stock Unit Award Agreement means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.

(tt)Rule 16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.

(uu)Securities Act” means the Securities Act of 1933, as amended.

(vv)Stock Appreciation Right” or “SAR means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.

(ww)Stock Appreciation Right Agreement” means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.

(xx)Stock Award” means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right, a Performance Stock Award or any Other Stock Award.

(yy)Stock Award Agreement” means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan.

(zz)Subsidiary” means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.

(aaa)Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.

(bbb)Transaction” means a Corporate Transaction or a Change in Control.


Standard Form

EQUILLIUM, INC.

STOCK OPTION GRANT NOTICE

(2018 EQUITY INCENTIVE PLAN)

Equillium, Inc. (the “Company”), pursuant to its 2018 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice, in the Option Agreement, the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same definitions as in the Plan or the Option Agreement. If there is any conflict between the terms in this Stock Option Grant Notice and the Plan, the terms of the Plan will control.

 

 

Optionholder:

 

 

 
 

Date of Grant:

 

 

 
 

Vesting Commencement Date:

 

 

 
 

Number of Shares Subject to Option:

 

 

 
 

Exercise Price (Per Share):

 

 

 
 

Total Exercise Price:

 

 

 
 

Expiration Date:

 

 

 

 

Type of Grant:    ☐ Incentive Stock Option1    ☐ Nonstatutory Stock Option
Exercise Schedule:    Same as Vesting Schedule   
Vesting Schedule:    One-fourth (1/4th) of the shares vest one year after the Vesting Commencement Date; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date, subject to Optionholder’s Continuous Service as of each such date
Payment:    By one or a combination of the following items (described in the Option Agreement):
  

☐   By cash, check, bank draft or money order payable to the Company

  

☐   Pursuant to a Regulation T Program if the shares are publicly traded

  

☐   By delivery of already-owned shares if the shares are publicly traded

  

☐   If and only to the extent this option is a Nonstatutory Stock Option, and subject to the Company’s consent at the time of exercise, by a “net exercise” arrangement

 

1 

If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option.

 

1.


Additional Terms/Acknowledgements: Optionholder acknowledges receipt of, and understands and agrees to, this Stock Option Grant Notice, the Option Agreement and the Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan. Optionholder further acknowledges that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior oral and written agreements, promises and/or representations on that subject with the exception of, if applicable, (i) equity awards previously granted and delivered to Optionholder, (ii) any compensation recovery policy that is adopted by the Company or is otherwise required by applicable law and (iii) any written employment or severance arrangement or other written agreement entered into between the Company and Optionholder specifying the terms that should govern this option upon the terms and conditions set forth therein.

By accepting this option, Optionholder acknowledges having received and read the Stock Option Grant Notice, the Option Agreement and the Plan and agrees to all of the terms and conditions set forth in these documents. Optionholder consents to receive Plan and related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

 

EQUILLIUM, INC.      OPTIONHOLDER:
By:                                                                                                                                                                                               
Signature      Signature
Title:                                                                                            Date:                                                                                      
Date:                                                                                           

ATTACHMENTS: Option Agreement, 2018 Equity Incentive Plan and Notice of Exercise

 

2


ATTACHMENT I

EQUILLIUM, INC.

OPTION AGREEMENT

(2018 EQUITY INCENTIVE PLAN)

(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, Equillium, Inc. (the “Company”) has granted you an option under its 2018 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.

The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows:

1. VESTING. Your option will vest as provided in your Grant Notice. Vesting will cease upon the termination of your Continuous Service.

2. NUMBER OF SHARES AND EXERCISE PRICE. The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization Adjustments.

3. EXERCISE RESTRICTION FOR NON-EXEMPT EMPLOYEES. If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a “Non-Exempt Employee”), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant, even if you have already been an employee for more than six (6) months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six (6) month anniversary in the case of (i) your death or disability, (ii) a Corporate Transaction in which your option is not assumed, continued or substituted, (iii) a Change in Control or (iv) your termination of Continuous Service on your “retirement” (as defined in the Company’s benefit plans).

4. METHOD OF PAYMENT. You must pay the full amount of the exercise price for the shares you wish to exercise. You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner permitted by your Grant Notice, which may include one or more of the following:

(a) Provided that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”, “same day sale”, or “sell to cover”.

 

1


(b) Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. “Delivery” for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company. You may not exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company’s stock.

(c) If this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock will no longer be outstanding under your option and will not be exercisable thereafter if those shares (i) are used to pay the exercise price pursuant to the “net exercise,” (ii) are delivered to you as a result of such exercise, and (iii) are withheld to satisfy your tax withholding obligations.

5. WHOLE SHARES. You may exercise your option only for whole shares of Common Stock.

6. SECURITIES LAW COMPLIANCE. In no event may you exercise your option unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable).

7. TERM. You may not exercise your option before the Date of Grant or after the expiration of the option’s term. The term of your option expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following:

(a) immediately upon the termination of your Continuous Service for Cause;

(b) three (3) months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death (except as otherwise provided in Section 7(d) below); provided, however, that if during any part of such three (3) month period your option is not exercisable solely because of the condition set forth in the section above regarding “Securities Law Compliance,” your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service; provided further, if during any part of such three (3) month period, the sale of any Common Stock received upon exercise of your option would violate the Company’s insider trading policy, then your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service during which the sale of the Common Stock received upon exercise of your option would not be in violation of the Company’s insider trading policy. Notwithstanding the foregoing, if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six (6) months after the Date of Grant, and (iii) you have vested in a portion of your option at the time of your termination of Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is seven (7) months after the Date of Grant, and (B) the date that is three (3) months after the termination of your Continuous Service, and (y) the Expiration Date;

 

2


(c) twelve (12) months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 7(d) below);

(d) eighteen (18) months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service terminates for any reason other than Cause;

(e) the Expiration Date indicated in your Grant Notice; or

(f) the day before the tenth (10th) anniversary of the Date of Grant.

If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the Date of Grant and ending on the day three (3) months before the date of your option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three (3) months after the date your employment with the Company or an Affiliate terminates.

8. EXERCISE.

(a) You may exercise the vested portion of your option during its term by (i) delivering a Notice of Exercise (in a form designated by the Company) or completing such other documents and/or procedures designated by the Company for exercise and (ii) paying the exercise price and any applicable withholding taxes to the Company’s Secretary, stock plan administrator, or such other person as the Company may designate, together with such additional documents as the Company may then require.

(b) By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise.

(c) If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the Date of Grant or within one (1) year after such shares of Common Stock are transferred upon exercise of your option.

(d) By accepting your option you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for a period of one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2241 or any successor or similar rules or regulation (the “Lock-Up Period”); provided, however, that nothing contained in this

 

3


section will prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section 8(d). The underwriters of the Company’s stock are intended third party beneficiaries of this Section 8(d) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto.

9. TRANSFERABILITY. Except as otherwise provided in this Section 9, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you.

(a) Certain Trusts. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust. You and the trustee must enter into transfer and other agreements required by the Company.

(b) Domestic Relations Orders. Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.

(c) Beneficiary Designation. Upon receiving written permission from the Board or its duly authorized designee, you may, by delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise.

10. OPTION NOT A SERVICE CONTRACT. Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.

11. WITHHOLDING OBLIGATIONS.

(a) At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “same day sale” pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your option.

 

4


(b) If this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the maximum amount of tax permitted to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for financial accounting purposes).

(c) You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied.

12. TAX CONSEQUENCES. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the “fair market value” per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option.

13. NOTICES. Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means. By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

14. GOVERNING PLAN DOCUMENT. Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. In addition, your option (and any compensation paid or shares issued under your option) is subject to recoupment in accordance with The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law.

15. OTHER DOCUMENTS. You hereby acknowledge receipt of and the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. In addition, you acknowledge receipt of the Company’s policy permitting certain individuals to sell shares only during certain “window” periods and the Company’s insider trading policy, in effect from time to time.

 

5


16. EFFECT ON OTHER EMPLOYEE BENEFIT PLANS. The value of this option will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company’s or any Affiliate’s employee benefit plans.

17. VOTING RIGHTS. You will not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this option until such shares are issued to you. Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this option, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.

18. SEVERABILITY. If all or any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.

19. MISCELLANEOUS.

(a) The rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company’s successors and assigns.

(b) You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option.

(c) You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option.

(d) This Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.

(e) All obligations of the Company under the Plan and this Option Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.

*     *     *

This Option Agreement will be deemed to be signed by you upon the signing by you of the Stock Option Grant Notice to which it is attached.

 

6


ATTACHMENT II

2018 EQUITY INCENTIVE PLAN


ATTACHMENT III

NOTICE OF EXERCISE

 

EQUILLIUM, INC.   
2223 Avenida de la Playa, Suite 108    Date of Exercise:                     
La Jolla, California 92037   

This constitutes notice to Equillium, Inc. (the “Company”) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the “Shares”) for the price set forth below.

 

Type of option (check one):

   Incentive ☐    Nonstatutory ☐

Stock option dated:

                                                           

Number of Shares as
to which option is
exercised:

                                                           

Certificates to be
issued in name of:

                                                           

Total exercise price:

   $                            $                        

Cash payment delivered
herewith:

   $                            $                        

 

1


[Value of ________ Shares delivered herewith2:

   $______________    $______________]

[Value of ________ Shares pursuant to net exercise3:

   $______________    $______________]

[Regulation T Program (cashless exercise4):

   $______________    $______________]

By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the terms of the Equillium, Inc. 2018 Equity Incentive Plan, (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii) if this exercise relates to an incentive stock option, to notify you in writing within fifteen (15) days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two (2) years after the date of grant of this option or within one (1) year after such Shares are issued upon exercise of this option.

I further agree that, if required by the Company (or a representative of the underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company shall request to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation) (the “Lock-Up Period”). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period.

 

Very truly yours,

 

 

 

 

 

2 

Shares must meet the public trading requirements set forth in the option. Shares must be valued in accordance with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an executed assignment separate from certificate.

3 

The option must be a Nonstatutory Stock Option, and the Company must have established net exercise procedures at the time of exercise, in order to utilize this payment method.

4 

Shares must meet the public trading requirements set forth in the option.


Double-Trigger Form

EQUILLIUM, INC.

STOCK OPTION GRANT NOTICE

(2018 EQUITY INCENTIVE PLAN)

Equillium, Inc. (the “Company”), pursuant to its 2018 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice, in the Option Agreement, the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same definitions as in the Plan or the Option Agreement. If there is any conflict between the terms in this Stock Option Grant Notice and the Plan, the terms of the Plan will control.

 

Optionholder:

                                                                    

Date of Grant:

                                                                    

Vesting Commencement Date:

                                                                    

Number of Shares Subject to Option:

                                                                    

Exercise Price (Per Share):

                                                                    

Total Exercise Price:

                                                                    

Expiration Date:

                                                                    

 

Type of Grant:    ☐ Incentive Stock Option1                     ☐ Nonstatutory Stock Option
Exercise Schedule:    Same as Vesting Schedule
Vesting Schedule:    One-fourth (1/4th) of the shares vest one year after the Vesting Commencement Date; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date, subject to Optionholder’s Continuous Service as of each such date and the potential vesting acceleration described in Section 1 of the Option Agreement
Payment:    By one or a combination of the following items (described in the Option Agreement):
   ☐    By cash, check, bank draft or money order payable to the Company
   ☐    Pursuant to a Regulation T Program if the shares are publicly traded
   ☐    By delivery of already-owned shares if the shares are publicly traded
   ☐    If and only to the extent this option is a Nonstatutory Stock Option, and subject to the Company’s consent at the time of exercise, by a “net exercise” arrangement

 

1 

If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option.

 

1.


Additional Terms/Acknowledgements: Optionholder acknowledges receipt of, and understands and agrees to, this Stock Option Grant Notice, the Option Agreement and the Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan. Optionholder further acknowledges that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior oral and written agreements, promises and/or representations on that subject with the exception of, if applicable, (i) equity awards previously granted and delivered to Optionholder, (ii) any compensation recovery policy that is adopted by the Company or is otherwise required by applicable law and (iii) any written employment or severance arrangement or other written agreement entered into between the Company and Optionholder specifying the terms that should govern this option upon the terms and conditions set forth therein.

By accepting this option, Optionholder acknowledges having received and read the Stock Option Grant Notice, the Option Agreement and the Plan and agrees to all of the terms and conditions set forth in these documents. Optionholder consents to receive Plan and related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

 

EQUILLIUM, INC.     OPTIONHOLDER:
By:                                                                                                                                                                                                        
Signature     Signature
Title:                                                                                                 Date:                                                                                            
Date:                                                                                                
   
   

ATTACHMENTS: Option Agreement, 2018 Equity Incentive Plan and Notice of Exercise

 

2


ATTACHMENT I

EQUILLIUM, INC.

OPTION AGREEMENT

(2018 EQUITY INCENTIVE PLAN)

(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, Equillium, Inc. (the “Company”) has granted you an option under its 2018 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.

The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows:

1. VESTING. Your option will vest as provided in your Grant Notice. Vesting will cease upon the termination of your Continuous Service. If a Change in Control occurs and upon or within twelve (12) months after the effective time of such Change in Control, your Continuous Service terminates due to an involuntary termination (not including death or Disability) without Cause or due to your voluntary termination with Good Reason, then, as of the date of termination of Continuous Service, the vesting and exercisability of your option will be accelerated in full.

(a)Good Reason” means the occurrence of any of the following events, conditions or actions taken by the Company without Cause and without your written consent: (i) a material reduction of your annual base salary; provided, however, that Good Reason shall not be deemed to have occurred in the event of a reduction in your annual base salary that is pursuant to a salary reduction program affecting substantially all of the similarly situated employees of the Company and that does not adversely affect you to a greater extent than other similarly situated employees; (ii) a material reduction in your authority, duties or responsibilities; (iii) a relocation of your principal place of employment with the Company to a place that increases your one-way commute by more than fifty (50) miles as compared to your then-current principal place of employment immediately prior to such relocation (excluding regular travel in the ordinary course of business); or (iv) a material breach by the Company of any provision of this Option Agreement or your employment agreement with the Company; provided, however, that in each case above, in order for your resignation to be deemed to have been for Good Reason, you must first give the Board written notice of the action or omission giving rise to “Good Reason” within thirty (30) days after the first occurrence thereof; the Company must fail to reasonably cure such action or omission within thirty (30) days after receipt of such notice (the “Cure Period”), and your resignation from all positions you hold with the Company must be effective not later than thirty (30) days after the expiration of such Cure Period.

(b) If any payment or benefit you would receive from the Company or otherwise in connection with a change in control of the Company or other similar transaction (“Payment”) would (1) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (2) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment will be equal to the Reduced Amount. The “Reduced Amount” will be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax, or (y) the

 

1


largest portion, up to and including the total, of the Payment, whichever amount ((x) or (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction will occur in the manner (the “Reduction Method”) that results in the greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the “Pro Rata Reduction Method”).

Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code (“Section 409A”) that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.

The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the event described in Section 280G(b)(2)(A)(i) of the Code will perform the foregoing calculations. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the change in control or similar transaction, the Company will appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company will bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder. The independent registered public accounting firm engaged to make the determinations hereunder will make its determination with input from you (or your counsel) and provide its calculations, together with detailed supporting documentation, to the Company and you within fifteen (15) calendar days after the date on which your right to a Payment is triggered (if requested at that time by the Company or you) or such other time as reasonably requested by the Company or you.

If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 1(b) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section 1(b) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) in the first paragraph of this Section 1(b), you shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.

2. NUMBER OF SHARES AND EXERCISE PRICE. The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization Adjustments.

3. EXERCISE RESTRICTION FOR NON-EXEMPT EMPLOYEES. If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a “Non-Exempt Employee”), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant, even if you have already been an employee for more than six (6) months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such

 

2


six (6) month anniversary in the case of (i) your death or disability, (ii) a Corporate Transaction in which your option is not assumed, continued or substituted, (iii) a Change in Control or (iv) your termination of Continuous Service on your “retirement” (as defined in the Company’s benefit plans).

4. METHOD OF PAYMENT. You must pay the full amount of the exercise price for the shares you wish to exercise. You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner permitted by your Grant Notice, which may include one or more of the following:

(a) Provided that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”, “same day sale”, or “sell to cover”.

(b) Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. “Delivery” for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company. You may not exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company’s stock.

(c) If this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock will no longer be outstanding under your option and will not be exercisable thereafter if those shares (i) are used to pay the exercise price pursuant to the “net exercise,” (ii) are delivered to you as a result of such exercise, and (iii) are withheld to satisfy your tax withholding obligations.

5. WHOLE SHARES. You may exercise your option only for whole shares of Common Stock.

6. SECURITIES LAW COMPLIANCE. In no event may you exercise your option unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable).

7. TERM. You may not exercise your option before the Date of Grant or after the expiration of the option’s term. The term of your option expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following:

(a) immediately upon the termination of your Continuous Service for Cause;

 

3


(b) three (3) months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death (except as otherwise provided in Section 7(d) below); provided, however, that if during any part of such three (3) month period your option is not exercisable solely because of the condition set forth in the section above regarding “Securities Law Compliance,” your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service; provided further, if during any part of such three (3) month period, the sale of any Common Stock received upon exercise of your option would violate the Company’s insider trading policy, then your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service during which the sale of the Common Stock received upon exercise of your option would not be in violation of the Company’s insider trading policy. Notwithstanding the foregoing, if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six (6) months after the Date of Grant, and (iii) you have vested in a portion of your option at the time of your termination of Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is seven (7) months after the Date of Grant, and (B) the date that is three (3) months after the termination of your Continuous Service, and (y) the Expiration Date;

(c) twelve (12) months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 7(d) below);

(d) eighteen (18) months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service terminates for any reason other than Cause;

(e) the Expiration Date indicated in your Grant Notice; or

(f) the day before the tenth (10th) anniversary of the Date of Grant.

If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the Date of Grant and ending on the day three (3) months before the date of your option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three (3) months after the date your employment with the Company or an Affiliate terminates.

8. EXERCISE.

(a) You may exercise the vested portion of your option during its term by (i) delivering a Notice of Exercise (in a form designated by the Company) or completing such other documents and/or procedures designated by the Company for exercise and (ii) paying the exercise price and any applicable withholding taxes to the Company’s Secretary, stock plan administrator, or such other person as the Company may designate, together with such additional documents as the Company may then require.

(b) By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise.

 

4


(c) If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the Date of Grant or within one (1) year after such shares of Common Stock are transferred upon exercise of your option.

(d) By accepting your option you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for a period of one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2241 or any successor or similar rules or regulation (the “Lock-Up Period”); provided, however, that nothing contained in this section will prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section 8(d). The underwriters of the Company’s stock are intended third party beneficiaries of this Section 8(d) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto.

9. TRANSFERABILITY. Except as otherwise provided in this Section 9, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you.

(a) Certain Trusts. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust. You and the trustee must enter into transfer and other agreements required by the Company.

(b) Domestic Relations Orders. Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.

(c) Beneficiary Designation. Upon receiving written permission from the Board or its duly authorized designee, you may, by delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise.

 

5


10. OPTION NOT A SERVICE CONTRACT. Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.

11. WITHHOLDING OBLIGATIONS.

(a) At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “same day sale” pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your option.

(b) If this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the maximum amount of tax permitted to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for financial accounting purposes).

(c) You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied.

12. TAX CONSEQUENCES. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the “fair market value” per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option.

13. NOTICES. Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means. By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

 

6


14. GOVERNING PLAN DOCUMENT. Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. In addition, your option (and any compensation paid or shares issued under your option) is subject to recoupment in accordance with The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law.

15. OTHER DOCUMENTS. You hereby acknowledge receipt of and the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. In addition, you acknowledge receipt of the Company’s policy permitting certain individuals to sell shares only during certain “window” periods and the Company’s insider trading policy, in effect from time to time.

16. EFFECT ON OTHER EMPLOYEE BENEFIT PLANS. The value of this option will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company’s or any Affiliate’s employee benefit plans.

17. VOTING RIGHTS. You will not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this option until such shares are issued to you. Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this option, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.

18. SEVERABILITY. If all or any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.

19. MISCELLANEOUS.

(a) The rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company’s successors and assigns.

(b) You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option.

(c) You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option.

(d) This Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.

 

7


(e) All obligations of the Company under the Plan and this Option Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.

*    *    *

This Option Agreement will be deemed to be signed by you upon the signing by you of the Stock Option Grant Notice to which it is attached.

 

8


ATTACHMENT II

2018 EQUITY INCENTIVE PLAN


ATTACHMENT III

NOTICE OF EXERCISE

 

EQUILLIUM, INC.   
2223 Avenida de la Playa, Suite 108    Date of Exercise: _______________
La Jolla, California 92037   

This constitutes notice to Equillium, Inc. (the “Company”) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the “Shares”) for the price set forth below.

 

Type of option (check one):

   Incentive ☐    Nonstatutory ☐   

Stock option dated:

                                                                                            

Number of Shares as to which option is exercised:

                                                                                            

Certificates to be issued in name of:

                                                                                            

Total exercise price:

   $                                           $                                          

Cash payment delivered herewith:

   $                                           $                                          

 

1


[Value of             Shares delivered herewith2:

   $                                           $                                       ]   

[Value of              Shares pursuant to net exercise3:

   $                                           $                                       ]   

[Regulation T Program (cashless exercise4):

   $                                           $                                       ]   

By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the terms of the Equillium, Inc. 2018 Equity Incentive Plan, (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii) if this exercise relates to an incentive stock option, to notify you in writing within fifteen (15) days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two (2) years after the date of grant of this option or within one (1) year after such Shares are issued upon exercise of this option.

I further agree that, if required by the Company (or a representative of the underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company shall request to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation) (the “Lock-Up Period”). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period.

 

Very truly yours,

 

 

 

2 

Shares must meet the public trading requirements set forth in the option. Shares must be valued in accordance with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an executed assignment separate from certificate.

3 

The option must be a Nonstatutory Stock Option, and the Company must have established net exercise procedures at the time of exercise, in order to utilize this payment method.

4 

Shares must meet the public trading requirements set forth in the option.


Non-Employee Director Form

EQUILLIUM, INC.

STOCK OPTION GRANT NOTICE

(2018 EQUITY INCENTIVE PLAN)

Equillium, Inc. (the “Company”), pursuant to its 2018 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice, in the Option Agreement, the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same definitions as in the Plan or the Option Agreement. If there is any conflict between the terms in this Stock Option Grant Notice and the Plan, the terms of the Plan will control.

 

Optionholder:

 

 

 

Date of Grant:

 

 

 

Vesting Commencement Date:

 

 

 

Number of Shares Subject to Option:

 

 

 

Exercise Price (Per Share):

 

 

 

Total Exercise Price:

 

 

 

Expiration Date:

 

 

 

 

Type of Grant:    ☐ Incentive Stock Option1    ☒ Nonstatutory Stock Option
Exercise Schedule:    Same as Vesting Schedule   
Vesting Schedule:    [                    ], subject to Optionholder’s Continuous Service as of each such date
Payment:   

By   one or a combination of the following items (described in the Option Agreement):

  

☐   By cash, check, bank draft or money order payable to the Company

     ☐   Pursuant to a Regulation T Program if the shares are publicly traded
     ☐   By delivery of already-owned shares if the shares are publicly traded
     ☐   If and only to the extent this option is a Nonstatutory Stock Option, and subject to the Company’s
consent at the time of exercise, by a “net exercise” arrangement

 

1 

If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option.

 

1.


Additional Terms/Acknowledgements: Optionholder acknowledges receipt of, and understands and agrees to, this Stock Option Grant Notice, the Option Agreement and the Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan. Optionholder further acknowledges that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior oral and written agreements, promises and/or representations on that subject with the exception of, if applicable, (i) equity awards previously granted and delivered to Optionholder, (ii) any compensation recovery policy that is adopted by the Company or is otherwise required by applicable law and (iii) any written employment or severance arrangement or other written agreement entered into between the Company and Optionholder specifying the terms that should govern this option upon the terms and conditions set forth therein.

By accepting this option, Optionholder acknowledges having received and read the Stock Option Grant Notice, the Option Agreement and the Plan and agrees to all of the terms and conditions set forth in these documents. Optionholder consents to receive Plan and related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

 

EQUILLIUM, INC.     OPTIONHOLDER:
By:                                                                                                                                                                                          
Signature     Signature
Title:                                                                                        

Date:                                                                                     

Date:                                                                                    

   

ATTACHMENTS: Option Agreement, 2018 Equity Incentive Plan and Notice of Exercise

 

2


ATTACHMENT I

EQUILLIUM, INC.

OPTION AGREEMENT

(2018 EQUITY INCENTIVE PLAN)

(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, Equillium, Inc. (the “Company”) has granted you an option under its 2018 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.

The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows:

1. VESTING. Your option will vest as provided in your Grant Notice. Vesting will cease upon the termination of your Continuous Service. If a Change in Control occurs and your Continuous Service has not terminated as of immediately prior to such Change in Control, the vesting and exercisability of your option will be accelerated in full.

(a) If any payment or benefit you would receive from the Company or otherwise in connection with a change in control of the Company or other similar transaction (“Payment”) would (1) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (2) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment will be equal to the Reduced Amount. The “Reduced Amount” will be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax, or (y) the largest portion, up to and including the total, of the Payment, whichever amount ((x) or (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction will occur in the manner (the “Reduction Method”) that results in the greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the “Pro Rata Reduction Method”).

Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code (“Section 409A”) that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.

 

1


The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the event described in Section 280G(b)(2)(A)(i) of the Code will perform the foregoing calculations. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the change in control or similar transaction, the Company will appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company will bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder. The independent registered public accounting firm engaged to make the determinations hereunder will make its determination with input from you (or your counsel) and provide its calculations, together with detailed supporting documentation, to the Company and you within fifteen (15) calendar days after the date on which your right to a Payment is triggered (if requested at that time by the Company or you) or such other time as reasonably requested by the Company or you.

If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 1(b) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section 1(b) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) in the first paragraph of this Section 1(b), you shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.

2. NUMBER OF SHARES AND EXERCISE PRICE. The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization Adjustments.

3. EXERCISE RESTRICTION FOR NON-EXEMPT EMPLOYEES. If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a “Non-Exempt Employee”), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant, even if you have already been an employee for more than six (6) months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six (6) month anniversary in the case of (i) your death or disability, (ii) a Corporate Transaction in which your option is not assumed, continued or substituted, (iii) a Change in Control or (iv) your termination of Continuous Service on your “retirement” (as defined in the Company’s benefit plans).

4. METHOD OF PAYMENT. You must pay the full amount of the exercise price for the shares you wish to exercise. You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner permitted by your Grant Notice, which may include one or more of the following:

(a) Provided that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”, “same day sale”, or “sell to cover”.

(b) Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. “Delivery” for these purposes, in the sole discretion of

 

2


the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company. You may not exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company’s stock.

(c) If this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock will no longer be outstanding under your option and will not be exercisable thereafter if those shares (i) are used to pay the exercise price pursuant to the “net exercise,” (ii) are delivered to you as a result of such exercise, and (iii) are withheld to satisfy your tax withholding obligations.

5. WHOLE SHARES. You may exercise your option only for whole shares of Common Stock.

6. SECURITIES LAW COMPLIANCE. In no event may you exercise your option unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable).

7. TERM. You may not exercise your option before the Date of Grant or after the expiration of the option’s term. The term of your option expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following:

(a) immediately upon the termination of your Continuous Service for Cause;

(b) twelve (12) months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death (except as otherwise provided in Section 7(d) below);

(c) twelve (12) months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 7(d) below);

(d) eighteen (18) months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service terminates for any reason other than Cause;

(e) the Expiration Date indicated in your Grant Notice; or

(f) the day before the tenth (10th) anniversary of the Date of Grant.

If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the Date of Grant and ending on the day three (3) months before the date of your option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but

 

3


cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three (3) months after the date your employment with the Company or an Affiliate terminates.

8. EXERCISE.

(a) You may exercise the vested portion of your option during its term by (i) delivering a Notice of Exercise (in a form designated by the Company) or completing such other documents and/or procedures designated by the Company for exercise and (ii) paying the exercise price and any applicable withholding taxes to the Company’s Secretary, stock plan administrator, or such other person as the Company may designate, together with such additional documents as the Company may then require.

(b) By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise.

(c) If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the Date of Grant or within one (1) year after such shares of Common Stock are transferred upon exercise of your option.

(d) By accepting your option you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for a period of one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2241 or any successor or similar rules or regulation (the “Lock-Up Period”); provided, however, that nothing contained in this section will prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section 8(d). The underwriters of the Company’s stock are intended third party beneficiaries of this Section 8(d) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto.

9. TRANSFERABILITY. Except as otherwise provided in this Section 9, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you.

(a) Certain Trusts. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust. You and the trustee must enter into transfer and other agreements required by the Company.

 

4


(b) Domestic Relations Orders. Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.

(c) Beneficiary Designation. Upon receiving written permission from the Board or its duly authorized designee, you may, by delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise.

10. OPTION NOT A SERVICE CONTRACT. Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.

11. WITHHOLDING OBLIGATIONS.

(a) At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “same day sale” pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your option.

(b) If this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the maximum amount of tax permitted to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for financial accounting purposes).

(c) You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied.

 

5


12. TAX CONSEQUENCES. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the “fair market value” per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option.

13. NOTICES. Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means. By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

14. GOVERNING PLAN DOCUMENT. Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. In addition, your option (and any compensation paid or shares issued under your option) is subject to recoupment in accordance with The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law.

15. OTHER DOCUMENTS. You hereby acknowledge receipt of and the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. In addition, you acknowledge receipt of the Company’s policy permitting certain individuals to sell shares only during certain “window” periods and the Company’s insider trading policy, in effect from time to time.

16. EFFECT ON OTHER EMPLOYEE BENEFIT PLANS. The value of this option will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company’s or any Affiliate’s employee benefit plans.

17. VOTING RIGHTS. You will not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this option until such shares are issued to you. Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this option, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.

18. SEVERABILITY. If all or any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.

 

6


19. MISCELLANEOUS.

(a) The rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company’s successors and assigns.

(b) You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option.

(c) You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option.

(d) This Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.

(e) All obligations of the Company under the Plan and this Option Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.

* * *

This Option Agreement will be deemed to be signed by you upon the signing by you of the Stock Option Grant Notice to which it is attached.

 

7


ATTACHMENT II

2018 EQUITY INCENTIVE PLAN


ATTACHMENT III

NOTICE OF EXERCISE

 

EQUILLIUM, INC.   
2223 Avenida de la Playa, Suite 108    Date of Exercise: _______________
La Jolla, California 92037   

This constitutes notice to Equillium, Inc. (the “Company”) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the “Shares”) for the price set forth below.

 

Type of option (check one):

   Incentive ☐    Nonstatutory ☐   

Stock option dated:

                                                                                            

Number of Shares as to which option is exercised:

                                                                                            

Certificates to be issued in name of:

                                                                                            

Total exercise price:

                                                                                      

Cash payment delivered herewith:

                                                                                      

 

1


[Value of              Shares delivered herewith2:

   $                                           $                                       ]   

[Value of              Shares pursuant to net exercise3:

   $                                           $                                       ]   

[Regulation T Program (cashless exercise4):

   $                                           $                                       ]   

By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the terms of the Equillium, Inc. 2018 Equity Incentive Plan, (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii) if this exercise relates to an incentive stock option, to notify you in writing within fifteen (15) days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two (2) years after the date of grant of this option or within one (1) year after such Shares are issued upon exercise of this option.

I further agree that, if required by the Company (or a representative of the underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company shall request to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation) (the “Lock-Up Period”). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period.

 

Very truly yours,

 

 

 

2 

Shares must meet the public trading requirements set forth in the option. Shares must be valued in accordance with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an executed assignment separate from certificate.

3 

The option must be a Nonstatutory Stock Option, and the Company must have established net exercise procedures at the time of exercise, in order to utilize this payment method.

4 

Shares must meet the public trading requirements set forth in the option.

EX-10.4 7 d582934dex104.htm EX-10.4 EX-10.4

Exhibit 10.4

EQUILLIUM, INC.

2018 EMPLOYEE STOCK PURCHASE PLAN

ADOPTED BY THE BOARD OF DIRECTORS:                 

APPROVED BY THE STOCKHOLDERS:             

 

1.

GENERAL; PURPOSE.

(a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan.

(b) The Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations.

 

2.

ADMINISTRATION.

(a) The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in Section 2(c).

(b) The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:

(i) To determine how and when Purchase Rights will be granted and the provisions of each Offering (which need not be identical).

(ii) To designate from time to time which Related Corporations of the Company will be eligible to participate in the Plan.

(iii) To construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or expedient to make the Plan fully effective.

(iv) To settle all controversies regarding the Plan and Purchase Rights granted under the Plan.

(v) To suspend or terminate the Plan at any time as provided in Section 12.

(vi) To amend the Plan at any time as provided in Section 12.

(vii) Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan.

(viii) To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside the United States.


(c) The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references to the Board in this Plan and in any applicable Offering Document will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy and expediency that may arise in the administration of the Plan.

(d) All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.

 

3.

SHARES OF COMMON STOCK SUBJECT TO THE PLAN.

(a) Subject to the provisions of Section 11(a) relating to Capitalization Adjustments, the maximum number of shares of Common Stock that may be issued under the Plan will not exceed 343,275 shares of Common Stock, plus the number of shares of Common Stock that are automatically added on January 1st of each year for a period of up to ten years, commencing on the first January 1 following the IPO Date and ending on (and including) January 1, 2028, in an amount equal to the lesser of (i) 1.0% of the total number of shares of Capital Stock outstanding on December 31st of the preceding calendar year, and (ii) 343,275 shares of Common Stock. Notwithstanding the foregoing, the Board may act prior to the first day of any calendar year to provide that there will be no January 1st increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence.

(b) If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not purchased under such Purchase Right will again become available for issuance under the Plan.

(c) The stock purchasable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market.

 

4.

GRANT OF PURCHASE RIGHTS; OFFERING.

(a) The Board may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and conditions as the Board will deem appropriate, and will comply with the requirement of Section 423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The terms and conditions of an Offering shall be incorporated by reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference in the document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions contained in Sections 5 through 8, inclusive.


(b) If a Participant has more than one Purchase Right outstanding under the Plan, unless he or she otherwise indicates in forms delivered to the Company: (i) each form will apply to all of his or her Purchase Rights under the Plan, and (ii) a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be exercised.

(c) The Board will have the discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i) that Offering will terminate immediately as of that first Trading Day, and (ii) the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period.

 

5.

ELIGIBILITY.

(a) Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section 2(b), to Employees of a Related Corporation. Except as provided in Section 5(b), an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in the employ of the Company or the Related Corporation, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in no event will the required period of continuous employment be equal to or greater than two years. In addition, the Board may provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee’s customary employment with the Company or the Related Corporation is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with Section 423 of the Code.

(b) The Board may provide that each person who, during the course of an Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that:

(i) the date on which such Purchase Right is granted will be the “Offering Date” of such Purchase Right for all purposes, including determination of the exercise price of such Purchase Right;

(ii) the period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and

(iii) the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of the Offering, he or she will not receive any Purchase Right under that Offering.

(c) No Employee will be eligible for the grant of any Purchase Rights if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of any Related Corporation. For purposes of this Section 5(c), the rules of Section 424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights and options will be treated as stock owned by such Employee.


(d) As specified by Section 423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee’s rights to purchase stock of the Company or any Related Corporation to accrue at a rate which exceeds $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, will be determined as of their respective Offering Dates) for each calendar year in which such rights are outstanding at any time.

(e) Officers of the Company and any designated Related Corporation, if they are otherwise Eligible Employees, will be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may provide in an Offering that Employees who are highly compensated Employees within the meaning of Section 423(b)(4)(D) of the Code will not be eligible to participate.

 

6.

PURCHASE RIGHTS; PURCHASE PRICE.

(a) On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board, but in either case not exceeding 15% of such Employee’s earnings (as defined by the Board in each Offering) during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering.

(b) The Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted for that Offering will be exercised and shares of Common Stock will be purchased in accordance with such Offering.

(c) In connection with each Offering made under the Plan, the Board may specify (i) a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering, (ii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants pursuant to such Offering and/or (iii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date under the Offering. If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant’s accumulated Contributions) allocation of the shares of Common Stock available will be made in as nearly a uniform manner as will be practicable and equitable.

(d) The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be not less than the lesser of:

(i) an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the Offering Date; or

(ii) an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date.

 

7.

PARTICIPATION; WITHDRAWAL; TERMINATION.

(a) An Eligible Employee may elect to authorize payroll deductions as the means of making Contributions by completing and delivering to the Company, within the time specified in the Offering, an enrollment form provided by the Company. The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified by the Board. Each Participant’s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where applicable law requires that Contributions be deposited with a third


party. If permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering Date (or, in the case of a payroll date that occurs after the end of the prior Offering but before the Offering Date of the next new Offering, Contributions from such payroll will be included in the new Offering). If permitted in the Offering, a Participant may thereafter reduce (including to zero) or increase his or her Contributions. If specifically provided in the Offering, in addition to making Contributions by payroll deductions, a Participant may make Contributions through the payment by cash or check prior to a Purchase Date.

(b) During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company a withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant’s Purchase Right in that Offering will immediately terminate and the Company will distribute to such Participant all of his or her accumulated but unused Contributions and such Participant’s Purchase Right in that Offering shall thereupon terminate. A Participant’s withdrawal from that Offering will have no effect upon his or her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings.

(c) Purchase Rights granted pursuant to any Offering under the Plan will terminate immediately if the Participant either (i) is no longer an Employee for any reason or for no reason (subject to any post-employment participation period required by law) or (ii) is otherwise no longer eligible to participate. The Company will distribute to such individual all of his or her accumulated but unused Contributions.

(d) During a Participant’s lifetime, Purchase Rights will be exercisable only by such Participant. Purchase Rights are not transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section 10.

(e) Unless otherwise specified in the Offering, the Company will have no obligation to pay interest on Contributions.

 

8.

EXERCISE OF PURCHASE RIGHTS.

(a) On each Purchase Date, each Participant’s accumulated Contributions will be applied to the purchase of shares of Common Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless specifically provided for in the Offering.

(b) Unless otherwise provided in the Offering, if any amount of accumulated Contributions remains in a Participant’s account after the purchase of shares of Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be held in such Participant’s account for the purchase of shares of Common Stock under the next Offering under the Plan, unless such Participant withdraws from or is not eligible to participate in such next Offering, in which case such amount will be distributed to such Participant after the final Purchase Date without interest. If the amount of Contributions remaining in a Participant’s account after the purchase of shares of Common Stock is at least equal to the amount required to purchase one (1) whole share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be distributed in full to such Participant after the final Purchase Date of such Offering without interest.


(c) No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable federal, state, foreign and other securities and other laws applicable to the Plan. If on a Purchase Date the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and the Purchase Date will be delayed until the shares of Common Stock are subject to such an effective registration statement and the Plan is in material compliance, except that the Purchase Date will in no event be more than 6 months from the Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not registered and the Plan is not in material compliance with all applicable laws, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest.

 

9.

COVENANTS OF THE COMPANY.

The Company will seek to obtain from each federal, state, foreign or other regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell Common Stock upon exercise of such Purchase Rights.

 

10.

DESIGNATION OF BENEFICIARY.

(a) The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any shares of Common Stock and/or Contributions from the Participant’s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. The Company may, but is not obligated to, permit the Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company.

(b) If a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock and/or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common Stock and/or Contributions to the Participant’s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.

 

11.

ADJUSTMENTS UPON CHANGES IN COMMON STOCK; CORPORATE TRANSACTIONS.

(a) In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities by which the share reserve is to increase automatically each year pursuant to Section 3(a), (iii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and (iv) the class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final, binding and conclusive.

(b) In the event of a Corporate Transaction, then: (i) any surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for outstanding Purchase Rights, or (ii) if any surviving or acquiring corporation (or its parent company) does not assume or continue such


Purchase Rights or does not substitute similar rights for such Purchase Rights, then the Participants’ accumulated Contributions will be used to purchase shares of Common Stock within ten business days prior to the Corporate Transaction under the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase.

 

12.

AMENDMENT, TERMINATION OR SUSPENSION OF THE PLAN.

(a) The Board may amend the Plan at any time in any respect the Board deems necessary or advisable. However, except as provided in Section 11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by applicable law or listing requirements.

(b) The Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan while the Plan is suspended or after it is terminated.

(c) Any benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i) with the consent of the person to whom such Purchase Rights were granted, (ii) as necessary to comply with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section 423 of the Code and the regulations and other interpretive guidance issued thereunder relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii) as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant’s consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies with the requirements of Section 423 of the Code.

Notwithstanding anything in the Plan or any Offering Document to the contrary, the Board will be entitled to: (i) establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars; (ii) permit Contributions in excess of the amount designated by a Participant in order to adjust for mistakes in the Company’s processing of properly completed Contribution elections; (iii) establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with amounts withheld from the Participant’s Contributions; (iv) amend any outstanding Purchase Rights or clarify any ambiguities regarding the terms of any Offering to enable the Purchase Rights to qualify under and/or comply with Section 423 of the Code; and (v) establish other limitations or procedures as the Board determines in its sole discretion advisable that are consistent with the Plan. The actions of the Board pursuant to this paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as they are part of the initial terms of each Offering and the Purchase Rights granted under each Offering.

 

13.

EFFECTIVE DATE OF PLAN.

The Plan will become effective immediately prior to and contingent upon the IPO Date. No Purchase Rights will be exercised unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section 12(a) above, materially amended) by the Board.


14.

MISCELLANEOUS PROVISIONS.

(a) Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company.

(b) A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common Stock subject to Purchase Rights unless and until the Participant’s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent).

(c) The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the at will nature of a Participant’s employment or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation, or on the part of the Company or a Related Corporation to continue the employment of a Participant.

(d) The provisions of the Plan will be governed by the laws of the State of Delaware without resort to that state’s conflicts of laws rules.

 

15.

DEFINITIONS.

As used in the Plan, the following definitions will apply to the capitalized terms indicated below:

(a)Board means the Board of Directors of the Company.

(b)Capital Stock means each and every class of common stock of the Company, regardless of the number of votes per share.

(c)Capitalization Adjustment” means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.

(d)Code means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.

(e)Committee means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section 2(c).

(f)Common Stock” means, as of the IPO Date, the common stock of the Company.

(g)Company” means Equillium, Inc., a Delaware corporation.

(h) “Contributions” means the payroll deductions and other additional payments specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions.


(i)Corporate Transaction” means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:

(i) a sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its subsidiaries;

(ii) a sale or other disposition of more than 50% of the outstanding securities of the Company;

(iii) a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or

(iv) a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.

(j)Director means a member of the Board.

(k)Eligible Employee means an Employee who meets the requirements set forth in the document(s) governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan.

(l)Employee means any person, including an Officer or Director, who is “employed” for purposes of Section 423(b)(4) of the Code by the Company or a Related Corporation. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes of the Plan.

(m)Employee Stock Purchase Plan means a plan that grants Purchase Rights intended to be options issued under an “employee stock purchase plan,” as that term is defined in Section 423(b) of the Code.

(n)Exchange Act means the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder.

(o)Fair Market Value” means, as of any date, the value of the Common Stock determined as follows:

(i) If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing sales price on the last preceding date for which such quotation exists.


(ii) In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith in compliance with applicable laws and in a manner that complies with Sections 409A of the Code.

(iii) Notwithstanding the foregoing, for any Offering that commences on the IPO Date, the Fair Market Value of the shares of Common Stock on the Offering Date will be the price per share at which shares are first sold to the public in the Company’s initial public offering as specified in the final prospectus for that initial public offering.

(p)IPO Date means the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering.

(q)Offering means the grant to Eligible Employees of Purchase Rights, with the exercise of those Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the “Offering Document” approved by the Board for that Offering.

(r)Offering Date” means a date selected by the Board for an Offering to commence.

(s)Officer means a person who is an officer of the Company or a Related Corporation within the meaning of Section 16 of the Exchange Act.

(t)Participant means an Eligible Employee who holds an outstanding Purchase Right.

(u)Plan means this Equillium, Inc. 2018 Employee Stock Purchase Plan.

(v)Purchase Date means one or more dates during an Offering selected by the Board on which Purchase Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering.

(w)Purchase Period” means a period of time specified within an Offering, generally beginning on the Offering Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods.

(x)Purchase Right means an option to purchase shares of Common Stock granted pursuant to the Plan.

(y)Related Corporation means any “parent corporation” or “subsidiary corporation” of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code.

(z)Securities Act means the Securities Act of 1933, as amended.

(aa)Subsidiary” means, with respect to the Company, (i) any corporation of which more than fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%). For purposes


of the foregoing clause (i), the Company will be deemed to “Own” or have “Owned” such securities if the Company, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.

(bb)Trading Day means any day on which the exchange(s) or market(s) on which shares of Common Stock are listed, including but not limited to the NYSE, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading.

EX-10.5 8 d582934dex105.htm EX-10.5 EX-10.5

Exhibit 10.5

EQUILLIUM, INC.

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Equillium, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board service upon and following the date of the underwriting agreement between the Company and the underwriters managing the initial public offering of the Company’s common stock (the “Common Stock”), pursuant to which the Common Stock is priced in such initial public offering (the “Effective Date”). An Eligible Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash may be paid or equity awards are to be granted, as the case may be. This policy is effective as of the Effective Date and may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.

Annual Cash Compensation

The annual cash compensation amount set forth below is payable to Eligible Directors in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service and regular full quarterly payments thereafter. All annual cash fees are vested upon payment.

 

1.

Annual Board Service Retainer:

  a.

All Eligible Directors: $40,000

  b.

Chairman of the Board Service Retainer (in addition to Eligible Director Service Retainer): $20,000

 

2.

Annual Committee Chair Service Retainer:

  a.

Chairman of the Audit Committee: $15,000

  b.

Chairman of the Compensation Committee: $10,000

  c.

Chairman of the Nominating and Corporate Governance Committee: $8,000

 

3.

Annual Committee Member Service Retainer (not applicable to Committee Chairs):

  a.

Member of the Audit Committee: $7,500

  b.

Member of the Compensation Committee: $5,000

  c.

Member of the Nominating and Corporate Governance Committee: $4,000

 

1.


Equity Compensation

The equity compensation set forth below will be granted under the Company’s 2018 Equity Incentive Plan (the “Plan”), subject to the approval of the Plan by the Company’s stockholders. All stock options granted under this policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying Common Stock on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan, provided that upon a termination of service other than for death, disability or cause, the post-termination exercise period will be 12 months from the date of termination).

1.        Initial Grant: For each Eligible Director who is first elected or appointed to the Board following the Effective Date, on the date of such Eligible Director’s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be granted a stock option to purchase Common Stock in an amount to be determined by the Board or the Compensation Committee of the Board (the “Initial Grant”). The shares subject to each Initial Grant will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through each such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

2.        Annual Grant: On the date of each annual stockholder meeting of the Company held after the Effective Date, each Eligible Director who continues to serve as a non-employee member of the Board following such stockholder meeting will be granted a stock option to purchase Common Stock in an amount to be determined by the Board or the Compensation Committee of the Board (the “Annual Grant”). The shares subject to the Annual Grant will vest in equal monthly installments over the 12 months following the date of grant, provided that the Annual Grant will in any case be fully vested on the date of Company’s next annual stockholder meeting, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

 

2.

EX-10.14 9 d582934dex1014.htm EX-10.14 EX-10.14

Exhibit 10.14

EXECUTION VERSION

FIRST AMENDMENT TO

COLLABORATION AND LICENSE AGREEMENT

THIS FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT (“Amendment”) is made and entered into effective as of September 28, 2018 (the “Amendment Date”), by and between EQUILLIUM, INC., a corporation organized under the laws of the State of Delaware, USA, with its principal office at 2223 Avenida de la Playa, Suite 108, La Jolla, California 92037, USA (“Equillium”), and BIOCON LIMITED, a company incorporated and existing under the laws of India and having its registered office at 20th KM, Hosur Road, Electronics City P.O. Bangalore 560 100, India (“Biocon”).

RECITALS

WHEREAS, Equillium and Biocon SA entered into that certain Collaboration and License Agreement dated May 22, 2017 (the “Agreement”);

WHEREAS, Biocon SA assigned the Agreement to its Affiliate Biocon Limited effective March 31, 2018, vide Notice of Assignment dated April 16, 2018;

WHEREAS, Equillium desires to expand the Limited Field, and, in recognition of Equillium’s progress to date in developing Product and in securing funding for such development, Biocon is willing to expand the Limited Field, to include asthma; and

WHEREAS, the parties now wish to amend the Agreement as expressly set forth herein.

AGREEMENT

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Equillium and Biocon hereby agree as follows:

1.        Defined Terms. Capitalized terms used but not otherwise defined in this Amendment shall have the meanings provided in the Agreement.

2.        Limited Field. Section 1.69 of the Agreement is hereby amended and restated to read in its entirety as follows:

1.69    “Limited Field” shall mean the diagnosis, treatment, prevention and palliation of: (a) Orphan Indications; and (b) all asthmatic conditions, including, without limitation, the symptoms thereof (which shall collectively be treated as a single Indication for purposes of this Agreement).”

3.        Exhibit B. The phrase “derived from CHO” is hereby deleted from Exhibit B to the Agreement in both locations where such phrase appears.

4.        Effectiveness of Agreement. Except as expressly amended by this Amendment, the Agreement shall remain in full force and effect in accordance with its terms.

5.        Counterparts. This Amendment may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. This Amendment may be executed by facsimile or PDF signatures, which signatures shall have the same force and effect as original signatures.

[Signature page follows.]

 

1.


IN WITNESS WHEREOF, the parties have duly executed this First Amendment to Collaboration and License Agreement as of the Amendment Date.

 

EQUILLIUM, INC.     BIOCON LIMITED

By:

 

/s/ Daniel M. Bradbury

   

1. By:

 

/s/ Arun Chandavarkar

Name:

 

Daniel M. Bradbury

   

Name:

 

Arun Chandavarkar

Title:

 

Chief Executive Officer

   

Title:

 

CEO & Jt. Managing Director

   

2. By:

 

/s/ Siddharth Mittal

   

Name:

 

Siddharth Mittal

   

Title:

 

President, Finance

 

2.

EX-23.1 10 d582934dex231.htm EX-23.1 EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Equillium, Inc.

We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.

/s/ KPMG LLP

San Diego, California

October 1, 2018

GRAPHIC 11 g582934ex4a.jpg GRAPHIC begin 644 g582934ex4a.jpg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end GRAPHIC 12 g582934ex4bb.jpg GRAPHIC begin 644 g582934ex4bb.jpg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g582934g00h84.jpg GRAPHIC begin 644 g582934g00h84.jpg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�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

'B*HAN< LW(.C/LB7:3E*>]/.D1[14>,(W S )8V(,9+] MAE(PE$-'JBMBO2E.E*=*5#3>'+KC333'*%9-RTR.MT-<-=%2\-@U\UZ,1&[( MKC\DT>1'C%A"&QC !A$E'/DHD(]@=QXP9AK&%]*9^OK\?+QK/6J]V:GW?#$S MVJ+Y7KQ&A/8'D%0Q>5&1CJWBF&$RD42@>5C/6U@EJ 4>$,@]D=P@)3XZ?2]* M5%"ZPOD_-_[^O.I+W7Z'L#?DY5(RD7NO3$!:URRH>"D)-00T 0%6 MYL(&S1B&)%3@9RRU"+PL^2:(U,>NZ3+J4FCQWB-J46[?:B.8,NQ!(WKF,1'" M$-Q(?+KQ7HEY]E'V@Z?V'M?M(N^S=Q#V)O>Y]%UTWFFM#+Z3 M\N4:(;[1<$;FPA#&?0X[(@[ H[>&AQF6AV&D]_-;990EMIM/?.<]D(2E..^< MY[8\Z:"46]U)-%;3%#LGD@[L3)&?\31F6,''B MV!D@@6%NK=II[=9HS/;)%)/'N&Z))@YB9Q_A#B-R,^ R< C/]*[882V0<79: MW)B3,#-ALR$5* N>E$.#?3YS3[*^V,Y2K'AG"L)6A6%(6E*TJ3B+JUN+*XFM M+N%[>YMY&BFAD&'CD7JK#S'LR".02*FWN(+N"*YMI5F@G0212HZ>ME)C]?.&A9$(=TM MR8C8IEHTI&6"6-UOO(K>YN(5O+0XD, M16&15[WO8XU5V'$,L^22$6N.[6]DKOM)J'9B\M=?U;18]%U7TK4K;3M0O;.+ M6--*=X]C<1VLT2.S74-L%ED!,=M)>*IW2+4F^NEKMZ=*4Z4ITI3I2G2E.E*\ M2P9[1RO_ +\UC]_/]?WNI!P^K"RKOGQSCV>SZOX,?\?L] M]9RV,X]OLSTXSU]AX\_'%FJ9QCQ]OL]F/?XX]N?Q_/GVX[9[]"/ 9.>><^MY MCPQC'OZ8-*C7R,Y7:AXQ5E^>V%+$$R60##HJFUUIF3MLV@-MQ2LA1F2!T#BY M=;P,J3D2 HMDA:6WBT+SVZV^D:)J&M3=U9Q$*"!)<2DK;QYSPSD'+ >L40,Q M4#C)K8V6F75^V(5_EJ0'F;*PQ@XY>3&%^\!SXEGZ7V&M[31KI]0ACN+^YAG6-\ANY79(83!N VS H"Q*L00 .,BNDATRULK* M=+J.&:XN%93<(QD]%YS#W0Y&Z4A'57+R!L--N. \ M99V1T/\ BD4[0K,-^X 9QMV.C \=0W"7E"QRIT;4]BR3$+!V^5Q.HF*Q'R@1 M9(R82:?BTR*@&S3#HT!)#*3!<',-DI0IQ">O%^T6BMHNIW%HO>26\; M)W<[Q.%L"/!L\<>58,;%6RIPPVD,."#[". M0?+'4CKXUSXHKP8=PX2ZAA0I25D)TO9\7'V@Z.GU!$.1&(G%'9FR9&) MC0PP5V -Z$AH\9QT=X9AAM;6765>K]E^VQ>1K?M)>RR1(L0LG:)6B5E#!_2# M&%D=F*Q$.[D;@6/(+#J],UE@SI>7$:+*L8W-$. A785NG*LDXD =?1XUSA""Y&5]8G=CG)Z>UEL' MB=\M>R ;UC12%5B'),C'9NVAXQWK.Q)7:(S& 1A'85@G<(-\Y+4!&DE8D@@( M!9*,@I<;>%4[YP@(8,TX\4$^=ZT3('-L(<6WE'G+?<3L[:.+. IEDX1IY=N6 MP<\Y)*CG;@*I/3PJ'GFEBD[R5EC4N_HX8E3WC[CM0A492V&9?6"J%W#U5QA8 M^;#G)1QWSPHTIIM@'.6AY,*0D5,M@@LOY0_W7(EGX;<=?;]&:[E7I%Y6VRAE MY&P"NJ<_=RQ&65AALD\ 851G:N3G QCGG$^ZI8.&;._^8N"=QZ >.>F.G]., M9KWUVQ^*.8KU-17_ #<#!JD"'4J!8<'>$5O&R#SN"DO\ MGNY=8(?>4W8]&#J9)1+U(5?58!L@%C][=ST7[OAC S5\2%2%BPG];*HW' X1 M2 2"!UQECUSY3RXF[!DHB"J,O#&%@$U^SOER0;1#N4+">ESUL(0\]AS^QR\1 M'3*?6W&RG1U$G%$%H=RP@KDNT-HKO<1N@830[4) ZJ &4*"#E79& RO08&!6 MVTU!?VEQIPE2,\R)(ZA@6^]N+;@5PR \<"4U?REP\6:4HB'AI>$%GZX]596:&+CR9>&4"X#&$J3*A><^ MDH\\ EF>"6-+B9"RN\$>?1BKNHVLR2.D@F6/UE4AMQQMK47$[LMM&DL,=U U MS.C/ERZLD<9):,@!Y.ZWD96 M&Z2.W>!G:-77;)-:+WH1RL3/NC)0!E)QG;DZ_P!'8+'-$ZR%0S3+'F1,AMC[ M&*KWAQAV #(%=>N#4--<749%8DHRAP<=Y\M8 5O2P277)BM05?4<"S$A2*6T M2L6Q/.'LR$_@MXIV2E4 +-,1EMILWIW@!=&DD,A1' B/,;O)M9I95)"NT87$ M:X]4;N#D%<&4=ZR]YZL,#-&J !=V[Q"XR*^3U+:ZC0,\9X5$GQ@&&0L/5'*9R,8 .T]"AU>!K7_ ,3V=TFR> MWD:*5?\ ,G&X=5X7^\AP>N.F&?'MG';&<=OG[9]GTY_#U8^O;]?WK'JOC[L8\,9_'[^WOSC'L\,?1\ M_9]?7[?OBE<\?_- T^5$5SAZ$@HP88NR[LD\>@[.LHEX./U@_#EK =8<$,+8 M664U&I*7YK9!79(A?I%(;];^RB-'D[0[E5CW.FI@\%D=KS>NX$,$.U3(%QG" M@LM;K2%!,K8.Y"A5QP4X?@<@>N0HR3U\">FD77.UB0)"/ 5AV-":8)*B"IL( M8.'L3,2\0HI N4.!%O!B.^F:CR2XYXHEEIL/*F0V'$H])O;#$+JN74, >KL]1",\+EFBD)4*C_<=@JC;@QC:IS(HV'<<9&# M@SJ7LRN6*L1<,+E0 F3M;>V:@;@J&F"'3[1 M&XE),P89#"GI,VI3L'Z0YY:Y8 Z-2>R?#E"Y)BR2%-HCP5%#HE"VE9R0;U[H MT:B.(E5 9B BRB0;0"-I*X;?@G&&8#*\$UR;-(S^K+W;^##UE8'/#@\JV3[> MIZG)KY++*Q4!9O3C5R6BWVPVYZ)$,3'V5D9@Y'HF\YDPG&G#&9!>/4V"E99. M,C?S"W.ZEO*JB"2VZCO2PR59D#IRI.24.[:5SEAZPR#QC:!?C$RC<_=%B "6 M"@R)N''K8(7"X_SS=HG50H>= MAW4 P<+WC2LH*XVL&+<8-9;[H[62[.W=&7=\D'!4*<,2"2&)7:RXRY"$D-QV M0^4$O]8UOH2AUSXBU>Z%V2TTN$IE>LN2O@&*/K_I9N)E"@XTZ-DGQ0YEBP9'68%&4.ZLNYN\9SD; MO5R"#@UA]B]+FU/5Y]EU3(5%9@I( & MG'4\JS]W7^-#441"(!KUDQ,LPT9@YC#[RK)>) "NA". MN/%RP!@@HBR<#X?7W5Y$T&FQV%M(99[E+;3[9_NR[I(>[:1MG'\BU$DKD!51 M]S$Y.*]FU<'2.RYM('F>ZOXK?LY9/-$L32*P:)[WNAOV?^&&8R@Y80*^P%QL MG;/;ADM-:9LO*G9LL>YM[;0_K]:&3C+WQ/JI\A"LUVJP$8IM]UNOP\)* 62= M%8&P[(32W1B"_3G9RK01:5TP&EFD1H8 MBS82,Y7A2,NG5" M<[&&W=NBF78T8&6!C)P)$I(D>D):R2[T>"ZZ !.IEG2SJ?-%(RYZ.:=CCAV59#=)Y[M/>Q:?IFIW< M\46#$+=;1T7!N9(5CBPWWGC,8"SQKA6V$J!R!F&%(;.YO+VVD6.* + JA"CS M2(.ZA:1O7P2R=_'AP1&[(1MR.YN$2TW#Q3;&598;C@VV;C'G97W5G/?*LYSWZ^:B(0KI2K#\F!1*Q6.+-6LD3!U$&P7.0LSMAG:UAEZ3L8,)=;8)52+O)"- MM14I?&(M#3@=ULA5PGX=ZSLV:S2-@:BB=9PL\+& JB8J7'04!(SA MBE; ^E*=*4Z4KGSYS9U4]R$V_F=X17&\3M=K]#GW]F15KN4'#6Q*92J,/D2$ M9"!MQ349) &/TM4T$0?-+D1/O\ C]#QK8%Y-,ZIR7'PTNH: M&D-"1RKW/-NPTC*S4\JT/H%C%9LHTU8Q1)HT9"7,06$$-NC"OP[[(CZL8=98 M5-:W>=>Q%<0N;C6U=/:G0=L.RTL>R3=UF9"US$<\GM1/+=RR7,J.]P9('180>Z M4B.)0,9Y?.,@5^G?_3SV8'VU_8%)V/[;]LVM^S.E:]+I5AH%C:Z-975O;Z2M MIJ]M<3:BZ&_F#7E]+(V[8#%#W>\KN(VR<&>1MQY/Z2QL6\T\>F3PEGDZPZ") MD[ \BW% Q3_PPVU(#L.L>N/'/)RPWZ5AK+7FMNJ\<)]#[*:W!D#& :^-?^H+[+]#^R7M\>S'9_6Y==TZ;2;35D MN)A;][;->7%Y'Z$SVTLB2]PENA$C;)&WY9!P3%+EG<:'QWV[:3H&J6NS6S>V MNYD#8K[)]U/;^#CW6XR&BPW K/& Q;A@T::, J/&P= !AJ4-Z5J3PVS]+]B; M+4>U&A6<=S=V=I9]G-4@ETI3'81DRQ*9IY7$MG/)-L>9&D[Q^ZNI) 'VM#EO MC+M9=66@:O=/;V]QT]_J.I:Y?W&JB+T])FM;@PI"@9K4F!2Q@2..5PB*AF"+WBJ MIP!@#T/0+.RL=)LXM.,GH;Q+M UIH),877WQ]M'FT^UWB!##=LU L3PLB[&5]V.G%@R M#@D=,XC8_ ;>"R3.O&-0U'M?+JFL6]JAL[;3HV%CW*6K+J4CV]Q>VZJUW973 M&5H('CG$3JD,D5AL4DE8R&D8:\W'8:!=W]_I%E>:E E MM=W,0E:%-PV1N282X< B1XMKNN %9BH5<8'H78[5-7UKLUI&K:YIR:3J6H6J MW4VGJ[R&V24LUNLIDCA83O;]W)-'W:=W([1X&W%9GZW%=-3I2M>N[O*7\?=# M;F/T1:*UO"R7V.F];54A.O=3S5Q@\W#& MQ0SHUUR?,AHM;5(XG6ROUZT1,Y<4P5D.XVQHI\A4B(Y !G M*8VS1NN&9ALPMIZ-S&GU&>%NWIF_]3;H><9]=QGOA4D$?C^%6@9Y7'C '2:O ML#XI\BBJ]=:/<-Q5-8>CK2^;/\>:'$UN>M'(Z."\Y+KNG8V&M]=/S*9\VT/I MDFAAZFXW+^59XJ1L-OBQ!.["GX+CS;X&D7>7B:L"/&FS=@') M*&5!G6"?@Q6XIID1QQ$Q9G:U'333@1%6(GQI*->+4QT]M3)H6U*3O/36N]SZ MWDW)O7^UJ?5-A4J7=$( =D:Q;H@6>G(\OK]?;5M^GQK^RL^&,G&[K MTZ]1@?MCQX\,U; R0/$X ^)Q4,-[>B M W7$0LK,Y>:#"D#3DM1C(:7'7_6W4LNH:5G&<]!IG9G4M3421JDNQ;#:=P[(V-.RI$RWL\F4F(UX0YIW,.[(2)DJ-6XEI;C(X3(;1Z6 M7O2L@CORB%D/MM*'6-GL]-%SV,[<6NFW4\K]G.V5K%%I\ET\LD.F]J=(LUAD MLX^\9^Z@UO3+<7-O$C$-=V4RPJ!,<_5$>F:5VZ^P9)=&TRUL^VOV,W4CZ[!9 M6L-M+VC^S_7=0:2/M!=I!LDN[OLUV@N#:WMS('D_ANK64MP["V!6P#4DMM1N M1JV4S8;*%E\2$ 5*.RJQK+5@K;$2*5%!!.F>DD(LY$BP*Z^&,>*<,A3P\?G# M7K22((WW3((8&8&60Q!-RR21]UZK,<%6]48W$8.%+"OG1]_>%'Y1BD@)8@#) M)92" -W5>, $'GRR3 <;LZUJC=LM[PDW5X!R7LT@R&A+R/!;QF&><)"CMS'&H#M++,Y*; M8EP5C"AC_,W*,C%7E;;OWHWK1OM8'GO/6$:G ? 0X8=?GR51$3%0;2D&Y91\8YQ_;C39K_3(4M',Z:0C33S,1_-5(<2RR2D ;OO.BJQ=R[G8R,I M&%J$%Q=6JI&%?T5999,>2J6DW?=VE5!/3?3(\/HCXU!OE-S.U3Q MHS"UV?LM?:V%:W1DU^N2[\NPA(9C4SE$](N1$/,%-P[)4,^$XZT-G'K:V&'G M0VW/6$=/H79J_P!:$LL4,IM;=2TLT:H21C>5D##DX4%@I(VG9V&G MW%ZRB.)FCWJC,"@8YY98]S*&EV!BJC=SC/)KD5W!MRS2FW9R\;"IVL2;).VV M1-;?C(85-/D',G./_" LQ!2ZHB0$+0-APAU0S9S[@)A1S9;DDHQ?T!IMA!'I M\5K:76H+ D"+B21^_0@#U&25-Z,IQM*^I@A4 KTB%8[""W5;6.5,NL4Q'\ MS8O"EIB2-^W.Y#$I3;CIMJ'-YF&I!!;43%5J&>+3E M0"!6+ M-I_P]3@BL:@Q=6%2^T8888J)>9;F7WUHB MBO7BCA1Q7% +0]+>HI8'9*CO@]81F$CNX/2OLX^_D9F4\ N"%"X92,<^M]W M/7VUB/&%WG@_>]0@CC(4Y9E*@;0"#CJP!.+\A*2!89)^4<>4D0]P>- MCB66 E,@J%9!):E>2\ZZGS7,J<89QY+GNEV 8(&Y ME];+'.T!%()V[VY8X]PS2."25R?-\J1C*;%+MK"6"HXUW&%)0ZR(TW*C^LE."IP]A@8##B/A%:= M'JY1CAP-W=LT4Q4[\DE77KD9)3A00!@MRH%;/18V,S$ABL;J6B5BH!:-PC,5 MXUNYFDW*557EL\QK]TX M20;B-Q*AB, ==CHD20:_N)V(]M>F(K%E1(3\S%#($9,.;(E!"]8WJ#.9DHQC)"WL1I$26(B1RAU+X;[[ 17HD% MQ(O=/ ME<&X@VHDY!"ID&.[AE0*^Q2H(='*%]RD!B"=A-;#7M+A6^CO+54BM MKRVG!2$+$5N[4%Y6&Z-TS+$1Q@.<87/"UJ)M=(LU$N\GK,L_%0U?:K2Q:):R M*AW2[&3%-XF28*'%6IATD5H!>?@S(0X!$,6^P[/$FECHCVF.FUCM;H/9_11K MNLWL-MW >")'1YECPEG86438EU'4KR=UL]/L8QS-?7LT5M"N"SEF56N".LK MTTZF)!%9BZ,U(CON90]F(8F2HT8<-@^2.(R_*GJ(':8\YF-1ZBQAY20L"+Q@ ME7 1:1VM^T1TO==.H=C.R3,&M]!MI3#VHU^)7[V-]9O+S M LMY=*%05[6VM_9M]AO>V79-]#^U+[565HKWMM>6GIGV>]AGDC[J:W[(Z3=K M)!VKUFW9FV]I-2A_A<#I&VGZ=,S3-73)Y![8^>AEXHI;69-6/2K\Y2E8GVEZ?!:ZCI\T1;= M<6027>2TC/;%8UDD))RS*0&.!N(R^?GQX]O?WS[O9X]O?]/NSX]^O.*YFGA^+W8[>[W^S MWYQGMC';V_/CI2N=_P#YH$+CPH?A\5*K);CF9+?ZS5A,))D_4V8_4KQ#$6RM M]MK![[;.4-E&-/1\\R8&2J?>* MJ06("@\Y&ZTF0HEP%5"3L.6&67:) 2AZKP^UCTQC@G%-'<5H[K3'CF$L3NC/$8P#(S0A2[R=X\/*=X'8[=Q'JA8\X5@ M>@%[-#'*8Y)68YC5B[+"' $BDQ$G+ <;^IW-D .JUYVQ-Q5MF>FAK#&$B4BT M8=BQ8V&<]?.@X^: @!ILIUG*TD%K4T!'.N26"CI=P2/(':6LA0(2\2&S9C!: MQWD!U>W07PB>2-99XH)W0R=SG?W"O+W1.P0B1QR.AV.G375G:S:E?6%SJ&DW ML4FD7EP8)5BBN9DFF@@%UL]'74(Q'Z5%$95E:",D(8PS5&2"@INO"/2,;/QY M,2%(O1T84Y)N'1F!7"'<1;\NV8UDD,2U^JML1DZ*,.N.G8MB"GXXF0PLB.Z= MY@VU6B?+*&DCV@,A&W<%<9#M&#EHQP8SWBDK7+%5F=8]IC=V]1F8#( (R2V% MSY$L",YXQD>9!2!GQFFH&WNP56)4XVF,&P.6YZF\0,P7^6O20(<,?O$9 QG')\NN1N;\D7IJ2MO,B!DU!X$3J2OS%IL$N(&AP M-T65C%Q45$#2(R/1>AG6K+'R#;;CZL$!CE)=8;)#RTCSW[1-3A@[.O'A7-], MD,*,=KJR.KR2%,@FIN>50*DY#D;F-D)#(\;%:UJ$;4X TA:5K?] M<2*9Y[_927AV?0Y6RAS+/&]C.[32ED49>2ZG>=1D[D0JJAR1@ CU>/#.2#@' MV3[)K&)^STLXA"RW-UZXB>I]QN%6.>@R7PF4W,('"2Z:F6R;ZWA^L4N18DKV=7VFQ2)XA $EDSU M" 'CIS"UW4ECNIC:S&*Y@@G19%#L;8L&$X3:5 FN%:.U64ES&-R;0\K-'RGV MD=H6GUJ.VM9^[&D1O;ILP6CG9=MS.P4;1,^4@4J2(UC]7E\UKUYN\F8;(E[#/P\J/*L)&*?-C)5B&'>0AD@; $<5Z0 M4AUM/3]BETN""]T^._LSK]$;03PREPN"6? M#;QMK2W'8_M)I&@:5K^I:)K%CHG:%;B;2];N+&X33=1:VF>UGCMKMHC!.UO- M')%.BL) 5=L;2KUKEO$S 5@Q<@$[+@,2;GP5-ZPM,>J-DH=@T>3+-KDZ0P^< M/+PLN5AIJ&D$A/DP4BZB1=]*T([A'HT"R2(.$8(,K<0[65R"JK+%T$;*O+*2 M5DCX#8-:VWBFFVQ/M 37W:_P>UMRIPFOV09 MT&<*$Q$C%E+1-^=(C+S&);2@=!,FBJRY,D1@,SX)-F(@IY \K!^NG'KHO"O\ M/G>5N[>%6)/!!$;9D7#9V=^B!2^6"/ZS+(5"G+GLW%K))(9$D6,M(5CV+'M[ MQ []YQB2+8P93ZKL(P6( :]]4T&W3<#'5"R M T =)GJCC5EP+D>+"&,GFN"%CI&D&26Q"C'SFL+4+ZW@A6[GFAT^W:W4EKV5 MDD'>+OECB 91&="VYE*^M@RB M,NWKH #NVCK+X+<)ZQQ>A;+;3\%S.V]G$IE+I89=02R@F',H+S7HD:/99CHV M/03QFI:K<7R16QV+! <[8AM6278(S*_0$[$"H#]Q 1DDLQVC@?[! M$_\ !F?_ $:>N0/4^\UK1P /97&]RA^Z8Y$?JZ;;_C_8.HJ:Z6N!'YQMZ_7I M>4C_ )1+E+TJ3U^ _(5-+I45!CRD$E-@\0ME"PE?L,_FPR%%JTK\6KMKRAG0 M\'8;U78V2F"I7:-AJ]/EHEIIY($M3#YD-5Y!D'JEA\1F8?.%4_O[?"O(\F$= M%R7"[5\A!RHLQ!G2^RRX8H"T4>TQK463LVW/A Q2]:RM@HM+9#K&+#,/1CQ[RGU]>^LQ;!V;3[K RD'!F23RQ<2Y+QLA&/M'QLS$).B9 7.7@S'D)5G"E2%*FN$&/'B# BI<2,(RV.PEU]\ES#32<)1AP@IQXAY?;&/ M.=?=<=7G\TM:E9SGI2M17,KDD0U!;/TJSRYX\T2\JE8R*"BG-;;?"@_292*WQ':CM!I(LM0TJ/6+>SU7 M^7$A=[B,VT_>1.LCRPP2L@C!#DQAG !VC(KZC^P?[(/M!?M-V0^T&[^SC5^T MO8%6O+^Z6WM]'O4UK2_0M0MIK.VL=2U.RANWNW#VD<=RT5OWK+WY$1),L>#F MJ=]:AU(;7]^[0A=K3LG8W[!7K!$SENM#C-?DHZ/]",58;@+%'%-K=:40($/" MA, (=<5DHY96<"[/LK8:KIVF&'5[Y=0N7N'F2X2XN+E>XD2+NU$ES%%(,$,V MW;M&[(.2<<5]OW:_L'VU[=C5/L\[+7'8_1;;2;73+K2+G2=(T64:K:7-[Z7. M;/1;V_L_662&/O3/WSF(AT"JA,"^6G'/;$7MPN]!W^C4/7=DF$5ZF0TE==XJ M$'F[!$R\>)-R3L15)"*&M3LJ0;+ 1\=)E*%>;CAF0BP!W%.?1_8J;L;/H@T^ M30-0U/5;=6U#4;E(-'[V1+>X@GD@A])U2*X:P$21P2F2)(G1IBQCDDVCX[[5 M1]IX-5-ZNLV=AI\S"RL8&DU3ND,T,L22R]QITD O-[/-'LD>5'$04.B;CLTX MKZOM>IM0P=9OC\1(W1*WG9V=A9VVSH\]C"O1Q,V\A4=_'$+6XN83;]Z& M: I)@1L$"X0,W?:##J=OI5K!J\T-S>Q*4>XA>=Q-&"3$\AN(8)A,(RJ2ATR7 M4N3EB!KWV%):XXU\I)^>VSSEVO +L$@!/UVFF-YL:ZO#V&J6]-CDBH<_5MJH M:1#;+B(CZJNM0<>1#1CTI&O^=W?>3XGT_;VZ$>IRVU MYIW9^_GU>YMM%MKC3=32]NHK=(I;4IY@VC)9-GFE+57KU0H MZYU'9T[MNL6%\LJ%MT]&0$2\\P*\J.?%$%K]+HK/J@YH9.,.%P[A:GU/8];< M8PRVUZ'I^H6>J6D5]83"XM9MW=3!)$#[&*-A941QAU93E1R#7MNC:UIG:'3; M;5]&NTOM-O [6UW&DJ1S+'(T3L@FCC? D1UR4 )4XS66NLRMI3I2HKV_A?QY MO6T3-RV6FFG;!D+]I?9I4PW:+,(RY<>/L5;X;5-?"]Y) MGA4_5*Y27*EM+XM5&$LE*K<>GD/OI'P1JFWQ\'$V31P9"=BX(9T7+1=:@H\K M4:7<4;(T:.A,,G/GJ6ID_0'UGV]:^Z^>2GX5;+L%PM=PH%RD;+I\TOB;HJ.L1 MMYL#+(>R-A5TE<>[01C$!'CP-?,]"]@RTEQKZ#9-+:%,QL64RRES,@6M(?I/ M8[LLEU&VM7\D2V\2NUI;3+O](*Y!EE7(VQ(^=ISEV1C@*N3U.BZ3LMQJUU&W M=L9%LU*JT;/" TDL@+ E8LC8@')]9R0 CZA;/7)+7-?B;!R$B;VO6UR2*Z/< MH(R#L=I7:RV)",!'-I[Y9TFY8 VO75V);:(S$1.@96.>49YX)?HL$L5R[1Z/ M):B^MR1Z/()8K?N499!(DX4+W;L5V9W&2)R&10 1N[_4_3YC<97='"(5A*&* M-4'_ *]JQ*A*C M-EB 6[,CL'!#U[$OE/GR @BCS@C7H>,%!DW2Q,GZ+MWI-_V@T%[8RP173]SJ M.C744317.D=HK$>EZ=*CJ9&*072)&[,!WEK+.&(5B%[;[)>WQ[ ]M=+UNZ@; M4]"O%ET#M;HV#*NL]D=;3^'=H-+:,L$F:6QFDFM0<;+Z"UFZQ UL/U!1M:-T M77!^\K%(P*P*G7HZUCD10:[E<2@:^Q#1842J$-6B)HXC,4T/(&M2\:[8'4ME M/0/PJ(X:#I+?4->NK"U:>QCM]6GAAEO;9+A)K/3[P@M?1K+&98[B3OWX)6HUKLQ8P]JM=M.R,R=H]%M=2O8NSUY=QRZ-_#[N]@O8;>9= M6GM.Z9K.:!#')O[T#^6K?1RAC]/G('1IZ3F *W?(LYZ)N=9"6R]'S\=%/N6* MN/NS4D,+E)CP3ZF<&6C9Z$^H*_\ YZ1O+:R#O(9R6#QN MRK%,HA1CZISL M-GMPMY);1JR@3"-!* &.6 !;.%];.0?(@^-V)ZTAQ(+:%IP*^+DMA3WT-800:=8 MV=E;SP(L,4$',>DR\.N M2??)R$6PTM),2V_A/HU8+] G+JM]!()0"C1R#U6H*JX[K>K=TY7#$,R9+<$ _P O!'/*GUL7AQ)52;<9E(8&0(/',#CY MV/2,6$.HUI2\&DAX?$GD>I"^N*&_M%#"B$-NNE-.C^=C)9Q(00[+M.YD8$9V MX]48RN">I)(*@@YJA[=E!3*$LRX*_>=2/NX;^8H)Z'''O&*\@"'8R6<;-K)) M08V>6;)/E81,3!C?I'V2'5+:?2@=IICX0SZJM9#V64-Y.%5A2$^:ZQ]I"27T MW9[L+IS=LNTV':V!%CR@:.^O5DC>/;J]^+ M+1X4E26W+VDHEAMAY,5%MB2A*LH#: M;;26Z. *E:&4)SAQ(S[E[0NR6NQ:FG:3MEVCN=9U\6\\45EI@N+#LEHMO.=S MP66G;D:]D.%5K[4VN;J4JKI' 0,:_ME]I'96YT27L9]FG8JV[-=DGN[:>[UK M6%MM7^T#M)<6H;N[O5M?:-[?2H"6>2/1] 6TLX>]=)7NDV+7 M))F%'.CR(VV+F!XP54C(11SZB7"25*+<$<='6(4"MT0Y#8BW,Y<<(IU1 M[F75+.=5D$3--:!!(>Z4H=N[&/5W,6L&LI>$A"1LN/PR;Q691N3@,N&Y\ MW+25CQ\@+A]]MD1O.7!Y-X9EXU6&I7L=NT8(RZ7RJRLAW&.12LB$+D>(;[I! M RN& %;KM'=A-/C@0OWD=\CR,NYT2*:,PL@D3##?(BB1E7 /!.;EX 81*'5$'!#%B MX(( 4[AR]INAZ'/VBTW5]0L/3=7TO3+JPTY[@R3I;+'>;HKBUM7+VT=[(HFW MWL48G,7=Q&8(F%#M?VSTW[/+SLYI>O-IO935]9@DUZSL8K:RO=9NA926L4>H MW\*1:A?:7%;V:,NE2W,VG)<-)=-;B:4R&.\9 R=2&$NJHHQ49D-!$1+V)]R- MB9@D>+&<-+BS76FWWH9EMY2$_!8(K*,K\[UMQ\<7&/0BPN&D@:9-X(S'%ZQB M7HC-N;=R@8@&4 *I8[%7_+SC'7?Y M'B@UNH\/JY)>+>?S@HLV3*#A&%(+6HAI@:$&$6+EQ2DE( M)5(I=>];RZKY^[>7<*QG&%8[^'U^'S^SW> MSYO;CY^N,'/CS[./S\LX_/FM!TZCY_7Y5_3V=\8^;PQ].?'W^WV9]_OSW\,= M55%>>!CQ/&>#C.1NM*D6-;@EE]#Z)O M+.,LJ02G#*6(J+?PA ;BUN>W@AG)W>HBG:O@7&"3G #%1@ #)R6')K;@+M4; M22[!V.I]P&,\5<90:]4V4PS[3Y22(^3 L*< MK$7DPDS&!Y6'/AWEC"-H=]<)<4AE+(JBO,NWV@:C=>A]J^RJ1KVM[*>E3V.6 M"#6=.=HSJ?9R\VJ$>&_MQWEHTC;K;4%@FCV!I&KVS[(>V^C:?)JWV:]O99G^ MS7[1(K>'4[E5[R7LIVAMSLT#MKIXU:8>-II3=?@W(JLHJL=92&QX]F8BLRXTC$DW%0.%A+'3AAF*G++E(YC#$?4 M9PAMP:NR8\MN^S.LZ?VBT>T[4:0\]Q:W[-<7%I-Q=64\:-#?63QDDPWEA.LD M<=N^Q&N?9WVMU;LGV@11>:;=@I<0LTEE?VLT2S6&K:;<8 M"SZ7JEE);WMG,,AX)@"HD5T%M,G^L9B8B]J"@+U'L% SY,Z%*Q0DLHM#R:[7AW@&#EB');)&>D)8F6;PVO'JV 8\!<;WCW6''? M!OM,U6*\UB*PA,9338V20KLSZ1*59UR,@[8Q%Q_A9G!]937.ZS<2.\5M(Q+6 MX^U*"TW.H874_=Q0LJL< ML(LF4A!DJ&SZN[&<^5?(*B<4J;4Q'QY$$KX?^ J[686,C2IA^.9@'JM9;*H0 MUX)2&8&K99K,'\'D>A?/(RT/%*;CPV$X/9[1KK7KJ9\JZK#WDDKNXCWM-WT$ M.X!AZ\W\Z7< 0F 64N37C<"O?7$ES<3;V;O)&DE]823%WE7<EZSV"T/M"TS]@/M=[:_9ZMUIMKL=E-2/_ -U.QO:.V37> MR6L1D,95O-'NV,<-P7#;;^Q>SOH\[H;E5.*^/7R MU\Z?VD[/2P7/HW:VV:+2K^P$<$DT<&OZ(S107#S.BV\-WHSD/,X,UK&)6=>] MUR+[%-S]\TEQ&DTO8[M#AKFTBM^]- MQ-H_:)5S'_*L=0N'1(Y.PSBEY,7CGQ@^#[#%Q"[CL1F#&ARKI81&E.84,AMI MTV'B%I?$B22%8+7DK"B#$)D#&1BF1'TCX\^UKMEK6M%DDG[FV[PNEO"648;. M%>3.9%48X("DCUE+8-?+VK=J;[4HO0T$=I9*=WHHR(U-2X^IC29I,E*/#N$E2$I(F+](2;*21KQ!L@4ZK\ MSZ8E]S+;24,,^C92E&-+J.KZEJCJ^H73W.T!8PPP$51ZJJJ@ !<= #U/-:> M^U&[U%XVN9=W=H$5 JI&B+P J* BY\3C)/4D\UG?&,8QC';PQCMUKNGQ^O[X M]_6L'K\OK]OETJ_P?]AB_P#@[/\ Z-/5D]3[S5Y>@]PKC=Y0_=,$!*3::97YG:NK=OUB5OLT=$AKI-::JC,S,3X8B8 MJ'NJY6NVG4]SBI1=ODVI_2=WUQL77Q+\C M.MFIM::BHITG'F/O@6$:)H<0Y%3P\C%'NR1X9$B4H>OT/WJ];SINCT M>HM$ AES1DIR6TUL7X1MA7QFE(VV6'>FO!9*2B965:?D05YCGE0P?F%*7'P# M8U?"<8A0Q &%14L>E*=*4Z4ITI3I2M1?-K@9I.4#VUR7E4I2L)Z'LGK4FN:7Z5)9>@F&=K58>\>3*11Q%7W/'&W._!X/3.>:\ M?_Z@OLQLOLI[>#0;'M+_ -TIJ&E0:]/J/HMO9[;G4+R^6:W$-M=WD85# )%/ M>@XDQL )RGO3CIKOD3&P$1L;-C=C:W(ORT<)!SI$,TJ0>9P/@HM+#:\$O,, M^D;%6OLH9+Y'HLI],YW]*[.=J=4[+2W,^E"U$MW&L,KW-NL[=TK%MB%B-BLV M"X'#;5S]T5\X:YV>T_M#'!%J!N3';NTD:03&)2[ +N<;6#$+D*3RH9L8W&LU M1H*(R. C6GRB6X\,4)L@Y]11KZ!64,(>,*7^;)*<2WA;[Z_S;SN5.*_-*SUS M\TAFEEF*HAED>0K&H2-2[%BL:#A$!.%4<*H '2MS%&(HHX@SN(XTC#2,7D8( MH4,[GEG.,LQY8Y/C45.0W"717)^RP-KVO&SQ\M6X9R!BUQ$PF):1'N&NGJ;( M]$$X\7G!+SBVTD/N-,>>[AAIOU@G+W(:_P!C='[27,-UJ7I1E@A$$?H\XA78 M'>3UL1EF]:0\,Q4<;5!+$\!VR^R[LCV\O;._[1V<]S<6%L]I;M#<&W"PO*9B MK[$W28D)*AV94W/L4=Y)ND=1J57-<4ZLT.H1[<56*C"@0,( WG*O5X^.'0.Q MAQS/YIXAS",NDD+[N$$..ONYRXXK.>ALK.WT^TMK&U3N[>UA2"%.I"( 6/^ M)F^\['EF)8\FNTTK3++1=-L=)TV!;:PTZUAL[2!>D<$""- 3U9B!EW.6=RSL M2Q)JZNLJL^G2E.E*=*4Z4ITI5K7,UB-KTA(E.):% :<-)=7GLAL<5IQ]YQ6> MV>R4-MJ5G/;.<8QX8[]2J[V51SN8#'GD]![?+VXH!N9%'5F"CC/+9 X\1SSC M^U<,VY)R+WA9)O?%8A;/?J_MW.+);:Q24OW2TTRV6&8*,2&,$(<984A^D;B9 M.HL.!1PWNH$0!@S,HC9 MBSN)\.7B(61,C>I[^>WN(+."$+NBM-\<4D17:RLJN2P3(PQ&X$\ESDYPRC(> MG^*][V1-V*=VM>RZ;K6BQ-LI0438ES,HY;1 &"I7X2UQ,/#R3'K-9N@GGRY, ML,0?7/@R1@ISU=Y@R(ZLZCV@L[-(DTZT26\GDBN'>/NX_1V;=&4NHPT999[8 MGNUC9>]+K+&!D/6HN)0L:L<.[' .2$P,!E!RJG.%XR1@IUS4KM>27ZP6"PIT>NUZ)P(&8/&FC88'DHAAK(OI'"([,11 GHEI( M86*C=(#EH8" J!SCO97!==Z$OM8^MG!]'MBRQ16MD?1B(P%8QH7A9R0MR V M\O>2X/HS2KL2,W$LC(\8JR;I 0U8H4/5 &XT2]6K";Q!04\W&- 'R+EEJ$]7 M&0AY2)*ATE*>C8PT*&D'QXVRQI+L)ZHO#S#J^4+)"@B+[!&P4Q[V.UER3WI5F8L.&.Y]PR0<^LO*6 M6T;%A3R>5SM9_DH.7D)*VLJ+&I#.Q@J>N M%C5Y$@(&,AXTB1!%DW(]N+-;L=E)GEN-C$E.O.FR[HYBLY],WY'VHMH$[=:* MT=NCF=[+OP[9[Z8O@,R!]ZF.(Q@9('JKQP16JN4A&NV1@5VS/$6;.\NZ2\-& MI4P0YC5]( MX&T;55KQ*$#+9I:\3KB[5E$?#22,O*5>GLZ7]R]N]A!/:QAB;G* P8=E2)D;.20I)! M";0P7C%;;OY))IN\C:174JTTC+*@=H@)0(V*[W ]7U2V" 36*;1MN>L[ST?L M&.-M*7\N-L"R!,N]- Q221R6&7W)D1)N?3X=?4C#:G,E!M.(>;0M>4O<_P!H MNUO9KL;W$$DTTVLWJ_\ W-[.Z+;C4-;U68AAMM--MFW]UE3NNIQ!9PE2'N%( MQ7IO8'[)NU_V@1W%WI45II79;3"6U[MKVBN5T3LAH,>$5FU#6;I5M_2 'C,> MG6@N]0E+(T5JP]88>R1K<:=-.FZC( !,MN) K8)+6>QS",I:(,D"L%D1K#3[ M"RBT?!['9YE;+2QE86EGF?\ M[MWV\C5NUM^_9/LW*5=>RNAW3G5]0A9C_*[ M1ZW:[5"2(2DFG:.Z1 $=]>2,F#Z5_P!X_9K]D:B#[-;*U^T?MU$"LOVE]KM, MC;LUI,ZCF7L/V/N6(DFAD :WUSM,C3!UWPZ8BO@6;.#54NR8E(YDR$8:]5+; M2<0":81DB-4R.A#[*DC-BOK(1@B0)0$A0C#F1T+(6PM7JNC:1I^@Z;;Z5HUA M::?86P"Q6MC;K;6\8!&7** 9)&QN=V+RRN2TKLQR?"=>[1Z]VIU>Y[0=K-:U M'7-;O&9[F^U&YEO+F9F#]VBR2LRPPH6 2&,)##'F.&-% 6O*5'Q$41'NQXT> M5ELJ-:CVT*2)#RSP[@>22!UR8ZBS67SPLKR^G.$FN,J&2TRPM&$[4%Y(R&; M*MNR 74$,!PAVJ=K8XZ9SD^&F"L1E%)90%V+( F1AO$;0,<9^[GBLGQNS MK4>7!A05F9"D9,H1YQYA04;%/O%F,!'#V-PUYB(%B9% PA,@"R1F$]0CR7SB M$%9PTK!:QMXT;F(1L=YN?"X!XR7U*\GF,LDLS/Z MNYO68LJQB(1>J"Q38BHL>-H55XYQ6VSAWOR6UUKO;-T@"19Y-0V'0XY1,2*5 MF/OM3>3L^M&92 :RIR!#L,<(8\GU5YM\=M2EB*!PWAK'G_:+2H[NZLX)5:,3 M6MU@L5[RVF1K*9?67[[1,5!)4*Q7'/49W\O6X+2SNCB06]_+D"X,MNP>T6W9 M@%"AHW"G:"T0C#/($)K%%8T;%Z;YGQ>[1X)J*KU1L4Y6[;3%..$GOG2H[E(F M#6*8F"'"7C'D9ARUT\:W,4X "M*J!@ MQ5?5W*R;"4"ACNDVJ6Q6\2P2]T)[B2[9[LV1O-ZJJQ^E0]W- &"\,I*LDFT# M)R2%9B*QYS)C/BS\!4ZJ+./AHFTSL$14$I^$%*O=1GW:=7VG?5DNOE.HK9L" MVZ/'MN+4?(#LYCPC4,)"ZGLTR2&:YG$7?M"DB3$A#Z-/&+EP,\* XE;+8&T, MHO,T%N'.Q-TLB8&VW>$O(4D7!(W!N]!YR!X\\1:(/9M49(,/$V-U;D M:.'99BP_VG(5Z.C,'8EV<*-S#&?'"MF2&0;"JM(O#G(.SUMQ)0$J"K M'.02!GG.,>C'V&XT!R+([H92,*7CR6EI<*_?V<-TSN0JRQ1MERO4LR[@GJX;&"HQCG. M-E<7PG)5^X(7NDE3NE=)#$O=A5W*0TNQ4WR%F V-D>L!71KY&GG7L3<\M>>/ M>Y;H;=[#68EFX4&Q6@X0N^OUQ9&!386RD@",#2KHJ'1I $]Y QRFLGMNM*'0 M.T)Y#]H'9:UTF.UU.QB6WCG<0W4$"L($EQN$D88ED5P"".F1DGGGF=9LXR@O M;:'NH@XCD11ZJL5#*Y 0!\$;AA6QTR:Z _F_P#MN_TX[8^KV=^_C]6/;WZ\ MSKFZYSO^:%T(8':$<-44Z@/4;;(V&&\91G+Y3P['=]#C7 M9Y2%M*PO/F^P?9(<2]H,LH!CTS<2=N%S?Y;/^4<]1Y=*W6E?AR+',V?)!)#Z7VPP5->I8#P\T<.&"*T M0X4\EQ3S[2B<9*9>R.R][&TBHH]:6/AR/PP\0.42^<^ZT%=PSAX6]0;'YX)+2# 9#SPN6!'& M>N>.8N"FT '.^(*[8X4$D8Q@#/F>.?;DU[BB)2S/(CHL!9#X0DVJ2+?(91&3 MC@TJY>H)TLK#HN4_!^&;*''L-(8RVX(2PC&7"4LIM&.*(N68@.5"A1EDX6 [ M%&XD',3,>G/(&,DV2D>_"[%53Q_A<8!/AXX.,^&#QFO+E8QL=8F$^A(%,$]= MBB1E+PEH8M@.1>":=_Z=@V$=,%:=PMC"2P_[ E65&,NM^/:D?_AKVGD[3PYC M[%]J;^"#M=$>8>SW:"4BVT_M.%&$AT_5V*6>MN<"*Y-I>L3ETKZB[-?_ )=_ ML_B[ W/\W[5_LXTNYN?LZGVCTOMKV-M%EO-4["RRXDSG,_:%7ULTP_FG:\D_AO8VV8XK!H(] ?'!;BZW"EN-O)$L M,AZNIN '>2M0HI!N2A\C1YS..T[3]H8^SEE->!HS->Q*EE9,.#<+N+SR>M@P MIE3(R_?.T ^N*^;+B5-/M&ED8]^KS*F'*O/*XP(^[PK*(L;I@?NH54^O(IKN M!K=?B:G 0=8@0VH^$KD3&0<0 PG"60XN*#9CP!6DIQC&$,"CM-)[)]B<9SV] MO7S3+))/)-)(6:261Y'!Z_,RD5SN0]C=1;Y])M[22ZE2(NRY&! M$%.% W;79O('?'4KB30['2FE46EOKM4%(P#D*SD#G- MYD10(!+$^P(%<=]NPOJABPVJN M.F#L($[L0)%W85Y.[[['\H,-H!8MDL6RI[L_X1C&0:U^A-24K(_":FW@SR!Y M>6<2ZIQB;E_48YR26)#OL@O@*(-7'./N5B2$S'/-@EO#E.L8-0YU M54^KN51N^^02I&,X#J=QW#U1A<;@VTA,9D1WB]2.-P 5P3AGI;EK1,EK>"$AED#HRQA)I%4 /&\C",MNQ][8KS MTYE;XXQS5^8J>-05VH1&JJ);JW=+N!8;+B.GI:_25=F7+K&C3M*CQHNQ&,P& MO*7'Q\XLW-KLX4L0<8X^%57?%V)!X\NOQ^@.N/#K7!(JG!/F<@>/'Z8SGX58 M&J_*AV.)U+R"W'R(B*'%5O5O(6OZGSB.*=U^'K;-HLLO6G:+LB=M0Y%]'OVR0S8&?WN%M". &(G;8:=$UK8J-A5[*CIY<0Q3)&1 M>"@H2;@HF/L$,#$P3(T*YM=[LLUB471;!(A Y.,(:="V- M9ZD.Q#/:^D("-@7(.&>8"),C=D$A7TB95A)A\.T["NG/# #U^64K*NFZW>JU M7NMB6"8:?D@8;"UCQ0RD892(H MEV/#4K+_ $I3I2M=-$TKRZB><-RVM:-H'2/&F438<5[7Z]C60\('UR$#%B/, MHI#*8$+(LDT^1A3#F.(B1,2 "-L*@K8MV[>SKM*^8J=*4Z4ITI3I2G2E M.E*=*4Z4ITI3I2L-37Z';IK(7J;DAZY\%UV3.]5]09QET MS#_H/19%:QZ1_"LM(_-*QUEV$?>WUG%G:);J",MD#:'E12V3TVYSGPQFK]K' MWMU;1EBH>XB!<'#+EP-RGP8>!YY\*XO=/QE]UE>@-KO@0SD#:*.8"_2_CU!0 M4B:Q.Q)S4')1&O(;*IAF+K%@BR8YS!T?,XBHU!D3%XFCF%O[N9)E6(437-W++:I)("+:T$KHMP\C;CWD: MKMM@0RY"R8RJK5B;>VI/;/DCWW))P()8J<5BM!J5DB&"&;$CQFAB6'<"^MJ? M3ALK(S6&!UDLBM(5A'I3!.XCUNO3M-*T MB/1K*5))$>24EW=4/K[V(;;(2S,@W;68G'&<*O P]#Q_QIN]7J+CT.L((G$" MV6$SZ,*-C8H9UVTRCJ3$-M(*)<:+DS22$)>-P7A+CJ@&4J1FSDP6LT^) S@R MA222SNP6"-2I)8#A0,D* 0,-Q6XM;L6.G7-TT9>YF;>.1N5G5MJJ5+,#'!W: MA3CK+""R!;@ ML/$99=@S'P@3'#60S'VGE)<;ZO1++T6S>4QY2,Q*VW^;(TJR;IEDMY6 W;G. M)5#,H4E5.<'S#5KA9;J5(I!&D#/&"[RL,2#@-M'*U:0Y/\PR*"0DC,Z[ ML!3EV((8>KM4!MQ;(.X &MRODVJCL_8?%3G=$DA55Z@#Z(C:K60HA4G'VNV^,<^7YKVPNH=/[0:!4U'6(UBP>\AL2X!/T\>Q'V7_8\._\ M+OE^TCMRI%S M;_9SV3OF_P"U]*:4Y7_O+M=:8]-V.$>71.S4K2JX[NXU%8G<"T(:^.1I+PM? ME!R"3EC)D)&0 :BBG<.//I6P^2],2![*L.X:].UD9IM+&/.;SEWOA7;=F?L_ MT#LND\]I:RW.JW8)U+7M4N'U77=3;(RUYJ$R([H2%*6T7=6L1P$MT(KS7[0O MM6[4_:)Z'::Q=PV/9S23C0NQ_9RS31.R&@18=533-$MW:V$Y61D>^N1/J,ZD MK-=RJ<#\VN0,FXZ6/+V %+284PF+:CXALAY9Y@OGB#N+D' 7"4E]EKR^T4W M(N)RIS*6>RLX[&-#&RA8"D97>3ZH"AL'IO8^_C8, YX'F =-P2.-QSMY?A= MW(7 48Z>' 4# QUQO%BX6!),CB!D1I**RMDIYUM3SN5^8]D,QRO.2$ )W+@DDXR>N1X*!DG!YK*P"V25 9@HV@* M&93U1AYJ%Z\8)SGI7UN*C7@G5&OP<>/$/X RY&N.E6&=-40E*5M&.,D,! )R MVT_ZVVMAA2" F00W7W&W%Q_,!RJR'>JJ 8 )P<09'D<@*-RK_ .PY 8\_>W'!YY)7H1DG-;1/)B4,S<+%YJNQ29>H M:XMNP] 1L#9) 9R'8N^ \[*C)BMPDD\R(T0J2CD.'"E.+PE@P5L8-E9JPAU\ M)VYO!9+;36B1W%U%:ZF98D97,!/H9661%R?5X!4#)W9QL)86H[^;3I9KFTB- MS,EC>@H&($*2=Q&TTR AVC1F#@X!+;6/J@UL2\HA7:H'OXB6J"&4-WRE1@DF M\(2M Q=JJ9'JY:EM92I+\H; YKXC!;+BQ&Q(+@C$?\ 4?YG M?,=WJJ7!!PQ6L(;+U%7MKUJ'M\)BQ'R&T8QJPNK%E$0QX>R*-4WSY]BOR+ H M;M]GV=]-I]R\+B)/19A$QV;EDMIY0D9D5 MBR2Q)GTNMA)LM7< ;K.=FE0MZN0@[PG;D(KRR M88LM:>+MI?9-#A<-1CD%.1C9R?2*KTXV*S%X2UF20788J2+8G(F1+AF3&XR- M;$*5Z?);?PHXPD;!?I,.KVER1ZK12!.CCKC.-2D$ MG+[&;:2-X&0F,Y/JYY&TD 8P%W9P"1;.Q)@8F81)I2V?$PK4?"GRXP6!PSY= MR(8',!%6A!;>0JO%A,*BP%EG-I2O*"C'R2''R;UEN6,[LJS[C%&Q)949SM=L M@-EW<[V(4G'"J%"AL6*X[M6#@=6 89X!8G<.N[JPW8+-DBN]B*DPYB/!E(TM@Z/D!&#@3!7FB!BPRV4OC$, M/L*<9>9>:6E;;K2W&UHSA2%93G"NOF)E9':)PRO&Q#*0005.T@@@$8((P0/' M/->>2(T;LC @J2I!!!#*<,"" >#D?K6G#RTO&_9^]]U2:NH&N)/9Q% MEK]7%,/LKV+"S0QE+!,>*JOR"9/S\/&(R\$D,5Q#ACPWHWV M:DE]-';F]CM!%+.0( (6G[U')&=S"12A QA7#$9K:Z5*B][$\G=]Z4922H!: M-7 !9A@ B0CGC)!(.,5RT7VM3FNX&4:V#&V&ASSZVHXN,M]5+K#$1A@5SL_@)L=!XJG'5C-+94R MEE3B!\UYRDA];;L55) !4DKN]HR#G 8\C ."03K_ $.[/KQ0[PR[5^[M W+D MLF6=5W.,,RC/.W.&JXAQ7Y@Z+B8N.FGYH+S4Q.(ZM/6!A.(YVP%"N-.PX_\ M:8?IW2V\K9:?S*)D!C9)#K:D9ZMO*(1WCO&$8$RAY1"?YFP,"7P"0JY(.T @ M 8S67Z TD7>$.@*AG=P\B22*65R&4>HH9 $ ;+!L].:V4\P7&G7FF[TEM)[>:+;*+MUWJ(RDF/4.\ONVXVY$Z5 MVHN^RVI6>LZ5>R6.M:/?0WNEWUBYBNK6]M)5FM+F&;G8$=4=E*MG:(RARU=5 MO&OC9K/BOJZ(U9J^.<8BP/.(E)J0P*Y/V>7=_P!D3$^<,,*DLQ2<('&0EE X M(+(X8K2&6<85X)=7TFJ=J];U'7]9DAEU#5+VZU"Z:VM;6RMS<7L\ESW&#GKQQ MQ6B.>OSYSX^/4XZ>?A@]!5A[@UXQ?]?WV 4^:R5;=96&G#O J98,#;F8N2$> M4"1C#3J'B5D,X5Z8G#2CR/YQ"W*Y09)"#UB2K ,O3VTD<"-'WJ/;RLN6V<*>H)#$E=AR PV M[<,0>,5KL> ;S+LUB1!.#DX&0G!8:'9+>;N7PL8(X;!ULF'1'C&,*D30HMN, M^$&C6DQ3C(1R)1Y./-Z1Y<0O,KHR'NR[DJ41%XEDW%L';&23SR0&# 9SVNGS M)/%;P* %C$C"=CZCG:&"Q,%.=[Q,/YA !QD$5WZ\.]#1_&OC?JC4(H[#4E6Z ML"]:R64)Q\)768;3*VZ16XE* L$1V0@ M# "Y0!V& -[,?&K(WWY0?B/QEO*-;;MV7+U.Y.0W4%E\_P/7C'Y?WQUD1R?T_BN?S]_T*OFM>5LX 6VQ0 M-4KVZ+ ;/6::BZ_"!N:$Y&1Z"Y>9.8C8T99TCJ0./"0^84RTHLXL8,=*\O%$ M,L(<<2W#CG\_9]=/PS3NWY./Q7\1D\UM?"_V&+_X.U_^@GJV>I]YJM>@]PKC M=Y0_=,15X:)P5&L$K,'R.ZI+;^'64997G"'/-5G&.E1 M5P]*4Z4ITI5H6JCPMQR#F7-MX>8[!.!_BKL*_47#GK?H/2^O8I%EKV)3*?5F M_5LR>"\A^<_@/+&"BO3*5:/V$J;^C6W?W0.^OZ2>E*?82IOZ-;=_= [Z_I)Z M4I]A*F_HUMW]T#OK^DGI2GV$J;^C6W?W0.^OZ2>E*?82IOZ-;=_= [Z_I)Z4 MI]A*F_HUMW]T#OK^DGI2GV$J;^C6W?W0.^OZ2>E*?82IOZ-;=_= [Z_I)Z4I M]A*F_HUMW]T#OK^DGI2GV$J;^C6W?W0.^OZ2>E*RPPR@=EEAO+JD,--LH4^^ M\2\I#:,(3EXDEQT@AW.$XRX^^ZX\ZONXZXM:E*RI7]>E*=*5:=TOE&UO D6K M8ESJ="K CC315CNEBAZM C.O9SAELB8G# 8]EQW*58:0X0E3F<9PG&>V>E*^ MJJ6^I7R M5&M%=N=7E4+=B[)5)N-L4!)-MN+9<< F(@DR.,0V\VXTM8Y#B4 MN(6A6<*3G&%*N+I2K>M=8B[E79FKS.'U1<[&G11V!G<,D>J2(;X)/H7LH%'%!]?-V\UZ9)8RUHBS,CR;+;!9EV9R6=C_,[M.\Y M];8 ,#(.S.L79NA=LMNT@D67;W06,NK!N40KP2.0"."0,9-9<&\FWQW#C\Q@ MQ.QFA,^G[)3;T>D;]:2.@A3+V8K+K"W6A!65.,K0YAH=I*%I\WOU@?\ =.I[ M@V+7<,<]P?\ #G&E52]L]9F54= MK?8FW8@278H4C@ SGA@-K9R<$@$9I">3QE.V"()@R27[4+D@, MWU=!J8Y34*R@9\H4= +A2D.D("4ZPPXUAYS*HD[5:G*82ZVG\F19540MM9E) M*[P9"6"L2P7(&[DYJJ7MMK4L:1/Z'W<9+!5MR@+\E7;;(-S(QW)GA6 .#6%1 MO(N\-D/FE2#^YYPLN2EI)DF5V@#B+"%#,);D2D,J2\PEEE#;3 M;>$]:G6>TVHZZUL]\MKOM6=HG@@[I_7VG:S!RS*I4,HSPQ)SDFL:YOIKHQ-( ML0>(Y61$VNQR""[9);! V]-O^' J(7VC7AZ_+IFI:R[LGR>61\&MK;UJP6'&(=7YV0P"A$$93A1F2596I?0#[2NT"Q"*.+38U"J 8X+E& M]4 %CB\PS.!ZQ<-U.P+6UNNT^IWR=P'R265')))SUDED*C_*A5?$@GFK= M<\@SQ-<];[[2Y))P42LGS$V74OHQU./DD+:';SIC*,#Y=*<4EEY+R$92RIO" M5M(5B^/M0UX;?_!T;U1C/[;V-WI'R[W\\^ MS&!BS\?\SQ\-D96H?;?*@-3B7L*4'>=7#?V1Y:G%/8PUII*4N8=6XYYN$X9< M4M6'FG$X2G%[_P"*_:'QL-#(XX-K>D8'@>(1GKA7'NX[S M'X<^.:]UCR ?$-CX5S]E7DVXN81Z(E:K?JQG"6L-^C0PVR)IP890Z.ZU^KD, MOL+<<6MUMS*NJ?\ XJ=H/4_\'1?4(*GT:^)R.,Y.HD[N>O!\B*@ZU=EMVRWX M)( 1PHSX =YT_'VU;2?^9V>%W=#;FT>3CH*!&@_@_-IT^RSZ)GTF6LH*$TB/ M*#K;6ZM;>19!A*/!M"<,)PUBH?:OVB'(L]&#?U>CWX//_P#S)!./&KP[0 M7H&WNK7;@#'=R^'3![[<,DK!;QW$:06D5S;JWI)A,IE,ES^,Z2['EC/F>8>J.(%<;;?40VP\RPX MPV)J-.[47>G.[10QR+( CQ2L60QKP$'J[E]7";E(X )!/-6-,UVXTN25H8XY M$F&UXI2Q0ID':,$$$87#9W JI'(S6/0/);5X"CFT]&]K\DAZ6K]ECYT:#@17 MX>UP)39'P^%'(6L!+\FTW@.192AM+@O9MM;>,9PK,D[8RR7*W!TZUP(Y(6C, MDI#PR+CNV<^MA6.]22'7:R[UB7?MQN? M<_5FSIOXI*&=DC"]XN'&]R"Q&UG&3PS 8/A[*C2S_P SVZA8 1&-\C-H)#;( M:]%C%)=N<= <8X!YQYXSP*_=L_YG MGT/:_6&E[INT2 XV^P+%Q]1K:X\%@@3 ;JFF#RS,D'*;0R[F0-620DIAI]OT M:DXQU2GVI:BJJITZV<@@NS3RAI,,2 Q55]7DC:H Q63;ZW/;A0L:,5+-EN>6 M&TX&-JG;P"!D$*0O\ /;!:H,/\7XZSSX004H3"B$O_ M & 0P&XXSYD)$J#A1G,K6Z\* TZ^I3RUJZ\^U2_&I:A<7ZVT5KZ0YD:&)F9 M%=@.\;C3YO;M[_.[^'; W'.>F?+ZY^-8P M7 QD^/3V_.K5L>IJ'< %Q=MK\99XUQ;;JX^PQ4/-!*<95E3+F19*.)8RXTI6 M5-K\SSD9SG*%MT,LD3#@-&[QM\T93SUJ['))"VZ*1XV\T8J3X] M5Q]>X8BW:/)G<&+B4T9/<;];.O,O^LI3'0(< .X]CS_S9 D U&"E8_LCGY@E MEYO/GJ[HSWZW4/:SM' G=Q:Q?!-H4!IFD(4=%5I-[(!X;"ORK,75+]!@74G7 M.6(?*L_T/CIIG5P6(_75 K%*$_,>(>PRA#>7GW''E(0C"EJ\W';676I7]\Q>[N[BY<_XII9).IR/KRK7KNKR7''G>,Y.VF(# Y'4;2.1Y9!LNH>1\XM5;8E+VA(3VV;Q::/8HBT@/W*;I)+4I M,P+OK<2_/N0FOX(Z29"DDCR;0GKK(V"Q!F\M9"2X(YD7?;[6[NSN++NK"VBN M8GAD-M%<(XCD 5Q&9+J54+KE6(3D,Q^\002P1&-$FBDA. Y*)(I1M M@,A0-M+ $J2I)88?##9Y\ A_]E)S]/GM?S,XQUQF\^SZ^-:;8/;^'[4^ 0_^ MRD_5Y[7T^/\ TGOX_7[L=NWCWC>?8??S[?/ZQ4[![?A3X!#_ .R$_P#X[7_[ M'J=Y\A]?&HV#S/U\*? (?_92?_QVO_V/4;SUP.F/']ZG8.F3USX?M7KM-I9: M;:3G.4MH2A.5=LJSA.,8QWSC&,=^V/'MC&/HZIJJN-?E#]TQR(_5TVW_ !_L M'2E=+7 C\XV]?KTO*1_RB7*7I4GK\!^0J!_DK=(7&L;KY^[0M&EM0UX*?\H/ MS@^+VT9:F2D5R+G(>7VL"9$,"V"0K(S1^I),%MTR)>"L1 QS[;3HPSC.%.I5 M+'IS_A'SK>%TJFL3;LUL[MC7QM.'DW8@MV;J,X&<@^6!:;)JUKAK&A!>(

5E^/(=6UDP5YMOMA2HO:]U?L;C9\$LKO4?("[(Y*M+F8T",24) M8(.TUQ,6]-3A4N-\(@7::DX'-NGWX,AD%4U($#./RXR?*':\OCO*#B+O20U[==H:'U=0N2E< MD1Z+J29Y$R&EN0&P:_4A-,\@9+CS61I"T[1CJL)%7"NMIK4/,2M>)L"7L)B1 M),F595(\?,X^7Y>7RJ2?DVIW=MEXL0E2>OP'Y"II=*BH3^4$W-=='<:Y^UZTLS-0V/(V6HP- M+GCJO\;8AB15,-3TL#-Q:62G68R.,&LK/L+84AM6UR*;:DZ_2U5B:5+6$,*\64"#>E:Y!!1L,%)AP(T;'2#L M;' "'EB/2#0C*2O-Z4K =4WEM#;;=37L#6!3X>K_" M\&;90[59E3ILN8?)2-??77(LIP63CU#V2 J!3!HS*E;+.E*=*4Z4J+7*3EIK MSB;!T^=V!%VB78N=B5 Q[%9 '+=&2,RV3(R!;AA80R&PQW6UM")>48;QGMG';..^,YQGZ,]NJE^\/C^54M]T_#\ZL[UHG_MA_\ _*N?_7=5 M_P"+&SC^K QXU;R<9W?#)S3UHG_MA_'_ )9?_P!=U Y]4^0SX_M[<=/#PH2 M>N[C /N]A^/'/7C)K\Y+*Q[2'\X^AUSP\??X_-_!^'JH@#_"/E^?Y_"J_&/KWU3)A.<=\$$8]_?TJ^WX_.S_7\73@^'GCU?D>@_,4);P+#VYX_/Z_ M/\MFD.(2XDMU:%IQE*D/N92K&?9G"L*[9QGO[<>'OZM[26SGU3G 49' \?+Q MQXY Y/C7N.-IZCJ23USSTZTP03YW?UDG&>V/:^[V\W';OCS?.PGVY\5=N_[_ M $4 #_->DV84W%%O)(=PZE\?&%K5E6 M4I5GLK&/.[XQC/CW[=O#MW^?HV,^&<<@>9'[^/[,U$XODENB.BBR9#;A&+?-N/GUN =E(P&*^"@GV7#HT-YF.?>-*4[+ M1(GKHXYJQD% M((0I]M)6>\%HDJ1K;QF,0R!1+*5EFF7&9&9=Y2- KY]4#[Q MV'"BJD0N@8!V 9=[1*7PIXP!D LQ/'(Z?>'2O+H_,_D?;&,YSEZLOID)!M<= M90FSY-UACUS 2!$0YZVG1SE,(6V:.24EIMQ""'!26GQ$V8+2TE0M+#/%M.TD MR! 6[Q4R"R$/'LW/WBE4\ M@$;L'# @]!M/."2/#/\ M8GDSME)L:=.;WF!8TG&")&*BHP*"6TVMY;XZ&BY 20#5R2?(O=Q(22:%LBP2(<*1)A#KL3$:)(3Q30XQOPJ[C,82-*U MA@1F20.2&\-E!HIHY!;[P9+#6"EO 6G6:SB1N%SNN8HT8,@Q$S Y5P6E!D7 M.%V@,6%YE $1#G#8.$V2-@@X# 'ARPP$;:=I#9:KF?W]NE%8F+"9L&88D B8 M'SFH6+>E0O1R4U77Y$0:,=C8Z0,%%:<2H]Q("9)UMIM.OGCMC(HC M'=]UWBR8)=6*2*,D%C0C"LN1*/4+X5@2KE>=Y5>1ZP8D MY&![)FP5^V 7J0J>)F41 5W2-E4P.3A6((!ZE<&K*@_XL \DC.<8)XR M,32,_!\N. U&!OM%#): MRSD04A]#JWU,D#L(&;D2,U;:WE,L1=;><+WJL[$PJJ;@X9MQ)5P0V2JF,A<% M]Q05%<=%9\L%]7[PS[!Y,"O.Y6 /0D8G73=D#WFOQ]F@SEO1LBUEQKT@Z&7F M\X5V4VXVXUA>%X]O;.,9\W*59QCOVQ@21,CO&P*2(Q1@<':PZX\"!P0!R2?=CBJX MEY+_ +8]V,_]+9[8[_/^8[_/\_5!W#C*Y)VC'(SC/7/''PXJK<,#)(Z>']L? M*L8;/GY!A578;E90%T@2V&NN1KCK*'68[-=%PE_ ^,84XV[+(4,G.%KSGTOH MVE*SE;61!&6!)"MM:-#N/4L&.>" %RAW$D> W#=@R/'D^SCITP#GW^/RX-8? MC[/:&8P<5J>GSW\A=DR69 QS*BBLI]4RI2E+:SE67'G7*5@Q1;J'P9,-*76!VFF!&W_7,X3VPI M*-@PB6(*(P9=VPY5/#EAT #J3C.69EP1C'.(-S,<'U1DG& 0.<-@'E<=>,9P M.:LNX[,LP$)#3&;K+CCMMS4.2''2UB62^0LIW+3V3VSLJ;<2)'O98R\(2^AY M13@Q3B4M-JJBM3++)&T3(&1)0,*#&5!#$G !0F104V[>!GDFJMP4!AAVW@@QP:Q/B]6BL@Q]I/W1:\S 1Q"':58Y"]$I&&<><2\5,EQ_ M]B*<>&83ZEE@+"(_)"EH:N M#7SF+*Q,$-D/@ M-QMUGHY):A&&77"<.OKA,M!]WAVVTF.844\\A# SZ\.XQCW-AZ+@JP*L.I@W M;2.H8QF5$/4X)!(Z&KT?KY;:HVX&,CDL< @'&X CD#.. >36:]%1^T8W95CE M[#8Y]^LSL8E0-=D;E,3S<$,>L M#D^&1P,5-U1)/H0\^L/]U#JRK/I5]\Y]:(QC.?S7?.>V,8[Y]V,8^;K'P,$] M?+@?TCPQX]=_#G_CI7<1ZR MK\AGKY#V>&?=[8;@C#OU]N#]'QQ\>E1WV;:9ABU@"Q\U,#I8B'FR109$UE"R ME^>3A3C3:L(4IMGT7]DPYAU&7V4*PI+N/-RHT7N6.Q>7&"WE]P 'KR><$8 # M-G@U>C&2,G.<\'D>W^Q\_G6/6[%:)$P4=$]9E?";P() B)Z5#>9?-> 88_-X M+2IE",-F><\*ONO.7U?V7*4JQ4%PJ^JGJ98,55@<$E@#M.[).!OZ<#CC%QB M'.!G'3&",'BT#C)+](F''6,.2V.0PY?LU42,[Q*\<2ERJQI*VQP5#,&& M&"X5F)P5Y&06W"T.0!R&YY+$ ],=?( GVY\,5%F];'O4"*&7A+6U,>"R ML%B+=3D["'F6Q)'/)C8.2//.*W/PC3C$-$L.N+>=9C0FG'77%O..K;&;0MQQUQ2W'5K4G*E.+6I M:U9RI2E9SG.=#TXJUG//GGW?#V>7LKCFY0_=,PQT<-2["%)TX(H2 MPV!J:"@AYM,Y+?"/KSZG]J]RR;;H.X0-:S.O)UNPQ5?Y,U>IR)[#!#0V)F*! ME72VAG'VVTE#^B,&=9*8RMEUMU*D*[9Z4J7O2E.E*=*5Y$Q7X&Q,#C6"$B)T M80P>1$'F(T.38%D!596*<.T:R^VR8,K.5#DMI2\RK.SG Q^ M_P *IGLK&<>/M]WM\,X\>WU_/_Q=4H^[*DC(.!@Y)QQFCC S@D'!P/R^%>7- M3437XTR8G)(2)B@&G'S) Y]L<85EO'=;CKKF4I2G&._?.<^SM^&X S,%4,Q) M )))/ &.3DG !SP.AYIPS;L#/4>[ Y)]GCDXQXFHDW?D^B9'- MLBC)!BB*-*QQN"$Y*ICC>1N:/@,HW BYLS@?XL\9SCI@'C'P'0C/& :PS%[U MVC7)FRN3^5U=NU3+HU:7(8!;>E260XX,")&;5(ES3I$!6HN/&0,X@V2^$ M:VIKJZ]A!BXEC#)&EQW:1[RQ*K$&<>%2MT5O(#:D:_$R33<;>8 =ANQ1S>%H"(=RIP=V1A MW7%.-E@+*8>;7@4DQL$A+@2RWG&5KS@75LUNRAB&CE :)_9M4E6#!2'7C=6GS9C'YKOC'FY[]LX(P3][@QD?G6KF;VBJ<%(<#UZ,+)NSTC'H(E@6"(9P *0:;,*9 *.03(.C%,I0^P MAEEOUG"1U.2QQ@)D@5DF0J M &RQPI)&/5SDX(!./+A1TJM*UE%6%I^T7%0)L9+CID1885MM,?EI([&>YI# M[*\.(]42[B-&(]62^-CUG)1+3)+-NXN^[9(8B=T1D_F2*"XW2%E5=V0-ASMD M(WG)(*@X-:IX@J,X)56.,X ))SGUB.5'JYZ>=>99=X:\UR@"F:VB8N9DC<2H MD3$17]@B&2VFD//MRDH,$_ADPLMEL1@9U'=2DM/*+0PAU28[F:>;-[)*LCH6 M1-C332@1E4\XR015(5BA:/;W8;#2$[47UN/:^/Z5!/ S@5%BZ6 MVX6^0;E38V-F)%S*WJ_$+:C7$@1Q4: ,,S MMZJQ'=M VX;=D$$D;V'D!Q5_P>O)VUU:4^%0 H*MUX5DZ9CGWC(\Z3N8X@+@ M$@5,>D$S@( 8# ^37$)!00Z4+&CN#NH]7UD\D0DBB11*+I4]56W-"G>!A%$E MNP&_?ZVT.[.P!8Y&&OJS@-("V^,N%;@!N"&)W@DY'0D# \,\U\I5U>@;U390 M,*NPFO;#7)(>_0LL7'L+D;>P)K&:.^EG,JM;C$1!95V--(D4JY$4DF=P51ZQD5@N% )+#< TT*_9)&K\;-I#SP0Z@0K>-70Y".68U#R M<%."-^IRU;4*Y*2;P[*CTB904Z'E3PA)#;H\>H9YRW;QFZOHA5L'(QDGD\#GC-?J7?C#*Y QCC9 MP<15JW!V%X*!<(&=>E3,!"Q4,HB(=97@HU?GJD%-*RZ1&$$>LK4R:ZO%,H9& MEW$$SS-$&*D[=K>O+M.3M !W9']7]/JRIRXV@$* 3D@C&,8W$\\8P,\DC@DU M8ITO(<<@ZT-4["*&DUF0E;!"R7HUPLP3('M%)8!-D5JS#( ]--X0VPE*WF8O M#YGH"2'%D9:*NH-/--E"-B+,KF:(R7!R1CH[+[:HN0 M4A"7$/X>]#C&?.Q@MIT53GIDIPO6W$:PNB,XE+IO4[=K*"67;(FX[&]4GEL, MI4ACD@08B5=DSA?O#.<@X^Z<88#/.1QXBL_HS^9[^./'OYOAG/L_Z'P^KV^_ MQQ[.K)8[6/15R3XY&,\ 9Q[\X\O#%@8&,MY '/3IP<^..F/9UJO;OGOV]F?; MW]_S8\?#OGW9[XSC.?''4X)3) ) 8CR!P?#C\_EQ3 WDC/7!/YX.?TY'QK]> M/?OV]F,8]WM]O\&>K6 6SC)V@D @$-CDCV 'G'Z<7O\ #U\2,GGC)'/[]*Q! MMYQH9JGEK*\Y+:Q07CJEZZ^T[ZF4I+F$--M^BPIG#C;CBLK3EM# MS-^W5F1]HW'&T*1D,3N XW+R,9 .1GKQG-60,YZ'UB?+&!Y>T5A_,P67'$^J M$LXCTL/9:.<\T S*&WQ_,=:4YYHSBV14^:WZ3T"2GE=EJ%99RMR^(E5QO5BQ M/K*"SKD C8>=P!)/(SC.,DG%1O !P?5Y\"/+.<>T]?A5G#2*I"79QB/\Z'.4 MP20[@+" V4PI)JFW$J='#>6(8Z2IM)&'#,$-J90I ;&5)*R9$V1$$[I57& Q M+XD"L02"PW1E1D'8WWOO'!%*'K@\=.A' ]_@=P04BW9,DM1Z&H MTX>:@S337,I.+!8D_A>OC,LH<6V.U$.V>RMFM);;:.'0POUL=IAE6_A]VY2<* ?Y;B3:S,S NI8;,C"B03M*89O7W <;?6'K9/WAC*XZ+Q MZV.*N.(L\22$+1MRT&1D!# "96L3C33JY46%C?,220IZ-8])YXBT-H=4(0Z4 MTO&5$N*7G)*S1JA-UIUPB$L!-'NV8D?@( ^5=#ZVW> G! P1M%8+'"RJ.@(. M ^1X9(SM/ QCS'QOE=-9LE?S%U>2/#$(3Z1I#,R ^*8.4 MR4ALE+LB(24I3C:"'UN,M.]8;2M#(2\4L$H_Q0-W?K>//S$[<\9]_^''L_ MX\NAJ%+YY3@$99O6ZUE1(HW9.,GCCS'P'M/L]]?;2 M23R;,&V*,<7&Q$=*GO2#:F<(.0X$I,7Z%WT^7G2$9=!0AU6$>DQE1.76^Z<* MH)78P9@'=E 0@AT92-V1@+MX)*X(R0 , \NE87Y M%$2CEWCI^MB.66NUH--=-A1G RF'GG6(TXPMD8LMAY[#N2AF25H?*<8R*.2M M+7JWG+V>GJO<20RE8FE/>)+@@CUG&7<9QC"[ !R3@9W#%@< ,/ $%=V<@$<+ MC_%SZW.,8'&*Q) R UO-3\58HJQK=ETDS%3F6A!Y:OA"ORBY,:,?7DA\?$?+ MLQ8\2^069$F+.98BY.-#$,>3=N(RBXG+Q$&1([B)9 DWK+M[Q&"AU*]YDA06 M'K$.&%5JW/56\T)'JYY&,<>7GSP>0:D?QMHQN+2^]"V0XFBUYQ]PVNSP;[4G M$RQOH#H:) ',:>0!$@,N*,;0.80WYR65-]E^:_G4WDYE<;T7OFVL)8SZDJ*& M5G9>?7=NI!7&,<^%V1A''@!LDX )!QD\D$=1C (Y.#U !!VD ?[!$[>SU=G\ M']C3X?@]G6N/4^\U87H/=7&]RA^Z8Y$?JZ;;_C_8.HJ:Z6N!'YQMZ_7I>4C_ M )1+E+TJ3U^ _(5-+I45"CGM9OB[I$%@O36D=V5^RWN$@;1 \CI8*"TI 12( MFPV &Q7N8D:E=P8@,FSP->IL3-FUXJ.K]AMT1/RKC,3%G*RI60^(-I?N7'/6 MLZ[K.IZA84'.Q431J$PH2B"5ZO6F6W0&H]6&:G,IE-!".,Y+UJTM2,D0?89&'E)FO2$ )5!1@,,S!5]Z-AQHP=(; 2&5+2M2IK]*4Z4ITI6L+=.XKWLW>MYXO# MZ>GZ8 +%UL2K\BG0WC6(LVP2$"VF38:(BF(_,.25*.Q8S(?P\OKS^B9, E MI9:I.2$"($,-P\9YBAR)(B/81@,(?.5360S>0VAXZ:LU=,;:0+Z1'ILH\['6M;6=(26>!]3L5F MM5D>YB:ZA$D"18[QI4+[HU3(WE@ N1FNW@^S3[1+JQTG5+;L/VKGTW7I[6VT M2_BT'4Y+/5KB^W>APZ?<+;&*[DNMC^CI [F7:VP-BKPHFQ:%M"#^,^N+E6KU M7?7"([XV\J31[UQN7>A8;AD9&U&AZKV>U/N( MKK^'ZS87.G7GH\Q<13^CW4<4O=2&-PDFW:Q1@"<&OZ1U\J$M9;73X^?CR;)2 M!X@JU1:'L8?A6)P5XV,<,RKS4(20*.X_G.%Y]"WEO+WH_2M^=N)=-OH;2ROI M;:5;346G2RF*Y6X:W=8YECQDDJ[!>0-QSMS@XY>._LYKF[LX[B-KBQ6)KN+. M&A6=6>,OG PR*6."=HQNQD9]Z)EHN>BX^;A) .6AY8,>0C)..(:+!/!+:2\, M6&4PI;) [[2TN-.M+4A:%84G.<9ZQIX)K::6WN(I()X9&BFAE1DDBD0E71T8 M!E92""" 0:R(9HKB*.>"1)H9D62*6-@Z2(X#*Z,I(96!!!!J+TQNOD''W.2@ M@.*X].Q M0H<>6J3CV1I1*!FE8%08D5U>2&7DI4K*'2E.E*=*59VP[_3]44&Z[/V#."5B MAZZJEAO%SL9_I/4H*K56*+FYZ6*PRAU];,?&!%%+;8:=?Y1E?DK6"21"MU:09 M-^"6U+NPY25Q,C4@9?+(+RIQ[1Q]8^ORJ\:9Y2#C?L+8G'F@TU>PIL/E)656 M73&Q6:,>+KVRY;J4S=BH-X\\@6Q1DS&P5>FD3.3JPU#0<_'%U*9F +4P[#(4 MQU]G45.27_\ :XC_ ,E_Z=KJI>OS_(U0W3Y?F*LC&<9]F>_NZNX\L<<>?L_Y M^(]M63X9^O"O&L,_&UB%DY^7>P/'1(;YICO;*E8:81E7F-(Q^:>>=5 MV:891W<=>6AI&,K7C'41#O94BC7=*YVJ .N3C&<<>9\.N<8.*F#8Z\8').0. M/?\ *H?W_;9E\T0?;6*E-13,EB6BWX)]H ^688.2\#$RA.,X4 R,EQP4B024 MII@88O#Z376Q\^L;>"R$>H"V:XA=E9")5+=TY0HY1.-S,3E5V L3X#/%()CC M>0!LNI !Z@DGG&[RP>AR![.8[-0X^+4J<+F/3U"8'8: EXD;&9*$7)P<7*1L MI&I!=DDMXD2C#SGFT-X;+-K3RGX_UIQT569.HFMI+54=)P064-M,@B9E*\HG MK)M0 ,"A'WAFKB,R$2D[AAN7&1EA]XXY&0V"1M(.>15ELS,Q$U%^;9BXZ>S MZC&1[LHT8/Y[A<:$5#0PSZ"7DA" !RSJL;L&FS@ ]X1A#N.WN\]V2V%:%RIZ<@#:V#N/& !Y ]1X^9XK^? M&[)%5VO09E.$-GR14E5[2W'%M,Q0P$J@UJ 8-CGR\.#.K>8!)CWRAV9"2<5) M.Y90I#8J9U?^9;N.-L;++'O0[P0!WG=OCF,AF5EY">HO7-(\8<$$%L=" .// MD^MU(Z>)/AC="MO+T!(-*\W/I'&$9[IQV_->=CQ3WSCM\_\ /VZY'G/)'3J M1X>_KY>WK4J<+]W&,<$@]#TZ= ?9CKXYK3OL^K6>$V5-UV$E(P*$DXR=L 0I M[#[X8Q09##!"T,.I*(=)=1)#R.&!E>IO$)'6]G*1RDN=)93026BR2H[S+*D0 M:%MKLA#%%8Y4 J5RP+8R%/(Q><.3E=H5DW88<;MRAL< @G/../.L8GEV\,Z M6CABF#(98!8MVQ'D.CQ\?*CM-M"2 !38P<1+I&*RX%- D)1ZNR;F3S)"LACC MD42=ZMPA18DMVC5D>X7^:N3,ZOEGD!&U?N$QEB%VL!W@:X!$8O6+F42%!W?K MJX&WU&^ZR]05<%E"CE2V*RY 4K2L;&0DQ:[+'S%D)CQY(T]F54*B5(!;$<(< M:!B"1W38_&?186'D4UE_!W=AON[CS;'I-X9W-M&R&4*A<0@LX"X5C*P?;T)4 MHP"]>OK$0H4JP]1&)V[F]4DD$%>/'C#*<]"!TJY!=NU,64+BM44$>R?!F&HQ M9<2 **0P0VZ"Z2 2*T,[,MX;:(;?=Q(1S?H&_,;>6V[C&57#9SNI>ZNPH5]K M)WO>%6 /5F=801A>.]+8\,C%6]V-O\LC<"P;:54@9(( &XC/F ,]3XU:#HPBC9')]9%BW,N0.]S50+!U=B-JD%A)&"IZ< M%2Q!7^HL>1_A(K$^'ZVSEFS.6\24"@#1O31C9D+(CGH'L(*_4"XDPIB)=N$D MJL^=690%^!/!,DF!B_74O/)^*J!MWMM;< A$.TIO4JVY%/4C-3#U':8O?G$Z? MP( 17W8FR5K.0Y8<"!4R1$GM$192!\FEA,"^>*TMI@4UUKSA7F67#$><,]&F MZA'))%=VT>U/YL:P-N=XD ,05V5/6)3U@R!L C&".,34+1[60Q2OO+!9#(IV MJ[-AGVY(( .5(;R/&,5B=UF8U7"PQ9P4BT]B:%+Q&KGTRE;)<;*%* 8>F7?4 MLS,JN3_]A05%B92)7T!/HC?2QN5==#&?X@[*[1;NZ*,ZPD2*W*MAU:[B/[H."<\L<$;O9GUN>5WDJ\UHM^6%,$=B_@_MEW,YEISNMP,1#KS\8 MLO#GHXM;Q(]B&V>-5GD $TK;!WC*%9?6+12ALNJ2A2JN-I4X(( YK#L^Y -Z MA6.,'.>!O0@J 5!R0?5/3;UQ-/1USF+I2!BK"UZ*PQA1]EEJ M52RVAM++4DVG!#:4XRCS59QA>585A.-<(J3ND)]3U60GDA&4.%;QRN=AZ9VY MQ@X%B10I!.<-G.W& 1P?/@]<<8)QX_/]?=[?9[<=6' M^Z 6VG'^'//L Q^N?95(P2<<^PXS[SSY_,53&>W;Q[?/X>&?9[.V/FQXY^?Z M^K'J]I?CLR#Q+ER*# MP(UZ>5 5'LUYLV6 9PVM];,9%GR!L+DY,5YAV-:\Z8($R-GTP>6U=P,]S3PB2"%B*7A!+.?/* 0OT,>^G&>\< M\-C)4)DAY M\E@++S:FW;F4/&.YD6;@P<$D&L:R%-581%>Q7BZ[80&5#K*"E+A M&E3,M&C+-C4BW<)X48(,N0 >(2PRIWS)*.;:'JT^V$B2)-NB27U+977NY%<% MF9HSNW97=$=I56 5B>&8"J4")%V;6='>D8Z1J9+3[RGC*,7*%F%Q)O92\YB"7'(XY*D-(] M ,2I+EPTP+'FFCBCH^#00!W%-D;%0 MBG/AQN(9F(W$;L;F(SU/6L6=ON)G.T%B?:^#CX# S@9&.*D8O&,CA=\?_8RO MI_\ LHKW^WJG:K [AGG'B? #Q'YBK.2,8/A[!T)^L?"L/[CP0JKC#CX8]&1, MA-EX?(>&\X9+!A"LM.L)4OTB'&6UXQG*<8PG*DJ\Y.$JOVZJKG"DDH0, $Y8 M@8];'52P]A X\:J4DGD]/+&,9Y'['YGI4=/5F3R7UD2I6&)07#(K8#^/5!U> MI+(#,P^IO+[19##RR!5LJ0SG ["\X],E"LY.W 4!?N9!RN">?6 QQ@8 .<_X M@,C-7\GCH'6K]IP.!HB100./&L);BXEEIQS!B T#J22A.'L9&2 MXH9N-0\M3CN<99SE3CN<^=G%A\M*6!+$[V) Y+,?$>L1DGGPSXU$Q;:GD3@ M9VD8QT '3..![>*AW>[-2YF5+DK+7Y8N0&MDXU&W"$3\'MY2M;[6 291PMH6 M/5B+ >):.+1'N1>5')CVQW%Y3O+>&Z13W$T07NHS+!(V]CZI)(B*.2=Y.UE MYR<%B>MHF/U2Z-U.U@"!UV[MP('ATY/'(\[#;JIT IN3:FIIV@'Q@J9.Q4.2 M4NVQV91.3'$#AY(>D0P&Q7&I(EP$![#$:2N.4#EHQR0C9:Y$N8YE6.\4L%BN M,&V8[MJXX"[U5=JA\(6Y!& M5JI ! #QD!MV,,-I.0#SA:H7[H]U<;W*'[ICD1^KIMO^/\ 8.HJ:Z6N M!'YQMZ_7I>4C_E$N4O2I/7X#\A4TNE16N[RCX]*5KW1$E?K;(Z[K\+R9I93V MR'4:E50=?*DZ!M&L/VS;*]WTC8.NFZ:!'3Y[$#B8KV"2=LEZS!BY>#D2QI81 M0>[/S_2KJ\FXS!-<.M9NUMNSHAY"?V_+L.VG%+RY($3&Z-A2DE-5=[757I-& M-UK/R99DYJF3JU2KT-*ZUD:K)"10B"_1X5)Z_7ETY\JMW[&6[-?3<*5L+:E; MOP-VYI0M]%RW5[.-(!U>5UQ"P<15HCX2OLG'4\6N6. F'&H\(*?CCX1X5S&( MZ;/E#>E16PGI2HLWOE[I[65L?@[W9H6NP@MD722K"3)N$N!7!NNLV?U"0B0( M\O$?&/ /M1PAQS*+LV/)DZ-8PIX<%](T@TT M@H.1C7W&\/,-R<1)#ART=DH=22@\G!#X,$6V4+EX=Q#BE*T**K"VV*).:XQ;A433T-824@.XHZG1@A@BRXJ'@"S!+"UZO'G&3Y M2"<^E5&>?#X_I\>HZUM[X@<=H/C7JABE5O85KV!#21[U@9(L?P\FE@9?B M5WJQW&*.$^%(PPY5>L<@TX2"=BMRQS CI7J;>51)[WKK8;C*9(%#KOF]?,G: MMY[/M-KPC<#TJ:>-MDB.3#<%69&[I_58[<&.3#@<.F2"?W3^P"WTKM-]AWV3 M/=V[O_V_INCW4'I5C<6RQZGH\4L4-S!_$+=._B02%X[ZS+V\DFYK:X(0@=#_ M )*[6=WU/Q:!K-]JEAJUN;34)M*GO>]O;"XM)IX M9K*9K@=Q)O#,%.Y%XK4]RML5KU[R5W"1#RP$9/V+$R-=082^25NC5-64)U" M6BB*)1/5BHB,,#SF,6F9=A))",C2I2QW&F/N/L!%+JW9'11JVFV\<%I)&=,= M5]=HK-XS'<2*^XAKJ9)M^P*DD.W(829K\W.V3QZ=VCU0Z=?3/-*VNF+%)0$P(MJ1,K$E 6"2GL*K M\@>^:B,E$2=>@EPTM7I-^2KYD.,[-!BJC$J'EEV@2X1RBLRR!F&XDGV/L1%W79G356Z%Y&R2212@ M%2B22NQMV4LVU[>0O"ZAF560A3C %^[SWEL75-]TG4*AI-_9L7M^UN4\JSL7 M-=<8I,DRUB3=(F <5"P8) Q7!IN=;(2<)E;5?DQE-MN>KN/>2ZSK5]IE_I%G M;:0VH1ZM<&U])6[,"VLJXD;OD]%FRGHXEN%8."4MYP578I; [6=JM<[/ZOV5 MTW3.RS:];]I-2;39K]=4-BND2HGI#2W,/\,O>]A]!CN[H.)HB19RQD!FC+2< MZZ.N[ITI3I2G2E8KWGIVG2WEI2E05F>!&[YH_CY:B>;=KT7%.SSN'F*B%&MKBWU3 MY^[S^OE7CZ_\E)J[6]\XFV2O;%L2:]P\C8YC73+M*UR/M>PF#5ZWQ$Q'WS?$ M578V]S^O;?.WRU[#M6M4)#@9&]S))K#H=?2Q6V5,GGV^'A6T27_]KB/_ "7_ M *=KJI?O#X_D:H;[I^'YBK'[>;C/;]_Y\^&\?X.JL,HX8'_ZR3R3[![> MO'NJWZIZY'NQBH];TN\<'".TUAZ/.DK EX<^*?(PV^1"-,X(FA!,?FO.D"(Y M2T""KQ_;&%>CPV[EUIIW(L(W,X=2X[O#;T'$4AR(BQ)&U6EQZPY&#TZBY@;" M3PNTX!."Y &<>)PO7S]O%8-:HDO9JSAX.SJ(K*AY8R_0[$J: MN+F/5C2 08 M>M?N%H]3AHYQUWX7'2\, M0_ZNIN*;D8\J9!0/E1HR(@&) "'&4ET*)R&]'(*(+DY,1XF2(<:MS3W$SA2R MAAA1(NXCU&.UHR7=F).=QW;B H3U$45(VCC&1XJ<@'(R0PQ@<<8QTR2$M(&&\(P8+OWL0I&XC 9F7:0V#DX4D2X!P6XP0<9R#P M<+XC//&>!YD\5BJ%203N.CC2T731,!7FNLBQM?\ 22< \DI4!4,&5B%-4L2K*V>> %50W48VDG;LPNXYVEL]/*MNJ,8^!C<=LX[$C8]O MM\W/?OCWX^;Q[9_AZY; 4Y X/AX9Z'S^-.JM[,>TXR3^7CY5$G?>GA+H$'/1 M4HY7[#7\&%+*%;&=\'R1E)4DCS4Y%O<26 M^Y8T617 !5V.%(8,&!0JV[<.,'V\CI?B=6(63<5)P"N 0<'S5L<=>F>@\S"] MH.DSV:S&U)B<;CAFQ$V0X@]<,*A&6AB\%'-ROJ+H;I3X#XC21\,.M%,^J8'< M'P4X)MR;J-9'N>[W/L[M2J2 'GB-8]P; 96]8%-N"7W%0UP[-P$>01D<$@G( MQ@DD-T/7.?):_ENK9>K7BDT:NLQ&;B_#SX@QT"PZ89\7D12&R4MG!1Y90;IR M%- G/(*CB!EA^;'R#A;PV,XMLJF15N+@QRA6*18;O8VR,R]VC;HPO^'"\N5] M4+S4B.?NS((\P%PK.2.[O%#1K M\Y9+$ID&.RM\1H@D\\]+3XBXUI'I",1C!,;Z )U"!(T=.<=7KF$/,[W%XFP% MC%%$I=BN]AM"X0*S%?O_ ,PNV&D;!!J@'C"I@DY9F&!D8& MR0I33(6!SW4EQ<[65 ? X'FZZAZ7B-K=@L.W;X^ MSJ8[) )K&*G'W1 MCIMQTR0,G!'*D9&,^%8.CDV,^U&MV%T&H0\!3(<*<$%#!0A+*)5[PD'^;.Q!W/'GG8P) 9E/!"_>;BN$AR3P/\ !D]!@YP>0#U/&3R! MCI4B-.W 2'::9)883AQ+BE(](EM# M"\.D#O,.=8CP-"4W]VID4GN@^^2,H5SW@/(+$Y')'JGH142$%WAG&?FQGZ_;W]N.K>.N3D#/MQ_QC M'0\YYZBK'.?R'_'/7\*_6/.[Y5CPQ[OJ]F,?3G.!WRNXC M+-M9E5268E2#@<9\!4EE ;&68,0?\!7U@>,9X!ST!YJ VY3VHFQ2=8AV 'QZ M+'PL0ELU]\U3$:,F/]8+1ZL.0X[(=R#&4"+8826\Z*A)8KCZ6V]SI\,LD<=P M=O>7D[RNH/=JY9RH5B1SM3,D?+9("LJKN:HD= 2I!VJ@ .,[=PR,#IEN >35=SK:WJN=TJ+:,Q!))#"6-@P5"@4'@J!E0"3R6P$:EX]A;; MZYQA?O<'C@9/)()/7D <#-WU5I3/KNVQ'TYKB@*_1[73#TK4$FORB'5YE!A4 M9<$+>*EXHM<3(-N*:8E?56DMB,M&H1C2H69+,EFD823P3B0$F89DW M%D#MQC?I PWC7&DVO>)-$)86[Q$$G>-$C,&"NO*X88W*,KNQGSK)...?N@%@,*6Q@X) M\O D9').>HK8)#!-QT6 "A3BD"C--^< #'0$^)Z<#V^SKQ6%(2SDXZGCZP/@.N,>RKE>5YHP:LYPE"1 M5Y4KV=NQ17CG/LQCWYS[L8SX^/A# D, .N,>& #USQD8SYC(QX4!P5.<#'/ M7).6QQ[*C5L&:8GK:""VES(\ (IYK#F$^C,).QE)+S;*NZL-BHP,TAU?HR%N MX*0TC OG.%["%62%F8J2N3@+SR01Y@^7/!\I3&>.@//G@CS_2L6FD>@PM M'I'FVO0E*3V,\[SRA?0D!Q:6,'*:69EQI[#S:'F4.^JE,XRH9TA*15@-QZ\' M[O&WD,Y(& N".FYO6!)W5>7:1DY!XXXZGP /7V]/TJYXB3;)J@4<2 %,PT[% MY?-$9DWF)$I,Z6Y3LMC(=R$2Y&98,5YYN2$$(QY[S2/3.#I;M]V"2#N5B2"6 M7@*H[S!(SAVQA<<>O7R(YJ-S-OM,7F2C28> MOS4:Y,30"X )P=R?#9!EG(Z0PTM\YDF2\Q."5I>]5C&Q(=019/GJA)&'3*+@DM(7?<%]4 F Y^]@-SP%.WD#478L2Y!.%RU(@+7'PEX)&0=!"1,O'Q+$PIYZ)<:*L(TI'I>%''2D)@=* M@U.S"BB#WBF-=I7$9$FUCQG@@C<$4,W%]%5 MF4 NBL W=E.@P6;IC(!)/(Y& 36Z355"CM9T.N4R+4XXQ$B9]8??<]*^2<6Z MX8>0^]YJ?2./%OO9\_"$=TX3A*$8[(QS4CR22ER57O&W-M4*%Z (JD\*%"J M.2!6/(X=F)!/@ <\ ="< >?CS\ZD6!X@B>_^UV?_ $:>J#U/O-2O0>ZN-[E# M]TQR(_5TVW_'^P=14UTM<"/SC;U^O2\I'_*)E2>OP'Y"II=*BH_\ )+?$ M/QXU^+=IJM'VX>2L0E4&KT47'BRDG(RD5,F "@YEU#Q#KC[\6E@A,G(Q0C(+ MI1N3'7A68\Y2K@T-?KCLW5U>N-_H)6L+;(N2[$Q1S4SZ2H)Z,F#HUIE[-CKE M7.=6\.*T3Z<>.(AR,/8?@YB;B' Y4M2HNJW5*[3(H;B8^&L=?C>7493X6[40 MT%4!B.K=9=)**L$;,3^;($[FTDSU3B#!(Q]%G9A1K>-&1-5GH:0,4K8%TI4< M=P\5]/;H2R[9:K$"R:'#_694"*CT%20\LXP])-2:Z.F+WLC<<@-0K588!NSR M!M=2D:/:%EXD6+D' XNRS(@(\-'G9AUH<]6(PX4T^_EHU4>[Q^L]",_G\*V M<2^.T=Q?T[':QCK/8+6C,M(V0H^PI98=%-FFQ,D1L?'#$>+ZJA60V"R6 MW)%Z1D,O*<.7C"IK3)Y2;@K; -I(VKH^B;"VW.;MD+V;L (>!?L471B\_%?$ M.9#XKX0A<<^0HF54*Y,$2*%X$W'9.X34!J&E6EYJ,NJO=M>*( MFFCM&_\ '[IXNY560G=)M,K./5/'!K]/O^EC_J%T:X[(MV/^T#M%V9[%Z?V! MM>ST'9J>34(],N^T$.=7-]!?'4KB>&ZCB$5F)DL8K5E[]-S+O2MNG!_1%_X[ M:+#U[LFXLW>QKL*^+?M_^T/LW]IWV M@S]I>RNAOV?TL:78Z9Z&\-C 9KFRDNN]O NGEH"MPLL>UR3(RH-_05YW)/3[ MUIL&M"Z?QZUCL9HF]"2>UIFP0]%8E5U =IP0H!@V;2-)&2!GPD](L.LOKPR] M$--/*RDS*<^Q=D]<2SM=62_[4:OI3)IKPZ+;VT^I- MZ[!UE:.WWQ1QQ]TL3 M(5&Y9V91ZE?,':327N;C37LNS^FZB&OEFU2:>*Q65K504>/?/LD>23O#('#' M:T*@\/4KZQ4ZQ2(,2N4ZNP]8@8]*\!0L!'!Q4+O+V\U"X>ZOKJXO+F3_V3W,KS2MCH"\C,VU1PJYVJ,!0 M,5U=K:6UE"MO9V\-M F=L,$:11KGDD*@ R3R3C)/))-1C79Z$J$=KQX.)(C2%"S::M.ES$E\.)GP_6GX(DM^O^J)EQF"1&WA$ MON8Z^:M?[9]J+?5=1L;RZ:S-L\\$4.GL;=V_P!MG;O1M?[4=G=9M[C1YK=KRTT-M$Q X)]*33M0DFO._P#3('+6 MLS&VCA[Y$EB)CSW),Y!MD>])8)2 /+4;"GS#2 MR''PC%,$*8P 2+&O""L#-+"QG'K#_L/8M]5D[.V,NL/))=R][*'G,AN#!)(S M0F'Q_*J6^Z?A^=1>VMMANCN14#%MQ[M@GL%8;-F7B1J]7&41\@2-)V$ MH4XC"$F/;WC@N$98PY"EE!) MR3M!VJQ&X9MKG(\">@(/4CC..?T/3//$;-=T,ZW29\D[=S9V97+Q=F(GA7U& M1BCW(U0TD]%'GH#)*J)L[%.QP&:^Q'MLL1S1 H[#+_IGLZZEB0^I;Q(C0]TL M>-K;>\W0EQ'_ //6-U9N]:0,7(8\;19_P K8SX#ICC'^$5(262X MII,7"/005:!CRA9)D,)02IFUHRT*.",TAA#;$>(T(ZMUUE1N'>S+><^@ <2_ M@J5!+R+(9RV58MN$<.2S9/.YV+<#U<#/)8Y !B<\<@X&,D'P]V!U..?A5ID^ MIY*-+?4Z^TR3EEJ+C5-+^$"LM%C*CG5K6EQ;;S;[>'FBE('!?;PK#K7FH>14 MI; (V@,"2S#[@!!W #!4@\# W,..:E@,[<]BHY]0B6)678;C"8@0(8; M^V\&I=9>'>8>M3R'NY4-VLC-M_EPB0HXSEE>1U#, KC<6!"YY(3-_@1$;" M2#G.6W8(!V\ ;?!O#=P.M;+DXQB'.QX^! V,]_#_ -U[?F[=L_5VQ[.W6I<^ MMXYX&!X9SX\<>=8X'JGIS]=//R]_NK7=ROV$R0?!U"C?"LM<_0&H-)@27$-U MT(\D0,4@E]@0Y3!AI8Q@0#S#:7QULFNX7Y[32%;;3K8%O2)C&L*OZHM M/<(O?K*S30R'(5F11 L"B41MW"X=@Z$8!5PR\9A[J/+11EBG=A8YD4C."S2; MU*Y/>#*JX<%3@@8.;[&AI?2IHJ1(MB';<#P5FF.QLHW9 )KN8@F.!&+ M9#9[O?W<0X9AR.@)QU%'+A3*]ZJY6 MG707#V6TS&RYEUE1Q#>4&E,PL%)FX5E)!$>">@=0^'GFF6\L)<0MM26KIA=@ MK7C1Q!&_E60;9&NW8IDEB7 QZP+9Y(YP% 6J=Q+,(HRX^]WF&8_#J0,YY^Z, M\SWA:%880@B.)'CW$D1@^JQ#.R;SWGJL,%@('&SA4R M0[DDG//W03@#^D-@@$GK4Q>.6 T:@V$X *RR\Y9(MT\(3)[Q&"E!,X(7EA_# M&&EEYPL@,87T&,#.L*7AI:^M5J*OW\89LC<>[8[<;=^U/E[.*QIL6$69$',A.Q:IR*\UR.BW0_3.? I3S*\"I'R*\ZD@!QA&8YL M'#:5BC"MJPWW898R[6;9(FY6[M@065@!WBJOK!U8#[I.[)&6=B"",<%5Y8\?>\N.!R.0//!]N,;%N>WQDZZ_4'F5Q +]>% J& 3XZ0/$]> M?S,J22PSGT9AC1\,(R(EE;@B&76_1.*'=P3G)IT!AQ=;T(,[/=)(A16*)W0* MD_=&V0Y'#9&2. MOO&W94!@V,(R]1C!*D<9Y\3D8Y!\?B] M'4UV1D%RA2TCR9T*(PJ0-63(^9A"7B"P0FAT82ZIS$@_W2IMM*=;W4;0R-&K MF;OFP2Q[O9G@$8P.!([-TQM \35X@,1NV[1Q@#USD9)'^(@'&/ YQ@U)&A[" MBKU& E,-NQQQ<+'6!4,:I.#F(F5=+9CCG$)_]Y,<",0A6.^/.8<1G_H<>=9* M=W-)&VTNA*$HP9#M.-RD>!\#QG/0=*M.K!0W.TX^]PP)&2ISSD>/P]]8LY"E MXA[!HR;>>RP&F. F_Y MY" #]]CD#H!A0,], 9!\#CFOJK3>PH@6N@0T S-35DD(';#I+CH["%#Q0Z S M!E),'P(QAXL81\,H5O*,9-8':PTZM)+%5QZ-+)*\DIB[F,V#*-S*DCEG+1G^ M@8<,C8(P6)Y(%*@JH50&W$R V-W//4$@8X/->"95Y.N:#F9:0FY:=& MN\1(P9:$9C1) 6P5<]YJLLQK4@A@9@H7U0QEC)(P[0L@\@AU+8[KGFXK.LT\ M4< ;=#ZO>*BI))'.C),S+M"@C]%PMW"Z%.\*22[E0OM*J2P"[$+,RQE,DN0'B MW;CMK7!"@Y#,.%P" >3@$DEAT8L>G0XQDSGXUTV';H-0MK]7@X^87!"L@'A! M);<=%4&P,\>SZ5AHEE''F$-.N:B=BT\OK,P21E&]F()!/ M0%O\+$J,]!R<&J)9"/4#'! .T> X(4GS& 2,8_23Z<8_Z'MCQ]_NQW]O;Q[> M/S?SY\;/Q&,X(Q@=1T(^>3SQ6+[:M*W66&%O3).#Q@\\X)(\NF8M$!2TH*);4_V9^7M4F*0(:M*G(6(_-S4& M"P2ES.'GA?6"A9AUDHEK+[I 0S&6DD=LT2*JF,C:J(K+M8#O6)VR.0!QN&UE MXSCUB3Q1%];C/(YX/4'CV9S\N?AY*PQG15(P84:S#*89'&94@5QIE X:,L.I M>=RB09?;&46E[/G.>A=(0&A1.4-XML^7&"JAU)Z,2>?/'CSQ61X=K(L.<=Z3TR1*7&">F>&]=,8(:(9.8=>D/2.H0 MDEE;QK>5O-M9;>9<;>RG"4W6\P+$W.V"9=J";7/OS5DFWC6*9"7#[D)!98QQ)'AF5LXYP? M5 &("[%+2'&267:H]G!\B>/8??7CZ^V]M"$B@:LS/0$>;AK&>Y$4\"R>T$H M-D&#-CS'HXB0E'C,$)C!/1$J4PHYDUU#*'Q<+4;.%(6N4CEVE?7$!!42;=[% M8Y!WBJ"#CDG)!88X.7 3(P5BISPA?).T [0S J"0O4\<8 '-;O(Q67(\!>5=O.SC&59[Y\%9[>S&??URZ^LV,'(];0<9QR1\ M/C6*Y.3SXG@= /+/CX>SGCBLK@?[!#_\&9_]&GISXG)\3TR?$U6O0?7N_P"? M'K7&]RA^Z8Y$?JZ;;_C_ &#I4UTM<"/SC;U^O2\I'_*)E2>OP'Y"II=*B MG2E.E*B3;MJT+:K6NC*#/IGAJOR7J=4FW,1LQ&>K30$?+$.H'1,Q\C$F0,T$^V9#R9PJO2]*5+;I2G2E.E*=*4Z4ITI3I2G2E.E*P7L+C9I? M:NPJ-LZ_4:&LMKUZ/)C0)$D&*2(\W)*$=;Q,AO,+;F<1#XF28-H[+K$628>^ MPUZ0I>>M)J'9W1]4OK/4;ZRBN+BQ618N\1&CD#[2OI",I$XA92T"R$K$SNP7 M+5RNL=B>S&OZSI&O:OI-K?:CHBW"6,L\2.F)S$P[^-E(N/1WBWVHEW+;O),Z M*&D8UG)"$-H0VVA+;;:4H0A"<)0A"<82E"$IQA*4I3C&$IQC&,8QC&,=NMT M !@ < = !X 5U( & !P !T '@!7ZZFIITI3I2G2E.E*=*5YLO_ M .UQ'_DO_3M=5+]X?'\C5+_=/P_,5K+W77KY'['>GY!I(Z8)S^%?UU;.(=),BZ M\P60_C!J9\G*WJZ:L%"(S ,7)#>HK$49&J+E$$2$*2"PRK/GN,/&RS;F;=W' M(G=R2JB1D'.") 9 W$BY!.)%VL!(V<\?X=JW%V\@;BVT$,00.IR#TQCH1@XZ MGPK,!A)DBL>,AT-X=3E8@CK:U*%C!')\<&KHVC/('JG)/GCRX/LSU&/,<_0T, MRQ)M1Y#KSK%=B#WCY YMU [AF,);?>6=Z7 [:QA&R$O^8E""?7$D,H;<;=1B MIF?!(*@ROC:IZ+RV F,GD#;R!ZK#G<0+?@3XC.T,,YR,>\'IG/CU.!FH%/60 MC9%@7@<&I,:%:K\ULOT\9(6*675JV:>: MNOL[H$;]P;'(]7/!(&><@C(\.>,<@3Y3XPYN.V?^GB^_&WTX[_ #=_ MJZUH^]T\L^D![)AP)[CCBQWGXQIAEX!]YI6<-D)3YZE-X+4QN'2%K"VD3_ -N7 M,@P2@2(X?>QXC;!$@\2N<\8SE1ABS9/#!0O&3N8>"\GCD>W'CS58_EK2[&&^ MW0H]N6.8'>?,.>R\-7EKP06Z\D*9<;)0Z^K##16 @&DK<&)6\_YBRH1[/6 K:>J'M$XD9]P MM)LD^@+U=LXE]GX72 COZ('+3('9S*UIRZ_G&:J*4>>::6S3@(6F6-6;:-R! M5";T9@0A8L[=!T&+&6&41>]?;N?"24^H]UUYLAU)C2Q!1A4BR8P3 ^&O6'BDR!SV6QLB9=21MN$R1V_< MPPED!XD64]X2Y)W'D*O.T' 90S= 1PJ[-7 M"B&[LDQ;$E:*ZA4A'$L 1WFD"KC$OB&2B9F10AR.DAR!@C 6FH\3*VF\EE@O M,9RR_FQ++)((Y<0.47)F?:'[T,P6*&)ES$&! D9@'P5!YJ5 4$$,0=N5SM4< M'G*GUL<8'0^((QG89Q_8AF]3WCX->(-?Q9PWI-TP<\(5Y"6>P;C(\@A*T)S& MI;P2YA#B7'4*RX\0M*G,Z&_:0R1[QLPF$"E'QS@^LG5=V>#RJ\ 8 K /JG M@DD$Y&,\XZ#H"/#&>N>A/AD"?'PY&5V] < M^77S]WPQ7BRR"S1&9ML44Q03#WI1\C>LH* 4L;!Z6VVTD/J(3Z'UR/$2AYE# MX[B7\N>F:>:K3 8PAMN74@A@"CC(5LG:,;3A^A(((Q@52P_^8M[<^? SR M?KQK#Q]F!B*>76V9!+,7-3DK+-V;L-&M"U28))ESF2FUN-ELN8%1(0P2FFL- MDH6P@?ST86AK9K"S3]]LR\<:?RP6?=,BQQKR 5V\"5LD@8.[[U6<\;,XW!LY M&"%W$G/(P<#:,C..F!TM:H0\/,2JK@&"!P<9.,D=M)W494^O/A M=G>$1MM*Y$C!2.@B+9WX-N)W:4X.5VY(/^ G!PO0;B ,\="< $ C+6O;U9+M MM(RZ0 1H54K:SJ[AJ7:D(X23C,B$K/4" Z^EI4H3.A#+:D'A4#H!"=RP\M@L M1V0U,\45O;%#_P"\N6/J#1EYD?+;IK:U19!1Z3/+((X8HMLRDL&=94D4*F%.7WA=JG[P M).4P=Q==IXV@C)RQ/1?:.X=UO+R,Z M?S&+JN>Z#8QM;!V\9.,U<.<,%!;HVXC:,'C.>K*,X&,@D],8KS0;!/4NT@@V MS"I=BIPCM$1+1PS; /\ ;@X!B%R![SJ V'65-!LNMI=00P\^XH,?*-R!>\7*@G%5Z"I,_6&DCGR"+I#"0HJ9M_&5J<,EO0E9('86* LXTTC!2$2!#DJ$C MU539WJ:,A6M&9;AWW2K'&DXD.Q$E7"QE< OG5)Z<@D')]U20IFO('?E,IRWFYAAJ$6V$9)-K3'JR" V1%'@NK8PVV4!, M*9R4]'HPIMW.(YY*VE"J6K423S6T]PJ,C%F1O64O'&21(KKNP!(IX!XQRI!4 MFJRRJ%9O , <9X*XP!RN3DGI[,DU/T $2."#CP!VQP@AV Q!VD^8VP,,A+3 M#2$]L8PAMM"4I^?"<=\Y[^.(?,<\GPSGP!Z8YZ^T_(818DDD^WY]?A[/?7VX M3GV]_-Q[?=C.?Q_/CZO?X]#GICU<."C;5*N1L8Y*FIR&IMTB0."' 4I;N79AQ:&G7'6FG M3C='DGU<,,!.N" M;[,_",VPUD[ H-9G8]4:KST^IQ.28?(C#;((1[;;D@V^00SZR_EX1;/85U@E M#GHTY (ABW,#F1,.J\;L28)=F3[IV@87GJ=V<@W(EWDD8!QU//&,$#I[<\'K M[L>I$(,DI$=&63FV32UKS"-LLB/NL(/$3(R+LJX2A>&8\4S)SPC3K2W$97&L M)(-PRWU:3:4;?:=64AUC*F"&W?7 M4OL $J\W+SS=VT0M,7VF6.W5I6"H1PQX]4<@ G[P^[RPP1BK)P3R0N#U\-QY MZD=1CIC]J@K*B#QPSU5BSI'#"PHIEFBV6P .P#I\=#B"AEU!I9BA$J!]6=9) MBX8HJO$.Q,B*PR"5Z5>-@I1BC2QB)$8NMQ;(5D10=ICE"]#AE7=L$@4@L7' MR0QQP>,\\<8 .:P7J:NC;(V75*2 &XR-3EEA@8+-N[T_RSA0 MY9>,MN.Z3+'O4+* @C8KM(4&J((%+L@ 0;L>!\-HQ]TCH1QDD#'!KH"&9;&' M'''1E# S+8[*,=_[&VTC#:$X_P#[$IPG'L[^;W[]?><4J_[IL6OT',;BJ8E\@YD/,)R!@G 1GH%*QI*\H=5P8K1LS'[IC!'Y*&AV23>,O M)0=ER5L4P#7X*/0XYJ7"5%RTW)Q\4 QC/GDG&C#-84XZA.5*]+Y1% _2_O3] MR]R8_HDZ4KS97E#JN#%:-F8_=,8(_)0T.R2;QEY*#LN2MBF :_!1Z''-2X2H MN6FY./B@&,9\\DXT89K"G'4)RI7I?*(H'Z7]Z?N7N3']$G2E?#(\G-7Q+#1, MG&;K '?.C8MEXKC'R59; 1%B&QFZQ29LYR+B&'^,?)5MV2D6HR1F70@T*U+C+Y+<3$2DBIIO&5X$ M*?SCS&5YPI7W?*(H'Z7]Z?N7N3']$G2E9N'?04.P2VEY+9#+3[:2!R!"$H=0 MEQ*7Q"VF2A7L)5C#HY++1#*_.;>:;<2I.%*_MTI3I2G2E.E*=*5\<@PX2(ZR MUV\]?H^WG9[8_,NH5GOGQ]B4YS[/'V=2#@Y/UQ5+9(X]E1-V+KG:]@NL%.QT M/$GP-:5@D"%S9V0?A&6#Q(/@R4FHB+?2PTV2X&H=@;TZTK;PHG*TXPH?80RV MBQ.KEQ,V!WO=[]B' =$7O ,E2<9P,#H.>/+CZ(O3 M=QS/OV0EF/B'9(4=N2APBVG 5D-C+9 7V8QNW>'GCRJ^ M*W0[1%9,27'1;[*$*(BTN&I=<%,0,TRAMAQ:'UL-O+66K+B%M>A2K'9M67G< M)LLX.,'!Y#-M&2I?=T 49Z>PD<\X-0P!/&?'I@<'P//3W5:,CJBX.UNP1[<3 M%$NS@Q(AL=F42.@]F292V8AP_+:TI3A.4BY(?&()6.+E:<><\EI%U98S*C.S M[5P 2H?8%;(.PXW^+;=RKNP,=34G.!C:",D=?O'IR/;XXS468CBOO]IM,F.+ MKNLSX_J,<"AI;,A'QU48)PHJM1K*F2$"I>!R0-'R;?H%PY)"'W@9\*/#CNME M=WMC(J0Q"=X$VG;(2-S>J&?"-& Q50 /N\ @(2Y>F'@0.QA#*-;/-;L__CQ-%$ ,*SEV+8&XDEB ,YP .AYR>:2&1]H9 MM^!C. OB3[^,]?'\*SE\$F)CBA_1HRXZ\PI"$N)[92C/YK.5*\U.,^.<^WQ^ MOOWQ>,^0]Y\1R>//QQCX=:I*G!\22/'P&?/GC)^?OJ#/)/BW?-@.G3VNEQ29 M2?C6ZY:J_.-Q1,'8(5:3&'LR#9SF,.9;%D3TH0VXTI:WLX M?1>,]OU_3@AHRA1RI\"-:"9$"E:V**VED9+#(83JC&1XR,9] TW@,!(XR6/0 MY2,I;*D*22K*W=]X4MP0J+AR$C7U1A5^\RK]TMST&X"KC2 DMD%VR68@@MGE MNG R23TQSTSS6$Y7B=ONR-&6"1J[P5NE)-II[/QAICHX46(EMOTC+#-C6.TX M\VAQ I3);T@H1: 2FPT/&/JVD.HVT!2./)MDCVM'(75I).])+DB.7(*A3M)Q MD[L!Q@63R&R1NW;E8 XQ@ )SR".0201QCQR?%=X>;[ :!1%T*,=PVA_$B^BT MU9N2-2X>H=Q*'W9-EH!144\XM8[&2!F_-]&IUUYUS.;LFIVL@+NPDD1U]'5X M6985_J7=U=.,C?@9*E@/!B.H'%>ZSQ-Y!B M-K-^+428<=+BX,&^$JCE"(8,PIZ#2]ZW+NK.^ A))3!029(2/.-"/D!X].)S M(HMI=0M=Q,C8!C,8,,3(V[O'Q)(Q;G,94MM5G!)P0C=V#CO2(QE9" M02Q8+XR3AG(.\,/!0,%@O()P?5Y7!'3IGQE+K*B;)@:I=(N;K#L0Z58(;XN M_#$!*M$Q(,>K!!9&(XA2!$F&Y=<.%=>=>600YEE61%X;:UL[1$0%)-S!6:7: MLB;7+DE07R6&WA3P ,' ;(J,DDY&!P!TZ ?OSX>/AQ5UBZ_L3LL"ZX$^$*.Z MD@U:?4LI,PVA"4C9RI2W5A27%,Y93Z%;G?'I?,7C'1MJ$$AL@C!W>KG)R M.@ST&#GG!SQD2Q]7U02>/( $>//EUX_&OB%I5H:)*9&A#Q(_/8F+=P\&ET5E M:&DX#>9=(>PHEI;:G',K0XRXAY32O/PI[SZ'.[:P&200X81L TH.B08*8(,@9"2; M%%48*V](MLKB_/9;,4#C#V1L-/*CO5'5I\_)%PXC,65"A&0#& 05?:2 H.]2 M>&4H3XDXJV$17#8+8<-G//'3J",''(((YY%8G=X[[5JNNQJ13!WR1422R2'Q MTA5^4RHJ,%:E"VG\21F6/67FCLQS@KV3 3) =64H]29DP]C!=VSSK-<@92". M-%.YT!CVHH*L.0%4,REL$!@,[MM42AB&V9]=G9AT(#3\/%A./ M.VY1NOU&7K3U?IZJP&Y:Y,>;8382IAHMT@>(:>![X5\&,3JYV MJRL"47U\#(R"1@ X !5N=QR" 3E*4TU>95XVJQ$ ?6*>9%RW@A99#K@ZI-PY*Y%!;>75$X"3)&YNG99IY&)VMDK'M V.1MV MDG<< $;"HX)Y%_AD$9+*BC V@ G/WN0..0.2"3YCBLYZXU[F.I\%&.5=^$?J MLE.APC,T0P<>'&$OA*]( ?@DTA,?(Y$;<2TMYAY33##90Z,M)QUAN[,YD=E9 MW.YMO0DY'.%"].H \?/)J),_=C/J[0#X X''!Y^?C[*^*_Q9&3<4;!9=C*1 ME77P##@';DX.0?+ XHCNHVLN]<[L$X.1Y,#G&>H\JQ07Q$E5TV2J;%_EG5R< MPS,.RQH\4LELI"\.D/Y1D)[UDB0>QYQJB'5M>C6L4)L,7#33=\7;B42E(B<; M=F'6/;X#:KY VXPP(QYG)K+J3_ZV&!@'<*3QCG''LJ3+@ 1J1C@EBI/0= #CX$]1678^F*B16@8P$$ M)A.4LBAX;88;QE7G9PAMM*$8\Y6/@?=X>6>.E?=\7Y+_P""SW[_ /9>W;'C[/#/T=O9]6.J MMW!\">// QX=.?D/=5&Q@>F1UZCXC^_G5<0$CXXREKMGQ_Z;CPSC/A[L_P _ MA[^_16.,,<\8]IX^ \_;T^ H?+\?;Q6 -LT_G(JV4R;39%.8 M/8L0,X_)AL@N6+&'5,28^6AY#*O-PRI@%R*/B" !'K';USCG..@X\#[^/S\$?6&Q9N/80[2&Z8^# M)K2E#TU7#W3!R(ON\9G,))Y:2R,(6_B084$IW*G_3#&L29(E+?S.\WQ MXP%954[L[<,O4X^\!M]8C!P>,'Y=?RR1X$U?4-K6T0*7!A(EQU+;<6 M("6IA[UIT 4TAHM8Q_JCC9>=:WL-JH"; MK"Y0^+K[\'P\J-I4*BDE$'K-NV@9.&P"23?=U[ MMT7D,1CCC PV[G&3N R#G.2>AJ86(&2[?['3W\/_ 'YKQ_!Y^>W;V>WV?BZQ MU8 MEY2/^42Y2]*D]?@/R%32Z5%.E*=*4Z4ITI6N[E5SSHVD;?1- M)K5^KM8F5$26M2P/U]?V\ZV0RLK%P47)3< MW(@Q$-#@%RDM+293 ,;&1D>.X6=(2!I*VA@P@Q6G2"BB'&V6&&UNNK2A"E84 MK7?"NSMNZ!#"H+.R+(U4[Y6-P:YMNQ;')9U%LP/3-_JM?M%Z MX]S.*^V_C<-0B2X<(DL2VUF1L]6J^PI2CJG'U^?Q]G]L[(.E16GT7RFL/L#E MK ZBUM3HK:&K MA ZEG7PZG=D[2IFW ;K/!K<%TJ*UU3/E#Z"1ROI'&G7- M5^RR))RJZ[=MAU":D9%N@7-!DU%2=<1#1M.EXB2/IJ&:_-;";E[K4)*%H]T# MN5:B[I UZ^OU53Z^O^/EX[%>E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E* M=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3 MI2G2E.E*=*4Z4ITI3I2G2E.E*XT^4/W3'(C]73;?\?[!TI72UP(_.-O7Z]+R MD?\ *)E2>OP'Y"II=*BG2E.E*_*UH;0IQQ24-H2I:UK5A*$(3C*E*4I6< M)2E*<9RI6CX:R:U\YI4GL20C(L^WU75-^LVMX'=5;J&P*U5MB1&P*Z+ M$OJD#Q\/=]8Z^WW5G?ASQ)C^+M( NFU9^$E-CQ- 1"R,V4Y7'H#5M92\_:+I M#0M[Q4*/,V8>4T[':$X MQ-P $.WR(IVO/C&K;$2Q,;=$D=7V[9(?PAKQFLRHI''?;-*B;++:>VVU,;)H M-_NFOTP>S-9OZD)N,B*J?#/UY?/X=#USBI]<$>&S_&"DQTO>+-.6O;LQK^GT MB79,LQ-BINLJG62YR?!U5JA)0$>7'T&(M-KL\L S)YDI 9$B)709%FG5FHPD M,J*ASR@YR[*V,NNU7C);:05JO=U\/&IC< >+4+ MHG4\1>;70G:_R1VE'R5@W?9K&:+/;$-E+%;)RXM5*VVL"5EXVQ.5(B<=$=DH M9\.!FYY<_<8Z%A"K7*!=*BHZ\IN<1>P]DU3B7Q0F)2>NUZLD;'N[>U]8X]-' M?.IUC-=W!IP3:,;3-H0U.O-7J\/Z2\&M5NTV/7JK/2\SU/C*]:W;O75/KZ]] M3 X8\3X?B[JNM0LBJ,G-I$52"B[W; 1Q,B))&P1,R52IA"8>'/C=81UUF[?9 M*A4'1V(BKOVJ8$K4378%T"O1:F?^/*IB]*4Z4ITI3I2G2E.E*=*4Z4ITI3I2 MG2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4 MZ4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*5QI\H?NF.1'ZNFV_P"/]@Z4KI:X M$?G&WK]>EY2/^42Y2]*D]?@/R%32Z5%.E*=*5K!YU;&V'90FJIH79$G/U6@R MDE"\M*-QJCM4;@Y05$6VP3;&N5NZCO\ 7^#G:&]($%$;+U^=6H>[6BJ$#'5 M:91&QL['2JI]_P ,YP?K\Z]K@YP9K.DP*WO/95<$*Y06RCP"K?*E.HD3M?E3 M=5@%VG6P-C;(?-O$13[ W.5NBVZ[F6B]UW6OP-K5FY2M8@1G#%1[NGA]>WJ? M;4DN56G;]O345EUS0M@0=)#LR_-1\QR@M]*C8G==O MKEKN,S1;!K]TFI(6T1ECGD$U:VMV'6&18@Q M@&PQE8MU G+S3;9I;9YM*D9J&Q+J#S^OK(]]2TT_QRBM6S=AWMOFQ:WV!N=" M3L![1&H(.O:SIW7*:=1ZH;KW50UALMUF]>:[.101[I98==X+BR;I8K?-#LQH MDPZ$E3Z^NF:P'N?R@5RU'RQ,XZC\?;OL<*1HX!5-8URN!DMC6*UR;.20+%$Q MLE81J^;K%!A@=0O1QY$+9]-R[<-?;O!F:=NP]WK*IQ\/KZ]_..:F)I;1-4UD M(%:'HIDG;$]2Z5 [(N[S,$)+V^0J8$@R 9."4Z%JE+*E(E,W*PX4W$5*')5 M^J0Z?,B0@0AE16L#EMRPWKLWD'$(5EN*:_7WQJ[LZVZHA,25F7J+/"4G-7#K9N(7>J#K+I6&N;%FT[NABJ2MGK%OK*I&/[?7]OCTJ>7# M_AO2^*,%920"@Y_8^PWHTS8%JCJ_%U&#?S%(*Q$URH5.(0IFMTFO*/D&:K!' MR5CD:Y#$!5 &P*IE8IU?KRHJ9/2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G M2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z M4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*XT^4/W3'(C]73;?\?[!TI72UP(_.-O M7Z]+RD?\HEREZ5)Z_ ?D*FETJ*=*5 KRB,!ROG]#%#\59&!2>DQUO9\!\#W4 MC:4OKT@52#)30]@I&W-/&0>VZ><@:R5L&1L6(VT+#/D<[L/=M_9V7R'L\?<0K?.UP1F$UT+\>-CR>RK=(4^OOP@5HC"MBVT MMJ^W*(L]CM<-6;K(6"-U8/2*&4Q5VU23D],?7T/[UL-Z5%.E*A]SGEN3$+Q\ ML)G%.NQ=KV2[*0\6=!E,S+TX34ITA<),/U!4);J&6%.1A$C'2QLHU;(>1BZH M!9#JV1BV,P&4J?7UUJS.$?">F\9=>4LF=KE=+W$+7VVIB=';%E$UD^2!$"G! MJZ>W&0T0-8)V*C*[&;8N](J>N0-VV:L,[%L5)B9N4)%:4-18YO\ * _>%ESP MTXM6*0F;P_-F!;0MVO;".!8J?8:5-1RM.VZ4G;M6]G:_#9A).PZ:N&QZ"=E4\?73GI_?I@^>#4^>&W#.B\4Z@[ZB* M\7?;,78;!8B2+1:K;"4TR]6,V\VJB:O7;I TFO:_%MDL*>B=B''*!?(=! M,89+&>:0J3^@_(5FK[;GQ;_07;W[$Z[^6?2HI]MSXN?H+M[]B==_+/I2GVW/ MBW^@NWOV)UW\L^E*?;<^+?Z"[>_8G7?RSZ4I]MSXM_H+M[]B==_+/I2GVW/B MY^@NWOV)UW\L^E*?;<^+?Z"[>_8G7?RSZ4I]MSXM_H+M[]B==_+/I2GVW/BW M^@VWOV)U[\L^E*L0?RD?!078\AN ;5=R8VK+50*B2>Q6M:TM%S.ID=)/RX-7 M*L2;7B4>@QI0AT]N-63D;UGT;N6\J99]&I5]_;<^+?Z"[>_8G7?RSZ4I]MSX MN?H+M[]B==_+/I2GVW/BY^@NWOV)UW\L^E*?;<^+?Z"[>_8G7?RSZ4I]MSXM M_H+M[]B==_+/I2GVW/BW^@NWOV)UW\L^E*?;<^+?Z#;>_8G7?RSZ4I]MSXM_ MH+M[]B==_+/I2GVW/BW^@VWOV)UW\?\ ?GTI3[;GQ;_07;W[$Z[^6?2E/MN? M%O\ 0;;W[$Z[^6?2E/MN?%O]!=O?L3KOY9]*4^VY\6_T%V]^Q.N_EGTI3[;G MQ;_07;W[$Z[^6?2E/MN?%S]!=O?L3KOY9]*4^VY\6_T%V]^Q.N_EGTI3[;GQ M;_07;W[$Z[^6?2E/MN?%O]!=O?L3KOY9]*4^VY\6_P!!=O?L3KOY9]*4^VY\ M6_T%V]^Q.N_EGTI3[;GQ;_07;W[$Z[^6?2E/MN?%O]!=O?L3KOY9]*4^VY\6 M_P!!=O?L3KOY9]*4^VY\6_T&V]^Q.N_EGTI3[;GQ;_0;;V/_ #3KO\USZ4I] MMSXN?H+M[]B==_+/I2GVW/BW^@NWOV)UW\L^E*?;<^+?Z"[>_8G7?RSZ4I]M MSXM_H+M[]B==_+/I2GVW/BW^@VWOJ^*==_+/MTI3[;GQ<_07;W[$Z[^6?2E/ MMN?%S]!=O?L3KOY9]*4^VY\6_P!!=O?L3KOY9]*4^VY\6_T%V]^Q.N_EGTI3 M[;GQ<_07;W[$Z[^6?2E/MN?%S]!=O?L3KOY9]*4^VY\6_P!!MO?L3KOY9]*4 M^VY\7/T%V]^Q.N_EGTI3[;GQ;_07;W[$Z[^6?2E/MN?%O]!=O?L3KOY9]*4^ MVY\7/T%V]^Q.N_EGTI3[;GQ;_07;W[$Z[^6?2E/MN?%O]!=O?L3KOY9]*4^V MY\6_T%V]^Q.N_EGTI3[;GQ;_ $%V]^Q.N_EGTI3[;GQ;_07;W[$Z[^6?2E/M MN?%O]!=O?L3KOY9]*5I!OE#O^]=B;-W#1*9)+INQMH[,M5:7+RU2CI-R'D[W =870W3 <60C(CSK79S+"G5+;PK"7/-7A2$J5__]D! end GRAPHIC 14 g582934g04t71.jpg GRAPHIC begin 644 g582934g04t71.jpg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

+_Q; _ERO\ J;%;6KMIY/.W']V5KMN^SRF,[8K=.JSZN',-^Q&D+M%U-W2F MI_V-=&] 6AZ5*5*]\=YT84JYJMS5.[U-A;SMZVM?738:@[6MM7KZ6MM;>PUTTVF[O_%IOOIZ_P 5G?B2;,?1&VP_ M>#Q5^RGS]6@&ITT'D238[#E?D?TN5&8]3\RN/$EV8>B-MAI[N \4^2O_ %3Z MOR^_I\AH- -2+VY^O7YZ%+GJ?F4\239CUT\4;;#Q[>O >*N'7_V3[/5VZ6V] M+KR-(T(GR]6KF@T4VYQX\J@K1!)2MEW 1M<#IIO^0)&@OMY%3Y+Z$R!6)S/%NPF(RE"C6J\:D\(V] #Z-'Z22["JH8J+:$4Z/4 M%D5VG=MK>^4E4E$:WV*4NNGPZBPO8[VY^>GD18Z7/1/%OXOJLOANUSD_LB!* M26!;;MH4RCMQ,V%M-QK#&'30NXO&C#Z/2$;:_81E=M<]"G1A 03;44YUD29. MFCBVQ=%2RV#EU%^FUOQ)UYD\MA<*+NYD_591XD>S'T1ML75U?2#Q3U_#$J_# M^#AII?J";#;^%M3KY;&PU7/4_,IXDFS&O5XHVV'[P>*N/EIQ_P 5/?IU::7V MTY_E8?+4'E?8I<]3\U@DMV\FW3?RL;GXJ,QZGYK%FNV#D_'LQ>X]9[<=H#J=#8P*FKZ'M\-8 M=6DC2'G")(0&D[@0G&KGR0(J4#%1X\K>CWF[=CGC=%:Y5NK;; /T/+2_P - M;CIS(TZ+GJ;?%=X7V=;'@(HF=-[5=JPD,%'O"Y^ZFYY$GY_!?/' M-H^Q*7Q\)*XKM>VG2*,R04/.QX^&P?B(B(-!2K5)Z,*C'[6+J-GK!^S71:B[NI^9]Z+N*[)=F/HB[8?7PP'B MGCU]G_%3WJ_#2O5IH1T-M=/372VEKW.^O/13<]3ZW-O>WYKFFR39CY=HNV'J M_P"8/%/7_P#*GZZ^[QXZ:;;C;8'IJ"!Z6&NIUUWBYZGYE/$DV8]GBB[8?=\ M>*>/7YN$3X?/KIY=-+VN+BYZGYIXDFS'T1ML/'S> /%/[)\=,O MEM;3;D+"]K^OQO;*>SKZZ5]B?77RU[?UZ:=-+6O:^I%[^G/K MTTN!-SU/IJN:;)-F/HB[8?O!XJ_!_>I6GZO+V5II:U^FFIZV.EO/?J!J==5% MSU/EJGB2;,>/M1=L/W@\5?LGY.'O\>&H%M#RT^)WW-@/3^:7/4_-/$DV8^B+ MMA\_T@L5=GQ3_KK7U=DFU]/,ZBVWPY6OMKJ-]USU/S/ZI79)LQX>U%VQ>]@/ M%/N?P3_DX:9>7*Y%^9^?\.8NESU/S*>))LP]$;;%Y*?2#Q5Y_7$_+V*?V3^?5Y]#;306/QVM? M4;;'77GST2YZGYE<>))LQ]$7;#Y/^0/%7[*>Y^'JZ]38'4@CT',6L+WMUUYGG;ER M3,>I^:4V2;,>VNT7;#V MI^9]_1/$DV94KQ\4;;%[G@#Q5P]SC[$_/Y>SR5\FIL#8<_2UK ?/;G;?8:VG M,>I^97/B2[,>'5M%VP\?L"8I\W'^"GF^?#KU'O86 .H)Y7MRY^JBYZGYE4)\ MH]B?%N(MV2 +$^-8!C (2V[XK+$0^/(;'84*?E+LE9]9W$WH^-C1C1T0N:-& MK6YXNBHXJW;-T*JU213MMQ/OXZJUFHWOKS] KW]B7M']FWD_>J;>:]7JQ'$. MW\'5V^368Y$[#2]_(FWU^EE4=SZG\5*GWNOJKPX=75PZZ=O9V=7P5TYGJ22- M>9VZ:7%QRU%QS3EZ>[?GKT7]<>%?G\Z_/A2O7J3?UZ7%[\O@?+GI?Q;PN.OR M>?R\/?KU5\OY?)3MT! L=;'F3T)MI:_RTU3W[OJN?+[OK\WS^#M\E-+WZ::$ M['KOI:WD-Q<@!%Q[GY?]OF\WEKPKVZ6Y@VMM?;KYW/30Z 'HI'G[W]/Q^:Y_ ME\]>JO5Y*<.-/=X>?33F?H=B==B;'>]^MM-E"?X.%:T\GKTVZ=3TWVTY; B_/X@E:<>'G]SR^JM>/#L]? M5[VAMH;6N"-]OEOS%K"VQTLI]_+^?Z+GKZO+V?R5_!QK_+Y&EQSTV/D#Y:W^ M(&VHLFG3Z_S]_7CJIV]7E_!QK\'7V>KCUUU(TTTU WYD6MSM8\C\%'X+GLZZ M]7X>''M[*>?\G'4:&_7I;H;:BWH!;:]NI).'O=O7YNJGE_#U\=+WTO<;MU-N77NI_\)1*UI3K_ _UT_7Z MM8\CT)\NO6U^MCY'3I-OI?\ ,JJ49$R>.-[^ZN8Y;P%-LL,,X6X I@3(X/&= M,FQH''89'K!)6 F2*5'B6+[8M/ZNYXZ=GN@ YA)]0ZS(NS+%)M9%M=OH"==A M^HY_AF/NM\5M[ZVYJLXKB?E#&&8R;&:6A<)-[HDI$6#$E*D6$F'JJ/%M_2_OX:K*[1:UO MIM8\_7KS\UM"D4WHX;(9Q?0?'FXI*/Y&RORP%(^&QJQ,4O=9#R[D("9VMY*( M#&Q XMI3)\ MTHQRPV9Q>3# Q,6V;S%^S)3,ND!&EVSL;WYW-O/D>>^_+X;@(,O5NF;IUTY^ M_BI2;#X9O/E6:X+.-S\JW(@0\)V>;>55XH>.D06/);G,FGDT!DSV9QVYOWB= MEH<94$1+MT+VO/6H59I(N2 3;E\OP.]O-0XC8 :WVY=].4L'8^FC23%N3A@D:##@="C(M%-U6?,V M!<(_6Z.6H5M;/F%]]];5D^,6M[OTVM?^7JH;:P%_[6M[=/PV^*PC)T.WB0?< M1MUQIC>N\&402+9"V[L9[F ]E;+,P99!QCD&3R!3/:TK:@&P;% 2V%H';!:Q M$Y8YR(%9M0!.#6@8Y&[W:,V-_B+Z\^IZ?'4*;BQOE!UT &G3??RY*,.(-D>= M86&VO2%M$-S(J5P["/*:/2:3C(>75$HED,]+;G&%F28=U*%1H)UD=MWN4J); M-&S3)#MNV*'VQMXU1<)Q;\"?Q_19$C4:;@';4<_EJ#T6V;H1NWE6&\W0C.$< MW?G)B:V'P.*X#CL:5F#C%I:0%-HQL7F(1EP2&>4C9'*+O-"I5DHAD9JXEJB] M\,MA=M4KB=]RVG.VFO+W^&R@9?\ P[F]]]S:WZKXL21'E (7!\8F07<4C/8 M;E3)J<\(B74HLQ'X)'&RN;C\ M,>BVZEHB*BX])DXQ&I3'[E'I]OFEDJ6D!1 M\1+AKT1OH-;]/+E^?NZ>'746-O,[ZWZW^5EJ^?2W?+MVP_C^R52_51HH0W#2G(1FS.>+8UE4JNH3BO)5@9#CTGFWEA9CD?+#/);=^EG=W'L@6BYRU4/93/Q_%8Q$B+L7QZI0S-([&55H?>*<&$K MVD\N=]OF3\?E8:_." 'ZBPM?86VY_'\E$J,PKE&9QCQJ/EYW>+%G$/VY[_RT M7N"RW(L:D)G)D9R:%(;41,H)K/5)1*S#X!7E7/V%2V68AN6D):)[RMD>3 K< M6W*I[=(S@T'BV.7Y&D!,"@LE&1^1 N6B4HK+%5&%)B-MN=TLJC"DTJ::D@F_ MK]3;T^BFX -LNSAYG6X]^05FFXW$!J7[Z>3\R .QXK(8A";=UE,E2E( B^% M/9#B,$)A7LG?W-[[$>DBS=9D"H\NN[MVE?8UX7V:FVOPZ:;:?/>YM;,'7A'BD?91&1;L*.<.V2&K.5Q!,6!'/B*34[WZG];7]]=4.36UM1IMIRW^NU^2UA M$([RHCX%M4%S25;BX<49X+QO?[)E&N4)D]0SLRSI)G.16N;Q,5*4&GD2N-F\ M/%I*9O54@:$8>G7H9^SD:*+BC7IKSWYGGZCU!3PZ[?3:WZ]-;J:>^?:+DK=5 MNY@,:#*-(EBV3[+]PF*L@Y0.XLOR8(!^S/(N)%K(]'K5Y3%1,;R04%CR!.)R M(I?(4!2(@FYLBY)6B;EA)U-]OPWYVO;?GJ-CU6+2 .OBVO;E^"B+DK%V\J79 M9RI@F*0K%XYE$R^L/W#G$6OUMR^MA?;=97;:^E[@[:[ZZ:GWHMJD-.8QOEE&2,F"ZL M=R;^0%I_O5$9"&%7QIQMB,;52N)9\,VV"\XO^:PC'D*WWQ0-AZ),Q&YB+3B M'Q+D^P>"!$?='A&WD%CH+&HDANO&Y\%-7:,-4D3*K6:L2;/(K5>86J^Q!#'2 M5++7M4XY<^5N0U//\?AY*=#TL;WUUTT%O?HHS8ES7N,S(CN0FK+X<%&SEO?TO_/UMZWMU4D 6T&X&W4?7U_-7U\G7(\H9&VT"\Z9;)26^1;CI MI.L] (K(RCDE;C;&&0#RSC$4 T<*7V#P@C&+.*/^\&B:#;IHL9>\WN'" MTC7YW\B?G;KT_2MUKZ;#3U(W4Z?+^3AV>OR^7W*>[QX:GI]!J?@#MYDZ6T(6 M-_?X?+WHG;PX5XT\_&OX>NG77W/=T-MNEN1&_/4_$G373FI]^7NWZW3APZZ= MOEZ_G6OPT][4D&W/:]CN=;^MS:]K';K=0G#C7K\E>/'^KCU?A\O96NH%@-]M M?AJ-M/([Z@@=%.G\_?Z?'4)[M>/N\:4]?;[E?>\U-.AMS ]=+6TTTV\];\P( M]_'W[*Y]WM[?U5X=M?+Y/P<:ZFUOEY6M;\>=KVOK=$XUIQZN/N>KY^;U:FX! MT!MMZ7^9UM>VX^*)Y./FX^K\OY??IJ.N]Q;<@V]/(<]#?3061<YV(Z[GZFVEM?BETZ^KJ[.'KKYJ\/]ONZRW(W\]/B=>=B;$? M#FB=?;7J\]>/5P^=:]?;U<>RO#47U^/3GT T/J3Y^EMN=[W!\M_B?-[Y'Z>_HN>VOS\OK_D[?>U.OI;;IJ/ M1OBW(O\ 2XN3K]S\/\GSX^K4 ZCR-].?0@6^)^EKV+3W[_EYIYO@]?N^3R>6 ME>/7V:D;;[:D;7 ]#>_4[7 UTNB\VG*P^W&&?:SXI_2GN$U@?6_I[]^MU:S; MX_D%8;LLRGN-8[.-IC$-LJR?)1#/;/@9J*D;'+>V\>RD UMBZ*I,3;-@9RP/ M,,6I5K8D_;LRS%D2;)+V(/F;9S8JC;-_+E8ZG;\OG;R4%ER?B?T^OOI)GPN[ MH/00RSV4Z_#-M=[?+U>&3AI?U^=_+ROZ&^FFBC(>H]_!/"[N?X^T0RSPZ_\ MEFVN]OWY.%?/^OS+Z6/4GI\+=+[@%,AZCZ_HGA=W/^@AEFG_ 'S[7?UYC^?9 MUTIIF_AY>FPY#V2F0^7U3PN[G_)L/RS3W,S;7?ED^?9V:B^NVFO(>@YFO+TY?.Z9#U'U]^_F\+NY_A[1#+ M/D[,S[7:4ZO^^3R]G^S3-8DCI;7ES3(>HM]?P^B5R[N?K_D(99^_-M<_7F.O M;\_6N.G*W+ZG?0::=.2C(>H3PN[G_0/RS]^?:[\L?]7OZ9O+X#3I^BGAGJ/K M[]_-X7=S_H'Y9]7^&;:[U>3M\,G7I?K?UOK;^!U49#U">%W<_P"@?EGR]7AF MVN\.O_OD[/G3AIFWZGG\>7O]$R'RM[\D\+NY_C[1#+/WYMKOX/\ #)^7R5KI MFZ@'WI\!T%@IR'7;RW_3WHE,O;H/+L/RQ[V9MKORR=7X=,VFHO[.NFN@T OL MF0\C^7ZI3+NY_P! _+%/8]CY6&S(>OOZ^:5R M[N?] _+'EI7_ S;7?>_Y9/P<:>?MTS>6O7;?H!SZ'7\+,AUV]_@GA=W/\?: M(99^_-M<]?\ SQ^3Y^MFVT'NVOD=-_HHR'R^J>%[<_Y-A^6?OS[7?EC_ )=, MWX VBC(>H7'A M>W07_#-M=X_ID^?GU%_KZ?$^OQ'F2IR'K[_+ZIX7=S_#AXA^6?OS M;7?EDU.;RZ_,V.ORMZ=5&0]1]?T3PN[G^/7L0RS7S?X9]KO5^./\/O>?B+KW M_"YMOSU_#RM93D/4?7;W_-*9=W/T_P @_+/WYMKOX?\ #)UZ%U[:6W_"WK\- MK *,A\OK^B>%[=!Z"&6?OS;7?A^G)^#A\&@=K>WOF/P]$R'J$\+NY_T#\L]G M"O\ AGVNU_!7,=?R^7KX]NE_XGRVT'(D6^713D/4>G\5T$FF6=YJ&QH-#ALL;4Q8L>U3X\VU M8CV.7D&C1NGQ_<(MT;$[?)92O7I?^'L6%QR_!,AW)U^?OI;HNT\+NY_T#\L? M?FVN_+)I?R!//^0M;\U&0]1\S^B>%W<_QI^\0RSY?^6?:]YOLR>?AH' &]O@ M#8?A[.OI(8==1^/Y:)X7=S_H'Y9]7^&;:[YO-X9.';YN'PZ7TV_/K:_I?ITZ M6+(>NOO\D\+NZ#T#\L_?GVN]?XY*^'0NORY_3H>>^N]O)1D/4)X7=S_H' MY8]SPS;7??X_X9/-V?!H3?E\3J?+WT3(?+W\$\+NY_T#\L\/-X9MKO9]^3YT MTOY?/7\A\#OOKT9#U'U3PN[G_0/RSU_\\VUWY9-1?R'3R]]>O13D/4?A^7U7 M/A>W/^@?EG[\^UWY9-3FM<^_0Z:\K_Q*C(>H7'A=W0>@AEG[\VUWM^_)V4_# MY?7%^0T'I^>IZ\_T4Y#?EZ'I\OY)3+NY_P! _+/O9FVNT_!X9/@[?AU.8:Z7 M]>GZ^FE]>049#U">%W<_Z!^6:>YF;:[U^[_ADTOO?F?+\=_QT/),AZA:_'WY M*$UE517)AF!GLZ29'U][IX7MS_H'Y9]?^&;:[\LG9VZ9CU.UKC?G;^. MUTR'J$\+NY_R[#\L??FVN_+)\&E_Y?+;Y<[_ #U4Y#R/O^2>%W<_Z!^6?OS; M7?ED^?P\5]]+BUM=_+4>^7)1D/E]?T2F7=S_ *"&6:^;_#-M=ZOQR?U^OKU% M_+W^6MSTUV4Y#Y>>_7^2Y\+VY_T#\L_?FVN_+)J;_P N6UMOX[*,AZA<>%W< M_P"@?EGU_P"&;:[U^;_EC]SS?JTOSM[V-_7^.][LAZCZ^_?R>%W<_P"@?ECA M]F;:[[W_ "R=7X=,VWE]=;_#7:VR9#U%_?DGA=W/^@?ECS_3GVN]OWX_GV:9 MNG3KH#U'Y<[]5.0]4IEW=!Z!^6?OS[7J_ES)H"+BX]BUOP^I3(>1_+]4\+NY M_P! _+/WY]KOK_YY/7Y=+]1^'GSML-K:CX:*,A\O?P3PN[G^/'Q#\L]GUYMK MOG^S)_LX=6E^8TUORV][ZV^.J9#U"Y\+VY_T#\L_?FVN_+)IF'2^_P CM\NG M75,A\O?P5%O*0NU32(NVSQ59-Q?8WJA9:I=!-S=9M%A;\%Z&M@GM$]E7VI6W' M]#L-U"R4M=$31$T1-$31$T1-$31$T1-$31$T1-$31%T$KE *$1>1S.4/[14: MB0(M)9"3N;NG=HX(#8+DRKZYJQ0=/7-&C%LNO5!FV<.EJ)\VW055NLLNNIZ> M:KJ(*6G9Q)ZF:*G@CNUN>69[8XV9GEK&YGN S.>GC4'.2[4) 69'!N=A< MOR(^>@;90W4QUCTCC9K/\@"[H[6IE0Y#HR;"(#TG#AP02L;.*I]P]E<;%744 M0AHW34<3IJUT>,8-)2T+&3=W<*ZNCKW45%)Q_P!T(:JHAF<\M:UA+FWYPQK# MC#%4<2H$<[PRG#J"O9-4N,?&'=J9U,*BH;PO'G@BD8&@DNT-OA([YMJHL!"Y M2ZRVPO 3UF4)!"3"-38JB/% Y0RA!TQ-[!<:>+XS# 9D0:Q4Z7R.E%!H:0WW MAR;IJ_0<()9Q]D.TZ-S8IWAK8YA3R/GR1.-,R.=PAD?4B M)K)+L<0X$#OF&[_;J3E\M@K#(MCF2PIM+W1EJG%IMW@\IC\DR#3IK$S]T;MC M\])PXP28").(@I21E095V@.),VSQ2B.J7]F,=CI::L?0EM/5NI6Q.-329V]] MC?-1NJ81/QZ*.JBC?+3RUD<$6 3%XX4^5W=W! ME0(9.%PZAT#W-9*RG?*^-Y#7M#C99:)W!8F/8;#Y_!R1\8Q/(&(HF&D@N(35 M^]?L39IM'AJZ,3:QU69THJ6=HH+)J1ZQ5DC55^^L;#V[ATEJRX)B<&*RX)-3 MLBQ*!\L;,87/+6FYF(4DE$S$(Y'/I)& ML>R1D,[G.;(\1M(A$9GU>0".'=HNYP#02,ARKE2'X:QU,O/.5**7VV43LX5K7C3C3A75&&X=58K74N'4C6NJ:R M5L, D<(V%[AY5E750T5/-53N(BIV&20M!5MP., ML,QQ:43DD8;#4H3.\@VW"8Q(CUM\;QQ'K9/*UEGXH:Z#BWC43?9>P9&R8MQAN"XABM0VFHXXG2&LHZ&TE1!#:HKY^[TP#)9&RR-=)?.^* M.01-&>7(T@FNKQ"EHHS+.YX:(*BI\$4DG[JECXLQ+F-+&EK-6M>YI>?"S,;A M=Z=S!CZ,MH@]/FG UG.&9=^"?5!GWHU-F!BCV:EW)XL,&/1,5;LHX.>/*NI, M^$M7+A*T8R6(0ND>6MG:]S'9)'- CA=.\R/:US(@V-KG7EDH"6 0,GC9=B9C\H$CCT>+,E[56A<.69HD!Q!E?U55;NV3A%PE M=2VE:IJ6UK2E>K6K/3S4TTU/41/BGIY7PSQO%G12QO+'L>.3FO:6GS"NCECF MCCEB>U\T.:YO4%I!'D5A*F8H.GEY3!W?;]3("6,G&7+V* QVY M9TAK63(Q)5>UZWL5M5)=-+V(IB4K+WJB7]ML3K2MM+ML875G#/VOE8*(X@W# M \R-:_O3JQ#F^32V'X[=Y!>'X&YO83)M)\(YNQTSC9:QN*>U EC&1L>1,,U MDEX\V+)HQN\AT\X%/+"J Y0=8JYLVL3[/8GA%/2U5^?OC"TLW$?[S9YH M@\4#%AQ"U.E;JBJZ:*EFGIY(HJV$U%(][;-GA;+)"98SS M:)8I&7_TFE;D=3!*^:..5CWT\@BG:UPO%(6-D#'CDXL>UUNC@NMREE*%X;QY M,\HSPI>.B$"!/)#(731JX*/4F+-/NJ)-!K!-9X]>NU;DFK%H@E*UU)AU%&)*JMF;! USFQL+W'=TCR&-8T7<]Q-FM!)6%75P45-/ M55#\L-/&Z20@%S@UO)K6W:#O+8)'ACFQR-@L^3B%K&9FM+\Y#5M219;A<6R)C M?%Q9ZYLE>5FD[>Q%)!I>X8+(8X'""DHJ0(65Y@?>W:'&%S:Q?K=7WJ6)\*IW M:YL&&U=10U^(1L::;#74;*DN<&O#J]\L=/D8=7YG1/S6^Z "=PMJ2KABJ::E M<3Q:ML[H;"[2*9K'RYG;-L'MM??X+O(M/(O,J2*H!Z[6I%969A)KI$*= W3*-V/3XT7TR/2O=(VMCP7I 1K==T:3=\VKW%511U%+P.,UH[S315<7# MFAFO!,'&-S^!))PGD-.:&7)-'_\ F1MN+V15$4W$X;G'@S20/S1R1VECMG#> M(UF=HN+2,S1N_LO-BLLYY'G.9YU/GNWFNXX]UV=?9V=?9K6L;7L M;=;&W3=77&U]>BQ2)3N,3=F4?QUZ\6;!I*?B+^XF$.QU6P[&"2H@R@V;2,:) MZ-SB&2R0NSLDC/$B<6/ $C6%S0X:/ M:"QXU8YS2"OYB^083-%Y9T$P:;\*9K6/=&_HX->PD='!?U+I_"X$G'5IE)14< M2ETI#0F-*%'-K>PU+)!5>@4"PNK2M%2!*K9?O5+JI?1*^M;J4IQTIJ*KK#.* M6GDG--3RU=0(VYN%30VXLS^C&9FYCYA)JB"GX1FE9'QI6019C;B327R1MZN= M8V'.RZ?&>5H=EL*;/0UXZ[49H2 " M019O:?VEZVL3M7Y%M9?2RO&Q.MZE>J MRM-1AV'56*5L.'TC6NJ:@O$;7N$;28XGS.NYVC;,C<=>>G-*NKAHJ:6JG)$, M0!>6M+S9SVL%FC4^)P"V#SR-.U5.G_I__N6__MUX*>7_ -2O5?\ ^[7JKPUI M6/0\N77;Y\NJV;CK[&_R7\U<-[;**7+HVIUNK;2^JME+*W4[;:75N[GNJ<*\ M:<>-.&F5U[6-][6-[=5%QU'S7ZTK2M*5I6E:5IQI6G72M*]E:5\M*ZA2N=$3 M1$T1-$31$T1-$31$T1-$31$T1-$31%YS^6=^G3B7[%[C\ZS&B*WO8)[1/95] MJ5MQ_0[#=$4M=$31$T1-$31$T1-$31$T1-$31$T1-$31%J[.$)*Y+POEO'0- MPP:&I[C2W'9GG\-R?'YCPP+S=-@^)4S,(FCCHQ4X2)XS _$JVH@JXZFD MBIY914341DHWM?"UT<$<$L+6%[0YN91KC')Y[L#03-0J0BL41$KG83G/$>4R M;Z?%"P1E$LNYK3S0GE'"[0'#GY(K0<.DDA@]('D&W&[]0\":2F\M:.>)M%.] M4=N.S<4V$S028E4QX-)@^)X=&VBCCE?4X9A)PHX=BSI:MD<9DDIX*OOM#W]@ M@F=3"(O87#F1=G,6D96LE920NKV5]'5O-0Y[&PUE?WX55$&0N>\-;+)!W>I[ MJXOC$V<-(:90XJV8YYQ5D8;)4%<3R6.896W=%<,-E9K+0!S(1'=%/Q\R0'Y- M63QF:98_:0IF@\%+%8];DE>0.56I"P4'3;W,E//8CVKP;$:&2!PQ*"?%6]F( ML6<*2FGBH6=G:)]*9,/!Q"%U:ZK>YLC8INX"!HN(2UP9':Q[N,[0\Y5Y-X/M!DU^ M+1.38VTA(%@9"3.52"$%1,2R9%YNJ7=DWV-XT<$OWS$:49V!48X6;MW2;&MQ MM9)XO>PIJ>T^#GMY+VGIQB,F'U#JN=\4U)30U<4M305%((FQLKZB&5C'OC?Q MC/$XM+_W(+&A^<6#U_\ 1IF#R]T951-@C:^.>62![(:F*?.7.IHI&.VFDP3#JJDQ:2"-]6UD;ZN6:,Q.:0ZHCC'>#%D8U:$_9>I?'/PC1LFJ&8 MZR>3-(TS-Q&KAFHFR.$)<]L$;'A[7 B)SCP@_,XKM9YR:>3WUN4P6.GV(XE! M)&CNG0@$4;/Y"($QE'/.V+%^)125! N&K#Q*=^1XG)Y'*4Q??-MHXJB9:]*F M7[\:WKHNWV'L.&S5[<3J:R ]G36U+HX)99S@W:'$<3D/%DJ@^4]PJ::"G,F7 M]Y$8G<.)C'G*H[,U3C5LIC1PT\HQ<4\0=(QL7[0PJDI&>!L):S_*899)0V]F MN#VYGN+9,/8%X0$ M:/9=-YB?8368B70UHU8-&]]:R:5F$*NGZ?M_0B/]R[&*FJ91TS(\0JVP15;I MH^T])CG=WOBJY7,IJ.E@?24LK9'N>X__ (>FB=E8C[,U)=^\%!% Z>8NI83( M^!L;\'FPWBM:^",.FGFD$\['- :!_G9GB[NMC')J97:S#;?(#S#$PX3B;&V$ M86Z!0#(Q6,HXZE6()P6D9S(N/'5^WQV1DCO+ECQL>FP-L_P^Z>'JO!$CE,S# MK7O%LZCM]ASJ7'H89,2?+B>(8M5MFK:"*H-=38I2100T-:W]MM93MPLM=%22 MN9BC&PY98*>DE :,8NS-6V;#)'MI&LI*6A@,=/4NB%-+1SOEDJ:=W[.+I#69 MN)/&UU&YTEV2RSL-UN+9/L8RCMSSC?DF:(X=L8-\%R?$A*0P,O)W\VRI)B69 M;AZ4.V;H4RM0.$QKENW"3#'(TNEW,$P*KP MVO[S.*/**"6C=)3OE=/5RNK>\MJJ@/@CM(^,Y'CB2EI8VSW-(#)=X(PC+,8S MO=A)CQ0(HQSKFRS(T0J#FQ"C[-T\,Q04,U+/BTLCV9:^N[S#PRXN9'W2G@_>!S&@/#XG&S2]N7*^Q[*8 M5T6H48M7<8R8M:J6D%XZ>A'M@=XT^@Q_:!A<>*8E71S8TUF(4\(HA+1PS#L[ MP:F"=V&8=!#C=%Q\.F;%PW/;48>+1P<2BE;Q6N\N_LO6NHZ.F='0.-+(\U)9 M4.C.*YX9(Q654DF'5/"JHR[,UIBJCXY,M2QP8X2+Q%L9RACO<-"LI/9#$7D2 MB^4?9BHV7D\E/RY<%;LICVW%)%P_(1,>B7.TFHE3G)8.A MEW)VEY-F/+)YS$\&DL<92W'@R2MRMBJF[./EK:N0Q4+Z6KQBAQ*0OS<6 M2&*#A5-++$*?(YKI,TK+S.;*Z5_$:PW+]$SKDP,[3R;[ES)97;ST+EG'^7HA M%:-*=$H$'\GS#!IYBTK*8J$PD+H(=06*QI^$N.KW%!!%@R*.&+'L M4?VA8/14> 11#'.+AE;AE549K2.C93X7646)1TU3-BTG%;65%0R9L3*7#H1" MWA2QO=&U[]"?LM7U%1BS60XN0Q'BRS!5@L>S M!Q1@U2/"LGREY,@\>;DTH_WB[(F:F69QXN/6X\';J(T5)!B+L3Q)\'9RHPR: M.JEX\-17S=J:;&3(]\U0]QAEP^G92RSNC,V=L<7"?$P/&_+V:>*B>2D%'2-D MQ:*LC?"SAR14S,'EH.%&^:-P,-(T,>M*?LQ734N'PLCPRDDHFS\40R3.AQ!YBHPUU6!2 MQ.(JWT[VUC?WCA&X$23DN"R">\F3DW(Q'+Y216X5\*R0DVA<_ MW!.,+/,3'4%E8&AWBXA#G'TAJ1.#FE2011P'=Q]H076<6CJJ'[0,/H(\+C@_ M:K>ZR]DXZV1L=/&ZJHL%&+-Q*%P%8[.VK;6P!D+WY)@)63.8T-SYS]EZJI=6 M/D[D>.W''T[2^1P@J,1=0NHY >[^$P&FDS/:,T9+#&'&^7I]G6#LH1+?O.L@ MY+PU*"Y1P_SN)2RN>C;P.QB AT1AK:/G6DS-P&E,GVY'&QY-A%$PV69$^@\= M6,(.8O"VYPJ 1S[48QA]3V,HZ&@Q6GBB:S!I3AL,[97U9>8C+.9##]\%<8JEB,D7 MK$0,G!='A6/%WZ%L=1,HK+/V]-%]H&'T9P MP1LQ.-D%5V0_:+8XZ<"JP_!,*K*'%:2W>AQ8ZN::%T4,F2.>)CN.8B QUE1V M7J:CO>=U&\R08[W7.Z4\&KQ&M@J:*?\ S)R.AC9('R,S/C>X<,/!+AW9+D[< MD#C61WP6';[8/N3.3&&8FZ&9[XV5L M3J,P/I*O+1RY605!=50&U0Q\CG%T4;_$[94IV'S0IM#VN84?68JRC/=O.5X' MDMV-R*H42QX>$A9#("!S&PXV\B,X-L(PQC\AMBA3]L:6/M-VAQ9AQ+#J/',-K*!LE"(S70RRP0,AKY(FU5)#)4/G@[S.&U+J+*DO[M(QDDCGTS9'0SR-B;'+PHBZ$Y MF1,#F-!LW1DVY+W*IEID-S")7C7'\NR[0C"AI_=&6DE26747[%)]H>'1.H6UE-7UU+A[>R8I M*65L!BII,'P:;#L3GIVFIM'+)42,GIG-RNJ!$P5#Z9AD#YF5]?'54<0H39--Q6R3+&W,,UA\. MEN19?24CQ%,@D)C 8]-AI@9AO%J04>[LC;][8#CV+1HMH4?J*6\^H M\>/M<.;M;22=K<-QR5]554U#2]V?+W)E+6S@05<372128KB)E>WO#&<:?$7R M/B8 X,>RBI QIX;G"..E:T.=S M+B5&Z?[N6!I@$]E(=#'BC"-)0 MUP-O%$50YZ3K/D[K2C2U*^O1]G>HNWF 4S:*>2GQ5]4'=CN^Q-IJ,T\3>S%- M+2S=VE=7!]0:ML@EC$L, 8?W;R?\XN;4=FL3E[Q$V2B$)&/]WD=-/Q7G&)F3 MQB5@I\L0A+2QQ9)*7"SVV/@6@-Y>QC(L9/$XU$,2JS3!TJFF7Y_%,:XJB)P\ M%'W&,1[?H-U3JP%^(44F)TM'355"R2A-2^28 MQM@;A]1''&]O/QO JF*1\4-&9Z":>MJ(J6DA?(QN>CPZ%L!RTL[:2:>:&H:U:W-@/<,D;>AF]65B3*J O MAWBC5HFFUJFA;5O98EW%M/A4YO-,>*9[RR'CNS9IKO/[UVD<8R"+P-_=BUH_"/ ,OALS[HRZ:::+M]5+--$31$T1-$31$T1-$31$T M1-$31$T1-$7G/Y9WZ=.)?L7N/SK,:(K>]@GM$]E7VI6W']#L-T12UT1-$31$ MT1-$31$T14X[G,_;F(C/=R8T'-LW0%Q#2&*VF%HECO;6WR9#Y/BB+I<*;A-Y1_<+MFC1\C MD^08KE,BSF)EJ\DP(\@S^7XG!.\Q4PWF:=6+8/CH3'ILZD!@:)1FPRG"B*BC M@9W.WY%K-DBP,BPN1\HCO;&/I/*DMM#Q&)Q=;D$CRED1R&;S5X;40=Q$LWM M)J,@SH8U(L5FO*<;OL)8BMG\[VVT?@Q\9QF!K)9>+FH62K9*G,0PX;5(RD>' MALR&>B%C$-9'W1*6AT :=H15%[6I%)M&[]K5>].EMRO#]S4B_3:]N(G^3I_N,P7F.+1,!EW;/ M*H*)DA?'C\L]Q_-8UE&%H3J#2>/MY G:> O%!MST:?CA)P5J-(C^=:F2#9ZG M1 BF5HBJ$+\J))0^X'(>#GVVP\.1@IN$,BUH].(.T:## MS-8>;&+LRC_FQ:[AR0HRM;V\[ILJ7RUAI(V1DM:][BZ0M<&,REQ#2S*XEKLS M6AUS:PNX@+T/[$B&'15[JS27( QL0< Y[7$-+N*""US2UUV>$VWY?#COE399 MEB732&P/;,4).X0V:/2Q1Q/V-HQ%DZ740H\<4'@2+MLTK2SGFSBY&ZUT@@0O MMMLJQ4I=93U EFJ896F PQO?'F:\.D+;6:YCV1F+-F:03^%TTT^-U+1(UP!;=S>9%B M+]1H?F-=%R'T\C"\%KK,^\2PC*#:Q=OEN3;>WJHU9DWY2["@B][*< F+BRZ+ M5(,!&2)8V[.%55+ZJ-62X:./6]K6]!%:UL\NNK2CNJ"+I-"V]6]&VI#8:>:> M)[9^$YEF M:^1KW-8T1L<1(^2YN8VL)R O\ NBZVJ*A;631Q";A!P)?)(S*R M(-:7.,CBZP:+#Q7L=AJL?@?*91IQCOV6YMQL0PA**MGSE&!G9"T=EB"++G;Z MNA]KUB$(WM+FR5[Q2KH0U=MF3=X^5:=XH6N5==DD@;$^IC%*R8O$;Y'^%X8 MYYME#@6@C0MN;CJ%?-A)XSHJ*85P9EXCHF$!A>A1-HF^ M251L=I)K76;)X,@9W69LSI6220L?:,RLBS!SFNN]EG.!+/$26!Q(!L#A)A4D M,KF2N>&1%C9Y6PO)KP+.;J.BW*+ FUSI>'5DQQM82\0$>*2V1AXD MC&AY) MF(O>QL+G7C3EE7]Y)LF2P(P$A&1!9"8FW<\D;=**AD6S-Q23K(D,8 MC[EQR][A9FT8.*CS;IY:R11'7=*,KU*X,0$SJ<.:V-LIM(]TC0V-Q=D \64@ M'?/(&, !+G E;,O9H1ME+:MSW-:#"P0"\IM^3Y<))7$L "YC8S8/G,/&E( M[&7Z1^YB@^M3?&4+6@YJYMHDNHG;?17403\4./!F<('0\*5K,Q:P!A$EG MDR.: +M(81)E+2K9L!?$TDU4+2]Y%.R4.ADDC!),CV/L8_ "0VSB7 M!NMD2 M/E)I8+B#V0",&B3)QL38#F,12R3?>7D%'(Q0F\7!=Z0]S8]O'(U:559I44>* MV/+%TTN8254MW\0IW4C&N@#ZISFEP8&<)P:TD'PESG$DZ#*TMO>[A9:='A\5 M1+DFJ>[LMXI2R[&NS!K0XES0&DD^+-86M8G1=MA+E)7L[Q_D29Y6P2?PV1B5 MZ2\4CQJ2,;+LCL%F-UU+8^4D3*+,&I1N5;NV3YL44:LVC*YF6O(5;7/[1^A' M),Z.25\#HVQN<#G<&V#1?,\N#0P=2?".IN%94X7'%504U/61U7% +G1L<[(; M[!D1E+[BQ:&7<3=M@1K8MC2:69'QW!L@)#50RRY:YA.5Q;^'[%1.MJ=M M]5DR+9^ \EN,OXP!9!6.8:DJ)UP6HQ/8#R??F+&!)H.)NAE%04^NC<4L+N$' M+-RS+(HB+$AQ-LZ8=\+J-U+J$6Y=$31$T1-$31$T1-$31$T1-$31$T1-$31$ MT10*R-N[E\:WLQK:'&8IB6UL0P;$^U"*>NB)HB:(FB)HB:(FB)HB:(FB)HB:( MFB)HB:(FB)HB\Y_+._3IQ+]B]Q^=9C1%;WL$]HGLJ^U*VX_H=ANB+-=R>W*% M[H<>C\=3@U+XXR#3R!Y*!GX*0$#9&&E^-Y&SE45(LUCP*2AUDVAA@V5<-"(5 M\U=)6U152[FZM=$7]8*VXP; =V02H I+YC.'91T M->6>L1P8,Q%QZ/CF8:/1^.@PD?#,4K[& Q%1PZ57(M_:(O*ON4PS/<-YRW 9 M10GF2V825SR2&LCE&;A&3FV\=DLP%IQ;V-@@YSF6PQN+<^QX*1DU]I0"B)?W M(![$TP]+N5/A@?Q:MAFBRR'Q,EH3#3RN$3.&Q[;1MFC;9ID<]MR][K$\)C\V:P=H0>CB$8<3&P=FJ"9#5 M Y(=5<%+H D] S58$R&,F5!BSR[OU7OYZ^?D7SZ]%N88JL'#]9G5VYJM8AU MJ)C*N2O[O,YK*L14]JF)DS^% S[\-6Y[.&XY 6U$6>Y(&9M@5IU50:/@TM32 MM>^!CWL<),T'$E?FM)3V(1A6HB0HA2QN*AI7*&8UUWW857'" M3+9_&#I-8M)4R2JC%\DHPN6O1O3I6M$DK6R=\5D$[2:LTS)88)(XY&3S9G,: MZ)VH$;(V&GDEE:Z(/E<^/(V,N<0XK9H)J)\/=>,Z"6=G& @:W2;'\JR^_(G-7F<1V/R)24-@P4%@-JP"->:04(/W5 MR2S"2AAUK^X.D]BI9RG1N-)$K+T4TW=]5)3\*:"?$HY.[1Q/,4DC&AMF>& - M:\ATL43AE8&.9=C=-FD36XA'W0QX>\&2I>QKF->]U6YSM9?NAS&\4$.>R]G8-N4MFQ$T*&(*Q./N5 MWI1%.-E[19-]<"=,[E;*NVRHW"2EA%36NX%565D1M(8A'/!3<5^=LTLD+C%& MV\@%) M@S-%"#EL7M64+&$^\VB-G-$$A[]&VH:6-C[K:.JAG:6!K8V-TC>XWSM7.F/# M<&V>2 YK6!N_B1H'TXAIXI:J5D6=CV3.DAI8@6ESBULCA8-L,KP+ENN0GQ;/ MQ#CW.TU@64,]XME ]TS;N)L^R7'3A29A93DR01E$B'N@Y&3TO)N"E\;9"[5@ MI*Q^[;'2;ZG?B0V]W5-+2I&54+#6G(]Q:\@3^(.<"YLT;HVMR.82;1$YG!S? M#8AX2NJ: 308=-$\>*)L,D+698(W%KF31YB,KG.+A*T!I L07-RD]UCS<'(< MAPS%F&3>&H_M\;$T9$TF;R,E!@(?2-, A&ZRI.)N+4C;-^LNR=%':/2:)EQ; M7BTT,43I(^\2D.XH@;"\$"!K'97.:X$M#, MK7Y6K1J*.*GDJ9(*[O4S.#,'2L;*8CF;E+I7!S"'ES00RV6_C.4%1\C8+(TM ME[D!B&.NB.+G$D59X8?YH3.C[P5K(>@ )*,7A,]*!CAV6=%RD::/"JZ[)W82 MJX[PNOO;(#L'18E+3R2S&GH68;*R*EIZEC8JT/D+N%8V$F;/;/(]SB1G.CMM MTR8?3<(3.DGGJ(2^M?1G/ ]HL7!P\&@8W,&-#0,H))%R[.3F4L8*+JP8I'E9 M%*IPLUC,FBI^3F?8"S1AALO%R;F-+/5^CR2SXHX>-([='6E@=U==:8W6X2DV$9/))#$!4C*0PU21Q:P0J;&$8-- $X#K-43PXL)73O*QUFB[1 M>CW":K11=.E+;[K;[2+9^/(S)8C&&H263XKDLR@X>*JRLT!B<;?.D7"]RK=K M>*A04 239)W4034;C4UEK;><BA1%NFXYQ>\BDQHB:(FB)HB:(FB)HB:(FB)HB:(FB M)HB:(FB)HB:(O.?RSOTZ<2_8OB3>,VC]VT'JNZ(V/'+5B]A47Q/E^&R"+DL:]-,W1P M;.S>09P F R;#.!<B+7+G"DBS!(<_L)E/8R VZ M\M9.7GD/'C&D\D\[O3FDC>-V!)0JA:7B(8*16Z0:(W4?V6F4WMPCFA"::C74 MC)-H62.TRS?7&C3UK81>%5UG*B[=!C:.:W08:>"=[Z. M9U,26'@N9K'5M)W@C,R-[\S!),ZS M>)*ZQ:\VRQ@.=8- #3=RQZ>;L&2@X3) N&XO(UWX,7%A!V+8J(.6E[AU19).NJJX0^6I%(^2)SLLDN=@ MD#9"\1C*_.]T;9&L=)*2X!A^ZTN:!;3X7,\-A?7F-S"^40QN<6Q;&0&5GA;, M\9@R-MRZ2XS"SK[%*L-N4YVW MQ&?Y7- \M+3L=;&:8UCBH@Y'2L>+IO[(/& M!J =9HP&EKV-SBV4R!LT<(AW"-K0DDS03L6V<2DA=2B'A.%/"8I+,!=+Q2/$ MX226X9=G <(W1Q.R,&O+KJU]1)!54[[QM<[A&2LFCR!D+O 0UK0P-8/&!8EX;9EV!MC] M<3R1B)E()[+L[X@R=DS),>L$'(U 500\?'0DD;D3+$]%RY8>^9M9(J/>UH^+ ME"[!PQ6;1?FVH]](QS]HXUII)I7Q2R4T[6-;W:G[P9)::&6!K<[P+3.:79F/ M=D9D:]S18!H>+.[R-A;#25M-'$]SG3S1$-J)(I+&,@$-RD .:T7#B"276> O MT9*;?WN>21W+9 8#+F6/-9+Q^+6(8PBKF476/G11%Y>N?4;&JE!QSO)JZ%DK MA-6231TA:WL?,KA]4+::*EJ9)C9YJ QY<9:>*3A#,^.,9FT\HX[FS-.L@$@< M,C +9SNQ!T=/%3-,D;6%T$Q;'5SLCDL&/=:,R1VB:6/:YH-P1G>,0T7- M+) 73$$3E(E;&XUU&$A3=8:'&VM13E9T]7?D7;>56CF@2]Q;:K8Z=VW?[Y]& MC?&]U1-54+GO MS,YXB;$8Y7,DN7<4W<"+M.4;ZZZ7"ZK$PM6QM M!6;4,\+ KQ3(LTI4$LFX(7$T7#%.C-_(GJPAZH@U<=[H.=3&&4DC7T3F31BG M="]KVQM8>!*R_P"^@+FS._0+9\NC7 1EC4Q=!Y)'YICK&FQI=3M,RMDXL]&QLARU,D0):ZG:\969\ MSHQ)896%Y#M\K;&RW],MJ^4IT4B)@>PMEI)*)5V:\S7HU[*B41R5+N,3%#QI7RF.F/!B>8 MQP&!C\\1<,A:2!K<-#G+DT5?20\6.(< <=XIVB S51,KHV9G2/)C#7LS"5KF MLR"P87.#;ZE+Q^4%%Y%E*!1[H,[!))&@,89&@PV'!DHS=%41]AYF6)5+%C"D M5EUY2V2VO7W>[BYX/?'VE%V:J6L:AV*5#B)YJBG=)PGOE+@T\.1D<+96NG2VZULA;6B=O1!$ALD4A)7I:."I-$PU1,=!$_B9@&E[<[+#P$AWCN-7>&S@XAP%AV0V:3 M7#%!>:7F(]NF5+SCV[%@,TU)1J.S-VFB?O:@AT<45;-55V+.'N6#"3-[ U7% MBRS$BY<+!TU+4-*2T3A)71,95RN>UK@9.\R!SPUK.'/%F=;-(\O%0P<(&[;W M)NX3*MII*:IK8X(FMG?$YA?3L(C+I)'&.3(TE[0&#(3GT#KW"PR=68ZD52DX M+320A\D96C\C5A.*4HM"B0W%9R,JHOJMTY/11:+.W$@>,U7P]D[O;/B<:DT? MM69MUJ,U$XGG;&))07&8YX*=\9A(A:V.1CH\KW&.TI,;BUQX@ \97Y&CBY8@7-O&W)G:77(OFUQAB:O8EMQ@^()B0 MA0J+91GA^09'+3@=2QXB9%%FA "/B80F:7C(]JC9'6#^RQ13ODX]0*+(-$G3 MSNG.I1EM.YL=7'$UL)RU=/*PPN+A9HT9PW-#"6R/E>UKRYCLP=X7G?Q"'C5$ ME32NG?(R%G='0.SMR2!V9SWNSN<2+QM8TN S-)+?$&?I(9QDC"Q/I_'QN_!4 MA<1\.)&RZ:P)(_"9-9*GAF1F%H46I[*^G7%PL,/#7(."+X=':MT M4FA-^,) M"NCBTS'U5740US6Q 0O:W) .]Y V%\K#E:Z2H8_P2V8'.N)"'-\;=.A@9400 MP34PK/WDI>UDLS)*8 7CCF%P&1O)SL%@39UG"V1^OAA^89MR"XK!S!J'DX$# MCJ+!N>BI)I$$54A;R\H4=-W#IXK+34.&45-WR / M;Q)'%\4C0 UUA&UIO&ZH='$X7?9TC0'6VJ&Z#VJ="+XE>JUO;7XT\ (D=6P M2T[J9T)9,9 QC^$2'OGN"7N:WPQE@8V*,$YG'::O%.$R']G2PU)J1*T1M;GD MC$Q\&2)I)!N 'AYN^0D",<[#]L6)@VY?%^0!KI5".PH&T/8BBL9AY!8K!JAE M!Y5E8^(E7#AY[-ET4%1*3INFZ;=YD6[@BV>6HD4FMG6AJ8YJ,P&!A#I'-=(- M (&D.C$,>O E N)@Y[SUYRC]V; M'*6@-\ #,6E^TZ4N,.2,LUE@5->/!6X]0T>:R!,<,-?&]L/@(+PYLG$:YP M?E+ 7,N,QRARWW)Y+WUD?%,*7&(@8<=@%"OLCK98O$@9990E?1T2>L;Q;SOI MPT$+U18/*((6+*V*]&WV.JO6_38ZH;5/#J+O#@9(C5\+-,R6!K,\1C+98'1\ M62(78&R7:&M>&M.;EB.,4T M4>E4KZJOF%>OB;J5PDIGU-165U1)QG0312\2 9!)&6L 9&Z>5@%P?:*/(T$N[0K M:*C?(:IS)IS*'R]P,IX@;&Z-KI!G;%E%R.%8FQ,CW'9>KO;ZV),\%8=:F2E3 M9=OC.$HE#-4T4:E2"<='VO2/,MZU02H\<44<431K5.RBE+;/W-*:Z#621M;' M*T97'* +N!T 'HO"U3XY*F=\+,D3YI'1LN3E87DM;ESNJT@YE=,&=3O#*I.;))WZ_[ZN4:.",6BZA$.94'"70 MBQ:0;99V;R#%9FKF DY;C)G!93(V+RT]:B8NBX&)"SR@P0TD*4>"7RVV+DA# MT*W'7QQL%GLM<)C[RRU5WA%MV(!GL%R .@@N0DG,$0QB@H"B;L?&D6,<6C3X M"!L6&OQ8$<;<7%$7*[L@D6)DF]CQ2M1R+!M;8WM(MX:(FB)HB:(FB)HB:(FB M)HB:(FB)HB:(J8^39QY$3V1S5@J%8]*EA&/Z(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+SG\L[].G M$OV+W'YUF-$5O>P3VB>RK[4K;C^AV&Z(I:Z(L;F5C]6(2I,6@_L8O-KL\X.BX<'$9NP9BE9+-1N;S!AM*WL:D944\4I!D95FGN MGA$6J$*#Q JM;B+3$XW,M,!.<[P@/C!,3GX[GZ=(XS;2.,%:Q^3!I:M4M9D] MV<9-.?30>+U"J,6JC=C;2]K355,TTD<;&O+QP:6$RNNRQ+1= MMK!K6EQ.0:BV8DN+EZ"FP]D[(9W5 [JVGXM3PR!+&^-MC"6N+KO>>& ^U@'M M=DL!FA]MK'[>D9*\FVZN2#HT;Q("1D$:QBFT65@)\#/&ESZ^3AQSH/;-CLBN M-LG9)P,YAJ]:H*#DU6CH4FI;31:RJHZZ?OTCN/32&&!P+)(@PM>TMC/[P@ES MWNMF %[,)##E[%8^2>BBBPF+/%66%1+=S9V20N:0U^4L9DX8:,Q!! )=9S@I M4Y7RIL$EX9;'4JPJ22QR4-.2+Z]2ZB+9S_ '7/8QS XD9'-+Q8Y[-8 M9#<+DP08DQ_&96QMGA/!$;ZC,X-9(T&(N+BQT;76=E#B+ DAK;7AJ2PE#6.9 M(0YQ_#'9N /(2^D*-QQ[,DGP>?$9 W+.WDBB[YT4D#XDQ07"$W[!ZW&MKWU$ MG->\&C-NBC+*2I#8YZ2F$%.8SWEU2\YJESG&S)^*X.D;^Y):P:/-LSW&U^D: M\&"9E95!U2V<,C[LUA#(6LN1 Z*S&!Q;@HQXMD6R@]ZLHUUJ MR5=X*BG=%!'Q89(YN(V,FSW#AF&4R22,GD=F886Q1'*?WKC<-6Q%0LI9H9H' M2=YE?')"&O?+F:""\3,#&L=&P.:XRF0M_P! &USIO >0I#0FRQSBYF":LIBI M$S*@Q>*KG3*%@=I5>7N#IVQ1I:2))H)OX^R&N"=B0NTHJ66WW<3I8Y:6KFG M1P83,6P!DSF\$Q-MF;F:YKW$,RES S,0YQ%E&2<;S?- 4OBO'8TL8=4;1Y)U M0,8$Q>&Q\&^=6N22<@(E[";EY>2:4)M4VP<781YM5[(CM!DEF1 P>D4H;M& M[9_8BYEQA4F3?N:#VC5%H@YMHO5O=WLG52UPIJP1R/>U@;))([*0!FDD?X2; MDDO>79&@FY)#1:N0RR"X :"6,8R.-A=H,L; UK 7D7#0"76-R53M% MY_-]QF5R1;(T) 10Y1:V:O9#((_O1B[1XFZ::T,]*Z2H-30/X ,4D4AF#JF*7-DB9(UD0.21K7N)$0,? M@<'@$W]--3.I*:$4E7Q'D20&)GA9*TL,LWCXCHW.8"&N-VWL!8.L%C(:53C* M$EM=0-_)9PQ;3:.#Y6W%D!T7CDH'IE[&K[%47&G%XYWVY(1PA>:3=*$7LC6? M*6"%K'32C)RI$F(21R?Y$USJ*"K9-2/D=%#422R"-Q@!DR2O;&RY8QV9KW O M,;77#;!1P,C#:MT5/4RTLK2W)),V#*QQ%5*Z,2,9F?9CC9H8TD-)S$'@EFR- M(R<;<3B!>-!8#,IJ/;Q$\1#3627JN(^641931XQ6)&TT56Z=X.,MG;=L@-<- M'[1>KE,??2RY^,-BC-28ZJ.4O8*F6EJ&\$C-=LDD<+6'-FC>YHFRWD:Y^A&9 M51X1*]IA9-3RB2)KHG.B$ \JC 43*2YG>DZ.@8F\?VE2BH%X11L53*&4UF];S!59,@"$-"M@]95^3L1 M9Y3!V)3][<^*$F"W&B(BDJ&D/<&D-)/$='9OA(X+6AH;&UIGNS$96"]B^Y7;-$YQM.TL!$V MTJ*'JD+D2^/V0QJU27D)0U1"/NW(\,T:&'*ZZ+5RFJ^N+(6JD'#ZQ,R2K93T M@F,8B>UL?#8<["7%P!,8XCSF?<..=Y:2T&Q"Y5!6&DK155$3I ]KR8\C0'"2 M]W!A&4MODHFI<163Z(FB)HB:(FB)HB:(FB+II$?& MQ4"8DICO^@H"->%B-183!"]PX[P!1]B4.%W?-)W2?50%IO%V":*MKJTS7&OIY.XV<&$M:]S;/:S*!E<3E-P66$(-T65,4Y MN@;V&8VA,D/EFJ\(?W;0"" M>_A6'3T\S)YI&@3";NL'C:&<6PSM802YQ8T!T3@PEH&8W!MCN,X./:-+\JQB M-$2LW2(J!F%DHE0V8@5R3%[WDL1,B%B"JSY(VR&3 .T-G79D-PMB3$'8>.[4LL3Z-D[Y&F&=TL MQ;DW0@&1<4$,I7S,&Z?P!XD]*HW M1A(.?,R8RDD^=)!X(DX:M[C93OZI5X-(LU0R+E-5&J?3?BLDC(XWLRS"H#6Q M1TS33Y(VAN>;BM,P+7S<$-#'#.'/%P6./)&%Q-FF9!-'/#'&Q[>-(0^\Q(C'BCMNZ3NMSQ#$'1XU''20O:8VL8V<, M%&'-:1#&1DT8Z7+&U[@2W5Y O9A[X\-JJF6JX8+;BFC=&_BRM<>%Q"9 MB'9KG(P9GAA+O[(+IIY9V/PR%S;*V=TLD8XQ9B,Z$CI0F6DH0K)WZ!6J5P)_ MW^^C&L]B[U9!=F@4'Q!N20F,3[^=LTV8Z M%O+GS4 ]5(6.G+BURJU3O#QM=TIQIHY)'56(T^>-X:\-NQG,-7IJ.H#HZ2DQ"G=2ODIBREEC<6&2%S@W@$M!<'2!H;(RP MYN)S%91BUO%2A]P@&Q(L^/9&R1%CQ.D&#,67L4LF#E.+/8=+#SMI<1?,:DKB MCAD-'ARP$.YN<&2)2ZY0BVMZ&'054?'BEI:>JBG:V61]26NCAIHV!X<(I>$Y MSHHFDPZP,8\5[Z?NL4\36M%C/-'[8\()N%QJ+QTF[98 M9)&L(8_+&."US6M>X88;4PS0]WGA:\5)$X M.\6C5IF2[D]Q,7 E1U&[*+0 P6'T+^RL:L*D/=/B#_O@BT8Q8J 76[V5:M1S M-1=14HZ28O&1.ZRRO0"[;[Q )WL%N_6:UDT1-$31%3ONR@6S?&N[?'&XS+&6JD5K[><0QT0 B6\LCBA>4B;3T:$4,C[2QX)>WN=T+"!ESBU\0'][6*+W.VK M=5"Q)-2^Z^EJ=]:$7ZOIC$1CU,:2E,<'D5GZ8I(>]-C&KY4HL/O*HC4VB[JQ M>]^J+34)),[4ZN%&%E[RQ.K>VJE"+ AY@3(,JQPV")CS08KB4R^&%A3QN0&D M63B4QI1!VQ?-%%6SILM96EZ2Z"JB2EM:7675I7CHBW#HB:(L*GLC]BP*A/V1 MPJ+_ -VMV_2<]?\ 1P*M%;%KN]J.._AW]VJ\WW3>SOC]U8FM7F[N'&TB\.F_ MO" /DT][D:Y2T'/@&X\E-=SIC,_L"C))G&XH.D&12^5):[CE96SMFCARS"KA MU&U+^]$'JZ#UO>K:C>C=5R"4S6. M*1(?(UY4U:VQ,XL(3=V&'(<$JK<]L3HO>C92=8?)!P5QLKAT=BV0MU7I^?#;6LM6 M#Y>R4T?2A1C%V3Y\#*1[&[.'L@9.EH(Z+:"1\?NCD=@&3!;<&LU4DS^0J2$>*DD9< MD'MH5(&ZJ]OYEZBZLO8V$4G]$31%3GRCG+*[==BV/VZL>*B\QY:F8>55QO'H M<3"2:((2*,W"++F>22X62(DXN/=W%K*-E&C)\[<5:N[;$4^8NNT14GB?]U"3 MZ3[>-PY@MC3&&,]P,?KBYOMW$,V:<_;BX3@+=/!L.#1.3#;YHQRM'"KS&87 M'S$-$9&>7J<%R-]*&9Z\N0%L![5>Z0QVQG)6KW#CL?)LC =_:V"[@L\ M:X3QTU&EB5[RP[E5T7CK.3QI>(N7SUHXQRWO6H_%-)M([$^<[WDC-H.;C5$K M[GM7+I%JII2/?).V"+[Y)!\48#COPCQ2&WD +6-NS-(YC,XOKZ+#,-:^G?6U M&8,:+0AI>QX>+6GLT7,45_$YN?9QR'*JJ#.-AYG:\UR'),@Q=/.-A:1(#X%C M\!%!XY4(N?;!6L@XL@B@CI604&(QY)(LE1 M!+'D$LD+!421.,F4,9(6%EFO#I2&MW.1)):B2MDFJL/FXD1N)HWM#XX9261/ M RRNC))#@'6:"YVP<)BX=F&X_&"^-)PR9"\EL+XR4CLFC!B6&R*%$8^DK& M">*KR008SCMI-X M4,(%5&;)L3N>MKW+B\FR67O MTV'_ .'X9,4=L[@8VY@W*=B+#ESMPV<2P3":G>UQ,,[X\LOC.<]ZW?-I8AY( M<0;@NMX125 ?E9'2MDX3HP7-S% MP$L@XDF81-)RN=F!+M.CIYZ,][8YT0L[*[AAT-\M. R-NXJ-1=HF2%^0IFSBYJ+E7 M#E=@@);!A,@+7LDV\F#INU13BG.K3'#")A &2PO?Q'NJ&&GS1-#89(8?WCG- M=F+3F&=Q:TMOV5Y#HG20QM+)&!H>79G1M#C9 MP%PHW8CS7E60IO(+E.(LPTECL"*8UC=I@(<%)#T*6/+"88B].-C89HG:R"1U M8HDDS;6VJVLZJ7.[U++;:*3$YG254]5'&V- MZ7K=#N$76T^5[^ZS.90TTK R9\HGXPJF /DDBX$3))8A,^PX=[6!-FYRYM#* M:*GGFIP:RIBEXK&7.#O &DC0W:#E>*I+/\J,S^*1 M4(S'8P)-3D>-)-HO*$"22 M9!FE1K?$8,1I:MCV/AQ"5AS/G;W>!A83=S'OD#03$&@1B+1[OW0<6DK6J8QA MU135'%IWT[',>P1S,;4F-QN6O;$&ODR@GQ$V>P $V("U]-<12'"Y5&.O6)2( M6AV,;B>3F&.J-6#R3I)^Q:4-;W;P#5)4R]0N-$E*/TF8Q^>C-4VRK:UQ:Y9. MZ&88PF)E*TU,\\4<4E+33.$<18'1NGJY7.98[.=')D:6NC=GRMRG=9B0J Y\ MKFMC;)++35-5$38.S#APQD&PNP-#FE^23,"-0&R7V4SB7X&CTFB2N!I#,-Q, M\=$:Q:1NB3IM#&-(-7[I_'KD3Q K95B/-% M71=RO)PS-P6L+7%Y=: /9^\E+07@MN77<8P"VUHH)\/:^E#Z!T54!'4/:;N) M< TC.^SR&1"1_P!TW\(!+O'^^7\>6[A+KY(4QD3QTJ !C62T1,A(_)S(&H=5 M&U@MTXX18T*(A:5.N[FR"8-L_#E%:4KN3X/'/#!(S@][J(8"Z**5K MQ !*'MD!>P$&-O[F6"/PR.:YA.H55)BCJ%SX#-Q8&RS$3.XC!+G8X.8&!Q#3 M(ZSFS/S.98.#;7MZ3=N-M]FW_"=BE&]M]F*H%9=1HT28-:76Q@9;6C9DA>HB MT0ZO[4V2OOL03[E.VZZEO&MOB_MD.=_:(! )YD!Q(.08HN3C!!ZX DPUC$YE')PH7E=AF/R*&21PIWV)7OD;R#,XN';['\/*%BJ+QJ8?*B;V%[^T00?L%R+,!$3#1K-S=0/0JBF]Q,NSJ MP=2*0DP[!J".1D8.0!@RA1Z'CB?>EEO?] #$;TNYMH_+]_/_ .Z=$6]-$7\W M76V6W7WW6V666UNNONK2VVVVVG&MUUU>%*6TIUUK6M*4IUUT14_\M-LWREOZ MVC!<)8+,X^;S,=F2'SQ>Z<2=0 'N" P$Q%O;4GS(895N?=\'F5R*%S6RQ1*U M>ZJUMUEMBA%"?DMN2LCV$\;2K;1OPQ_@+,[U$KX80 991GD2)BNF7#B*CR"" MI\,+HV/6I"3B"M$&EW-L'ME*.+JN%4TR+T 8EQ?A7 T+9XYPO#H'B^!CWA @ MQB4)8B@ %J^*N;GA)V@.8JJJK?:F MFDFG;6^]12^^M+;+++:5NOONK2VVVE:UK2E*UT1?S:NA&Q^4DUKU83)XH! MB,2BR_L,&)QN-1Z\>1M7(K,=$4?LGCDEMEV%RZ*39N[L(.5&9%('1$T15H\H7R66 >4EN MQ>IFV3Y.C:N)K)79';L=F8^*H[MEU0=Q&A:T[&9#1?F;@#.K6K;O6ME%'%%> M=[JSFR+S?8K_ -RH9C5R2WMS=N)QDQQ#6IJKM;%*TJ*9'LIWJZK';6S27P 3 M&;^Z>]Y6F;UGUM4VG?5S*U5:B5M2+T-;*^1TV6[*FN.CT6Q\SG>;,;N9 [&9 M[EB:Z,]=.#]YIO>HJT&/D8XWJR FUHZV[V%6<1R*:BM;W=UZ]2*U71$T18S( MYI$8?>%2E4E"1Y22%; 8&PP2:C[BY=1!9S8/84-JB1AY(862 M;JJ7LGBH8T*))I+4MK>T?MEK>-JE-$65:(FB)HB:(O.?RSOTZ<2_8O0HR8J+@(L+! M.!SDBB3N191.39@DXGPCQ.8N267)"Z"MU6Z<:,#I)&,HD!C@FKZ))\'ECCIG0NEQ%TMFRF;@QO&2G$@F$;W"[90,SC&0& MFXL+*)D:AV7'M%&2*2"(]F/[WY^YCSZ?O\4[&S2\:*G<9HZ:KE>X31$ASXHAG>UKKO M'B)C #7 N&<,'6GDPZHIB:>3N['\.-\U/!EX)*V"A@\,I+-"ZXD+VM)+61W+N(& MR"S0T9J:K$8Z%S*,RBLE+XC-43/:Z,L.$B9=X%.5,VO;&1*SI!B"1== M,/CM+$Z,$.I@L--&YXJ*QLPBD)[JY[XN&7Q$R.? 0UF1CR&Y1-Q"6/98E[2M M+&*ATK(B^B%,'DDS/ E,I9_FR)Q]XN8,Q&5K3H,H !4A=RD$?XE6QDNA$8T" MR3/478(\ZM.,4BLLCBO.7'&9>8 (Q:1'R%T1(V$N?2"DQ!%[:\*"C#KAV::GDD+96N81 Q[7Y\CG"PED#@0WAD,,A:_3PU@JWS0R35 M#X(AX QP:UH.:TK8Y@66 \ >UVMV^%I(B=CV;0?-48G[;(&4R[83#V$RL<0 M5])IR>Q;'XY':IB0Y!W21NUV#N45'VN7;1J$M'*5M&,' 8.*)VJ7L>2:ZGQ" MJEJ)XI6P$0\4L+XX\SC%&"$.F=GX8X37#[QSR N7;EI*C#6P"!D72:-6[HB^ "&1BT M?S$:Q8>S%U'$2!"'6A"RCX^X=,'$;O"!%7TCHY/T495H2>6-K9+NMHPD- M!+ANX $%I+N1)\[/1R5&*,CE'";4.:YSBUK&-BA@H<6F@F^[ M^(/T**-TGS9RHI1UJVEIJZFB?6!\-WVE<8*F,SMC<^.)@>QK8R2[PO:-"&9K MCP$J^MBI*AT%-15,L3:9G"$%0'MA$@=(^1W$,CF->Y[B",H:7#0MS-"D!C#> MFL;R+B<6P(XD&X!DS.7Q7G4KKXJ>C1.,"4'TPL=0,H\3BX.!&N_"Y&4 M\QX-1WACF/!8.)"^-Q NUS6&_B-PX.+76R@!P-] ADQF38W.K :Q N0$S,( M)9R%J@G8W<++TD5H=_(E28Q.&I%@HY@,2>$77=6JWT4F@K*CON9K0Z::FDE[ MJ:=C\LK;AEQ42/\ "R?[HS.#PTEK&%H#NGB%'3BF>QL3K4L\#3*'GAO#HR77 M#(@POX(%Y.&Y^9P:2="/5MMKJ[KMZP?5]<+O>UQ1 :NK@B[AT'N<5C VJM13 MEVX=.G _N^/>:SARX65;\W>JLK?6M]W5)G))J1:H))G&4-M+?]X,H #;.N+ M #D%X.JX7>9^#FX/&DX6-PLTD4+R]M[JQEU9P9 [<48T-S+C^72Z70FT6")WBCHD>V8NB+=.45A Z!8E\(V.+H*J3>V#WK4.;?RWON M06+"DI :=M8R'L:(,HO8RM*N&][]S(W']J5%,S!Z($6)2"?[J4\@Q4>*Q^+2 MA!Z9P5L542 +$7\9BYD%$59DS)2&Z5),+W<;DJG==9?;=;6M-$6MO 5A'ZSF*_O>Q'_RC1%XXL=S# M>T^Y;XOB\WC>4W;:Z;L<@0:HMUMFB:$#MP )R).D8?\ WP>#!).V*=Y)(T'2 MNA>BA!&RRZIEU;2E=%)_(?AK]5['? 5A'ZSF*_O>Q+_RC10MFM6K9DV;LV;= M!HS:()-6C1JDF@V:MD$[4D&[=!*VQ)%!%*RU-)).VU--.VVRRVEM*4H1?OHB MTSN%PJ)W$X:G>%3\FE\/"9!%H!2\@@9MQ'I6S&4(LGC]$45;7?VBXDT:K#'2 M;I%X/=,GCEJ2'$6"SABX(H]X=V+ ,09GB^:T,V9VF9B.X;"8A13JT1-$31$T15.\F M/'54GV=ITVQ!BS&<=F2D#81DMC'(Q&8CI<(B#S( D95,"ZRA/T8\-!@50;5, MFYCV+I%*C[J2$I%"6#RRUD,(K")WG/%F-'I$=-938'?"00Z3DFU!1LBJTCY, M@1'(%U*"QKWNF+=006=E%DZWT#"!;\V6HR$-5GMI%B+R:QG(\@PG)H9(U"H0 M9FC(D1?)-D$DF2T@C6-2]V1K,'PQ3#+6YB1S%9 MG=VA[))3;:IDA-K>U2(4K:8I?8%2HI>X3B5MU(M8\NJYM#T5Z]$6_L+;6\&[ M>I#E&4XBA#:)&\S26LNR(Z0?DWMIP]W\9?6.DFY!VZ0$MT*G'+-J-$)L1C4< MV',F[--%BA2TBD%HB:(FB)HB\Y_+._3IQ+]B]Q^=9C1%;WL$]HGLJ^U*VX_H M=ANB*6NB)HB:(O)5RENR/2 -:&1F,ASG2$NN'R%Q&!AU #8X@T#*0=CO_I'7H%3,^^E:3)G> MX8+LN8?)*6))VJVJ*WV)N&U+*UUC/"7%HEC<1H&B5H<3ME%C?6[;?VB.778; M0UA;Q#33G,?O]WD,8YWT:;>9.WD=YZ\GIMT.&9@/#-@X7 =8AMMM0;*S'PBX;VJ5IJ(&N@=6BJF@8*REIQ1N/$;,_-Q72LCD(#F1AK2"UCW<8_NSF+0 MO1X<9#1]TA@A,LM+4S&9K@S+&Z-[(Q+-$TN:\C,'-D+6EA:'$ DC4>?=P1O( M$<;P_#6U>(0E@]D2E7AU*+LUI< F;IVW(2,:-7DPMHW7;:,D]33&6CIYWQ4]7-)'4QP22L$K@3&>\,+LT3'-?G8&M=X3HVS MGM;TJ.ABNVLK*A]1/!"U\0<6N;P@P%I9PA^^;1=N_O9/689H]L[S(V#FJXA^L_DCXTN@W".XZ[MM5 M'AQ3NCY!113>X;ZC#Z>%DCHH9:IT$3K07XTK<[8R]T;0_.UMS(]K2[+9^35B MTJU]1%BSJB.G94"G@CFDSES2UH(!D:P/O&0"U@8R'3AX_9U3/Q\ACZCAV^I%@3UP$-20F3]Y&T 2%KPT!@<,KGDF(@$M#KEJU):N6I MK@:>J>R/A%Q@JGLC80]UY( 1LG=(RX8\+B21.3R$=:/?.JL72]1[\,BN324>N7%I+>9A MU$*:GJI@_BSNJ'35 +()G2W:"(VQF7NPC.F8PL,@L2XZY'BBD*D"\C&WMF:UC%H4O?))NJ:,[3"*CAS222/ # MX9YWRM$#A&UAC'$;*9>('YLP/AD:T"S;+9AFAK>[R5%*(B9CDFIX&,X]38&T MCC$]I:6$7: 1X'.=>YO@-C\-BC$PF 9Y#MY#;ENY)]'B#&1('%0*%'H4V,"R ME4S+1K*1PY0$]4=E.[6N(-JO6P].:OVK=I>QF5[&1"IEBB9#51B++*&RS1RF M.1@JFEV5KVQ.=F8(W-EA=8>/[PO8Q]34O-')+FHGN+@ Z**>,GQ1M:QCC'*] MS;>,.C> 79&&[3KXE V3U%O(3K\NCB@:;%1N?.Y%-X;,L>!S!%D3:M#CQLR0 MRF]B!24*E%&"*I!2L28OFB]RI91VQ&+)$VW%,8+6NS-%\HWXZB9S)W,CA9521$4\#&F&1T37\3(72-@$KX MKDDQYI#F 6N\BXK$X6QQ.1,1QT/)H"VY(5 M*ILHYCB5ES2UH_LC[9V@_731(MG"Z@K&>(02,JW20/ENR>*/2)L31, YL,9) MOE:X9&O)1Q)7-RQ R#QV!#[M;= MALO6ALX.JR?:7MHDBZ::*Y_!.*S"R2*KM9%-4E"@SQ1-)5^NY?*)V7K5MLO= MN5W-UM*56644[J^O7CD=-&R5]L\C0]UKVS.%S:Y)W/4KP=?&V*MJXFWRQU,S M!?+>S9'#7*&MY<@!T"DEK-:B:(FB)HBIKW52V70W>[AAECZ?$' LQDC;=?E: M+$=UDXCJ )ID#)Z4&:I"<(V9BA43O"O6$>9H*!4XI,59M(Y[( MK6GN2X,.G;7&CZ0-VTV>1VR6HA5&S^G][RI-<,@26)4:5$-;')5LNP:H.GZ+ MITY3JFW04K6WB18J4W X@#R9*'/YDWMDB\@$19$:W%'GW.'#S (0#-;7K$6X M'T;D$I)'FKYO&&\/$BK"KQD\ M&O*LG\DC#EK>Y'$$6SYFHJBI8IS#MNBM;2ZG=64T1;KT1-$5?_*1[^([R6.I *D16PE>0(,"*',-4X\JE>A1M516]RG M6V^RVR[B1>>'=?R@V^C?#M@B6\/D\,69SQDI7,2.W^4A,.K2#+&5%6T+BTGG M1 @:!PW&[EJ/@KMQ.XZ@D54(56L.#TFJS6VUVW4J4]?3\U>?R-DGW4R_8Q"S M>\JS*R><5IMD9$M;FB.&(I/>@F\E<)1VI ,=$A22+/O"E.C%5F-MCAG1-5%1 M1*ZRNBA6GZ(FB+^+U4T^M12Q.G"M>-]]MO53MK^ZK3JIY:^31%!+9CR@^$-[ MQS<6!Q6^LH]V[Y>)XT*6KOV[BLH!()U3!9&#VIV)]S&9.3'R4<)XW+WW^Q]5 MS>K1-XA90BGA2O'KIUTKUTK3RZ(FB)HBQN8WRY.)R12 -XZ[G%@0G=$6LN=D MF$6<2.UHK4.C(GH=F0*M0RC[F+2*XYB[>I-:JW-D%%:6VU(H&[$,<9W@)W/" MF?,1XHQ<>,GXDM&UL$8^QI#<5R:/I@E'#]XR)QXR7R=(9&RF3V4MWZ^2K125 M8]=%2H00,)FI2-8D4Q9[A?&>3E'*LXC-AM5X'0C[I7I4X,47"(/7+ZHJ^\.3 M'W58N[WKYJ4;TK1,P)($ 96CP,_>,%B+4638L(:[E=K4C8#0S%]W[F44^8^+%D+%.Y94*/FC9_>6>7W)O4V;1\6<+.FZ[HJFLD12NT1-$31$T1 M-$31$T10UAV_S:I,Y7N!B#?+$;!D-M.3!.)\F.Y,18!13:5F0UQ-E8,?N7?- M/&=S]C)(Q5>_O=2LCB4A8V(WI-F[AT1:#@?*W;3IWO*R[M":3>/L7F,81&I" M.R.ZD#&D5FTGQE9S?8Z<*O7BLL9WM&-(I>N1CKT]W M^"FWS]^_JK$ .298N'Y>/ BK0$:.#V5BU73H4 M*-/V(H@_11N;-"#QLT74L673LNE0LVT1-$31$T1><_EG?ITXE^Q>X_.LQHBM M[V">T3V5?:E;TM:U# MJ7!RS0>] MTD!L9 >^Q!:XL:X9AIFT6PR%[FW#V@$;$ZFX!T N?+^947HV#V%B%F,<$;<% MG]+ 9!W>#,$2DK 7MG-S%I.1K-/"!<\[9MUF0C(6UQUCX+#7^U(-%X^]FC.V+XS)B*UJ"=J9MM=Z22L3>ITM7+()7U4LD@:1Q#*]SF-#2",V8D#*+%H_LD7%B MI5@\L8EN9,6B0.D9OK:_Y@ ]>C!B[1N/*.Q;R_O=F448I6VO6R];4;%J*J?N MN"=%[5D[-5[2'%SLSCI=Y)<"2UKAXB>;2+7.VFRU^$\@EOB:+7(!YWL+6OO< M:<_@H*9AB^R+).4F)"7; M2C;8%Y^1V-7!6QW*),3JHY[R:MKTDD4Y!1H+N9),FK:Q455O9=E"O>+.SI!TOTH:#A4W>(BT1,F)\69SVRY.)=G$S. M#R5%W21B)ULC'.C;H&2!K6YAYO!)L"3I<;D8[@]K M..FQSGHU="%@A!F +#5^Z[[1?MASN2,;%VC=^Z51MM'7J/Z%W*2+.M]U&EY" M]XUN;(##4REK6LDF+F\1N1I+BU[FPW%A=P+K1@-+N9 RFYU>[ROL=P=03IYD MZZ:>O1=H(W<8Q/+-J#<;S6X:^4K:R,NG(9HP=)KJ !-GY]QD!)QB.Z*W.#CA\?3FTJ*WVS*X@U: M#R)QPV)2IXF]$KTM9L'%I"WO=Q7O1>YO5!RR<.+)Y*AK:4\;B%L8$(A98P-: M]SF-:]K&V?F(VO=),2S,YSPTO).I>]Q<>5[D !;,6(X@W.(JDPDY M2X1,BBS9&@-+A&QM[ #5PZDZDW_/'4RV88@BT]I%,)ML9@6;/H^;#EPJ:5ID M0&N(JL[7*2CU_P!-M%$3!)RR0R+RCFSG;VT,F:&.*)I?,&&-L8 M:TFPRM#B,OB;H#UN71:: M\"_)T2YR(N8[7'K];*!X8I(;B,EE$6OCUQ)$ M%;;<7Q9E@RL($,61F6*$@1BS0T6B(T %BXY@+V.NMN<"BT9@\(B,-A8E,#$( MK' T>BX1)9RX2$ X]!@)&IKO%W3M:QDQ00;VJ.7*Z]]$Z7*K*7UK=7%H#6M M:T - &P &@'HN1)(^61\LCBZ21[GO<=W/<2YQ-K#4DG0 = LLUDL$T1-$3 M1%3;FL_CZ>[_ "!+Q#,.'\?3O%,_Q;C&>QN6QX4SR5(2J9&*Y%38QUPG"9 Z MR$,GL"R&TQ[&DSLOAJ.,)$[+3",ID#/=)*D5H&0L*XQRNLWNR1%TIHR;#WPN MV/GB9M[#UV9-J^'DJ/X3>2I$2;@@*)DPKU\1".GSH$2( EW-XAZY9*D77.]O M^(7QJ/2%Q#6]Q>*D(\3!.4BIYNFS=11F+91VU1FW*I,G[(58"!.6XPBV=C:E M 84TJT4+B1[YL1?@UC<>$9XJ6$@0HLH=Q<]M-DAPMBR(&:!Y!&V BA5XV02< M$*"V']Q#J.U%J,6G]S-N:1_<:(MU:(FB*+^[79Y@?>]B]IA[<1&24J@;&5BI MJV&BI*=BKJR0!F)4C9 M*J%RB:=MZRMUQ%*#1$T1:5W#O\QB,-SXU@$8VD.70L<+E(+%';4*NVE\C;#7 M=0L9<.9#(XH'$M29:YC:]+O#3>C%BFYO2366N33J1>.T_@?E^3\1P1#,M;3Q M^6[,29HG&524@E,KV]3(]. ,[?$'LAQS)C"V2G+VL2=WRR;)6A4%1S=L@^CU M1:C9>+!UF#X6]^5U.VQ]_$"RQ8YCA_D.+Y6#0.(0%W%)?'XU9?)B3ZZ"T6]_S)3W MIIKOTY?3DKC>3S0Y8E3>+D^7[K,1W8EVVY:C\;7"A+)!B&3!,7+8V&MAD2BD M>B,9R8Z*1-C*(\H48R!V&"/[[Y):'?/F2#5%=5O*:6\[_3SY?)>AC10FB+0N MZ8ZC&-M>>I"O+I+ D@N(Y^1NFL-:]^RV+U:QDDK8;C37I 15&)4.@.:\PJYWO&C9$2RTSO MEH7("V6\J]ZNS+\&YB96&M?8RB#&0.,%7U)@>D1B8E"*R?1%IC(U77A'V^TL MN+T95GTO[YM0L#5!UXLJ?M)6IU>4#6BE+!5[>XU4W8HZL!53( MMSZ(FB)HB:(FB)HBZD\(3/AB059\6&)$VBK2\@!)N@QEI:K3N:KC2K*]-VP= MV=J3ENI8JE7]U9=2O7HB\PN^GD,7\3QN61Y.8G.8M.(4Y8FU& MO7@=:3R1O418WCC]RN]Z_/WT3X]/R]-K;;*=FW7:/F?>_N(V_P#*O8MWE'@6 M&Y+"PL898:*JSLE/(_C)!90;E?%#S(C6=W*4,*3YM*"B1*QO:U2*H!5U1ZC- MBBVJ3W^GOFO2XDG1))-*EZBE$D[$Z7JWU45OI9;2WNU%+OW5ZEW#C??=UW75 MK=7KKHB_31$T1-$7G/Y9WZ=.)?L7N/SK,:(K>]@GM$]E7VI6W']#L-T12UT1 M?"4)C@@TB9,/F@L0(8NR90F_<)-& XW(PF4RF M,!HQ,5;F:*SQ!.-&"E[IHBJZ:T6;IWJT(HD2M=PU,9 4," Y\!9.YT!:.4[A ME.<7DA>BZ3$AVJ:-US9W8DBQN32L8'^ ,D=F%I'$AUV M!A-G @7 (R VO<$EP)WQE(:!=CG1L\(_M6;ROMZ YBT'MU5KEZD+$K- MZ,3M M/(^2$M,<31<9Y"YSFYR;%\=VW98N+G&P&0E97M?4B^MB7;YC:X(T-M M0=CM?DL?B32L3F+UG0N8(M 9$36V:S"VB0*=[+ M+LPBO>8^]H,=,2-R;:^67O,0 BC:Y_$;P:=SC(R-D<+(HW1Y ) T-(XFLA,P ::2 =V.( L0+GA[X.\-1]M<0-D9P/< EDU6'1%A!J[%R",HN'#M MO1]1^/70<.%[>;M7O0UG!$:B\#G.D9+Q1')E;#'2RR2M:R1TCF%I@F>T,>06 M$!MA?*LP YF1VN@RDFWW2XEO*]QJ+&^H!(4D)IN)7RI&HW%\>&GP20G;6E\N M3$CV[Z],46!(7(L4#!+O%B-X/C8EZZ6;N["%&31VS:+7.^<3KI1TO=Y'FLB M8W,(@^1K 9&2923&W/(^^20-T+2?$?#O4(0PN=HX"V6X-R#>ULNEQ8#4V MU MNL-QS*S$;1:Q6%R9M/CD-B-]3L8H4:B" %RTE,@>EPA%ZB#(@!1%FFF2%+5) M7-7EKSOI)4V[2YEPM;51"=[I9&R4L4TC1&]S2Z-SP3%]\R*EBI>]=W2C,885'/B9MPH_36-^;A M9"UC3F=D:&M!W+ YH8VUBVY#2CKM#2_-L9+7K*2^3BJ)(RY6.DGS$$Y%#;F#(P1O;CQ(&P4N4[M5TT)*6"Q"C:P"XY1E( MLS,+%I&VO.W,$?VNA7[!7DAI,!#*3@%6N-V*)(4M+B0=-M(RE4PM5R!E,C85 MM3OC=3S=$ ]:]RJ^=H,E[N;"QG$#61N:Z($ M2O83,UV;( 6W(D?D9+@W*,CVESG--@XZGF-=R&@ ZC4ZDM6025 _&CB-L2O[EG][T8=8*\4FPTL2).UQK5JF08/D%GR)ADTJSL>.J M5QD21@2!D;G2-@DGS%M2QN3*8LC2A8)FTF;@RPMF>:CAMG:V.0-.0QNW$@;&!BD>9 92?B] MRTN$N$6#80/>EV2%]*,&KY6TH)&O&Y-XOSZ7>+Y!BLL0;66IO5K[J<^![V/> MQ\KX(Y.JV7I*6UMMZ%MJ-]O.W7\+DK;4[J==EM MMO"E-4V!(&H!T.VG+3EHM!XL]XZ.[2:%QST8Z4'OG8Q^FV?ME6J][(DP6;OA[NQ) M6ZYL^9.$';1:EB[99)9.R^TBA!M)Y-;:#L\R3D: M7,3;%B1Z49*.A4NE!L;T@R=W.*M"EC6P@W1?$6Z3FU @[36)[V4\-$31$T1: MDSY$Y5/,(9^RI&\!'BCCBU1("'[MBHLNWER<<2A9 M=(;'S),AHBST/BF1B3,577R"X/@8WD"=9#JTD(=P_DBK^9-)^P:@F4ELD"#- MC&8VQG-&0H+D7:]C=T# M5:,E[DEF#=JHU:W(D4U\=XQQQB*-)0W%<#B&.(D@[=OT8S!XZ)BX%)\_OM4> MO$Q09JS96.7=]MM[E>U&BBUUMM5+KJTIHBSG1$T1-$31%YS^6=^G3B7[%[C\ MZS&B*WO8)[1/95]J5MQ_0[#=$4M=$7%UM+J5MNI2ZVZE;;K;J4K2ZE:<*TK2 MO56E:=5:5ZJTT1>>W"F*)3+.51E"(O.4^3@F),A9[SDO!A

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g582934g29h41.jpg GRAPHIC begin 644 g582934g29h41.jpg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end GRAPHIC 19 g582934g31y00.jpg GRAPHIC begin 644 g582934g31y00.jpg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end GRAPHIC 20 g582934g33e76.jpg GRAPHIC begin 644 g582934g33e76.jpg M_]C_X 02D9)1@ ! 0$#P / #_[1D 4&AO=&]S:&]P(#,N, X0DE-! 0 M %X< 5H QLE1QP!6@ #&R5'' %: ,;)4<< 5H QLE1QP" " < M @4 ,D5Q=6EL;&EU;5]);&QU2!3 M,2!&:6=U7!E 0 $--64T 26YT M965N=6T 26YT90 !);6<@ $UP0FQB;V]L 0 X0DE-!#L M BT 0 0 $G!R:6YT3W5T<'5T3W!T:6]N

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g582934g35c23.jpg GRAPHIC begin 644 g582934g35c23.jpg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

_XM=WUFK?;26]+9U%P:[](XM:6"6>QKWM=_.?3V_\$DIH5&T]3PG6 MY#,MQNK_ $]8#6N_5^I_N.>S_-6E1ETXE.;D7EPK;DN!+6.L/NV,;^CI:^SZ M3OW5F4LV=3PP<1N"[UJIH:6$#]7ZE^=5]+^TL;Z\_67/Z#@?J=5-OVO.M98+ M@XP*VUW-V>D^O\YJ2GM,_I]&?4*[G/8&F0:W%I\%DOPJL&_[/4Y[V XCIL<7 M&3E@H_2+[?K#]6,/)RW&BW-IKNL.,2S:Z6V_HMYLBRVVUOZH M0;G;R)RY]N@\4E-W"LJIS>KVVO;76V^LN>XAH ^SX_TG.6BQ[7M#V$.8X M< M#((/!!7'?6SKW["Z?UG(^S_:ADY->(6;_3CU<6L>I.RW=MV_06Y]5.N?M_H. M-U7[/]E];>WT-_J;?3>^C^F?]S*/^W&?^253.LZ5F.87=2;4U@<-M M=U8#I-;PY^[?]!U7L4_MV-_H;_\ V%N_](I?;<;_ $-W_L+=_P"D4E.3?=7C MW"G$O.1343DU7?:\9C3?8^YV158U]?J-]M[[:_;;4_U/2_0^DJ'U8^K_ -7N ME95^;2?V7E:TAXS:\@6U.]*][OTF_P!+=>W9]'U/T>_?^D72_;0SJ=MSG4=0MQZ]Y>UGV&UQVRTLI<=C=M3&MF9%/I M?;ZZONK_1J'H=8]3U M#U6[;P*F]/L:S;^^=M?\_P#\+_-_\$DII5_5[ZM]0ZN_K/47''SZ;JGX][LR MI[GBEM1HN?33^KU/J>STO2_2?S7J?I/4755=1Z;76UCL^JPCE[[*]Q_K;-C? M^BL)@Z\Q]+,?ZPTNKK;8;FV,SZ'UM?97-KG&D M8UWM>S[/M]+T_P#1K5J'6&V5&W/]2MKVNM:.FV@O:TM]2MK]NUGJMW^_;[$- ME'6FAH_:USPP#Z?3GDO,>\W14WE8E>%C9['8 MU+&UTUV75NV-;/M:X;7NY_PF]5\IG3PR^^GJ/K9$FVJDY%36NC>]EO MIUMO_P"@J>WK[+:HSS95NFTNZ?:'P7,.UGZ&S_!>LVOW5?X#_![ZUM?;<:=* M;O\ V&N_](I*>6R<3%ZU79C=;H<*;LFNQ_IY^,[6MGH?;+-GV5S*:ZMFQE7J M6W?X7'99]/?Z+C]!Z)B,PL'/:,2O=Z=+[JW!I>XVO=O_ )WW/=^?8K/VW&_T M-W_L-;_Z12^W8W^AO_\ 86[_ -(I*;'[5Z9_W,H_[<9_Y)(=4Z83 RZ"3_PC M/_)*O]NQO]#?_P"PMW_I%.W.Q]P_17#4:_9KA_Z)24^??:,?_35_Y[?[TEC? M9K_^X]G_ &V[^Y))+__6]+Z7_P F8?\ Q%?_ %#46K*HNNNHK=NLQBUMP ,- M YVW1 MF]WTG;/S4E,TDE2LZWTBJWT;,REELN;L<]H,LW>IR?S-EC7?RV>G]-)3"[H7 M2[\A^3;476V.#WN]1X!UC&M0[_ *O=)=NNLI>][0XB'OW:R]P' MO]VZ?SE>QLO%RZS;BW,OK!VEU;@X P';3M_.]RY?ZP]6ZGB]6MJHR/3I:QA: MS8'"2#)XW)\93.@D?M9<'+RS3,(T"!Q>I*;NAOJI>[I?40)Y29]9.LC=N>TG30M)G^5]+:C63][_G- MG_1>;O _7^QZRSZO=)ML=994]SWDESC;9)W?3;_.?0?^>Q9F3^P*2_%LP\UY MH+VS6S)>2'>F^QWKU%SMGM;L]2S_ (K]&L=WUASV8]E]L/R'N:RL-V;?=[7/_EJC]MZFZNR]O78'2N@YC7NHP[J646%@;8+J 70QUAJJL=7^C_ #7>S9ZE M:+?T/HV-A&S*%ME>+6]QL+[76!@-F0[VT'?:]OJV;/9ZRXN_/R;KV%F1:0SW MN<+'EVO^"^G_ #?[E?\ @E:HZGU*BAC6Y3G- T!.XMU^A/\ .[F_\(G>NOF/ MVJ^YFM"/J[3\KZMA]N2W%S"YTM>X5Y%>[U*WM_W?SWO_1?X13Z4 MSZOY>37511EMMK/JA^1Z]>YU6QTV-M>WWM=;_-65_P!A8O[;ZO,B\^$DD?\ M?DW[_%;]TG_5>QIZ'TVFYES*W>I4[>PNLL=#@UU7T M7OBDDDD$/F" M22227__7]+Z7_P F8G_$5_\ 4-5I5>E_\F8G_$5_]0U6DE,; ]U;FUNV/((: MZ)@Q[70NKW-M(#PUDR[:/HR/:I,43*5#LS\MS./EYF>2^$CA](XM7&#; MMQ!&D:2/XM4BQVFYH=X <_BY&%F >'-,]O5_\R4VU8KB7;3('(>>_P"[K[E/ M[,^P;?\ IKE-_P!8/\#_ -#:610'MWO)'IM+M#K(TW.;_6]JK-KL#&.H= >. M"V6!T/\ ==^:_;NV?16CDU5NEH8Z XL+B"/.9U_\C8A[.3P8)?$.7F21Q43?R_\ H3GXV/DN=6Q[YO!E[@(<'1N:]D>YVW^2 MQ7 "^L%S2 [4;@!H?\[VJS7^S+#[\:QI=&YU=X^>S=7_ "/WU>JKZ'M_2MR1 MI(]X>Z)/LT#6[&?F?R$/;R7K'[*0.>P ZR-;;./M@\ >(TY2+9^D)GS6N1]6 MH)8,MT#VP8F$1F/]6'&'V7TN[[S G]W>QCVH&$_W9?8N^_\ +?O.K]4Q'28X MBU_//*VE0Z/5@U8AKP7FRIKW27&3N.KAPU7U!+<]&KDD)3E*.Q-A2222"U\Q M22222__0]+Z7_P F8G_$5_\ 4-5I9G3>I=.9T[$:[*I:X45@@V-GZ#?Y2L_M M3IG_ '+H_P"W&?\ DDE-I9.9TSK5N99=B]7?C4V$;<YSW MLW>__27?\'Z=S]J=,_[ET?\ ;C/_ "27[4Z9_P!RZ/\ MQG_ )))2W3<7,Q< M?TLS+=G6!TMM'J[] MXQ?OAJ^SD_=*/I]>_"EW=S@2_D$'^5]-'LQ[&M%@)D0'3H3.FGYJT,7I=56. MVNWJ&'Z@+I++1$'Z/*(WI^."/\HXH &EH(Y^EM/_4*$YX6?4-V88C0TUIR! M2X028#3&Z!IJ7;&C^M_*1C6[:R6D';R"3$'GVA^S_P $5]_3:'U;#U##W"(( ML XT/[WTD]G3<=S6AF?A@ :M]0 3/TAM^CN2&>'[P6SQ3K0$N2=SMI]0$:SP MV._^OL4&O#7 -< #K[8/]HANU:9Z/2=1U#"F9,V:?E0;^ANL:!3U;"Q]9<6E MKBX1&KK#[?WD[W\=?,"L&')?RT]#]5WN?TYY<9/JN$^4-A;"Q>B68?3\$8^1 MGXUMFXN<]EC0"2&R[87>SOC_Z6O\ SV_W MI))?_]DX0DE-!"$ %4 ! 0 \ 00!D &\ 8@!E " 4 !H &\ M= !O ', : !O ' 3 $$ 9 !O &( 90 @ % : !O '0 ;P!S &@ ;P!P M " 0P!3 #8 ! #A"24T$(@ !BDE)*@ ( #@ 00 0 - # M ! 00 0 #@$ " 0, ! +8 # 0, 0 4 & 0, 0 M ( 2 0, 0 $ 5 0, 0 0 : 04 0 +X ; 04 M 0 ,8 < 0, 0 $ H 0, 0 ( Q 0( '@ ,X R M 0( % .P !IAP0 0 ! L 0 " ( @ " #0A1T $"< -"% M'0 0)P 061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W@$ !L!!0 ! @@$ "@! P ! @ $"! ! B@$ ("! ! M # P 0 , # ! _^% -VAT=' Z+R]N&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP M37!#96AI2'IR95-Z3E1C>FMC.60B/SX\>#IX;7!M971A('AM;&YS.G@](F%D M;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q M,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @ M(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UP.DUE=&%D871A M1&%T93XR,#$X+3 X+3,P5#$P.C,U.C(U*S U.C,P/"]X;7 Z365T861A=&%$ M871E/@H@(" @(" \+W)D9CI$97-C&UL;G,Z9&,](FAT M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT&UL;G,Z>&UP34T](FAT=' Z+R]N&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O&UP+FEI9#HP-34Q.38T.#$R04-%.#$Q04,Y,$4T,S)% M-3%"1$9#,SPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O M8W5M96YT240^>&UP+F1I9#HP,C4Q.38T.#$R04-%.#$Q04,Y,$4T,S)%-3%" M1$9#,SPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I M;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C R-3$Y-C0X,3)!0T4X,3%!0SDP130S M,D4U,4)$1D,S/"]X;7!-33I/7!E/2)297-O=7)C92(^"B @ M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8W)E871E9#PO7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA M8W1I;VX^&UP+FEI9#HP-#4Q.38T.#$R04-%.#$Q04,Y M,$4T,S)%-3%"1$9#,SPO7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E M9CII;G-T86YC94E$/GAM<"YI:60Z,#0U,3DV-#@Q,D%#13@Q,4%#.3!%-#,R M134Q0D1&0S,\+W-T4F5F.FEN&UP+F1I9#HP,C4Q.38T.#$R04-%.#$Q M04,Y,$4T,S)%-3%"1$9#,SPO&UP;65T83X*(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; M $, 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M ?_ !$( A@!Y ,!$0 "$0$#$0'_Q ? $ 8# 0$ 04& M!P@)! H+ P+_Q !_$ !@$" @0&"0L+#0<."0T! @,$!08' @)$1(3(3$4 M%1E!46$6.5EQ>(&1F+@*%Q@B6*&QM]?8\",V.%17=Y?!T=;9)"8G*"DR-TA6 M>;7A\25'4V=VM+8S-#5&26AS=8>(EJ>SR!I"0U)FAHF2J6)E:864E9FHN<;' MR=+_Q = 0$ @,! 0$! 00" P4&!P@)_\0 4Q$ @$# @,% M!@0$! ,""P4) 0(# 01$B$%$S$&(D%1811Q@9&A\ 1Y=!FHR?,_,U'R8 MO#9]SUV._--P+V]G_('L[??U&,#IOC/ATV\QL?=OGSS3)\S\Z!PQN&Q[GKL> M^/:;@7S\A_R ]?G_ -82,;;#SQX^XY'EGT]V0:9/F?G0>&-PV/<]=COI[-IV M!/Y@_P"WD/QQMUVP/F?$?/NQWEZ MMIV!?Y@\NP?7RY#V]VF 1L-O0;G;/0[]<'W'J-Z9/F?F?O[Z4#AC<-CN'AZ[ M'/5_:GX%^/OH//L^/OY: #R&Y\1Z9Q[LCTSN/?&3YGYFH^3&X;/+LX>NQWGZ M?L3L"\NW_P"H//N[]"%W.WN&.@S[NI\M_ ;;TR?,_.H>3&X;/=Y/78[V#V_V MIN!>[_T!Y>CSB/(>[F'/48].O3H!Z#U]3G.,]1N9R?,_/^_W\:!PQN&QR]KU MV/<_7M.P+W^O^L'L[>ST>OF.HVW./(XQ^Q'09\#Y=<]&3YGYT#AC<-GN\GKL M=[NWGM.P)Z/^0(_@#N$>W66/,8V&#T\1GY9\O08H2?!CX^)^'7^IJ/DQ>&QV M?W/78[\TW O?_P"@(??#WM1CTV\P,=>@Z9/AT Z^6*C4?,_,T\F+PV YCY/; M8Z/J^Q.P*'_]@\OO>OM'3;?;?/B!X#T.WC[_ %P13)\S\S]^E0'AC<-CW/78 MZ/FY?8G8%#WQ_6#^GI[=9#!R<8]XVV\?3UZ=/?3)\S\S0>&-PV #VO;8[[WV M)V!?1Z?8"(]G(1[/P]X@9WQCTVQZD]/#;S.U,GS/S-1#AC<-GS\/78[\T[ @ M?@H'?ZN[U]XC&!@CW8/3R'ETSGW^&33)\S\S4/)C<-CM_N>NQWW_ +$[ O?S M[NV@_%YO/W=FL<#X>?IYX]?7SV&.DY/F?GZ>GWYU$.&-PV.?M>VQWWOL3L"> M?M[O8#Z//S]/FT^&_3HI&3O[O#'B3\A3)\S[\G>H#PQ>&QW>3UV.]_+LVG8% MY@'+S_U@]_R^CSZGJ,_3 V&_B ?GUV]:9/F?GZ_>WQJ/DQN&Q[GML=^:=@3T M=W;01^]_+H!GS\<=/GD[XQXX]V^U1D^9^9J'DQN&QS$/)[;'?BVG8%[.\?\ M(#T<@[.WM[^?+4X&V ,]3GW^6WGX@#'T9/F?F:CY,7AL^Y[;'>[ER^Q-P)\O M;0OX_OZ8VZ;[^ \>F<[_ +_$8ID^9^9J <,;AL>YZ['N79_BG8%'GS#S_P!8 M/F]7X.>A49SCQ^'RSOCRVST'JR?,_,T\F-PV.7M>VQWGV_XIN!0$>0^CV ]O M=Z>[W]1C??&,CICQSC'4#U^F=J9/F?F?ZU\E^&;PT&J"SISP_-C+9LW24<.' M#C:E@)%!N@@05%EEE5*$4B221"F.JHH8"$(4QC"!0YZ;;[#;PV\M]QX=2-_ M=/%D^9^9JWD7LKX/,[ 62UPFTOAJS%5IL:\F+A9(K ^UZ0@*I$L&:\@_E;), MM*JK'P4R;AJV:LV[ATLJ1%%50CN^&Q]V1_; Z[';S\9RWKZ;G[. MX<_"XM\!"VJJ;$]@EGJ]DBF$[7K)7ML.W>:@9^$E6J;V,F868C*0YCI M2*DF2Z#R/D6+E=H\:K).&ZJB1RF, \<#'A\?/?(Z>N>@ZU&3YGYFIQY,;AL^ MYZ['?/S_ +4[ WHYA_V@CR]X.8?@U.-O4=3VV.AY_P!B=@7S^@?8!YQ]/;Z [N4X7?8'W#[QY^9'F:9/F?F:>3%X;'+V MO78]\6T[ GX?8"'O]G+^6,>B_P#PDCT\_/\ D,XV9/F?F:IPO#VX50V<])+L M@X?)KF2/"6-4?L:=N0VBU\'$>P% $.6AQL,#Z'S MVVW\<9QG(\?!ENN3CXU4GDQ>&S[GML=#G_WIN!1]'9^L'EZ?]O;J, G^@.?= MMD#&VV-OJ9U'S/S^_OTVJ'DQN&P >U[;'1[?N3<"=O/N_P"T'E[W;Z ]]TP< M;^(P#Z[[[;>GAX"HR?,_/[^_G4?)C<-CW/78[R[0_8G8$_F#S[_>]>H W/B? MAX8S@;[^'E[_ 9/F?G4/)C<-CE[7ML>[//]B=@7GW#W\Z!^'L'WNS4[>(\/ M+I_,^.=L[;$D9ID^9^=/)C<-CW/78]\T[ OG[^^@A^#LY?F&A'3"[[ M^&W3Y8SYG;PR,4R?,_,U'R8W#8Y^UZ['>[F/]J;@4?D_K"'E_'R'3 .PQZ$C MRZX\_+X;]&P'_<]MCOG#]B;@7GV]H]H1CRR>FV^V?'U/CTZ? X]W6FH^)/SJ'DQN M&Q[GML='OY_VIN!/-[U!#T>8!UD /0_'R]XZ^?IU'04U'S/S-/)B\-CG[7ML M=^:;@7Y.?L 'E\7;WCR[>P -NFX\?7W'X;XW.QZ"F3YGYT\F-PV.P/)Z['O, M//[$W OO\N84'M\P>CO[1'3 R!]-^I]>N-NN/WV9/F?G3R8W#8[.?#UV.]O/ MNVFX$^7G[ >[T??[>6IP/!1OCPSU\? @ >@WID^9^9IY,7AL>Y[;'>?H^Q.P M)R\W/_M #]![.T>6L=MQ@ ^?48\\XVWVVQC/ILR?,_,U'R8W#8'_ +GKL=[0 M[PVG8$^7]8/9S\W^K3;&XSL#GIU]_P!W>'+OT^'R'3)^6PR!GH00=L4R?,_/^?W\*>3&X;';_<]= MCO?R_8G8$]_S4'XN78/+MYZ8VSC'0^'3QZD^/0#'D?"HR?,_.H>3&X;'N>VQ M[WOL3<"?S \WR>^(Z$#.-L[^'J2/#W# &_3RJNQX/- M^Q.P(/=[U!$1'\'X9\M@<]-O/?T'S.?'Q.(R?,_,T\F-PV!_[GML>^:=@7X^ M0>P#S=@>_P";GWS@>0VV/AN-^G3PSU&QWVID^9^=/)C<-?GR\GML=^:=@7S] MO^0/9[_F[N7:&H&GR&_38?#T].O7&?1D^9^9J(<,7AL>YZ['?FG8&'T^?V ] MWZ<@U& 3Z=3C&VY^'\AMOL9^?PIY,7AL>Y[;'OFGX%^3]8/+LY=O>/ M?[^F/#Q'N/3]\YP!Y@"HR?,_,T\F-PV/<]=CP?\ FG8$[P_^H(CS^4!#4@#X M;;XZC!.<^&?>3[NE-1\S\Z>3&X;';_<]=CO+SB.TW WH$>S^L'[W9R[N\=3@ M8QCT\!C'7Y9\R-NN3NR?,_.O/"^J2<.XBP7Q-[10L)8LQSAVBH8;Q)*(4O%E M(K./:FA)R45(*2,BC7*E&1$.D^D%"$4>NR,RN'1R%,NUL\/;GRY?8.;3N0C^\+0.P0[O3[X!ZM9#H-C[^@/7'D,^ / MJ?'%:CU/O-9Q=_> =GJY\P\W+U\@]?F][4XQMY;9VW!SGSQT)ZC:HJ/J#E^G M9\7J^/L[-03XY]VWAU'7&3D^OF<^*G<'W_TYCW\^WGI\AC'KI]WH3X9(SUP3 M2@^KG][\'/X^WT\Q]4@'&^^-L9/3&0=NO7TZ8&:4]8=_=S^/EV@'Z>L U(SG MJ<[;'ITZ9&WCGI_,TJ @'>/?V' M,.X>X/-V]_/ES^/S??'3)WR/+(&"1CX[>/J#[J4Y\A^^'O<^WU=P<^\.\.?+ M3&?0],>7ITWR!USG&.HZJ>H![>0/V&"/$GK@G^53_ 'Z?/[\J>G].SY>X.WT:C/ACT/\ M(^AR=\^-1\?7[]]/>[_T]?\ '_)J-B=AXX'7XY^.^V-L]-J4[??^4/O1\O'YGS)ZY(G[_ -S4![>7:/9SY_[_?VZDX/A^PZKX[C< M8^7P-10>_EV>CM\W=S .?/F(AW^^'?ID[9(\<_T\1GQWP!TZ9%3\_'IY_P!/ MGT-.SNY=G;V<@[.0^_[_ '!Z.>GFI.Y/7P\"/CU_N<5% ] ?AY\N_L^+N_C[ M-/3U]1X^[U'AU\, "E1[O5_M[??Y]GK]?;IMC?RVV.<9V/P&^PZ=32GHY\O/ M\H?>_C#M]>GJ0/$^GQWW.-_'8G S2@>G[WZ?Q^KL#EIOOYYZ=??C;8'(SYCQ M.:4#^+].?R>GT\]![\^O38$$[GW^NV*5#L_C'L[^?/D';W=OO!S] CJ<[9\. MGEG]]MN@ ]:4]/H]7:'F[O3Y^X/3Y^^",8\CT!'0GW[=>OCTW.]*CS_B^_R] M'RCV]WI =1[L9)V\#[QD]#[O/R%/O[S]_&K.;B63R1V_9SCHYHX?R#_#N36+ M)BR04*ZJV&:6J_;ZAD)XQQF6 \6L)R)7G?;]L#X>_TK' WS MC]77SWZ>GRQX^M2O%.YS?5![;[E=7D= M_3YX\QO0@>0!&3X;X] /H.I'P]W\_6F!WNGO\ #?P_GD9V./2LC>&AEOB#9)W+J#N5NTG# MHM8_<4TSIA6V1&63JQN<_3H/E@?0 &C =/<1_,YR?E5E M241)L[ +:D.Y")DYA9Q&-]L_+<4ZJ,[=/'8C/[_>>N+@CGK)GL V8N";@]]S MC!%UG;$3?#EAUANXM,LX[R>WP,RG*C0X?J,#,[34*+/Y8&00LJM,KTU#PMA; M,*:VL%>B'ZD:YGP&-@?[9\,X^>??38$[#(W&_AZ[^6_UJVF&;IQ6IN[; MD/<56K5COAMY"S[6*,O0*E4H;-^>J]GK+=:P36\S1TK15FL;9;IBA6A3%XH% M??4^:?/RLE),L81NY0"!GY;C[^^E2=(SL-SI]VWQZ?#>LT.$)D7=]D9:^3.X MC)4M;*ZXQ9A]TZIMS8Y><7FD9R7)8OKI*/YC(.U';96ZXUF0+&).\24V4R/$ MX_D8@#Q4PE#SC1U)2HR?YXSC?;[^>V16+^&WGOMO\C6[KD >H ]7+\/OCW=G M;V:G;?!W'QSX;=/#KUP/7-84 .WTH?7^$//RUD.IW!/J-\[G89VWWI3L M[/7V\Q^7\'G]7:.H'GX=-AGQS[]CMT'AC?HJ/,/3W_Q!W^CY.SU=^GAZ]" # MMDC;W$=-P/+T4^3EW>OEW>OL[0][S]_9'7ICU V ^.PSOXYW^5/L?3^5.SS= MGG'T>C[W^L?-J?AX;_''CG!/CGICJ-L4IYP]?R?ZM1T&1X;'KD> \?EL.GPI M4!#GZN?(?-[WK#N]'?W:;YR/' SD[=-B?C]G-3_?^WE]^?2GOAR]'J[^\?-Y M_/\ )YYR/IC?'B?>,DXQD;>9/6HI_'YN0@\2,'J!@ M>>-\#UZYSG>GW]_?]G;V]@>_YA]\ ^\';Z.?/4^_QZ[^&/+P\\[8WVP*5^OX M],9'7/3.?CX_'?IYDCI2H<_]79_%V?Z^7I$-//Q&XZ_+H0,8^.Q\!LJ =G9V M_$'9][N[O3R[1T!Z@>.3UR?7U]1D#R\N M,8ZG&_3ICU/B- #EV\[8/OV)&W3'D!N-\;C.)SX_?Q\_ MO-.7Q>;F/R_A]X!'GW\PTSC_ 'Z[G?/EGZ$9)J*<@$>[N[/C[.S]/7S#3KCS M&_3KMT(/C@>?A\E1$.8>?T_'W^G^/E][4[CC].?=J,]/CCT\!L!OOC'J/"G[^M0](\^SGS\X=O9Y^?=ZOXM!UR-]L?$ M^&,CU.,XZX\@H/\ 'Z/1Y@Y_+S]_M#0GKUQ\#UVSN0>AZ^N_B2^_Y_?]:CW\ MN7<'H'S_ *=_OZ;]-A[B,[9\]SO\SG?!I3[W/N[_ -/3S] >COUCC!Z]#UP? MVQZXZ^/EO2GH[_>^3O\ >]/=\NLN@!]QV\N@.=]O3KXCR"O,F^JG/;9+;^\; MA?\ T/)AK ]>N?7X?>:W+^D??C73B,;OHJ211>M5DTG\8]>Q[PA2N&3IPV535/.1CKX M [;9/J=SM\O=BL"K9)QX^8_K69'E%-I'^7UR_@&W!^CS?V+0'U\^7=J=6VYQ M[L[GKX]-^IZGSVJ-+>7[5#RBFT?_ "_N7\ VX,/P8M[>WWM1G/7]M\^?A_3& M.N*:6\OVJ/E%-I'?[/KER'_B'W!\O/\ \5GZ?%J3CS]XP?'W>7EOT&YP!30W ME]1_6H>44VD>:_7(/2/UAMP7Y+!]0=NHR.F<^N-ACH<8W\>OQR-Z:&\OV_K3 MRB>TC_+^Y\QY#_@&W!]OG'L^M:'>//NY!RT!'Q\?7^7J<]44VC_ M .7UR[.P>>!]P?O_ +EGF'T@'JY><",>7KOUP?W],8S30WE^W]:CY13:1V_U M_7/LY\^6!]P?Y+.S[W;SU.H'.W]3^_N]WB,"FAO+ZBH>44VC^>_W(?7]8;<% M\@_V+/O>?E\6@/G\.N,_OC;IY[^YI;R^H_K0>(GM'[!]GUS]'^ ?<&'9_!:& MG=Q_0?7?Z?MUII;R_:GE$]H_?[/[EYA$0P/N#][M_L6=WQZC(P1GW8SCZ^'P MSG??>ITMY?4>/\_7T%/**;1^[V?7+E^\-N"_!]:S]/P,CUSU&PZ]>F^.GAU\ M?',:&\OJ*CY13:0/=?KGZ>S VX+Y!_L6?I\7:!QGIY>.X\,[=.@P,9\::6\O MJ*_(\13:/R_7]GU\Z:6\OK_>OUY13: M1_E]<@ .7(?K#[@NWU?X+/T[],C/3'3SR-]\^>V?O--+>7U']:AY17:/Y[]< MOBP/N"#G_P"JWL^74E@<]1G_ &'GMY_/R :6\OVJ <13:1Y[]O7;/3'A@#UZXZ^--+>7U']:CY13:/V_U_7/U_V!]P7/D' MF_P6>_WCS#G\D9'P.=L=#M\#T'E\*:&\OJ/ZU'RBFTG_ "]N?+S"&!MP?/\ M%9R^_J2=MC\-^GR /CU\ !32WE^W]:>44VC_ .7URY>;^P-N#[Q_\EOR=GO= MFF1@;MX;C;WC&P_?Z4T-Y?4?UJ'E%-I'GOURY]G^\-N"[!\_^]8/=S[/]>F1 MYCXC/B<#QVQ\L['PII;R^HIY13:/S_7]7U']:CY13:/V?U_7+M_P"(;<'V]_<'UK?3ID;GS\/YY.?' M!SL2>HII;R_:H>44VD=G]?UR#TA]8?<%Z/WK?3Z--0]=\9.V2?'?RQL/]\M+ M>7[?UIY13:.(?K_N0>;_ #;@A#Y/K6\O]6ISYD>0V^N^?EMD>N*:6\L_$?U MJ/E%-I =]_N7J_L#;@_E_P %GZ=_GU&1Z#KTR,^GSZY],4TGR^H_K4/**;2/ M\OKD'H_L#;@O1^]8/;YO>'GJ7U']:AY1/:/YK] MH^44VD!_V_7+^ M ;<$ =W[UOQ_&';RYCID>'IG.Y^?ICR]PVR6AO+ZBGE%-I';_7]U!(\#D9Z;XQ[ACH?G^[0WE]10>(IM'_ ,OKEW@/^ ?<'YN7_%9Z/O\ M+3(QX>[I_+Y;@@9&=Z:6\OV_K3RB>TCG^OZY^<0$<#;@N7Q?V+.?=_K'3/K] MGQ&!MX_/IM32WE]?[X_V^;RB>T?SWZY\A\_UA]P7;Z?]ZSEV\O?][0D'Q\<[ MC]_[$[>&V*:6\OJ/ZT'B*;1P#LOUR\_(/K#;@O3^];\?^ONG(VZG'GOZGW^7 M0?':FAO+ZC^M/**;2.79?KE[_P!8;<'V?^JSM'EZ?1S[-3J'P\?Y#W>8WZX& MW1H;R^H_K0.(IM('OOUR_@'W!<_1V\L6^?O[/X@YP2.O4[>&/AX;>&XS@]3C M%-+>7[4'B*;1_P#+^Y<_3]8;<%^2SWOD#0%?3S.Q]< ?3(.WOII;R^HJ \13 M:/\ Y?W(.SEV8'W!!R_]5GJ#XN?QLY)S[O';U_H//&=]Z:6\OJ/ZU$.(IM( M/U_7(//_ (!]P8]X^O%O/X]1G.7U']:>44VC^>_W+EYO[ M VX+T_O6>8.SO[?.&FK]L9\O=GR\.GKX8:&\OJ/ZT\HKM([_ &?7/^ ?<%Z. M?[EO?S[.7/UZG4.OC[CZ="#MC??']VAO+ZT\HIM(#_M^N0]G[@^X+XNWZUG\ M7(!YZ:OYYZ^/7Y==OGG7[4\HIM(_R^N0\^[G@;<$(#ZO\%G\O\6HR!G' MCZ;[]<;[8\*:#Y?4??W\:>44VD<_U_7/S=OUA]P/=Z?\%G/U>CWM26ZX\=O[ M^NKQ\?/.U-#>7PS_ '\/4_.H^43VD>>_W(>7?_8%W!!R]?\ @M^,?O>C3..G M3Z^0P<> .V?#RZ4TMY?4?UIY13:0/_;]44VC]_L^N7/\ >'W!_DL^_P!_+4Z@3DGZ;8WV^/AG8 _"FEO+ZC^M M/**;1_\ +^Y_P#[@OR6<^7JY^?EW:G*GKD_9\>OUQ[O!I;R_:@<13:1Y[]7[4\HIM'\]^N7\ ^X/\ M)9J,CP^&1GRW.V.GOZ>9S30WE]1_6H!Q%-H_/LOUR[?-]8?<'W^G_!;Y_0 : M9\_4Y]?<=C_<=,5.EO+R\O+[^S3RBFTCN]G]R#_R#;@N?G_XK/>'N[!U.H?U M&.IR#UWZ_P MQN,1I;R^H_K3RB>T?N]GURY#Y@P-N"[?_59^G+XM,CSZ8QL3 M]? ^>!CW[Y:6\OJ/ZU$>(GM'\]^N7\ ^X+U>;ZUGX>?\6F1MODCS^N>NW@?I MT.6EO+]J\\7ZI2R54EUF:,DT>,?#R,!9*NVCM!%=11LN5/$]?Z?WK8HP #][UZ0/"V]K)X='P$ MMHOT?\?:BLJSMTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI5!X]REC?+,7*3 MF,+W5,@0\)8)*J2\I4)V.GV$;98<&YI6!>NHUPX1;RL>5VU.[9*G*NB1P@*":1%DBB9XXW=%EG+"&-F4%5>4HPC0D,Y5M(.DXV-)&K!&=%9E9E4L S*F M-;*I.2J:EU$ A^I3D<-15K0MQ=^/B MV 7 1GBCP4!<>'BY!L"0"<5.CVZVO87L=ZW#GM+A;]9_9FLC#)[4+@-HY/(T M\SFZN[HTZL[8K!;B!X!48BNH2"3.G1I[VK.,;YJRSC>KM%: M0\98'.Y3"J$),R$G%14HID2LE92$E#,V$A+,FJXR'05<1S"4C7SQ,H])NT?M M'*G11<)'-U5[)]IFED@7@'%C-%''+)&+&XUI'*SI$[#1LKO'(BGQ9&4;@BJ9 MXSPI421N(V8CD=HTA%5U8=P^!ZE%TN;LN8L:PD M1D,6)$3.6@)*"ND0"&$-DW9_CEO9+Q*?A'$8K!XXIEO) M+29;;%S%76FH M$:ER,UOAN;>X,JP3Q3&"3E3")U?E2:0VA]).EM+*VD[X(-36FW>GY$@$+51+ M/!W"M.GDM'MIVN2;27BEWT%*O8*::)/F2JS<[B+F8Y_%OTBJ"=L^9N6RH%52 M.4-5U:75C,;>\MYK6=5B=H9XVBD"31I-$Q1P&"R12)(AQAD96&Q%3#-%<)S( M)$EC+.H>-@Z%HW:.0!AD$HZLC8.S*0=P:JC5>MM-*4TI32E44.1:4&10Q+[( M&GUQ34HV10JW5N_#AI1)TE:-8.N\'\!!H$ZPB[%C[1E='M9A-P(<:M>KD@R9TZ=2JZ18F/CX).48'>+2#UK]JX**)5>@IT+%EP;BG$HI)["QGNXX[FVM&Y"B M1_:;SF"U@6)3S9))C%)H$:-^DYQD9PGOK2U=4N)XX6:*:<=6000"#D$9!'B#T-?? M6-332E-*4TI32E-*53%QNM1QY7']OO=EA*A5HM2/2DK#8Y)K$0[%25DF<-&$ M=2#U1%L@9_+2#&.: HH45WKMNW3Z2JI"C8M;2ZOITM;.WFNKF0.8X((VEE<1 MQM+(51 6.B-'D; [J*S'8&MME6RM^:,541JY>6J^5V-28W*GX]D2I MO0DG,5=;_(1<93:W+LHHKYY$R5@>3445@G(MVI!;OVSU4Z3)0'&NA;<*XC>, MJ6]G/(7M;J]CRO+62TLDDDNIXGDT+)' D,I!2RYE*BXW5M) MI$M;2N5DC(%6=&((U4E0BDY!PB=]XN3>LSO?!RJ>#%W5FC*3\:2U3U7; J M9Q/Q4&9P$@]B42MUS*/D$#H%*@L83\DCB74.&<1-G/Q 6-T;"VG%K<7@@D]F MAN6QI@EFTZ$E.1A&8-N-MQ6?M5L)X[8W$(N)8C-%!S%YLD2G!D1,ZF0'JP!' MRJ18\W!8.RU.SE9QAEB@WZP5D'9K!#U*S1V4%QIY$MS;R0I+K3FIRV=0&U1]]<= M5[PVK7;\0L;J22&VN[>>6+4)4BE21H]#:&U!2<:7[IST;;K5X-P"\%@;G*Z/;#";@08U:]1A4R9TZ<#]6=JT^T0^T"UY@ M]H,)N!%OJY(<1F3.,8UD+USGPQ1YDBD1^0X/%#RPM$,AV6K3MU@ZP9)V+V1J MU9D8>)G9A%8KD,B@JF18Z9+"[>QFXDD#-8V]Q#:3 M7 *Z([BX262&(@MK+2)#*P(4J AR02 1N(5N([4R 7$L4D\<6^IHH6C21P<8 MPC31@@G/>& 0#BN-4ZW4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI7FO?5C M7MFV#/@)8R^D!N>TI7>TX6WM9/#H^ EM%^C_ (^TI6=NE*:4II2FE*:4II2F ME*:4II2FE*:4II2K,;BY')L7@G++O"]=!Q\/DXQPU>*SK;<,]L@:_F97 M<"UC<23*%C5W+2QJ8DPI[[J6PN2*=^UREE=-9QF6[Y$@MD#*N9V4K&2S$*%5 MR&8G_2#@$X%:0X'9=O%P8PL^$L=5%>&QUD)79;9Y&X8+RR]BO%,[BBX5#&>= MW#J:ED<;VUI8\DXKC&U\LHQL4_8.UXB1(A*O)9\$>I],6 M2RV<,/+@G;@-KQ=JI,[:Y^:=S>4&4G/5!!@SL19 MA%^K/V*1CRP<7;X:7;Q$(SCZ,G:7@LG!^)V<%WPNTGO[+L=>W48X3'%#<\0L M[2YBX_#$L7#FCANB[V_*9!# DG.DM98VEF9]Z<)ODXC97$L5W-%:3\Y#R0@+,K!C+*5Y2RHP1--PK-MOWFWGATU+!\XTHLQ8(K$N M"E)C&UBPV]M?VM];6=W;6(M8[I'MI+BWG +D MCEMIB#:0-\G#N,7'9^&Q?D%UL>&Z[>37[3)<6TEM+&-<<2;@DUI=Z.,& MU7V/B%S/.H<\-YXF$96;"PA"\@7F%@Y6S=&\EON$WZ<)O.7;+Q".:#58\X<^ M"%(V*^U\HQLRE?\ ,+ +DH!C.$47LVWWX=D:)=,604S"W&2Q3DF J5=I%['D;<^]RL6A9$'(X/#JXV:8\G21DT^Q>@O,+RU:0C63A1@"*KOUTG:GL M=Q1+RTXC+%-:Q\2X?/:U5XYFM;J.&.!K-X+*6YXH]X(+GVD$FU%O(LJI;<=Q4P8F)9?!$S7WS/B3S^ZOZ^LO-T1&FPF-F=\;6DRU0")M\E>W5AN MT6R<5PD,O6(YJBPF%#2SI,J8@ER;GCO X@>)Q<8AG1^P<'9S^#10WINI;]K( MVV+KFVJ6:PVY'87[GV1K&2,IVDEXK[:[V_)6V%VUP&AT M3-<&29/RM!B3 D.HZ0:S%V>5C(E8W#;TYJSX/O>,:9ES)51N^/9F>^MV2&>Q M-7QM4*$]9&9U&\6%_'R3V6BG\G'MU8PC16'*#AT\:/U C]>8[47%C<<#[)Q6 M_%[/B%WPRPN;2^BA]NYJ2W-_=7J/JNK.!'1(Y$CD99"PE[JJR#775X4EPE_Q MEY;*XMHKJ[BGMY)/9M#I%9VMJ1B&>1U9I(7904 ,>"2K'2, K#MBWU2%+LC: M./FR&FJY@?<_*X\9UC-;FM)*YYD=VUMM^%Q>HP]Z8LY997%4N@M'H3_A%:;P MJJ$/,E179-V#;VEOVA['I=P-(.$RPW'&>ST5\UQPE9R."IV9M;7BV@RVCO$H MXC$P=H=-P9@TL60[.W"EX;QMK>8*;U)8^'\4:V6*],>>('BDLUB6T3JKGV=E M*B3,03\N0# 4);)$+-MXQ+(D+,31H6?M->3*]:/_$96)';-0T\*NN"\4X9=<0C' ;;B MMGV10W]Q/P:$V%AQ#_F>.*UE>SCL)HFD]@FBBYT%M.=+)SB^EA2[BOK2[AMF M/$9;.XXZZV\4=\_M-Q:'@4DDR+.]RD@7VR.631)-'AE;E:04S5^.]M7$,#'M MZ>VRXY-0S/![(:55,1/7F97QZZGFI_8LTH6%G,,V-E4A)K(T#C.;I%=4N]CC MWL:6RF:V!G+O)"+0E8^M?7/%%CX4HG_A*0\):!H7> M 30V,U_%=SBS@=).0&A:)4D,;[8.'<>Y%PTDURMXG [:*S+7I,8OR_$A() L MG+DN([>2VC:>5&3F:9 [E Z\1YA_?Q482UY;P;6,\QYZ3D/%LAC#;WE[.[2X MV:UQLMBFS4#/+R9DY+(ML@A@EK5/U2[5:+G+<]\&D*=+247%1!Y%NT4E.)]C M+J:VX9QBYX,XO+'B*<1XYPS@SVMO;21<1M[W@RQ1I8VLW.%M#_,DC7,T?*,DD5Q"CSMA MH&9%C,@6N32]KV_BGYWHC>;REFR7K-0C,%$K-XB[&2V5!^C#4!)EF")R4VLF M?*J5%&PWQ>>DY%PKB')4Z]9NXA2 FXT(U-EK&Z[0]C+K@UX8N'<)BN+J3C!N M+.2#V6Y0RWK/PN7A[0<$N=1@LA!'&HXI80HZ2B>)]9T0,99$O&4\JQ&2&]MS4GEN.LL](4A!O=;3(5^G3,)I=7D%TA'!S:7,]S=)<":^%XDLCPJ)Y3'#(N6C M 6-0%(,:']6(MPVE;X[)-62QOZ!F26RNTPIO6S+!2M:LUSR//)N,/F MQ%%.,AK+T2(<5AO&QB96L%2FS5=DW1D6P*L?#E/2VO:7LC!%;P1WO"HN'-Q? MLA=16$7"9HI[>TL('7BHXG*MB!>2BY>1\M-=LP=FC;$FFN?-POC,C3R&"\:Z M'#^/0&X>\1HY9[J6(V/LB>TGV=3"BH-,< 4IAAE=9O?E;#'$+=VG=.VQ8AED M(*X-ZI)UVTV+)GBJ:281V1,>DLV,L0P4/G$M8&%DL?Q%HE(:R.(K#%U9"Z?5 M1_9UG,X269\GAO%>PZV_9UN(GAG-M6NHY[>#A^N(M)8WQM^(<3EEX/S^='>R M6T4L DXK:N$2Y2W AY3W+JTX\7XFMK[5IF6U:.:6XTNH6XMN?:VD:7W+*-;+ M<%9--E,K,8FF)<2I;K+V#.(LGB*HU;&K//UAD&"&7;'6+))7M:K9!IUDD;E5 MW]*ILO$L=W\E$'J;.);3SNOV>[VW.4TV9')5WU:;I+>%J7N%\8[#'B=U<\0; M@L"2-PR"XMTLQ<6-U;I:W*7=W%*_9>.07+2M LUO:6O"(F<>TI.<:!5O++M" M+&&&U%[+(JW6 MK=@TQNVRVK3[ADFN6N&M4_D=2-N$C2V^94'%EQ?B6N1.?4JTC5QQTDM(5^:: MN, 6]Q#"-,F9,DH]\9M:/#N*]B$M^S;WYX9[5:\/N+:6V@L.9:I>'A96WXAQ M.XEX*;@S^W%4FB9>-6JR_P"*CC,:\MK5W:<>:3BJVOM(BEN8)4EEG(E: 7BM M/;6L4?$!%R_9@QCD4\/F*GD.P=N:N2SK$.X]+A^3>-4;'N#>Y7>7)R^@WG7U MUCER+J0Y/2L#*M.5AW$2"ZU8""0/ .2&W +WD*4],@6=-,H$2'@+Q/@)[;0W MY@X*G#4M525<3OPR2Y'#S UPH' D47!F(G7_ ,"+9^UH&,(B.:Z)M.(?P%K< MRWS79DUJ1RUNUB]I$H@8GB#%HQ'^4V.(<\P'2)1(*LO6\7[XW,F>0NM&RY%W M9WMOH4%@E[3=P#MYBG"&5H^MWIG<3Y@C)W)B*1YGY^K/Q#L@L?+M+OADEHG'KV;C*77!%7B7%^&O/9O:CA"*=;CVQ'N==P6D,#! MW2[V!75E2[6V@=NN^";8UV)09;E*'19"T;/H[)T);=PZLO>9>P5Z0LJ>YK(5 M7L\5D^PR-=H4Y$/HU%>*BIV)1V_:B M3A\UKP/E6<<$\4'_ "_8W%O)PZ!)[V&9)"))(91$N4ENI Y)KQ6'&'55"\1M MX'DX0EQ'-Q#F3O)',_\ %+B*1;F5H[>6)E&E94+$%HX$(%5(^VZ;XTLT9R7< M7?6QW8H6$*MGP)YP.$RW\5]!-#.G$HN()-Q&5DL> 2& M2TN(S(CC^)R0BT81QV9+1%:?B M2A+B&32P_P "DC3J'>Z*.S"^T9B_=;*\.2R8VEJG:XC.@7N!"MQZN0I*3N4O M48C-U.FO9#)S=FR9?UJY(2M18S,G(U8N2[ RC&O6Q<<[,DNC&I\>3B'9N/MW M!?QW-M+PV3(+&VI]#Q;(UA*"T"$%")6") M(NHQE@8Q146B,<3XMV=N.S=SP^).&"[AX%V2-D\/#5AO&XQ"1'QW7>+;)+(_ M()$QEE,,ND/%KDRQFSL^)Q<2BN)&NC$_$.-B=7NFD@%B[L_#L0&5D4:L&/0@ MD0$JVE,*,?,T;)LLS>5MW3:OXRR/(QN:-U>TW+E;R#$9/\#@#X]@+'B-]E4C M%@_R&E)05SJS!FXA8QR< M*[.=IN&7%E+P[5-[;/;\43AQ=TL3'+:7,+\NVN&%[Q?@MY'.MT1&;:&;AQN]*M<:HYX6@GD!$2L(E1(7P$C%/Y$VX\0% M7 M6X7HL 8JS>S4-_X:4Z%BRX[V)'/N);?@K<1GMNSS6$YCX88^-6L<< M/ ^)I!*U\==PEI:67/V-O>IIWTW'#N/GE1)+>K:QS<4CBY4W.N8P]VK\/GD> M3B-F9$2WU",SRW'+QIEMW+97,O=UBO-4SG#91DJI0V;)Z/Q16$Q<( M[66%S+PB%^)3\)DL;?BXXJUB\=KVO M'O.#W$*7TBVJWBW$E@;(7"F6*)5RMZPA*2,K:PH+#_21L:QRR-M_W?6G<7*[ MR87#\::P4/<1B0F.J[,WB*;9;?[>J37GE"NL&PAV;1U048Z]H9%OMT?HO<#XG[=/#9R-PQ.-WSHTX%XW#X(WMYXUC53 M!IG%UVM3K#+[##1G8 M,JV.?B5:$YI\D[R2,U.Q$TVDI5.W^$1R1B.TF@L3D105X7;R_P"%\5GM;WAU MSP><>R<-@=K9>*IQ5G@X;;P2B]6ZC2PY4,L+1QFUTN1H+:\L1T.SUO=VBW$% MS%?1YN+R51,UDUD%EO9I4]F,+&YU21R*[B;(!U8QMG$F2VF;Q98\G*NIO<:E M)3U+WZR4JV8;C;5&,"WA*]2C[9TRCV$?D1LRB6AXE9J\BV<4FTC03!-G=!(W M3\!#TL?:3LM&(XUAX%RX+OL:D1;@5M)(;0V<:=J6DDDL6>1N8&65Y"SYRUIE MCJ/*;A?%F1CKXCS'M^/L^.(2J/:/:2W!E4+6TUKSOS)VN!/O[.^IF1UF55Q6+;':EQ"2EGKA7JMFBN9<6VIP>,,C7NXYGB M;7.W^^M-SM(N^34<32">5P>U.&M^-$)4:RS;2^-F!B-)&*;J5:5=HR[CT+]H M^Q&J&VGN.%7'"QVCFXA86=KPJ2VALK)^S]W:<./$T/#2ES+:\0,8N&:*_<%H MY6]IB4Q+S%X7Q[2TL<=Y%>?PN*VN;B:[69KBX7B5O->>R 78,27%L)!" ]HI M_3^0V'K.':;MYW$4_<7AO(&2$\FS]2KV)-SE?&0;G08I+>2[2<6)(?:;KA\D$! O+V1AIAF*,]Q,P5=+LO=!W':^6UZRFE*:4 MII2FE*:4II2FE*:4II2FE*:4II2FE*\U[ZL:]LVP9\!+&7T@-SVE*[VG"V]K M)X='P$MHOT?\?:4K.W2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E M-*4TI32E-*4TI7P5;-EU$%5FZ"RK50RK515)-11LJ9,Z1E4#G*)D5#)*'2,= M,2F%,YR"/1,(#(9@" 2 PPP!(# $'!'B,@'!\0#3 .,CIN/0X(R/+8D>XD5] M]12FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2O->^K&O;-L&? 2QE](#<] MI2N]IPMO:R>'1\!+:+]'_'VE*SMTI32E-*5J%WV\4)WL[W*8,PW$XMC[]0Y1 MO2+?NJR*M8UXQ3;WBW*N8ZM@C&EO",;L':,LI,WJY6")J]=C@75*BB+Z:FW;&-: LL(EXF?BX^;@I2.FH66:(2$5+Q#UM)1>A4;*_9+23&NJRC%.=>1[:]]6->V;8,^ EC+Z0&Y[2E=[3A;>UD\.CX"6T7Z/^/M*5 MG;I2FE*:4K41N"X.6WW=+;-Y5]SA:;K;;GNLJU4I-;F6LM/5UM@FKT.EC TR M-K$#!65C 7/Q'<7$CDDAKG'/45;$_4(FV;%!5PX4K:!C2K2U&QU0Z5/VI[>I MNH4ZM5B6NLDS2CY&W2,##,XMY99!B@NY1:/YQ=J>2>().%DTW+E0I%#E !TI M5;Z4II2FE*:4II2FE*:4II2FE*:4K@L)2,E4U58N18R22"ZS5=1@[;O$T73= M0R+ALJ=NHH5-=!4ATED3B"B2A#$.4IBB *5(;[^L:Z?\D['_ *'>:4K&OAZ_ ML!-COP/]M'XEZ5I2LP-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-* M4TI6MW=M@/*\_G#"6X6#KKO=-CW%"MN1D=G]F=XFKT!$SEGK2,-%9OQA)VJM M1"%@R?5Q;R,&,+E*_F@V]8O%H?4I]6IMKX!85*K#8KMZR;@ZM9!DKS+'I$+D MS(]]R%4-JE:4HDOBO;C$W"UR$\C7:E9X2D0EFDIR7!T>P7AB6R26.HFW34VQ MQ_%-XA!*6E5*EF1MO.:)"U9QG MZ[42/J][&\>I[F,YW5*N0*]HQT3(<-8;3+,(B1R>I/5.(R6YA)*XM'+FO/+H MP@X48A"$CIE@I5'X_P!FN\BD46O037+TBC)1T8TKL9'([FF'0.LR;*#V\TBZ4J^&E M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2O->^K&O;-L&? 2 MQE](#<]I2N]IPMO:R>'1\!+:+]'_ !]I2L[=*4TI32E-*4TI32E-*4TI32E- M*4TI32E-*4TI6/N[,BRFUG/([(LPJI0IXB<70W\? M#6)\RN+\Y@:UITSK\XY0F56:J,1(J%*S64K2=P"<*XWQ%&9I/4I7=FI8)FKX MV9R%6W [,YG9W3J-7D;/E6[,:Q4HM6O1->R/:X^U9'N9+1:HB0=-VT9X@91< M3 Q!VZ3M3[^]A]^-=@>^_K&NG_).Q_Z'>:4K&OAZ_L!-COP/]M'XEZ5I2LP- M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI6O[4G#E[RI)S*]CJ^[+%$-9&TZM2#0K")3J%?5@TY M0'SB6G3,1:O%*S]1!8J*17!TU7 )I@NHBD9!%18"@"ITD#K.#HIG/TC)I'<+ MF3*($,LJ("*AIL;RMC_'\3)!/@W55.)81L='JK2 MRJKF8RG3$$7[F.:P;L7S]"/EGCV"G&L>I@FI!0-^F)K_ )&<4@C.1IT.0_@[ M&XY 71JL=+R"%7@K!+1;-LZ35*RD:[(SB57FFUA?09SS292P'CYNL50BE<57 M=IDQQ3ZMD*%P767E,R?8J;7\3R4GFKQ3(R1[MEFIXSAG&0X)+&,I(4OPQC:B M6]LG4RY03;M(US"V%S799S'$=J5:*TI7>TX6WM9/#H^ EM%^C_ M (^TI6=NE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4JRVY$T$3;QG<]GR# M+8FK9<.Y+&P92@/"/'N.(4*9,^,[U# S SL96ILNNG8\K0!=&=L4BM_U82:4 MK3OP8=NM4VSW'/U.89%I:UFM6*=LF0E<28NQ-FS$=%2I=EB\ANZMG2;C,U94 MRX[GN'*45-3-"M+9@VG6\)/*MF#>5-#$B)> M&?R"E4EP]?V FQWX'^VC\2]*TI68&E*:4II2FE*:4II2FE*:4II2M0G&9J6V M![MGKUTW 1F(BST%FS;C7J)8\F+5QC(,(6R[F<+#EB(KC^=7;J@QE<:1MA6N MK1DPEW,J0(IL[4(IDCH<5M!QE5L=4O']2K&(XBKP.,XN$:$I$52DF"- M2:U]R47K$:\2+$8X8MPFY\*:J,C&;+)K LD8Q3@85*Q?J&_3$MUS_);:8O'> MYYEDN%%HXFE+!M?S97J9#0,K*7&%KURE;W+4]K5H^CVN5H%N8U2WNI).!L3B M$>)Q3UR9,0TI6;6E*U7<7)GB6*VS$R'D?*%EQ1-5F]XP@J;8('<1DO J;DEP MRWCR/NT I6N^^VG#-LN>=&5 M&R;O!M5DVTNF-=X9LWM_L.Y/+U =Y"D<0L5;0LTR8R&[4+..2'64KO;<>970 MS]<+E5*GC)9C7!3K<,2S/ 4KL!B MD6'XW FV''_UL\3P\S.V&.JHVJZW,6\O97@R$T\&=R!8[59% MO#78];U"\PJV;!R3:(H) !-*5][#M.V_6N^/5)]*)QI9%XW91+5P MZ4;PL0DR4J42>TC;_+.9!XZH[Q)T]D$Y1DO&WC(,,I4I MRBLAN'.-S0]J8_ M6M/*WF#AK9/EQO[%B6*=BV$C.DD7#1$Y%*@[VB;=7Z31!]C9F\1;,I)DZ2=S MUK<$L)Y5W9I%U+70JT\8WE8R;H)'ULM]BG+2YCZ?*0[!W7 MH=29&(BSD<$:L4TGS\CE2KY:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2 MFE*:4II2O->^K&O;-L&? 2QE](#<]I2N]IPMO:R>'1\!+:+]'_'VE*SMTI32 ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E8$\2W,.0,&[2;E>,?UJ/L0K6O&5 M0O[B7QE8LT152P]>,@UVJ9;O$CB6I@:PY!9UB@RTZ^6KL>DX(H7^K9%H[BF3 MYLJI6M;@55NU4NP;HH1YM0QGMOJ]HAL%9<0:T+ UYPU(TV-,MJ+'O$G;QXI4ZX>O[ 38[\#_;1^)>E:4K,#2E-*4TI32E-*4TI32E2&TP1K16 M;!6R3<]6C3\+)PQ;%5GR<99H(TDS69A+U^16;/46$U'"MX7&/%6CI-L\216. MW6*04S*5K1X>4!:H)'<_>LF;E,[Y288^W%;@L,1C?-60(69J=:H>*[H5"'GS MIH5N (TL#>*:G2F)]P]!HJS,Y,9HW 1.52KA]VFVS;I5]P&W^@ M8@N>"*=9,HY ;8M4OUANUK@K%8LI[>$)VC6IK*8N\&JD;3;7>I<\ 3)#)2/? MXU)9*W7%G-H4JKMOM&W\;,\60U+4Q5@?<=CEK-7>VI8\PMAMBW0UG;]M5IE-J]T&U[I8-W4\R9WCL776>Q&SJS:ENARGD#-J%3> MTRMY:FYZA,$(2Q2BLD#VSQ=/4K.7Z^6^/(WVN*=F$'B>,7Y=3:=W&WQCGF2?F_O^KB;%=*$],'5^%JL#B=,BE63LF!M]$-G?'FYZZ+[= M=W$O4L=Y&Q@QPA U>5VZPV-4,\AV+'-8;7;(,#2+5,4:FO9%.(9VNWQD M&^>UNMNI54Q$HUO-S"+.-6?*'(1JFY,N8Y0()@4K6+PL-UF^C-@!; M#R5%)7F%?FW^,K!AUW9;5(6O))IJ.C*79[]D"5D*W&4%GBV2:6@'[1F\F)N< M;,U)5L1%9HI]_?A\JVDWW]8UT_Y)V/\ T.\TI6-?#U_8";'?@?[:/Q+TK2E9 M@:4II2FE*:4II2L5]T6[6F[38:MV.^8\S3<*_9)>.KY9G%./E;NP@YR>LM:I M]7B;$JE)L!BWMLLMKB8BNIB18K]V+DIC(E;F,*E7_I-H]FM2K]L]CUIJ?C^- M;R7L:NT0,!;87P@!'P"P0PKNAC9)'ER<-!<+=6(@'3'2E8R;[-RK?:YMJR5D M&)G()GE%6M2\5ABN23-S8):Y9+>,E$Z]#UFC10GL-[E&RYO&IZU MUG;UFQ< M L=JT!=VBI6JO >&L,YDW$5O#E$W:WK>OM:LU4RANFW-TYW)8W>X]6W)S]VQ MRI2E,GR.,*/4B.X3(RLID6SFVZV1\M#1TI0VLE+P+B*01CQ4KL)H((-4$6K5 M%)LV;))H-VZ"9$4$$$2 FBBBBF!4TDDDRE(FF0I2$(4"E "@ :4KZZ4K$BN; M&]M-4RHCEZ%H\LA86%NGLAP5;55LV1*AAR0M#K%M5O$ZM. M3;I_9H*I,9/P^:FI)NLWDIJ6=O5*RWTI32E-*4TI32E-*4TI32E-*4TI32E- M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E>:]]6->V;8,^ MEC+Z0&Y[2E=[3A;>UD\.CX"6T7Z/^/M*5G;I2FE*:4II2FE*:4II2FE*:4II M2FE*:4II2FE*QVW>J5E':AN:5NDG:X6GIX S">U3%$12<7:+KA8LK3(&=XYK+-*#A3*>6/8\HU;-SU2%;6>8C?%V.JS0TZLUDZS( ML)IVI79BOOZQKI_R3L?^AWFE*QKX>O[ 38[\#_;1^)>E:4K,#2E-*4TI32E- M*5K"XIV3JK7L)5/&HELEDR1;\R;?[Y6\>4&EW#(MXE:3AC<9A^_Y0MR-6HT' M8)I*MTRKQRKR7FG3-".(\5:MS"2L%L#K,;D2-5 K> M7W29*C;!!;<:2L)^JD&=>:BG%7/-U\A3 H@[IU/0AJO$RS=S"W/)%5EV;B*. MI5XL);1Z=B^T+9;O5CL&>=QDJP5CYK.^32L7-A81[KD9Y6<9UUBBC5\040Q_ MM2U.AQ\<603307M,G9Y MN6/(H(FQ_ SJ56E5(J9O!7)3MAJ,8^*@]L8."'0\4(O.N(=+I%%2M(G QLV= M+#);H&V:LA[<[C+5OZU\%(-L2WG;SD+(J\SX9DF8A;5D*7V]4#'\1%5UWBR6 MQS4*) V1F\?MVU)DUXYI7$57D:LI6PZ9K^Y2IL=\3NI/$[[(SUFK\UB0F=[3 M)P%":U)YBRKIW.&K3RBT^;=0\/77A; UAV3:L+KR4^U!6PR:[I_(39U*N!P] M?V FQWX'^VC\2]*TI68&E*:4JFWURJ$6^-%R=JK<=)D%(IXY].1C1\0RY"*( M 9HX=)N"BLFHF=(!3 5"'(8G,#%$5*IW,$CC:(Q/DN3S*_AXO$;*A6U?)TA8 M'2K*#:4$L$^]EJTL[042<-X\L$+[PI1LH1R5(3>#F!;H:4K1KLBR_MYVOJ9: MK]1VY;A_LDLL9;S)8\,8:'$&6J_D/)6W*1R;+R&))F'>973@Z95L9UF!?03. MP62W6&N,Z =[$Q%L.REY2&C)%0_T_:LQ66!M_=BS 7=BKD;;?B_*$ECE;#[7 M DI0KEE7'M3QF[L9+@W7FO2E-*4TI32E=8K"GU3_MMS1O5JNRY MIMVRW5I^U9MD<)(Y!GK11BU:.E&$_(U_Q\_;$=E>)Q:KF/%84RJ"X216 /U1 M0O1,I79R253633614(LBL0BJ2J1RJ)JIJ% Y%$SD$2G('OV;+K>EU7A;I!MUG0Y=/H=<:]]6->V;8, M^ EC+Z0&Y[2E=[3A;>UD\.CX"6T7Z/\ C[2E9VZ4II2FE*:4II2FE*:4II2F ME*:4II2FE*:4II2L&^)#D"/QOLTS7.6#ZTHTR7K2E%OR>:+G>J)3W=*R(;V# MSD8UFL:TV_7EQ;)E.?2AZC"UFKR,Q-3[]E'QY >+( 905J5^I]H"@MB;B9:H MUO$,+-,8O'59MJU9S%N9OV8'#QY:,KW\DGE2G[E19^0R8[<(XTP4\H*T,./GD4BXC"6V<\9PR2E;;K?M+W%;L\;V"L; MJ-T1JI2[_! DKB;:93Z]3ZPP0=(I/(TL]D_)"&3[SD!>+>D9OA=09L\NPV66V:]PV<(+,UXJF.;-B3&R=,Q2CB*NURGWBQTF MT7N6GHL;G?'EEO%RD\:8^\822,I"5J':UL6]:J<2,O+*NE*KK-F[G:WMLD8* M(W!;A<.86E;0R=R5P72:O7L6UGY)BL]:M7*R2"Z[Y2&S-+2N M7(*Q6*K#BRFURT-4(^L2$=&R(2ZT[=JD9HX.YDV_@J;9)Z51,JIE#HB4A3J5 M\L'[NLQ\3O&M0R-M#AK=MGVLW9JZ5D=QV6(.K*9LMS=G(O8:9K^ \6MY:X5J M 79OV#Z->Y=R6ZDXR-?-U4JICJV\5^.R_#97G*)3 M<+Y1J-&N^XW&^2#W[;KGWY- MRGBAFZQO*9&MV(*I0V,?(&:8YM]I"YS:HLWCR:'Y@C?AM7VP<,?$UZV19(L%IVEVG/-SRBYA\P;<11=&RS";A*U%Q<0I)9<;J M/I-@IDV EY5=02LC,0=E;.W#Y/P45*[.:!SJHHJ*(F;J*))G40.8ASH'.0#& M1.9(QTC&3,(D,9,YR")1$AC%$!%2OKI2FE*:4II2FE*:4II2FE*:4II2FE*: M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2O->^K&O;-L&? 2QE](#<]I2N M]IPMO:R>'1\!+:+]'_'VE*SMTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32 ME8G[R]L3W=EB2)QS#Y8L6$;+6,<8OQT%;J6-;#?K-#L6+3&$) L) ZTKD6?56^_K&NG_).Q_P"AWFE*QKX>O[ 38[\#_;1^)>E:4K,#2E-*5IAW0\ [AQ;P M-Q%KW09MQU=9C*=V>UM_9E8?($O"5R4<5:#AZ['F7K[9(S0Q5XV#9$D"B8?" MUAY3NE8@ L"#3$],7G+VZY37@0U-Y. M5%BJBNH_"QM7#1)!PI7)^J).%CO4W-OL!YVO^Z3;'8BTXL;BQ2O.ZW,X(:0T MCES+E'I\.-&KRC_+D[9J_%R5G82=TG;-?%'T1%-#.&$6;[9!RI6[#AZ8&XB& MP/9?M_PH1MMFJUGW&TW C M(I1#15V[84&]5CV6XFRI,KD1.$9 XVR#:)^2,9 B$4"RY$A4K&W#_'JV+[II M]_C;9JMES=#G'Q4>3@<34S$]VJKF10(Z;,E96?N]]AJ]1:+4XMP]:GGK5:9Q MDRCVZJ:+%"7F74;#/U*U4\<'A]5'$T3'N&M&K$$S>)R*F" M?OSKL6<.O;_A_:WLPP5@K 62G68<04:O2Y*-DIY(04JO;8N>MD_9EI#QC66S M2#=(IR$R\9MU(] J?4-DRJ&46*HH92LH6F-L=,)@+$QH-*96 KI9\6=:5:#; M3 /7(J"X>!)HL"/0=.!55%9P"_6JBJH)SFZ9N:E5KI2M:?%%GY6,P'&0B^6= MN>&*7;<@XSC9>X;@)ZVQ!5;/#90HUOID%5&M6C9 9%27?5QVA8UWG5(UZ !W M97:B$/$2SUHI6>V.']OE*/6I*^*TE>UR$<5[*.,<2$G*T=R#E55:/=5J2F6[ M62>QSF,.R7*X<($!1514R(J-^J4.I5;:4II2FE*:4II2FE*:4II2FE*:4II2 MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2O->^K&O;-L&? 2QE](#< M]I2N]IPMO:R>'1\!+:+]'_'VE*SMTI32E-*4TI32E-*4TI32E-*4TI32E-*4 MTI32E-*4TI6OR4WR8H5HN9I?+QV+IUAG;E2U$XFL.I.5.^86:J$;R9["]E:["J5@TJ0>MO GCZI4^O5Q MX[9@J1<&CIS#QS-9=L"R::W4*G.EUJ9%.ATR%$%*IG+&W3;[GD\$KG'!>'LR MJU@DBG6E,JXSIF0CUY.8,Q/+$@SVV%ES11)0T9&FD"L!0!Z:/9"Y!06J D4J MX52J%3H-:A:91:Q7J73ZVP1BJ[5:I#1U=K<#&-P$&\=#0<0V9QD8Q0 1!%HR M:H-TP$0(F7GI2K+;NMOC+=AMASOMKD+(I3F>;\86S&ZUL2ATI]:MA:(M>-+- MHPJ[Z,2DUHTRQ7230TBQZXZ8%!V@(@H52M)7!ZX 5.X6FX.\[A*QNS>Y^/9\ M:63#CJNGQ=%TQI$NSW&M2TF[4F(_(MP%20B7]14B'D0HQ;J(.5ERN%T5FID# MJ5MWWSI;R5<*-1V,'Q^7-+>_4Z2>H9&C4'T-)T"$>K3ML@&;IU:JPVB)2S)1 MC.MH/5BRH.6\NZB"FIQY,N3*,I67$.223B8M.96:N9@D1ESL&RSKK5$&1I:4,U2,5 TB]$@N55*F.E*:4JR^=]O.&MS5)2QSG M2CL<@TE&;861.OR+^9CVA9Z*1=IQ$MUD')1;H7L.J]4D(=<7 FBII".G8_P: M9BHQ\T4J\B21$$DT4P$J:*9$DP$QCB!$R@0H"81$1'2E M?32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E M-*4TI32E-*5YKWU8U[9M@SX"6,OI ;GM*5WM.%M[63PZ/@);1?H_X^TI6=NE M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*M/C_!^,,72]KG:16U(J M2N;D[B;5V.+7(P>/,SR#Y&VF\*:/N; M>SNEZ] QVWFX3U8R]3*G/9$LD.]G['C::GDH+)",%+2[V.)0:Q%RN3))8@H( M5..@GTU:W$;%,7:I%*R*R5L6X;&'*':LH92Q3C^B8^I,0XG;5;;)<+K&PT+% MMNB4[AVZ6M8!TU53I-6C9(%';YZNW8LD'#QR@@HI5(8YV'\.F3L%JQS$XE5N MUCK,U,S-@EG;3,7B.!"ZK,\E0%,6NH/4:860@:5D&HI0M:+.'L9*D:&?.F'1 M,LL"EZB>S.F].KLQ- M6!W7K"Y=-J2_%K&*.Y)K-RB$.1PY9.C-5*KK'&Q/ATY9J$?>J-@B,D*U*.99 MHR=R8Y;J[Q1Q!R[Z"E"*0UIE8::;^#2L:]:@=S'I$7% 5FYE4#IJG4KEWC8+ MP\\=U]:S6K <8A&)/(Z.33B#Y9M,P^D99ZC'QL?$UVK2\S8)A^\=N$DDF<5& M/''1$ZQDRH)*J$4JPV!=E'#%E7\E0:_'1V8[#8YJ[97A)65E,DF:(5+(,RVR M?!4:N6-*5:UN29XXH^1Z/'1M>;23FTP]'>U&2L#!NG*-W*ZE,_[)N&9&@ACJ M;@!P_96-AQU?5)^N?7:=&D8W'UNCLMS>,$IQ-W(5Y]*Y2H6.K=6IBA,'R]^E M\?2=EDH"$6ZI%V52KVU78MPX;G2SY"@,+5I6I(>R(C^1DI+)T"XAW-0DY.%M MD?/1$].QDU 2U8F867B;!$34>QDX>2C7K*0:MW+95,JE6#KFSOA">VVU8_=95G9ZK,:A=?#;(!BQ[R616K3I:DVB@76=;)N8F!4&>A9*0CYMMX M.12JCONQGAF>S/;[-O&$'16;]XXM<54TK'?&<+E>#N]7>4RK,KF9[. I"0Y+ M+;8"5K"DFK#GD;PSA(- SA^L,>=2KKXVV2<-#+\,[L&-,4T:X0[%^G&O'L39 M;^8C=VO%QTXS*JDXLJ"Y49."F(>>B'?5>"3$#+1 M"JD%%Q-5&=-J823V8"&9.Y-Z@$E( @5XZZZ6?2#OIK@V0 Q/".J+U8= A>9N M:E7.TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4 MTI32E-*5YKWU8U[9M@SX"6,OI ;GM*5WM.%M[63PZ/@);1?H_P"/M*5G;I2F ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*POROM$4R(C MGUK"Y$0JL;N)+7HV]PKNBL+'#.JW%T.?I,M$*-PG(-XH[EW,VC;4)9M(1ZC2 M?B6J4HUL$*\EHJ04J^F5\2L\KX+R%A"5G'Q&F0,76;&KFTR+9M,RS4;%5WE< M+:%VQ_ FLA,,5G19H 62:TBB4Z9VO,IDU!MO6 >R6SX%W&9]W)9OP=D5C-* M8)S)D':UDN,BJ17*U,6+(5'H^%*I(3%FN\%+N764:&QBJ)$CC%[,12:D4]I5;\0S)>'-J-23WKY@R%)8[A\?T.U;?6K^"@H^6EQF-S5[Q' M68*TMP=RD6H[-CN2K*=F<1H'.0T 6PR)E6Y8XP+J5G1C"I5N@XVQ_1J<9JI4 MJ=2ZO6*RJQ,F=FO P4*RC(IPV4146251<,6R"Q%B++%6!3K065Z?6&4JF\YT M"YY1QM-T6BY*2@'C&:082#12M/*Q5XJ# M@('+U6H.-<0V6RUI_'6^QN"XSFZ;36,E0JM()KNF![%+N'%CFF[.&2CU*F_$ M=R'%;6F2&['*^Y&.QM2F[ZB8%P]$NL5M[D\Q5E'-\VOCN5S-5D9')M8KUCML M!7+)*6NPN+#6YM[ XEHUTA:>T(>RVQG:U*S]Q/BZ0Q7AR.QO#6"$/.Q["RG0 MN3.MRQ6C^RV24F)U>YS<-.W2SS=AGI2V< MW:]R]9(9Q)QCN!91..J##U*F5-M2:6VC()2MWVE*T[[IU*7@:P1BFZ_,\ _; M;X=T6$MM..$HS'\JS-'TR1R,:ZL\$R:3J]O*\PQ_:ZY"6""R3;TXIM(S\W;W MTW8/"85.#KL I6ZW%8MJJWC>Q8^DZ=(2KFT6YC)-'U4LB M\VTM42U52HJK4OE,C5Z\=JG/H/[1",UH-1\BX- MVCM=J5Z5 SA%JX52 Y$5#%4J55C+V-;I/6.M5.X0]AEJ@\EHVT(Q;CPI&!DX M/Q0,K&2;L@>"MG[(D[%++-CK=8"+LJH )2*"12K0I[R<$N21'B^4O$LXLKV( M:U".B<2Y3D)2\-)^O7.V0MAHT:WIYWEQJ4G6\?7&:9VNN(R4 K'PJCD)#JG< M>9VI7X>;U-N#1H]?DO3V181M35N$B_AJ7>)=BP9HPCJR*0+]W'UQPW8WLD$R M=2BF/'BB%X1:HB*\ D,EV,H\5B+#+,8.(FDF4>NX=*0KR2D6C< MDN1(8X.MZPSD$R&,"E?5/)F-U6K!ZED&D*LI25-!1CM.UP)VLC-D*F<\,P<% M?BD\E2$52,:/;G4=E*JF840 Y1%2JWTI32E-*4TI32E-*4TI32E-*4TI32E- M*4TI32E-*4TI7FO?5C7MFV#/@)8R^D!N>TI7>TX6WM9/#H^ EM%^C_C[2E9V MZ4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4K! MK9-MAB-MZVZ%VUQ30<:/,K7:T/$<<4VGU).P0KB?DEZDZF J,>Q(\ M.RBGJB<>WD>FXBD'"S4B3;IJ)BI5!\0';:UW3X(K&-UL9TK*BT1N;V=Y)4KU MZBJK+1+6I8YW3XBL^8)-%*WIJ18+&P6RRA#2#)'^K[-7)B=I;=O)$LJT2_4K M--FS:1S1K'Q[5LQ8,6R#-DR9H)-6C-HU2*@V:M6R!2(MVS=$A$4$$2$222(5 M-,I2% 4K"/[&&)4XB:NZUQBF@JD1VM1V.8_*BD'4%+PVOR>09M1XT;2)D#7 M!N8^/GZ40I+)F(S6A53P NS( =D"E9RZ4K!G>GMAB=R,WM&,$;6BL+@J]D>4A1U$Q)%WCURPC'XM%@AB+M%* MSFTI32E-*5KC6X>,%+9]<9NM.27-G;*Y%7OQ*1)U%!Q%J)FL5AL+"OOO#+$] M@C,XH]C'9&,64R?;I^*B MJ*UHH1T4W4I#R;8^(L7Q4P:VS$%,J+V)G..\Y,\4B$I! MXI5>M=JF4(Y'$)66XH[@^ I*#'%3.:Q9%OH)I#PN+UR+684E@#F3*[5.?VWW^/E_6K.K\,6G(IVP8'([F*E+NI; M[7:+0XH\.^ML[E2]T*0HEGL$I.MI2+57QW*"_"X*XC;H-(I"ZQT1-,9YFG'D M9G5%9%'VL>.%4)^X7Y6;O3G/^/,^6&P1=8;0,2_D<:P4%6(&I0U>4EYA>"@# MPE;C >+.)V;DG$H=]('*8UAEZE2>0J%#W"XPU'N4S58$TVC97YJ1;71"#B$ MDJQ8F3]-%>%D2-U*KRS[JML=)(V5N6X;"=22>-J8\:+67*%+@T7+3(S26D*" MZ05DYIJFJWN3>QYEVS%RJFI5DMW_ !#MO^R64QO#9>89 M[-6F6'\2W'+CI"LXU+6%+G8YMI2V,D[B(.'2M\&JM).$!;"FX,8# M\R6K%L+FR'@75]K<5:C8IGZXUM\9>Y"J2DBS ML417E*T\;S3A_*QC-)E'G%P]%!,AS%4JF8K?5M'L62\,8EJ.>\;7>Z;@6.09 M'$[6CVJ'MT9:F^+FS9U="MIR >/XA)W%IN>B2/5=E?NSM9$&K94L8_,V4JJL MF[K,$88R37,796OT/CZ:M&/K-DR/F[>\9UZE-ZQ5;E0*#(&E;?+N6<+&2+JU MY-J$5$QSMPFO*+R(D:],Z0D%2N RWH[/Y&-D9F/W3[=WT1#M*T_EY1GF;'CF M/B6-SF K]3>2CQ&PG;Q[6QSIBP\.X>*(HOY,Q&3S2Q;=9,?FC(".7FTWJ?:Z:+-@DXOQ26><85JUVE:X)P5"N= MZJ5:ODBA1K)<*O8)!O5GTV$FK&(/J':72;Y)(Z)HR*=/E3(D;N2HJ50-XXG& MQFCFJ:1MQ>-;@M>JOERVU N.[5 7=M/1N#Z\6S9#;-)6#DW$,G+QD:HGX)$O M)%L]DG!S)M$E"(N%$5*OLINIVVM7DS%2N=L1P=@K%%:Y,MM7G,BT^,L]/H;N M-9RY;5:X%S,EDH"#1CI!D[BY/K326?0+JP8^MD%<(5M-QAB%D8AQ)U]](,T9)B*J7A3)18KE JJ1E$RE5 M()E*N!I2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*: M4II2FE*:4II2O->^K&O;-L&? 2QE](#<]I2N]IPMO:R>'1\!+:+]'_'VE*SM MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E8&[TMJF M8MP=FVW9'P-GFMX"R?MPOEWN4#8;9B0N8X.71OF-;!C.6C'-:/=Z*1%1**L3 MQTV>FD714W!$N;0W+GI2M;$=P+U:IDO 62C;D)?)$-@N?I&3)ZBV?&Y!?Y*R M'"Y2SGF'*WBKQ5DRIXZ@HG-%GSY=1"/ME)M\C2SIP\9"V]K6#3L5*JD''U\_ M'[^]JM1B+@GY'O6TV*AK]>E,*9X7S%<9^J3-^A@RK?\ $.WVK4)+;GMLQ*A/ MXPRO28,\S1< 52L.K%&GL5\QM8K59KBSMU=N39\JN945M(W)<,C!^[S(NU^R M[D&L;EVC[<,790HBM!LT.YCV]YL60DL5(-;N]>5&;K;.(6ADL.1064K&R]\&&H6R]W#Q5D6F5[!DY>;ME:NXK-@^*DIZN7.X;8% M=JR=*<7Q.XQB'?HN&K2*:75C$M6Z*2GW]_[U4>UKA4V_ M;ED;;ODN0W$Q-]E,(6;<"X+B$(1**4J[V^CAQM=ZF1\1CZ_EFP9)GX!+$# C2X1\WQ$J7OL2JLL8EL(DJT81%1^LRFX= MMGR1H]\%A(Q1;-O8RLJ<^GECTQ_7Q]=ZXY."/XA>T^R8_P ]5ZHW#'DHXM52 M>#A5!Y7EK@SW_P AODK#JUP4=?H%W.0$21XGBQW$LYR&D'3!N2>8S<4'1A"* MBOK6N"62/J-ABK/GJ%L]PGZM4X/V:EPXWCEHF2@^(UEKB!3DK"L5+S)+QC>Q M/ONN)!M5*DSW@P9;5E*XDUW9T8:I2\6;G\ZO)>4[U?LM4:6)F:.AR9.:0F1&5"A9>U5NTQT57(20+$Q4,G(P4:_M\E&UF-1 MTI6T/;#M7BMM%BW&RT)-1SV*SSEN"RBTKT366]9CZ86&PWC#$YX1NFT?NF\B M#Q3')K =\FUC.@>8,R,T4,T%XY4K+32E-*4TI32E-*4TI32E-*4TI32E-*4T MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E>:]]6->V;8,^ EC+Z0&Y[2E= MM#AI\1?:]7^'7L0J[IQN#DI.G;/=MU)G7-4V6[T+O7B62E8?J%5LS**MU-P! M/5.Q-XRP0\E&C+5V:E8=VJT458/W3<2+&4K-ORE6UK]K[I/1^P#WZ_FTZ8ST MJ,CS'SJ'E*]K7[7W1_,#WZ_FTZ5.:CY2K:U^U]TGS ]^WYM.F*C(\Q\Q4/*5 M[6O^ W1_,#WZ_FTZ5.:CY2K:U^U]TGS ]^OYM.F#Y5&1YCYT\I5M:_:^Z3Y@ M>_;\VG2F1YCYT\I5M:[O!]TG/X >_7\VG2F1UR,4\I7M:_:^Z3Y@>_7\VG2F M1YBGE*MK7[7W2?,#W[?FTZ4R/,?.GE*]K7[7W2?,#WZ^?N_Q:?/I3(\Q_MUI MY2K:U^U]TGS ]^OYM.E,CS'SJ'E*]K/_ &Z/Y@F_7\VK2IIY2O:U_P&Z/Y@ M>_7\VG2F1Y_9Z?.GE*]K7[7W1_,#WZ_FTZ5&1YC[W_:H^4KVM?M?=)\P/?KY MN_\ Q:?-I3(\Q4/*5[6OVONC^8'OU_-ITID>8J/E*MK7?X/NDY? #WZ_FTZ4 MR/,?.GE*]K7[7W2?,#WZ_FTZ8ID>8^]OWIY2O:T'>WW2!_Y@>_7\VG3!\J9' MF/G3RE>UK]K[I/3^P#WZ]WI_8TZ4R/,?.GE*]K7[7W2?,#WZ_FTZ4R/,?.H> M4KVM?\!NC^8'OU_-ITID>8^=/*5[6O\ @-T?S ]^OYM.E,CS'W_L:CY2O:U^ MU]TGS ]^OYM.F/OZ?O3(\Q\Q3RE>UK]K[I/F![]?S:=*9'F/.H>4KVM?M?=' M\P/?K^;3I4Y'GUZ>M1\I7M:_:^Z3Y@>_7\VG2F1YT\I5M:_:^Z3Y@>_7\VG3 M!\OO[(J,CS'SJ'E*]K7[7W1^G]@'OU_-ITJ<_P!*CY2O:U^U]TGS ]^OYM.F M,=:C(\Q\Z>4JVM?M?=)\P/?M^;3I3(\Q\Z>4JVM?M?=)\P/?K^;3I3(\Q\Z> M4JVM?M?=)\P/?K[WW-/ITID>8^]_VIY2O:U^U]TGS ]^OYM.E3D>=0\I7M:_ MX#='\P/?K^;3I3-1\I5M:_:^Z3Y@>_7\VG2HR/,?.GE*]K7[7W2?,#WZ_FTZ M4R/,?.H>4KVM?M?='\P/?K^;3ICZ]*G(\ZCY2K:U^U]TGS ]^OYM.E1D>8J' ME*]K/_ ;H_F";]?S:=*G-1\I7M:_:^Z3Y@>_7\VG2HR/,>=/*5;6OVOND^8' MOU_-ITQ3(\Q\ZAY2O:UW^#[H^7P ]^OYM.F#Y??V#\J9'F/G3RE>UK_@-T?S M ]^OYM.E,CS%1\I5M:_:^Z3Y@>_7\VG3%,CS%/*5;6OVOND^8'OV_-ITP>N- MO.F1YCYBGE*MK7[7W2?,#WZ_FTZ8ID>8^=/*5[6OVOND^8'OU_-ITID>8^=/ M*5;6OVOND^8'OV_-IU.#Y&F1YCYT\I5M:_:^Z3Y@>_;\VG44R/,?.GE*]K7[ M7W2?,#WZ_FTZ4R/,>=/*5;6OVOND^8'OU\_=_BTZ4R/,?.GE*MK7[7W2?,#W M[?FTZ8\?"F1YCYT\I5M:_:^Z3Y@>_7\VG2F1YBH>4KVM?M?='\P/?K^;3I4Y MJ/E*]K7[7W2=O=_:![]?S:=,$=1BHR/,?.GE*]K7[7W2=G?_ &@>_7L__EIT MID>8^8IY2O:U^U]TGS ]^OYM.E,CS'SJ'E*]K7[7W1]G?_:![]?S:=*G(\^O M3UKS[/JJG<#C'<5Q%,5VC%KRXN(RJ[/<_IXY(WR,GK MCQ\#X'8'X>&#CTJ/8'H]?RGEX'( M^FXV$[_T_?']OYT[N[G][GR](<_P"',?BU(W.VV-BHIS#G MYQY^GGZ?1ZO>]8CVZG'@[W^?W_-YO?[?7S'SZ9' MGUZ;XQ_OUZ>603U4 /D#N\_8/;V#Z/-W#V>?0G??IOC.2-O$YQGQZ$YV]]*= MO/UAZPY#S'M'SB'=\G=K'(!Z]/$$>70>?OQGH/(T^\4[?7\@?+Y^[GW=XAZ> M[0C'4G/C\@#G'4$X\#T/J:G[W/\ M\?Y5'T>?N_V_(//4[;=-M^F^1C;N<'W]?+)/7KCPV?>*AZAY>KOY\NT![1\_+G MR^7MU/CZYSTWZY]-N@W\<^5*'2LJ<:Y M"890J3:X1E>O54:.I2P1:E3^/[4FI7IZ2@%WCFL6AE'S#:-E%HU22@'Z M[5-&:@WO[U7W;Z//\G;V#^G\HA. M,?+P/3W^)&PQD=#C_S^GTZC8G?XD>ISX],=#_ #WIUJ'O MH\L]-E87YIXA6T;;SE%?#N8,H2E2 MO$?6J9<;!T,4YDL=,IE5R):7U)I5AR%D^J8_G,8XZB+';(UW Q[Z]6^O(&D2 M)(JJ)>%-3+#@;9W&/#'KX#;&<[;XVJ0"?#Z@5D=3Q5."M+M>OQ%A\<8]F)MDT8WNK))3"<6O9*ZJ\B4YYA+1'A NHUGO^_O[\ZX[QXB MP9NGSDPE;LVRSM7 M3?N@T^_O[ZU:';WGG'FY[#5!SSB=[)2&/,DQ:\S6'DQ%N(6279-9-_$./"XM MW_5#-0CZ-=I]!3M,4I5"B*9RCJ!O[_,Y/Q/A@=,_0U)&"?3[']?G5Y_-V\@[ M?-W>G]/3\>LL'SR#Y#;/3/U.,;D@>-13M\_R^;Y.?F[OT'0; 8_M^WCN/,9Q M@FE0[O4'Z=WR!R#U]G<(:RV/3P\MB/,=/3QZ^.!BE/0'+D';YOD$.?Q^OS\N M7/6)/D//Q!R!Y^><8ZG;PZ&GW]_?US4.0]X]GJ[/,'/WN_NY]@>H=3GW C'4 MY\QOC '7)QTI4>WY![_-RY=X=O\ L]?+GJ-^H'EOD]-]AMXGP'H,9I]]/OYT M'GR]/9WB/9S[>?;W\_D#WM1C?/IGWXP?^]Z'?.3\Z4#S?R=X^GU<_/S[?1J0 M,XWV\-\'P'EU'AO[MJ4[!]/OCS'E\H]GK#S@(<]3CIMTR/,9Z;[>?C_/8*=G M9S[^0AS[/-^G/U>@.?+3&/GT_H#Z'?/E@[4IZN_N[.[D'I[/]G0\-_7]L;C/AY;D8G/]O3^?W[\ MP'MY!V<_]H#V=O?VAZO?#0=?7.=_'T R1GRWZ>E13OY#S^0>SG^'M[NSO\^G MN.YQC&W78[? './2GW]_?\Z<^7/L'[W;W!^G/U^C0[$^6^_7KT&PR,'J/7?K MO/EY_?P_V]]1[_.(?)S\_G[O7V:CP)]< ]/#P'NQZ@'.3BHJ';Z?1V#R[>ST M=O+M\_K'U#K+KGI[@?COCQSL#GQS2GJ#SA]_N[>P>_TB(\^7GU/[#W;#'G\, MX/\ W3MBE._M_B]',.[XN[M'EZ.\,>@Q@[Y&_AM@8\.GEU\_"E.WGV=W;S\W M;Z0^3S"(@(^G4; Y&_7TVQM\O+;/E@U.WW]=OCGX8J(#\?QA[WQ>GY>SGIG& M>OCN=\G?;'0;Y\_EFHJ ]OO]O?W#RY=_+XO7\6GF?#K@[]#CPZ#PZXQYCHZ? M?G3G^#O_ $[/T]':#KN=O/IC)Z8'3U\-M\^)??WX_2G?S[.0@/(.P.?=_KY] M_P"'MDXZ>!QMY9Z=.G_PG;F'G]/G'0?IQCWCK]-R,'KY>63 MLKS)OJISVV2V_O&X7_T/)ZP/7Y?MM]*W)^D?&N\-P0^?DG-BGH^L;$<_1R\< M37/GV>_W#Y@Y]FLAT'QWVZ$C/C_+?8=.NMOU&MJ?=R#G_LY^C^/ER#MY?L5#GR#L][M\P=OKY=@ /GY]W/4>/7R&WGU!Q MOD>(&3^PJ*C\OZ>CL[?1^G:P?+IY9'AGR^'F0=^H:GW]_O4 ^\ ^CTA][O\ MO]OG$7ATR2!@>.PSX=1T\<_$5/Q^_P"OC0.WGV\^_G\G+U]X]O9Z_>UB/?L= ML;_$XST&^_[>$>7W\Z?@[O1W"/H]'F[O3K+'B >FW7T\O3'CYX'04^_OI]_. MG/T]G+M$.T>[WO1S ?\ 5VZ';P\!N#T/CCJ#GS_5U\,4^_OQ^E![_D](>D>7 MWA]'+U]PB=OWZD#.W4[_ $ZY&,C94?B[/0/H]7\@A\FG7)\L>_;KD;D@9R?E MZTZ4 /E\_O\ I_3T]H:;[KUQX?M@GQQZ8P/?2H#V]W?ZN7K_ (^SN'^,(/7H M!GS^&P^AQC/AC&Q4Y /K]7+T]OF[.WESY\OC#S/#UGY8_J/7^?@"3X]:4] ]G;R[?3_ "\_-W]W/49V\1@^6YW&/R0R3CPSD>7@]V!Y_-V>CM]'F[]1D="2?([>OAU'TSX^9??W]^-1[_7Z.SN\P^;XP]/O: MDZO YV'V0?,$_(GPP'W][_M4//S][N[>8>OLY?Q\O0&F0!Y8/AOGY;;^_P / M(8I3D//Y [.?=Z^[Y0[0Y_'H?#P]Y)Z^/CMMXC;8XI3N\YA\WR_IV#Z^6A) MV^!VP!L-^@'3RQY'K2NMS0=EV\&Q8JC-J%DV]/L=PC/BHW+>1/[AK3D3#$G3 MF^(([=+-YXK'UM("BY&N&47V1;?#$C*^,=;:-0XV#;34EXRF3&3.V-@!G;^8 M^.WG^WC6PD9+9ZC88/\ L,'W^-4#1>'=N]I,SLVN*&%ALN3<29CRVYL##)LY M@6_;?:=C3(6\NZY7>W5N9SD1IEO'&;V^.9",FZ??<)1-R?2J;IGCN^Q<5&MY M9'4X(\/GT/P./CY==J9!SOC./ YZ?UVQ[]ZI?$O#CWW8S/GR[RF/BY#W"OJ# MNC@7LW;7>%$L&[N5LK9";S-+;9.M,%FEEG._.(6N)IKU"!RQ3,9UZA+M7%-9 M6I"K2+A4[!W\>OC]>N3]^ZFH';H/CD8\MB ?7/2J*;<,O>&& LTM9IF3;H;.;S$5:QVXOWL@6=(8KN\GD"BV0A MRO6\P8I7P[(U2(Q,A@R)H\EMPE[E<\FQ6XQCC)A/#8(U+%T'B6Q46 M:>>)LAN;$TLCA^LT8.GY3P)5\2!F#%F:;OD5-CN8I62[@WNMLQ+"J/*S, M2$/4L>W0UA24>1";)111;P:6!Z[D$=<^H\/+?I\:A2,8]<]"=L>%1ALY/GXX\_O'3/A4@C &<'!Z9]_KY?OT MVJQ[KA,;GK9CZ+KF2<2Q-M85W93Q!JOB2CR>3:O/-\)Y1RYGAGD3:7B6.EY* MS-$WDYB^I>",X*[LC.J50I>#12A[2T1BJ_(+@O7[WS@>/G]]#34/#S&=NH\3 MO\L=?&J^?,RW89! M;8ZO66Z51L@YD;EA\/#)'A[L_#I7$VJ\*O/*F0]F3K=+AXKNA[=,4[U3,(UQD:J)QM)R5:=U< M7DG:^Q;5C']_?,EH^'H9%I.!@HWQY1Z.K',HEUX$^CHI K!R,[8\\XZ^?Q\/ M3UH6&#@]3_+'WT_KBKB/A.<1G'VWE]C.SXW8VVQV&.VS33N:5ON)YN6@<+XP MRQ/3&6]B)JO,Y!B\?6"LVAP_8YGC.E(1>.LG.G$S3,NW5)TE%F",'^WC\OKG MIZYK+6//[^7P_E6;N'N%/>%\T;+9'+6-+S.8,PG5=W]L4K5WN6-*:_Q%D.\Y M:QMD/!-'A*;A/*UNKC2KUB2K\M8*)7ZU8KS2J$:,AT'SULZBH-!.0-^FW]M8ENN#@[>'4;>8WZGUQ6:O":VP9DVK0^?*3?L9%HN.I"U5!_BFQ71K MAPFX?(!RQT\>[R^=9K MTNE!R!)1\F[C&55R?*JPN3;K'&?.<@0;%RSC$@E0 M1GS&^,CP/W\,@XS4,0<8_G\/OU\:V]]G\8>H Y>CL] <_1V<^S66_7'@,#.? MZ[^&PQ@]_P&_B6V]14?3_M'M\WQ_@[=1@>/CN. M@QUWR/IX9VQXTIS#^+N[ Y?>#]/1V3X[YWR/ []"1OGZ9]]/O[/WZ4'_ %=W MJ[OTY>8.>H\ML>1VSX>..O7UR?2E.?9\GX//V=G?ZP\^IR/+<9]>@R"/#'ET MZ[8\50[^8>]WCY^_N#N^4/0'9RT\.I&?'&WCTST&XQX^GC2G+T=G;^@\AYG7S\>AQ2GF[?E'S=PAWC_*//SAH>N<9.P(QXGU) MV'@,^FQ&*5'ES\_9Z/Y?T_BTWZ]3DC'CCUQMMY8QOG?."IS_ )??[_1V^;^3 M4?0==SGY^_)V'Q&^:5#G[X>GY?./WQ]6IR, 8.WAT&-QX[>\] MWG^'WNWEZ._U]@>;0[;;$>'CXC?;?8#!\_4=%0^3F'+_ &><0\P]O/O]0"$^ M0WVP=1'PV]^=\^M*=G/O^+\'9W\Q[P[Q'EV#YA@]0>H)/7_<>1QGP/CO2HC_ M !AZ_1W?%V=@=_QCJ<],X'4'&!@YS]#X9.[KTQTZ^G0Y4[ ]_O[.7/S<^ M_P!/+]!U.^^W[>I('4'RVQUR0:4[O1W>]W=_J[ Y:C(W/N\=SL.I'NSYYV\: M;4[.7J'[_9R[/B#S:GRU>&PVV\O,9QC?^F]*AW=W>'(/O\O/Z.?;RY=@]@@& MGAU&<>/CXG;J=O'R.?$FE>9-]5.>VR6T/1@W"W+WO$\G_LU@W4_SKR>G(\//=!?X]#;Y0IV$N]-R7L3:U>V5JYQH7.L6"&:7G> M-3;BS:2M>L$8\!C9ZI7YMDHJHTD8IHY142+.1C']Q\OY=">M04R?P^/CC/AZY)/4UCH/I]_"GV1NYGEV<,3> M-_"EPZOS[.W_ &ZG((\>F/3Y9QT^I/I30?,5'[([N,-!\Q3[(W M-3H/G3[([G3'D?'X;]C]!T##H1L#M@?USU\?WQT:#YCZT^R.W,^YB;QOX4>'3^?9 MY_T[>Z,@=/KZ'/U& =J:#Z?6H?9';FO-S[.WZZ/#I_/L]'R^C4;?8__ &O/?_>F@^8^_A7Z^R.W,^YB;QN_]U+A MU?GV?Z@TU;8R?B/IUZ=//Y;4T'T^?]JA]D=N9]S%WC?PI<.G\^SL]?+0-TR3 ML?F,@^?IZTT'S%1^R.W,^YB;QO/S_LH\.GO'S_L[-26&V/#S ^ VP//U'A30 M?3[SZ4^R.W,^YB;QOX4>'2 ?)]G8/^S49&XWW/\ 8^/7]\],"F@^8I]D=N9] MS$WC?%E'AT_'_CV?IZ=,C?;K[_J,^6<>5-!\Q4/LC=S/FX8F\;D'F^NCPZ>W MT\_[>S]![1]3(QXY^_CCP]WEN"T'S'[5'[([W^YB[Q@']]'ATC^'?9][\&IROE] <_M]]>IIH/F*A]D;N9Y\_)B;QO MX4>'5^?9W?A[^P=,C&#OZX&?O^IWIH/I]_"H_9';F?@SN<^[;P]?+PG0?/[^_EZU#[(W^[L]'=Z-3JZ^7AX>X;?'W[5.@^ M=1^R.W,^YB[QO/\ [Z/#I_/K_0/BU&1XY\O?U^6QZ?7K30?,?7^] W&[F>W^ MYB;QNWG_ +Z7#I_/L#EJ=0QC?KMZ;;8W\/+[,:#YC[^%/LCMS7FX8F\;U_V4 M>'3^?9^@>C4 X_D/#/KO\??TZ;M!]/G_ &H.XWH]23^V]-!]/K_2GV1NYGG[6)O&_A1X=//Z=GO /:/8'=J0^/ M=Z>'7I]/K30?,5#[(W[--0\,CJ!Z=/#._O MSU^C0?,4^R.W->YB[QOX4N'5^?9]_O\ 1RTU#/CY^'KTWV&=\'/]6@^GU_I3 M[(W_P#LH\.G[W]O9[P_ISU)?KC.3M^^/'[\SC=H/F*?9&[F>?;P MQ=XW+]]'AT\_E^SLU!8'SZ8QMYY]?GZ?)H/I]_"GV1VYGW,7>-[_ -='AT_G MV=WJY_'IJ&W7;[\SX^'N\MV@^8J/V1VYGG[6+O&]?]E'AT]H?/L[^[\'HU!; MW_''Q /\^OU)G0?3Z_?I]:?9';F?[--0]?[^9/4]21TQ\:G0?3[ M^_6GV1NYGM_N8F\;M_XT>'3R][]G9\OI'[S4/ ?# ^ONVQM[_.F@^=/LC=S7 M9_&//R Z8'R%1H/F/K_2HAN.W,^YB M[QN[]U'ATC_[]G/[^HU=?7TQ_;ID].ON%-!\Q]_?^U/LCMS/N8N\;^%'AT_G MV?IZM,C&^HGIY;9^/US30?3Z_P!*A]D;N9]S$WCOIT%-!]/K_2H_9';F?-R_?2X=7/Y?L[/3_)H'.WV?GG[\MA4Z#YC^WW_O3[(W7V=G+U^;M]&IU#U\-]L[>'\^O6HT'S% W&[F0Y_W,3>-_"EPZ1[? M?'?9S[OT[=0&P?GMC;?X_>/4FF@^GW\*?9';FN7M8N\;U?V4>'3\G[.S^3U: MC(]1Z^.<@^G3']JG0?3]O=X5'[([GGUZGK4:#YBGV1VYGN\F)O&_A2X=/Q_X]?GTU>G]/=M\#D8Z=-R2T'S%0 M'<=N9$!#R8F\;M_XTN'3^?9ID8P,_P!]C\=QU]:D(?$C[Z_VI]D;N9YASX8N M\;^%+AU>KO\ [>STAW_AU.H>7[=/+IX^./,^ZHT'S%!W&[F1_P"YB[Q^WO#Z MZ7#I]//F']O9H6'KG;PV.,['?QS]G>F@^GUH.XW7Q::AZ^_;^6/'U\*G0=]Q[M\??SJ/V1VYGW,7>-_"CPZ?S[--0]?V.??D M^.^3DCIXU&@^GU_I3[([>A]4TK M9+EN)66X9-PA?< O[SM\Q7.UZD9)L6'K+:'-;C)*Z4L+ N[PAE#+E-:M']AJ MEA:-&*]K)-E3CA=/8IFV=L%76)W)K8HP,5Z,_"V]K)X='P$MHOT?\?:BIK.W M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI6M[B$[N^2$;D?+-QB+BF^7;HX0PK60G+\>)2CI2*72M$S(RM;@*NNJH[;^'/'(FC7W M4G*E[OL3V9X=QZ2]DXO-=V]FDEAPVUDM2BL>+\6N.39>37L>EH5] 83B[@]2D&]E;9. M ])<0:E:*WMDG.0.RNY.*SV7"> 7T*P M\^.5)N+26JM&UNW#\7:S"?-LD4T4D2%3.3,&A-.RX]->!;-)K_B5JYD, M3HT=BMRP<2+*,84*_ MVC(=D@Y3*C:[R^1I:R-8>N50*A?JC'1L1&,*I(&F;&9_.+DE'"3%&)'P=8P\ ML<"X=PG@-IQ7C]KQ62[XEQ"]LK>Q@FCX:UI%8Q0-+/<^U6-T\DLCW,?*@"0C ME@NTG> JU_$+F]XA+:<-GLUAM;:WN);B1#="QN&EM[6XN;22V2RAEMQIG;D2K<3=Y0'0YWHIQB_CTW4YMI;.3C-SPHP1P M21W$*QW$]O%,LS7#I,2T2F1#%%LQ*MD8JVM?XF.7KAA!._1-JQA#91OTI@"3 MI^*Y[!&5XA.A8]S7FMGC0MF&TV2ZP$;G2.CF+\C-2>I!:S#(6EDX;&65:KH@ M%^;L#PRUXN;*6VXA+PZRCXW'<\1AXSPV7VV^X1PE[_V?V:WLYI.#R2,A80W? MM$IMW5L!@356/M%=3V//26WCNKE^&-;VTEA=J+>VO[Z*UYIEEFC6_"+)CF0< MF,3*5RP*FKKY=WG[HL5XFWSL3CA67S#LL=XXL2]Q)3K:WHF0L>9.IIK/!(HT M<+\M+UJZ,7I31LN1>Y2L.1D0'[,KD[A%,.=PSLIV>XEQ/L@X_BT7"^U:W\ M M3PJ+PUJ:3[AX@R,6U5'3 U9D^M 4/'< X3%Q5>- MF4.3P[@5]Q.+3.(,2V[0*A?_ UQSD',.J$<@O\ _>(\8;N\0NWM#8!"H]IX MA!:MF,R921968+B6/0W<&'/,T_\ JVSMKZRWQ4BS^WVY7+#6/ MUX9^'1AXU:VO%;WA][:B_NN%\0BLIKR.2TO!P:ZXI:B622V@!C:*$2LUN\H7 M2T4F&RM<*Z[2A[&:6UM[F";V>&[MFF2!UG@]O@LY^6J3.=2M+HQ*(R=:NF1@ MU4N9N(O81@I8,:P;LM/:W5A=30P3\/XW MQ22QF_)GL8[EI/R9(^\]HT+#F#G A:SN^/R:)%MXWMIXXN,K-%<11R217'#[ M2.XC[\=P\(4\V-\J+A9%.@\M@34UJ7$5G;1&8>JHT.WU?+SJU;<(F_U6W5BH M.W-_KV<\=6^SPD[07L)E".KU71M$I3WR+)_97GA%<.=-K,U%(BJJT?KN>P\- MO)Q.Y]MM;CABVW'9+*YM;BZ5;*XX1?6MO+#>I-PYY[DV\5TC,MLI6<9:*Y. M'V1\?:3V6$P30W336*3131Q,TT5Y;7$T%>6G),:#@%G3MM# M1515=FOL].-)((>L.8[P%VZL7'X974_&>+'V5U?VSP3WBW,BPQRVV##:N M$DF1I;A,[L$2'/M$CJ_+B90":KNG$*?7'-6W2C8+KML3Q_9]T$!AO)&3)Z!K M 5.?\88:?Y,D:+ H.YQ:Z1=@CD)BIO'E[,RPBTD@D,=RB1"X=\-'(\2AD-6 M9N/&6]X=!91R^SR\32SN+ITBY,@;AT]X88P9#.KKF!B_*5#AT#DAE-V,D94W M+0F]S$F ZWD'$[+&^4Z'D/)?*5PU89>UP,9C21I#!]6 G6^9(B.DW5D"R/54 M+"->CR08IMR&@IGHG,IS;#AW )>R/$^,SV/$GO\ AU[8\/S'Q6"*VFDXA'>. MEQR3PJ62-8#;H&@Y[F;+?G1;8LW%QQ).-6EE'S1HN M:+U%8R^T,1)R0(L*"DFY-R;IO,I-.R;E;'WL'R%88G =.B[MG;)$&WJOL,Q7 M%3E3L5VB$IE"4M,9;)EV[KE:=/U25.M3R3$KR.(^5;FRUW=^ MUV4,O&;J2TX/82FY]JXC)#]N5$7)ME>*29%<-*LSLT<9;$,4@7*ZB,UA,;BDP^:7^%6>!VDS4 MW$SN$Q/3;^RMS>AV0LOCK*&/,F6F)/$RM.M%RAXZ5\-IB:4U&+2+"U5EVV"/ MF8QD9X4JGK?^GP&*^X=>\/MY!+'=6UI+)'HNR M8I!&]M<*=<4CZ#CBKVECOC:"QU1ZN(6D,XD]GE#V]U;WP_ NYW-*2=DL-_J%*7GRQ4SC>@(/K'9FCE]E!<]LN,]GN$DP065U=K#S8K^]9((&4 M ,MC;7ET[=X=_E%1U=U&]7K;C!CX%9<3O )))H8RX1[>W#2/JZ-<300J.[TU MYST!KC4+B/TK-+!JXP3AW+N45_K5P^4+(:.+CJ&8T!M9U;2SK4-;'%ER#">$ MR+]_494K@U5]D#!DQ!"2 M+<+X;?I<75GQVSX5:W-S-+#&7N>'\1NQ936XX=F2[DDLEB2>*<6P>6- )-3/ M%0@[22&WL;R[MFABGX;->S1(B2,%CN;2'GI*+G"PJEPTC1M&TI16)T,H1[O9 M1XJ>"L60-FMDE4[M+56L9'R9CH\XSG,2PY+"OB4:ZWN,_2HNVY*KLY=(IM*S MR\.S:UF+DYMT_@98/%::/B]5]R^'?ASQCB4UO;1W-I%<7%AP^^$3P\3DY XE MSVM8;N2VL)X;21HX1*S7$D<2I-'^9G6$MW?::QLXY9I(Y3#%<7-N9!):)K]D MY8GDA26YCDG570O&ZA,Z=5,16_W(]JF[@W0QRG2*S5M]&#=M,1:)%C M"6Q&W4W*2%!59(UJ1QQ4 M\,,*N\O4KC+-$519+&F0,N8NM;N&J!F&9*1C*VPU1MC^E-&MS<2T:[;N+!$2 M[&.N\?574C!/4'[8ANO025T+^'/%7N%M(^(<)DO(^(67#.(VR2W6OA5WQ"VE MNK9+MFM%C=66"6-WM'N5CF1HV(TL1M/:>S6-IVM[P0-;3W=I-HB9;V"VFB@F M: +,74J\\;*LZQ,\;!U!Z5?^C[SL<63&V>LD7&O73$+?;3+SD1E^N9 :P1I^ MN'A:E$7@'")JE/V>%E$Y.O3DQ:;DW FNI;/2?:8;>6,QSPR"0O$$"#F!BF]="'BUN]O?7$R M2V8X:\B7B7 CU132 W-7M38^S&[>"[CMAIFBUXRE#4QQCAUDV<@+FHRGG M+9*<6AF+V.8(0:\TU5F6JC55VBD)'!_/\/[+WG%I.*1\,N+6]/#+BR@S$9P+ MP7U^O#XI[0/"K&$2NCN9EB81,&"$Y4=*XXK#9K:-=130"[CGD.OE?X.OP*QELX6L86C3VF"62226=Q+ \C T7+^4ZHE<:]C6RM$KFK9',_'Q3IBC:'5;@IR$K M,>)<)DGM;*_XG':1RW1GO.%\.N3:SW\#&T%NL M+R*YMUN)X9;A$+QQD8SNB[0VTKP+[+>(DT]O:/,Z1".WO+J%9HK64<[F&0*R MB4Q1R11,0KR Y V0:\)7H*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F ME*:4KS7OJQKVS;!GP$L9?2 W/:4KO:<+;VLGAT? 2VB_1_Q]I2L[=*4TI32E M-*4TI32E-*4TI32E-*4TI32E-*4TI32E8\9"VH[?LMY$')^5L85?)EE3H9,< ML$;]%,K?7X6NA,O9U=2"KD\W?P\/./G[T0?6%@T1F'#1LS9F> V;E3'N6/:3 MC?#+'^'\-XC<\/MS>&^=/"4EEA1$[D#L8E9G;1J8FN?<<*X M?=W'M-W:PW4@A$"BXC6:../69#RXY R([,>\Z@.0JC.%%6XJ^P?;C4:L[I\5 M 692%>J8$47+(W.PR+P0VTS!9S$")7SEX=R5"O.R))+I=/HRK)%%F_ZY$@!J M]<=L^.W-P+J2>W$JCC(!CM($7/'XN3Q-M"IIU3KD@X_++@7#HH^4L MA I."<[(^#V,4 MBNB/A+FYNDC:5WB26[1TN-,;$J$DYLC%,:=;E@/"IG=MH.%KI>6&2465NH%S M9UA*E.YK$E]MN*U9ZGMY1::;5NPH4B5AFTM&-)-T\=M <(^%-5'CKP=RF542 MZPM.T_%K2S>P+VU[:/<&[6'B=E;<1$-TT8A:> WD0K?8L?0.0[ZM)+66X1-$D952M)3KKQQ*)MGSB/=*QY'S M@6(MU3 H%BX[9<RM.'37-M96L%[/8V0C%O:RWB1BX,*\J,LBN MHD*#7J&U:XN"6,4W/TS2$7$UU'%+<2R6\5Q.9#+-';LW*#L97W*DKJ.G%4DW MX:NU5I7).L-:]=TF+MM2(R&=GR=>']HWGCN&FLRZ-=R2K_ ^S6*\GO[,6%W<(97YDFMVU;9R\!L)K2>S?VGE7*UD:GRL[:IB0L![ M?4T9%"'E9^;6<"^L!R)RCL'*N.V_:$7,UV+F'GW'$/XG*WLL&&N_ MX=-PK6%TX"^QW$B:!W=9$F-0!JF>!<-,<<1BDT16_LJ#G29$/M45YI)U9)Y\ M$;:CDX!7H2*G=AV*;=+3,6V=F*U-KR-WFLPS]@43M4V@1S)YUH<1C?(JJ*23 MHI&J-RT[7;2$2N,F^@BMKC !VU10H MJX_0067!)-<>E;"]N-"D(Z8A("U.YF(NF.;O&3-CO]PM,LQ=XCAIJOXX@6TA M/RT@Y2J%2BK#+M8NM%4".*#L3K)JG21%/*[[9<=O4>*:>W6*2TO[1XH+*UMH MF7B2>:5E:UCDBM MT!D=B(HDFD"1#NC43C.]2V.X?FWF#CJLPK7UTJFK1GEX/2YBK9AR+!3]5@LC M.&;RX4B$FF$^D_9T65?L&DD6L L9BRDTO&+ &STZBY]DG;7CDSW+W!X?T$:WC.B34F!6"\!X?&L2Q"YBY#SM"\ M5W<1R1)#?V>6K+-E'S+$WPF,-T2=R[2LXR,>[5R' MC^I6ZDUF2))/$F36OWAU"O+"W7BR* R=K.5Z_&F1=.$CK-2IJ%1,4%C\^1%Q M2\AX9=\(C=18WMS:W=Q&8U+M/9K,D#+(1K4*L\F54@-D9Z"KCVD+W4-ZRDSV M\,\$3:B%$=PT+R@KT))@CP3N,''4U;FV[1\+73)-KRA,Q=F3F\A5IC4LEPL1 M>+9!TK)T'%0LW78IKD*G14LT@;4:.@[#*1;562:*'*S5114%0K5MU5ZV[3<5 MM+"WX=$]N8;*X>YL)9;.VFN^'S22Q3R-8W4L336VN:".1A&P&L,1C6V:\G"K M.6YENF6027$0AN42:5(;E C1KSX%812E4=D!92=)P: M2.[&*CO!K$W:[B\TE[-IX?#)Q&UNK2]>UX;9VS7*7DT%Q:26WC?F M,24.O0%YCZMS/!DYAS$^#58NT1M+P?(0,MBYW W6RP-LJ*<2XP)+>2[XO'-%Q%9K2WFMKF.X>.61 M'MI$:+29(HW "C#(,;9!R;A%DUG:V6F1(;)HWMC'-+'+$T8959948/G2[J22 MP7;IB>3J$XJ1LTUX(>P)O%19O#1[D[AD4B!=]]VSXYQ*.YCO9+.X%Q<270:3A]FSVL M\T,,$TEBYA+69E2WB+" H-:LLC6XW%N4L+Q<1/W:RSS6+QEF! M:"7N53C@E'[E1I'B>N1?B7JC@K!]!<\>HDHY7.=/VRX[/.UTT\"3OQ'AW%I) M(;2"%I.(<+69;6Y?EHH:3$\G.R,39 <$* $? ^'1QB(1R-&MK=62I)-)(%M; MPQF6$:V)"#EH(]\H!@'Y1%6H-+O>/8L*]DFZP4M*T M[)V9G/V!FVEWQ)91P*SI("J"9N=1 ]J+M_P!I8K^[XC[1 M:RW-Y=V5])S^'VDT45WP^)K>SFMHI(F2W:"!VB3E!0%;;O ,-#=F^%-;0VG+ MG6*""XME*74Z2/#=L'N$FD5PTHDD D;63EQGH2#NXF>$%CR6D9DP35K^#V(D M>0)(#)W=I;O:VT_$)$B5KR2*"1U7G%AEV< M@R'56@=GN%A9(^5*8Y(I8$C-Q,R6\,\J331VJ,Y6W226-'81@?I"C" +5Z9+ M:QA:8@-P-7EJTZD(+<])KS&8&#B:E>C./W%5A::9:/52=).(+H0M?BRHA$JM M>I>-_#DA*X.8X\F/M%Q:*;@EQ%<*DW9Z-8N%N(H\PHMS-=@2 J5F_.GDSS0V M4;0>Z!5QN&VCQ\0B>,M'Q-B]XI=L2%K>*V.D@@I^5"@[A&&!8;FK56_A][>L MBU2,I>2_KH9*@(5&S^)VM_RW?+6I%2-IA8JNKST8ZRZN,1BJV1%TJ[5U,23;KIF'C7,2F2>49 MKH*3T7(,':Z,U$R!E6$N4W)\@L4 #7/X1VDXMP*6_GX7<+:R\2M9;2X98HVQ M%*ZR$PAE(ADC=0894 >+_01DU8ON%V?$4MDO(S,MK,D\0+LN9$5D_,TD:T96 M8.C95P>\#5!WK8/MDR4P)%W6D/)R/^OM);BW31>P2Z*,EDJ7CRP\@K*$:N40 M?5MQ#D3ASU5?I0AHLA6)FAFXF3-/@2L(8F,=A%)S4$ M996T3K+F47*_G"0EPP;!&B?@?#;D!9X6=1?MQ$@RR=ZY9#&VK#9:(Q_EF'_+ M* (5T[5/([95M^B\O+YI:UN<&T*WQWE5*$7N-H7H#+*#^!1K#O(C&@J29JNW MMRD(B#).6".,HTZ:B[,C=R?K@U/VLXW)PL<):XA]F%FO#3*MK;+>OPY)SB,7+6HF.OE:] M]6->V;8,^ EC+Z0&Y[2E=[3A;>UD\.CX"6T7Z/\ C[2E9VZ4II2FE*:4II2F ME*:4II2FE*:4II2FE*HK(&2L=8FK3FYY3OU*QI3V;AHT=VO(%J@J;6FKN06* MV8-7,[8W\;%H.'K@Q4&B*KHJCE8Q4D2G.(%TI5@?L^-BOW:6TSYQN'OYXZ4K M)N!L,!:8"&M=8G(>QU:Q1$?8*_9(&393$!.P,LS2D8J;AIB/7<1TI$2<>X0? M1\DQ<+LWK-9%RV6414(I-,M-0<2 M32'1ME+N5MC8:LV^MJR72E-*4TI32E-*4TI32E-*4TI32E-* M4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI3 M2E-*4TI32E-*4TI32E-*5YKWU8U[9M@SX"6,OI ;GM*5WM.%M[63PZ/@);1? MH_X^TI6=NE*:4II2NF3G7..9J'Q.]P5Z;9)O$=3\7\4;95CUUXBW,7U2YAC# M).(*9"3^&:%L]>NVN.,BTN[6.RLYFY69"2)9*HW;RLK$UJ55;K+%4^_VKN;: M4II2FE*:4J2656Q(5Z;6J#&'D[4E%/SUR/L,D\AX%[-E;*#&-IF5CXR:?QT8 ML\ZHCYXRB))TW;"HJ@QYNR"2H9FN1<4LF.[BYY%I.,&+O&HG<;634+>+BS;.A*S[D; M807L-7C[+"RAB]0Z;.)EL"8]6N4%3)@05*P1\E78?V_PVO\ ^$IC'\OVE*V3 M[:\',MNFV? NVYM/N+;'8-P?C'"B%H<1R<*ZLK+&U$A*.G/+12#N02BEYA"& M"04CTGSU-BHX%N1VX*D"QU*QI2V:Y0;5?!=)3SE4WE,VR,JY&8DJ$QAKQG7Y M]M6:G)X\AY',R*V0?#;C/0E%DC-J^YJ3W'\5'W A[J[AI-8L3$0BI^_O^^:Q MS9<(:$@\<4:AP67T0=4=G;6Q+),8Z;/W]B7L>8\'919OK 1K:(]5RYB8[#0U M5$Q7@"*5@*\0,V;Q7BM^J,_8VJNE^&$T\+Q&VCLHPT36\39TI3 M2E8-YMS3F'&NZ?"=5;.J03!]MQ+N'M4U#J)E;7.;MN*ZW6I]DI(6R==,:W4J MPR0EA23Z ',[<.'#^;EXV-CDVKE2M9>%-T.\6ZEQOMUR=N*L6%-Q%P;U;(N1 MOAEYE7*.%E< MOR%!BLCG;K0J,A%QD-:5? 'KT7;9M$'3X>M,KQ!W6W^ R=5:'$3[/'&*6>P6@[L8NM0D?D/PF M&M5PF+.]?5N1MEN8E22I":V@'S\ZSA'6@R[B^1A):SKC)5^!A9!]6$,W$ZD)+L.&ACF1)(TT+W((*5L-Q[OJJLHOMFJ.1<=Y@I]XW&U7&:L' M8"XJMZF&E,@WK#3K,3NE,,GG:FKXR$;#0MG0.V7= ND\A'4>M_5:9BBI6>&E M*:4II2FE*:4II2OR<3@0XI@4R@%,*93F$A#'Y#T0."H+;=/* MEJMLFV4JM$L9F:D8^4GW<(%@LB,'7HYN"$(I5B9?B,YX:8]E-T% RM&W3&Z: M5DHE.P5><O[B6NX.WWS=/#X/M^/2!E?#&$$)6PMJ]?<&1 M^7II*ZTO$S9:%C8ND W?ORV=LT:))U6WT!C,>'3"YYR:4K9C4;1$7>J5BZ5] M95Q V^O0MHA%UT%&JZ\1/QK:6C5EFRP%5;JJ,G:)U$%2@HBY>DG>WK%+A_GQ$6^8G:M1C#KW MY(THG/*!-J"CS$ZUA11L;A5IX*JXLB"%A7.I-()/B*5C[OSQU1<2\-?/..L: M52#H]&JF, CJ[5JXP1C8>):#9(IRHFU:(%*4#N'2Z[MVN?IN'CQPX=NE5G*Z MJIU*R>W.;J,![-<22N==RN0FN,,4P>I-S@F5FK4\1C,LXZ58(R<'(LGY6LJ MP8R#4BP)/6C9P15$BE6 #?AM,\*:,AS#&)NWI'3I)!6N75%1*)9HT=TO9GP* MUHGBVF>!9)HTDC=I'P6HN8JR,95M-+1Q7#I!2OQ0][.%L@X5O>>XA:R-*+CV M$:SLZTEH%Y&6]-!]!-IZ/C_8R^*V\?8Z!J>(F+BUM%>:1%FR-$LGTE8(!@S,,5-F2.*0U]6PJ5?B'W?TN0 MO6*\8R%)R-!WO)>01CR!;/(2AVW&=-L%ZEF-JN<5(/JFT M\82]N0O\IC]/$-$)3Y"[MFQF3:V.Z^6#",7L#9BHHP;RJC87B#!55BDJ1JH= M$RE8>\2%JV8YIX0#)DV09LV?$EKS5HT:HIMVS5LWVE;J4D&S9!(I$D$$$B$2 M112(5--,I2$*4I0 %*S?W,;H<8;4*95+ME).XO&5ZR=2,.4Z%H5.F[W:K)D; M(KQQ'T^MQ%<@$',B[=3+YL=H@8B?5@X.BF8P&5)S4K5GD/B[[J:U=K+ T3@O M<0+)5/BI1=I7KXC ,*BE:8U,"]3+DK4_%>.84KCF8 8R/]4I='[?O#2E9S[> M=]\!FNS8WQG=L#[C=NF8\B8]L5^0H6:L46:L1K4*3[%4[S!1M[=,&]:LK^L. MKE HN%(I04GB;PKEJ44>8@I6=^E*:4II2FE*LY>]O&!\H5ZY5/)&&\9WRL9$ MM$7=[W7[=2J]8(BWW*$@Z[6(>U6)A*,'+:6L,97*C5X)A,/$U7[6(K\1'HKD M:L&Z2:E<=OMMV]M+_ Y5:X/Q.VR95J>CCVM7UOC^KHVZ HK=BK&-ZA#SZ<86 M2CJXWC%UXU"':.$F*,>NLQ21*U542,I5$CLCV&E*:4I MI2FE*:4II2FE*LI?=MNWW*=;G*=DO">+;]4[-<"9"L-^K&O;-L&? 2QE](#<]I2N]IPMO:R>'1\!+:+]' M_'VE*SMTI32E-*4TI32E-*4TI32E-*5JOXB.]/+^U>X8:A\71=8DHN>@;I>L M@#.8KR%DT#PE2N&*ZRWAYJP42XU>+V\U&4C[U9I>4W!Y/:6#'52=55JREHU0 M7IDEU*LI-;\MV#*97:64 M$VV86DY"9#2OJ4344,/N&=CB3T--^^2D26!BI4KWC;NX-[P[\O4?/ULJ$1GN MQ.\PX=;,J?6;?%U;(-EPSGA[BE_9:M%O7%N5J<795Z^VF4(*PV^55A321XP9 MZ6*S%^JI6QS>OLMPEO\ WJC$EV^.\2XKIV':@F^E7#B>0IM&J<=2X$CR<1!JZ7EDX6,:@O*H@W M74> 9VF"*@AT5*PDI/"FVX44]Z5C9W)+E7(.(IS"\\8[C'L*B6J3XXM!\_:, M:?CJM1H6A1/$%2!S87;-X]EW2DW+3PRLS++R!5*NU4M@F!JQ3[O2'8W:UPEY M:+1CH+!9A;.(>)]BK.F1\=##5V-;;",) 1L8C#RDRUF)UJ^CV\N>56ENM>*J M5,9#9XG*6EA?7VXO<0XR T@+=4%;BK+8L4=N*==&U/;RU;:5U3$YJ/6D2GI4 M4]3FJ?5:[:7,DL^?RD](KG:BS4J@1X;F#X\M6:4^SY,H4+CB<9V;$==K,C2U MH7%%A+>L=Y&FY:KH62BV!S+JVJUXPJ[^;:WUWXXFG4W;I^SX[RA<0A9:Y7^]4>W8]G9:W)1$!$PZCE*_/%I_6 M_P /C_.R;!_QG.]*5MDTI6">8?;!-D'[R.]W_G>UG2E9V:4II2FE*:4K GB$ MY^RS@/%^/G6%4EE;SD3+450TQAL13^?KFVA"TZ[7*9>TG#%:M5*E+U+MT*BF M$FD2Q-6](?(BMXTN;.RJL#;9%]9WLNDW49*D[?? MJ1\?@:J=/=7OK6O2^VDN5-M),LQ^.G.X9QFLV&K.-&=45/%<+;TL3%QP&9@= M(39+K+G2=W@MW640Q8+AN Q M-FB;QJ#&=,YKL/>=DNX6V=6:6<1:40X*R3M4T:B, M(I] ,C'N#"8!* "I77 W!<33:A*[E,/&Q=QX+K"2UTEKS).F+@6YWY7YPDR*5O V?;_\ M91N5=16#MO6\>G;I,GT+&3*H59*0EK!. MPJT\:MUVOP:OWCL3?\ 0* TI5O-UV[N VC5DETMV&=PN3*@UKEOMMJL MN$L=LKS$T"OTIFSD9>2NZ[NS5\T.@K'N7+V/%%-Z+IO$RQS=4+4H+*??CO51 M[;]R+;LB@FIUPB13XUDCI2FE*:4II2FE*:4II2FE*:4II2FE*:4KS7OJQK MVS;!GP$L9?2 W/:4KO:<+;VLGAT? 2VB_1_Q]I2L[=*4TI32E-*4TI32E-*4 M$0#M$>0>D>S2E-*5CAG/:3@'8S'27=G?5)E*1$>9C=+W4&TK79Q[$R, MU3[DPI=FKS#(%'EW\%$/)*D7EM8:F]<,457,.H83B=2K?O.'MM!?OLHR3K$2 M9W>7_"36PQ+KD1%&+-,:P?L>IU;QT\+&1ZDE+S;U1Q*7!C,R\I+3 MU@?RM@L$Y-S,@_F)R>GI22FIJ6?/)*4?.WKE91F/Z0BBM/VZRKHD49U>$( M54Y8UW/N(\LV=C+A#@^"%EQ9*5CYF>N7DY"Q$/C]KMNSZK ME^QQ]CI$[DR!NM;Q"&._KBSN.9;'M7LMM9W^.KB]6.R@):-/)$L3):%*I5@- M_MLK=^R/P8;U39AG8:A=.(52;959^..*L?.5NQ[.]T,Q!S#%0Q2&49R<8\:O M6IQ*43H+D,)0$>0*54'%I_6_P^/\[)L'_&<[TI6V32E8)YA]L$V0?O([W?\ MG>UG2E9V:4II2FE*:4JS^:L!XCW#U=C3\PTYM;X2)G&UEA?]TIN!EX"PM&CZ M.1FJ]9*S)0UC@)(8R4E(I=W#RK)9U$R/XRT4VFQ]!K:[2,51B(VL1-7?T>*;^Q'!LB''J6+/L>J=["$;::[DC =V0'HSQZVE2S@I80G/9( MM!FH[=M1!JBLN>JC1&K6E^)O8PV0BB*5)=X#%E%WGAS1L:T;,(Z.WQ0#%@P9 MH)MF;)DTVH;JV[5HT;(E(BW;-D$TT4$$B$322(5,A2E* I5C^*H0BD]PMR' M*4Y#<6/;8!B' #%,'UL-P',#%-S 0'T"';I2MK7BZ/\ VBS_ /V9'_\ XTI6 M#%];MV_$SVB]0@BCT]C'$3Z75)$3Z71SWPO^CTN@4.?1YCRY]W2'EWCI2L\] M*4TI32E?DQBD*8YS%*0I1,8QA I2E*',QC&'D % $1$1Y ':.E*PM?\0;:T MEC]UDNN7:>R7629:G<(Q),/X]OV6Y^W9#J]>6MEECJ/6<>URQ3]QB8&KLY*P M25FK\>_KB43&/GJJY)2&'G5LAO'-(R-7ZU9V3*?JMA@['!2*D9X M!*14FBJV<'62=H-U*OWMJ,)=LF 3%'D8N",5F*(>80Q_ B _$.E*UC[6=H$G MNZV![;[GG+=_O3L[KL80TFXL4 MHW18HNA,U9+%037$4P4TI5+\03!5]V=;'_B#T-L+UB$')N6A4C.DS@/5J=9TROI2FE*:4II2FE*: M4II2FE*:4II2FE*:4KS7OJQKVS;!GP$L9?2 W/:4KO:<+;VLGAT? 2VB_1_Q M]I2L[=*4TI32E-*4TI32E<"45D4(R16B&C=_+(L':L8Q=NC,6KR13;J'9-'+ MTJ+DS1NX<@DBLZ*W<&;IG,J"*HDZ!E*ZF>_7B:[C+:E;MA6;H[8#MSRC:;'B M2/LHPF^7(=POM' ]YI-[CVPP$1MEC&OCJ>AV31-O"R%DAG)X^<9O%^@T=H"X M5(ZC;/I7;;TJ*UA[X]^MGVNY,H./J?5*G,INJ6[REDF=NT7FEY"PE(1M\74F M3?QYB+&618G'+9ZL>PO)?*V7UZOBZF#$PS.=DE!LQ'<2I5JY?B([A&4S#-&6 M&<1NXS<):;U2=ICH^0;.5PA-X_W,8_VW23_/0(UE9LQAY/ZX+')C ,?K2CM* M+CG-,4!>4<)3R2E4;O4WG8WF>'KEJH9\R)A'$6X>Y_73Q+%8J4R=#LG61;QA M_-J^++&YP_#VY:"N%QA):8@22,4V;0KB48H2S2-?@J\3,JLI6\+2E:M>(U>= M[>#JD3-6W_/V#*C1!R)MCQ*;&61-L%BR7/#,YYW'XTP+)W$,CQ>X['C<&4"C MD]M9VM6]@0G>J5U2'/8VH302<2I6>>&*]F2L4=M%9WR?2\O9!)(2*SJYT'%# M_#%=<1BRH&C&"-'DLF9;=-G3!$#).I UQ<$D5!!8C%@ =4*E77TI32E-*4TI M32E8B[@=L[C.&2,;V09B.A:U 8RW'XXN $25]D;Y#.-*KM0CGT,)6JC)8\&2 M+?KKEDG"(%!9N5L58!6(52L(H397O;@KK5]R">0=L+[ M%9["^.*'F.NMYZ9=)).+E"Y'F+OF65OZT7%,WT#'PL(RQJ6>D$WJEW9*;??W M]]?2K'[G=L#+;QDK@95UED[)EJ0Q?NFPEM^;5Z4LCA+&KEIC+9+N$K2%WCL? M?U0SA;=,IUHBCR02D72A&\@_9]-0JQE14K*/BT_K?X?'^=DV#_C.=Z4K;)I2 ML$\P^V";(/WD=[O_ #O:SI2L[-*4TI32E-*5@;OTW6W+;!5,4M,:U5&TY$S+ MDAW1*Z1UC[+V5FL*T@J';\BV"9-C?!5/75ZR[4JE7FO^YWLM+DI2W22N/1DS].N)14>.2EHM,C] MM12J5-LS;O,!9LR=PNZI7LJ8W1S-;MQF,,U/L">S^JO,P56FWG97N(MC"2GJ M$A)!:6<:@PMD(!Y=Q#MV"H2+!8B@)O6W34JH^*C^N#A;?YV3;7^+' M*;<&4 _GF]K+5; 3,P92D=C,ELL58GA_#O8>K0D%9=YE]!\XFUY\[LC3';F, M6ATW%B=*5=+*FU3,$KMBWH7K<+E/V)94R!3):W/4-J5HM]*J;:MXCV^3E$KU M2DY>S-/9#:8FTNW$_;K9&OV+!HFM(P=<;JR"%42G)A2MA.VS]C%@/]X?%GXO MH+2E61X8'M:7#Q^ SM*_$'0-*59GC6>U@[J__$.//QQXZTI6TS2E-*4TI32E M-*4TI32E-*4TI32E-*4TI7FO?5C7MFV#/@)8R^D!N>TI7>TX6WM9/#H^ EM% M^C_C[2E9VZ4II2FE*:4II2FE*^#ITV8MG+UZX1:,V:"SIVZLS5"J5VI-*5B_N!VAXCW+/H9]D9?(3+Q?"2E0G65"R3<YTQ^^BFZAXN4*9=JBYF64>\9L+%8&LHI5IGG#7VPO7]ZD%6 M63$U+>M).ZZW;9KG4-'K18ITS) MJ58&&X;^TF!L=?G8RAV!.+KM9CJVCCUQDC(;_%O\3Q]RM>.']EO?K%'25GD(Q9-:2D7DDQCW[12J:'A>[4QJ!*EU&:0A.LI!> N[C&JF/F#"IFHJDR: \#9-I/P3V2)A-BI7-W80 MWKU>#@XEBF"+*+AXG:5NH81LW(_O"9A_%Y8M*5^]MG[&/ ?[P^+/Q?06E*L MCPP/:TN'C\!G:5^(.@:4JS/&L]K!W5\N_P 0X[_')CK2E;3-*4TI32E-*4TI M32E-*4TI32E-*4TI32E>:]]6->V;8,^ EC+Z0&Y[2E=[3A;>UD\.CX"6T7Z/ M^/M*5G;I2FE*:4II2FE*:4K\*)IK)J(K)D525(9-5)0I3IJ)G*)3IJ$, E.0 MY1$IBF 2F*(@(" Z4KI);[YUSB_>!N8B,39=VW;1'NF2*.C.3B5=82\57)15.2D8UI:JW%SYU9J- MKETCV#2WP#"37>'J]LR91,=6?),^_5;NR,*Q2W=_KZ2HF0,K,6*;KM;:"DXF0=-5*Q) MF>)-D.+FO%B>V=!TWRK9+C3=IKD1QYGL3'/55&22E M7+XV\K*0?">WVR\))/X>588'GW#&3BWCB/D&2Y9"* J[1ZT41/0:RVU7%TFV,:.>BVD&4H\;B\CW+:28.A1<2BB?A M+&1:MG[-?H]8U>MT'2!B+HIG*I6/>?MG>V;;YD'99>L*XAK>.+.8"7J.2CR<.YZV36178/CLVIG#=5(Z:AFZ1A#F0!TI6X/2E-*4TI32 ME-*4TI32E:G>)7_ASX1'^+3^M_A\?YV38/^,YWI2MLFE*P3 MS#[8)L@_>1WN_P#.]K.E*SLTI6C'=AL.V;VGB(;)UK%MNQ1,*YQ=[Q+/E\SZ MK,UOKC6&(QW5I^+F+8 ]DL^834@^DVJ[@#&1>.EEBPCRXST>P?-J+CR)=(-)S(ES",?R, M758I=RL]-*HK,ZQ5HN=M$D3Q9#/#%4K!>3XF]B@$DLCSF"&*&W M6%;T>KWR_,\DK.,@1&7+QMKC-RS.O5O'*M&;1=CI#&$L%9IKFVN;W"32EIGD M5$*>>'8OGZ:E<,G$+W*JRZN)$]IM -N1:5U7++VCCN'D"XW)@DF/V%W1L*&2 M38:"45R(XEI$F.DZ0I1$80+4S?29KJ%232G%5*GF=]QN'9N7KD"YEZ? TNR5I"M1$+DQDPI ML+#R=CE/ H&KH1<2@R4;QY&A6;1NBFI]_O6ZZN032KUZ!K+!S*/&-=A8N"9. MYR6D9^;=-(ABA'MW,Q.R[AY+34HNBW(K(2TH[=2,B[,L\>N%W*RJAE*G6E*: M4II2K";J_P!B]N1_>$S#^+RQ:4K][;/V,> _WA\6?B^@M*59'A@>UI-9[6#NK\_^X..^S_RR8ZTI6TS2E8;[MMZ]'V;02MNR/BC<1:]]6->V;8,^ EC+Z M0&Y[2E=[3A;>UD\.CX"6T7Z/^/M*5G;I2FE*:4II2FE*:4II2NJIO-QOO^=; MN=Q64J%MNXA>3;I7,Y8=D=HF5\2[D\74?;Q3L&P5,[!8ZRM5P@;:V_7"SDW*Z>S4MB1FVN\01GMJG+)ER SQ/ M3>#R&JQU(Z0D\LU:NVE0+RK>VC=M%(5=DU;5-9[".E*LGORVB8)H7#SRNC)4 M>!RC=,9U6SVBMY>RS6ZE<\M(76\9);7FZW1M<5Z\U<0-@M%PEG\_(GJ;>OQR M+M9-*.CV+1JT;HJ557'+]J-W\?O V#_2,3I2MJK7_K9O_P" 2_\ 9ETI6#.^ M'_LILE^';AK_ *'Y3TI6=NE*:4II2FE*:4JG;?+.8&IVB<9)HK/(6NS4LT2< M)OE6ZKF.C7+Q!-=*+:/Y-5$ZJ)"JIQS%Z^.03%:-'#@4T3J5U>\(;B3.J3CW M%F9O;?DNSU?'+3,F1*Y6PPA;DK72I/( M5YPM6HYE#.5UL85DZCYE:9&H/%*NWFG/NE*VR:4K!/,/M@FR#]Y'>[_ ,[VLZ4J[.Z;=]MO MV3XW8Y=W1Y2B<18XDK7&4=E:)F*LDNT<6N9CIF6C( M&4D4CIMCHIN%$5*V"Z4JP.XG:[@;==2BT'/F-:SD: :&E74$%@BV<@\JTQ+P M,G6G%BK+AX@X+%3R,1+R#5K()I',F1PH0Z:J1SIG4K&J!X7^V&N/ZXWBT\@H M8YK]9@8-?!Q+:DAAJRSM:Q,XP=$9$LM3:0[9V\O:&+W)JTJ\8S,= .Q;QTN[ MKJTY$Q4DS4J5APO<+! @T+EOE132E:RN*-<;/5,48D1@,O5#"T9,YI;I7"S7;<+D': MS#3==BL9Y*F$*:&;\=56SR]3=3%F9UZ0207-$HSY(56"2=N'+]*/=*5JME=X M.7W\;*9+Q;F#-%?W%/*M8DZ9L\MUM>75]5]OB?"\E<]4R_SF,YAFYF+?:F>? MD*XZ?9NE68REJNCMQBYW()EE0K[=4_?U^_/^E]Y'MJ2UMRM,2^2[];J?'V^@X_LX1DA+,(23L-GK4[D9 M>GQ$*$97?%$ J*W,;;/V,6 OWA\6?B^@M*59'A@>UI- M9[6#NK_\0X\_''CK2E;3-*5K^XK7M:N^;X,67?\ HA):4K.6L?K:KW_B.)_Y M@WTI4\TI32E-*4TI32E-*4TI32E-*5YKWU8U[9M@SX"6,OI ;GM*5WM.%M[6 M3PZ/@);1?H_X^TI6=NE*:4II2FE*:4II2FE*:4II2L3-T>YN>VTQ+2UIX1N. M2J'%QJ]@R1<(*R4RNLJ3!)3,-"-VL8RM,NP?WF\3+J8%6OTF 2*ZE48YTW)( MHRSN#C)=2L=97B6L8N6M54VVNTY^B%)GZQTG.U2VZV-DDB>; M!QC5JWOUW@)5I(W%,B#N@J/;.8K=XT\0JJ5*]WN7B9OX8NY"[J526HDRV@[S M1K;2IM]$RLC5;MC7*:E N4(>6@G3R'F&K.QUR1"-EX]?J).-,T? BU.N=JBI M7$XY?M1N_C]X&P_Z0B=*5M5:_P#6S?\ \ E_[,NE*P9WP_\ 939+\.W#7_0_ M*>E*SMTI32E-*4TI32E-*5(?8K5_%ZL3[&X'Q4N\&17C?$\?XO6D#*E7,_59 M^#^#*/#+D(L+HZ8KBJ4J@GZ90$%*U=\2O_#GPB/\Y9!_1.W5Z4K\\6G];_#X M_P [)L'_ !G.]*5MDTI6">8?;!-D'[R.]W_G>UG2E:2OJOSVK6@?#'Q/^+#. M.E*\SC2E=KOZCO\ ;/,Q_ >RA^/';?I2O2MTI5E,ZY)ON,:FTFL=8D=9>G'4 MDLWK2% M@8DI$I 1+BX0LLO'JVZR0L=&L)"*5>3C)2ON7B1WA1V:@I;0;ZIGU"&6R&]Q M!]*ZJZ2!!RI!6S9WN@GHA1P@!S@BN>/D&YED@.? MJU!,3I& O2%2K;\5']'/X MM=!=>+7E82(D%69SBD=W&LUA+TT"""E= &3XK/$GFK35KO+[X-RTE<*0WGVM M/LKS*MH<359;6ILS9V5"%D%'QG$>E.M8]BWE"-CD*\1:()K AN!I>Y+<[FK-]2K^V"2M$'7-PC(\)7P,(_QF#-L$AX M "@*@Q\-!/PGP,%0!0&W6]3U@ ?H=(.>E*L-N9BXR'VJ;CV,1',8MD3 ^95" M,XYHW8M2J+4"R*K*%;MDTDBG55,914P$ RAS&.81,(CI2ICML_8QX#_>'Q9^ M+Z"TI5D>&![6EP\?@,[2OQ!T#2E69XUOM8.ZO_Q#CS\<>.M*5LQLLR6N5R?L M)VYG9(&$E9D[4B@)&9FQ7+1QI'JR"3(S@%C MM$WS0ZP%$A5TQ'I I64.-/JQG&EBL% Q^38A>FJT[,56G%E#9Z@%4VRDF]80 MA7YFH8N3,J1$RX.!;@N0QREZL%2B/3!2NZ_I2FE*:4II2FE*:4II2FE*:4KS M7OJQKVS;!GP$L9?2 W/:4KO:<+;VLGAT? 2VB_1_Q]I2L[=*4TI32E-*4TI3 M2E-*4TI32E84[G]J%UW"9!PY>('<#-8O88<>2$[&4CZVU$R149NYNG<,36BJ-&*[.GR8M%EZRI+2LI$':RCA-VBJ1C?;K]*LO(\,R&DI.8DE= MQ.7TC5^8LEFVY-THO'();;K/<M'-43+WXDADJEUXJ$;DA6P,6-, M;.*BBF*+Q=^*HJRF_'91A"I\/W)LI?:O7\W9;Q?"W>^P6<\6J"I+V^9=OV\;6&DDLU2"T1:DU7_&1K'!18^-(M%Y'JO6_@LBX_4B/6X]9U9^G MR*)14KS<TB.J;0S- J!W35K:(:V2 MY'3X2^$/C*S2R1US&,@BW3$$P4K;SP2/J@+B/;E-\VUC9QG:]4#)./,DV6_L M;=<)G'[-ED^1:QN.[[>(Y(E@@7\1!M@92D)',T11JY1&*1%LJ*JYS.Q4KT#] M*4TI32E-*5J=XE?^'/A$?YRR#^B=NKTI7YXM/ZW^'Q_G9-@_XSG>E*VR:4K! M/,/M@FR#]Y'>[_SO:SI2M)7U7Y[5K0/ACXG_ !89QTI7F<:4KM=_4=_MGF8_ M@/90_'CMOTI7I6Z4K%+=[MEDMUF.X/'#?,%KQ+#L;E%6JQIURM4BWQN0(Z(: MORMJ1=ZW?X2?K\_3%Y5RQFY.">QZK*7=0T>SE47D49XQ=*58N3X<%8M]F6E, MDYPRK>*?92QMAR?BL\7C.LT+).6HK#J^"FV5GZ5:HT?8:Q)#CX[!%2I4Z?A* M1X]@*].I0:3J/5*[4JF2\,=%-F,VGNUW&$S2J16L.\\@VPV-W=X@5HL?CDV( M5(,V+1H"4$%?BV4P2QMZFE<27XJ]T).%=NEV9U*IK<7M6V[XKSAPVK_1L/T. M#R/";IZ)B9KDIO7(P<@KX]J>SGCCI2FE*:4JP MFZO]B]N1_>$S#^+RQ:4K][;/V,> _P!X?%GXOH+2E61X8'M:7#Q^ SM*_$'0 M-*59GC6>U@[J_P#Q#CS\<>.M*5L3R?\ X-!L'^D8G2E;56O_6S?_P"7_LRZ4K!G?#_ -E-DOP[<-?]#\IZ4K'7 MCU^T_P"_']YQ+_II5-*5Y!VE*W5?4['MSFQS_EADS\1&4]*5ZWVE*:4II2L; MMQ>XH<"-:(RA,2Y+SI?\DV"8A*?C+%/L)0LTBVJ]5F;K;)YQ)Y%N%$J$;%0< M#"*I%\.L:+Z6GY6OP$4TUG2E:2OJOSVK6@?#'Q/^+#..E* M\SC2E=KOZCO]L\S'\![*'X\=M^E*]*W2E-*4TI6,.Y/=!$[CCI2FE*HO).0*SB?'5^RG=7:S"FXTI=IR!;7S=JL^<,JS38-]8IYV@ MR;E.X>+-HJ-=K)-4"F6<'(5)(HG.4!4K"FP[CX_<#M2WD(.<8Y.PM>,<8CR7 M!73&.76E-;W"')9,*.KK4YH'&/[G?ZC(PMDK4ZS=-'$7:'B["3;3->F6T=.P MDDP04K)+;9^QBP'^\/BS\7T%I2K(\,#VM+AX_ 9VE?B#H&E*LSQK.WA@[JP_ M_,.._P &AI2KIX,_PVX=_?3Q]_P!+8C2E M>XKI2FE*:4II2FE*:4II2FE*:4KS7OJQKVS;!GP$L9?2 W/:4KO:<+;VLGAT M? 2VB_1_Q]I2L[=*4TI32E-*4TI32E-*4TI32E-*58K<9AZ5S?C0]1K=W4QQ MX8_R+1+N$$E:6=?NV,KK!WJM.)FKK24,2RUUU)02,=8H(LS#KR<*]?-FL MM&NCHO4%*QS;<.C!5WQ?!TC!L&5,T3,+*,SB4QVLC%R.17+%\V.)2B9!R@JD82E$2B(!I2J.R-LPX M=GXRM,0:9#<=%\[AJQ//TA<=0 MV!",7 ZY3BF0ZE1HFP/APYXQ_CO+%'QR7(6/K?%5_).-K63+&=73!_'2T=X; M7;9!!*9!2=LEUXR0%5D\\':/T4':A/U+K%""I6/]XP?P8INLY:A[3&PV3*GC M:Z,,49E@H.^[D,RP]55G(R[1 MR9NS9JHK%5D$F)78+MR,1 MJH'+S#2E9C:4II2L8-R>![UE\^-K1B;,)\'94Q9/V*1K=S7HT=DF$=0MSJ$O M3;3 3E,E)BOH2!%F\BPL$(^3F&JD59ZW".72,M#C*PDFI5FG/"^V7SM8PO7; MWBQU?W.!%AL/L98TEAP8I/$AIF.L<.29RGFB4+%6&'6%Q$3L:5 M]D5<&,S%+B*\=*-02>L5A%1LND?[;2E3GR:6R_\ 28VI42#:V_)T8QS&2(;)Y)W&$G(Z/Q1D6+Q1F=&/E92X-2LF\%D1&(K, M\@W?)%EGC9DY:$DF#5)XFI4OW5;,.#QC.NU2*W;8YJYZ];)QRI4ZWD"Z9WR$ ME(RE?8F5E9]I5D;79W#=A58R4%:P6]:-;PU5CY,JLU+QK5^4RRE5"EP'N#ZL MFFLEL0PJHDJ0BJ2A/9:8BB:A0,0Y3!9^1BF*(&*(=@@("&E*K2D<%[A@XSEE MY_&^T>D8^G74>M$N9JD67)%4EG$4X<-7:\8O(P-U8/%8]=TQ9.5F:BQFRCAF MU6.F91ND8BE908FV9;B(H*IB8W-2LH=*4TI6(VZ/;GD#-CFB6?$N:$\'Y#I47D M:H^R20Q\TR=#2=#RU"Q43=(E2KO+)5$T+"W6^1QK5:)4ZO,R&0,DQCI@UQU26V/:U)-&-;M\ M+"QLTA56YHU>3B8QBZ<(O'Y55# ]<@JI4IF.%AL/L)H@\_@Q2K56G;P\"Q9ACA;5&&LUSJ%>E;&M MT(>/G+378IV\2?34<@Y4JW&-L!\&#.5AI;[$5YP+ERUV-;(U+QZ\QYO M%ZL M$XO5(RAW++54ISFNYJE)&14KL/*8RM.0H.%.L:*CG]'F[&U0;.()R92KCJ<, M'A=;EL?U:PK89HF?<6V!)C<:5-+Y:R/E&A32+EFX1C;36)!7(\Y7Y!-=@^=H MLIJ+55!1F\<)H.11<*@=2J4\@UP@?N#<+_\ W;=_.?2E5K1N#)PQ\8R+N8QK MM+IF/)=^R-&/I6C6C)53D7L<9=!T:/=OH"[1[EPR,Y;-G)FBRIT!7;H+"GUB M29BJ5E'B#9YMXP/:E[KBRCR==LKB'=P*S]YD/)EI2-%/G+)VZ;!&V^XST40Z MCB.:'!T1D5XD"1DT7"::RY%%*R:TI5N,Q8SA\TXBRGARPO9*-@,LXXO&,YR1 MAU4T9>/A[W692K2;V*663612DFK*5778JJHJIIN4TC*)G* E%2L/:ML%@+=4 M\D1F\*W,]S-HRE<:K9K+*PM>L.#:N2/H>.0QA4J^QJM/R%*R!V1()Y992Q$E MK9*L)VQ6Z:=)Q<9%MH*(B%*FC7AC[)&+1LP8X@E6;%FW1:,V37,&<6[1JT;I ME1;M6S=')1$4&Z")")(HI$*FDF4J9"E*4 !2L2;!BS@>85N:.WVTY;VUXGR# M4O8[4V^%9W>K-4>W5D'L5%K5.M(8[?9QC)>&!U!OX52O0Z<0W!:+>1AHYN9J MNU$RE5!;=MG!DE:4 MRDW-:F+%B;=-D?)E8:S";-L[=P$E*U+,,U%HR)(^09N7$8Y7*Y*T>ME5$.I< M)F.I5-^0:X0/W!N%_P#[MN_G/I2OLWX$7"):.$';38IAUJZ:K).&SEN>XHN& M[A$Y5$5T%D[251)9)0I5$E4S%.FP Y!VCS$>SSB(B/GTI4=*4TI32E-*4TI32E-*5YKW MU8U[9M@SX"6,OI ;GM*5WM.%M[63PZ/@);1?H_X^TI6=NE*:4II2FE*:4II2 MFE*:4II2FE*:4II2FE*P.WV;=,A[B";2BX]\1<\+[P:)F^Y>/),\;_637<7Y MDJ,AXIZ#1UX=+^-KS!]0P-X.15MX8L+D@MP(HI6$NS?;AQ*(K:KA+9]EB6JV MR^)VW8WQ/4JSG[;5E:IYPNV62XZA25:1JUHH&5\#I5NEUVRL01G7;Z*DIB:: M/6#:-8OTT5'#E52IC:N'MF2KT?BF8_V[Q>-\4P.]"]X/CL5-ZD_1J2-8QDKB MG%>*-P4P=I$1""%>N#B,:9/EX$[;PAS,SSME*NG[9](K.$E*L'O2X4V[W/6X M*9SK@?+N*<&0.V"@[?*;L?Q"M1&UH;S)L&3L?EK_ '1O)Y2*>8(96'(#&*H< MB>LP=O7EZ)762/9K2<<@Z*]182"K=,[ MUDB]*1,KM)JY,H@FZ*FF5P1,%0(0#]$%*F&E*:4II2FE*:4II2FE*ZZ-&V3\ M1C:WG&"SE@3'6V?+DD:1W[QDY7,DYLN..F;*M[G-W[;KP7']?VP/L\PM4-5KS@>TX=Q4WGYX^ KI58^?@8:YMSSMD281+E M"W0\M'$565&?OW_?U-=A:K1DC"5BN0TO,+V&6B(&(C)2?=)E2QP,UL'S'@@\NSM^/ZX^:Y"NF\#9%DV(B&:%SG&'1<*X_P 19'L2 M$PZCG-<;+UQ.+D'7C26AHN44'W]^E68W$\'O+L)<]H;[:SDS)]JM6UFK;T?T^_=4GCMOO$/VA<-?"$E)[KC89G<$X+VW8_INV&O8RISOQ1N M"D;9CK&"\3D[.=8MM^^NIC^PN['8&)JA6ZW",6LQ.0,V2WNFM4!&24^S]^ZN MQ=CJKR-(Q_2*;,6JSN/"K'<92&B6D?(6F>7Y]%27L#QNM+2 M/5 5 KMVJ1!--$J:95*K+2E-*4TI32E-*4TI6J+=)LSD\I[X\*9R@<*T:R5. MO[4-Y-)O-Q?,9<-[%,2O@5*MR,+94&;YI4T&!T7LM" MED&!'BE: JMP5M_- QY 8>BJLXFL2/N'&\I$17QR5C ;1@[1,K6%[+BBY99J$]')2U*CYBS62%&0<)J0K204K>_/[%-W.WC;U(8\V M#[SI.-GXN'S#9G">X[#V)LCW'*E_LM4:,<=1*>2:3&8;K.,HJJ3,6D9M)*XM MNZKD) ?&_7,F1$3*55W#[@-Z%^K&O;-L&? 2QE](#<]I2NVCPY(O?BIP]-AZE/W%[ M482I'V9;7CU>%L6S'+-IL,17380HXPD7.V:-WV5".LQ/,H!W M^GRAWZ>?EH%)QZY_MGW^%1S/3Z_VIXHXB?W4&SCYB>9?1S]T.TQX^&_AUQG/ MT'SV\":*.(G]T_LX^8GF4/\ _8=^GHT"Y\<#?P\NO3/A]=O6FOT^ MO]J>*.(G]U!LX\_^(GF7S?\ VAVH /P\_3(W^N?=3F>GU_M3Q1Q$_NH-G'S$ M\S?%_P!T-][X^?H$=,?MGZ _SQM\NE.9Z?7^U/%'$3[?[:#9Q\Q/,WW_ .Z& M]GW_ $Z8^_Z^6^!GIZTU^GU_M3Q1Q$^S^V?V<=O_ 'B>9A#U]H<0[4Z>N^_J M,9WQGK^].9Z?7^U/%'$3^Z?V9OZ0W]//R\S3T]3@8\?V^N_I37Z?7^U/%'$3^Z@V;^K^ MT3S-V_\ XAW\NFG/3[\^A/3/V=J*.(G]T_LXY>G[!/,OR^V'=W=^ M@:C'W][?7U\J*.(GY]S^S@.7;^P3S*/F_P X=\7KU.G.<'^1^_GX M?!K]/K_:GBCB)_=/[./F)YE#W@]L.\^FD[=-_7X>F_WFFOT^O]J>*.(G]T_L MXYC_ -XGF;^D._3UZ!?7Y _/)QY?U\<-?I]:>*.(G]T_LXY!S_Q$\R^;_P"T M.\^FG[]? =3U_;?I3F>GU_M4?%'$3^Z@V9 M?Z0[4Z?#QV^OWC/3/PRYGI]?[5#Q1Q$_NG]G'+S\]B>9@_#Q#?-J ,_R]<^\ MC;^M-?I]?[4\4<1/[J#9Q\Q/,O9[_P#=#OEU.GI@^?ATQY^_?'WAS/3Z_P!J M>*.(G]T_LX /@)YF_I#OT_ T^1S\#Y_7J.F?VRYGI]?[4&)XB?W3^S@?>V)Y ME_I#O1S^333MG(_;]_E\O.FOT^O]J>*.(G]U!LX^8GF7^D.]0_IW-/J/3S/E MMZ_?G37Z?7^WN^= B.(GY]S^S@/_ #$\S?TAO;^GO:8]_NQOX]!X]/2FOT^O M]J>*.(E]U!LX^8GF;^D.TQZ[^0&^PSZ>[]LTU_\ =^O]J>*.(GRYCN@V].FG^6V//Z>?CX'.*:_3Z_P!J>*>(EYMT&S@>WE^P3S-_2'?I[W;J M,;X^7K]CI\J!_3Z_VIXHXB7,0^R?V<]G+_$2S-Y__M#M,'X=2?3SWQ[Z:_3Z M_P!J>*.(G]T_LX^8GF;^D-U(7/3[WQOY'Y^E-?I]:CXHXB?W4&SCYB>9OZ0W M]/BTT]N].9Z?7^U0\4<1/[J#9Q\Q/,O\ 2'?+V>?SZ:?O'J!@;]?3 M;>FOT^O]J>*.(G]T_LX^8GF;^D.Y_P"SMTQY'/T_V_F2/7#F>GU_M4?%'$2^ MZ@V<=G?_ &B>9?Z0[48]_P O'.,>OH?=TIS/3Z_VJ'BCB)_=0;./F)YF[^[W M0[T]GFU.GUW^/IZ8Z'.V=O2G,]/K3Q1Q$_NG]G'S$\R_TAVHP?_$3S+YAY>Z'=OQ>?L]>I*GW]?IU^OWOBFOT^OF,^5/% M'$2[_LG]G'S$\S>GT>4-][U^]II]??Z>7S_;<9VIK]/K_:GBCB)A_C0;./F) MYF^+_NAOZ#V>C48Z_P!-L_>/#J::_3ZU'Q1Q$_NH-G'+T_8)YE_I#M25QG?I M_7^X/QIK]/K_ &IXHXB?W4&SCYB>9OZ0[3&V?#[_ +?/RR:9NS_\ $-_DTTGZ9/IU^_[TU^GU_M3Q1Q$_NG]G'S$\S?TAOH\W MQ:8ZY/3Z[$_7&WG3F>GU_M08CB)A_C0;./F)YE]?_P"D.\W9\OJTT^'C[OYY MQY?/X4YGI]?[4\4<1/F(?9/[..S_ +Q/,OJ\WE#N?Z!Z=-/AX^[;Y^[?ITIK M]/K_ &J/BCB)_=0;./F)YF_I#M-/KX> SOMMMY^?QIS/3Z_VIXHXB?W4&SCY MB>9?Z0[T=NFGUQ[_ +_?'KC;+F>GU_M4/%'$3Y<_LH-G'S$\R_TAWW_EY::1 MYGXC'CCS\_V-.9Z?7^U/%'$3^Z?V;\_@)YFY?+Y0W_5J,?R^OOIK]/K3Q1Q$ MONH-G'S$\S?TAW=Z]3CUW\L=?=]^!V-.9Z?7^U/%/$3^Z?VTT[XZGQP.G[9IK]/K_:GBGB)=G+=!LX'GZ-B>9OE'^Z'::<8R<;^/W]^ M[>FOT^O]JCXHXB?W4&SCYB69OZ0W[VF.N_3&?C_3Z^ IK]/K_:GBCB)_=0;. M/F)YF_I#M-/KXD?+R]/AUVWIS/3Z_P!J>*.(G]U!LX^8GF7^D.U&.OA\O7KD MC'3W^E.9Z?7^U0\4<1/[I_9Q[WV">9OZ0[EY_P! TP/,Y\L8_<^?Q]*9OZ0[4Z3]X\\#H3U^5.9Z?7^U0\4<1/[J#9Q\Q/,O+GZ M/;#OXM1C?'GT^^GNW\1YTU^GU_M4?%'$3^Z@V*.(E]U!LX^8GF7T\O=#OT'LU&!Y^_;Z]>G3'^V6OT^O]J\\?ZI_ MM6:9[B5QD!G6V8RNUKQWMMQ;4(NQXJQA9\20#VM/['D3(#5-_4[7E[-<@,VT MEKS--'$HWN"+%Y'HQA$X5DX;NG#V*S!R,UZ /#&]K8X>OH^P=VG"//\ >$H/ M+WO3\6LUZ>!/E[]^HZ'8^[8[;UI/4^\UG%SY!\7;Z>SO]/QZG'EO\ #D[CW8 M\\@ =/&HJ'9Z??\ /\7+M_U=O+EVZCRVW)\_7J#U]W3'CFGW]_*H]W\OWQ\W MG\_F[N6HZ$^/ECKMM\, 'P]?(T^_OSIW>\'R '+]/7\6LN@( \"/F?+KC/3! M./6E.X.?8 ?IZ/TYZC.,;88;;G_;KD^/AMY%]?O>H>GO]8\^WO'S=W9R[^_E MV!J3@=?=OY>'0C/NQ[\=2J/8(=O=W?R?IZ?0/9I^^_>Z'KG?IY'XCP&]*@/+ MY>SMY]O/G\G/T_ZM/#KC&^_0>?R/3QWP1@Y*H^K]/B_CT]-NF ?/P\]R/#?/ MIO2@_+ZO1W]OF_C[>[MU!&V_A\_?CX],[]<^)5#F !R]'FY<^P/Y0[N8_P 8 M:9P.G[>!'RW.=M^AV&*=?OSJ//S?I_M\^G4>7]"?'?/7J<#J>NPI3N'].?=Y MO3W?IYA]2<;GICPQZ>['ETZU/W_<_M][A[ _3Y?]0>]IGKC&_EG(QC^0R.F- M^F,5%/-W#^GG#GV>L-23@_V]_0[9ZD'.^=MSO3[^\5#T /7I68 QDC.3@;X^_C5H9[C XP@]R4YM \6>/+M6KX;;O-9' MC[32(N;6SF3%CF]*ST?@-67E;VAB-*203K;Z_+.',3$V]\V@_!I6-(O.!.KJ M/#'7YG8>6?3Q\-L I.#[CC?IZ'W>'6L ]K7%EW U:!HN4-P-BF,SU4_#KVJ9 M7GZFPBZ/4GDMF#->[Z9P1)WHLG$U=F+4Y(:1A5'D*@"4$=O$&\!C6;]TH\-C MJ/CO]_V'PVZ5)4=!MOM\LX^\_O6(A>)3=KA#"V,B2M"@Z)Q&)':MFU-V M-5EFN6JP39K*9^;F9.):,Z^J,49>>@$Q4;2,?(%>U\RKB7"+>KM-3GX>?EX> M>%V\/WZ&L=.W_P"7/U^/7SVV\-C5//>.=C6-@MP3P,,&NEDP1%X$L(US#6=L M1YB9VN'SSFEIA*+A27&G2"]4@(R//Q\?/RK+1Z['TQ]"??61'$#S=N@QQPZ,B;K:%*2&U[,V),0SN5+#BJ M9B,89C;C-,(Y,0H=BGEFDQ!.6L<[$RAYNG.D1>__ ";D4?M0GPST/3'CMC'Q MP=SU\MLU U8Z^O0?3_;Z50-?W\Y5Q+DV;VX6K'MRW*SF-=M]0W19=W'2EOV M_8&I-.J.1H[([BN0$S&33ZDP#($IZA(UYK+(K';$8RSRPV)Y'M(!4TE ./OR M&!\OOSI@-OT\/%L^/WFL/,X\7#+^?C/1H4M$2\>O RCA1%RWC/EYCK MY^I(\2,_.IT@'??8^!\//!_WJ48$XANXMGEMK;MSM[R7 T>:WV;S,*QM(JC[ M!U@Q]$T#:OBW)M@F*_-(M,+P^2%RP85=K)+3T;=S25QLB;-VS2@8!)] 2+<; M>_;UZ4P"#@;X!SN/=CZ_'&<^%V-T'%DR+C/"^R[=W9\7]OEFV_YFR)&0[J%AFLB_H=I=2=9(SZ#R^7GGX55.2.,U!XLJ5F]F&WB6K>6Z;GK,N!;/ M0K7F3'-7I,;-X6P?6MPLN_+F21*-<>N+5CVYUE"CUQM$&FIZUO7D$FDDWBG4 MJ(Y\1U._4=,'&_3.<^I^% N?'(QGIY[=/AO69]JWG'IFSG&VZ^ST&MTQ7(E7 MQ[8U*3DS-5"Q7 TT,AQ:,PP:6S)M]3A(M!9@T<((O&47 2EA<2*O@0B52I&V7+4ET9K#5TBXNR6B(3%W6YZX13.,2_47 MM@B8SY=.AZG8^'WOML0, O4]3WL>N/'Y^%9:\2[)FYG#MAVCR>#<_N,:0F= MMVN ]KEKK1\7XXNK9I&96G)YO,WJ+D[9"OY1*Q,&C5HW81IW!X/^IQ569G56 M5,,DCH"?4^AW]_O'COZT4 @Y .!MO@_?J?VJQEOXF#O:C=]R]3R2XR+F]SC; M<7@/ 8VN^2.(\0XBH[^[[9(')[ZVSMWA*?%L<=5"QR3=]X0XO*E@2'(-D9PL M3(P%77;(Q<9P?4'[R?/WY'PZ@N0#G&QVW/CCI[L?M5R\A<7VET&W;H:J[P\] M,MMAP+*9SD6DOE;'\%:LE1D7BN'RF=SB^HG4?NKQCL[>7+5#94J#ZQ0K:T,' MR;B,3ARH2R[.#L/#?)SN?'UZGSVWIIZ;]>F 3_M7(SEQA,38%G\TUFVX\EDI M#%KG:!!P3V2NU5K%;MUIW@P-GL-78R]GL/@,/0*[1XNHS,A7I_*OCDGB12&0>%)NDWO;?63:F M7[$-,S7'Q+>4=UW(U;B\B8FE'D$XDH2>B5'%4R)2Y!9NA.5>QL/]S+#!OV+I M1HW5,X9(QU4GX=/5?'UZ_/WEI[P!W!^'7T&X^\XJP6%.)-N"H-3SM=\S^QS+ MF$8.TX&KNW[/>:#T[8>QO\[>L4VBYYFKKMWE)&NQ5JCL;6>#A*U6)JBT)=W8 M7=G727;N8NLSMEC@..O>]_Q\\^?A\_-I!]#C<;M]_P"U4=9^+?GW+KR[.\"X MP@ZCABS<(N];Z:+>K!-QQLL4&XMT['$QDN]AUD)RHSK&OVN/:UP*B>.5&1<) M^R]2>5AQ-7#SJ/A_+[\O>??BITCQ.^0,#IOX>?3QJZV&>+Y+0.&*9"Y^P5D$ M^X!7;UL,5&D#H=LGTV&YQYX_>I=D?BAW5SGS;93W,/8=O MI\<[K<[X:WG8S>J53(+22A,?[0YW<% N:W..-)5*S1GEZR;MKR30(^ MS[;:QNMP>@OT2;-\A$XGG&$UD2ESEJ:V%Y)P]=J4NO M,+3[I>-=QI0.!O\ #S/Q^&-O4[GJ*>OC@[>F?CM7'JW&DJQ(:(N68<%JXPQI M/67=U287)\)F"KY-HTO;MI%(+>9F-B+#"P$3%2['),7%7A+'TS&/7C63<4YT MF4JB[P6[)D>7SWZ=/+I_/QZ5.CU\CTQL3[_3I6VS"609/+.'<5Y2F:;(X\E< MCX\I]Z?T.8>HR$O37%L@6$X>M2CYL@U0=2,-X=X ]50;H)&=-U>@F0O( R)/ M7I@#'Q/3.,#;&W7&/6L#X^>3]_?7X5<_GVAZ.8\Q]X![.WO^+NY<_7IOT)QM MD;GY#)QMXY_;>@_?8??7W>?S!C_%^G+L[?-Z.0]VAZ[CUZX\M\[]#G'PQZQ0 M.WM_U?H'R_'IC!./ZXP,D[CP)\QOUI4.[EZ?, C[W9Z^WMY]_O\ GDC'C\/= MDC?PW&_GN<^2H^D.ST#\G\G=V_@UCUQC;(Z8'3?W?+ WP?6E/XOXOT\WWM!C M/EOO@=?EL![NO6E0#U!VAV=H=SX [#.< ;YZ;>5*=O MQ#VNV-_@<;^6-_,CW[':?Z_/[]]1#S<^?/O_00[/TYZG'7!Z9]_S]QS@8J*??'].[T<^0^?OTSUSY]?1AZ>&!UZ^.,[4J ^_P#%V<^S MM\_/GYA\W+S\N6H.V^<]#T(/^H8V_KX>5/O[^^NU1 /TY_'Z _!W??CI@]>O MTZ=<[?T\QFE/PCZ._P#3W^S4^N-O#.<#?/O_ &WV .:5#N$?E]7\?>/O"(\] M0=SY_+/AT/\ 1.?,[=,?#W# M$_?]O[^[I4>\!^/O\P_ZA#U^G6/PP?'PQCX9R?>?,["HKS)?JISVV.V_O&X7 M_P!#R?/TZ@]?OY_'K6Y?TC[\:[^_#&[.&QP]A'[AW:;\GUA:#[W+S>GN .T= M9> &<=?#/4>_R\0-NF:UG]1]_P!?K]_*LXNT>_EZN0<^X>_EV^;N[]-A_48' MEZXZG/3KML.F-.[M[N7X.0>8/1V@'\>H]?#X9&2<=-Q\,9WIU^_ZT'F/O]^GI_#V'R=GR\N7+U:>)\=]_0;D[^AW' MG[Z5'Y>[U^?U>?\ BY<@U&QW(QUW^!\Q@G;&=CGUI3M'E^#U??\ XM98Z_// MD-C@D>X8 ! \,^"GF'F/9Z0]'^KT^]Y]03G??/AN,^_Y@8 \7W^ MX0](<_3Z>P=1MW\_Z=GO_ "><>SO@=#TQ@;X]?'8[ M[X^(.XWI4>8OGYP]'FU/AUW.=B.H]-6?Y[FE/]@#S[^?;V=WQ> M]WZ=0/EN2,CW#&? [9\.IS3]JQ8S7LXPEG>_5C*]H;7RJ94J5;DJ7%9+Q'E# M(&'[RXH\P^1DY*D35BQU8:Z^GJFXDT$I).%F5'K1E(=8^CP:.5EU5(/\@03G MRZ CR\-@/<.L@D?S!Z;>_P#K_*J?KVQ';[4LC3F3:JAE"N2]K69R%TK\-FW+ M;.@WNQL:=ATSUVV\]\SJ.WTV&WTJUS/A2;(V5(?8\)C"74JS_ !3=M!VBU_NYG3; M%F/;^[RC36L?)DG22,?9(&^NQL;"W,W*-A3>-F91?"@V32T&/'IT/I_/P\1\ M,TU'S\<^O3[']JF5;X7^SZM2+.73I=OGY9MFJ3W"/)>YY3R-RQ.8B4P= M-V:RRUELDG)3_C?'RJ[!ZPD72T>9\J:33;)NP3.2=.0)*&E*KA^B>"V7,^5+0,31\"9*8Y9Q)3: MZI/VJ04KM9IMQCVSF/AH8S)DHQZZ.=I.&[IT"T #)!SY>X^>?3;WYIK/W[S] M_P ZS=SIA7'NX[$&1,$Y8BG,YC?*E7DJ= ML^<8 WWVV&^*@9&XJR]XV*;9\DNLSN;K M0W4V.?L&4?;ID]%2SV5LVFL5XY>6B0J$.S29RC<862BWUPFG19^),TF5EQ9G M7>J"R;B2-NAZ],^[;Q(_V\E3X]=/5JSFW.NX2.;2- MHL;^.5R9N1AI^OY=D)&.0OO.WH! MX^/EZ@CJ6H[';KX#TQZ_?PJP&\[A&UO<'=H+(6*;97J%,+Y7R]FC)$+>FV4Y MV(N>2LJXHQ;B%O=HN_8#PV'@?OXUF&KLCIE\VQX(V[[@[UD7-,S@L^-+)%9 MJ4N%EHF4WV5,9QRS**R>VM-0FF4[%V%3PV4)UGCA^X.SD%TI%Y)/#*OE!'AG M8>.-\Y^OAX^(/3%1JW)QU\/OUWJE:;PPMG= @FU=K-!L#6+:8&SKMJ0(\R%> M99S]:3?BD5_ H^11;E*F$$#P)\C MX?/..I\,GS\*:C]<_M_3PQ4DG^%%LILD[#SSZ@6]LM$-\ I%Q&6,F0M8GY; M:\VAH[!]IMU5B[0UKMLMU(A8*.K[.QST:_DG,(@#%XNN4$SIL==OD=@//KGX MG(W\,4U$#&WR]_\ O]XK+?,F L89\^M;]A.=\^!Z#?K_N?*H!QG'N M/Q_V^_"QN1>'YMPR<[S<^GF.2(ISN-M$):T1FC$2M9,08>06YR2[49/HNR1M@[;[''D!MCIGW[8Z$D^,AC\OOZ? M>U2&=X9^S^T2PR%IH-BM$4TQ3:,*UFD6+)F1Y?'5 QY=J!'XOML/CFCOK.M7 M:(M/42+9P#Z2K3&/?]415T@X1?N73I9COJ,?UP*:FV_IUJF(GA2[,XF M'N\=[%,BRLGD!UAB5G+S8 M,49%KEDJ]U&[Y/OENO$_%VQ9=>:![D2PSTC< 754<'!HHC+I%C42I-HY-HV1 M31) 'AYC/C]/7/URH]6HYSX_?\OI7SS=M%PMN @<505]CK:S4PA86]IQ98Z) MD&ZXZN=-F$JG+45PM$V^E3<+8$TI.GSLO 2J!GQDWS)ZIUH=>5)9*2 >GTZ> M'GX^@\QO0'2<_?W]XJR*'"]V>L(6CUZ&I-MK\10MN=NVGQC2 R?D*'),8 NA M9 TICJX>!V%+V8Q;5[)NY>%7L0/WT-,]1*,7*3MN@HG'NSC&!UWR>A/3S/\ M.F3Y^/H=_/[VQFIQ9.&OM$MS'P">Q]+.2(X/P9M[C';>]7.-E:_C_;7:92Z8 M66K(\<@X/4[XWP< M>L!B/GGY]:^L!PWMI4 YI4D-"FK%.TO)E]S"-ENE\NMULURR-D['SO%=SL>2 M9^SSDI)W]64H+PU:(SLKA_'1\:(RE8GQGE.O968X5IL?8 MK^TFL>8WEIFOH-ET,;V*I3D4'@3V*E$'<1&F0C&W0CR^'A[SY;>./*@8@[[C MW#Y^&]6VG.#C)9"VFPNUK+.:HVZ5M+>#1MQOB]Y!WZR1C:7BG$S<[M:RHM;I;"DB@379)-F/#QSTQX8WZ[^77X9J0V^<>& M/><]3_M6\Y---%,B*1"II)D*DDF0.B0B:8 0A"@4.12@4 H <@#NU(/0 M$>?@/@!D>>1CS^585]/T'MTQXYVP/D=O+T(\*5#EZ^?=W^KM[P^+T^?O\T^> MV<$8&-_+'CC.<]!G? \E?KG_ "?+_MTV]X& \OKC /KMO2OSY^7W^7=W= MGG#G_J[-1^WEL.N>NXZ#/3&1OMDTIV]W;_LY=G/M][F/?V^K0#!]>NWJ/ '' M3KL#Y>%*#S^3UCS\W>!1#S=OG^+3IT/A[L].[CKMOOU]<;U.WC_3S\2//KT^ M/A'U=WZ=_O\ I]/>(=NI&<>O08\\'YD8'J,;=ZHIZOO>KU_IR\WOQXXW]C[_;IL3TSU/E\=\YR?#TZ;X*H=_?Y^SW_1ZPY=H_A[M3G /EL?'J=]O= MU.?LY]H]GHUCMG8_U]1G?(^>^,9\7A]_#^?W MTCR_3N'L_3U=XZDXVR=\' (&!C(QTQU_;H-JBH (\_-R[/?[N?Q^\ =P\]/# M;J"1@=.O4 ^9./4'&*?8J/?][M ?C[?T[>8:CQ)_V'D ?IMC'@2*?>*6_AY;#;8]S7O'BGEHV8[7;$[BZQN_SY6:S&NIO"%& MDW#"O5N'NK2(K\&S50^59G>3OQG^[W MOD^>UN._G[I3 \A\J>3OQG^[WOD^>UN._G[J0^0IY._&?[O>^3Y[ M6X[^?NHS3 \A\J>3OQG^[WOD^>UN._G[I3 \A\J>3OQG^[WOD^>UN._G[IFF M!Y#Y"GD[\9_N][Y/GM;COY^Z4P/(?*GD[\9_N][Y/GM;COY^Z4P/(?*GD[\9 M_N][Y/GM;COY^Z4P/(?(4\G?C/\ =[WR?/:W'?S]TSCI3 \A\A3R=^,_W>]\ MGSVMQW\_=,GSI@>0^0IY._&?[O>^3Y[6X[^?NE,#R'RIY._&?[O>^3Y[6XW^ M?NF3Y_?3]MJ8'D/E3R=^,_W>]\GSVMQW\_=,GSI@>0^56[5VE[94,GM<*K;M MMWJ>6GM5/=VF/#[\-P86QQ44WBT>>P)Q'UP?"C1A7C== 7'0Y=)%00#H$,8+ MXX9Q%N'-Q86=R>&)S+=% X@,N-(D*%3IST('B!50E9+(C9BS1%55-(%7*Z9!44(3I=(Y0&M!!/8[Y]Q*\K5CVB/4EJZ6::$OPJ,1F8Q%5]'@J M >$-DS*$YE#6R6SNX+>UNYH)H[:]YQM)G4K'<"W<13\ICL_*69F.+R/2$3.T$@*;ETHNS7:">&UG MBX/Q"2&]:)+206TFF>-[RU5[9'DG4R) MF)(QER^_=T#=@=U&Y %/6]S:V4W">()=7NKV2 V\ MI:YT$A^1I!$G+WYA0GEC=](WJ8^)<-FAEN([NU:&''.DYB!8L_IYF2"FK_3J M U9&G-2&8Q]L'KK"MR<[OVW,Q$?;XR5FJVZD-_FX1JC*Q$'*F@YF40,K?2]6 MPBI@AHY^[< BBT=E%%8Y#!RUOA[*]I)WGC@X-Q"5[62**=8X68QRS1B>*,XZ MO)$>8B+EF4Z@,5J?C'"8UA>2^M46X5GA9G4"1$;0[@G_ $JQTLQP =BTX]VJ&.$=Y>ZIS?;]!JV:EU)GO_P \O)VRUU)@K*C.Q#!KD999W$*1J"SY M"0(7P5TV156;*JD3.):'\(XJ+2YOSP^\6RLI1;W5TT$JPV\YD$0ADD90%D$I M"&/.I6(# $BK7M=GSHK?GP<^X0RPPAT+RQA2QD10$2=#(D;JY7J%8'H:V"6 S-; MAX^>L:S-%MK$3,R+(5ZZ2ZLH/3*D>%<27V;;?H*^4O&,MN7WO,[UD2'N,_3: M^?>?N=46G(C'XUP+@]2=HW)6.:EA1MM=!5)^\:KN?&2?@*3KJ'74916-Y-9W M?$(HF:SL9;6&ZG#H!#+?>T>RJ5+"1C-[+/@HK!>6=974NJ&G@2>&V9E$]Q'- M+#'I.72W,0F8$*5&@SQ9#$$ZQI!PV*4D]N&TV'N[;&K[=YO'+>W5YA,:A5FV M]O+ M2VC7Z64YLULY;_VEM*1M:6]Y'P^:>-G9>:L5Y-';N(M;K(WZK%BE*E9=X&[&N6.$ M@8"T3$5/[_,]0SB,KUJGW%4K4N]&2R,V2;LYZS-5X"(444+X?+I^ -@4]\GSVMQW\_ M=4,GSJQ@>0^0JA6&SG;W)Y%L6)F.YG>ZXR'4ZO6[K8:V7>?N>*XC:Q;G\[%U MV54>J7(D8LG)OJS.-TT&SY=XB,><[IN@DJW.M<>QO([&#B3PLMC3OQG^[WOD^>UN._G[JG6_ \A\JLA:MO^TBDW,V/K1NU MWLQ-Q+8,754T*KO%W7+JA/YI>66/QC'>%,[.X8"I:GE0L:+=8'0MH\8Q0\PM M')KM3K]>WX%Q:[M/;K>S:2UY'$+CFB6%1R.$I;OQ!]+RJ^+9+F L-.7U@1!R MK!:.@(QQ.[\,_Q"$C/3"X-8B$8JR&16Z;N7E'(@ MWCHUN91X]7$$6R*JGVNMT-O<7#.+>&:=HXY)Y!#&\K1PQ#5+,X16*QQKWI)& MPJ#=B!6#O%&%,C1QAG6-2Y50SN=*(I8C+NQ 51NQV )J>>3OQG^[WOD^>UN. M_G[K5D^9^=9X'D/D*L-DG!>S_$-G5IV1=W6]BMV)K0IS*$BR4WA[L9%&&Q_7 M"/CRMJGY*'LLA%U^+(:-?-V)YMZP5EWS<\?$)/GPD;F[%AP#C'$[<75C9/<0 M->0\/1A+ AEO9R@BMH8Y94DGD_,1F$2.(D8/*43O52N.(6-K)R;B9(Y!!)=, M"CL$MX@2\LCJC)$G=(4R,NM@534PQ518LVO[7\U-91UC+=5O8LIH$(?V01WV M9NZ2%GJZ>?CPEH5"PUNP6V)L$"YDHPQ9!FTEXQDY59G(X*EU1R&-HXCPGB7" M6C6_MGMQ-S>1)KCEAGY+\J8P3P/)!,L&(K([W<YADA5'".67].DJ2%U:,+HB6/%BS)= MLP*K RPI.VMF &%AD20L"5 /7((%=P>PK#MEA8BQP&XS>S+P4]&,9F%EF&^# M<6X8R<5)MDGL>_9KDOPD6:O&BR+A!4@B51)0AP[!#5*:*6WEE@F1HIH9'AEC M<%7CDC8K)&P\&5@0P\P:WHT!XY89%U1R1D,CKTRK#8C;J*YL'L6P?9RRAZUN_#/\ +%A[%$F3)*P$H9AD5P$?-1AU4BR$6[%%\S,HF5R@F)R@ M.$L%Q;F/GPS0&6%)X>;&\9D@D!YL+KAD .B1(%?N>V)82JS$DG9]S.\NN1JK^,BDY&>WW;@(ABI*3 M3]O%0T:1W(9$;MSOY:4=M(V,9E4%P_?NF[-JFJX633-$,$]PYCMX99Y DDA2 M&-Y7$<*-)+(50,=$42M)(V-*(K,Q"@FCO%$NJ1HXU+*@9RJ*6=@B+EB!J=B% M4=68@ $D"I!3]G&WV_2-YBJCN9WO3,AC:W+T.[MTMZ&YYL,#;&T3%3B\.L=] MV;%D;G6SR21 M+*H1F*@R0R+I<*_=SIP03A%/!.TRQ,KM;RF"8:2-$H1)"AU*,]R1&RN5WQG( M(%<>3OQG^[WOD^>UN._G[JID^9K=@>0^0IY._&?[O>^3Y[6X[^?NHI@>0^54 ME%[*\ 3=NM=!B=T.\R1NE'9UV0N%8:;Y]Q"TS7&5M1?N*RZEV1;\*K-&<0BY M!6-.J Y39KF3Y@F.K4EG=Q6UM>RP3):7CSI:W#*PBG>U9!<+$YV9H6E02 ? MI+C/6M2RP/+) KQM-"L;2Q@@O&LNKEEQU ?0VG/72<=#56^3OQG^[WOD^>UN M._G[JMD^9K;@>0^0JC*3LQP'D9E.2-+W*[WYQG6KC;:!-KI;T-SC0&%OHLX[ MK=KACED+FT465B)M@[8J.FY%F+DZ(JLG3EN8BQK5W975B\*7<1B>XM;6]A!9 M&+VMY"EQ;2@HS "6%U<*Q#KG#JK @:89H+@2-"RN(II8'(4C3- YCE3O 9*. M"I(RIQD$C>JS\G?C/]WO?)\]K<=_/W57)\S6[ \A\A3R=^,_W>]\GSVMQW\_ M=,GS-,#R'RJ@,:[0-NV8*R:Y8WW.;W+16@G+)6QE6V\_<^R2\=U"=?UJQ,01 ME+BQ=&-&3<8^8'6! 6RYFXK-%G#8Z2Q[E_P^]X7<>RWT+6\_)M[CEET<\FYA M2XMWS&[K^9%(D@&=2ZL,%8$#1;SV]U'S;=EDCYDL6H*1WX9&BE7#*I[DB,I. M,'&02,&J_P#)WXS_ '>]\GSVMQW\_=4JWX'D/D*>3OQG^[WOD^>UN._G[ID^ M=,#R'R%/)WXS_=[WR?/:W'?S]TS]^[I3 \A\J>3OQG^[WOD^>UN._G[I3 \A M\A3R=^,_W>]\GSVMQW\_=,TP/(?(4\G?C/\ =[WR?/:W'?S]TR?/[/6F!Y#Y M"GD[\9_N][Y/GM;COY^Z9/G3 \A\A3R=^,_W>]\GSVMQW\_=*8'D/E3R=^,_ MW>]\GSVMQO\ /W3)\Z8'D/E3R=^,_P!WO?)\]K<=_/W3/TZ4P/(?(5Y]'U5' M@&G;>N(MC.OT^?R79RW+:'C>]6&4RQG2FD_KGO,M,S",:VK] M,@6;.)2=$8-#-UUT$"+/')U%37H2<+;VLGAT? 2VB_1_Q]I2L[=*4TI32E-* M4TI32E-*4TI32E-*4TI32E-*5HQLFW/>$\W3+;R6&+*PK-0N\"$+$0IKBS+E M!SM4BZPI@:2BF<:42:\5)8<8/ M%/XNMM"2G%X]"<[_ !9X6L1X][00R \AH^2/AUO-,8Y9 MAX-5S,S)LY]R$B)2CV(NV'9>VXY;WD$O#H8++M18-:S6W"%@DCX)/P&>#B$W8F2:]9T:_@XC#)8J T M[(C-:"505Q'I.)"& K8M@W&>YR RSN!LE.C&^(*RC;@JS\-EM^(^V6"VMI#:3Q:8[-[5K M:!HVF1HKAVUVC&3=W58]1$E)1NL^?QF]:&!RW:H DD-O@O:/L_P $M?X5/Q:U MXE)=7':*Z6\6WXD>&<,/$N&^QVMN[M;6_$"MRX8WALX,QHXPS')K"^X=Q&_E M-['9SVJQQ<*C-N9+/VRY]CO3I=WO9.XX9>\+X9QBSX*/XUP'B)DY/%S;O):<*D@XC<<,46 MMS$S0Q M%C;IIF>$2*#D88[F?XUV\YWP[>.%]77N&;;;V>VNGY6A\PW^HR6.U:G!.\QU MYA!PD7&*6"^0ELFXK':Y5FTXLWKINH@&;=:MMYMPH$:GIO\ C?!^*6?XA3IQ M6VM6X_=<-EX78W27WM,R\+N&GFDD$%G-;127JX:%6G!,SE9S$H,E96]E>V4W M9F$V4TZ\.@GCN[B!K;DQM7F]E>+< LN$V\?$6LC=Q<2[1W!CNK'VH&*X[,QVW#>9JMY8Y M(VXDI6.)BP27\V140ZS9XK9\1GO9GMA.('M^"QAHKCDD-#QEYKW3B5'5A9," M[+@NG<4LPTUB[9ME.Y6T3IHR4ALJ+UK%SWB=M,)3"6:'[:R1$#DAMAA]M>C2 M6U&^IW%[%RL[ 61W$L9^5<)QJT.W+;$V34C%);T5OVLX#;P\R.7AHN.(K^'K M<6B/"D:WEFL&XLG:&0VQLC:I)%#/;K*\,8+B5O9M;:RO-EX-Q"67#)=&*V7M M,EDXO7$B+='A[\,3FBX$[(SQ3&-9'(3EJ)=(T@_"V;9]VUK>4NR90QAE7)3> M)SAM2R+;H2KY7KE:N#^+JFPE[C?,#JM39,@UPD4^',L@\B99M'SD(>QOG+UT MW*80(JJRB5!'2?AW%9I();BVNKA4ON&W$J17<<4I2/@$UM=F-_:( MM)-X^A@KQ\QF)SH)>J*N.RO>??L"3%7R/6+O=[(RP%MU\30K[*[)_(N[=1MV M>2K[,4YQ++W&.92UUK^"9JLP+ZP2[L(F3E6K0[.?=R$:U>-;=KVK[*67&8[B MPN+.S@?C?'.;*G#72-;6\[-6%E'"6-K+#PB[=>2.+@VMQ%?3WJ\8$]W?V0CX M0J/'<6@;EZ8VR5C=6T[8]O]#2F\N9/B+\1G]JX%+9RV3+V;C_A+VJ<)_-L M6:WXC)_ KIVGEA2:..80\1",LV9(_:=0HM8<9-C;1"/B"W"W(/%G-VLS7QY4 MZ\ZT3^)0!81,8W:,RV9*Z.XW*TFKD-H^YQ2XXOF)>O7BZ>)+[PV)J;M]]G*, M%R=Q.#K-N >Y*D+06,N,XWSM.=9]O(HK6RAO/95DXO!P9+".WYEK"RQ74EK([7C?)LHI4MKN3\9O):QY4ILW"Y0RC);OL4Y$J\U%MU+\_=KE0Q7#S0Q5@M MC6)?M6S:5@2I,@%HE)]:/C_8NVXF.)V]_P /C]J[0\.OTC@X==0R\.X?'V6X ME87,,C"R1%U<2EBYD-LTJ,S1S9?O%*3\/X]+![/+!*HE^=A*<%LBWM5MW+H"R'4U*P M6[:MM[H=.IMXR1+XBS7A/)%EK7UR)%6^3T1&60TGE R-MM-WA2RM@6"7EGC( M\C:FQ6:@ G7W4:#9@"'E.S':."U[1\;O+JZM+"+B?".+V%O<>P(+.&66WY?# M\VUO:2\N &*)7T6[:QO.LA9R>UQCA;3\-LH(89[DVM_973Q"Y<3R(EP'NL32 MSQZI"K2%=4JX.T93"XL7D3;MNB+2LVSM=I>4;#:L@[P)46$2MF.?3B M6TC7WE&J[+.N-ZJHNA:#KMUX:4N$2Y.DNZ>OFT@BPCFINO8<<[/>U\)AGN^' M06UEV8CURCA4 2X[0F0QS)>7#\'O[D!K?!$T=K*H*JB-&SNXHW'#^)BWOF2* MZEFN.+2X4WW)X@Z1<,Q'%P>2PL^;/&KV(D0->>T@"(+ M[)9[U+FX(B8BX*,>2("2Q,1SN[, M7)R"M>VK=! 9"LZ452\NV?;LEFG!SR6QS1'<1CFE$<-W)P\7UFS MV\%YHGFM(^%B B.22YC;3'>:6E1YHVDTEP6QWJ0>[8]XD/F'U:SMQO+5 M!5"4\?HVD[0=EI.%\!MI;RR7B7#9>#O?W;\/E>"ZX?!VFXE>7G#;1/9#[&4B MN(>(GDHBW%N?8F*E.0=)X=Q9+[B4RP3FUNENQ;Q"X37%

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end GRAPHIC 22 g582934g46k96.jpg GRAPHIC begin 644 g582934g46k96.jpg M_]C_X 02D9)1@ ! 0(!>@%Z #_X9W/:'1T<#HO+VYS+F%D;V)E+F-O;2]X M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](EG)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N-BUC,#8W(#&UL;G,Z&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN&%P+S$N,"]M M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N M8V]M+WAA<"\Q+C O'1E;G-I&UP.D-R M96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-#(#(P,34@*%=I;F1O=W,I M/"]X;7 Z0W)E871O&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I4:'5M8FYA M:6QS/@H@(" @(" @(" @(" \7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @ M(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @ M(" @(" @(" @(" @/'AM<$=);6&UP1TEM9SIH96EG M:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9OF%' M.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C>$$[05%"24%! M04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G445"055%0F=5 M1D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T M4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!9 M14)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T$P M045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%04%!04%! M04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!028C M>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G M35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX M6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]- M2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85&18 M;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT M>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9 M-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C M>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U M8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7 M;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%- M4D%$.$$Y531Q-T9867$W1EA9<3=&6%EQ-R8C>$$[1EA9<3=&5TDV:&-A,4PK M62MN-EIA871C5RMN0WAK,4153$Y9-U9O,CE/84]+2D9:-$AL2'%%=GHK4&]0 M:#0U64LT8G!Q3CA9,S)3;"8C>$$[=GI',5@Y3S9R8G!*654P>5$$[,FQF5W T8E=#3#8S6DLQ,UIT07A65U)R<3=T,FHY92LK M3#9V0W#A2,5I&9BMC9DYU;2M69DQ40R8C M>$$[83%L,6I58D-F54Y2=6)Y1FU2571R5#9Z249J9V$S;V542VYY>7-1:5-E M-7--<$-)-S!R;B].8GIJ6F%.9'HS9&Y9>5AA4V%5:7EX2R8C>$$[,&-&=4Y3 M:$TX:&XY961&8C!L0W)Y37-A:W-+:UI)66]K+TYJ3$Q)0WHU9FHX56A.4B]/ M1'I7;6=25'E$5'1)=7!D3G5,*S-U6B\S-B8C>$$[6'),3C95359MDAO.%8T6C5B M2S-K45@X=C$O55=U6F]R>28C>$$[5%175S(K7EK9F)Z.'9X*WAV569Z4S@K85I08S--=C%2-TM7-VES1DUS0U)1 M,FLP3FML>B8C>$$[8VIL3&17=UES.'!24DI-2SAF:"]L=VI&16]N;6Q'+V8K M:C-Q=7$O;6XU>6UT67)333)':&%R4&)A95E)2E X05-:-W5B54IF5$PR4B8C M>$$[1&U(:$@Q4$E394)P,7=$1D@S<&QL;'DR2$PW9350=GI0+TU(5G9,='I, M63)%.6Q9375M4S,P5GIF23AJ6$UW:SE.3%$$[=FDU.5)6 M859/47A9=V5B4$YL3658.79K:U$O36YZ2'!U=%=T:S1G=7)M.#%+4W=V1DIN M;6UK5WI31TAL0F(K$$[2W Q8DHK1T-'4&E%1W4X M<5=L+VY6-7)V3DUV3#$W0WAJ:&I3,DQ80EI42%EV8S-8;VXV,FM6>E!->5)X M+T=Z1DEM0D9#;W%$:$]%028C>$$[D%B;E-O M0DYP;#%(<4=T5&%A3'4S:6Q);'19,FAI4V5#17IL:GEK:V5P1$U!04YI2W1K M9D-'+U!K>28C>$$[.%DW8W1Y9W)4.#9F3G0Q1'$Y=TY0,"LS:G1,95=73T\T M;6IJ83%L*W-E:$)(8R\V4S!J8R]W0G)L2$1X3E R5'EW;D-.;4EZ>4XX="8C M>$$[=G@S+T%+;5EE5F)Z>C-R9#=O=FU"D52639T,$1),&5L331Y<"8C>$$[=&1I#=Y.&IN831K041'3S=U;U8K14%#:5)3;R8C>$$[9S)(65I)5$E9;4E+12\U M5G@U5"]!3C@S6"]39F9F.$%69D0T:%)W0C,O2W502V8K*V)R+T%+5#$$[3C$O,&XS,R]!1EAX.%%R=T(S+TMU4$MF M*RMB#54+W=".#-8+U-F9F8Y5CAF14LX060O M=T%Q-#AP+R8C>$$[-S5U=BMK*RLO=T-Q*U!I1F5!3R\U5G@U5"\S>F1F.$%3 M9F9F.58X9D5+.$%D+WER:GEN+T%,-75V*VLK*R\V"8C M>$$[-50O,WID9CE*.3DO,5AX.%%R=T(S+TMU4$MF*RMB$$[=5!+9BLK M8G(O<%!V=BMQ*U!I1F5!3R\U5G@U5"]W0C@S6"]39F9F.58X9D5+.$%4,U1D M3G1.3G-O-TLP5C%T-'5805-34U-T.%1&:B8C>$$[5C579'IU,V,U16TR449) M;D%L,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+ M=7A6,DMS8S@O3#5S;#AV3B8C>$$[82M64G@Q939L4TI,;W5Q3$)'0UAE46QG M,UI/1W=*<3)4>#%E+TIH:S1Q.5!.:FPS&U#954%Y4F9%5"8C>$$[3V)T0U=763!:4%-!5E(Y<'4X>$=(97=-<#DS-"MB9FQM M."]/3DYA*V\V$$[1TUH0W1L9UHS4C5*5%E86#4T5V$S2$-Y935J3DAL92]A,6UL.552<4IZ M8DI$2F)Q135K=$5H3SE!4&@S3U-)9WA">4EN>3%(*V1%*R8C>$$[='DS97)R M1D9A6$U5:71:>4]S36-65G112&EA23-216XY-WA$2U%#1W%F:49"3&=R6EEE M2F4O3"MZ.7%Y2S$$[-35:4F5.4$EP36%W4DI" M2'A!:VIO2FI%,"MX8C1M<#A09')'5G9)2U)+83,K94M/16928DM18S5%36]# M<5!H4TIL8W(Y6G)2=C-O,B8C>$$[2C-P,'@T660W2SAN8WI0>7)C*V%B:E1) M-69-5G!B,FPR,&-2.4]#4FYB;55(<4-24T]+569P>&1T=D1+<$%861I$$[$$[5W V8WEX<%-&555,-E5H3E-3-G-!375Q1%1C,6)43&HX,TIR1SDO4VQV M.$%6-VA)$$[$MB4S5H="MB8RM)15DU04Q8:3E446E%4R8C>$$[>$TU04HY<$=P+VUV3&,R M>#%(4W)/1S(Y54,W05969C!M34%9>&QB>6-$:'IM8FM195%19D-P3U)):#!, M3TIN,2](,G-N.'A7,35D928C>$$[6#E4=')+<'9*-U-E3S)!8F=F5F5.;%0T M:E1J.%)'*U9X3S=:3&LX;# O42]Z,3 V3U-+,6MC;S5D*V-K.6TU-71%17%W M:T1L=#%8:B8C>$$[4FQ#,$I)871->41,1U=J:'E,6B]+;C5R,T]I<&(S='!. M9#9G8C97*VMM*W9X44MR>5=:9VI:1$-6665J3V960SE.<6)6>#0T5V=W;B8C M>$$[6#0W;31D2R\U>49T56EG=$IW='9(26I%4U!:>4YX1'5Z:7)62D1C:'18 M,D)!>'9'<$=4;W(O5F8K8VAW1SE/54)I6FEF56MS6$98:B8C>$$[055R4D9+ M9U-66E8S-&IR>3=T-#%R23E*.&QR-6Q4>3%:2C5L26)7,%9L=3-(<&M-47@T M;CDS.% R85I23W(R-4XX3')F;6PX6#5N928C>$$[56XY0C5:-6)3>G5P:$)A M6#DQ13EV87IC:VMC4$A.2T92:U!O:U9R,4DX4FMV0TQ(>%EO=V5F.$%Y3S!4 M>7)R,6=9-&\Q;&M96$52-"8C>$$[;WHK;4=0>&1/6D$K-WAW94A,=50T:V4X M2VUN961V2VUO3TDW8E9,6G!7.61K:4UQ0FUJ='!':FML558S:G)'>$1$66=6 M-TA!645D128C>$$[:5E05D)72#5L*U1B=%I'92]&:44K2U V*W!T5$Q%62]7 M5U=-4SA3>4Y(.%$W,#9J<&A/3U-":VEV,'8X>'9+3W$V,BMJ,D8X;'AC$$[1UI&;%%G=W914DU6:F-(-#)P3W5W.2]$131Y0EI56DEK,$AA9"M9+VLV M.6A38CE)>%=S8W)2>'A.9$US06534T),:C Q3&M!=6E3$$[>D@W2DY$ M:6-C9V]Y4E!617@K979*8V=":C%Y>%E-449)=4DV16YG0BLQ-'I*.2M00DQU M6'A).39A5T=O,D=O5WE83FIC4C-.=DEO9"8C>$$[2EEM1'%68F]A:DEK57E" M=$59175X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5F=V;FHX$$[.59T8FE#4&LX64IL3'5R0C0R0EE3:&5V M,F$Y>4-TG5B>6%A5'ID<49J1D4W>$=+ M9UE8;$QE3R8C>$$[3#8Q2C9C.59-:DMD:65D2T5-:B]!0EI--5DY>DAW<%@Y M4E1#5#AQ9%1-.'0U1C5I;6=V-7$K$$[<6UT0U-"47@X560S-"M43'=J,R]!22MA6F%9,FYE53=Y6DY8.'I3,W,Q M>$=056=U<$I:5U9X3DQ)2E%H95@P9UDU5E-I<7$O040X$$[231-;5%8 M1T]Z5%!667-2<54Y,#=N.#0K5DE,9&)I8E8W4DEM1E9*;5-P2'-O4$DO9&QF M-6)*9&-*=',O3C1Q-'5+3F4Y26)Z.#50228C>$$[1G-31G9N=4-/;VEH;% T M&12<3AX>"8C>$$[-%!S-W4X;'@Y5G)X15=4=WAD-6$O35!5 M$$[3D\O33-Y1'%$0F)B5S=9365I>G-B8VXU97-).#9/5VYY M1&U(4&AR355U56=J.5$X,RM88D%Q$$[*V9767-2<5(S8DHU;U(U;&IM;654=GDQ,6TQ:V=S,6MN9UAL4S%A-75Q M47!*1DI#>5)23R]W0S=4:F-38DE+5E!Y>2]"$$[241(36)* M5#5X,%0X=5!*5FQ:6&1Z<&LXCAE9TA),$)Z2VA+56QM25%(3#A$*WA",B8C>$$[979F:SDU57,S;C!T8G!( M9W0U:VIS4V(S,')P47,W+T5R,6=M2$Y:;S%K4$I183$$[9G S2G1,84\O3GI->F$$[;F%!8DI+:VQ:83(X6D$$[8V4S-#5S=T@U4V51:$MK=C908FY'-G5P.65F.6A%4E%F:C-!.4I'*UE" M-UI6-'-M,W=O.7EE95@O3$=G*U@W45=U:S)C9'%N0D5K:R8C>$$[540Q2D)' M0T4Y4U$O12]'<'!5-V1S:DM24$YL1TE(2DY-:7ED:7)S5F1I7AX4B8C>$$[=$I+-GAX;T-Z=7A!54%D M4U-C248X:T5G8FPU-S5M+T]84F103#(K:U(O<$6-T-65K9F$V8B8C>$$[5F1T-#1B43E:*WA+=$4T>5=%9#)4-FQX M9"]V&YZ6#54=B8C>$$[=%@Q94](4DQ1,T8T,&9Q5'AP>%5!1FEV2FU9<6]R-VY- M+U-A:7-.>D]W3D(Q2&%/:DUT4E=)8FU.;C4X+VEP5W8U1V5D-3DU1&%7:"8C M>$$[-C!L;$I0.$%Y4U=41UAA1U!Z2TDY:C5J+TY#23$O44PR>'5'6LP<7!Z:'5Z=&9,%)/,V1T,"8C>$$[25HV+U)( M2DAH2F]H8F]M:&%H9'EF53=#37HS1%9B9C161D(Q62]S:C-W.6\V-EAA5V]J M565'23(W.75P2S9(4DA(2&A'-4Q&=%(O2R8C>$$[6'HU65-Q.35P8G9B8W%Y M>C(W2DU!;&9I66A#5T%!,S-'9'!K,6M"06M(8T)H3',O3$4W:EI/8G%5,FM- M8V-#0E5!-')T$$[4%HW$$[8C!,;#EN-G%5;T-:96XR,3$U02]-8E0T<$5L1BML=4A* M=#%M;'0U;W97:DU59VM33C0R;WE/>4=T5DE*1V1"2TTX6C-D.4-C36\R,R8C M>$$[53(O2C,X=6U-:&)3;5EZ37IZ13-6,F5B34-'6G8S=35)63%R9SAA6&5Y M.$=08W%Z+VQ0-41U3'!R=694-5IB<&=I=&-095AJ4T99>28C>$$[<%%&:DY7 M:6Q&<#151U!I>54T;S-A9V9Y82],67%Y;E-#5F105&-F5V)V9$$S4&EF,W4T M-6(P.&-0:E,W,&5$2'561B]+2#AV5FQI;"8C>$$[1VQT-FM":F%&=G)6,E-H M:$%74&HK.3(T0558=W=E3$QV5#15935M3U9T:G-69&ER$$[4Y0<' U5%5813%M='@V95!&32LT9%,X3C@R M965.8SAY5"8C>$$[1DHS359L>2]D5TU24$%E2$PK9'9C+U)43VHP*VIH:$#!Y>6)C2W=R3R8C M>$$[=SEK+UHO,E@S6FDV:G1+14YO*V\O634K:C=&>50S;C99+V(K>&YC+VM4 M>3EP361V8G=A,4QP;DU%2VLP$$[>#=D$$[:7(R04HK954U$$[9F)"1DYH5VUN25=86&YN5CE4=%IK+W$$[6F1',6TVDAC4B8C M>$$[57%Y=CE89#0S4G9J5E9%9G%/5U=*9WHO04$P,F)W>5)#56AV=DI.=G%. M>D]F3'0W839H8G%1,&QQ%4P,U5G8W%(8B8C>$$[,GI25#=/ M>EEP.%='4DAU3D@U=75Z84AI-VE/-&]06&9Y:S@Q,V5G5'@R53ET2&1S2T,R M66XT-#9'<6AW3TMS96YH-VI-=G,W46U'8B8C>$$[>&-X-&IZ-SDK.'-*84=8 M0E%O4$1P-&9-=FQ05W5,:30P;E9R53%"0DM/2SEW4G-Y;C)Q1&Y86$=9-W$$[$$["8C M>$$[*U!XFA*-$5743-*=45)2WIY M4TMQ3%)&1E=+,'%/,E-J;4$R3 Q*R8C>$$[>3@P,FUU M3C5R=5AG:5AH9#99:5,K;$]Q=$E9,4QZ6$9W+T905C(U;'E/>$$$[83=N;'0T3&5E3D9A-T%Q M.4DW=4U3>4%I<$TS3F5Y<6='27EJ=54T:C,O:C5T=V9L;#5N5%0W94-B>G!F M,TYZ0W9!,T5J6%-+.5=L628C>$$[;&QG=3172B]E2E%L>E1H5&135G@X55AY M55EJ5D5Q,VQZ.'0Y9C!N>DAA-G9C*V%R;E5)-&A+3'4Q:U-59E=!+W$K;#9J M1S1C2#!V5B8C>$$[*T=Q;G!T>'=3>4%I<5=/36#9F<#9X0U-'3FEN<7EY<#9L6$LP4$9626]->5EN=W-9:T(V<%AV,T%B3R8C M>$$[2$M0:C5P44I00D-T:'1:3RLO;%A2:'9M9GDQ8G9B:31T459N1$I(=TQ% M:'5B0E(Y;VUM-7I/-U Q,&I,:&QU2%8Y$$[=U!F6G V M0C5,+TQB5$Y!5DQU-D,S;7)B2#%I2W!%9D-)2"]I4C,K5UEE5E90EHY52LO=3EZ37,Q-W1K:28C>$$[.#!E57)(>D%L$LO3EEK5U%S1E)7,R8C>$$[541P:F%P$$[:UAK>7-H:DDU57(Y:'EV>4]+$$[0U)22U=K;&-H5E961E-Z13=!05E&63=R;6=E5'90;6I'2UHT3E)T45=% M1C=A>4DW4E-5,TUC<49G1#!Q3VYI37-X-41!,D=V3&EJ328C>$$[5DHX*S8S M*U-U7-U+T8Q0G%F=WIA-&,P6E)- M:GEJ>F1"<61,3T4T=VIZ;61J.7 K5#%84R8C>$$[<'9-96E7345&:'%C;'I( M84E%:G1B'AU M3U%Y239306\O3&-F3FM/<"8C>$$[9FU*1&)75VLS555D<$A(<6M%:R]Q-FIE M9E5O5DU2:E9O56LY2V)N351*.$M51E%P,WEN2G!Z1UII96IK67152C0T>DA+ M439P86XU>B8C>$$[-EAC6$YN8E=/:C,Y>&-86D(Y071A2DM)>D8V<&(P>D]3 M3FET4%4T2W=Q5EIQ6DAW5#-T;FIE6#-+-2].+U)V,%)D83,Y475L,&UY5B8C M>$$[5VYK:TU#5$U*<"]Q.$)H:CE1<7EU-E-6-4]R3'@K>G5-2&=M-E-C=W$K M:4@X=V9M+T)O97$V:F$S3VYP4&)A9$U)6E1B,U-V9&AE128C>$$[36I3>5=Z M4F]S8V1**TM-6F0R1DYQ,7=X=S)%4WI55#5.4#A!;G(U4E=7+VE&$$[-T%95F\K0DI(-6E/+VMM M2&QJ.#)F3&9M4'I&2F]&:F(S$$[-54S3WA6,DMU>%8R2W!"62MF.$%Y6&9. M0VQTBMC+THY=28C>$$[44QJ6&10:$I65T%K=31&<7)G1E1U-#)934MF4$)W4S=K M;6-2,6)(;DAY:3%X2F),$$[=D%$9DAG4&-J>$DY-%%E<&9M3#5),#9*6F)N5TQC>'0V=T1W=#8V:')D M43!Q$$[8WHV5F5X M6&MA.&95.4IG5U%S=DI2278R:TI5,6]W0GE*:5)Z6D-14$IR6'1B$$[35)$4G%T5$A$:DTU8V$$[>6E/2350-&9U*U0P5W&-E34AG$$[67AI8F]B,E)YF%F8W!C,C%U M94UL,4=A=S%P56A:9G-.>$@R=4HR-S5H3W=9.7(O;C-J3$)P*V=2:3=V$$[:65+,RMS4$A).$544V-J4FQ3:G-W0U9),C1R5FED=4I.2WEU>6MU2DQ3 M1U,U:3E#-&1&86%(:T$$[67$W1EA9 M<3=&54AR1VQW-G)P9#%P,#=-:U8Q1UDR9$-!>3$W:6]),CEX5'AX5C4O2G$K M=BM3=%HY2SE6.5,P*R]U;#580E96:VM74B8C>$$[2T%22#%"5U9*1'@Y37 O M9')8;G-&0E%N,G5W=RMA9$ES=%HX=GEP971A4T\Y<5%3<51)87A3<7)-04\S M=W0P,GI*,#)3275-=G!K4"8C>$$[;#-/2'$X37!C331B>F=B$$[>6I':$-82#5I:#@O,4PO>4@O3DM(5E9F>71Q2$='-VA, M>397,U0Q25-3-U)(>&1+,4AI=GDS:G)O;55J4'9:9&QZ16-9>&YN1C=0;28C M>$$[03=2,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W-5=69Y<2],*S5U$#%Q04%E9WEW6B8C>$$[6F0W5V-- M4U%A-4U985 X04Q',78R=#5T2S%',4]O5'I2,F0S2$QD>6TU;'-I,7!,2&)R M87IY,T5A;TI'5&E54E-V5&)**W)V665K2"8C>$$[:U9$5')J.'!V34XQ6F%F M<#EL9'@K;F-2,V1R>'1R<5-+4DQE-VU65TEP27%133AJ.&UD46Y&*TI)-DM4 M>&A!34I*=C59.&MF;$IQ;"8C>$$[;DDK:#999G$X56MN34XY9'1Y1W4T54Q& M5FU-8D9(:%I3<$AW,%!W-4=C-6IM5U=/14LR0V14851O,VMV>3EQ=#=O;'%9 M5TU9:UI':R8C>$$[;&Q"94Y"1DAT27HP0VEM=W!K$HV.&0O:$AG0FPX=&1K0B8C M>$$[.4AP:4]11&IX-TUX4VHK.$A(23AY9C!D,W=46#AS9$,P*WHQ8E8S5D,Y M>&(K:W--:F(X635L3$5$,W%U+W1L,G4Q57-M2T)05S$$[8UAS>E$T M.$]B24)Z1E8W:G8K4&=Q*V0Y86XQ,C1B>7!O3'1.8VE72#E*;$%W45).24$X M8VHQ:E!$:E5U67ED;%I$>%EJ3E%(Q,R8C>$$[54QE=U-F>6IO075R=E5B M<'6]O628C>$$[4D1J5#!96$MH>$=V465053%9:VM*6EAI ME=.-T5*$$[2D=V4S)%$$[;"MX279Y4%AX1E)K$$[.4A2-E13 M4WDK=FE-63)13TAY3EA:=#="-5B8C>$$[2%1F<4A967 U3651635N M:45H-E0Q,C5G.5!C;DXW-7HX'!I:28C>$$[0DQN1UE#.&5C9DM"1E)R;6YK8U9F+V5Q M2#=,51,<45.:$1R5G!08S-" M:E="65I6;"8C>$$[5C)L6C!2439C;'%8:DLP5(W,%50 M3G9L:')3-74T9%9T8FE#>E):8FQR959*>6EU4&=Q$$[-$0S2C1G:$QR.'=F2C%N03!T-W%3,F)Q07AT3&Q*64QV:5=#0FAA4TMT M=U9Q979#;F9P:$=/4U!%:6E.0C@U95=.96ML:3!N55ER<28C>$$[845U2&E5 M;%AP17=2,E9704Q+1UE$:TYT.$5O16,P>&U$>4MC-49K-T9867$W1E5K=G9* M2&LV+W5$8UAM:3)5,#=Y:6574F])*U5K9R8C>$$[1$M$2U%0,VXR>G,Y4EAF MGAQ M=$A03&)V=FIX2'94=VIU4B8C>$$[3VTV4G!/;'A01'!L;$)9=WE/6DI)-V%* M259:>4%#>$-"4511059W16LX,&E)2$I*=GI%,5=$5"]!0VQE;5969')P9G$P M2TXP3%-G:28C>$$[=BMX5W)F4FU:,F9I33AW'=V2D9(>6$U;4Q"5E)A06-U26)K86XV9GAZ628C M>$$[-C=266-FB8C>$$[55HX,T=2 M47%-95%E9S R;CA-16LX57!'>69X,#=M2W):5V8U92M78FY5;59N.'E8=V5R M>3A:>$9X56,R2'!,1T)"1VM3;FLO2%E+2"8C>$$[6E)4:E,U3$E0>2\X&)6+WI).'(V9"8C>$$[86%T3THR=5@P8FMT-&MA3W%#5D-O8454 M=49H36%,R.#)O-6\P9C903C5X92\X-4U73G)R,35&1EE, M939)$$[-%)N:&Y:04)Z8W%Y>4(K4G%Y03A+3#$S3S)6*U0Y27,P M6$-084AQ24%U22]"+T=Z2F1$+T%$-#AR86AE8619>DE9-W)51$9'5W0U0B8C M>$$[3D9$3$\U4DEP1VM&=DIY2$@T:7-:559&1TDS>6U7;DEU;DEH<6=A=FXX M*V)0.4XQ;E-T5&E%,FXS561Z1U,T5FM.86E/4F]M665+."8C>$$[-#)!66)' M;3)5145C,TI"0C5)>D%L,DMU>%9*+TYE9W!R5VI45V]51S9J+V975&QM5&IC M240V8F,P*TYD>E%S<$1!9$-$:7)'4'ET,28C>$$[:4\Q,#%V3&PX63=E-G-B M:5$EA4TU%;FDX>4]X3&A+9T%J-&TS3T5Q;&9M3S-M.&]2,TYZ M9%%S*V=I579$9'AL5#91;28C>$$[979P>6AI=$M/,4$S43=D.#)":DA04D5H M1V1B,S5D439K5&YP45%9;5=/>5%9,5ES,U)"$$[85-S94MM9&Q";V8Y6D991#-P-#1C=4E9.%)I1%I*1G-C M1V,U5189$1-5G5,:28C M>$$[3F53;4IG-DEK:7%J,70T-G-G0E!%5D]906U1-U5W0E%J9FQB-49K,4(Y M4VXP,#-&+TEK8V-T,6-81GI.239X1E-N3G!*6$QK8T9&5R8C>$$[,V]+9$U0 M:7EQ:T1$1S=R9'8O;%=(:V-W>E%V<'AL4S1P-GAL=4QM5FU):F5)174X:DY5 M2DUW0G)T.4%O*TQ*4&AX5G)0.'5V2E9N2B8C>$$[<6ML4MA:'=A M44(Y*UAW1&Q326AV:4)J-#!/+U591&MK83,U24=+275H>E5R=CAS+TIT-'), M95=T>&1",D1Y979E,W-V3B8C>$$[,4)#=2]/6G542W)&5EDW:&9H1S(R27E3 M6'=W:DY*.&LK5V1),4]453E/$$[>45!1&%E6D9K-T9867$W1EA9<3=&6%EQ.&@O3UA6:DYQ M='!P84XK-W19+U9K2"]&:W R"8C M>$$[,$8O3FMF-5%A34Q4>2]*<4QR4V)52D-62DFUF$$[-V5!1E-F M;WI5=2ME5C96<#%T-70X.3-M<4I+,#)K>% K*VA->#929W=O$$[$$[;EI*,6%10U=*;6DT2WDX=DAX,C)/3%1X M03,K<#%/9E=42CE0,#$K1#-G=DQR<39U8FTO:VUU2EAA5V%6<$HU2D=,=5AK M,VM::7A*2B8C>$$[4&1J,7I+15%$,T]$2UIL2&,S,5%Z33-J>6\R,U5J8F(U M,'=%<$%#-&XW3%4T:R]%=DA957)4-D181$E):6%/>DMF24@U:&%P-5 Q3B8C M>$$[&)N9W)303$T<'I:2D-&1#A78FI2:4(Q2%A+.#)-6DDQ M,V9S8G10;4]+5B]W03=N.$QP.5EE5&1C,6I6=$YL3W,R0R8C>$$[-F1Q;&Y+ M3&4V9VIK5U=-E5Z04(R3F@S28C>$$[5'AR8T=/2712668S:WAC M>%9L87-#37E$9U)69#)!3D-537HQ+U(W3'I$-65V9$QN26$Q,4#=Q84U-35I58E)/228C>$$[:T-$,69%:TTR<&589DU+4W)72%5D2G5G M86)J:DYB>6)G+S=*85IT:E5H-S-106U%=DU&.7EA5G%-1W V6%HV;&(O,T8W M0DAC43$O:R8C>$$[;%%/=C1.;6]);S Y0419=$99175X5C)+=7A6,DMU>%8R M2W5X5C)+=7A6,DMO5%9D5G-T3',S=DQX*T538D1U>DUE:7%/-4]66G,P8R8C M>$$[8V5+6$IJ3UEI3$QW;GI+>F%X4]T-U!/8DQ,2GAC+R8C>$$[2C=6-5-L M$A)04)..$QK2U56<&%1>E1447=X>'I80B8C>$$[1%1Y26]6<$-O;T,U07%X M03(S>%96>%9:8U1W5SA%;'AC4TQ$0D-R4U-Y>45+:4EO<7I->#)!04935&E! M<$Y0;5 X-69Z56DQ,U9B$$[4SE.5F)J4FQI4T9:2F=F-S)+6#%'=4QF M-TI2,D@W=74Y57(T-V),0G!Z1VED:BMH,4=Q,5EN8UDP62]P+T@T-RM45CE1 M$$[5C)P5' T9$UY964W9V-T;6U&3CEY=7EG;F)993,P-&Q) M8E9446=56&U$=6%G141F.6$T9#!&87%R-F$$[2F5Y:'%#345":GA&861+*S-41W4U8G)M>69Y4#5Y,51Y>G)C3CE&2C9K M9'5S<7=21EDS45-42498:C9G2E5->6]S:&HT=55Q;UE:2"8C>$$[3&DT>%AU M+TAM,C1-=WAM+V8K4$QP.&XR6F)Z=S-&=D9C47E*3$1-:7E24WAS2%)L6596 M;%EB145(635P;F]65$9867%L9FU4>3%P4"8C>$$[;4Q4>%EA;D5*8F-/2D%+ M2U-'04DR-4)U<7-2.&II<4LP=E1,6%1,1TMX=&95*W)W:FI%2EI(;%E+3VEH M<$-Z54A10W4R2W9L-S@S4"8C>$$[>2\Q830O33=6,3!M,DUK3C!9-W5V65!- M9TUL84$Y6D]2-F0X,C)M:51J0D]W.#-1-C)11UAH04UI9#9!=#=:*U,Q-TUN M:W5Y,%!51"8C>$$[-F5R-E=R>%113E5-66952FEC06=(:G=93#E'66UQ=VU* M-'5C5#%(2C)':#%-6G@T954T.'=D:7HO35)Z;EEQ-T9867$W1E5V.'A46"8C M>$$[54]G86Q,865T.6)3,6U.=CE75#%:=E8T2&@V8V1#1V)L4V=/,VIH:GI2 M3&LX:C O.'=0>F=T-$=H4&PK96%/,G1)4%)K=DQ'.&5E928C>$$[9%=14VAN M:5)&1$U'8S=R44%$-&U/-UI">'$$[8611*TA$=EAX2C$$[<%!B9610>F]'<"]P2UA43')H=T%B5$1P M=#)90U,Q=6I5+V%5.%)*2418>$90:4=3-$E65$AJ>5AF-E!C:7!V>D8O3VE/ M03AD06ML;"8C>$$[645G<'!.-$],0E-W1D=L555:;4-K,3)#,6]A-%!$:#,O M87!Y6DLU9EEY=C@P,VUK=#E,:U5-3%HO56%H1$ME4D-L95-S05%A5C)/+R8C M>$$[6$]A-V%U;SDR-UAR8F]03%(Y92MU+W1C95@K>#0O<39:,&MH,F(O2B]W M1$(Y2&QX.%9F3S$$[-6)8>3)7 M;F%R8S-*8U=C8E%M<4DX;$=024U1$$[9T=G86@W9SA70F]E>'IE M3V%J8U9D:7%&,58W*U!43'E45#1L;C%"24I'&A(4&1%$$[9DU/;TPY5FMS4%1U2DEP8E-:-'!':6QJ M25=6955%8T56031A9U9!2V)$<%A.>D%K:7EB961Y9T-2049*6'E:6%!P=G13 M;DE60B]8:"8C>$$[-4A::%9J9'5H-&1!4V%"5%9A.3EY3W V9&-04E)Z<$YR M+WER38W="8C M>$$['!B M5F)E4S1T3&E'-71**T9X039345-2$$[<4-+2&)% M=W-6>E=/466972#5,95IR4%9F3&YO=G)#-FAQ;S1Z5#)8;W)B1S!J5D5G M4T9)5D-O150P=C)">'%F9F96-31%2&-5-R8C>$$[,U1416\W4S1V,&9"-DIL M1&M/>%8R2W1+-E!5;W=906M':')U1%%J-D1I$$[;F%U-FA8,#A)$$[>#AD9EAV.$$V5W0O='!.=%)K+TTV,75.5&5W4T,Y=#1: M1EA3:V19:3!Q5'-:6&%24%9T9#=B849"-G$X;'%Z8VUP6$=(1',U:#1T-B8C M>$$[+T@S2F9B834K9$17>G1D84)A4EA!85E22D@V36ES1E941GI*=C0K05IU M435$;50S4F5P2FI$=B]!0CAK0U4K-SAF3D-8$$[2F-7,79( M8C)(,6U&-')/;&UX1G558FUR35I395%02&XX6G$S,D-":$A"4RMU,V]E:E,V M;DYO.6I,<7-+,BMQ4U$$[1$MQ:TTO=V@V9V9%9FYL M37%V6G-J9$,K84UW36Y9<3=&6%EQ-T9867$W1E5T.'@V9F%8,FDS54YY;DY& M:F%23WA6,%5L5T(X8VA05"8C>$$[=WIE:5A);'%Z>$)G8F5(*UA75%9D8G,Y M3VQ":E,U:T-.27!Q44]U=TEW-FHR46IJ:5IJ265%9$](9C4S*V@U5%)D;RM. M;&I!>')I-B8C>$$[,RMX-C=R=&Q.;V9L0S1I,$=/6#%O07)Q:T-,3E!,.%DY M44%/0W!:,7%+,$Y/=TY+6D1":&IJ:G=X-5!7=V=):6=S+TQ:$$[8E=5;&ER3S1K:FU+1GI*1V948C=#># T1E!4;UDP<'AP>'!43%-Z6E)I M$$[:U=H53%1 M;6\S1T5':6=I=RM&D0T='%K9U9/8F]2,F5C;E Q M13AL2C%:1T-/=D5R$$[14AC3S5!24]20594.6M# M:F(W.6%F$$[141C9TEB5W1'=DY(84$$[36QY87$$[>$$O1%1",5=/26E#3UI,5A:;FYA-6UH:&QT$$[2U(O5UI0 M5%5#85-#5F]W=$=F9TAR,5DT5E,W.#(W5%9.5CAW869&-6-U:&%8;&I(2TY6 M;E92=4I05&%"0S%256=+>#8W5GI:-E-80B8C>$$[0S5N,&YK2W8W2%-A*T)Y M-4MX1#%X-6M(:')U0E V1R]Y9G1T5S!F6$Y6=%!-1C),;3$$[*TI!4V=B:DAP>7(T375Z=V-5>D1)2VY, M:V(T=4MV4'DW;G)787@S3'-69&ER$$[,VA::CA03T=#2'%96D=J-#A:;E@P,DAX1E-A-S5B1U52 M>D162TUJ>4M742M8+WIZ6%-7:&LX>3),-FEJ=5E*:VI25EI/55%14T9R4R8C M>$$[5&]G;$]Y,35%9D52,&QX63E9T$$[1U!(1'54 M=U0W,'AS=DPO-7)7.70V:W5R5S%Z<51M-S502E!)26LY84LS5S-924QB,#-- M5'=V.$%$-F%R.%I)-FM91$M(8VM2;E-H$$[15@UC(X M:V]6-T=Y:%=:-%5D;WEV0FQS<'!7-&9V1EIV4F8T84AH5W!62$%E;C0K87DT M:'8X06HW:V9Q=6\V.'9K1"8C>$$[4FLQ0U(T=%$$[16%7>4E6<'AL46-:05(P26-F1E@V8T@U-TQD.%(O4CAK M+WE:<"M':$%$>C8O4&UY87EU-S=6+WDY=E)/;C%Y.&IJ=6)C8WA&4UIO4R8C M>$$[>6]4-GEY4B]&459,2U)8$$[54-I0VI3 M:V5N46)54%%G-6EL>E=967$W1E9'.7,T3#)Z;G,W:%,Q=F-X=D1-;TI5;$I& M2W-!>6M%8DAQ359F2$@U;F578C=24$YL,28C>$$[1&0R>5=%531%,6QB9U), M4S)Q66]Z>&AE5F8X061D1%9I>D=R3E4Q2C(K06E5969V+T)D0G%9;44V$$[9S=$9G!L=D-7:FE'-U%+0FE75V]"-F1. M>#%P=%1B,W=$>E5G.45D<"MS87)P4U-I=W5M:$4V*VY/:4Y8:W%I9T1F.$%" M8EE*44A6;B8C>$$[1$M9,U=Z5V]AD%K-$HO=7E:-6Y) M-&A".%1YE%B67AI23-32GI--DI16E%S:7E"9V5*;T)5,4A5+V1K<28C M>$$[,G1J93E,=C-K>F=$8W-19V1J$$[;'EE26QJ M4EG9T3D--63-(*TQD;C)53U$W1EA9<3@Y+TQ*$$[4C94,T1H;C5I;V%G,G%U M>'=L549Q1$IP+VU053=3.%I9<&)M8S-D=7I'9VMI;$%O5DHO;$ML9F]Z3WDT M>D]%6E(S06I2.&Y764US8R8C>$$[95=C2BMK>6QX1"MK0U P8VTY35@Y2F59 M.4YG&1857%B$$[-G(V;#%'66A-4#-D>#9Q M8U5F,2\S:6-0:7 Q>3)/4VA45DQ(6G1!>&9L:C5V4S5%>BME3#9A25$$[>#AD*TUG87 K,50T8U!I:G59*T9++W%5 M;"]+=GIM3&=3+S0K,4%2*VDX4FD9/5%$$[0FQF,48V3F%1>5$R:TU-:VAM:VEJ5DAM3F%U>6=!' P;&QC;&Q6:4=J;%1:,&M1,58Q4&E$;'5(2R8C M>$$[8V-R1%1Q34%Y>#14+UE2>4QX4%=V35=U869E,V5L=3!::W1P2&A.=W%& M6%E+4T$T,TMJ:TXK;6(O0C)D:&M"4&9F975J>5=Q-UHQ3R8C>$$[3U5S4C1B M1S$Q=C$$[-GC9P;W5O>#-#4UA* M:W5)2G)R,5A%<&AL2VM14WE&*U59:&MI;T,Q46588DLR.39$9U8R2W5X5C5P M*V)8-5-A9#5R:&XQ;&)X-R8C>$$[8E9B93-626I.37-D;W%235=:<$,P8W)) M07)-9FA)1F5V8S5K64TS1'-E5&DV;E1C67-F5BM092M66DQ6,&0Q86Y*1C5' M;7AP-&I.<28C>$$[645/:45W95-K0S=H5C5&5D1';3%4=G-F2$DS97I+<3-8 M379(;7!*-41:92]48F9%:71K03(Q24M%04%R4MY;28C M>$$[:&]19FE$0VTT-D1O4$1#9&Q'-S$S.'$O>5@Q4%A:8E183E-5,E=K3$E3 M23-R.5EK57=H-#59,6QI:V=K:F0S5W1A<5%#2UIJ86I00R8C>$$[<4A0.&,S M3C!U;&YX8U(U9G,R23$$[<7IT4FQ245)U>C=D=7!! M2W%59FPU1F)A6#5.*W1T4$DQ;'AE-%5U-W5K8TM,$=*:R8C>$$[95%91C5R.'5T-3(Q4DYC=EI:3E!C44-# M>FAH6F=Y4F-M9%,W0FQQ>#4W-7-O-3191'=X0FM2>DXQ.&Y55#!U5%9!5&M2 M145B4C1B*R8C>$$[8DMF>5@P<$Y%,#-69$AL;F4T=E5U+W),>E-N:WI1>7AQ MFAW0U=)9T-55# U14AK43E&>B8C M>$$[0F1M-T9867$W1EA9<3@K950X,6\U1FMT-#5:8FU/85HW<4,U1VYM=VQJ M0WEM3T\P351X6&%H;3E-8W!J56)%9R]%374Y1%0V+W=!528C>$$[="]3=C4R M,%92<$]N96]9:3!J1E(V46-20G=IE%K$$[3EIJ<$UW4S)Q-$UV=V-: M4F-U<&PY3#=):W0P5&Q4:WA&86=I3WEB;'5L=W90>FMT8C8V3G!:3F9A93!4 M1WA457AP-&Y%:7AK+W9M$$[-31%2$M46F5+B]& M274P=G9Z9F=78WHV9F%84WE4=CE746E.6&I35G)G<'I96$E5<$9X9W)18RM, M1VY):D%20B8C>$$[:T1.1%,S=C4P=F-A9F52,E9V-F-8<6Y53DU+5SA#>6-6 M4C%26F9R5C14>BM*16LK1V@K2FM!,DIQ0TQN*U W52LX<%@S-6E487!Q328C M>$$[2&UN5')+,7-93TLV9F578FLK=61W>F-':VM:5E!7:D)33VTO6$EZ16$R M6E%-$$[.4UB9#)0 M0W!/8DA0<5HT:$A(13!!0CEU-W%.3F]S5V55$$[;TA3=&5)24)"1U5Y;C0R M2U5P9E9#="LX2&)D>4E11T1.1TUF;VYE,V-2=G0U37-G.'%A2$)R1&%X0D,X M5V]055-32DY-<75'2DI$>"8C>$$[:"M$1&MX3D-V6&9R;4$W3DXX5F1I$$[$$[5D9A9$(P>EEW:UIB+W!T,4=326EA+U)8>71,;# R.6QA34IA5#AP-%AM M:4-2$$[2C5$.# S M5FIB,W1R6FTT.65,,4Q7,G1Z.5EN84-.;6IE67!#2D1(1W)J:BLX-#%**T5' M:#1X3U=01E8X=3EM3E!,:$5Q*W)F6C9B*R8C>$$[6'8U16%X4'%-9#ER16E1 M-E!C=U1M3V4S-%!,27-S66I5:$HP4'!I6DIM6E,P9DIE3D-Q3GA/55I.6$=I M04XY;DMW-D-1:T-:8F(O:B8C>$$[9#F-Z6&UK828C>$$[4DA,86U'-VQ$5%=T>7%/5UES231I16-T-FDQ8S%8,'E! M94I,2G-C259K.7IP3FIA955:.4QM;4UD;$1:4$1*8U!U5E)9>4=K86Y59R8C M>$$[8FY*-'!M37A)9$,Q6CA9;FIL13AI0TAJ*V&I%4B8C>$$[>4%I63(R M0DE0=7 V0F]N;%,K=G1-,6U3+VI7,6)73&(V;D1"8TMZ;$E#')L3V%C67AJ0TIV:#-*."]*>28C>$$[9%!J;$]5$$[*U5J2T(P8VE71U(O:7!--VHX=2]-5#-% M:S!8;38K:DUO;35%=&-S5DUN<3AF5%582W=+1D5I02]U:CEI<6-#835(>$(S M37IJ3C@P1"8C>$$[<$@U56598D,K;FU0;DLK87IN9C%$<#A8,6A),5DS4758 M260W;5=8-'=#:DUZ1FI5,5EJ-&-K8V]04FA(0U%F<4MT4"M72&U%,GEW,B8C M>$$[+VY(54DR<%-6-4IB,E1K9E)734U#3'E.,4MY8S5A0G%%:T)G>7%"9SA5 M9'I)-&I832]B*W0V16EL5593>%EG049J,4Y/*U5T>D,W>B8C>$$[.'1G,G(V M:G)/;39N2G R<39R8T(W=39J171486DS.40P07%Z4G%'5G8S:5-D;7!65%%: M84UM,49Q.$QC:V-Y;#%J*U9'$$[*V(Y45)O;R]354LY=TEE M4$=62T-!6$A"4GAE4#=.0T]&5DE:<6=N2T0P44U8;59E3#AT=DUK65IV.%@S M$$[4')N4)R,7)987!P;7!E66)V57)E-W-:8E-#-'5*2DIF,S$Q>44P M<&EK9#(T;R8C>$$[:7A,1W!K3E S:#(U-$I:0GI!5T]-9U53;$UV-4XV,')Z M4S98-6\O455S-%%/;6LR:C)K245C5%)G2D5,;&=!>%E/,C4K2W!&0V-L-"8C M>$$[=S9I,DIW;71J6'529'HK5TAM-E51:%!01CE%.&%22S@T*W-E;R]P<$=P M*T@V,$E+37E&=C=O=%9V:5IH=&='561Y5&EL+T\O2'I:6B8C>$$[-5 P3%5T M0S!+2%1T4S%E8EE-.4F9D:FQC-4%M=TMB36-3 M0E).$$[8D)W47E->"]E4$5W+UHO M84MN<#)Z4'=Y:&Y-650R;'E"*S8S5V%G6DY-2EI-9%-H>DU4,#=Y1#EP1$FY!*V]+<6E72B8C>$$[-V4P<%5,2$DY1#,W=G@T+U1M9G$Y0TUE M06E(9EHX,U5D;CEQ;DYQ9V-L1%EI4&PO83EK>FXS$$[1E(O4EIO:4$V2DY4,#-D83=Q$$[=VU9;7=A3$1*:FI-5DE715!P+VQ,>3EP,G%(5DQ+>D5..%E8='961'E% M0TM763-$;T5,1D)Y;%ET$$[6F%D<#EH M1SAD:F%W,FMC:D=2,&=J5TY78V=!$$[,T9$45EQ>&IY>&]T:&-E M63D)B,T5Z=WII3G9Q1'IY3VQT9$UP331#23%5Q5V\S24$T5E,W M>E1F,T]S-G!F85$$[855T-6)E36QF6&0P1% V:$FQV=C!$$$[8D-/3T,K9SE73F%566QX=TQ60C5,>G!Y0C=:8D1/8S!: M4E Q55-$*VAX.&UK:G U=VY%;F$$[,G%15SDQ<%123&9R8T5W2D#9K;U-.:7$$[9D-1<3-) M2'14<'8P27=C174U9D5J,W)0.&0K5'IC$$[:V4Y8F4K9F9+;&IE3F$S M5C99;E8T;VI-65IZ8BMP3V=L:E0V=T5-2$IO,D15-3E.*VU)>&MQ6FDV4D-E M8W9+1#(P=#!M=6%E,71!128C>$$[33@T=6]41V=K*WAZ64Y295AA=EA"=U,W M;#0T,61H57103F9L93AU171R5%=,1S1U6E=:231)$$[0C9P<&M75'-69&ER4M69%0P2VM524]%1VI945%#2TPU-3@Q-D1C95AD9FQT05=%87-*8D]8;R8C M>$$[5$=45D18>%AO9F-:,D=L>FI.:D(K8C4S,FAP1'!S>&E/6$]0=65Z*U(O M33AF;412234R669866%2,W%$$$[;$](2E@X M2C5083EM83!A:D5*9GA$;C&-436(R M>$QG>#@U-4]5-TMS,55I3794;$=667-4$$[-5E$35(R1%!T1S%E,#%J M5$QF56)4;4E,:&%H2E9-8VE-<$MV2$EJ8F\V3T-R2V5H0D="56)I28C>$$[965',V=K;FUC4G=X2UAL:UDP5E955EII M9D%$1EAM3W0V>"]J=GI!;6=A5DTW849B,4XQ8W=V>%-E4E-663AK6G%P1CA, M<'E5<7HP-28C>$$[3'A+=&A1>FE3.3AV958Y3W1B4V%D8F%"1D5C161'95(K M4%5H141/>#A45$Q-5T-E5#91,#5T5&IX5GA'4B8C M>$$[5G%L-7%M;5!B-F9E>D$R>3!!2V]I:$5,.&58>'-Q.&UZ87DP;T]/35HW M5GE04#1/:FIR>DA.2U5"66QZ:61J,U@X;G%V;'9Y-7%M<"8C>$$[5#)'<39L M14Q/>6E+6%9V6FML<&YE;DM.<&1G130Q%I-,&]Y>4%2:$4S5C)396PK-W4W,"8C>$$[,#%N.'(O275T6$XQ8S9P M<&XQ<6$X:U-A9&UM=4(X8V%H5EI!D=J;&M/5&UY=WAL M>D-P3BM82&LV5C)C,DQO6"8C>$$[:6MT-49I=6)M2EAH;6MA5U-*,6IK5EAJ M6C-*2TU#=F%L34AI4U-C8U-V,'HX=F9**VPV6F-A6G K;B]6-TLW='IA6$5A M>E16949M9"8C>$$[:7!C=5@V>71V5W4O6'!I8VMI8DMX>'A!;V-M$$[<6-9=3!(<"\U4V9L.7 P53AD:G!2="]R2E%Y>4IC6%%K$$[8DQ34DAF M,G)T2F)Z=$YC4T97655/,&MJ2U%/=TEO3S%-5&QK4E9Q34U18G)D;'56=')S M5F1I$$[5EET*UE(;%-0>D)O-6%' M9S%#>C508E T+W=!.%I0.$%L52LO32]1879W6CF)Y6&%A.5EN.4HR3B8C>$$[,G1P-GEL3T1*-F=K5"]+56MD*VUB3'1( M5C1R-$I2-'$K1D]L-T3$U:FXQ5U$$[45!#5T5CE5:D]024)X9UA9-45F:FU'2U@X1W8X06M'.75R=E-B43-7:28C M>$$[>E-'6C1!23!I-$Q#445B,#1U8V)Q>6EJ,31L4C!A46IL:D]9.4(P9E@Y M3C%32F9Q.'EM-#1K>E$$[+V)!;$UC M5F1IFYQ9FUQ*S%76'EX8G$$[3FA6;&9L6'EX6F%"<'-D M=$5%:W53;RMS,V%X$$[26-A269!=4&QN>5-/.&=14#@R=C$R;S9L<&QH9C9J;SA6>D%L=WAV-V5K8D1L>5): M07IG:BM50B8C>$$[86Y(4U-01$UF=SA**V929&9#4$9J4#A!2'AI=F0O1CEM M-TQ03FXU;39*-5DQ94Q3$$[-F(W2VXS>D5H:DUH8FYZ>6E*<%@P-SAY+TI/;WDS34YP<5A/83!K:FAU M65=H;FIE3U-:+U-25U(T,6%V33A7,BM%.6%9;D9)3$A,128C>$$[.&EP42]M M<#5(;4%-5C=/+TUQ%DO:3!-;C5W95-8=&(R-5=A-4UD:S=)-"8C>$$[*W$S1E1X5D15,5%#24TX M9VI5>F-+=E599D)K9UIO<6PQ*V)(:RLR,#-59%-K;&Y&;G!G="]7:V%&:SE1 M,U1S:UEG16Y!>2\S6DI:9B8C>$$[:'!U0V0X07A3=6Q/84E"2C9,8C,X,U!* M,7!F4&)02F-Y=WAK0U,K:'1P<$QC1W-W66@Q6#1W=C%:<7-G665'=V)I:D9* M2GEG2T5(-28C>$$[>BM3-714*W!!,V%X;#1O,'9'='!"0WI4:&I(5&)N4G5/ M,58W,2MZ531F0FQ34$=J8D]S<6)867$W1EAN=R]+=E525U%E6G)S,U18128C M>$$[="LP+T%O5G4W<4-31S1-66EK:C1234A49VQ3>5501C9T55AE2T\U<$=) M.39#8CAQ+TYS-S-36%!M-C1%4$Y($$[-W%13'=9 M14MA=$HS36Y68U!I:G5135(W+W=!9DY-3EHO3$$$[5#1H;6MF'!S5G)D961D5&YU231Z1V)P6DHT;4I*;5E-46QW2R]& M2D@Y;VLP5&I8:3%!*TM,-28C>$$[2TU2<6E36XQ83@T450K836IU6'=V4#AF3G9Y M$$[,6$P=31F34TX=&Y':WDS,6AW:U),;'!23'A:=C,W25!4 M33%10VA&4E552G=Y>E@P44U.9&1K=&1*.4)5861Q8U5S9C%F.3-$8W)'-R8C M>$$[>%-O4'-S31$;6QX-#901C!S5U!M-$=$56I4=T=02T-/ M2%E':5%2,#5$-7!*1#4Y6%0O041.0G%.=D0V,7)$1S!%:28C>$$[=%976DA) M3$9F03=#;&,R3U!S,"M#67E0<4IT,#)F='-F;5)/275%4EAM8C5V6'1/,5!1 M=DTR:T\X0FIV3$$$[43$W2&-(3D9M=WEX>31: M0C9J5#9I1V%01D$R1T1E669+='@U5'4Q,3-Y,S8T:65E350R5G9$3F-.4U)P M4%99>'!-:7-N1U-O0E%N:R8C>$$[1C-!-E9T>5EE5W9Z1W9:0S!(;4]Y:W-: M,$M2=7EX531-,TE)6E4Y4C5!6E-!<4)%6F562T\S24%.2EIF<$]U-E)Q.&-K M;6U8560S2"8C>$$[15%K%8R2W)* M6C1):6=L:U=->45R1T=)2$IG<%EG5C9N:7!0>4=+<$9E965D070W=#=73R8C M>$$[6#8S3DAX-6DR84]13%AN>C5.>D%4,&QI3%!Y<%%5-FLP>%9K04E)0D$$[44(Q67IK M26=K.4AM33$S<75V5S=81B]E>GA16&E(:EI7.&AI:5='46)),T=N3W%N9FQM M9&MY>'A3-$EX0C1E<$8R9C!/$$[2D]5:'AB9U).04$X=F8X M049H=6"8C>$$[-D=1,4A">$553$5H>G)U4%%V861'.&XV M5G!D,&)X6&UU-WEH5DQI-EE/>4ME;U%+159A.39$3F)K,4UP4C110D=08TAC M661(1T5U328C>$$[:WEL,WDO4C!(>51#.3!84C6PT9S!I>$MA9W=A+R8C M>$$[6#9V1%-D;&)K1$U/4#=W:'0O:7)V:#1J,V\T23DS3C S;&9Y>$Q#67!T M2G-P25-25TXW94EQ5%9I3FET3W-R9CA%9DA(:5!E=D-&328C>$$[*U1V2C1I M:FE/:#9E26]35$1(.59G-&]7054X4GAO2VA61S-G365-.38X164U15=V;#-Y M+UIZ1V$P,'DP=#5M;#ED<$EO23!9>F-75"8C>$$[,4-654AN>&MC8W5T1U!I M8T)K5D52,TQ9+TQ(;'5/1EE).4IS,&A694-X3&)X0E%T2$A%2T9P4VMR-V8U M4CA4:#1J,W)W:G573C54."8C>$$[<7-!1S!A>$E"4F=$8E$W1TE5:E R97%$ M-U!H:GAN=EAH2&-M=5):3WA6,DMU>%8R2W5X5C)+=7A60S9B<3)L87!#."MM M6'-&.4)'-28C>$$[:657,FQ36D9K54%L0WE&9T=&4E594T-/84))2&MR:31G M33=7-&M5>G%O:V%(:T]94FE1$$[,$IO,#%312\V6EIQ>6A86F=(,R]!2DI#$$[>49H0DMO-4E69'E31F)O M464K659E4$%M=EA(=39H,E)),#)3231V,U4W1S5V:%!0;65H6GAE-E9P3W%1 M:#5O,6Q$:%-L>$=A4%)(128C>$$[:49*1BM)5611=V]E;WI!3WIT06)795@O M04,Y<&5G868Y43 R3FMG-71)4S=&,UIM-W,W5EIQ04)A:S%O34-5>7A6-71* M$$[<&IT-7)Q-'5I26)Y2S5T-$=31S0Y2U=2:&%R1DIB33A1 M6D94;DI)9&E#1U!X6596<#E.+TTV*VQJ4U,V83!H1GES>D$$[.#1Q='I:>$AB;VI)84-P86@R,D-Q;% K5VYM4%=,,D=B>D)R2')1=V]1 M,&%T2DMS:VI2;V=9=W-9-$4T.%AR>&HK3&YV,'A6:S)N+R8C>$$[04IF954W M4&A3=VEN.4UC67A/:75Q9T4X94LP-&=Q1'A"<%=M,DYQ:&9.+S5N955F2W-4 M$$[4FQU4$)+9DQK-"MB5E%X M.'IV,U!N=GHY*V(S;5AZ6$E903,V4#!L5S52,DU,2#1Q1W%M6CEI-3ET;#ES M,E=(5&E'+U8P,F\Q8W-U,R8C>$$[2TPP4'E&92M:.5DX=E%8165I5'E1D$R0D)!,B8C>$$[.#=P-DXU4CAU6'1J4&-A;G%15DPV-5)9:V=1.&A&17!, M8U,S-U1->'%C>&,K5U!#25$K:V(S,VQZ=$YH;GAN3&LR;$E!5C-!969E:R8C M>$$[<"]+:64R;3E84F1C;3!P-VEE*W5T5$U);G!D4S-H2FE,:&)H06]G0F]/ M27%E;TMS8358-'0X=S,K1%A),7I55R]+G5*,3@S,R8C>$$[9C%M-&IJ M:3E2=G)8=TQ(1WE$:7E88V-V=W,O3E$P:$9D,T1N9DAX4C-,-%(W+W@X,%@U M9B],3R\P5%4OE=C9R8C>$$[=59$96]W86Y+3S9J1'1T M4W-Y>4PO:VIE;VQK'@P96%':R]+5RMM4U=+-3AZ6&LY=F14:2]U-&%. M17)8$$[34E73TIU6' Q3$)I8U!I*U1(=U0Q2VA. M*U,W>7=W5S!N;4LX:W,W9')*;TQE4C=I4EEX85)C2E)(>G5$-F9R4%(O:'!X M-D1B1#0S:R8C>$$[=F61I$$[$$[-G-L=7,Q M,F]12T=E='5Z3U9:,D1T>6A98W@V;D5/04=!04%)-VYX:79G>%(S:W(X<"], M,VQ$5DI.4S V-G9*-35,9')6;'579TMC1R8C>$$[:U=1:T-/2TDX<6]/.5!B M0E!+6D-I;DAH151A>E9F2BMS5SDO8UA/:FE'93%U<$1-.7!+-6EA3U)Z5GEJ M55E&4V0V2'!M4C1U4$I%0R8C>$$[9&E1,G-B,DA$.$A,:6M4:G%56D#-$,FE4,GE!:W$$[,U!5=6\W4S!U<7EK4VM"=VIP2&5V,7-,,&YZ5C5L,$=1 M:E1R,E31)6D]9=#%U1%9:8TIQ2DDX=B8C M>$$[,DTP,'8X*W18:$-R<65N43-11WAK:%IO5RM:0CE25"M'82]*,EI(*T4P M-V9&,C-,*TM)4'5:2F$O;C$U4FM59E=B83AT,S$$[+V5R,2]W M0T9Z1VPR9$UC:4A.:#)X:5!/=VI&+T\W.'9Y=%=U<&M0.')14U8O045:5V1$ M;#=M,&1Q64\O-T-H-5!Z,3AM33-P5V-D,R8C>$$[8S-$,4530TE+0W=',5-Z M0V$$[0F]1$$[,E!E-G).&A5.2M55=43$=(37--3VYN:S5"-V0U1R\U>"8C M>$$[*S!84VUJ=F9-8G)Q=#AV>$QA<40Y5E$K-%E"<&8Y;%%E,F$W3'%Z3&%/ M>G5D4#)F1T\X='HY:C%P15)%5D552VEG2W%Q2T%!8D%!1"8C>$$[34XR1&5+ M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+ M=7A6,DMU>%9+9&$X<&57.6%"+U-E;GA81"8C>$$[:U4Y86Y#5VXO1U)/3"]J M;#)04$](,&QO>F%82&LK<4E,0CE5+TEB44HR3&%F9C-&;50K>DE&;E%F269U M,BLY$$[:31Z.4I)*S%J1C,O04TT+RM99U0Y5C%+ M>FM(67DK#)L1'%#-'-U>%HY2D0X9DY,2"])8GIY96I79B]! M0T]B+VUJ2B8C>$$[9GEH:C@R03=(>F0X9G@X15)P=C5#*V1OF$S.'=W17=81R8C M>$$[:UA,,TLP0F%"5FMI8SE+C4O2C(P9%AK M07%73UA(-5519F-B*SE.9$4O3%12-5I$<79M3W=H=DY7:R8C>$$[8FMS56@Y M5TM&04%&5&E4-F)K06)K:C59-3E4'E.*S=O M07IA2T=+1TY9;U573TI"4DDP05910C)!1R8C>$$[=WI#=#)+-T9867$W1EA9 M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9 M<3=&6%EQ-T9867$W1EA9<28C>$$[-T9732MA.40X,&%J9E=4-DYQ:# R0E5: M3'%13W=:1T5S57%32D1X94]9,&E:0W)K0VID>%5:3TUG3V)#44HU35DQ6'ET M*V1/;T$$[8GI*6E)7;'A!<&E3,U8W9#1B:&U6<$934DEI-6I18VQ1 MDA)975Z2V9*5VQE8F1-:'9O4$U';W)Q2T=C="8C M>$$[<#!G8FY)%8R2W5X5C)+=7A6+R\Y:ST\+WAM<$=);6&UP.E1H=6UB;F%I;',^"B @(" @(" @(#QP9&8Z4')O M9'5C97(^061O8F4@4$1&(&QI8G)A&UL.FQA M;F<](G@M9&5F875L="(^17%U:6QL:75M(%1!('-L:61E,CPO3Y43X*(" @(" @(" @/'AM<%109SI( M87-6:7-I8FQE3W9E&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S M951Y<&4](E)E4=O M=&AI8SPO7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @ M(" \4=O M=&AI8RU";VQD/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @ M/'-T1FYT.F9O;G1&86UI;'D^0V5N='5R>2!';W1H:6,\+W-T1FYT.F9O;G1& M86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD M/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O M;G14>7!E/D]P96X@5'EP93PO7!E/"]S=$9N=#IF;VYT5'EP93X*(" @ M(" @(" @(" @(" @(" @/'-T1FYT.G9E&UP5%!G.D9O M;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @ M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \&UP5%!G.E-W871C:$=R;W5P&UP1SIG&UP1SIG&UP1SIG&UP5%!G.E-W871C:$=R;W5P&UP+F1I9#HU.#$Y9#DR,2UD9#!F+3AF-#DM.3,P8RUF M.#$U,C1A,#!D868\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!- M33I);G-T86YC94E$/GAM<"YI:60Z-3@Q.60Y,C$M9&0P9BTX9C0Y+3DS,&,M M9C@Q-3(T83 P9&%F/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP M34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z1C8P-3-!0S-#,$(W13@Q M,3@X0C)#.#8S.39&-D8W.$8\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X* M(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U- M.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @ M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@&UP34TZ2&ES=&]R M>3X*(" @(" @(" @/'AM<$U-.D1E&UP M+FEI9#HQ9#5D930T-"UF93,T+3EE-#$M83)F."UD-F0V,F$U-SDU8F,\+W-T M4F5F.FEN'1E;G-IF4^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I7!E(%1Y<&]G'1E;G-I'1E;G-I'1E;G-I'1E M;G-I7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @ M(#Q%>'1E;G-I'1E M;G-I3Y#96YT=7)Y1V]T:&EC/"]%>'1E;G-I M'1E;G-I MF4^,C0V-C(\+T5X=&5N3PO M17AT96YS:7-&;VYT4V5N3X*(" @(" @(" @(" @(" @(" @ M/$5X=&5N'1E;G-I'1E;G-I M'1E;G-I'1E;G-I'1E;G-I4=O=&AI8SPO17AT M96YS:7-&;VYT4V5N'1E;G-I MF4^"B @(" @(" @(" @(" @(" @ M(#Q%>'1E;G-I7!E(%1Y<&]G'1E;G-I'1E M;G-I'1E;G-I'1E;G-I#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME M="!E;F0](G--/&FGC33QIIXTT\::>--/&FG MC33QIIXTU%Y]72S]HYWZBNNG\&[G=N+=&J=SYNBKD5/54IK#?'?4ND4WEJI! M88;C6;'OA6NFMLK[&J/*P^28#'Y3,C:;Q;9#TS'4GR:5[M.*W!+%.\G=:5>R ME>"6PSIVG3ZF$7#Z^0V;XWV.L/ZXFR%7!R7,;D;&/M0V*D<782NXLR7+<%)( MI1/#+^&IG[GX?!B5&[$#8Y9ZOU]SZ)>MU#@LK?I7MSUVR=$K?&.916 FD52] M]HZSU:UM=Z97G;M,AKM#J"I6%*1 ?8_X&$1/4JQ(>2(U:Z[ZGVU>LF8OS&-: M^,K)!):L*22.**M B*2&E[06."$L5=_P V%NO?4)Z[ZL^O-AZS[8^J MH7-+\1U2F2MC1)X?; MS)-6B[2I/ )9>)6::!HF$C*^X.PV(UX+BPW.X8;*>LON!;ZE]*VZ^]?6CFG46@:GV@ M[JG3-6\2;=M5%74^E[\DH #O16QT2*S*LKJ*):\N.Q9=]QZV(SMB#HRQU'> M9[KK'F,C&CN(^Y EVV:-99!&_;1H$@C5^V_ -RXOML<,VSZM'M+28NUB63Z> MJ]4_X?Z_4WVLN(,_M57)%:#B=E"L))(5A;1\I_9%ZYK/66(Z2A*D[@%GI SG M)LJ[^,7Q62ZBZ;QTWM#'FV9+=V7&Q$8Y^3VXR@#(ON=O;;2*6F=D9=UVC/)N M%A/UMF:XR"R]+HDN.Q<&:L*WA=8ZT:2(_%V,RA4$OM[ M"_6ZK_)>CV.E4#@TG10.7TWFMOZYO8>I \]ND172*DHOL5&Y-3-:=;8ND72L M4YZM9/A6%@IBW=O)_BRY@4REUGT4>DGLP1RS7.PUB6>.KVZS3Q;02/#WK4O< MC]O%)*A5"$E;CO(RA1L8Y3U"CI6YJ]7&^[6E7ISWN[=6K8WN01V17HUQ!/[N MQ#7E5Y TD"&3\%7+'?5[^RGU,.IQTCVJ>>K?KN9T3FWK7R++GJW<'W3T_-FE M/MMOY"-TU2-S[G;:L.3+VQYW6++6;1=8&SRFYBEW)KZ;1NVBAT)HT,#7[V.3 M(7EAGOVN-:HE=IUEBBM&NQGG61%A6>2.2.+BDWC9WXJ?%QENKKHKYJ3#8LVJ MF(H]R[D9;D=1X)YZ(N(*M1X9&LM4AEAFL"22OL>44?.0 '!G&/>_K?.+$51V M:OK7L;W^:C>A'K53N;V#J%30\_O_ +$7WUG9^PO8NA&GS6\-6GC$RM6HT^]F;\LZ5I7G@HPWUHU8 HGVL&1Q MM G"#C]3-(02Q\VAU)>J2M7=+V5R9K]-8B"I+<@BK6LK9Q#Y2_:9C5#4EBB; ME:D+VC)LJI"NR@<+V'^H][FVM0;QZB^MZWBOJ7K"^D7^Q2MXOM+B_) ML]F?H*]9-.0Y@7UBT4I((E,L!"XELGJUK/>L4 35-O7#)J."Q4;"U->:U4DP M^1R*ZW:2.9RPC!"/)&J!RCKO_ &'7_[!KD5NWP[HKFWW?%HQ;-P[/;Y?A]P_FU>)ZA0R MY1:L6.[E!LH,3[M;@-SO=WVYMC'"N2:"S@H93:$W;_%, V*:M+VA^HA[,=1X ML8Z];^)MJ!Q;JWL]SOU:XY[6#=;01= 96;7V/0\RMUN XUO5I"EM#LL]>OE& MKC>2WDVC)LBYN?4@%ILTJVIC\'CZ]M4OVUFM5\?/D;..-9^RL9H/8BC:WW # M-&'AF=>T(^(91*6 #6^8ZIR]S'M)B<>];'W/Z=S]@.^27LZE4UK>P^8TM) M3>7K4[&^W>[WLE#:YU*Y3FQUY>K6+:RV9V!HUU$$T@P//-KX&.QT5N&W;M6O M9TJ79665838E>6PS+###"'BY,W!V9C(JHJ[G?<#67YG,SX^QC\?0HC(Y/)FR MU>![(IUXX*:(]FQ8LF*5W"KML2(C^0>['L9>^P@XOZSM:>R6+ MWI]QAT_">?=#IS4=!0O2#U80[V[C6V^] =#]/KUS[6S,0+\I6E$D-L;)-9=6 MD6=(%@^36<31AJGLM4>./#XLO=F@E!>;+Y%^U:V$ZFN\510YYK+M&K1\?)8X M/0ZARUF\ONDR$>$>-JVJ[B.KT[A8C/0\U9!2>H\XE53&CPRI+J].<_5O==AH7/5',?6DBR^TO2NV=)XC7>/2 M]4#5\O(WY+2U'1+MU@?N9M+CU.Y2#3+"A."+&H'^4,7['_%8*]@J#<_:C/TT MM6:=K%_MX^"I7N/9]L6L 696@AK&F)3QLM*CJ09NVJKW"^QXZN*W6\EZM5CI MX@S9FWD+>.BH&ZJ4S[*NEJQ=&2-?ZJ2UY8V5A5[SROV!%N"^K9M7U>.JT_C= M[Z-8O3<2LV#G'N1-Z+CUT'E9JNH4TVT.P>?U!X MV1XKYS%DJ:6U_2_V"4XE6/IFO+:A@CRAD2?%C*QE*1-B2-YFC2&*L;(:681J M9I45^:JK+&DNP8T9NN;L%"S;EP*Q2U,\6FR05VFD6 MK!))'VF=HVGEKEC&OI[-_6C!X-UR[TE.Q/WB0*32#B8YHV/Z4-RM%8DN-"+;S+3 MXU'E0I%(T0FMN98S5CDD4A1PE8+N[ ;%E^OQC;UFG#C%M''159,EROI#*)+ M,*3FMCHEKS"]-##('T\]6V9H+S^UO4%I?-ZC;1"HK+410L??- MA)AHJ^,BR,UIG)MO7F@A@,L41BG,3QRV4F';F:-3/&CQHLL17A+RUZL/4T]S M.6<)6H+"JX^.Y6N6;8@FL+8J+/#/!1DK$S54F<5IY(IY9()E(EKJOG5U_3Q3 M>^B:K]2C][&-=8/B+XXGY]LB=K'.^$\EMN\K*:39:H T&2E"2UN2FPZSCQ1U M'"B":I4MX.]52T\XV&:2M]SB0(($$_-&3ZQ'$%'U,=W!$G=.Q/=Y$2RH485N MEDZE2&X.I&B:4V9#5[--/&FGC33QIIXTT\::>--/&FGC33QIIXTT\::>--/&FGC33QIIXTT\:: M>--:8^Z7$ND=ZJO.*I1ZORRUJZMU.E]8<@=.Z)?.>B[6'EED2V^@1C2T:@7N M5ZJW?KY)K$I91JH9H!0=(")LS3_@]7%6X*4L\LLMB)I*\M9&KP0SGA81HIMQ M-/ $;@VR,I8@D^!L->!U!CK>3AJ05X:4Z0W*]V1;EJS5'=IRQSU0#6K63(AE M4F5'X A5 )W.VOOL3POW1]H>=9YKU+E_J#_%B6.NW6M6"H^QGL;3KO1KW4#] M6=5O%'MJ+A@K:N6FOG8S,N9"2Y_V2D"%0DA%$C2WM&YBL?/WZ]G)\C')#(DN M/HRPS0RKQDAFB>Z4DCE)>R@=7O/O)[ M=V/ME6ZO6(A!JO?:/T,OC7[5(=5P(* %7!50E*; F28BU9?[QVQ-X,QC4M"U M$]B':N]4UH2)5"H(52/;D&1N;WT=4YE5K(MX[TB M3E/8&?=Z[:>I^Z/M1T.WD],94ZQT;1RPXJK3>.OB<=!$*ZRI-Q"QW1NS/&O-W+NRC@6XA0) MUZ=SHAIPRK0MFE>?)13W<_FK^RI%,_;BB6.)'/<""AT9!SO"P7V([[!8B*S7V*]I",58,>ON9YB&)*[3# M@C\.NQT))L><1_L9SK37)XY RF3$IAB=' ,OW9N2Q08>J&\_MS0>=Q6#8^DWXM@H9&D_M_XFW;3AO\ EV_B M=2V\#FKIS!GIX7?.5:E.\4RN34FO3$HBCA_^&'M;B:3N%=RY;<[;#:UKEZ'> MU]K[(?VQ2EY!RU]92J&=T6L<7]W_ &ZY30^J,.9A JJ0PZ!7*?QI;ED>C3*U MB6,Q4=[2[[]-?V,]B;9U>T6ZI\5JX?=UB$/M5%YE[G^TU#YQU-G5EH::MVB MZTM1PS"IQ8U"E:K7QDR:: 'P+ =W"UD3!^?:K3SM&C'6CBEM2&FSFI-8Q..F MGKK(Q=XXI6N\E1F9FV_,I8\64';5#)])97*S79IXXKD;ZN*[?3Z]CKN!>=)>;>M-6LMT[FA]C!.B47V MH]CJET.@=3K%$4\S1-N=6A7P*,BN+@*,I_Q[5')$P5SA,&7[(\TDT&XTD.:H MPF+^T7Y(XJ;T3!-C:,L$U>29K#K/&U[:1C,W/GX8$#8@;[U;'3&6L+9WJ8F& M6QD8\JMJMFGL=S,BN'*^ M>>N=C;5SV5)]M?YZ^^V7LM=[#8.WE]&CT!C>$.,H0HE03BQVXT2Z%0F0*"P&Y50#Y\ZA4 MZ7RM,Q,E7%2O%EVSG4"(L51FV$C,P\; 5GG/HQ[ M;\FZ_-UGGZKD=:7;W.W=%$XDK]X/;H'UY6WN^[L2+=9 N2!\:'0[;.SW#9G, MA-V,J8S%D22#7Q=OQ:Q2SY?&V:HK3/9D/9BKFVV'QANF&#B(HS9-PO\ 0%5> M8VD*J 7.JE3IS-TKYO54HPJ;$]L8].H9:*T1'^(SNYB;E KL2D M2^-K!%^F7[!!=#KE[$IG$8$]+[V'[+T7CN/<[VGDX31^P#V ^V&66J\JFX;+ M7%F&MG9GO2@L12CKS3#8Z]JD"8LA#*QS])H'A,ULM+3-":U]TX[WDU4H(Q') M9%WN-QC4(#N"P [G,JI%L.D,HMJ&R(,>(Z^37+UJ'W]F3C:]\2M.TT-(XXQ) MSF=I"NQ5&9NUVP[AL^^QWK![I>S)W-[%:ZKZXT._R7,NBU MD6WKQE-S0AV5'P?\N]>N"X!<-8%9$$NA6%P,L,@Q ^DOEE1R&*H+/''+?FAL MJ@GKVL;0L02&)BT3F-[NW22C(R_=6.[9..5EK)VC<,7;4.Q,?#B2? \Z#I+)5XXHHZ>+ M AARL,;G.YKO@9EXY+TGN!0$YGN6.8G/T3.9C):,35$HFE]T8XT#5CD,J1>V-WB.$Q,JN"'5R=F"_3J5>D< MJM1:RQ4!.M^3*+E!U!F1E1>EA%:6Q[T8[D3)658)$*F)XP.2%P&U?-L]$O;B MXPB%_;H& ETGQUEOQAH])77%>T,6/Z] M/KM7)5VPX@*@&($# U*+,8V*>U,KV2ER-(K%0X?&"DZ1%3$/;+<5 T3*&1_S M[[EF8D[W$_3>HLX"N>JWFX?P'O7[>+W/3)NV_QFO4*[U-M_HQ- M-T6O6R!*L&-Q;-6CZ&(>;<)\,2R;3GUUZAIK9%LRV'E6&O%%SPV,9*_M.7MW MKK[P=AXN;%>UQ3<^4(50+-^CX]R,]IKSO%WI_%/>#V]Y70.F2 M[[V&*C19Q5]Q!C^HL[ M3JW#21(JK68H:*EVABCCB#(\99$ 81HK)W%B"C9%0;#4N_F,ZSC3QIIX MTT\::>--/&FGC33QIIXTT\::>--/&FGC33QIIXTT\::>--/&FGC33QIIXTT\ M::>--/&FGC33QIIXTT\::MVNW"I6_P#G?\3M%>L_^,6)G3[+_CSI:Y_QZVI/ MP?S-7>?QQ)/\585/[(W\FE/_ ,@?V(?VAHORZ?*H\4L7#N1R1]R-98^:,G. M)]^$B<@.4;;'BZ[JVQV)VU2BG@G[G8FBF[,KP3=J1).U/'MW(9.!/"5-QSC; M9UW'(#<:Y-BL=?J"-I9K6\45FMI Y6#E^_9!ITJD"#'WF-9,V$PX0(D./[E( M)GBBTQ_>V^/(1QO*ZQQ(TDCD*B(I9V8_ 55!)/\ #4998H(WFGDCABC4O)+ M*ZQQHH^6=V(55'ZDD#59\DU4UB6@=\X9U>P6JI\N[+ROH]IHL^PMTK=%Z!5+ M8]J9&A4H.\5C4H6IYZ;;0\<@#?#" ?X'C$A;9P4//%'"G?IVYJQXV(JUF&>2 \BNTJ1 MNS1[,K+]0'U*5^01JZ;KT.A\W 6->@7<I:Z?+*LH/M#I>C$9V-SF7"I&"0 MQ('B*:'X'(W&"AVWGDB&)FQI^$>;?2G%!-.66&*25D1I&$:,Y6--N3D*"0J[ MCJ3) M%2YX[?5]X>D2:1<\EU?JLQWR66ML;C'%3=\%?&S2[U%.WM.D:7)N^U<5,G>- M#S/]#?@CN+%O+X_#'==8]WV_$94_,P!C[FN17(GAVMD" MJ>ZFUDF%[ $!Y?C$P1R3 1\OPD>3\BDBH5ZQUZW)5]DJCY-9ZZVAV(5OJ^S" M>33$D>^GR^6NV,2NCQ.4D1HW7PR.I1U/S ML58 CP=_(U-%-%/&DT$L--/&FGC33QIIXTT\::>--/&FGC33QIIXTT\::>--/&FGC33QIIXTT\: M:>--/&FGC33QIIXTT\::>--/&FGC33QIIXTT\::X;'^0_CSOXG]/#7],K^,R MQ_-E?AA^#?\ 2_>P-]B,A_L_C_9_7_YOP_/\7^_X^17CR'+?CN.7';EQW\[; M^-]OC?QO\ZE;EQ;AQY\3PY;\>6WT\MO/'?;?;SM\>=0Q4OZ7_8.;4ZT5=;[ MH^FK>@7OG?;.I4_H%895.H=4Z^I$NZ_J6+E+S0Y.W-JG2Y;/4[:40QR[=?Y7 MRFG1V#2R)"&(6,JFZ@JV)8Y&I/7:&&:G7EAD666O58Q-7[0L!E$E?MRQ@+Q3 MMV92G;<*VL!K]'WJD$T*9..XEJQ5R%R"S"\$%V\BV4N^X--HY&AN&:"=BQD? MOTJXE$L9=3<76?IO]5ZP+>Z>WZW3A>8W.HC&15:,+HAO\5T>/UXYMP#1*/\ MSER=23\M4YY[_J2IPS8-+9):6LD+,@J2,ET=)6SM:L894JRF>*4@R%H%Y0>] ML7>?T1)M8?O]A^(6,1H"H'A!5N])W;JV8)+T IV( P@XVF"6ONJIC!&.[8DW MI(:ONT#L\QFZO[#W.Y=PLMTK/71KZHKZ\)CNL/"2WJ[- M+0KG=Q1IX=MK#RZO% <]Y\XF?6/"RNP'1I1ZJD+"JBNUOY>&U6I114XX9*Q@ M9V*\E9X85C8+NY^BPX:>90D?)R.9E<&5K_%=.V:%[*6+&1FL17A:2-5;@RQV M;#S(9 (Q^+2B*U:LAEEX1!A&L$;+ F&JS]/+V DAYQ3+]WZE3\;X\BX1SU'S M*B4LBL5^_4GD/2N>6EFUN _RD;5AO;J51BZR\I".S.J,];7)\W9:Z+(UZ*"Z MDS=+^T2PTIO=6I+D[V)YA*\,MFO/&JQ^ LBQ2S"1)GC29%B15^KDYL8>E\F? M:5[.3@-"A%C:L5.M 88K->C;JS.\X\R1/8KUFADKQS25I'GD=_H"Q#',_P!) MZ\6:TA2=%ZA0;2F5-H6\V9X>D&6+I#<,'O($G4>@CO;WA*1*S0*:KE!(2WXNY^ MH.\EF>BK$TRFU!CCBVON M?HU>&/JU7N+43OU@J?0N=).#2\2M)=?J150X?=>.UI=4GC>AKTM8KUW/5]+0 MR6U=:1;Y=+D= -:SQJZ97EWV78\V'+PKD7MSTDE@G>X+<:O(LMR*U(TJ+,6D M>%6@?M-&88HE)C!<.WU:]JQTY9;#1X^MDY8;56/&G'S-% 8,=8H1)#(]98X8 MK#);C[ZS"S8L,!,PB:)/HUK_ -'^EM?VURN>W,/8-Y1.:$>OLG%N55<5 MS->!ZZYX*AJ4,Z==HT8T*)KC/7C!QK0IAUOY&[6"L;V$!/; +ROU%"D47N*, M4EK5#B_N^ ME"K,C5$7%?=D<(,:!WKA_P"W$"9 +1[@A,J1S)4;M].?N.]@[0?R3M-.H%;O MSYB/2:F:!>&8E1J-JX-U?A3^3=D$\6MOWZR!>J59.?U?)C) D:\\(#6LZ^CL MR93S^6+.5.%46:DD\D*+W9 8E,LD=RM<3Z65EVD:*:.>0!6=)@2KNCO-/8Z5 MR/>R#T6K#R>*-ZA5'BCFC2KM!P/ MU0Z3R/HO8+,;W.P0U"\==7]'252N"H&I3A; K;KFE=Z'8NB52UO\HVO[:4D5 M/2FU?95HM%(+7K@%23D] J?GW*U+:@FE[;[QE4KO$\ M+1%8K K,E6'>[SQ]9)IXTT\::>--/&FGC33QIIXTT\::>--/&FGC33QIIXTT M\::>--/&FGC33QIIXTT\::>--/&FGC33QIIXTT\::>--:.D] [#6KGTP%;I> M6Z:3H26+2Z63C73+A7JG6V*OJ<^ZZKBME8 MM30998=;40]]80U9(J['LHX@;>)+5>)Y)%:#ZI)I&D2+FDDKA)HTD#QO&I9. MV$QXVKT,]M5%AXS:C L2T+<\4,+)&"%I:\TD+1SPS.$E[QDM MRN=1]EH69YUEI[FIBO0Z,86P9=% MWJ_'9.F,NVUD,KAE7:-S.64=_8[7)VB1:LWL<5Z75ZEVULIG2:Y@)KB=DHBI MKUH;:P;F$RV5(%V:?"#N6A76I(1;D5!8E2./VO)N!A:26)&Y_#L&,J*(S$5Y M.VJIDM&&A[M\C"K8Z%W:G7EFF]_P3NBRL5>>1#'X,4;H*\KM,MA6*1+K&+[V M.]D^>\^&:])7T:L77_!+V^$KTO*;W:27EFH@=17QUV?-4Z'H.I L5AK>R;.\*ZPIK*@$1JSLHSLQUP[J\2SG,"J]H4Z>.>Y$7515NF?S51,>,X&]6 MD2K,%*HF6<:+2] L6_MJ"Q-(TC$JL90);K\IRT+LVT7::2#A*$4K)R;9MOS MG5X+N6>RL*0HJN\HD:3'70E4)9BC0&T M2FNK->S5>62M!).G;F>&-ID M"LH24H#(H5R64!MP%8E@-@23YUHI]0FFVRX[^L4M2L_5J/-3>P]!MKNY<@Y+ M8.N6I(D/]8.]\RBA@2@<>[37(-7UGZ564!N;/5X]L(63UI7C!G26$X'V,)+' M%]X=V.O,):L,216;*5HW<9&E8W+FU4<\(Z\CKVY/SJBN"CD''.J()YSAS!-= MK&O?M3R6*-&6]-'&V'R=, 1+1R$0[DUR*)N]"/PGE>)A)&&6,ZK&>YM.J-6H MB)_[0UY;4_7NK<_",JG#_9**NKU%>]/T'-Q>>U:C-O6'[@=96^TH!73HNS%V M6$4WGFFU9B=*MF(:RL^](,5+)),Z8^1I;DDS"2Y0+L[Y1YS8DF7(>:[8YA7] MJ(]UG^LH_$M)B,+9^O7@K1RYB)8,7#55H<=ENTD<6"BJK5AK/AQQNKF4:V+[ M2@-4WA$J%U2&Z@:[T5MZS^XU=Z/3>YW'K?LQU+&=6;A="ZOR(LZ:R$\YY33>!>T M\*?DM6;]+HUE"XO_ )SCUP0O1N:-=ZT\NEH34"=2EJS6VEK*TENJBOZ5FVW0 MDHRE([XD,;S!GD6,-(T+2&2*R,&5KB M2;&UKM$L96J4J^,S(CI0O;KS+C_G>N'M72&=SYS%UAX\8 \QN['D-DWY&V&Y;)7Z MO.&-6Z$(UF',72&;N--NGM+9HL1M4$<-!&6NZM))>QTJQ3^V1%:Q"+48LJ; M>3K8ZC!R#36Y)9D=N^HG'7'80UO]D<,CN6TL$PFQ<.]L+ PTL*7M2)S94%,,KO M#^?CX-YV%=Q((UBLQK*/93E>HYE^-]<^62]2>V>R=!C02P6EMC;5@3B.2$(O6/;I''#SWC M6*:.>/CQ'E9(F9-F.[\01V^7;*J5XC8N#:RV*IFY)-+:[9$SSUIJLO(.VRO# M81)=XUVC[C@F;CWN3A^1S$^OM%JS>O5^SW2IUQ];BMP:HD?6-.H;V<[3,>NX M=>6L#!S'16F98L;CK829M M#Y8@>-7\EFO"\44UB&*6=BL$>44C$!@DLP\N8"8)AYL1R;?BGAEAW^,D>^N)65D)5U96 M&VZL"I&XW&X.Q&X((_@=]3I(DJAXW21&WV=&#J=B5.S*2#L00=CX((/D:J/D MNI]4M*\2V-="XKSA6^4D2%PCM$K 1HNGF ,G7G10F@S3C2R!'BE EZ:2[;#F M#3C38TFADTUF='1BKJR,-B5=2K , P)! /E2"/W!!'@ZDCDCE4/$Z2(2P#QL MKJ2K%6 9202K JWGPP(/D'5%EZ!0X+@/SR:[5&&_F+]VPE&ELB:.X%*H]9-Y M&8]9W-PZG7Z:0R[[F1!;#:ZQ2;9DQC3;.)^S,8C.(I3"&XF;MOV@W_A,FW - MY'C??5,VJPG%4V(!:9>:UC+&)V0;_6(>7<*^#]07;P?.J\U:JT*MD\>,EZ9* MF7F-7#AJ8.N5JE:X>0Q@R9,#)(1 5X(D,Q1AA4T0XH\4D\\FD6FVV)%5G941 M6=W8*JJ"S,S'9551N69B0 "23L-57=(D>21UCCC5GDD=@B(B LSNS$*JJH+ M,S$ $D@#5&"O-)9U_>V+KA5F%6CV^$EE"L"DNOZ;_EC@^&[F N1=KM^>:&' MX[$XS^66./[?/?7&9C#*K]MHI!)\]LHP?XW_ "D9 Q3Y('S\D#5;%:+#BF8(3$$PU*5"$X$%+'(*4F$@B-!Q&8\4F\ MH!4ZP\%C# 5I%+*":(7IIL.1#)O(58!25(# E200& )4E2?! 8%21^H(^0=5 M Z,7565FC(610P)1BJN%< [J2C*P!V)5E;X(.N=Y#4VGC33QIIXTT\::>--/ M&FGC33QIIXTT\::>--/&FGC33QIIXTT\::>--/&FGC33QIK6SV=MW2JC5:?/ MS 2Q&M6EV)">0U.!)(^Q65O.>A6LR4"2P4SH0$.T3&MJMY(H*<]P5E$(C,G92K:F8J98+*CZXDW @DD<;Q1*9736$HO9OJ>CX:H.*<++.N M<A(<[M;CRA*PM2I,[,>'14/HT]R<+ZQJP1*"8E4(F5UQ_R YC) M1;HT*_#NK*0&6PRI*KD+QBLLL;,BH#- (E:39V!8GE%P"B;S_O>YW%@> $J] M-'E@>(%R\]*-ID20RM[:T;#K#RC1@@'&?NLYK?>G^V-_LZ,0]U3:?SF$S\9, M]MN3W8BFH6>R*)U+RUS)6#GA(O1HBI]4VL3)^U MW#3D,)D*V@2(]I&B;8,[0)*(ZLG@_KW1%]H8QWM;3\*Q^B/!:O<;DED6<_YD MC%9WW:O6)^80G@;9=SQ5E;3AG.;+7%YK.W5[\80Y^^P[HM:!HQV6EY&!#)%$ M_*>PY6(2(@#\> +M*5[>/C6J1J]KMRRDH) M.X5A6N).]$C//%](8D29>Y9V7H]YL*K6SJB"*15"C>4RH_M*MH]WG'& O*>6#CQ M#!H Q.\K1P[.>>?KU]/&FGC36E/LO[O\Z]>#LU6)>3>NA9'B)FK*TZ)>$EA) MCUE%WL3K> W]"* <=N-M&03$$,4&01IWU&]9NG^@9ONQ8),WGS&L MCXVO,L$--)%#1-D+C)-V'E0B2*O'#/.T962188I8I'Q#J'K&A@7]L(VNW^(8 MUHW$:0JP!4SS%7X%E(945'Z.27&LNU?LI< M382#.W^Z6/1B!*&PECU_O$&VZS27;^LDPX_OS4-#[45OW2_>?2=YQ49A)&Y@L,)47]2!)&4D('P MN\8/_B&I6N3=;HW:Z:#>: VPS3E[[C$0S:8'9IV4.D>Y2AR#\]]@F(N)8]MX M_G)#-#+ 8'.2$0.3+T]TOU5A>L<1!FL%:]S4E)CD1U[=FI80*9:EN'=C#8B# M*67=D=&26%Y(9(Y&V9C,I2R]1+E&7N0N2K CC)%(-N44J?*2+N-QN000R,R, MK')7F1:]#3QIJ/WI7K9T<_V/MW54'./6CLM2ZI7^/5M_)W\E_':^0BO6! M'^GJ@'FM^4W=*XP[VLJZLF6+EFR3H$)#\BP.86$,"GVJ]^!:,=9Y\A5DKO:= M!2"=JR;"(H[[&>%HF7AVVD"6.<)"!$V);&+>)MMEIKL53$WX+L5"*4Y-I1/0 M6E+(Y]JBU+*6(Y.YWDB:6GV[0,C22!P(]7Z-].?V1H[M"/7/8QO4:7"I->-U M2?K?:' 8'8)1?<;"VY(J8TE#K4E;6-NN>MSN:@_L):8[-X\7LUKLTJY9/8/0 MESE&5'[E%99>2HK-5J*6J@XLM$\J@R"1EK7U$^SS*+0 DV9@GCU^E1J!YQ$HAEX,7H+[CM*[.,;[ M LZ/.K1],-HM1K?M9[1W576NH,JIPA50;FXZ/9@$5UO"8FY<_P"D]!?4:TJ3 MZK3F-YU7(%=KR>^;3S',XM9-Q268,\"S2R8['PM)6$EQIHD@C9XH7$%)8 MW$DRP\I'CXHNI1TUGGB(;*/7*16VK019K,6$BN-!CDJV)+IZ53%F[V< P?V([Y4I.;#LVO36!- M?5<245W7E/8Q[,3;4#=M9.D-4S1&8%_' KW(]3IAXEG=R5*S5DCAC:"5N 93 M1I2B?BM=0[7&?W-4QB)U6.!65P02RF253Z.,PF4I7H9K,Z6X$[I5AE,G :BN M]QC$F.CB]E?$QGCD>:V\;Q,.*K((*[+CKH_HU[-,>JW5KRVX\3J5>MO8;_VR M;LK)6E;=T+)N%&'K:SFS &Q\)N;5''3MAI*A1NO\Q[KSRRT_FK259'2G;10! M//7@R^/6M$MB*W))'5AJ"JK.M,"*8NTX:.["K]W?NS5;%.>.6PH;O*K,-6MO MIW+M=L/3GQ\$4U^SD3?=(WR+&>L(5J.LN.L/'V./8K7ZF2JRP5'*>VD>-"<4 M=N^FY[:=&K]KH*;M(IU7M'+;13-W]Q]F_9N2346P^D%UX+OS-_RK10]HEWJQ M7LM8!_8MKU6S-"+\;$U;5TBM%1)E<#&YJ9W&P/%,]0K)'8CEX18^A\IEX;ON M$LETFAD^[T-!:\:B$<5D$@+-M8Y'I/.6XIZT>0#PS4YX.[8S&8WXR]/6,;[. M6D(Y:UB Y:095[DTC66#O$82(T#[G_)^UW'V986&D1, MFUWE95_N)I U:/GNW0-F%U16:G(-H-MA$3;"F>PY(<2DL&4TS,CR[&8[EBI; M2%?J3%5AXO34&0"*#C$\ M++XS=,Y\PX\_?#+<,]JUF):ER:@L]N>6J(+<6U*V+/LZ55:<56S'%&Z;LJK)LNZKT'JZ^F7OH?L;=N MSUA=S?EU\H=;H!JGGU.MH?*].C7*0YPYJM6KJFO6(V3!%Q599)&>Q.3XNZ>&ST=WW,V2$8EI MW4EX7;5U:]BUE;%^%*E.S6BJLE6"=:7N['*22""&.*I553RE#@TDC@ACFFR3 M-'%'I*1MII%M/)IIC7>;:.+&L<>9=L9WSI'KC33.WQTQC7&,>8^=B3L-AOX' MSL/VW_AK,!N 3N0!N? W/[[#P-_X>-?7R&HZ>--/&FGC33QIIXTT\::>--/ M&FGC33QIIXTT\::>--/&FGC33QIIXTT\::IK1,G=PC#NE2UN.&R6.0X&@(K" M$5PD.@:)FHT1<4ND#)0S%%8K#HM=2@#AH"Q98B(8Y-9E9D)*LRDJRDJ2I*N" MK*=MMU9258?!!(/@ZD>..0 2(D@5TD4.H8+)&P>-P&! >-U5T8>58!E((!U4 MO)=3Z>--16]S]Y>E,NCVKDGJY7:B=M06&Z*_];OW\@76%MDA^^#JU54RJ8>= MLU4R:[#'GE23A1&QSC;+]1L"LR]Q8WHKI3IW!8SJ/U&O942YR'WF#Z5P*UUR MEF@3M'D+G#,^IO7_675>;Z-]&,5@6K]+6 M3CNJNONJVN/@J674;SX;#4J)$^1R-38K8E;NUXI@TUAND/2[U#LKBNELCU!TCU W)ZU'/>TRE#)QQ@O+%4FAD@E2XL8:3A+. MH94/;AD D=,:ZE]0_7?T>HR9_KO#=(^H?2$?&.[E.E#?P67PDLS+%!/D:UF& MU7?'/,T<7.0MY:],C%94:6&I# MR0[,.W#"9U\[@CW+;;>#K6V3^U-UQD5YX:AT_BJLJ!X9%@L9&SP<=#XNI9LIT[!8-:O-8*3SW+3RF&-I.( M%BQ*H9^.P 7CN?R[>-8?+ZV>J6391-U=;A[CA *=3&T50,VPV-.E"VR[_F9F M?QN6)\ZV,NMI>2BNK4Z9,+)82,_MGMW9>Y%3?&XTM%+'6FGK[02I&(6V=ZA=3WNE>C\_U+$CY/(4*B/&;3/, MTUJQ8@IQV;; B26.&2P+-D!T9XXY 'CWY+A6MWA_,["&.(P:,>5$+O%M!!'F M+)&^(])8=H(H]M?Q;;:[;:[?+3:/&^,XQMG$FOU,^T=]BOT*PWHMUCU)T7T\ M>C>H>ANF\AU%2RD69S-U,HF%JO=LXS+09;(78;39.&&6O6GB6O;AR$M5DF:N M):<_)?IMZV]>7>ML/C,WD!FL=G6KG[@^P_J#2Y;1P2^15*=[:$H-D6,:Y6K.I>BQ+WFXNL@EB M5,=@B1IL_/4M1*O+EAS)"1-+#K'IIPA]B..MF/4?/]*Y."6UB\ETG:R?".>> M'VV0Q61QL=>T.TZJ0U:_0\+1N5W5F(V NKEO_ %$OM F8+UG2^*\GZD-)+ -K MK5M[/SRT,9I]]8HX_P!W]VZI,D2R9QK%H+5(<;;[XTQ'G.<>?2',>E/3M>M9 MN1Y>WBH*T$MFQ/=>O8IUH($:6::4LM5DABB1GD=[&R*I8D '4N'^T1U2CQQY M/"XG*@L$ J>ZQUJ4L0 .?.[!R).P"5!^VVI!.J?4Q[9T ==I0%<'%UTJT*5D M# 0MMEFPQF&CD/$FL1:N("(4,G.PXTBA4$3)B+:>0[?2? \'RD]0_M 9Z_E[ MN.Z%M_=V!KV9:U3*"G']Z9>))"B6REI; Q\-@!9(*\2"W&K#O3\V,,>T,EZB M9B\D?LXEPR&)&FC#Q6["R%09$-EHQ'PC;=5:*)"=BQ<@@#'G/??WV3I3<<\Z M\9OJ?$VN3T%M%".&,B^6,2:0M!1QW*^?&GRQ#(*?B".7.NY 96FGX=L1Q7K5 MZG=-9!!E,A8R,:LCV,5GJ:JTD3[,.,IA@O5RR$F)XY>WN59HI5'$^=C>O,Y" MZ3+D$R5?E]<UFO4.T6-==\\[]TCNF=/&AL"H.?6JSUKE>T3]K*OQ*1> --:/KHP*S_ !?F MUL0:OW>5EBA>8OF DCS1HT7?Q(KUB48CN![/T*&V[+?C?2/JUBO429!LOSK6 M+,=98NG>Y#%7FE6Q[7J!K=P"5%/9[5+:23AN;*_V?ZF^C6NJ?V1]_8A*],U= M>PY1PG4>"DWI9MQ_E,0=DWA*ZA%[#_Z?/Q.?ZDTGU7)"*Y2QH.;16[K[.?M) M7"8ZH0P-V#S2^;'X;=PJ4@#7NB%O Z.)"56 M/7E1Y7J<"(O)E"PN8PV$]E1"R[-<^]?:RBKRKX4JU)JO>BL9@F*2-X )&DUS M;04X%]7_ $JH-PHWLG[$N>5])Z([[345$%QY[>F2JQ$:J;^6FCEHT5LP0)5E8QSPJR3U&E'9)L M/O)%%,")%",S%2RJP.IINXN'Z?K3ULME9*5NT]^!.]6LLDM/)1P,;(%*,K#8 MGJD&*0RHJ+(J221G?'5*Z3[_ '*QH%%4(OKS\J3V)I5B&$KJ^E+=741N+5=+&BK*Z.KVNO-7PUDEGBA MCB$D';C6R?<1UCE;4LU>%5F6J@%&6,F1I6XD"**-W8R16L%GJ>D D,]F:=X; M7>G:BOLYKJ]/T*]:Y8>2L;\C'*UY0(D@7N!N]8EBB00SUIG[#_4-@YT_?\ 9\#!/'8W-8$6E,)"2,CG MGPU.^3ZI%./C8S$DY6[VPN,QM>S%/RJ"F,ES%NI-3XK=(:A(+.\L22Q QB45 M*Z>Q?U#RSS@J9<^ZI4&GL!VTA792O7'FMAM_.)>&2F48C%9KP7$:G%G MIX-F%TZ,W[M;)X*XVGKE>A;;H:S"*AA 98:C/[*H#&+UA(Q,O?%P"8=R0VY M3[=HSV%IQ@NO.0KSDJ6,GU4S,L%C(QQ?>F1*RG%4Y9S5[6 M8>[DR4Y$4ABB#F*'L9AD:EAB%:;9VT)&@(UVS!.+G;6:+637;(Q.NI(^--/&FGC33QIIXTT\::>--/&FGC33QIIXTT\::>--/&FG MC33QIIXTT\::>--/&FM@EU)W'_+K^&1J?N C%FSI&:T&VWT^65=+]%]1=7V?;X3'R31HP6Q>EWAQ] M7?\ _P BTP*!MOJ$,8DL.H)CA?8ZP'KOU,Z-].*(N=49>*M-(A>GBZ^UG+W] MB1_9*",)&CY#@UF8PTXVV6:S&2-^N?[/_6;[STJ9A6^& P\1IDV)(-'46P[G MI;(;?Y1YDE=S1;JZSF;3&)=(:\#EJOESG6&SDZXQOGISI;T*Z>PXBL]0RG/W MP%2]FU.@=&R2[[SD[&QYR+N9+OOO*2 1I)OG?3/WUW]H3%W*O657(&%EP]_" MXZ+#NB<:L,=&+L3T8N("1M7EWF,*@<$LQL!LVMR_8^SN-O\ IK?PRV%;J/$] M39FQU%%+)RO6)LI.+57*S\R9IH[<&U5;3[F26C,A8E/.;NYOD=>Y)?R[!+!H M&75W*@>";.OW/9-EY(*X^Y)YRIH_C\,9VATTD)S\8X-]]=?>FN,R65Z[ MZ6@Q22M8@S6/O2RQAMJM2C;ALV[4K#PL44,;;\B!(Q2$;O*JMM_UMSF$P'I3 MUW;STD"T[73.7Q4$$S*#>R.4H6*6/HP*WU///:FCX\ 6A19+)XQP.ZZ7\]^A MU[$==%5WBV] YWRI!:@5[X-64/8K+= 0VP0YL6K>OPKTBH _$RC5[MF SQM7KT9GAD,3O!8,DTDD3NC, MDHK\74AT+!@=GGV7^M:ZL^N>3??V>!H0#SM[FU8M?Y]I*>_P#$ M>-;GQ_V5<'"BKD>K7 M7E! T$"J[FC0&D:Z9@C@F7779:$* O<9E^?V)P$"K<1[ZSKXX9?VUP'R2]2> MB.I_3/K-^KNF%NXW%IF?OWIW,X5K$+=.6A;]Y5J>XC=IJ,V-FXQT9Y)?[1#' M$ZRM,)XHO>ZKZ'?&034;,$F7P5FJ:LL]N*.<3PR1=J:')(D:0\Y06#GM1PS! MMXU4\HTTK0T99"U'PB3$%-BI<# ##X,8%;S$?\>L (ORGDWGFSM^/3$6F\^W MSS'IG[;YUSZ_J!]JGU\]7.FX>A>J^L)\EA;#UEMXW%8;%8N;.S5Y$DJKDWP] M"M8OJLZ1S+24K3DLQPSO5>>&&2/373/I)T+TQE_O?!8'AE"76K))9NWVJ=X, MCK1BLSSK$[HS1]Q5:P(V:)90CNK;RV+Z,W4?9GE%>/M'6A^)NXF93H.CMZ'+ M:92X-P]!E1-A.@M:$BN,-=)V.W\;HN;3CCE1X/T@._*$)T;]E'I^QZ2_?'5O M4>%DESO45&#&U*C616LXC#"=+EA;$9KS;VLC9AIR25V>-JL=.%9")I9HH=S9 M+T*JFQF%PDJ2O.M&6@ULR;Q\(6L.MNNU9U#2_AB.9E63ZPK[HNAMA^B M'[7^N]N5]28,.7].YK1"=[38&%0L3$)ZK4I!YSMVIMHM+%ID:.4L]+WH$22)65Z\H520A M7QQMJS2)$.)(.P.L _[$.J^F[U?)RRXO*8VC*;<\E.Q(D\44"E^Z]:U#!OVV M57*P2SL I(WVU1^D;'ZH-9!#[YX/[2D)&H/M%MGUZ#7[F-H4CE(%SYJ12H;)Z>^ZYFRP//V*V^+=P M1\?Q35]SN#&I(W5XQ]5&F?3]MP%#Z;27]NYYU2;^;2)C%JZ3FC1HXY0L,Y?_([<=_8ZZ/RG4G3?7UF"P(:]+*X6.C' M.C>VLW)*=]\@@F7?M2I"N,W/;<$21A^ V;7?>%]1JO1-E:60J3VJ.1;O2RUI M%[])HMHQ*M=^*SI*&V<=V)U$(*=T_1KLG\ ]D^&^T=%&Z/P;I%=Z+5ILQQ%S MIR-XVB,Z6/\ -A59Z^=&*]K+?6/_ ),K'JX S:'.A$44@TD4V_0^2Q60Q%@U MP_45-;^&OP7ZS;!FB8B M2%R-^W8@<+-7EV\]N:-'V(8 J03G'SS]>OIXTT\::>--/&FGC33QIIXTT\:: M>--/&FGC33QIIXTT\::>--/&FGC33QIIXTT\::>--/&FGC33QIIXTUZ[[Z1Z M;22;:Z:::[;[[[[8UTTTUQG;;;;;;.,:ZZXQG.VV1 )( !))V M 'DDGX 'ZDZ@2%!9B "22=@ /)))\ >23\:@^]V_JSIZ)EQS3UA(6V>WP; M3KW/5)XH655KL^N=H9H:@)+B02U-H-_EG#@K2:L"[Z1_KP6+6:3]/I'T[]"; M.1C@S?6:S4:#<):V#4M#>MH?J5[[C9Z,##;:!"+L@)YM4XKW.*O67[5E+"R6 M^FO322OD\M&7@N]4.B6,50<;H\>)C;>/*6D;?>W(K8V,@=I<@';L];SH-QM= M_L1]ONUA<6JT/"I2VKUZ>0R9G3[8TUQF8DG>23\<6F-81X-,ZP#0:1CCQQ01 MQQZ]35,?1Q=2O0QU6O1I5DX05JT:Q0QJ/)V1 !NQW9V.[.Q+N68DG@>_F,KG MLAL_6'ICI=Y:=5_OW+1[HU2A*GMH)!O]-N_L\4;*=U>*!;,Z..$L49 M\CH7TR^SIUSUQ#7R%Z'_ (5P$Q$BY'+02>\M0L 1)CL3RBL3JR\6CGM/2JRQ MMS@L3;<=3>U?Z0OKU2*BN5TZ\]CK=\!DDGEZ>KMT([H_>>/3$Z\E%JN_QN)! MF;7:6->&O&89^^NACHW[;;2:'F]*X(/"(2;#+IKMC9F:2NVVUBWD7;SPQ3:>?D/5O(_=EO M$=+=/]/]$U,C&8LC/@:KIE+D+ AH),E,[2I"02 (DCE7=@LP5F4^UB/L]X;[ M[Q_4/7G5_5_J=D,/*L^'J]67XY,%C;"E62U!A:\:5WLAE!+3R2P/Q1I*S/&C MKL"Q]Q/6J]D>..AUWE@:JC[G7TW6[6D>WE)UQT-,#>Y5@;0\_O7[ M]A9Y$KJ>>GV4)NU"-3'#PZEUT%L?]_V\?X_X?YZU8M_U.^=IEW-[$LYYT<:N MWR*:VII;:E1I3K]S"3D_5[RKL7/XXK<1&J8F6.CU9(0OZABD$+%UN&9-1%X7 M[#-:_K^OZ_TT_?\ AX/\]P/]_P"OC7#4GL5DNZ54HK45GZ((3;*0BUFI53EQB].W+Y MAL_8,:[ ^_C0%/3@:J-)8)X MWAFBD4-'+%*I22-U.X9'1BK*?!!(.I719%>-U#HZLKJ0&5D8%6##R"I!((/R M/X'4:GL#].3I=6?L77%0-;]1#YY2PDT3 .&TUV";;._\?..Q(&T>AC_/6$(Y M>00PGBQC]U?'O'L41Q%UU]G[J7$9*:_T7$V8Q#S&>O5CL1PY7&;OS6$K/)$+ M4<)XK!/7D>RP ,L*LIE?2F>Z R%>:67$QB]1D+%8.2"Q K'S$R2,HG0;\59" MSLHV= 1R;#'/O07V3N;2!?-0=J(JS+C!CRX$B* 0],Y^^^^BX>0ER=)MCY?C MU"631[;_ !Q-./IM^7&-X_T=]5.KJANW'8R_4EXRO%"G@!4EGGOV. M"[B*.*,Q@[*TD2GF/#Q?0.:+K58JL*%CNS"&+\1V;]TB.Y_,P M^=0"?4D]./<3@'2&5N]@:!M_AS$S134^C4>4NSC^D[33252]S*R78TK9/)Y6 MRJ^]R5B!7="'[<4,*UY;$=6G!5JF9S%S?4'7?2G5.#OR6W9C@ED;FZ(5\ZTBX3[%=J]8>B+NG\*Z$_Y[<%V8]-S$Y. M,KW .LFLNZ>RI"M9TUE1D;ZZ[3IW@)P&\FL<^(-2(89H]H93&TR$^8%ZH;]N0;G?5S=L M?CT_PA@RGEF1V8F7'PQ1G1Q)1DD@^*TW?33$KUFB.J>A;>%YW*!DNXP;LQX[ MV::_/]H5 !)$!_\ W"*JC8]U(P S=:]!>JN/ZG$..RPAQ><8(L:\BM+(L0!_ M9'D),4[-X]G*[,VZ]B68EUCG;\P'6W=/&FGC33QIIXTT\::>--/&FGC33QII MXTT\::>--/&FGC33QIK4;LJGV1;7>SJ^5,R5%/NW-J]SJ![L2FAWYM;&+&_, MWW8D.AVTI$[*MUG5:A#6?H-(W%S?@ Y[ M\:K"J57V( 5Y"TA;DO&))@&YO&->'?3*O8F2D[)!8J15!)RC'M)F:T\E^+EN M2\47")5XN'L25F9#%#*=60Y:^TEX3UQ)O7+326T,-\8W%HDEKRS].=U8E9?) MQ*\VPS,&;3H:2:[!M(^X9H,=G4Q9<#DQRJY&-=%QT+R/W(Y5)A6)7$C;A$(L MEUXCCSE"&,[@F-CP(V8+0>3,6$BC,4U9P++3O&8EXF25&I")PS*YBKM(LP*L MO=0=P'=.5"IK?V916R6E&2WQB0D3\A:KY#E=2>J;478;(_27LKH]K8%2&HP] M*W5B&X\=*AKL2YG"44$ Z.8J*<]GF7'R1B5>RH9K*MLTB-&$1'A$$0 5SW) MI[A

  •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`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end GRAPHIC 23 g582934g46t15.jpg GRAPHIC begin 644 g582934g46t15.jpg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�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

    J'>^U>:V40W$Q #00S-(SR1 M#*" *$A98WQN:,FMK$7*6)XR2=$9I67NL.58R;;FW$[ILGTE("1BJ)]2@BFH M)O!3J\R]'4)N-6W E#QLKC*Y+'^GHO &. /%<'(Y.*YZ>1F.T1/(Z*YV\D8 M]TGACN+<'C.T9 QG.&5T>@LIU%?'$FR9WN;E"G@8MLN](\/Z,BS= M0R$P\*,"42H+;.ZLYX.Z2=8U2=)#"8Y>\+&(Q@G*#8@)< M;EE;O4'#Q*Q&;K-%$J/G,\?NE -P4R!MNXMC"G:Q&T9) ("CFL([DKA7ZIC. MVLI1P5-!Y%O(U>016[!V!GO2W2,W,F98ZK@RIR."$(B87 ]FF?D81+JU'MB: M$\>ZZ@ KDDGJ,8!+8SR,#DGC&:V.E6\D\Q<+GJS,,'' 0$MD@A>"N0.JF1DK((,2*$*YEE%E43"H1,"\F1U%D0 Q2"5 M7J'6UG5YHQ(UP\46T#NO=X! )4DHV]FYY)/B>#T]#M(RB=W'"LS[L]Z,^^02 M 2&(*@9(. <]>:C+9"U3<-EW&^.1D77]$3$7$.202#LZ+19T#@TPW%FV:AUE M:M$E5G#U(JC>/:E2)U&!X84L:.9K2&ZND,2=U"\H,Q10T<9C[M@3(-NYRJI& M/>G=F(V]S[U=]'&(5@[R03.NUA"K^Y)(I#HWNDEC'EBPPL:85MS2>[O):13N M]9AB,71DQ:%(EO(@OM;GG#L!*1:6"QW-K,[,@[DS71NI[>-6+=S M"PD"B1@8N.N+??>"2199%M(4;)V ,TA@*0XD<2_RTMH9F=5#2.[0YVL1)(PL M6F\N-UL457I2R69>CH5]!J#U8&T@E#B^DX>/;J)JE!0)J7*@S4=H]:S9PJ4Q MTDFY'0ZQ4EN&@BT\A([(3B5).[+%99UBMY)#D;F6*%=Q0$9"$>\^T5:E6&(+ M,YJ9E4$C!WLP55*[FW,IVJNYJZ#&]*'4*103IJ@OF75G<6BB%C;9,( MFC>WE,L;HS,J3(3_ $-,49A'D[=F67E!5IKN!F+1/O1N#_+*[.!F*10Y+=VI M&00I!.W@@YRK;7467KB8223BP81AF(+NRI]Y3D$D#N60 BDJNN1LN8R+A%!9 M-'MS%$J22AB@"F*EK(2BL[;5!?8#[Q4' =L#PYQGR\JHB;*F3NL!\!9"N8PX MR"$W,>N%.!SD$<]#;! $\*@5[&L9GHC(P6!%R-WK1ZDL1T114Y5RMDW)G"HB M!G)^[D*LEVB1DTQ.<-XCAHTB5R%;! 4K[BIC P0VWD'(*[V&/S.JI#+&L@61G&7 9^*B)3)GNPB*T3,6+A-N"X]W.X'NY'D)]> EI=6"C'-99,59D7Q7"DBY:2DH0Z;EJ=M&*=RB73Q=5!9R8 ML6O1<66IQ2W%G$=LUKW7MFSOYI#'/WXE9;<[BLGO'.UU2RD2W6 MX2WN4B4JD07O;@[BL8SD ,(Q$N^.:.)&F]P=UD(:EED#)I\,XIJ%YCRJ7FJ3 M5CEZ=[ID(MFU[BM%JOHE@\R%9Y:;9,Z]!SI4VT?)2B\](@C,"JY.?H*JY#96 M^F*\T\":C:0;%2Y:-V/=[) C".SB@6>6\G@1MQAA@#2(H*@Y4'GU/>7#"XMY M#*YE9<*Q,3,6=5D:1+9$A;!'>SSX1W[I@HB:2L\4W+>.<4XHJLCDMW7,'NI: M+FFE7K$[^P4RJ8&M4D@"L'7?*BF1ESL+MW9QC9WLN[^5+;H-RK M[6Z MW;8C9V%U)'*2 IV1L=J'^H*NZN#2K57+C=;W.QU.(99<8\K=9P5,0.MJY(\B6D$;W+O:)* MQ]B=Y(Y;:ZG.YX^X(8@LC1EI /ZRR@>!NR6G<8.Q1)M ;"J49%X#B085@I5O M=9AQ@NP]XC&>0ZYD]M<&,MB7)N.F;E*I'5#$( M)JNU&Z\:'<4GJB'(BB+EV4M$:Z8Y*W\5\$,BXEM4BWH%'OJPG[E=[Y'NR,), M%F"@J#69#/(L/\N&*4[E4,\LB*"2>[V"+OGVJ<^]'NCS_3D.RMZ-F@F%HU$W M+J%NB)NGGRZNS+SY

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g582934g55w46.jpg GRAPHIC begin 644 g582934g55w46.jpg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

    H6E2C@[>&=MP=ZT<>(QH M[1-7\-/Q%MA,=3ZX6L\5N2;KU2M+FH0+^UUPYMWTVB.DH2QO6*LO&"(E=IAZ M%\D(&.L4>IC'S/PS&#M]AL Z@W=(:4*."<(>4LC;&@K&7_ 9Y,#[MY.K].ID]64Q+N^KHM;GAQ#[ $?( >GT]/_'Z M?]/!_N78$YR>WRR?B8'Y_J:Y/AX:7'1C;DC!_P#>G;U?E^*O89GS-75TQ2F* M4Q2F*4Q2F*4Q2F*4Q2OX(] $?L 1]OI]OLP=MZ51NJ]G%NM5BI.61>1LO+_' MY)5BZ:K)F8,FNLV #GI@8SX>WV^W\U6ZF^;'."/K6AU?8?)\Y$Z@ 8/S M?VL#=WOU#H/0.O7VZATZ[;3I*4ZWFW,_"!*#A0Z],]/'X\>9M./!)]HR/'PV MQ]=JY!CC[@/9VAU_ZH=/;Z_I^S^S[./ M:/KO7'4D6W:J7UC7JF0#+ "R75(HCV@)P PB3J/YH"8 #K[!U'#KRRV4!QL$ MIP2D XR<>LD^6 ?C(-42D9Z'8[9Z'YA]-5Q8=B? K70:TS8/) UIMSNMR*J: M!@2C$FU:FYD[AQW=JJ92K,V D7\D6JJ3CRR+@=0O37BE]#S;962@*.H*SOX= M#X@[@X21X;9JJL$$C&>OU/CU^7:K=RB_P!^K/\ UN,_5#3%*D.*5K(\ M8&X7FB\"ME3^N+E9Z%;1V'QSA&5FI^QYS44XV96;D9JNN3;%/9=<4),4QA-0 MDI(0TQ.M07*RB'[U1PT>-@5:K3_#+33UYC(?:;>;Y,Y1;=81*02W DN(/9U] MUU25I2M"#C*DIP0<$8EN07 EZZPVG$B6U]LCI M<;6IMQP9TH4HE*AE)U\(6&QRECXN<<.0._=JZDT1-:1Y%[;&5UGS?M>X+CR* MW13MHQD;%:62YBO&]%NEH"LT"7?6YIKF$?UMTY=NVM>=.)**JB0!-Z$);N$Z M%"C2IB)<&-ID6AJ*U!BNL%1E^Y8+S3?,?2EHOJ#F "X E3MTW2YS M(-M=MUUGK\G;'L"W:?W1;*?!<.QW7 Z)NVXUQK-S5<4O=$ MC)4Y[.2,@C.W M;;P+F4D?1E,;X*5'4ZM0=?Y0:+BL50+3E'O6\Z#O^T;_RQW)4]F<8.'>K]B<2 MTHS:,M5$]_69QRGWOKQEL:\51D[9M-]O[]5M=ZQHLJVL3*P1LBUM;UT5B27L M"T@MO&W0V9C$=FV178]QNDABY%4=+G8FQ;H;ZHS+A!,-+#CTAT%"D*!:&5:$ M!(C$WFXR;9)FR;W/8F6>PPY=C")BV!;E%1*DL)(3;6V515)F$H MQIIA U2#3AZ1 %L1*T2&>RH)3$D[E!DY5X^/QJTLN6""X8[6M%ZDQ%.QV6T2 MGHZ8T9X(6]H4MU>MYSEES6$Y2D)TI":]);7*:XONC*9DCEN\,Q)Z8\N2\[ B MRU3ID;F-QBXEIEL-QVN:&@VI>'%J7K6I59=6"V6-EKC0T[8I"EVVURTC4W,_ M8*$[LL;KZ7L"FM;+-24]2T&MG5>O*=)RC-5Q7XVQR]E9J03QJ=]\1D$&LBE! M/)0EYY+:74-I<6$(>P7D("\)2Z0E YJ4X#FE*1K!PD#:NKC*=7&BK>64Y6H]X_O4^Q-F3EDDX^M+-E8-PHHR!Q]/J'E68$[9QN,]/9Z_75?;6V%LJ3I6TK%"V6CU2KU&]H:^/ OF$ZV MO*JK2S0$,O)&N;6V,F,!*SRLDC*5&O?(Z3^,P+V#*K+)J6E-Q"-AZ]C[.GY/ M'R/LJA)P?#!^/Y?7[/SUSHK=VX):V"^0I,I5*-=D:0]Y?Z^7 ML9;C(;F;/G$H+R/6M2-/3U*63D(DQ*]%K/))1K,O&!Y[XSX^6?+\OK]55R?+ M;./GQY_DKY2/(ZZLJ_10JP#Y@;]>I_)U M^:NO7V3MQ67BZ]?(?X6O%7S4LJW?PJ->J\M*1UBD[4R?P$I2H/<&UY$C%=2O MBK$3#V79QEB!60B CRNJVY>R5#CP^OQX%5!/C]?BR?ES7V=;WVA!T*J;*DEM M;3<;LW7URMM8K$'"S[:1ICV&U98]IQ(SDZM;Y!&[5]HA7R5*RR#&!I"Q;!+P MZ[5-HG(!'MZX&<;[$?'O@^SYZIDX!VW!/S9\]_FKDV_=.U]?U!Y9)!]JJ[/; M!I+8^T*UJ+IN_5BCHQJA M;.BW@6 ?,;@'/K^CY_;YT)/JP03X[8W_ +/#\E[ _IC%NOL9\6NR<?;/SV"((K46@03X\ MZP-NNYQU'J]7K]7MJN3ON-AGH?7Z_5ZZ_#?=^WY"W.WK&DQX:[9;E7U.HW?I MU*,>':L;P77[ZQ#\2DUG@*VF#J1=2N'\_$'C(*+<.G\VQF2L#'KQGQ M\L],?E]?JIDYZ;9Q^3S^;%^5Z!81-5LIW52EX2 MMW&RUV=D9-Q>BELC%Y&TQY\7@VL?6G+9Y*,T&,^=.,7=R@@#(WVQ\?3U;=?7 M5,G&=M\],YV!_-762CB]R7#;6ZJMM:C;+#7-#M)>R'CK!TD&5JLM&CY%-VDV MN;2>5=/XJ5,RFWQ;2DM+'4DG! CPD"(LFVH[;=[Y@?5^2ASHSG? J0*[1V'& M,I:UMG5#+2J;L^,U.ZHCB$GS7R5%.V0U"7DT+.KO.,Y\.F?[.O6JY.YVQG&/'KCZC'2K3TA:+I=]>PUSN MRU:];9DS2D='UB)DXUK%11U#HM&KM>4GIM:4?*D2!XX=)$C$$3.18IM%@:^N M=4. <#P\ZJ,D9/C5NY2JTQ2JY'3VI!HJVKAU;KD=9N'JTDOKH:161HJ\BXLI MKFO(+5$8SY/J/5[@8UK6='CS+J64QITZAI01=9G[5)YPD=H?[0$Z0_S7.<$\ MOE:0[JUZ>5]KQJQR^Y\':M3L$'LQA]CB=C*BLQ.SL]F*B[V@J+&CE%1?^W$E M.2[]L)U]ZJ[E^('$NP25NF9[B[QUFY?8#U:2ODK+Z3UI)25VD7$N2? M5E9U9'J\\DG-K.IE5ZNK+IDDCJ&>$*L&=-SN2$M(1<)R$L@)92F7(2EH!)0 MT X V @E "0!I)3TVK578K(ZM]QRSVIQ,FC9C6&K%INZU6ADT13[- U*1-ZB9FY6CZ_ MBZE)@A8)18J[A="JP9YJ??*^21N_>N2I*$7.Y(=,J!%4PPXHE2W&62T6VU MK42I:D)!422HDFK-D]/:@L25E^-ZJUS,I7IW496Y)S-$K;WY72%$^'GHC^U( MR$2H>4E[5SD MMX4-"7=2N8$X#FI6K.36RN!!=YP=A1'.T*87(UQV5\]<;28RGM2#S51RA'(4 MO46M">64Z1C@O==:;A+U#7]35M,)L>ILJK(V:9DF#-W$1D#4W4DQ2[2LFI*$Q M(1A*M/35EFT*:J>IH.@9R$FG6#J0:1@B>]MF1J=.8T!B9*9#:2AL-2'FPA!< MYI2C0M.E)=^VD# YG?/>WK#(M5JE+\*.\77$L]G2XYS&E%:Q M'^T!:LJ#/VL'1W:F=?TUJ"I!0RU756MZR75<5.P6L2U^CUF&+KF$M ,PLT11 M"QT6V"HQ=B".8!.,*^$>UE@9- ?I. ;H]F-U*/-4C4K0I>HIU'!&365J!!8[,&(41GL:'&H?*CLM]E;>T\YN-I0.0AW2G MF):TI7I3J!P*^4[4=0WJWNF%HIM%MMTK=?A'ZYK%4HB:E8NN6*0L;:$%*0E( MUP8C%_(UVR DU;N1!-=DZ5512\],ZV')'B0/;6U@'P!/LKCL])ZQ0M4U=GE. MKLY:):RL;2VFYZO5^2E*Z_C:_7:ZP;UJ25B@D(IBS0K3-^U2(Z56;RCI^Z0< M)D62109/3R_M_/32/GS45I%,TB-L>R4+6HZQ71.T;&L(766HGJ9.'F$KQ*L[ M3$,;RM66C9BI#V&7DXZ)B@EAE5HH7;ME\1CP>R!QS]'CZMMJH,9V&^^^/7OO MBK0FM>T&QPJ%;L-(J,[76KTTDV@9BMPTE#-I$ZCE4[]O&/&:S)%Z=5Z\4,Z3 M0*N8[MT<5!,X5$]*K@=,#%=VU@H1BRB(UE#13..KY6Y8%@UCVC=E"%:-%8]J M6(:I(D0C2MF"RS)N#--$$6BJK9/M14,055KHW^O*!*V5CC%868LIMPR4DFPM!<.!:BBY(+?U"_D]GG*=S)\Z8'E7'Q&>12C16,=C-*L#R0NHY5@P48N!<^HQTDJR7D8])T=,5TV3]>- MCEGK0ARH.E6#)1=-0[5 4U*B4%J[6=6;.V=9UW1JZS?OXB5?-8.I0$2V>2=? M?)2*$F5#F7;!,'3U-$UP[^@!Z](Z0:";ZO8?1@7KU'J)1 MZ_N<[2P@^YY.3_?#H WP.ZUY;_-Y^VOU*_8BNA?HC;:ZEKB.]Y!/0*$5:=O4 M>\-OA;CK5[^$W*B79%CBA.)2++JNDTN[\P1/6G13B4O7IUZ-$NH@'7KU^H Z M\_Q5M<;-YAJ6#[!OO\9Z_&<$[^$?LT4$<4\'N9.EWAZ4$C)P BXG;'M43\8K MT&Y%9WQ^;_[KXLKIK$ #7YT!^@8>3_\ 1+Y@?/VM[R#:CCV 54=1@X.>M82^ M&J^;H\#>/#MVNBU:L*/(I.7*ZI$&[="+LUC;*JK+*&*FDBB1J)CJ',4A"%$Q MA*4/;HN)RE-[EDX2"W;\Y\2JVQ2<^94HY/B2$@#8 3Y M(2D = D8 V VKLN6E(JNP:M6-FTVJU38N]='O'=\T>FM9X2((K9%8UPS2 MBGDJI-19%*_9E!;QZC=>2;,ADCQD@*R2S!-4G'KP51BEG*V7&4N+^UX+22DK MS@J*QW=@0.IV&5)/0V]]M#C\>0_RHTEIQMX84HI*DE*5Z=@%(!)U$' ! WP1 MAYQ[B.5E(Y QNQGE K5LN(MFVW&I M6K9T;4]9V[8UK)/[_;,DK-,S;ME5083U#K55):%)*N@1:7)U)E.EQR8RKFE. $\M>DE6^K5E8 .X\E=O<.)6 M XWV7#C4>&RS&9!2(Z'U*/,>Y:0$I<"4H2E24!93U4!O6YIB*!2"@@<@E1*F M0I"FZ]B94RE( /N!>T !^@>GT]>N=A$3H"TZLCN: N/)5TZ:)1JUA:3;J*C7 M0G5$)1TS2!J[!46ZFI.(# 6%:%M+!"@K2H@@@I2KKJP\4D92 ML:5#J",@]X;C2,;Y! Z^%>9FH^,75=L/]946Y\0H:/L%S=Q2[:TMK_ *5]@D MWDX>)\X']@I*3DR)#2Q%GJ;5Z<4"M5RF*H! $<#5TN,5$SLUUFQ]+;>@-2I# M)22D;CENIQX;[=2?55RK;'=4"Y&CN=<:V&U[ [[J2?#?&WQ]*]D M:+K*3DV,S)5MK+&?R4618D3E@EK$X!B#DI%S-$%I<[9!15-(ZJ:15111[ M_*)(1.:64F0ZI]Y65N.J6IU3BEJ*M2G%E2EJ.1E1))(ZFK'2DK5H3H0,)2G M3I"4A( 2-D@8V Z#:O+7XL*IPX*I.'LKRMN?Q9^ER(N<-=6403GC=( M=I*/./4F,BN=XX(@+F"CNN?AE "@HZ@!C)RKX0!JD? M 1Y.Z&XQ[!Y"S.];^PH#"VU:BPE>?R,7/2+=T[9S,^]?)*K0D3)@P211%!0Z MSX6SO=* ML!.KU 5PMON<"UZUSGTL(6V,+4E2MPI.1A 4?X8)P/#/E7M,I%VJFR*E7[Y M1IV/L]/M<8VFJY88I85XV8BGA/,:OV:PE()T%R?G$$2E-](& ! 0SY1DQ94* M3(AS6%QI45YQA]A9!4VXVHI4E6G(R"-\$CR)&]=DR\T^TV\RL.-.I"T+ ("D MD9!P0#\H!]52K,-9*8I3%*8I3%*8I3%*8I3%*^+C_DZ__N5?_P!ALH>A]A^B ME:J>)#^Z7RKA"-[S-0BK!])B=3M))-)=D*CA(8^324%%VGV>8=5!VT>HF*H8 MWJ$77YO;".G2F/I.G4I"3@XR#IZX.2/#'D:S'RQUSGZ?+Z]<&KJE]%;&9G42 MBJ-JU\/43DLL58['$V9TIYH"160^*LUS'5*D*A>U*=!F'>)2-BI@! SJ:>!V M2E6.FZ<$''GC!QC.W4>JK> MA'CZC]&^U=O$\?MB+O6POF6KJ>V;&36&?A!F)VZ**)&!4B!WOPNL)+-C&*7U M"3YR];J#W'*CYG8H%Q:OD "/5U\JH",^)W &<8&X^O0528RU MNBN5FEJ=)72PV1HVL\^=VYE7":0R!SUR1H^S:14-BTJ8,R/+5"]UJ&MU7E#QKYM*1QI&OV!E(1+ MXS"39LY%D9RT5%J^:MG: IN$$E"Y67WH[B7H[SK#J8Q):;?97H4%HUM.I4A6E:4K3E)TJ2%#! M -5Q)<6^,TSK)GI65X\:.D-.QT@K+QNJG>J*(MKF-EUW+IZM+1U*/ C6V$HJ M\?/7:D@TC47AG3QTX%85G"ISYTW">F09:9TM,I2="I(DO!]2E@UE>+'%W"S:P<:\K3[6+ZU0T4SA(VPMM=/H]Q2HB8 M;Q<;,_UO*6/1&G)Z2TXDQ0U&_F-9TN2>:O;Q?IAC&^O7#R M%65IK>-,R8GCV]>-'(LE6+)5L1)1HW,GA1/G-A]*)DI"9149(3(=2)!5G47P M%@.E63J+FHG)SU-;#EIM;RHBW;; <7 "1!4N)'6J&$8T"*5-DL!&E)0&M(24 MI*<%(Q.G^OZ%*SA6WBZT,#N3D''HO.>N3J8@\\E"6TNNI;0[SD(#BPA#V$IYJ4@Z4NZ4I' M, "\)2,X K95&C+<6ZN.PMUUCLSCJFFU..1M2E=G6LI*EL:EK5RE$MZEJ.G* MCGAM8.A5]O2];QM1BHV$A8,Y*178FEF3IU5A*U%)HJ:* MC142,+%KY5E9*C4MK'6L].A:9S7M(FK,5)% +#+52"D9P$&Y%$FZ02KQ@L^\ MM!)55-$GG]J2:JI$P*50X&KD^9JF!Y"N0&O* %K&]A1Z@%W'KUN(5J&"TCU9 M!&B(V &7Q;J,< ,!'U?460 T$?( $\ID],[>55P.N-_.I"I$Q2J4J@K&1ZB, MZ)QFT5&38Z4P*K!"*4&53,F)) 5(QJUCC^K!;O8-D&9NK=%-,JE1N UOKNJ, M_A]7H=,K;#XFVF_10-7A(AI\99ID19RWIV#%NE\2:(IIHM7W9ZINDF1)%4B9 M"E!G/6F!Y5#Y/6.IG3RZU=A2HJLV'9=+M#2SVFK49M$2O' MB5II9[)%D4XN5D'4@[<$-+GBWC9LY7)7)^0BJ8&^W7.37Y>5C2FL6Z;4]&JT M6?9D@A1G:$%KQ&2D+R\>Q\O)*QDZRK-?>.I9D:,93\Q,.)5N:(9L4I>2DUF[ M?U2PM_DWZ]*;#PZ[=.M3>*"E7R 2L[!A#S\#L&JQ(G?.X=,Q;/4'[-T_B&-3R/CV$2R;1L6Q9QL< MS2*@T81[9%FR:HE_H]J:1"D#K[!E*K7,Q2F*5KVUI571.\[*M98A2PFGU["\K\W2FDE1HK72L-Z2) MG7S.62B6C",;W$EWQ[8&WKQ[/G\MLG<58!Y#'>Z]!@'\H\.F? 5R*[K>PL(6 M*C9W4<_/ZK@KW(.INH2,=46UWOB3NFLFL;;=D5^/MLA5MENZS8BOF,X\.[25 MN\BI'W8M;DW]=9S4TSZ\'YAZAY?DZ9W.&"/#(R<^9V\O5\_7'C77OM'7>9A- MB.C4R5;-PTSNN+TK49B;CI!Y19>TNW):=#(B$T_C(VQ-T/5JUUVU>JH46 GQ MIT9+LF#1=MC.X]JU[3D=D,YJK;9BY:"8MF= ^5T5)1L6RL+FQL)RNPM:J*1JQ/Z_:QZ;6VR[22 MEC1LFVLDA.$9VZ[8QCUXZ^O??/A\E#UW!)SUZC&?S>'QU_":WN8VFQH1U&N3 M*J+[+L%GD[$V5JE:V3/DLFON0\?,L49AC;U(ZQ(0&/5OUS3'J/4^WHKUGSV)QX5/X*H7+]C9=*;'T\E; MFCM;1&U&+CHN(ICZ78J'+\,F7U=BIF1@JO-2J@KJR#6/DV[)VY*:<+'5\TL> M C&1J!]8\S_:?DI@Z2,8/Q#/KKCU;3TI R56N*5=62O)^1FY9ZR6%9^DXF3: MMM-OW K!1BSY1\JZ MOD(6=-'S.LWERT5"7:^GB-81*4'(Q#1.Q5S6,A5+&E2Y"2911QUQ[?G.WY33&^XR,G;XAYGV_DJ"PVI=H,ZS MZ6.I%J@X89#9;]]2%KG%J3\A3IKDQ7+P>DDG$+*X8%E[/JIK-1K1$U@^%)). MC5AW9V#1P,JFR,_)@X_\)'EX''YJMP?BWSZ^\3CKY>/S[U>NE*E\"V9M&:@= M93.KM>35*U-'5N&D#P\;&.[!!S.VW-L>0=,A9>2:U%#TT[62ODO2PPS+_P V M5-'J*JJR+VA.PWR%9/92KJ8I3%*8I3%*8I7S62!9 M)1$3J)@J0Q!414,DJ0# (=R:A?SDSAUZE.7W*/00]\4KH3UQ(X"'Q>Q%ZATZ MDFG@#_8/<.*5QJTS+'.K Q(NX;OQ8$2H\OQ/V]IG6GZ X[@_ZX$FKNV 1Z?89N!??[ ^K.RX> M*C"=&>Z)"L#R);0?G]6?77Z>_L-E(<]&-R0=U-<530.NR7(D$X\MR5?/4F\* MQ\5#?+=L8W0S]*43 .ON84*I/K![!]A4?K]NG\X9 <5Y]T;5Y%N4/82$;_&2 M:\E_9LM!-^X'6D8";/&P.,;9ZY)]?7:N[?6"+E8:V) M-%S",:WF8MR*R*R"7KFK=VBX0156(1)P9-1(W>"!E.A#)*& "*IB;&\Y]JE: MDD$,*4@*P K"%@:5;9RI/R8SC.*J/A#VCZ:PS\+HWF\$-!@< 'RXV[MN@]!# MM;;.N[4"C]0@!4^WZP'^?.HXF(5>Y!'146T+Q_YEGB+/7VYK0MQ_1NUMC%O.6.H_Z,T2NQ;*F0*4Z MO=')*I,O);-%3M$P2(7BU72UDX$HZ@L)TA+FYU:3NILI.-\[]!L>AJ<]R96A MJ2_'>9C.' DD*T8Z9TA:*@I2$'N'!)4 E)5R]/> M("59(V)[PW-:BF4M+.C2I(^"L #(QU&Y(]F?#I7ZV!49>U1J\8P;0;5!BBV& M$6<3$JR*JHG5K4KOJ"@,;^2MTY40 M( )ST.,_7>KH7]@*/T#U'W_ +,L?5A&K^%D[_$/IZ#:MA&Y(\,?E%8)>(;J MA+>7'I'6BKV2CB6+85.*+J*@W%E=)JL5'[YJM\":G*O()M'3=!ZH1(BRB'I2 MNTF[A5NFF:/EQUSHS:&W.6LO#*R=CA"P"T_J'P:7B;?J@:R]=LZ_'$O+.VJ/C2=P 8A%N$7':_>KQKA^X=I MIK&<+I%0/U]8*0I]Q821!GMME0?3I6IMM:@2"HA6D9&C'AX#&^<^!FX4IN1( M+2(:' &EN:=6"$MHU*()6!L!L-1)/QUZ(>/%&GM7:,U)K:U3)+!8J)K^KU*5 MFDW+MXG*.H"):Q9GB3I^FD]<(K V**2KM)-P8G:*I"'ZE#I[<>7%90L]_1YY MSWE';S !VQMC VKGY"DK><6E.E)4<#R]7M\_77DW\8>T,FG!G=-56RL8=1[?,B^XO0>@AVO^H=1^D#"/4??H'3I]N? MHY#_ 'UU&'7\ HAD@96M6O?KC1C(\,8Z;?' M7^C[P=BF\)PTXJQK5($44>/FHE@3 #H=[181ZL8>G4.XZSA10W3Z3&$<^". M-7>=Q?Q.L[YOUU3\2)CR!\R17JMH&+7;P/Y''/RMI/Y=JRESF:D:8I3%*8I3 M%*8I3%*8I3%*^2X=4%@^U)0/^\@Y:K9*CY)/T4K5-X?I>Q%X43@4"+2("H8> MT [5UNIA'K^:'MU'W]OMR%D$!M@E8; 6T2XI02E !3WBHD!('4DG &]9C\). MV=E; 9SMY5LZ2M%;7<&9IV&&6JK:_2_\ [,V89/\ M>[O^8:J.H]H^FM54V/\ ]=G3_P#-:IS_ /55K"'_ /'_ (YKV_I\2/I-8T_P M?8KZ16UO)>KZ@WPI:2L4ZLE*R,45L>.1.G&J@F#LQH]!4%W +@X1%0A3@B42 M($_:R$[NXW414KNTX1PF8IOE#/* 4P#V**Q@E-T$![3=(LINTW3H/0P#T$>@ M@/OBE5GOVN*6C7KB,2AIF?53F(B11BHN#@;4R=KQKD7C9"T5*QSM<8VBJ.'* M23:7B$95K(]%D'\>[C'3%.8CJC8^7U\-C@U173QZ^'Y?5YUBG9M4;4G;%,2< MW69YK9IMCKTVN).JLZ?.I:C*TH]4CIN&@=@6"R-9:EFK%[9VJP2SQE"2#:WQ M$BR\M*YN%G-385! &.OGOCH3ZO'ION/5UJW!/S>O&P\2<['?;YZNZ2UEM!>Z M6N.A)=O$T:-:7+8>M99=Z===GMO8<+)P98R1CNU=9S7*5,.KA?!(]!9F\D=A M5YI%-D1HI0%D?'L"/,#Z@;>7KJN#D^6Y!\C]<^%8[QFC[VY@9",C*O>JRY=4 MV*@KJ4R50J1[7-+76C.GKB5L%=M\O,WZU1T9&V.32V0Z=-WR;9T^;H33]Y8' ML>TKD==OG/@<=0,;XZ?D%6Z58/K]GGGSW]IJ57/2=L+?[6G#UN701<3-1)IF MP4ZMT=)GK.K1U=K,?K&,U4@D_1CRZ];4D*52$&2S,VNIW4+>/7;-&5=M<:LFM:IJGLA> M)-JQ+S)F$:2V2#5..6M22 I2ZLFFX>%7KGID^8/L/TXWQ5,;G;IC'EGK[/ MU\X_CTD\D*=+3U04=R,IR*WS,[*=O9$CE6=U)8)/>LO2:_8A,_4"7H#B47U5 M(M**(.(E%V#1:0A"'-/"=GK[!\HQ_;5<=-O$Y]F21\^*_,#7]DZU2LI$J#;K M-'35>?'8>KSS]--QX$^6/#<^ORQ]%<>.T-8(Z'O4N^A59C8T3=M M+*Z]LAY(KAVTB:7KG14/9)"J.';PIH!I+3RJ8(!QUVQ\0 /Y?;7)C]>VE*RQYD-?SC#;J&VGU@FM[+NX=: M%DM;J7-]*JQCB2)8 L,Q7Y;7JB-&B=9+Q0-*K/G92*#-JQK\?;EF?7MCIZ\? M)UW]GQBF/5OD[GR_^CC'T8KMMKZQVA;I.#9R3PUG8*_D_:SLE5$W-$;?#&/( MC3EGGFGI#6Z3DTEDJ-!6IP[>LY,BSF/3ZY'_ Z"-!UF%7XWV&!D9*O1!Q%.$;'V MB:*='8Q;-J<;,L>R%:^#HJ418(5E)O+)&'H5E3M*:DXOL2OF, MM*QRL?&)RKE>M1<8M7(\#C!QX^=4W\1G88]1QOZQOXUV,=Q\GI* MMSDC8ZU*&O2VR>-J<3+A/^5.16O86G<=ZWMM"O2[26*M7V4DRC-IQ-M3BG3& M0M#5!RFK\33^"&RF1GU85X>LD?DH!MZ^[[>@S[/'/C4O;:&(YV.:$DJ.S_(O M$[&N,S!5/JP+1BPH).?ART(OLA&^R24&YBS,4+*DM8 8I+'8OE M*9Z>>.OCU_-]?"JXWZ;;[>'0>'RU&6>C;_ 4JK_(F.D(78LAJO:55N-E7LAT M[!(/GJ$6>C1\[;1?/95PXC1CPBJA."I*+T=H=08L6CJNCN&G?E8TV!'430,U2:Y-<8MV4]>"GC5%E$6':,VYU\ M[IB0U=C9IB,7M+=Q"2"B^PG) ^+.6[(Y[#()Q3!TE7/3)SN//IOGJ/FJN/(8 M[I'AUVQXGRZU,MCZND!D=DQ\;JN4G9^3C(>/XYW.MKP$5":<;,J9#0T?'QKM M68C'NMS5N]LYNZ34A7X5;Y15V6CH=O\ *AS&)U-E0'IO[?7O\^WR>JA'48_S M3Y;?-@_+ZZX\K3;)JFAR^U(J&:*[D1WK=7[-M)OA0#8L-L#;MKI],I;^1;*2 M"[2 D(*Z0UBJ\(50K&%LZ4>\=H,%%IM4SJ?5@#V8'7YODV%,8W\=1^,'P_+6 M7-#JXTNGU^LJR+B9>1<>F25G'?4'<].N3G>S\^[+W&*FZG9IR_EG*28@BDN\ M.FB4B)2$+0G)S5P&!BI4DBD@3RT$DT4^Y0_8D0J9.]50RJI^T@ 7N45.=10W M3J=0YCF$3&$1I5:^F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q M2N@B_P!][-_7X_\ 4L?BE>;KQ=0%'EU C^Y]1HBCJ=1]@-VW;9R0].OL/3RP M 1^D/8!^K.RX=*C"?'5(E'&!T);1G)^(;>&_G7Z:?L+5)7Z/;^WG='%+^0#T MS;H"T[?'M\=1OPR)/T?*6DM.\0*_4G$ +U#M$PT>WJ=1^SIY70 ^LQ@^SWA> M+$J[;:5_P1V@9/34=('MSOMZJ\^_9NM!,S@1X#=<6ZM*.W1+\=8V/3?J>OE6 M]"WZ7F'ETF;:E2ZC>;M7 MK11)6)B3N2IF>F=LX=4ES0T-/P6M!TG3_"6H$^OOE.>H3W?;\#!K"EJV(6LJ MP?'NI '3U'X_,$U!)G0ER2J;*$G82NVELW8PCF0E#RA57\!+5N+L"S:=AUI6 M/%]WM[!(1DJJX9+M9B1:PGP]<1)(*>7A6ZE+3I4@%*8Q1OC.DZ@YDX.0&R0- MCDX\=ZO0CO#.-](! W!!\/C]?A42\)!N\9^'KQX82/E_$(V/V!&O?*.91#U< M?MF^M' HJ&(F8Z/G(G\LXID$Y.AA(41Z!T'$Q2J[K<1\%RW6-8]BK%!4/I\O MFK4MPQ'6/$3;B#^,)7U\_.J:1U!QIXT6BZ' ME+L!W<568!X\5,U9SDK\(0\A)L(LX<[4S11%!4J*-M2=TXU#<>VNKW9< H>M M)^Q=3D%,\3$D"8ZG35 2PGQ3XP<@)*&.1B8A2&$W3.ON:BW M$RD)5]L2,*&H;A7AY@[CR(%:;&D.)*AD)(41Z@02/C Q\U:9-G

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g582934g58p01.jpg GRAPHIC begin 644 g582934g58p01.jpg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

    7!E/2)297-O=7)C92(^"B @(" @ M(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z.#&UP+F1I9#HP0C4Q M.38T.#$R04-%.#$Q04,Y,$4T,S)%-3%"1$9#,SPO&UP;65T M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T M(&5N9#TB=R(_/O_; $, 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! ?_ !$( 3X"7 ,!$0 "$0$#$0'_Q ? $ @(# ,! M " D'"@0%!@$#"P+_Q !Q$ !! (" 0 %! @,#0\(! \% @,$ M!@$' @)$1(3%!4A.7BX"A87-SAWMK<8&2(Q-E%8>9>8U]@:(T%665J!E+3! MTM;P)"4T55=A<722E9:AL[G3)S(ZD;&UPM4F0G;4*#,U0T1'8FF%AI.9LM'Q M_\0 % $! /_$ !01 0 #_ MV@ , P$ A$#$0 _ -_C@. X#@. X#@. X&HMYD^^ODTT-WRTUK;J]6;U;-3 MB-J50F ^U_4FSZR*(W$GU;W&;,ZI*D!5_&".Z05 Z$7WXO7-6'5Z2#LNL0>N MY,U\^1B2W VD]$6&P6[1^FK7;"4@S:K/JG7EALQ>71B>L)96P&JB')&24K6I MN:2,Z\D3B,F3*>HQ7FX&9Y<- ME#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. MX#@. X#@. X#@. X#@. X#@. X#@8WV_M*M:4UI<]I6Y!22#I8.89D#@4%92 MP&GV&\X@@:\+;4A9(\;FJCBQ$+#C2'YTIA+S\=CVK[81JHG>S6NP+1K0&)JM MTBA-E3M>U6/W*"5V=!+5U$AP^+ET2 M"??M$8@$;B2EEX;PM$@NNT6TK)3+K MLRMF+?3*[5].;GVN0*UP 1CB2Q5Q&IZ!=4C8\0A*8CYP47#<<4OUF4.(2I6 MA =^R!_#1:)U:*6785_L1.EF<3B<=TJ(#1/62C./>"A0? :_P#/E3([.%.)"[JD6\)L*EU&_5IYZ17+ MQ5P%OK\B3'QAV*\[ FL+=CNXPXRXI3:\84G/ ]1P' Q?BN9P^@,=?I>'E&_L\._?XDO M27^3S@/TO#RC?V>'?O\ $EZ2_P GG PYJA[OSU<\K?5/K!O+R)W_ +C:A[ ] M;.T6R3%+I/=>:=+L1?2RVEV+)PK& M6PV%. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. M X#@. X#@. X#@. X#@. X&G=]D(]IMA7SL:CJ1H?NDCJ'8NH?3G;/>2U$Q^ M[X.G)NY-SMNC8.A>N>9;]EK:[(2."A%FL&*:IX@P49L05Z>-]@N)*:#97Z$= MHJ]W4Z9];NTE9?8=A[DU56;.39CNH>0,MK<7(B\@EJ1E6,/U^YC3P22VKT.- MOP'$.)0M*DX"77 <#$.[M'T#L#0R.O=BP)\L/,;(+ARA1DN"*AB&G09")L8<:(M-MOK?A/(D.-2XLAE:VU!'#5WC_U1J4]JR=6[->9-9U5F@GQ MM&,3AA((^54J2Z[^NK/ V!>!1KN+_TAKI5^]I]L/SS:FX%Y7 K1\S/S3'D M?^A?V'_-E8>!*KJ1^"GUD^CWI?\ -Q6^!(3@. X#@5I^9"Y6[7OBS[WW:A6B MPTFY5KKAL$K7+94S)&O66OE(X['NY((<$R(A,40CY5E3$Z#)8DL*SZ[3J%8P MK :P/AJ[ [>I7D'Z+5*U;*\C^I-2]H>E$PG8ZQY&+A:MBTGMMV(C4ZO6MX[U M**DI5V'5VJQXS62591>Y=!;'2KY!DC!-G?" MR1CT(BM+V0PMNXKLNP=H*N1I[VRI#3)SJNQI90%&PQU$6(C[OV".[I?;E%%M MQ:=*3'U1%K29*MB,//HCX!2*"KXA(?==#.^\N[54T%V'T%U^MVH=Z$F^P]A# M4VJ;GKE'8(:1 W:P*LRA--M]U>+Q%";),AU0B1:&LCICJH#D60GTX=5AL,M] MD^RNH^I>J"NZMW&30.@AS-6KTF57*=;K^=D&[I8AU4K(L54J*$L-I,32IXM M@,L"Q$MQ*W\..)0TA:TA0=Y%?('TO[K:/H^J:K>>Q-*(U3LKUKWE(*V#H/W> MGPI8G1NWJSL@L#99':+]N@B<@@GAHZ0O_4T>6^V[)_I*5<"S'57E[Z2[CVC0 M-.U,_NX;>-H6#-5I#%_ZK=F-8 3-BP*)FTB,6W8>J:U5XDUT6&)RV&)I>.M] M$-[#.%J3ZO LYX%;>WNK>T;KY1.FG;8*@!G4NC>N/:G5]Y+;2V M_?+KIX_Y-MM>0/N'J3:5U["[(SHK56D-J-US1>A]?ZUO"Q5;U[9M/-#_ +5= MFKF,#W6+4NV,IF&0\N/EZ0@I)EEI(;;*,*2E.%*]=6$XPI><83ZZL8QC*O5Q M\F/6S\OHQ\F/3Z,?)P/ZX#@. X#@. X#@. X#@. X#@. X#@. X#@:'O5S0V M_=T^.;R >1RO^1CO/JWM#UI[%=UB^NY,GL?;[5HA-=T%/^VX'3[+IZZ/&ZG) M!$XB)8.1ZS:HL*.]$4@;)B17!LL-OOQY]@+5VKZ+=2.R%Z',BKKNOK]J_8MN MAQ8WN4)-ELE4&SS<@=%QG.(XR<2A. F/P' &SHZ1["]I>S'8/3VM^W^R>T%^ W"3([/ZBU/MN#J4%5 MZXS60.O]4L6JG$EURLQ8##:IBDN+(%GF8BR,E_W*/Z@9J\>G0B@>.72UHT!J M>\76V:Q);?V'M*E +E@)AG5PO81".6DZVI^ @T:A%,"%$SIHANW ME.XRCT!._@. X#@5 ]X?G,/#A^,#N)]6Z;P+?N!0SOGL%X[*;Y4=<=HMG>1S MJYK.Y]:^O.Y.K=TT);;]51EOCV/85VI]L=)E)\RS1G04@ FM9@R0][CX9RTX%W5$OE,VA3*QL375H"76B70+ L=2MM:(1RP"Q@2C"9(XN')Q%N M1IP^;'6AZ-)8<6TZVK"D*SC/ CQWRZ_V/M=TK[5=9J@9#5VU;ZT)M#4]>/6' M$S((.8O-2*5X>1,8',2I^1T23.;>EXAQGY/L4+]BTM?H3D,RZ3H\_6.F=1ZV M*RXA IKW6-"HY*? ]KB#-GU.JB0,R7"P^AM_$23(@./1_;-MN^Q6CVB$K]*< M!D[@. X#@1V[;=<*OV^ZS[NZPW4X=K-4WEKP_KL]8*Q[A]L <KR MRG;AZX]/]E=B*B( WNL7"KXAL%:/>*-$: MO@*,0=MM_UCN8+7XOLP#I-+W8?JE;" M]LA6QPVW8,&+K[69)Z63A;3L%BM/LK(0*S;<0DH>& I=IL%DDUX(,$N16GY,]_P"A>G'R^C/HT9V"]'I_X/ZGI_6SP+#N X#@. X#@. X M#@. X%'(+P?U#5&RMCV/JOW@[M=1]0;@V61VUL?K=I#8=4%ZMG74[-1,LL^G M/&J:7M.MV;![)F+/;IQH<\F#'AP6)+<,>-CP@O#:1[)MMOUEK]FA"/7=5E;B M_43A/K.+S\JUJ]'I6K/RJ5G.<_K\#^^ X#@. X#@. X#@. X#@. X#@. X#@ M. X&N4%^QT-<0JGLO2A7OKW@F=3=P;8NVW-E]6*];->437ER,7VQ-6*PA3AZ MK4.'>IE;(/Q84.<+58DM38D-GVGJR,>WX&P30J+4M7T>GZVH(*!5Z/0:P"IM M/K8MKV X#6:T,C!P@B$UZY&E.FVA"]AV[O*OZ!+[)BV/7VH[M9!-I+CF]F2: MJ8*AL+9J("QDF,06Q[Y-R6H9(98:B*EZ'#\8'<3ZMTW@6_<#7;\C71CI?9O(EXL2] MCZH==3I7??9SL;]V\D7TY02,[;WP_J9M.RP?NDRI0%UZZ^YV(8..Q?MB60]@ M6@Q"#7JRH[3J0O\ :72J?K>I5VA:^JU?I-(J(F$ JM1J@B" K=U;6K7B*>M+T-=>#N$ ; MF+9="=5K3QZN1I.)R F]XA%=:G^N.P"/4O:>YMV:7)[ZMKX3:FY[Y=]G3+B2 MB4O78DQ,HE[V'!A6FPT(?*'?!(TF4X1@,VD7;(88G)$1X6&@M6X#@5F>2=7J M$?'BK]KR7=<\?\NJ[:1_\7 ]CY'OO/:9^FYT:^M)K#@6!<"O#OE^SSQU_3_H M7YC.P7 L/X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X M#@. X#@. X#@. X#@. X#@. X#@. X#@.!7WY%M/6#9.FF+F+[8;:ZA@=&IM MNT[Q?M*5+7EIO1JJAZ<73/KL?&Q:I<1D"!Z5)*2E0!*9TUX?%B*FQ8BI"\A7 MSXH7X)_<$2X&>_G8KL+>"VH-OP7.N78Q_JR5NFL(=9W%3Z<;MTYWK%&R, ^_ M$Z[ 8&_&RYP7;1AEJ16IKD6=BLP'"J!X ^(AZ5*EE#,5'J-X::PZ\XVC(1PK/>77EHN&NJU' MIM^&B[YG6 .?;3,:O01-"V7N'6,K;M$U5;Q^; X?1:Y]/:'YFS PHO6AYFQU MH.X<=E86BQI?1>O9>I:+N?9'VE]?]B!I) MF\Q=A6T-&LDJ'1[#L(830'K5AK\J8Z1"@XU:.,!L9LGQ-82(Z0]A:)V6H&R+ M_IZV,["T4/W1;:EI78< 3\, 7&G!@=3?.2*I)2.$QS]3K.RR%^H5>L,,>B&0 M'5)E$>:;1'^/% PUW]WQMW4$V$C6]KEU)T-H7,A#ZK,5NK=.O;1J41K M[0LS%J"&GIXN]0[I8&Y8"E.U^^$GD1)H2QCV1,Q+P>>[2]B-K4_N-UBI6N=B MM-:H-2ZM$VW7:_)U^LI'>M&Y!= &$'0EGKA>S;3#F)\,'AO)UO/4 W=_C:Z]SMBU6+N^P=^^O&R FKWB;*;@4H0^%M0 M(0M<,1G^G.A8A/UH+TW'ZA$E.6_U\<"1?D?^\]IGZ;G1OZT>L.!8%P*\.^7[ M//'7]/\ H7YC.P7 L/X%9?D.[;=J.N]AZS:TZ>]>=?\ 8S<'8FY;" 0ZML79 MN-5!18C7>OYU]+$VK"[#E1%RLPX+K2(DG+7M?1A+.5NJPG@0^_15_9"']BIZ MH?QV@W_RO@6"^.?M-M+MYUTD;.W7J^N:;VK6]O[HTY>M?U*U.7:OA;)IO8AS M7Y7 ZS.1HN"K+\T(\[B2RU[LOT^M'6XUE*LAW%LWEMNV]LK)U:TN]K>H.ZOT M7KG>6R+ULZIV2^))Q]OWC9]+HE/I53K.P]:267HZM.7,G:K84.S( ],ZMCAH M0I*?*+'!Y(AWG8UR8?IFTJ&8+FJ3L.@:1V_L#6OP;.MJANS:U5"7+6E.CB[/ M:8]]D0K>(N>N8K=@9#D00,O?@D4X6B185CF@@PP+\IK5[SJF)K?KKL19K95B MZ?SD![M8]:"):-1]PZGM6V42^#U!+P=A9(,?<>MX&;7#,X00A3VF9[C4B&IM MI\/7,^3ZHOTMJ[-]?=W*B/:TVIO!H2F9J)TV_I32)02 VAL*/"C[->2XD!8" M[ @;5G'F+79W6),H")F0&TREA(3JEO(YO GV7DS2HTU5J#OV#4M8D1XE0AR1 MKH_U^T/ML,HDVXM3LJ?B?LTMCWQ]N,^N%[FR]';=87ZP2ZX#@. X&&>PH+:] MGTOL2NZ1-!Z[L\U7)@VK&C= 8E/CRN8"I388EF-(9'%5P MYLAEUEA:%!6K1M!=VQ]_!F+K)/E8F=LTVPFYHS;#D8/"9A&VI/QN*'=NCF#M M)K5&;E5(M798028L]@(KE.5TF.BPS40)O&^Q+D !5J+K2Z"5L MZFHC\]+]^L.U1LL9)D2$+;?AC(M%&8@NX8;E..2IBY3KWK,I:#)?W,-]?NG2 M7\$6N?\ [MP/HSJ[L)_4[1R\8].?1Z=,Z]S\G]3Y?6QZ<_MY]&/3^UC@?'W+ MNPO[J25_ QKW_+X#[EW83]U'*]/XF=>_Y7^/@/N7=A/W4_P"7P'W+ MNPG[J.5_ SKW_*X#[EW87]U)*_@8U[_E_Y7 Q=>2>_M0;!ZVLD]WQ[]6]I;U9 MUA:@!'5]4 J4%F:GVOOAPY*J6:.W*BJG5[8DXE EOUP 0&?$$L6%N4)'C MY:/6GD,25"X[X0TZ\E._TC9E%C;+E71^IXJME9>EVFO#8((K9Y0ZU/R35Q9B MU$&3&!:K9,54$!KR2@6P6B&Y(/5Z=-KZ9.>!)*BW3N1=K)M^O(+]9AZ]3[%@ MZ_>E*I.TY"3;DW5^MME8)MM8V*UF"AMK8:!.8JER5*<%JF>WPF5B.P&2?<.Y MG]=?6/\ @_VK_*7P'N'X=S/ZZ^L?\ M'^U/Y3/\7_\ K@8<[#[+[CZ$T/N+=SQ'K/8VM2ZUN>Q'*^W2MICW#2*B G'% M"T3U;&DIB*G8A9CIDJC/88RY[3+3GJ^HH)_\!P' AKVTO2JX>ZUTB;N*!I2L M;>W-/H]J,G*_03@/8(UG5VP+&SIA3VPQ!D*)-; F!67H$I$7$N:(KUC#059) MDAZYA.C:=&E;(I1:F1S[->8-I;BD MY,FJ52ZPYHE2L^_B9M981EQ]UMEO&<8RMU M:6T8SG];&5+SA/IS_4QZ?EX%/G?R?!7W_P#"TM$R(M#79OLNIU:9#*DMX5TR MW#C&5JPO.$8SGY,95G&,Y^3'R\"WYF9#D*RAB5&?7C'K90R^TXK"<9QC*LI0 MI6?1C.<8]/H]'ISC]O@,'1\V*?@"'&/L$(,&,3*K3.C M0PE%JU_4T6LII^F/M"ATS7+\>E,UK6S0*'5:8]%#BC,6L0A5;0T'"XC!#8>> MR+B,,-L0B41Q+*$/)](>U(!A!9PT5$N$(,68X+*,MNM,DARY+3 MBH4]II]YIJ9&RU(;;>=0AS"7%XR'7_:?4O>QL_[5J[[\&F%" >;\$&>]BIYM MU3YJ<-D^Z^V@S"[ZE/%),5;3Q!U2G):W5YSG@5F>3>O5Y=C\=MJ=!!G+-%\D MW6,/&L;@N"L[&%2(6RW'1C!=3&2#(]U]S+KD-N0F.MU67%-Y7G*N!E/R/_>> MTS]-SHW]:36' L"X%>'?+]GGCL^G_0OS&=@N!8?P*N_(CHGNAL"^]1]V]'\] M?I&T.NEUVH7(B.QDZZPZ43!;*UB1U^_B/BBLJ,/$H?Q!R2RG,J(PA2$*6IY/ MK,J"./QC[(W_ *T/$S_SQV8_^]\"9?C.Z];UZV];R]1[)RM;RMRWC?&_]VW/ M&I91V90(<_=.TK%L/(VO/66-%->YC_CN8J&YZ7GF\-X2N5)5C+J@DM?NN6I= MDWVO[2L0:Q#]CUFO3:B-N]$V+L?5UED5*?/05>JA\KK2V5*5:ZRR62HJ/ 6A M9@2**2)A$7$AS9TQ]\/$$^E76TO9R5PET0J@X:15UG5P=C[0%C+ 8I .17:; M<;!7QESB #VQ*J*?;;KVRBXR9?A,P<#*PK&R5KP*:.#P%0\;W4*B/!9-8H=X MA2JW7M#56ORY6_NPIB6$ ]8TVEK1L(7*,[3(2(2J)'N]PAL3([B)QR!934"S MR34,A(86':1/'MU.ATJC:_:U_:':YKH'LZJU;,S<^\"%@:INYB3!?:%&-W&= ML>1<+;0[D1BPY16CVTZ;JF%P8"8@>,B#$2R&<]5Z'UAI4ELHKK<(5!R=N7./ M?[RS,N-UL@R;:8M6K])C3 @6T6$T(IL&/5*I6P3(*F0:^!;@A1Z$#,*CH7P, MPO:Z.]'>M^K.R,F3=1D+9-,BJXXI:U3!DPG1[+ M7I 23ZF89HJZ6@&0#CT*7 #FHKD]P<'&Z1;O[P[A,[*_1D]=M)]9,A1E3S0: M'KCL8,[ VDWB5*L6+#;3\L34:G'KU??RV)#A8[S[3]8[;?,:MJO8O1=EV;D@3$XUT VU0C%ZR5"HEN&1F*D//R#V2 EN!.<)0 M\0/>(+<.4N4VTF.[E 0S[4]N]JZ0[7T#3C&Q]%ZWU3=^N^TMQ9M5^T=M3:=J M'6+5MNU[7Y8%+5&W;08*P?K53B5S$$]-M M]HLMG*"&+.$#(JI^9#*ST!$^-Y9KUL'7=WN^KM4U<48ZW=;=L]A^SM,NLXJ7 M=64TWN'8NF+!IS5EB#D*_%;('CNDMP%0.R[&*(BF!PNFLSZ3EZRE7:P&:-8> M1<]L?8.M;'&K-6;ZX;G[9[5Z<:_FML'$;+9NVL:A;S#&QS,QXFH!(J5QMNNK MM4(=5BUV&6!06JW:Y5E)X,$:^""8W5O==KW?7]MD;@%KP,EKCL;N_2L5BM/D MI,&:(U7!,S@. X$7>U6M.M782F"NKW9_6XG;E(WQ/GAX=$.5;&P')ZQ01PU(5&C1W MRKZY(3BX#@5 ]X?G,/#A^,#N)]6Z;P/ ^?#6U;W/U(T-IRZ9+9I.VO(-T@UI M=&01B< *RZE>-TB:Y88<(P-<9G#I$D60DM-2XSB7H[BDO-Y]=">!'MS[%1\0 MKSK#SU#WXZ]%6MR*ZYV1V>MV,MQM33BV'%%-Z>>-SK)XUO-7KV@]7(&P ]9VAXWM_6ZVP;QLBT;!S).@>Q'7\,-E0G;),E M*'I:@2WVEMQ\)2YE>5*^7T^D-G+@. X#@. X#@. X%1?8WPS=*>Z'9S878#M M]H37N[7C=,UO5*(0)&-@!K55XE0C'&# : M7[5C,1383#Z>=)>N?0W7-DU#U=HJ=;:PL=^);'^TN,3)%18:PF*Y5JX5^$/F M),XHW#GMU.$2>8F3YBDDID]QEQJ,XS%8"6/ <"KWR=J]7]+V5^UY.^JN/^6Q ML)'_ %^MZ/[O R!Y'_O/:9^FYT;^M'K#@6!<"O#OG^SSQU_3_H7YC.P7 L/X M&NQ]D!4#N9NH+U,T=TP5D$/4.W&*3RTWWK%?6*S MY,NGEQ[+3E;9U\-JJTL;57K:;$J0V0#G!$CB1T)BQ5^Q8D5F:]+E,?$:J5'3 M VK_ %[==WAX\@FP&=K[6W969N]^QPW7FQ]WG9-CVD?UD'VY9!^OEW(I)0R MITRQ5F1K,UIEB/%8D)=:BQV6$H;2&4.PFQ.R$3NJ_J?6]Y[#KH,SJ^+V>FMZ M8K?3V='IUOQLTE2G[#8I>_:QBXF*K+&,L3)P&H$['852X M^UV^WM#]]NT5:VR/J:NE-XVM5JGI=ZGT@A3M@CM*TRL63,C:A(F)>OZ2F\$D MGC5%D:]NM)&@:S;*1(:A6YQF6\;".NRO)GV>I6M)._H$,8E=\V)W0U",T%8Z MP-RQHUCKB..(J.V+&1'Q(%V*Y8DU-VR;/A'CB*W*K=]K#=?8J;@SXA8PF>CL M=O"L1-PTJ1?/MP):2\AG4+KBQL@Q5JC',776N]3/5TA<@5E'UL("J$2V!QVZ M[K( &N.-36Y?P]@PW*(SPM=X#@.!51YGM<%]M=#;S01*>O+R#E_U!DS" M[5[9M.EM!%*^-V*!*EQ6Q;M2RP>S($D8T+,5D*)D/R3<]R+!Q#D87G"0KD\ MW6T;U^VGVE^%5KQKU./9M?Z<]H+\=6_MG;M"R'AEBV=_J_93>TRY Q7BBD3$ MQP:QD9@:1B,RTK?>E1%MLALFW"Y577]=)6Z[6 55ZR';:<)G#4QJ".A(?D-1 M&/;R7E)0E3\I]F.RC'I6Z\ZVTVE2UIQD/*3=UZC'E@8&5L>G(-68A7Q0 4@[ M!?(%B%K@ODZU'A18[SKSJC@V,_/&KPC#4J$TN2VO+./7X'@ZI^%7NW\2/7;\ ML.Q? D9P' R;0-NZ=T%M :I([63 MB1G8TIM;#2DA_5/Z&='M>[73OBA M=.>K=)W>DNIEB[/>.?LW7IF^ M]ETBLZXV7:]M5YDQK'L!/TS8++67#QF(,#,SM5;;JLB7;J;7K8(KUFJ=:A11 M]8L6JK8'K@6.+#L*IXRM4FM+A:CB!LW07VSZ&O/7'L!77;52;M9]N:XO=])W M^]/V^^#VRT*3;+1;SE]L,#8X9(4[&&;5N:'ZZ!+2Q4>IAG'7G1K3 C8%0VK3 M[45)ZS#;ELAFF7C9=BN!+MKVKV&;I3[U&S%CP]F;5AVG:1 MFIKEUJ-*@# 3<2KV.6&GV-^.YZD; YJ32E!47&WUFJ+LA1 2O(L9T8$4=,N-./MB1"24J-DD26RTX\B%#P])4VVM M>&\I3G. ZVG;3UGL0="+T'85)NPHG.)#!Q*IVD)88$\B&:0\7@0Y8F;+8DS1 M;+C;I"*RM;T-M:%R$-I5C.0Q'H;[YG \S/WF^G?[ MZ)X\O^OL-7,?^S/ M^X%05W^?=Z]?O7'9?ZSG7;@6^\!P' SN]U'VA78VO-'].OT/%JE@:F%WEVH[8_H>!3VQI]:M=K*5^6_-J9>OC![ M$"M)'!Y9$S%('3LU X>,D)0Y(;"3OC?[6[$[>Z.MFPMHM]>DVZK[@N&NY#W5 MW;;>]-.R8 856#@Q8/:,:/&'68I'AV5L?8UC&D11QR'-%NM1IT.9$8#TW;GM M/9.O:9/VJ5@#8'*CHWO7SOZ(UL(WP]L^!G4UC, MVFDF-4[.M.J[$-*GPCE>*^N=JL%LG2WICHOH)H&M=:.N(6RVO/JL-Y2VC]2G' ]-?^IO6S:=T(;&V'IBB6Z]EJU&IA2V& MZ)!PC4(;LB1&J\V?A:'I5?:D2Y4A(=Y2Q^7Y,AY4?+KSBU!AWL#X^]%;TN%" MVK%&IUSN#61BNF:Q>%'8P(/&)CY4X1B$(D.8Q(1(B1G&@S\E.$I M2E./0E.,)3C']3&,>C&/[F.!\\!P*MO,CKL=LGH7LL>[?'EM6+BV6IA34"OD#PUT:V3* L688VQ)4E$ MR.1!X)A7B$*=#S(A2&HID3-0W(4[#(Q9#;;J0A17?'M5Z?@K"58C/3'DS#,^W=AFY<]:IDB2M+CR&&4Y0TI# M*?9X]1M/ISZ0F!P' ]3.6%H=__%J2K(99RG*F\JR'D=::5\[@S8M#([5 M[P]%+1K"!<:U,V)6JKU3O0"SV"CQC$-ZU!:ZBTVNRZ8NFL=F[-N MT]!.H-SXYI^C[-'[!%.J.548;EP+)4,,V>/#$NB9\<(W=L=5=I+]<=LMZ\UO MLRG3;UHJERNFEEHEH9&A-!=GF-K[#LFPK3MR+6SD<0'(7*"=UY:+.<*0;;7C M%>"W"@*EEYDUT59PP@2U#OFR[,LP]W5/9@I$V1O?R T:V3+2[?']?EM$[)T4 M3'ZA9G0;%;)]<#T4SN-RNSZPEF*Q*KV8\EY[ H0Q.PH/-U+K9V&EU*[P]6ZD M[(:LO>K/&IU/JFAPYJ]777=)SV)K:NR 3LM7ZQ%';"508]^MFN[Y10MU'[..E'T MOA7U?.P_ ]YO74MNVK.UFT#.TD76JS<(I^]BK339UA)VP.-F"RHX #/#[$#D MU9C!H5!+%UKHJ51JWM<-:ZR,8 M#!P5T+;BP:D7"WQ"D0?B]5"S3B):(OXA7[C'S&'5VNCQR(/PQ#ZP]'U0I@;7 M]G[;U0 _89 D9V2%JBO6JWVN]G5^^]8^M\Y[WRT78U8+*1PE^2ZF,D@6DXAQ M<,PHF&8<>.PV$P^ X#@. X'QE6$X]*LX3CTXQZ!\\!P' \ MUU2[,;5ZX;(H;5JND-&H1>NYMFVR1@U$NQ6M:R)^SX4ZL!A9*P/PY;TQY,): MY4:&PX7%1%R920K;\/5B[47#>^TS6S]C^2O96L1VK<@)\[OQK+1NIJ^&V&Q= M86!,74HW5$M4JZ3),")=&+78_='00ID8&A,EYL@HTQ%"_&][&U[JT"NT[-OE M,UU6&Y+$-RQWNT!*B!1+DY5B-%67L$X>/3)D90K##"I&'7'#\8'<3ZMTW@/,S]YOIW^^B>/+ZPU;X%OW J"N_S[ MO7K]ZX[+_6[88L%2 M S)XZ#E[.]?'G+IU=#=-( ^^6,;K[KQ"FZS>L%%H+,((^.^WL9J%MNB5BVFS M4D^NSZ\R>DRSJB$IX)([7T'J;=_P+[IU578\5[XBS"2S8+17D31 M)G,!9VJV1NL&@J+A1;"X)$/V.@6U)NDV&0'#R30"<^*'N1@Z"Q]7]*V^V@[S M9Z[8#=FKY-\I$FS]D[.>BS_7NF-AP ]G#YN. MRJ-9N:4'J-2+<..4[7\E"& M:0"K\-"(^ K+\K'7[59+=_C:[,S0A9S<-8\@75/5H4^BXW*.%CTPS9;L5G#W MZ-'/-46?.=GON.MGB%<1HY-J,E+. EEY'_ +SVF?IN=&OK2:PX%@7 MKP[Y_L\\=?T_Z%^8SL%P+#^ X#@. X#@. X#@. X$">Y51E]D\1^H(%.T:18 MK!7Q>Y!_8VA#M5V$'H&RT*Y0)VMR]JJ6SI4^#;W[-9P\UD3454JS#; +!6G$ MY\&HHK!;: X$QG^GR_^S@2,X#@. X'&FO>[0YPC/O>K%95(DJ]DTM?JQXZ<*4^_G MU?0TRE*E.N>JC&,Y5Z.! 78B3D?6&Y-B6B, X M#@=7+-"8,O$&9/C1I619 U[%YS#:L"13D1DC/5E7H2F-#>BLM.ON*8( M*B1!L=EN,U(F.RR49E(:\?8+OIVO[0423:NM^KK56*WK_6PO;G8.7-47R!UM MCK[NF9MHE7ZJFSU0. VV>V;4-=Q-?MRZ674VU*L4Y$&:X]6#K$ +^.KO8JD] MGM+Z_P!L4ZP^Q[)J36)NFG:,5V%5!)8F;K#J[:HE;-NNK-9>1S4';VK:\U]>R.N=.=:^MTC M1.KM4U>];9'VRR'KO+=>)O%+24/DH ZAUUXBR(K@5%SS76YJYQMZ.%Y?:6); M#&MGJI4]/V';>;RLC1[4FK3=70S]/H5I!DQ-R/!D;5OFO05%"Y08F$1=.]6-H5/?=-.KJ4>E:]IVX+-O2&8^V4&;F2:O<.I%5 MZ[A]!2T0ISYMTI0+ +R4G$,QL-$VRFUX#5NOT!_1QXLT'J9T60E$ST>.-EQ0*'2L: M*M40>U(RG#KBTX";WF9^\WT[_?1/'E]8:M\"W[@5!7?Y]WKU^]<=E_K.==N! M;[P' O$[7VE=W;%T'LG=>TQFQ6]84 -K3M<5Z?+-/ M6RNV.8T%LNQH%HKK9N;)=&.#:#5(;)*U6"T%V0()I<8F3BOAF?P5VG5-PZ5% M#&G]5"-05K.Z[M&FUF%VJ)]QS4PXQ7J3[V;N6YBQ@_-?LTN&H?#55'"TA56! MCP@]U@;(]N+A!/Q7_[T?ING_EG;2C_ .+_ !<#)WD?^\]I MGZ;G1OZT>L.!8%P*\.^7[//'7]/^A?F,[!?Z?Z>C(6'\!P' -:Z:0:VZ)JSFO\ :.E>Q\0[G5VY:/"+R;!3Y ^QUOT& M*9?*$7,V[(B6V[%$V =;R(\Y,C8@#7VP[3Q\Z@[UBE[$WYY&;QJ OV(V7 J] M-!ZTZ^Q"S.H-.:LI4RQ& X& 3/--F;1=;#8;>>,7 _+5)CH99 QDR7!$-OK M">>R;E(U]1[%@J(. Q92M!)4B*RM'OC^2UO-5^O0(T"+EZ?+D$2 MT9"8T9W#6'G\M,N!%B/WAK2K8!IQ+4VT@)8_-H#S*#"*9'5!I^P4P6(=W(QT M6UV4P.#%R@\0<#-LO6>*_*2^T&>8:D*:#T6H+P,O7:#L#-%B+F';$ZIT"$D- M72C6ZB2Y,F';NPRW)8N';PP:47#.X>2F(<&-2A,Q:'D1ICJV7<)"7W :@.E&Y,R<,@)0(:PJ7*1.G,17869.4KR+C2VW5,2C"4Y6)86N>C MT*8QG@0:\CTK9\W18;2>EZ8SL6X;:GSZH2K$QUAPB[KZ!5BJ+$<'RI3B5QS8 M,I+K!& 2>7&B*F-XBS2<'WYM;@8-Z\4,[T:W_/1>LQ4:T[=[1V,!!6"89=,6 M 5L&1LB6>T;4WH(IB>F=#L=0N%P /'"$MA%8CT2H"EX1&*O)%A<;P' V!AH@)JY1EDK0@DFS3@;PBIVRQ6627+5Z.@B#B# D]1!V9!&(S@G)Q$2 M'<=4;@,OEH[2[)BTL0[?4;/1; U[GUBZW0G/?JQ<1(2PCL+=CK< MC9G#(^)D53,V+EZ)(8><"8? DGE!=MYQI:JR1(5D+!=%PG$O&O;3XQ3_6AMUJ2$?.ST@M0M,UT@BQ3INQY M%U+:WHJ8$,?2;%:S=]<(U$)3Z]7&4+#F8$Q]L5.EMSL*:> B7K1#4Q.@C6V@ MD+5-35:P=90NE#"'G:N>TW#UM8W1\1==G3X,ZH-U@[,;CNM*D#"$Y"Y X#@.!#/R+?@#]R_HS;I M_( [P)F7&@*?>0%.WB=H?D@H&_MA#NXM@W=9M7&-(5VX M4"=;-6]7]8T$;8;:7!DUUDU&T:5)FYNWZQ 22 V(2ZN74:]@82("+#88UM&9 M&AL!\!P*@.\/SF'AO_\ M_W%^K=,_P!/_7P/GS,_>;Z=_OHGCR^L-6_]/]/1 MP+?N!4%=_GW>O7[UQV7^LYUVX%OO K7!WAV/%]9M-9%@A%A4#QL&X%:]8V3T3-QD5YVOU=$1E4BV, MB:WEM#%QGPS-T-);Y*ZLNTOL-U]T1UMN;NW+0\/HG7BX#[]128:8%JT^;<"% ML'@*K@M;CEQEVQNQ.S*X)(-OP6692)JD)*3PS3L;L9JO55UJM"N)L.!8%P*\.^?[//'7]/\ H7YC.P7^GR_^W@6'\!P' -Y:GJ5(\EE\Z/#C&JG;%+IE"\<1[O,_=)CEM-#OMF,' MA4P6Q0&HK,!L6.$.2I;II3)"9["(F&ER6'>>$3M7LSL?L_LG!O7?_9W>:!4J M%J24+?OG1HKT;'Z^EF+#LAJA51DR9>>JU2M&LKNB5&Q&1!V#?BM+.8;&R M8[DAHG#76@#>)&9+K"XPA,>G'MY;OJ>I':] M./:.J0CTX]/IX'F*%7FP->@9?;BO'"$.)*L)I(.(!)GR.6?3DB=BQEO9474A M?HFJ=D/>B5E_+>6VU8:2&#:PU.N_:?9Q,\^F4(TA5ZA6->#V8?J1(!?9P9%C MO9B?+6Z\F=8,PA-:&#?8M0G @.<1;7B4BQ96V&0JG:!=;M\K3TA,S!&(RZ=K M:F1>6ARJH1=(28;'O#*Y&,*$KB2A#TX@ZF43FQLR74IF>J6 MTVC#ZHAW8E!V?4J+-*:;O>Z:%#M(S5EUO29&S*]2Z?1'K45R48,#X,D*RO#'N_7ENV=L2H-=O^VW87:]HH3]ZL%"V#U$M'3SJAKD M57CM>$R<:(UC;]85::)GYG6N' D)@76T/31#;,BPQ(DMH?)DAL4\/S MF'AP_&!W$^K=-X#S,_>;Z=_OHGCR^L-7/]/^'@6_<"H*[_/N]>OWKCLO]9SK MMP+?> X#@. X#@. X#@:VGF:Q?XEEUY,&HI),9"#UY59$6\4@A.O *ZP9<6"D:$\O$$9 M*'.N>PI=H_1DS;ZG>UB;V#9^]5+%:SWG<;.O7FL)*#N-9 !0@!KZBQZ[( 5R MF5H*P_ 2. K*>]NR2&Q*@0=LI6S!+3,)!+2V3KQMGX;'$%!,><^'#M?3PQ=>Q>A> MRQ;<=E%VC5-K(V.UTT".'XH5NCKU+L/5P@0#C&$%+'4XD9-^FF23;EB.19ST MJPIA1!4\ZHI#"#OENUSL:3N'QO;5B;PLPW5P?R']-:F6Z_LUNL/52R6J?L@] M(A[!FVE^(JV0RPR(\V-8%0IB!+S+*77V%/*4K@3$\C_WGM,_3RGU7<-JRG.?1G@9DT5V*T5V=I3N MQNO6V*+N2AL&IU<>MNO;!!L@)L\-9B2)XE9 >XZPF?#8GPGGX^5>T;;E,*5C MT.)](9GX#@. X#@. X#@0!\B4O8M@T#<=2==;X."=G+T,@3J)K\!NRG:(W+L M^HUP] EWJLZMV!9P]G733Y"ON$A@Z[IJQ.%79T]"GIH)&(O&-;^_P!> MA%N(=VM$5GK@S2:-J#5-4H+N\:OV!VM9[?3Z[+7?-J['N%,E2*_7U7>*1JTH M54L);*^EJ;8269&#,2=+"UO@.!'2J_A5[M_$AUV_+'L9P)%\!P' <#%9JQD* MK4]H[(G#4>J "V4J.#NP&1Q%X=1!Y93:2!!#LIR;C4"(F-.8CO8R.MP,T/4\VA4.2N,J3 >D078[ M[@9YX#@. X#@. X#@0_[4?LXZ3_2^%?5\[#\"8' <",VA?OF=R/I(@/JK=9^ M!)G@.!A'<,UU,NC"(_VOOJ,F)@\K (2)PZRO5PS&:J$^92#,526!1H<7M=?> ME.S/6]Z%+F08>$3I,=]D,P$B,(,-GEB,A$4<*@RB,^4[GT-QH4&.Y)E2',_U M$,L-+<7G^HE.<\"-O5U%S.A-A[BRH[J5-O,.N-K3E*LXX$:NHL M6#3Z#:](0P::VGK[LRYZU@A(C4%L&+I9"K7:S= M+=\O4+L/L'K&G4&_&TBZP'G%"8&35M@A"@XB/,Q&'(R_A1*I M'(\KW21$M0MAJ5[8(C^/6+M8'NR(R&@NBX#@5 ]X?G,/ M#?\ C [B_5NF\!YF?O-]._WT3QY?6&KG M^X%05W^?=Z]?O7'9?ZSG7;@6^\ M!P' 2M>[]7^5NC=#-7MSP4 M?9#& #86\&Q'P-<1Z[-RKE9A,H[*";OA;JMSK/5>Y2;C5 M=NU;[;-WV&U5A6Y.W]<[S'K'5I>OM8C85D ]AJM)(B;)4Y<\23A#139@6?VO*IT8Q_R]AST?_%\G^_P,O>1_P"\ M]IGZ;G1OZT>L.!8%P*\.^7[//'7]/^A?F,[!<"P_@54>6K4&I;'U=*72Q:NU MR?N'W?NC(C[:S=(K):R9$R^[W7@5*%Y.3Q<@GD;)%SYPV3!S*S%?'S9<-QI4 M>2\VL+*Z;0J-KH2H!KZEU.B ERWIZPM-KH>L"5SY"&FY$U0T)#@PU2WVV&4/ M2=0RTE:U8;1C >LX#@. X#@. X#@5$]_NX(7QX[EIO:7ZI5Y@:AV9/UG*1#V"/HUFGT MZ0L-]L.4V"$)E2AR& GM&DDY;S[26841Q2VG9;C&'F9#7KQW0B3?[KV9"[># M0XA'63K.;)]I5X&QF6#RRY4^;,S:0RM#61 ZV MU]UAIJ8&2-1/W]_M!V!5L(93AXR2;QNNUMZ&8 M<7E_$N#$8G0F4)9RR1?4M:6PEYP' <#SEIL<2KB5D9.'W77I$8<-BQ8KTV3. M*D'4QA\1F*QG#CF77UIRZK*VFF(Z7I$A]AAIQY 11WP+M5P&ZVZW5>YQ:.2V M6JTXV62&1HUMGC*!!K)>::BP&K MEUKX^;GBA,.:]EJ=&C/2),)#[(^2WP)F MLLMQV6H[*$-,L-MLM-MI2AMMMI.$-H0A.,)0A"4X2E*<82G&,8QC&,<#H'UO M-6P;C#I94::"+(5'9BLJ"LOP9HI:9,Z9ZOO#)%YN8MD='PK+3\=L@O*<+8QG M(1^ZU8&!BO8BB0_<(DFI]@K;,4(@>P8C01MY U6_B7(<%GV?N\1^/9LX?4F, MRPLRT70VI];3KRPE)P' LYONF M7:H,S9TPHN$Z+W>/EQ+A6(PQ9,L,B4#&N[%=Y[%+I!T1%EV%=XBAPPZH@G%5 M]/MY#MDR@656&9^J&;OFT=N,[%156[A^B2%_%4TIPN[6\8_0Q];_ ''X>X=: M9**SD?[K[W[RTG&)GM\,^LSAM60F'P' \F)8>(EBYF4N9F(F0@:(@2) 6<-P MQ!PRZX;'9AP\SH;Q&9E33T>83DY]0=$D)C0W%Y;P$<>S5U9,G-:]50QN,+N' M9-N[0S"G1,PG*&Z1IX%+FW+ -PER(.8(N8/56BC9;EP"$"4PM#C,R#,88DL*].6UK; MPV^VZPMUI8<8#9(A-(Z \B= .O5H38I0"?RIYG<]&K^T1"HWI:BCY6M&*]K2S,$ M65YPEXH4CF*C(ASXWM5OC1BX4[$=(H>J6$G. X#@0R\B_P" /W+^C-NG\@#O M F;P' <"&W>OM[K?I3H,YM[:FK=Q[BJC\INJR*-I;5LS:9TN\6-Q3<*8!<9AH2N,^7R(;6&%-,T';(_N$=M):LVN 65MC89,0; MBU*\Z8/S*,_U4JE>L4IE@#87J6 :8@,@1?MYM$-!-GO$&A/\ 5VG5UCSUE^ZYW.QU6QJ%R[*VQ]KV='G\Q,[?388S0!)'%7^%8>^U MYUUK)?WOU?\ 4_L\\"='F9^\WT[_ 'T3QY>C^,-7/\7 M^X%05W^?=Z]?O7' M9?ZSG7;@6^\!P' 8;1'?.MMS7R@ "-/@1'Y3XDR G&;D N'VO2P%=+J7(C*#*OC'T MS1M%=>SE)I6V>O\ MN2[L\^?NT[JUKRB:CT)4;D6K=/S*IFO-8ZZ+G:Y38,8 M&P!L!6)@K)(F;!8BUI()C/GO=& FD_W5EZ15*B0+18Q MTZRPF6M2X$%Q>'7/:X'D,1,9PE4Y0X@B%A]<"6ED..K"9LZ1AB! Z/ZZ6_;SB1!Z/#B, M^NM"/:R'FT>NM*?6]*L8R%47D^[#: -]0R8\/O+3Q:>KL/T>EIA#-FTJ=+S% M&]X.NI(C)Q'C&W7-':<>>=6EMM"EJQC(9AX M#@. X#@. X#@0KW%WIT+UYWHWJ;?>U]*Z2!2=5@]@B+3M;;-?HY2T$SEKM5< MR!JU;.MQ&RT(%'JKD^PFDFFU0'38&$T-D>]O2(P>]TAW'ZN=EK/::EU[WKK3 M=16D@0-CMCFL;8'N@P".LQ X,"()E@$N?&9B6(]EZ3"4*C.R%^]-%Q,X?D;"'QTI?+%##$9A3JV?8.!$GI'"-;;N& MXNW.S];R*/M*WE(VE1+$R404D/1-2H8%'JZ(BNOX&RQK6WD[!D-VIJ$B?8D8 M:],K(B&*@0@L7X'C;@PZVD&<9($(6:^;B2WV($"04^*0IWK"IHYX?'DQO7PZ MS.RMN:YB2D6MOW_$5U;"-8:B?"V<# M,=FL1#5?)PC J2\-G21A%E@@/>D1778)*'+@3&T.J5&FQ9$9["'F7$)#O> X M#@. X#@.!#_M1^SCI1]+X5Z/XOG8;_%P)@! MX78Q 9#JTR"4PRXU8W&JPS%?)/AD37C6%QEQ4EXZG&96%LY2ZVA" M'FW5MJX'3+76]'ZLLAMX7!%URB@[9;B ^NHRTSD<*:(FWT0T%)B$Y(2(3"4K M]YF,QW""U^AUEA2AK)J>+H@""SBGGQ[10PW(FD439'N_$;B.!FG4EM?OVJM9WJ4]#D2KGK^FVN2^.QZ(#TFPU MT<6?<@I]=S*8BW9:U1TY6O.&!79UM/^.K9W8[95@ZD[ M6TW9MS:>'W.A[DU[I'8@:8&KA&\6:L+L9NY:TKD]P#"N+Y[5L ')ND07%)S% M"I@$T1(K'PHXT+%. X%0/>'YS#PX?C [B?5NF\!YF?O-]._WT3QY_P!W_P#" M&KG_ /W^YP+?N!4%=_GW>O7[UQV7^LYUVX%I=TV+K_6\"(5V)>:?0A<^9@=! M)7.S!:O F$,L/2L08LPW-@QY$S,:/(D8C-.+>RRPZ[ZGJ-K5@-6?;'G5\D%* M[*XZ^4_HQTTMV;6UM6SZJM#OD!U9"%VC6^M+(%#9L)\JB)U\@[=-0R[ND(K436,_ M9F:509ECEUM$-7PMS*0Z6FQ2SDL?;Z-,ZB[,MFS(U"%;*>.SZ?\ 0OS&=@N!XCS2 Z?9O&7VBK>P MIZ15 L(77P.\E%S$CT#:<6V[0(%GGJGK]*8*8821.DYF*QZL7#?M\_(C@:BL MGQPZII%>MO6X)U@T7L'OYXNK*WV9UG$F:]KSM7\IWCFM,E>)3AL$VW8( M&K&4U]PPS$*$P]ZK(Q4&6X0/3)C(>HK6G>E6@.SO4K<77[0%"LG53R4]M.F6 M].D>[AM*'KO75??5?["ZT5OCJH;L,=I4^O )]<3:"($#)G8C )E;/5:+ <;B MR): _0(X#@. X#@. X#@5\]A_'!UF[;[]A;7[0Z.T1V!JP?4@;7U8KFUM:1K M98J:;%VZU6*>:K-@(SG8$,19H5ECP3H?X)B2[+KH>:V4]FAV)D,C]:^@O3SI MS9+I9^K/7_7.A9FPPE= W.!K$!$JP.P1JK/.D ] MNPUL17'%,QF$H"7_ ' CI5?PJ]V_B0Z[?ECV,X$B^ X$9-U]EM2ZH&O+N^P M*]6H4F%8&8(M)]H?LF]%1\(&J*!T[77EQ'[D8D2[,%BYE"94C$8D0$"TQG'" M^)@\,=T^'?>PMPHUX*UT+7NNM)MMN+5:D7BB7JF[5.G@(N74JY:;36+N.@1O M@I$J7LEJ"PYU;KA@.^(JQUB2=47<4'";_ <#KRT#XH,GCL2IT',V(_&Q,&2< MPR$;+K:D8?A2\(KGT>C@=-C(>V!IE?"12 M)1N-[,C!(P6)D:;+'S7QTWW&7);8RYD,_P# TT].EQHC3\B/#8ES'4LQ(S:W%)2M^4\M#,=K&=6EM&%*5C&0P&;N&OZ24)7[:>RG:^ M//#&E M?WDSHL^;7U$5L(6-;(3&%!% MT0"VWWAEMS-JUL+4>G3Y&9.&T66]F99=_!HC#X$-^;)B0HL:22>:D$9#$=II^?(8BL06'YKK: M$N2GF846-#:=?4M:(L=AA*L---I2',X#@<2?!AE(4P:0CM2X$^+(A3(KZ,+9 MDQ932V)##J,_(IMYEQ;:T_U4JSC^KP,?@ZC#UM'D0:F';S4Y2QJM#F3$S9BWD1&PAMKZU:XZEVPU57;;? MW^NKVLJ!+KMLM)2UW:G:A+U%^UU8G7+'8"69N-?BR58'5=H4/?9&@X"Z98)I MQV(:GRI1(+ A1@2=A((A"8\N/<6ZVW-&3(\Z(MQAQ3+[:9$5QUK+C#R%M/(] M?UVG4*;7A*TYQ@.RX$,O(M^ /W+^C-NG\@#O[? F;P' <"N'R7]AZ/UMU)1K MF?(;QA7HIL- '5#>A&JY/LTNSYK%A+E6K* OAZO:WL]!16A)5RR ;K/2S-5B M JN.#[:T$,#0CGXJ](:TJ3^-T!JYO)PGN#5(JSZKM5MV+>K[HN!J*S2PU@G5 M;3U4M!$I/Z_S&B*JNQ9=0W.::+#4 1@^E7W8UOWKCLO\ 6K'74)G>L]=Z]>97QW6)0'=FNX12 MTJ+;C)T#!&-F,7K%@L4\9B-MX8),Q8\@"U#@P]EA$-L28E<+QF'PMG^QE;UU M2V/VE[*VOJEI43UWA2ND'4D=OK3P9RTNPZ=V6!;5[% ]H,-9MY(L63&(LCJZ M6&,YFN(C!IPV+(2V39()X&YSP' /K'_+W/&1_ M\7 S9Y'_ +SVF?IN=&OK2:PX%@7 KP[Y?L\\=GT_Z%^8SL%P/$>:.'2"/C+[ M1#]FR$1-;3PNOH>PI3K[L9J-1I6W: Q;I#DEC"GX[;-?60<6^SC+K*4Y<;QE M:4\#75;HF\J$1#=:],;9B[&I= V+U-N77RJR[?X[/*;WJZ M?[\U2(7!:E/='N_53[%Z_);VU'-B+2A-/C7D.Q>W,P68\%Z!801@8,:=#O2' M) ;RW "RUCVR6;C+801QZ5CR08(J^LX]B[+[)(U_NALZ M?]MVMZ/$#0ZA;-(&B'O&O[IM=%N#R6V-2$X\.#59%O#PX4>0]@OF1)+M37)> M1[BHP9-LO2\E:PJ@)/N+W2C05F9!MQT#M2GULFX_*;DM.P'# #6@XHL%ZDMW M#=>5+R%94F.MJ"A<6.IH,,#O%A0QS#T//;#O:4&2 [8%X-8>Q"[(%<$MT^-0 MTP\BCM2(0<)56(J8+CJ6C:(O8S;!(%5X%HNG72 S]O**_\ ;# " MSXTW4+"\3<"'6#CPU:,2O@SB"2F?<5X>R&4 VDCU@#BCP;MYV**!S8V"7%$X M!+2$B"1&DHK4R#/AR&]*9;?BS(K[4B.\C.4.LN(<3G.,XSP.S_0]W#]U;V4_ MOO27\B7 Z6?U;-D7D27NTO9=F8B5 F>_0"FFQLYQP:[EV*T_,@:7CR9$3'K. M-.P7W'(<0H.OA]2S(][+T/MGVP83E+Z?=L7#62X/ID%<%W'/< M7-2+B>V]YQAA#V6?:-C/2(;4D9G,3(8IV+T$U=:2_P!M&Q>PF[\V(Q(@ Q5I M(G],@[#$GN+D+&#JD?8U$/)A23LQV20A1Z_+B2WBV5DVDKGIP^D,1=?>LHZ! MM;8<&K>1/M[L.![K6S]#@S^S@/<+#E:8&/!+'.E1[13K4#4IBYK+PGVX^/;L M99&*FM(6V."9T\.D>O"ELS6D>\P=,QW_= MW7&$M2XWM/838BWH4MMZ(^\RL,,VWQ\Q[L/K0L_W*[WKA59Z6_!;&;[@@7"* MYOO>'<660#HXZ1:VD-S7V8S-C=)M1&/9,QD--QV$MAB][Q'ZDE1IK,SLQW>F MR";L^82+3.P2I!TB5(2([[QZ<;22P\X0+M,N0I;S>6W&5J#. ?KD*M)S4^R#F_=V;3&42Q MQ=HT,;9"FMT5>68GTRR5@8:E(JVLJP5G1\5ZZEG(D?XHS'4_(CR'FGLVP]A;QD5K:F\KCFRW(1L@"^'[# M=L1$>%62>I-8:]F#BIN7>!(X[:HIJFDE&8/OI0Y6AA*O"S"1CB(T&.$GHG1S M1L%E,:*4WXW%1'EQ$Q<]J.RKL5,:<0^*R6,1GMK.,8;60_U2A.&_0SG"6V/9 M-)2W@/!TGQE]2-RO8V78'\0L%TP_;'B6TYI=SW5H M^98CY7-SEF*1DQ&\IBJPRD,O8ZDZR3CT8MO8C&,8]&,?HJNR7HQ_P8^ZEZ/^ MK@< OUBT^ %D3AR_;\$!@\*22*E"/;/L;#@#A\)ESO:4M(M=5VG320S6[ M Z3#O4V.PS+MMJH%BDSL3(+ T:^-48E1(YH>P0"4OZ$K6?\ 7=V*_C5]DO\ MU??2X'S^A+UG_7=V)_C5=DOY4^ _0EZS_KN[$_QJNR7^+:?^GZ_Z_ISP.HG] M+--E/=\3SO8&0F-(S*92KM3V40C#ZFW&E+6AO:B$O84VZZE2'\.(SA:O2G/I MX$(K?T9\96LX)RI1CUMUR7K.8%;4( =K.S8)BM6'8U9(#*\LZ'JFUV6F'RE? M!R94D@4B+ X#@8GW-H?2G8NFYUYOS4VN]RT7)2$;Q4=F5 %=*^V9&I?1 +L" MS\*=$CE(;9G[S?3O]]$\>7UAJWP+?N!4%=_GW>O7[UQV7^LYUVX$!?LG' M;>^- ZP\>6]>M :18MQ:9[R?=3K]?CQ43OC86A]<]YV:^"I4)6<.2QL^@#;/ M&+1XGI(."W)F!V,SO=^! ;MCNL+2K)U-^RBO'H/G'=37('7]9^2?2X=UM),K MKXE-$U4M/.BF_4C9O&N3*55HV17C+23(;7UI94Z"48GR LH\8M ZS@O+QW\W M'U->@R-1]PNF?3/MRQ)#K_U@FV+;=ZWVP=*A866VW!+)UZMLG"@AY*'1]C)& MV%,Q?1B''#9(X#@. X#@.!K@^5+L=JIGN#K7IN6TBS/MF_:UK2EV:]S;0+3G M9-7V->R%;"T]77XF'?A]DJA0RL=VP6B0FS4>[ZW8F32&J[K5;-F224%Q_3'2 M5>Z[Z1'ZCK6A:/UZ@U8\8;?JNMC>;'1[//F8B395^KQPBO%OG1+!E]$=UN_P MX%M&2A<@.ZB>%'A#90)3R9D2'AI4N5'BI??;C,9DOM,8>DO>G#4=K+JDXEQ?HSZJ<^C@?#TR)&=C,2)49AZ8XIF&R\^TT[+>2C+BFHS:U)6^XE MM*G%(:PI6$)RK./5QG/ J6\ORO5H_0I7ZWH\L?CQQZ<__M[S&H_Z_6]']W@9 MP\C_ -Y[3/TW.C?UI-8<"P+@5X=\OV>>.OZ?]"_,9V"_Q\#Q'FD716_&5VC< MV@EM>LVPFOW-C(=3*6TNAHVY0%7!#B(/^K5MJKV"*5IA_P"JE)SE,?\ IV4< M#718U7M.KS0/2O4EX9,=L>C(]WO'X-^QDN>W*@]H^EAYE,Z]=4[#:%*PW9%# MJP9)4"8&)N97+$1JN=9Q'!AW)3H=!"V>,%;%ZL;XZSTF<1Z&>4CO;U"N%^UH M[$CYG]'?)/KGLAKPGMFOSQ4O&'JJ/V2)"7> 68A-LMN6@2S*'ICB24-J:&\G MP' _C94N$B=F&1U_>0-N;7$ M;6I'L)LN.)DBV)J%>TA9GJDH2O+?LUA'WK3U #:&G3K*3L+EFN#TDC$B313, MZNUY%=S $APJ9U9^)SX,ZT1AHI:R-C7E#LN:8,*98CQWVFF@F9P' $P/@,J>=4IU MY346.TA3KBE..93E:U95G.>!W' 5+8;>XD1R@DY0I$T%18PF,08P[G,IP)M5JOC:G70%6"MN,AZT%%@!3+SSDEYH:'@L M#H+;LA[*G7W$18[25O.J4XZK&5KSE2LYX'=<#!VZ]"5/><8'&L\TJ.P!BWN' M&?#9@MREL7_75IUN42M^9#EJ3[H,M*9@UXEH*)'MJB1QL1[ MV[0V'[$,[\!P' ZTP+BFQ)(-.0ER&5@RA\E"D-NXRS+86PY_2WD.-*SA*\J3 MAQ"D^MC'I3G'R<",>M.H](UM:XUD:L-CLL,94J?6@=;.MA/A8>=4ANNAV;.Q M('BX1227*JU32)[S,V:^,@3ALET7"B-SWVN!*[@. X#@1-V_U&IVWK$=LTNU MVFK$;*FI0S7VO-5_+%$B2%?$X'L1LT/)@RH MF5N!G[7^OJEJVJ#J31A;@:LB5S7!XUPF6+9C*(SI!*9A,TU.(SU(V9M>1 MD&^SOF!N3?=8O_7.'#(1"$BPF&M4:K'O5-Q-E@C\T-8O[3ZXB2 FMS'0J.[N M[X\L]D[[Z!V?J_PWWG8FN>C^UNPJ*3;(?9_7 B)V!J^Q*1/UD%M,6)/J69NO MF5PLM6= ^6S9I#B'L"W5QEIS-R&+NYO:GS0]N*;IRI?I$FPZ']R?M'UX[)>_ MY[?:ML?QS&AMB#;YFH>[?:,#^'9M&!^1>#OMYOP?VOOF1)+U?=EA,#]-4\T/ M]KV;#_COZM_DL_WO]/3P(@&^U/FA,]\->=UOTB38KNUJY],*,\^AM^9EE.KD*>3&:4I[+25I4O"/5PI.<^G ;%.,YSC M&]&*%7XH> M/[+Z@VYM/8U2)!J%8;$9CU&H4'6^S"@VMPVM%;0H&^J[9;]N1+.G@C-1B$"Q:'0VZV5B#TFQ\:6%:?G[\@\32&R.I?7>!U5[;;E-ZZ[&]/.\ MAV\:8U1FZZ^S0=3[QL$ZPT&.;C%FI*=F2(5%FR(8>7 BBD,& 3TTU&:FN+CA M%'M=]D64/?-$H-6K'C8\GPJ;5.PW73;LY\YUS@MQI '3^Y*?L4^/BY@W":[D ML0$5Z7#$-NMM1'"+T=$R7$C9GZ-X3_ #\_Q<"+?9+[ M(FHFYK)U8,U_QL^3X;'T7V;K6[+*T7ZYP4/%*X%UQM"GR!@3$2WRT.&7"-V& M2&6YJX4/,.--4N8AY##+X=;WH^R"]4]MNK6S^O,;QC^33*-DYI<$FQ;^MT#- M;GU\/L*J66RB2J(%P(2G&"]?"DQ:&D1'$.ORVFG\M,+<>;"F.1WXN5>T"_IC M6G3GR, K=TU[&HWIXD]Z%.O1*5?M.48U)7.MG6K>#:#3KT_5,B$2/T1AROG; M+\3JD@(Z1 ,XKT0*X&3S?E%LX#L[.VAICQV=ZJ=H3L1M3JOV=[5Z(FZ&+?#Z M5VKT/N37NQ+QL[K_ "8JWX9:+M*N5ZPA+%$L,2ARBU@=$6.:ZQZTB%%#8#_H MIC4']C%\K'\6\)_GYP+7O&[Y/*3Y)@VT2E2ZW=JNNS^J2-9@%('9O6<#7B[* MFU1S$B%)IKD*RGE&6Q^ DELWAYB!\/C&/ M3GU4(PI:E?M)2G*E9^1.,YSC' @CK;R8=*=PGLU/6.YF[3;7B^W:P)KCM&V1 M59UAN^AX>9^V=>UZ1=J?6AA?8-)A8]^-4J'/8ZQ;1 MLT?L38SQ@DR'KJ3#VPJ96IG7^MPB<;$V6-A.5HM: DU,-Z:08(RI$-@7.#+& MHO(=K7;G?OLET$'UPL'NW7[65 V:/N!&6G ;:(RQ%R]UT;O5"\?[?4/2;NXR/2LOW'B$E]L[ M:U5,1QNR6-:M:ODD4]677FCTDC(:DN6-J.^"CX]HTE,AE*9BPRD \A%Z=\DX MCQ^6K15(A-6735_W&/V!2.PP:^W>CAZ(3K(V*UN_3F*#7EZWC;!S9X4S7DL3 M?KS*-P'8\B8,&>S-H!!:+P' 4G#;:5+5C&0P3U9[E=7^[&N MH>U.K6ZZ+N6FR&V,RY53+M/E@$J0WEQ(NUUN3B-8:H8;PE:715A&#IJ5-KSA MG*,>MD)+N9V'LD NUTO55(4!UAM2<:*N5YB0_9; 7CUX37R6$"6VR MCZ9KD((?C?.C#V? \9]EZ_Z# VRH>1>];(U)B5L_ MD6VYLS1GVM5T##D2]B;MNMCMNS#N)YX?,G1!=;)5Z<)CXB8CVYQK.!\,-J:O M@A-1KH:M!FWHH.MB( 86U+(3R;\<8)B-0X;U1YY!ZXP8D>O#P;<%T=NT0I!B J-(J$RJ&R(>OCBVS#IRGA5)N1T1 M&#"J-?94G5 F64K,9,.-/(6NO,L%'5-OCXU8;Q*01A!@T]=[4=#.Z&I M-DZ[SNOK]5-CTCLD/V?L^Z&*=MJC[9?($[M1:5]KFCQ!$4/G\Z?&=.IG4&52Y5INC>RGQY/8 MT;:LG8D=AK7CM7:F1#D=-<8J#A]QF8*3DXY:84Q[ 6.'#J/1;LAL+N#JCLQV M\OW6^X/=6;SNXWUXN&E=6VFB[FM%,VP++5@%0]SG"MAFU]JM42L%.$D2(Z3NV9&GP84^1'DRX4B'+8E1VG&'8S[ M;BFE!"GQ#_8VW6'Q<6H)O8ELS8^]>T,0.^.D7=PH0U[K4&DC']D4A5G6U=)* M64A/X6IIQ>PK!<&7LLQI\,6&EHQA ;'3N7<-.980VX]AM>66W7%,M+=PG.6T M./(:?6TVI?H2MQ+#RD)SE26G,XPC(:K=7\$_9RL;0W1VTJNQNN^MN[#G?JS] MV^N6U:Z3V)9*\*JFTH06H[U([9M866BP2C+=@!2VYV39>2N+7 C M#Y!^>%D-)Z%]@-!=I^V';OK\=TG]MO?#7^KL;VU=L(G>$T[6>]=:5%RIPMEZ MQN("I/&[U3)T.9->,ZYL]8HI,T4_UWC7ZNMS%AX@0#M7V/Q,&T#QH=?JF1T[ MM[0G3&];@V9V C[O)6D%8.REK[ #R _9[(^NUFAW %1A29!8B9K7MCAV9"]4 M0&]I&>$9LA ,DV;JAV'Z*^+#L+U;N5CD=D*%0#%?U_T6N6N!UJ,=E:71;WMZ MJ0]:5C8@J15R8B>YIDW)KA!%@K4]\:8J=<:$D@0F,+C25A/"E^.^1JGR&:7[ M8ZP/U(/IG67CU&]#\ZIDP"<>Q"1-/V7+V%3++6R$1#HF8RZB8D(9A$O<7HC4 M#WV*X2>(K0/"TK@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@ M. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@ M. X#@. X#@. X#@. X#@. X&NYLOR(>2[8?DO[9]$^FE,\?(RN=6Z)I:[$;? MVYM._:P8LK&V:U$*9B"'M5QK' ERAI)4MI3#X84AJ!B(OWN8^MW" V&(&9N8 M,+)+W3!',2-F?B IU<'$W+*,ROH[Y!^W_2#J+TAT;N.#U!^-'O%8K,$H]!B.DH,>1[VQ#GN1 MVUS(K$OU&O>F8\C+C+CEIL&:Q'#VFN-L4W:-3&W&N224$85,V:NQH5L#$J?8$&ZA8R]3L R M37;%''F(TN"ZD%IUAL.V*F.%; KGVXT]U4J1(DFZ@EF)(?MC(V)&D$X]8A-3X.25@FPX MP@8J7';(S(KCR$*#M+-V.T+36J#(LVW: (B[2BQB&O)LBRC5P+:*F/!XT4X' MGL/NPWZ\_+L5>A-V%3Z BIU@!0<3_>S UF2';1=WZBG;-F::A[$JDG:4",]* METADK'6=8Q&@02TN*J/C/J9)PA!069G"$.**P@Q,:7E0V1L^)*>#O:/LB@[, MAG".O;C7;H/K5H-4D].K16(7ABK=7'&F3U=F283CK+18.\\TR1A^OEV*\KV3 MN$N84G >VX#@. X#@.!K<%/"+KSLMY>>\';+N[UUU[M_KWL#7776'UO('+A. M45@WBD5F*&OLEZMU<^)*C,-J&PF&WCC;L.S@-D&-&8AQX\2,VE MF-%9:C1V4>GU&F&&TM--I].!]W 9GOK MVLW3X=-F>0;5NTC/4XYUEV13=J:KIL6C&=6Z(UW6KJ7^&V7;5+*O.9MH)F%A MDB)>1EVLK=::B.+5'=6PXXRMQM2FEK1E*LAS> X#@. X#@. X#@5\'M1;>U;WQM_:JCT M96W]>;NZZ:JT??JV(L]7 ;!UQ8M*7S:]LJMEK<6\DZY6;)3+; W"8@V<4FV! M2]?+5R"7&CK)\>FL#0B[V]Z@=BNP%QVY-=UY33L'SX7CTZA:3T1>"QC5LV$&W5I]. M^1^_*\/+44L9LU @[PHVTX6MK!?0@?WB<"*V94YR:V*%-%PSPYT\WJ'VA6]C M4'1ZZ-K:P=[.L^_'>O=?M>JQXO3=:U;HFT:WVO?VHD*WPZ;\:V%:;"(DN5NA MRBCY$33XMB))8L1J:*9"]+@. X#@. X#@. X#@4P]T(%O)>0CK\9!E.V6LJS M5>H_9:LV'=?7SK3<-Q#@EEV1GGS3L01%@GAGP6'F M29#)(Q4S@\$'W8&Z4=B.Q';[MH-VI6NO_8_2'4VM:?V/8M97@R5HI+6,.\52 MP:?V75 0@N5U+9-D6ZXBMA X5D% @Q8[;2P,T5BV()F"@(.UOIGVGUGHWLG4 MK/J*Z7$AV_Z9]AM4];J/7H,ZTC.O)O;G:;L!MB@:/OAL"R7 :T"5[76[=7HF M7&3*B484YJ@T&BE%20];B%0FGKCKSOT5MS4.L"U:O+]QUMY0=W=P;_OF97S$ M:CV_0=QU'M()6\0[VJ-D$5L!]O85,U1+H<8O(LXMNA3B)J[7W#P$JU#DJC$Q M2)<;&6_5>6TM;:5A8=P' ]X:".%) MV[V4O9ZV#A] KT*#4M["*V2<,![+47F-3HF6F*'FJIV\WG;]][9T(.Z;7.+,U "IIOQ=3')]T M&QS,6IU:V) /.D[<&$31Y*PAW1D3X=$(PGD2)"7TYX&=_NA=B?W.83^' )_F M=P'W0NQ/[G,)_#@$_P SN ^Z%V)_FV4ZR'B*IKTN5B",A+?G M/QHDE$)I:''49]9"%AK!ZE^RMNX._:BC8&B? /VRW50W2,T.W=M2['VAL>HN M%AN6L$1:+)3NEYD,LB/R^SB;"3-S)BY>:]NTW[1'I#)O]$E^2;^UK.__ /?> M^OYC7 ?T27Y)O[6L[_\ ]][Z_F-^OYC7 ?T27Y)O[6L[_\ ]][Z_F-RNEQ)4_N+P7=D-3@@1 :)-FME[BOU$$ABAEV M%DV1L.6\S(G.CIS<5MU<21AL-SW7MKQ?*#1[SB!D5BYU"M6O S,GWW([%B"P MB^(&9GN\3WO,/WSW?WGW6-[?V?M?=V?7]FD(V=F.RUIT,3A0QM!"FQ)&BF+. MW:S]LE PXPH*V!K&FNP3C4.O%EP S$#8:SLHTN3A?^M>8;4'+2Y,Z('UV3L_ M<]>T7:6V;[U]V3G7% K0^[PY=->I!D[/I4363-\N9YP08NU>(.N5T@V5KB < M4?BPS9@?Y<> M ^[;?_W*^^O^<] _RX\!]VV__N5]]8__ (GH'_%O'@=<8VK:+ +( SO43=1L M*6B2!Y407=Z\$1A*!*;4S)A3X$S=K\69$DM+6T_'D-.,NMJ4AQ"DYSC@4%]Y MO.S-\:>[=%=,NMWBKV+O(SM>C66Y476^L-F5&OGL$0]PN@FUUNG:UTAK_L3\ M8<#RJG8")M$6<)GBG89=F77X\<6]-<#!_P#1)?DF_M:SO_\ WWOK^8UP']$E M^2;^UK.__P#?>^OYC7 ?T27Y)O[6L[__ -][Z_F-^OYC7 ?T27Y)O[6L[__ -][Z_F-<#SUD^R>>_=- MAQB-O^QT^[U5'S"$01$GV2R;H!PY16?E28(R-*)](XK#Y"8I"TQ(32U29&4* MPRVO*<^@(HVW[-K+T&T6*CWOQ07"E76H&R=:MM/MO:V57+15[&$F/#C("Q5\ MQU3AE@AL00CR(),42B1IT"8P]%E,-/M+0D-\S@0@\A&=DQ.N)4_K;:9[54JL M776QJQSZN/%OGK56T7VNPIE)CF"C,O%9&V"1-BLV,H,AK.2:\V2"B9P64429 M@A59N795O#["V;:HG8?9@"V[7V/V)TUNRJQ=IDHE>TUHK7/9W0.J:?L.H4:1 M/6-U*>KNI+4F>G8UP M^B];=5 ,W==AFM;;H^S_ ");0T#LX7?GR1N4[V)]PUM5@FKX9"_.6X[26P2; M-$)PK189%@F!:%?.^!'-:WB(UOI>^5#<&JS6DZ\"']I:\9TWJZVJWKN_&CZK M<8MT#LW,K)UW -Q2Q%5V;-BAXL:1'%RG)B&,!BC[O'E!_K<\2/\:>[,6>J!:A8-C4TI8S%3K)J980(R>)-G TB*&.D!PJ:2@/ MJ#9?BRY0R&\MM]/KQT9QZ.!@X5W"V!KV@5?8NRXU;V0)ONCZ[V:FC*@Y!J5C MU-K-Z&)E;#1.$2Y99VTC*SBTUG-&QA<JLZ0UQM_?%A-RY69C-5.!(.F-?#9F1@PLV;9N M3DT!!:.1WXQ- 3?ZN;^L^\S?8N!::RS39NF]TXU0JL-SHIEP5,%:\HITQZUB MA)9BV"&1+GYA<.11"&OI"D!\,@.@DHLR*T$MN X$(-_[4WI0^T74*L5>13XV MBMBE]PB-C#U0Y1+8MNLM;T-M;8-9#BUO14BZY61,RF#B4N?$ER3U@*2HHS"! M0@?/P>"LC5V_>Z%SH52TP<[#;SU'VEL+ZME[,);YTCU@26HE6A]?[5L:O5S4 MM9UU4_M/+ZOO^PZY/%O3-ANS]QB*O3[N&(/5"ROBBP\)X=?/*-UL# 6C#$M9$-V VBZ98DG3KJV 81@DZ,@/G9(N<+"OHGV4[;/W MYL!$WNR/%=K=G;WUSK)N/K+7[RNJX[27>#7?5^(9J4^6"DXN]HM.OKM/L!"% MMIFXB&]ECQCHN%$JOOU9D!X85W1[:A(!?9YW;<6T5SJ[LFL]==B:Y9UK2AZ> MQY\_V"W=H@CMZQ%((G!RB3(D6G4.U!!>NYH2J,%(&PHI4.4&30\>OAG*D>0 M?T]UQM.Y^0;L"9M5( @>L>QA6U1>BS).0%D=GJI<9_W+HM5Z^T(V1, :?8M= M'I *QS*PX6AU8^#BW,^5(LI-$ MEU7LVD[KUAKCI-]KPZU50SD0>@C#@K)0$5@3LC3(T>5@Y?\ =2,&),:>8;#WO MA"5?:;M".JKS 3?6YH5IZM4^X;3[ U7L M)IOKJSMW9-C&[1H >+I2U0M/5F#KD/3,ZRL$ZP5JT:=E1K(1FW+7A*?;9Z!= M@K94,YZK[PG]*UJ]=B.XFZ")70=UT'7^T8Z&)U ^8=ZZ"3^W9>OX^L L73]. M*; V,+7 MNOH:)1T)9K@R> 6\U(*) S4P0(65]G^V>E:+V&T':GKMJ+9 M4,G/IMHD5NU5!\I&#'BM8)J>K=W"5RU"7(AP(4@KCF0@^0I47+S;2XSK+S@9 MMX#@. X#@. X#@. X$=]1???[6?C0H'Y@=3\#/\ EJ1F6V]B5ZL5,9YIR%[% MO.')"W6%M2O>,_TU'L6VWFO8I_I;GO'KK_5-(X')X#@.!'GLI1P=BUM;+803 M(P7U_KS;90"XPMIMO+QS5]KK,YJ;A3*W'HV1Y:2XVTVZSZLM##RLKPWZB@U] MOL0#YG8'])'>/_;5;@;1_ 2NV\.XFSH=+"5\) M+;AQ]>U!Z$5=D;%M\YV'+8Q%62'LB0=;;5'*GW')\V.['@!Y;^0]EY&._P#J M?QL=;I?8W;H@[81,B\4[6=7K@!R%!>.7B]RY$4%#)'BKC0>K5^,S"(E#UE*K M5%%BATEQF,0(+A#I@?WU8[L1^PNZ.RW7.RZ\;U_MWJ\QIHS-*0)SH:_/V6SJR/4/% MQL^_*MUJLI'8W:GKZ\_ L2*JY!J\$,)OD: "JTD16!!Q@"S[5^4D:8,&6D$) M<\BUEN<1(/R@VD>O7W@M'?B?UI^187@9<<9:>QE+K3;JTGUWD4\?M2VS!A_8#MC;I-1K50NFQ;S:6J>"DV:VSPM'UU7K5;9P MBK 8KA.Q&60V1(:.N-@A,CNS8;;X9 U=M'7F[-=TS;6IK@"O^MMA5\;:J7)E5ELSGXDB! ,*?9Q/G"9T(@Y$8=&..NBR)*'*#\83R^ MIPGRL>2-./1Z$]Y.TB<>C&,8]&-T7+'R8Q\F,?M8Q\F/UN!^W%P.EL-7)64NQILEI3BG<>TSG&<8#')OK5U5JP> M?8S]-KP@%64J/SR9&R6%H<%K=>PJ=*M>L"KY>J[3:_$M8B548DLNW8/=CH%O712C3XA0%Z[KP?CIO<9RHYF 7"Y<5MX,]<#'ESU71M@'Z#9;:&^+%-9EK&:J*G)DQJ)#GVRCV371_,V P^W M#+1YU1MIX8J(39E1FE3,2VFD2X\=YL(@Y\8O4->OINMGJSM*0'F7$;$5,GKX94P>TW]FN;% ZRA:\.6"@1]6A[-"U\BH6.Q!L5SV)TKF6& M5]PB!=?OO1<"#'Q!(4)V(.B! N PW&@C18WI=VOACQ\*,TE+4>)#B,M1XS#: M4MM,MH;0G"4XQP,S;&V_J;3P\>7VWM#7>K1)::H:*)[&NU:I \F00PN2N /F MV8F,C3)J(S;DA46,ZX^EA"W%H,XKI,BH2Z0;AS%PV2*8SLC$25[- M"LQGL(#*7 AS]G[1+UVR,CY]N,"3^U:N6N,VN[DO( M4]L"^V0/?]J#;=H'3XBS0(EMJMK,F9 M5QV)L'9QG*1=%? 5VO#3NR+-:C 6EU ! B!*;1P\V#4ZH-;<<(WRNO&I-CU9:-,EE-FS MHK+M N)029.#HK@&DUE 0J<.L8QV'80TJ(U($$X3V,.<"/+?C>ZGX&ZV M'S*KL$T]K.S&+9%.V'>N[[!;;^3/6 !;"T7=]O,;!FV7?%>EV:HTTUFJ[?*7 M.M,R:94V(XIJ!7QL-@,P:8ZIZ4T!<-G7K60*Q#;!MHDDA95'=@W^Z"1$9!VS MVE-;UY7KC93H'5E+Q9[G:K#]I6N1M8JV2YN5+R*RIN)B,$6/#_\ @ ZK_&5V ML^MSO7@69WWD-R M?BJV'^2)?@:XOV(!\SL#^DCO'_MJMP-H_@.!_#GM/9N>Q]3VOJ*]E[3T^S]I MZN?4]?U?2KU/6]'K>KC.?5]/H^7@:,?;SK7YAJ[Y(O$U:MLZ^Z>[&M[';S8^ MPX.V=,N]H;@%=F&LU"&2(=F[";UP*C46O :(."U/5XZILX#"88%D-A#4*(J2 M\%JOEPWU;>Y'3[LYUYUATRW9:ZYJWN-J7KMV6+[>T*[.9SHN06(3=E=DNJXM MF192.QL4QD>*Q7+B+"L&J^R>#K/ ;U>VMU!W5Y&M.U(K;[[X_ MX^QM4F^J.V]GUB0'OUN-RJ/[G>:[&LA@,(LM]J.N 4*E4> >F-YK,:2%]VJ* M(ZGK##B!C_[,*^9^D_2?TE_@5YX&Q[UZ^\%H[\3^M/R+"\#,' P/VF_!D[$_ MB-VQ^0A[@9PA_P"Q(O\ Q=C_ +)/ Y' H9GCT[?5BES9F%Y#P]JCYFF7G$9B02\ MRC/T]]3F76GY0P7(QZ;- #7;8%#A7XT:;;I $K,;)V"%&C2I)YA(IAQJ.%+#%(0EIUG*PBSKS5W=3 MIUNW2G<+K[WJZ]^4SJ9V![S -8;=HT32VN!5ZI%D[#;OD@[-;=4;#KA38I]L MGK>TVDL4,PY-Z%-#!L!;YL<^$CRYH@(8Z,[==P.OR.Q_>6L7@H8[0;9\\$#I MIV,Z_7:B4RPYM>D71P\)J_6X!^(_P"7_P"=;\DOTYNTWYZ;GP/VX. X%8UM\EH.I[8WEK%>C;V71J\) M:$Z_.C+5K]4G8L=#=DW_?VMZ_6K;>8@RK6*-.)'8\Y M@5#B/$0XM?\ ):@R=HP"3UPV0+E1+A6=>=GY#ELU]*A]6[K?=WV#KIKX<;>8 M-8SM 7:MK5.PQDF]>(GL"*?''7$JQ'AEXL3 8B\GG5O8_=;7??3JQJ*;51VR M-T=(]"5:I3;P3(AJI')-[ZW484LV3$ASY&'$]T%R4X=B!I[GME-(]CA*E.(# M1Z_H,KRR?[H72K^%_:?\@_ _0@\9/6'9W3?QU]8^K.RIE1([4TQJ)%*L4VI% M2I.FR; S.,2VG!1>:) &) S/OT?"I+@@?*3Z'?9L)4E"E!6Q7/&=V/,#^PQ/ M852H+QNZ"==A]6UYV]QBE>!"7-*;!J.Y@R(,<)$%#(5QOI@//=?)1K$>-0R) M$O9;*;/3['.(A835-$=@]<4C2T^&-J^T;+3M5[&U<2UG:S8@-5:XC8<&GO,3 MOCL8#,?M8&"%5;6\Z91K&/!FIKI-]UVP>Q"N308N- M80RY2>IVX2U'$T_9=*JF).KE[@Q53$^Q"#+%VL&RNU-=W0+ND(1#AOM5=59K M50B/PED9."S!ZP28L*'&0,P0EA;)P' <",V^/OI]*_I,VKZF_;3@1%[T5*JW M?NOXF:W=*S7[?79N].TCDT#: PX^%EKB=*=V2XBY0LM&EP9"XLIEF3'4ZPO+ M,AIMYO*7$)5@)N_H6^LO[G31/\$6O_\ -[@02H!1*C6*4"QI; MQZ37\--X>?]C[5W#:,+6KU$^@+6> X#@. M!!J=Y$.MD$ON0$J9LR24TP2( Y\:#IW94S[I-B"["@ZCL%;T8XS6U-;H/US; M!05K6P#-?K-/A[B5'BIN&O>FWLA_%>\C'5RS636-9&V*[MO[2 0SD,P4U7L0 M/5Z)*)E;I7Q%1V_9"E=B"-37XQ9-;W^L#Z1>Y06Q.V.HEPCL!D@F(Q*#MZCV MGU/VDT;O\MQI7OH\A%BAT7BU^;(\<_T$>HGU?M>\#KN^G<[9W2F@E-LU_J M+L3L7J^FT>TWW:-PHVR=2TQ&O!%60U)>1,";!L@8[8GYD#,J:PFM0"7LTQ%L MNXP^ZTA09]ZW[4V[MZD%++N?K;;>KUEAV>4'&T.Y7[6NQ"9D R("3XMOCF=7 M'[$!B09Q B3#-BYLUDPS( R9;\5$*; =>"07 5.EN83CU6XT2,_(><4EMII:U8QD,5M]F]3RIDN$/)EB#@[9(K5I5Y ML).A11UB,2B0Z+-5),(&M$*X@R((@9)T*HI#8,PI<%6U!^F68!;0;NUZ1&:,UHP/.BG),70FIVY4=L@+D2HBWHSGZA]I+N7&5_J7$I MSP)4\!P' <#%6]OO(;D_%5L/\D2_ UQ?L0#YG8'])'>/_;5;@;1_ "0GR$+L%E""HS#$=R5,ESDHB,/89DJ9##O8 MO;5 /]>NT :#8(KMM_D[V?X& MW'P' QSLO3VIMSAX=>V]K.A;1 CYV2@\/L"I ;>-@DE0Y0]4^'"/P)\>+,6/ MFS(*Y+#;;RX4N5%6O+$AUM8=:3T+H\U8=6VTQIW5Y2TZ.CS8FEK&0H57EG-2 M120V,&(1M:%'Q:YM'CS1$*&+E,5IX8T^/B1H;J51V&FTAYW6_5CK+IRR6"XZ MDZ]:3UA;+89DV.T637^KZ53SEAL$QEV-+.&B=?"CYA(Q*C/OQY!*6\[,>8>= M9<>4VXM*@[)[KAU[D;2QO&1HS43^Y\.PW_NL.ZYJ+FQO>!X^0(@2DO6S0FP"E3"8]),&2AEAZIX0G,"&8*9L!Z1&S,$&1\\03C8=]M )P9D M"4AJ5&>:0%-MJ\96VC'8/L1ND#?M&UXKL,=835"V1]S^ZSMS66YKVGI[;VKJ MKV"*JN+%/3L5!LPPV7VW MI=T?NS9=#VSW.$0*+<\^_6'4_9RT=GJ$%Z]S9-G2H.)D$;=*UK;2.PF#$Z?6 M@@:R"8@HR[/'.!)/0^@=8:,[F]AGM;CK1 ' LSX%9O7KYT;R5?B-\=W^!]LN!9 MEP' ^[]R"-6L'" K;%MVX AG=[@2%0WBJ7V^K>^J=7=.4^ M2#9C=;2'W-!AP1LE\PL8+O6WI5;L5EE6YH4Y=(7S5NQJ:(K.UCU[--? L5O%SBU(%7799>MG)$L=!"4GC%>7&\7/CUD-9Q MAUCH+U->;SG'IQA;77B@K1G.,_)G&%)QZ<9_7_6X%;FB>OG?'R3^.?4%QW/Y M'I FL=S^K-$M>Q:$ ZAZ/1%&#MQ:_%FCU;$V!$R&7PQ#28>@Q"6/=YJFVT/9 MPVYG.,!G/?X7R#=4J_J3:I;R$8V]7)7;3I'IZV:Y*=3M)TV+9J5V%[>Z1T%< M8J;0 >?,A)D>K[(*SAT\>W[PR0BQLI6WZ MR:O,$A&Q]%[*KT6\UD9=*S.A)R0<)0XLB!*PX+C$&I49 8TZ9^3GKKT0T ,= MN/0?S<5HV_KW6\[L5LO='6;LM>J*/N%3JS4&WV[-OW9LDN+H]3P:GG"1":/3 M6A+L);$HA#;3#BMQ@VO> X#@. X#@>?M=8"W:KV*G6.+F=7[6#*UPY"2\]'5 M+$&H+XXC&Q(CK;?8R_$D.MX=9<0ZWE7KMK2K&,X#P-3T3JVFD; 4$5>,_,L= ML3=I*C;S]@;&V-#I62B=7FC+DUNO9;FG[ 0:0'3$2U-/%WV_5S.>QD/%Z6@0 M1NU^U,4="B#XJ=I4-:8\*,S$CX6O0>IU+4EEA"&\*7GY5JPG&59_\[.>!)+@ M. X#@8JWM]Y#O7W@M'?B?UI^187@<7;>A*%NA4%^W?'8Q 4%* Q)6 MO&'@Y$9'+6*EVF1)AO-MNH3.:,4&NOQI#K3N&FF93&6UM3'DY#$/9C2FHQ_6 M+L![+6]*?=B:7OA!F60K8DE-04K6KRH4$7]\GQ)$C!86,AQXD0FEQ,QEIO'J M/8SE6S_ -N/@. MX#@. X#@?B/^7_YUOR2_3F[3?GIN? _56\FW<[N!TN) K[1)7CLI76LD+ @9 M&PNYV^-C:DL,C;9&=:'YE5!P:M5#8@D,^UD8()#W42LE''\'\R8K4. R^X&4 M/#E&>;\>6FRDJ_Z>V?,N-Y[.[)G730-KG7C3Y&?M+M;N[8\^!2+43&B"!@?7 M)EI?K,M^6.COLE@Y"*OVN6/;N!95DN*3(FPU$QZ98V,B81BYFQL2($1Q*UMR MIK&7/:Q8SB6UJ0^^EMI:4+RE6<)SG ?6@X%=^%^S,"W/CC:W0GJ$(B_C#3;* M9#CHOU7L_$&T1UH?6N)[9*65)=SG"%85D(]!/PR-G?1FT7^=/L3P,^6>SUND MUP[<+B>#U:IU<00/V6RV C$$ @ ,3%=G%#!@K/=8A#1@Z&R]*FSI;S4:+':< M>><0VA2L!%O7OD)Z'[;N8'7.K>Y?5_8M_M,IR#6:52-Z:UM%JL$UF*_.=B!@ M(:R3"9*0W#BR92V8<9YQ,>.\\I.&VUJP$P> X#@. X$&>R?8#O!(]1-#[6VA7*M5 S45N )'M2*#'GG[,2(R'9.)L$, M-$X3DD08""L'M+WI)/A]$L[-TDV%J3G7IA9YX'BTPV52 D! [G:0[ [7\>])"7VK-[U-6 M,'OBVZ:BSW7;93JKL'H3ONTQII&$ZTAQL>RC8599;?<7[16"T#*T84[G"0[W MN!^'AXD/QX]K/J0[PX%F? K-Z]?.C>2K\1OCN_P/MEP+,N X#@. X#@8[V]] MZ;:'XN[K^31/@1$\9GS67C[^@!U1^KK0N!YWPZ_-/^-WZ$76;\T-3X')\HOX M.6K?WP;Q4_\ >9]3.!8QP' <"M;?_9SL/JW=>WJD.J^N8.O@W58W?M.D)TXF MN\%AL3#!4$(1OT*&BO#B4PZ:;%'"<@D+;DAXR0BW9NX'<: MB%-@4,E?M1V _P!-LV*[;_MR-0F!<;L'2D&M63:S5ZC7(][FJU::1KW9A-XZ MTY>ZN#1 @- #!2"R&<]%=T[<$^VK9O:_9FL:_HV^:6$]FM;DX]4FTW. ME*$7V9,HD>A; L;MBL42[3E0#^MGFK1'@U]YZS2;='R*;%?!FXP=KX9#(JQ^ M.?2EA!3HY0(>N_9TR')Q%^TBD113M?O"7CYL'O=]&;:7Y.RN!8SP' WWD-R?BJV'^2)?@:XOV(!\SL#^DCO'_ M +:K<#:/X#@. X#@.!JQ?9A7S/TGZ3^DO\"O/ V/>O7W@M'?B?UI^187@9@X M&!^T_P"#)V)_J_\ D-VQ\G_\AGN!F^'_ +$B_P#%F/\ ?_\ S2?ZO Y/ %;Z/6V_R=[/\#;3EHF8D0Y$3UG<(7F/)B+DMQHRH\EV/EV< MK_44I]^7!0RKW..AZ*R]B0^A]STY9<9#L. X#@. X#@?B/\ E_\ G6_)+].; MM-^>FY\#]/7SKWE.O W1*R1MO=4.OQACM19&!>Z>Y0)JXZ8J"9/7'=#,\<8I M3[L9DN_;8Z\ ()=>GNF[5.V[UTWQ++1;D MIW;'4ROM5;KY;O=-BV^ AW78%DJ;:'L"&XJ %B2DI*]XMXJP2\Y:4_EAH-?> M[108[LWW9DWJ5K6Y7,O)W4[VAK]5UOL(9V%UIU.$]KM"D1M_9N! %M?3. MQ.LL*7!UK2WJ ,^U.FC":-:S2#LS:TB<',U_GK^K8U"^UT36TKLF_=,3O$$X M.KI!L".U-!\ANT"G8-SK$N' 2Q6*"_HV36)]XC5G(VHD>N+M"8CL2-=1HT6. M%X77XYV,,]SNQ:=_ZVT]KUB!I#24363FIMPV_;#MHI2=J]D<13EU:M>E]0)I M5E=0F*I^M!7;R-84Z^E%HD880I\)^D!\ M!F#"D*(2&D(ST.>/(1F9D&=#DM MJ:D19D20AR/)C/M+4T\P\VMIUM2D+2I.%.27E+"SC M@. X#@.!B^^:@INR+/K&UVEB;*GZG.6H_6HC4AML7*E7+7EKU@;CG(CD=W)& M"]5[F:0U&0[&RB:J-(4XXAE3#@0N_2NNOZ=>IH+=\[(-2HEN@6,)LAO>=JQM M>M5X712VJQVJ@5YSA4^-JJ'JZP'Z*U6)+4N1F&9G6=TLYL++%Q8#-^UJ^&J5 MSZ'56N#V!->K/8$O7P0J+A6(PP,&Z5=K1PP?'PM2UX8APHS$=K"UJ5[-M/K* M5GTYR$?NX'X>'B0_'CVL^I#O#@69\"LWKU\Z-Y*OQ&^.[_ ^V7 LRX#@. X& MLA4=H;R-[0V$&VQL[;=, ]I=QWRH*.5+MM<3C0'7%![[TG05E C:# U/'2: MUU*K7,3JJGV#2MZ=L%UAE[#W5MX8R7OP7L'N&X7_ *X; M-HFDM$40CMZT& .W-.6KL]V&17Z?L&;6V;%BOT.#?DQJ561=<=@"8X6#>,SYK+Q]_0 Z MH_5UH7 \[X=?FG_&[]"+K-^:&I\#D^47\'+5O[X-XJ?^\SZF<"QC@. X&"=G M==-:[>+6 O=HQF8]9M-7+191B 8D"6OM)O)8*;+OP)$!+),998I( -DA+ /( M1I@=]G$F'ZDM#$AD(T_I:&@WX6OF2]PWY8"]//V$Y<;6;W#8)5HWXS:+17;H M7K>_2334=J_555EIE*EP C,0(R(%U0;412X5*FGZX9#-NBNI6L>O5OV+'_P# !U7^,KM9];G>O [GQ3_@:COI+]^?K[]F. \O'S8/>[Z, MVTOR=E<"QG@. X#@.!7KY$Q)^%KC7^T0^V]_:M'ZLV4,,VC.@[EHBI&C@$X# ML%3]D23V)]WU^:;@%#P^3""_$HQ@E+RTR*A%B:8$9 <7IIM30\26NDBNU>U] MU[9W.F3M&(![%>X5S:" E<$"ZG/C@*.,H&M@XP"%;"LN3W0U>>:(RI*SBRI2 M&0@SG0L4X$=]1_??[5_C0H'Y@=3\"1' >!L>]>OO!:._$_ MK3\BPO S!P,#]I_P9.Q/XC=L?D&>X&<(?^Q(O_%V/^R3P.1P' Z?+AGV\E]I MAI3&'H41B!*<:C_TI$Q?Q$NB=&]^4YAV"^A40:]%CK]O ]FZ^PF;EZ.'82(D M67[#WJ.S(]VD-2X_MFTN>QE,>G+,AKUL9]1YK*E>HXGT*3Z<^C/R\#46\A<[ M,K[*R\-$?,*=&P.T+M:+B1*92U'(8MUMZW=A(QEK 8KEMIFL0&PMGPJJ-->[&15G#/VZ:2$[+KE[&SV8ST7#? MRX#@1F"?A MD;.^C-HO\Z?8G@?1N[N[TQZSV892NQW;;K/H&XF@3%H#U/=.]M7ZNLA6LR2! M$3'L(T'=[0#)S@<@H(+#62T:*[ =GC"$-#ZI$*2VV%8/6GR>^-@#V4\BAXYY M!ND@8'>.Q&GSE+,E>U.C!XJWA1G2_K1521:LD)=Z9B'A@ZS@#M/EQV@N6U-N346^Z,+V=HS:6NMS:V./DHP78.JKK6]@TDO)#$)(DO M'&6JIDBP.>\+*PY8TBU%G.KA3XLB')2W(9<;2&2. X#@. X#@1FWQ]]/I7]) MFU?4W[:<",O<#\/#Q(?CQ[6?4AWAP+,^!6;UZ^=&\E7XC?'=_@?;+@69B=%[FK6D]4 M:XU#73U?V7<3@+6=*KE&#F+:=KL]PU9B@VLC1D.>?++99R1+RF79\SV+7MWW M,-HPD,)^,SYK+Q]_0 ZH_5UH7 \[X=?FG_&[]"+K-^:&I\#D^47\'+5O[X-X MJ?\ O,^IG L8X#@. X#@.!6;X?\ \ '5?XRNUGUN=Z\#N?%/^!J.^DOWY^OO MV8X#R\?-@][OHS;2_)V5P+&> X#@. X%$'E-[IIT=MD/6"&VNF-,&]?];TKM MV,U#V+($QFV^R%N@VK98P71]$6V'LJBQ=4648,U\9@";O-KFSX1:SW,37C58 MCUS!C)(,L=.=RWKM]H;N#<:;VJU]LS4"/-6,2Y-KMEFOUR6_8(IQ ML/;]=X=K&;#[4,7BQA;,;:VM2G7S(2M/U :J(K0FIU1VL!Y5CM+C*XS>,I>D MJ,.)?S_3,,1\8]3@2*GV*./G3T25Q(PP$%^.'I\F2G"XD)[$W,5V/%8P^^XV MG N>N6N2B*CU4LX@JG.^]-Q@_@I9H -<*42E+]P,2AXH6Q$$$Y64NP8N8SK*T.OONS8[+0==FYC345O%3+P9CDP9DM&+9@E2 M=(WUY$=R3'E0H^()$C&D,K]-?22BD7<,O)P5&RTIRU(:B-P68I!],<6R0F238-<)#ZY:I#KDH2F"X1CS40 \KNYMQG1&W M6G7W)3K6I+\VY)=2TAV2XBG%DK?<0PVTPAQY6,N+2RTTTE2LX;;0C&$X#7$^ MQ!9,>/X>*VA^0RPJ5V8WC&BI>=;;5)D9S6WL1V,+4G+SV66'G<--X4YEIEUS MU?5;7G ;0?O,]IJ"EZ&R]-D/(1+:ART9:BL>G.'IB%S$Q7I+#'I92M#;/M\J M>3A+><8]/ Y.9L7U)BT/MO?#U*1-1'S[R]&=1':EY8=8CX<>Q(S&?8?3']GE M];3[*T-JPZWZP=:FQAEQ1,]$Q*H!IN.] GY2M$3+4Q#:H2Y#[J4)B8FN/,18 MB9/LEOS7V8;:\!P-6+[,*^9^D_2?TE_@5YX&Q[UZ^\%H[ M\3^M/R+"\#"O:&@=B+3-C$-*VZP0A?V@G YBKA[@/I+TL^O8.KBPZ<%-J&KF MCSDJGC;^)27D$,Q![4EJ,PS%>)/2^!CK>NK]U5[KMV>/2-N W)EFU%821T:4 MJ-LM,..- Z8EB+&(#HG;1B#!!0Z:8(DDGP004,:C/P8\BH3ID1XE."?,4C&2 M#C%LXE>YX%LS\XQ G9F>[^ZI?]&!N(V269'L_P#]"Q$]\]I_2?=_;?TO@=DX MZAIIQ]?K^S;;4ZKU&W'5^HA.5J]5IM*W7%^KC/JMMH4XO/H2E*E9QC(==F?A MYYC$9]+#3*(LZ?[\/G,I<'SV9S<5N-)?S$88FXF,-.2&E^]/Q6$99E0XZYT2 M0D.>S)CR?:^[OLO^P>7&?]BZAWV,AKT>T8=]12O9O-^LGUVE^A:/6QZR<>G' M Z^#[NI>'Q"!;@N=F;+ES(;R5+D$LNQVL.(Q':7'DX;>88:PV M[Z[JF U*_(C)CN_96'A>CMO-./Q>O>UL264+2IQC+U9[/N,X=1C/I1[1O]6C MUL8]9/RX^3@;=7 <#^4+0YCUD*2M.%+1G*%85CUFUJ;6GTXSG'K(6E2%X_72 MM*DYQC.,XX']HX5SBV&"=K!= MPUEZ%!@-QGE*FQPR3X@M2:%I_52L[0T:$V]7$;0ARP%]!;PLH>W[&#[%U%L3 M9U3VE"M-E!C!P^RV25NV9MJP62U0O;";.;.S3->;'UV4)&1 Y&]^_&Q*7O\ MV7I;5>O*I8Q]4TOB16+G9R4]D4=[&&-V: U'!J,G(F7A::#16^P-2(WR=$:6 M8EF%%JV,?&DJR2;E!BZN=_.S\NR1PYJG:%R.Z^[4UUJ/N*4'_;[&79RVW^T= MMZQTVP]>X<@Q.76((3[4L;.M 782[:]+&V*#3!!I! 7.L,@)::6WMI#=G0EX,9Q") M-*8>PN,G+2\)#&5>A0YGF/WGB9$C2L-^,[JAE&)+#3^$95VE[GX5E&'4*PG. M<8QZ,=MMK3O85II"&FF_(MY*T-M MMI2A"$)[Q;TPE*$)QA*4IQC&,)3C&,8^3&.!8WP' )#\>/:SZD.\.!9GP*S>O7SHWDJ_$;X[O\#[9<"PRZ4VK; M%J%GH-W"0;+3;H!+5>U5XFA3HXY7SL%X:7$SFT*0IR)/@R'XLA"5H4IIU6,* MQG/IX%#_ $7\:/0W7/?SO%9*/U=U=6CO7;;?7N1I F-&36Y&M'K!URJ5@-.5 M?+D]Q$-1(T5(DI7KH=PY*F/.>C'K>C ; W <"!NR.^M-IVT-TZ9J.OKCM#8V MH*YI5UL17I(00-N>R-\7:?2:9JL/9+%,'@H)L=(:#FKD8)S6@]5!GXZJ3 M'E1$!BX)Y/JH2,5/!71VRZU1VOAE=WKL(J:H3HCKUM@W==CZU%:KM P=8YAB MY%L[ U/OZ '5'ZNM"X'G?#K\T_P"-WZ$76;\T-3X')\HOX.6K?WP;Q4_] MYGU,X%C' I)\E/5M9W:_7+9(/LSW,UG,WKVRTCI*[5/4_9>_Z_U]'HY6FVY@ MHBM4X'):%U\P1#J#7-3UJ-M%]ND&H MC5#(UIV?;B=\OQEM4J1+]ZLUO,*63.S\*DJ93,F*R[B,TPQZ?4:3P,B\!P' MK-\/_P" #JO\97:SZW.]>!W/BG_ U'?27[\_7W[,/FP>]WT9MI?D[*X% MC/ A!V?\CO3+II:A-+[*;HAZQL1P /LXN'.J-]-QY(4J:GUX=*R3K%6-"V'9 MAH;,'QX4B8U.[NN(3[5<%+#OI]++CB<9S@,U\!P*X^P-+V/NWLK)U M!K;L--ZGR!>EJ1>['?M9T+4-KWMM2'*NNR0PBJ!2F[:7LBG"*#K=^ 2*6!$: M@'C$DML88AHM68^7$G@R!TW?LHTAO_7-UOU:W/;M4;(KU-*[Q#U2LU"S["CO MZUJ%G%P]JBZ4S#I_W3*;$L& 1EZL"@ B2&^UZ:W7 > T%HN68DB[05^,N(?&#E0_9J-)#K MJUW5"['O.J UC%JC6&Z5+6-J!WB#'=K5]!['+AMB!6Q56I^TD0VKB!8JCZZZ M2L!*/9F/97QJ?>)]>PV(B)"Q77N^!%_$E9]-LPYL[$( *J6DT(M3MB \(J#K MCQ44S7X!)LL-LCL2 7KT"8P-B!XY%&>9ERF UWOL M3&Z5>G>):CS+4:E1$2.R6^A 6"+&&BN'"4Z,!)NH-,"89+U)$J&!>36,.M0W M9LVVQU6RF5JZ&HP;; JGGJ0?B6 MBB[*"FIT$+9R Y^N6$>+2Y58L! 0S%GX'S75"8I=EU<,5-/30H> NO8'7(I) M^_E"E/O::;8IH^A22@:V5V6N]5PZ,@G LP3==DKG6*Q2Q M-@GEY,2 +B"88' R6HC%PZ,AM2PEU%DM3(T>6QE:F)3+4AG+C3K"\M/(2XWE M;+Z&WV592K'K-/-MNHSZ4N(2K&<8#[^!JQ?9A7S/TGZ3^DO\"O/ V/>O7W@M M'?B?UI^187@9@X&!NT_R=8^Q7R9S_P"0S;/R8_7S_P#0,]\F/UOES_4^7' ] MR*(SI8N>8'C4D+!!PT*;"2I(CC;O ZI.R!;1& +-2YXN9F(Z=7)C"%KKTV.^[+CQ:O'-Y^)0SAT:^DKF8FO.X M]*GUR)$7X[2$L>B$/=EN*@0W?:B9E]QQ"T1?8O9]>-AMIQ+DCW MC$=/LW5--^Q4\OVOKH0VX'(X#@?B/^7_ .=;\DOTYNTWYZ;GP/V#^Z?1C5_> MBL:XK.R[_OO6RM4WY6RJ9:.O.W[%I>ZC[0JL'JAE]5IK&,%,QO@5F,Q?8LNL M*]$QW'M?9N.MN!P.C?0C5O0&C637.HME=BK[4["2'D8PW?VZ[1N%JG_#VYZ< MCJ$W8O4CT\21?(R9Y8<'88CD2643I"5/I]?(8SV#XJ>KEPVO?MW5D?8]4[.V M'0=@UN QX4TZ$?KF_N=!984HFD&89*HCQXJ.&2-,Z.TIICN9OM[3VG]6ZG=OVA M=(6N]NZTU_4Z(Y=;1(VIV/5(LEM75Q I5C/OJD/J>,&,S"+JGWLKDJRXOU@Q MQ5OGD-[?O9O4_P"M-W0X%F7 KG\97WH>Q'[XQY+/KQ[TX%C' [W M]N-QZDJT*E7O2S_8RWGIMAL5=V?U=WMIP3I>E -'DMMR:B3IEQOXBW[*>MQR M./IU7V_7Y8BF3!V+2:'"29&MN"%A,3/:/3V][SX[V:[L"@XVA;+L+W08TU%N M]<([,I]5OW0[L3:()"P4MB?BT#1+4>YUYI!<@'APG_BXEQ*\8)P\.APNX'X> M'B0_'CVL^I#O#@69\"LWKU\Z-Y*OQ&^.[_ ^V7 LRX%;W4S\.'RE?C5ZQ?59 MH7 LAX#@4Y2?&#L2E;?V[NC4G9ZYFC%MS7+U0Z1O%D+:*" VT&[+&^QU]V-R=.SY%BECPM%,6_8H 9)AVIDB:%5_7L3,23+ M)V@A(&!Z]CHI9Y&A.Q$?M7?TVNR6#7%#JH0CUKN^]^MKL:@];]?6X7KG!VT: MZV?6[X3-GRUMN-ENP)%B;HTKXS"K:PI> %00GAG'QF?-9>/OZ '5'ZNM"X'G M?#K\T_XW?H1=9OS0U/@$!, MX,$V9Q:-#BO0!2DD93;RF(:DR%MJP%4 [R%[_D:[K=PK%JT-M./K6L6S;?9< MW*TCO;1I!=)KNT0&O']74[5.Q+=)V#KC9HT61L-M=L&P6C8PPR$K2!M2P%N\ M8Z-"2W7ON?;%( MJ4JU.1B&MRC1X&Y6!3IJT&ZTT$<2%'EBX<'PVD1YCQX:<+B)\,H**7[M&1&$ MQTIB4F%/@38RW8TR',C.M2(LJ.ZXQ(8<0ZTM;:TJR'I?%/^!J.^ MDOWY^OOV8X#R\?-@][OHS;2_)V5P+&>!75Y4?P/"WX]^H7UL]*\"Q7@. X%& M?EO3%JAU+9_4_1/876_7S5L3L3M$YL/>LS3V\0U(L)JX!R@/JS KHG%AN M%^^"ZQL1\U6Y]YU_7;3[A6:LDG++$X[@P)'^+I3#.L-CC0-0TMI?7L2\#96L M>LNH3->M130U+,5,.4B0=SV^L9D"#VZ=C3Y!#9-S:BEK @%BQ#P3EC/RH$HQ M-"SW@::GEK[-V.O>0BZZ*:#DC5+KUWZZ;<.IAJ)/,C9\FC4D5!>FU:):@S-^ M@E30JH@U VG*^73,GQ6HA(C DE&(@5#W7M[*)6,Q9 5'BV\?9W]S J5;OM"( MN5FE4:78JA$M$+%7VG:8 635XFNXIWXQ[D96FM1"9(>/;%&%*@-(C9XT(J:FV>:#LPS=;!*MA42-UAKH=-(21FO;I7+V]&(WF02JI MH'?!%EB69+=4L+RBYR4@%8FYY"5/(@;:4BP3@;'WC?K4G%(/^Y!34.$/%G:6 M3+1JF;=/'YL_7FO;L"@TV* W/8'K5571&N&P:$0F01+,0E)'RI$0BO PH&PI M9W9]PZZ;U:IY^L+JH#6]NI%J#+&[8'$!MJ&5>'7G8L4Q8BPZ*C/1+([, M&#+! (O3FY+IE@VX1D!01]BTVD[^E05NE8HD&>$+]B]UKK]S3,=((C;$#!/M MN&P[4$#FZR6AAQ4<%"<89E%DCK:V=EB'Y@9+#6#07G6M[L=9Z9=]8;%A:VM+ M=V&18VS8S';)[\^\2G276I4LF1?9B2W1C>6&&7')X9 MT0A#:$MMI2AM"4H0A"<)0A"<82E*4IQA*4I3C&$IQC&,8QC&,>C@?UP-6+[, M*^9^D_2?TE_@5YX&Q[UZ^\%H[\3^M/R+"\#,' CUVXGQA753LP3FN99AC= ; MBGRWDM./J:C0]>V*0^YAEE*W7LH:;6K#32%..9QZB$J5G&,A"K8'9X=;6*\P M#M(6VULDE6;%214")&L>$5QVH%1]@)Q$GT3(CIVNN%"HD*1E#YD.=.I:I*V% MBIL4@$**7VQ82412 -0FSZP?30IL+-CDV*JQJ'3)0HOJ 3%B48; MV95.(E85(N5EI=CIX\&T"DCYT2$:O,^4_)N%+A&WJV MP$/T^/"L3$@+J-,'REO0V14/S!J\0 -EU'WL],:L3[[)2W )J"]/:.%((L=& M5$>6,E/$BJ#,:; 0XN#)KC46*&LAW[DD7_LISPFH*PY,8@UUKV2J:Z\U#99? MG/U#LV[-2PU#(DD-^[R4AK+"Y["DJ6E:\H;QE6 ^&7%)'Y+G5Q8;< MT0/;)#LXC2!T:2OVWO&SCH4PRVIY];H=(%#%GAAZ MHV(/7X%8:'P 0!%5S*$Q7@;P%B$1B-PFI&'@GNCN M/J#VN(<;$AN7AE'O3494-$C./2ZF,M;;JF<+S\OJ*<:;6K'I^52$YS\N.!R> M X#@?B/^7_YUOR2_3F[3?GIN? _;@X#@1=F]V>I(V[;BUP1[#:K@7GK]42%\ MW16IEJ@1B6NJ>':$NFK!8D/+0VP/!X/@&SJV7'UA)!X)%*HB22XYF2'TC.[_ M %&,3=%CAG836,LAV7037HB$W8H^)6RU!IC8TI' ,+PAS$V$6=2$?@3TPIN# MR706(^2[#T)L.>$_#(V=]&;1?YT^Q/ C-5OGD-[?O9O4_P"M-W0X%F7 KG\9 M7WH>Q'[XQY+/KQ[TX%C' S<5[*1'=;?97ZKC3B'$I5@*T)?B^I!"K2X$[LOVNE[)>L(>7#W MZ_?J8YN891@6O[7JT;J5BP*UWD--HK=*O=S;?<,UXG;)=JL8-@#P8 M>,S%E3'6DH&POU/IC,^H&)^X'X>'B0_'CVL^I#O#@69\"LWKU\Z-Y*OQ&^.[ M_ ^V7 TPOLT/9^RZ+W6ZEP*1L.\TV#-ZMSIF[H%9PA*?3G@;,W ^/6 M3\OZK'ZG_P [YG'IS\N,>G'RX_;Q^WP,=[>SC.IMH> MC.,_^3N[8^3/I^7[6B?R<"(OC,^:R\??T .J/U=:%P/.^'7YI_QN_0BZS?FA MJ? Y/E%_!RU;^^#>*G_O,^IG S-WN[./],.G78WM9&IC6Q']":KLNR6J,^?7 M5FK2NO1L2,!W+$V'L"PR9?I]3,](0GEC_P [$-W];@:"F_OLQNP[UD:)D.^/ MD-6/N)=A*%OIM+?9Z<7^V1VCB[0-35UY5H,;\);)XLJGE&$X(JB9AX;P,D^W MRMD+[O##]DL&?+5V\*=6Y_3D9HA@;INY[7Q=HF^)6R'7G*D>IH5(+->>U#1D M-HGXMBI.2/QI>8V8&&L07_>QJ';:*[8K54,6L"1"HM=&-.UVX MUI^;'6W&/5DTRAW(\T)D9:G#WG6)43,AA#N@VMV41G6NZ;9KEW@1JO5->;414#U$T_K6';[->XN MLM>AH-5%+@\4_X& MH[Z2_?GZ^_9C@/+Q\V#WN^C-M+\G97 L9X%AQ&?\ R[]0ODPM M.?UNV>E?3_5_J?K_ -S@6+8<;5GT)6A6?VL*3G/_ *L9X']\!P(S;2Z8=2=Z M7U6SMX=:M&[IO.*F$H\6P;=U;2MERQ=6KQ:RG!H<+BZ!3;0:-@K;3LR7\+1$ M60_*D8AQ,,!T4;56A.C>J-X;!Z^=?*)0!F!4W9MLU_I^N5360.SEJC5V MH&""1(F((JXV?D")CLD"34#$J5&@I<<:(3&V&' ^W7W90MLPU^UN9(PUFMDA1QTRT_*^%(#3- M\U&P\G^ZO8B(4K$\(/.IT44HM>/T*L"KZ?O-.T48*OS#1)TX$N4>E5$6/698 M9)D&PT8X1#R0TL9DE85S JRV4# M3M<9KM!VJ;TV0N9VH1@E@J *9:@0>H6B MIE7J9KMROV-+C<# :WF -P9L9F :6S.EOVP,+%Q Y)T,46W%9N];-6(1J;81 MLBT#B/38S6O!4=X+2[)MRUN5R;!%V\B2.%?6%#JY:+$?=(G$QR5GP"E&(%9% MSHI(, 42L*#E3(B7IJR6W[;%D(M7BR]=B/MH;9L58(LP1BFPQL24 %'WQ)!( M&=%C>XV7W$B5KS$KWA4&4&U-XX7*13RM=!E.MVU=AS"9^U5X#*USK"6 J^0H MH0!KI*R!$JW8L-DNFR3X)&7 *3[J$ L5BVQ3;IL)0YNS0']LL2A MIM0XX/VV&'/"S0L2\)DP(T%NH^$X$]DOLE=^%'B'/"WK>S*A M5T=6X23MC7.$MQ!]<@5YN7)K:M]8KLPLWB$Z0'FW1N#H645-I#E(3)@BB0'N MC7=O[)>MA2F%2'A U$\0UM",AZ^5G3Y+MB@29[X!U:9ED!$544=.E&LH?AH>D.S) MN8J86]X;$9,^<[B=+89:1%7-9CRD,-OL()RFZEJMGW!0#@>S4NV"H9J9<1"#<:OU_$NW;N+ HT4LHI*2Z[+88_IC M+*42VU16CL10\W7M:T4&9@+<9>7"*B:N+@$(BW8SCT=U4 M:7'>94XP\ZRO*,J:<6C*59# _9GM(3Z]D84--&$F1Y&BFK9'LM@NS=4 Q)X? M8&L*0\/,/M@CKXP4PQLEDS./.LJ2QB B$Q!E9DO28(8S[@[/MI#I;VR($=3G MYX$]UMV.JO9"R $C+86R:$*&"9"Y8MA>JP!\,*7ESPQ%,%TKZ(T5N2MO.7GF M(X:A^M.\5F@)54!U).:]#&@86Z/6BFUWK]#T@=FP;H"C%9"I,&[#Z71VQ=]K M[-1K=HE65 0N*GU^/#CC8DZOV":'2P.WUD,OL=?C&I&E&;2[58&OYNFIO6>V M[)V;.KAR[QXN1V(=Y>=UO8K'/V-6-BB'9,HK/8*TZS$Y#911HX[@(KVWLUMM M!&QWTYK T;L9,I!!L%K? T$4KX^'7*30!IZQ7\56"J#Q"UU >"AF(1DU8"\Y MLFV_%A$!D]163+"2/2+M'/&7X?B3(-V,7>W+%51IS83>F2MCCS@%G!V>RQX= M' 7>HXI,G-+%'++ MH;"'G;$3!C2K;U@&L&Y ;A>DNP6PYK(@*YUNVO%,5D@ M=&61[!#KO)FSQT>>_DC\*%5&[BLR!,0Y)]UQ,D?"5Q+%@LR19,N1FYY(-8SS M'W#OK6/.%T9[H:$\<_8W>U>Z[Z'LM98<$E93T.(RJ:,CQIC/%7&3&3'DQF^KZXTW+2/7]FIQE##7I:RQ%9=9PZH.Q_3\_,A M_:VG:S_ISM/^:GP'Z?GYD/[6T[6?].=I_P U/@/T_/S(?VMIVL_Z<[3_ )J? M ?I^?F0_M;3M9_TYVG_-3X#]/S\R']K:=K/^G.T_YJ? TD^T?CX\J_ M.@]A- ;T["6]C9YJ<+J-JV)N4EJQ@#J>GL2(42:,@G;!93>[UKW./B=U]_Z+VQ1C2/569B&<%*2Z%D?7X!V)!=SNQ:M^[1U+LI@CI#24S6;>K=,VG M43M2I:MJ]D4BKQ\/H2P'E:M\\AO;] M[-ZG_6F[H<"S+@5S^,K[T/8C]\8\EGUX]Z<"#_?7[))\:_C\V?LK0NRK#M2\ M[^U0:K0:X:FU[K(^[/BJL]>#VJ+-B7*TMUK74V-%KY\5/E)CVUARF7%,2&FWF' LSX%9O7KYT;R5?B-\=W^!]LN!I$_9MOX< M/4+Z*<_\[MWX&E?P/U<_L0?YG&J_2'WI_P"\P7 VA>!J_P!LL/CSN^X^X9O7 MFP=$#-> =H@Z%W[K2]T5*S;%W6'5VSIJ]^;/[)TG%I)V6M=?=,8B$M2 +%?( M0\4K7%JOXJ*R%U2.K$D^&%J4_0_CU&7K6;#=[+PK!3V/&.WB:2NO;69X\: M#J';FN'-9:0Q8J]*W ;UA2X_8[D_ M+K3O _4XX#@.!6;X?_P =5_C*[6?6YWKP.Y\4_X&H[Z2_?GZ^_9C@/+Q\V#W MN^C-M+\G97 D;W"_!([2_1SW=^;.S\#\)/@;!7V+1\^CTJ_XGV6^J9O3@?KW MZII-FV#UE2ELQF<*>>0G(>5Z\;YU;VVT!J[L%J@BU9M5[LHHFY5I^6S&6MT M2\5E^ M_E'H4.-$=)3L,,Q<3)[C#;:YDOW:/'C>\2,N/>P899]?V;2$I#5"[[=>F.P' MD9[) 2,I\O,<:Z[!*&*5531@;5#);2AF> 5(;(6J N ^'' MV ?',UTTN(5BA5?L'J06>;N]UU=]I-CDV<]>Z[%-B(TQNLY05KE*$3+TQ3JX M,@5C7L/6(HH"L\5@,U*EV0H,)! H)SX/@!%#)>L.E@D?$IXVMBZ3:3VH7)-A M?V70MGA;^*V".M^T(/;Y,Z2 MX";N$L 0BWJOEJX>&2IL4$'8#8JZ3Z8DZL,PK)9*O;2,NK27CR#V"Y5G M+8E@2P/85"1#9:;)Q2;SZ7%0ESEO3,Q&H+,7#9]LPZK+:&WWLOS$^\ M9"2N'B/P]I[,*-@FIB.MZ![^O,5J0O#?O3*"/N/KNM1\J=PT_F TJ1AM.TSAL/O3$81*>FI0K$F0Q'CNK]H[E*F8JY#C*<-97EE&4JE/94M#:7',*2EQ M2TMMX0'(X#@. X$;^R'^QM(?20U%_P"]9G DAP/J=89?3E+S+3R5)4A276T. M)4A64Y4C.%XSC*592G*DY^3.4ISG'R8X$<^Y.,*ZA]IDY>1&3GKINS&9#DA< M-MC&=;67&7ERVW&G(J&L?JU2$.MK82G+B7$*3A6 _/.,W38C$?.O\F-H5Q.V M'PEZM%G(C=H8OXRO#]P5P5%-E[ 3<^%TA#FQ[T&V?9;!K8#?:7>:T-L+%M"'+Q?%5*GS:U61+,KX)/ M&7"W/,G??$E9P@C);^!Q(TW@?V2IFYM>P;1#V.*MA&_70""CL09EDMM=8P-3 M]M;3R:Y :'4W&1%8'RB%A:@!5G=>E*R>FBQ>8Z#A'@3EZG:J&S=D5$;($"(U M_LMT,EU09$C9I,G6M;A;U1:5=J#2JZ(I!4RN(F;8IMEJK9TN30,%D[!%+O0* MHVM[ ;G6F!5Q@+39'JWF;,B&(U3"X9NC+LZ?32\V&U;+-= T, -4-G@C80N) M#C)6)4GWH0ZQ)7#<4_,;#O\ 9D:6'WOU@$U@) 9;AS=SK8^)$E18T[,C64R2 M[*R_&8+$WI;IC,5!262CID2LRYI++\Z4C#]V;9<94VD>VVXO#'HE8S'2AJ,U']BG"TAR9,=J7&D1'_ &F693#L M=[#3ST=W+3[:FW/9R([C4AASU%9]1YAUMYI7H6TXA:4JP'W)3A*<)QZ?0G&$ MX].]1\"C'@?O'];?P=M"?B6U;^0P+@ M9IX#@.!&;?'WT^E?TF;5]3?MIP(R]P/P\/$A^/'M9]2'>' LSX%9O7KYT;R5 M?B-\=W^!]LN!I$_9MOX!P4#!K:GUH'P4+E)6F2M$1A*I"7,^LXE]6&\9=2XKY5X&F\+8;5C&%-LJ]7TMH5A*<*0C*4YPG&,X]&,<#'NV6& M6-2;12PRTRE6OKPXI+3:&TJ<77":EK5A&,8RM:LY4I6?U2LYSG.=\.OS3_C=^A%UF_-#4^!R?*+^#EJW]\&\5/_ 'F?4S@8 M\\YWS0'D2^BYLG_W:G@?BQ<#; ^PV?G;K1]#WAJ_(3]O>Q"@ZHXMDZ\U37HXE:X^OO558 &!(XS9!P.>4G)CBD MP%15Q9WO+W-2MNUFC]B=>!9]136G]01MT4.O76 MTZ]@S46 R@Z#;L9.29AR3F=>]:C:R0IKT>]C8=>,2)%H+#[.5':[N%Q)0WPJ*Z1! MRP\=4@,?Q.M*AH/9T8@#1KP-:MYYV;!OM:L>[F'S;MKB4"J7$88%E3(JVCB] MV/5T=4*4U6P4^1!'")-PCMJ-GAZ(OBT^J82RT'3(0&+'M"-V6S@0X M1L3F'MVHWPLZ:@V;:ZL%6&Z#D-(J9-L\)DRA5;%*:J9:HUL++!F0T27.-L4T M]8HL^Q-A8QJ.M!*VW&I[D*QF'AG^N$4];85@FRF90D73(RD1CA:J!F5Y?2H= M+5A>>?5[65)E27L^ MT?<=<]7+SKF4-^O[-E&4LLH;9;;;2$G. X#@. X#@1O[(?[&TA])#47_ +UF M<"2' <"-OX0B&N6>BL @]R$5X_);N\T]+C3&PC\OHY#OH=\%314X7.EVD#=A;Y1C8+ ME=M182;VA2Y6QHP6@')LJJRY9\F;L0P$!F5_,^RGC-T-- 8,H)"@AY+/4>26 MI8TG>ZT;"[MO<*Q0+#97R=\UW&-4FXZX/_!"3Y+-O.74P M$2CHW(HEFJ#)M&#F;50)4Z/8;G4%U?UU9,M!>;1*P80,GS;ECU9UBA-PY%92 M3D&1806V^3>;'MD)<6%+GR)/Q22[.D2&$+90XP*2Y+;&H(2PQ=LX8/;[)]8R MZ(49)21C;HUXAAE'OCD")0I$F/#4_P"CVGNS3\J0\AGUO9X=>6O*V[<"1? T^W=[UKL,Q+H&W)])UYH M9[I1-MNIQ52HEAB[YC=N.S=FT?;!]Q+6:O$+?6VJ15JJDGKF3KNQU1]VV$2K M]K58Q4.&(;#',SR6]4Z?VWVN8/.]DV1$746N=9K*C^BO>8Z-?NE%V9N^5:!< M"\FU@$1?0GO@2R0H&W.UNV-C:[L"7@W6TC'CHL=,L@4T@=+=8+C4S<03$ M <38DPF0T(_./I/L'VW\J?;GL3UYZP]K]BZ;V79->SZ1N-'(@336N M:L3>0%N&M*]9(/NIX&5@904#PG'51,R&$.Q'6'W0J?\ T O>O]Q7VT_BY;A_ MS-X'ZX.D/*STWJ6E]0U6PS.SPX_6=7T"OG!ZO']W^DY@F U4$CB2TZR@.TX$.^WF[-UZK&Z^KO7BEZ MYNFT[^6M\F.QMFPV<894-;T0[?+4_+(5849-K-F*VM?HPVMQ2?4SG"T>D,0=O; !<[V^)1U!L0MMC>':I3SB"4-2&4KZ2 M;O;0IU>'LI;PMQ24)RO.,*6K"<>E6<8X%E_VRUS^N )_SK _\?@5H]>[ !3Y M0O),\HV(2R[H_P >*6G5$H>&W5-0^V'M4MKR]ZJU-^NCVF$YSE'KI];T>MCT MAI*_9L)" 0[O=1'($V).;;ZJSD+7#DLR4(7]UR[*]1:F5K2E7JYQGUC/ TNN!^K!]B(F@\'P[55B:6&PW\=A=YJRS*GQ8[N$J) _55EMUU"_55 M_P#5SZ/1G^IP-H^+,ASFO;PI4:8QZV4>VBOM2&O73Z/63[1E2T>LGTX]*?3Z M<>G'IQ\O Y/ \];K+ IE4L]P*I?6+JE>-64DB,C#DE< $-DE)B8[:E(2M]4> M*YAI"E)PIS*4Y5C&?3@*^M2=F-F[?U-V/KV_:5KC6E[J^I:_L4-"U_>"]MKT M[56]-=6DWKMPP0LUAT^L7"LVH7$ASPCTL%', RTB(6]R'!S_&A80#/ MBV\?[+IP.T\UT#ZJ-.-.$X2'&W$==Z&A;:T*?PI"T*QE*D*QA258SC.,9QZ. M!Y[P]V "QXI/' R^;$,O-=)>M#;K+I*$VZTXC4=42M#C:WL+0M*L9PI*L84G M.,XSC&>!R?*#8 +W735R&38AU2?(%XK7SG#;32% MNNKSCU6VT*6K.$ISG 8]\Y!\%)\0OD/8CFA+[[O5[9"&F624-UUQ>1J?0EMM M#REK5G^HE.,YS^UP/Q>.!M;_ &')-AP/+39WYTN-"9SU W&WAZ6^U':RM5YT M]E*,./+0CUU82K.$^GTYPG.<8^3/ _4OBF0\YWV$$J-F/^KE?L8LZ+(=]1/H M]9?LV75K]5/IQZ5>CT8]./3GY<<#LN! ;JWVQV+N6ZV0?LVBT"B4:WT&#N_K MD=K5T+G#MCTU-N9RGI^J_4=)0FU^H[WT[+.MJ]53V,^JXVM#B%> MCT+0I*TYRE6,Y!Y<[ !?\8O>IE@V(>>7U*[1H0>#+6OKKNU*$)*05*4I6M+-A*4IP_G*E*SG M&,8QC.LI24X].1'B&!4F0YZ<-L1R$1YYS*4Y M6K"&FWE+5ZJ$J5GU4Y]"4Y5GY,9SP.UX&*-\_>-W-^*C8GY(&.!@3H47% /' M?TL-G2< ,&%=,^MT\H6*S(X\:.@QM)TMV1,G393C4:+&8;2IQY]]Q#;:,94M M6,8]/ D3*W%JR')Q#=O]67*Q-KZV4\R=%MF6TQHFA=42VD"4 MR7D(#3DDVAY#!&,A;N'QT5>6LOL1),4) %Q'M)!2>2*/L17'JZ\*BPE2W'&E MUJ2Z9S[*$EQ>)A C(S)8>C0XRU3(,>(RMF0XWZN ^G-;DN$X$]N1)E"A,!^6 M"&3RY:/A!F2PVRU\8:RRY(*1FF\.OM+./E'!\Z3[Q&&MRA\&0R'S/A2 N <\ M35(!)^ A@9EN)-RB:,:/'@+!AT?F8PTR^-B0\SS)!YV1&FN-B8\>+#D.2U(9 M#N0[9U]#,TU*S'?2X33D5&BQ&(ON[TEE,#,M?O)9]Z5$8C+6T_$(Q([R2#V) M4'+K;&(P8CW+;]PUNS:5&ZQH$JUURR[)'B]L6&/D&]]IE'6PXV[/]Q)V()-5 M[Q.?8=D$AD,ZX.@P):,C%OS(KC8=/T[^3J_I'_[!B_\ _)[@24X#@. X#@=: M9FK&ARI%M41#D ;.FMKGK?;@H7%BNOI5,6F7', M)0H(+S-FEMO:BZZ7DY""PBD[M#2ATG%;END*Y-; 7VR H9<$0<.4 69L!: )J$*&"V8T=,)F'F:077P@['QFWS5S80 .:(.'67CX.*18 MD80$!%#!:3%8#K:%51=$;-!ZY"J@ (=)**E$Q@@$#=8EX)'X M/.E4.3@**2H$5EZOTHL 5::]356I5:M#XA^ MRAACTT;'L@XO5;(NB!E"0+:'I=U^)EVPL08OX>%" IBPD6$KJ*I!F :^F0H5 M%GO2T^QO[T))E1&R+LL>;[\],D&E3Q:75B3#LHDA=BB+6P6>+,-QT)#,() . MOBVA44Q%>CQWY[K&9!!AQU#)GRMR=AI%&16#PTJ.7K3[EH:-4U/RV1PB7D@AEA]DBH MLPNB1A#JH"86,!89\6%?[9C_[]C?^)P'Q85_MF/\ []C?^)P'Q85_MF/_ M +]C?^)P'Q<5_MF/_OV-_P")P'Q85_MF/_OV-_XG ?%A7^V8_P#OV-_XG P' M9MI6,5O[7%&%30L^DV2NV"3:(V*X=<(!Y$.(1EB["B[MR4U)F J; C 9-??1 MDSB06AS48<8D-Y9#^>L3C;M/V&XTM#C:^Q79+*%MJ2M"T_=MN_H4E: X$$-+^0;3^\NQ!?K M55JUL$?=@RNU:9)4X- QZTYGJ)M+1FI=B>QE0K%.)9^-6'?U1FU#UQ:/?1 X M^\6^#RX\&&0#V79GNWI+JG?>L6K]E2K!+V!VWW$'TUJ*L5D1DI,DDIQ6OAS- MN/2'I$."$I%1G6RJQ;"7D2E2DS;,"'"QQ*>1:CX"/[/E J F?W"@[.ZV]D-1 M9Z7:48WGL63;!^ISD:T@"_VXJJ%5HCFN]K77,W8EYCTDC,K%*L":X9DPR5;D MS68+5B$JDA-CKQO.D]FM%ZF[!ZX40^TC<5"K=_KL6&9> X#@18[4=:2/8ZOT^-6-PW70]W MHY\P2!;&H8FJG#* EMJ!^A7BKR!EQ%& ST"Q5BQR\QY>8N)@.QC:]8X*U2PS M3+H>#-^,OQW7!8>=L3HUU&VK8PU3IU);NNUNN&G-CWLA7:!5A%*J,$S<;?2R M]@+I!58"(!CLSI[V(@T?$A1L-18[+* Z7]*@\6G]C6Z!?Q..NW\G/ ZXQXM_ M%#7Q!4\;\)%9=?>7GY$-M MJ5G];@8ZU=T2\*V[(Y*7J7HSXVM@1@X^CE2C]9ZD]HI M/6#K$W?28!AB?+42BUU5!]_4RY"%%IT9&6DORX @M.BM/1!<]Z.&:_TJ#Q:? MV-;H%_$XZ[?R<\!^E0>+3^QK= OXG'7;^3G@2JT]HS277FGXU[H'3NK-&T'! M2<U"ZGWB'7*;KF(B)V&TUJP_6 ]*TQ7Y5)&F@ MR-FMWCU\=%6K8AE,@J?L74SK2%"C&%NML(?(%"- C0H;*GWFF4N2'VT9==;; MQGUEIQD,,9ZJ> W!^PU7/6KQ#XM%1W"A?4[K M.0(U _2H/%I_8UN@7\3CKM_)SP,J:>Z*](NO%O^Z#H#IQU6T;?O MA4T%]O&GNO6I-9V_X(27'<(A_MEI50"&OA1!R)$7-'^^^Z2EQ8ZGV7%,-Y2$ MJ>!7UK3Q[Z] 9VK7=UG!O9_3UTK8[6M T=N/5^NC6M]8:9%7P[LQ8\2QE C<6VVI+2\I#RM:Z8>"^Z5\E;*?U+\4%KJX9D5(,62MZ#ZAFP0I@Z M:F5L(\1+C*G)@0F3%B'SP(MR3(;1/,PI8R*IV;'>80'WU7I/X-[U>S6KJ3U$ M\4UPV96U%T6'7E7Z_=1SUX KK\Y L\DS5!51E'1B@I-UL<6Q-@,9'3G$1)?L M7UI;R&8?TJ#Q:?V-;H%_$XZ[?R<\!^E0>+3^QK= OXG'7;^3G@>ZUIX\>@.E M[P!V;IWHUT\U-LFK.S'ZQL+6G6;2U$O%<>(C9@8@\!ME6I(H\(=G"") 5,<' MSXZY0V=,@OY7%E/M+"8? Q1OG[QNYOQ4;$_) QP(M=1-?!-L>+WJGK2QX_UD MO71?0%8(N8CQ)3L5@OHFH1,3HK,YF1%S-'N.(G0%O,N)9F1V'L8]9M.U)=E 1CD.:\-'KX&#NLU6ZJ;?V9M[-9U4;BXLF*Y>WH-L>6,(UE8\ "H$@' M*&"K>7DH8G.5QLZ+-//9@&'I9T9!6I^KD,8":Z^J?7QSU,KUF)7[)>'&_7GG ME>SGT9SP/Y?ZN=?F&7GUZT'K2RTXZM+,V MQOO*2VC*U):9:*K=><5C&<(:;0IQQ6<(0E2LXQD(/>MU/V;9]4PJ=J_8PC*# M &[3&?=)HH?81!E^1K:92[0B5?8Q"&]7"5_J][-#W!6 M$JH0S#@4H(19%,A#GVWJ4Z ^U@52K)8#<6$XCW2!!1'@XFF)4<6X' MM^L^C>O5^TC1##5/C658P<]3Y5JG6N18)EM(4:9(J!"V2BH.TF!\B599H5\U M*P@C*=8DS76)#SKS2W5AG?\ 0KZ _P!S87_SD?\ _F_ Q_LK3_6'5=>B6:R: MM?DC9EHI]21@$BRE7V"-VLXJJ"I4U+9AMJ$)C$B\5TF1E/-,Q(B7%)]M(RQ& M>"-.BQ75S;VZ[:,K^O;$F =U^#/C:[:B4N$W66:U*96@O""P;@7?8B;( ;"J MUC@DW4P\OQ1[8TBQ&-#IP^"$U_T*^@/]S<9_SE8/^'_;?]O@?&>J_7_&/3]S M89\GR_(1L&<_)\OR8P6SG/\ P8^7T_K<" MROW4(47H1^M:ZV-6CM'V!#N,$ MC%JI%UQTI2MGW?6#E3(PB]HQ.%O6&=3;@8CS7Q#L>#51"RA%P?,DPX#H6]XS MZ<8SC];./3_Z^!@O<77JB[L=@R[1,LPDH*!% HS52K DD.CE;-2+:Y,CNR( M!!E4^,7H )4-R2P_':C+)1UQG4S590$$NR9_KK"$[,T0?ZP0[*Z02+UG,,R@ M6OIIPNR/'CE0EIK+0G7 MJY:_J-I,=6](ULH9 M0^(]E;" ]OCJUUDPXIW'7/1&'5I0A;F-1:_PXM#>5J;0I?VO>LI*,N.90G.< MX3EQ>4XQE2O2&!-^U3JGHH0")F^H^J;0,L2KI'>D"M4:H;@C%U+7-NV&I@KD MH-C.JRZKZH"P#5I>L4! M9FA:]L++D@M'1%.BPDZ-38,' 6O'Q)(6-Q#>G-RH:&"BG(BB'N$8)*_H7NL_ M[G;1?\$E _S?X'E[IU]ZR5&J6.WYZNZ9L#E6 ESK8@5J/66"Q'X; >EN01KA M(3!@M2YB&OZU.C3U?;"UBS'I,0"< MU*Z^==+33ZM92/5W2M=('Z^(,S@$[4=&Q,"RR4!B7)%RL/U>(_[>"\\N,YEZ M+'ZS_N=]%_P24#_-_@1YWX ZL:&BUV42ZC:ILC-C3: M6XLT;J_5$$9"(UVJEK/&'$I1$8W)8<--BI$=B4S!DPX+3K MNR@@/7Q@90-'7JH4MR]6.S 1^*M/8"/)V*V.V:854,UBI-UV34A-CN9FL!9H M9V5#FM@')'O'MW'F& L X#@. X#@.!0#1^DG>3K7VX)]GM0T30>XVCUI\B<6 M;4;INNT:I6/J7;G?'57;M%.,&!NG]C8G&0T'K\5%'P*QT2.T^R=E0]'20^T+-=RU.[[:%[6V.+MVP 9\.@T2A699ZVZUU/+JM!KDK MX!#3B.W6!=DP1(3%QVEE;%G*$90&#]@=!^QE^J&^*M!V-5=?&^R_DDK79C8. MQ!6$6LP Z^Z71K;.FJN$K]G!R !:P36M#:N%VBI&8[M0;@G;U[7)51%_WT)4 M>._K/M+J%I&V:%V->(&R0U=WKNBV:GNC,:*-,E-;;8NY';+42S@1@\<$KQ8% M=+M&?A1@,6E[0J!FO6 M\>N=#FL.C)<5N5'?4AU */U][PU7RMA]JW0?>BK^P+Y1+AM/8FM';"*Z73-% M5[I[9=5VJM,4FT7$Y)![I1O@%KB>%418)69^KR7I@@S@%FRPHX;$_ JA6N!>N]D MXP2S^16CK,6YW=:;:1*6FIS*@T5,B(D+7 F+!%^X%4G)<$1EV2$I_&S5?(M7 M3GD4H;]2KM?V<8[=4[4UJ[";*G%A3T2J:EZ4=;-+4KLSKJB2:69 [KF7J-2& M[Q.JLJUU '%,37Q$H^\XS,BL!:KXO=I]B=Z=1*=NGLV6$3]A;)/VXN.' 10@ M6'!4P*:?IM<9A8$(PW,38T5J5>ER)+\I^.JV?"FGU0QT7@6&3 M*C0]A>//N_77:?&O!9WJ3V1?J8)ROM68BY<$Z6O+-=>KHQ42;)79$D'VF@K@ MUC)3$UY#<'/MW$XR&L)W=ZV;VHV\NR.UM ZEMK*)5 MCJ@Z#I2-&DBY=8C,%9D&*T5DAT>ENZ/=E<"4QVM@;/'B1+")A& M(L G",PV)[*7VHY0:YEV#.;0K]3A^*YG*VE9QGU!U=$H%,UC6!],H% M<&U2K"U2EP @EG+,*,N;*>FRW$I4I:U.2)3[K[JW%K6I:\^G/H]&,!R+?=J9 MKT$]:+];JQ1ZS&EBQ\BQ6\\*K0*//-DX@4+">+FI<(>U++F)\$2+C.2$O3R< MV) B(=E266EAZ1IUMYMMYEQ#K+J$.M.M+2XVXVXG"D.-K3G*5H6G.%(6G.4J M3G&<9SC/ KYV)L.B]>NUNA-5T/K&JPW_ '_K_:(RK[$ 6.IUL8" ZH:C7BTU MDY',S4$V6IKI@7,@210ZIV_O M<)IRTZ&JQJN6$P[OW;36GP!0.H-\-KI]^E7&\L3;$F>5AD?ASXRDE8S2@\ H M[B:N.F2B.ROVW C+?+?%V%V+JFGMM='[-.J5^.G*K7-X6"X:@)B9XC5X*RWZ M/8)-'#7>;LX73UF6' 4283KL-C)*Y!8)EEB+96XL@,[ZX[7:GV?V&WGUFK,H MK]T70(2@G[1F'("5-5FRNQ@A!;<]S M+*0DOP.G.U\+9Q_PFP#(A<;[\*)>Y36L/1_?P92&;$2_4S\GMAQ8?!(15_KM MR8K+F/E1C@=#0]<475X:17M?5<34PDHK/.2!H=C+$9TJ36A4R8I.5+SZZTM, ML-(PK#,6)'BPHK;$.+'8;#VW <#&@W3FK@]OA7X71J_ N0^%8!T*PQH>&R,> M':K 3M5A:0YA7J>DI839DK(=4A3V))%'2Y\$S!B.P(1:),?C.2(Q*)!D/PHTYEQ$EB*\[':=2TM2,A MZ/@.!UI0,'-L)C&10XM'1F1E#!.%&G,HS*@RQDK*6I33J$YDCI\Z _G"<>UA M3)45SUF)#J%A\B! FOBQX0$,'A0HF(Q %B1,...,9M+4:'!@Q&V8L2*PT ME+;,=AIMII"<)0C&,8QP.QX'UO,M2&G6'VFWF'FULO,NH2XTZTXG*'&G&UXR MA;;B%92M"L92I.VB"/Q)6[B'$0F/']FRG".!Z#@.!YR53ZE.*PSLVL5Z8;'$LF M!YB4&'/E()?(S 7)2'/=CJE1B&0^,"LS&742,CL8A9<]VQAO@>CX#@=09KX* MQ1:RW-'3)<"4CU?5D0Y4B,[A;+ MSB%!RQPX>(@0A0J#$&"QL2/ '#A\9F'!@08C2&(L.'$CH;8C18S#:&6([+:& MF6D);;0E*<8P',X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X M'\.MH>;<9<3Z[;J%MN)SZ<84A:.USKNE:DH ME3UEKBO0JI1**"'UFIUL>J0N$%!BV$QH$".Y+?DRW4,,HPG+TJ0_(>5ZSC[S MCJU+R'M. X#@. X#@. X#@. X#@>=M]:A7.IVBGDGI48=:ZZ;K4^1!4TB:Q" M.C9(N4]$6^S(81*:8E.+CJ>8?:2ZE&7&7$8RA05@Z_\ &MO'5M#I.LJ'Y9N_ MP"C:ZJ-;HE,!(I?CQ(("U2HAH5?KHE$\KT5G%)J1H@?#AIEDITR?)PSAZ9*D M2%N/+#UWZ!'L[_9??(!_!_XX?YA7 ?H$>SO]E]\@'\'_ (X?YA7 JB\VW0GL MB0\:^_ DSR7=LMQILY33M2C:[W+5>EX/69TC:MUZ]KXQ=M*Z;Z<4;94(<+($ M8Q?#M6LT&9A^"SAYHA$S('R@EGX/O&1VL\=6F6P/8SOEL+LI$.UP:U7-*)]< MEI;4C2_=I;.:,?O ^5LQ]]F-C(]J)"GTZGHC/R%+IOU9WV.LPVYWVWU>TG2>XJN#KH]L%#!ZLN@EN"$4 8ES)A PS M(F)GNL,0&OXBH0S <_91+WQ"Y2[*)1'$2/;U@MB_0_\ 95K<^Q+UO>PBJI>S]:11]ATE < .T_I2!2R9>(QL1^3"1)#T MZ)B/7H<*:0F22TDL/#.MIUQL)[;EKW+7G*>4- -$RM;:5KMB*&A0N-:[-9'K M1?"5R*#@)F0-!GY=5U) 8<"BSA&/$K1A]492YD:/@*[*QX^^R>K-P=+^P^N] MKU^S;0URQM&L=L@FQ[FB%2;S1-_28%[W'!UM-I'7P9:3YE>\AHW9U'D[(EQ( LP!$":!93%8M!25&"YW@. X#@. X#@. X#@. X#@. X#@. X#@. X#@.!_]D! end GRAPHIC 26 g582934g62o26.jpg GRAPHIC begin 644 g582934g62o26.jpg M_]C_X 02D9)1@ ! 0$#P / #_[1GV4&AO=&]S:&]P(#,N, X0DE-! 0 M %X< 5H QLE1QP!6@ #&R5'' %: ,;)4<< 5H QLE1QP" " < M @4 ,D5Q=6EL;&EU;5]);&QU2!3 M,2!&:6=U7!E 0 $--64T 26YT M965N=6T 26YT90 !);6<@ $UP0FQB;V]L 0 X0DE-!#L M BT 0 0 $G!R:6YT3W5T<'5T3W!T:6]N

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end GRAPHIC 27 g582934g63c88.jpg GRAPHIC begin 644 g582934g63c88.jpg M_]C_X 02D9)1@ ! 0$#P / #_[1<24&AO=&]S:&]P(#,N, X0DE-! 0 M #$< 5H QLE1QP!6@ #&R5'' %: ,;)4<< 5H QLE1QP" " < M @4 !5!R:6YT #A"24T$)0 $&L(6URE H%'FE =ZAKU+@4X0DE-!#H M /\ 0 0 "W!R:6YT3W5T<'5T !0 !07!E $YO;F4 )=&]P3W5T M)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6 MIK;&UN;V-T=79W>'EZ>WQ]?G]Q$ @(! @0$ P0%!@<'!@4U 0 "$0,A,1($ M05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F M]B7I[?'_]H # ,! (1 Q$ /P#TYC\H.+;65ZD[-KC]$?O2SZ2) M-O[K?\X_^00F/N=:/5K%<%P;#MTB/I<#:BU6-MK9:WZ+VAPGF")24BR:;,FA MU))K#H]];RUP@AVCMGE[E29T?(9:VS[=E. !!K=<"T[FNKG^9W[F[O4;_P ( MM0$&8,QH4Z2D-#+J::ZI]3TVAOJ/>2]VT;=]CM@W/=^>IS;^ZW_./_D%-,2! MSHDIANL+'[0/4;(:"3MF-S9='FHUOR" VQK/4 !=M<=NI=]&6?R5(%P]4M&Y MP.C9B3M;I*A7:X V9#12=K=S=VX#5X^EHDI)-O[K?\X_^05?,Q+X.S\MS7%A#3?&TL>V[VO92U_Z3 M9Z5G_!>HM.;?W6_YQ_\ (*:22F$V_NM_SC_Y!0>_(=2'8[6&PQI82&QW]S6N M1D ON9C-=37ZK]/:7;=/ZT.24S#['3#6Z$CZ1[?V4\V_NM_SC_Y!18\-,'E[ MW-'R!=_WU1MR"VNYS1K40W7@R&N_[^DIKYG3K_^WLKW_038?3+<:QMC\F[)7 #UJVP#%-C_ -,QGMJ^C_Q>]767"VT ->W87-][ M2V=!JV?I-4WU!SJG [14XN Y]KJX_Z:2G/OO/V;-+:+G%EX;MVM:71Z WU^ MH]C75^[Z:LMML^WVL]&S:*JR'RS:277#:/TF[?IN^@B'%#FW,>=+7A^G(@,_ M\@B"MHL-NNYS0T^$-+B/^K1^BFOD6V?:,4"AY!>^72R&Q79]+])N]_T?8FSK M;!C2*'N.^KVRP[(K^V8C)<#8ZP-&U\':PN.X[=K?\ KB+Z MCZ\=CF5NN.@V,+0?C^E=6W_I*5E3G74V B*RXN'C(VJ/K"G&:\M>_0#:QIK1Z6R/7?ZF^9CT[?YO9^=OV?3_P:!=7E/Q\YK[PPFT;'TL <&[: M"UKO7^T,>_Z37NV*ZQ@>=QGV6.(^XL_[\I&BLBP.$BT[G ^,-;_WQ&U(!]I^ MWV#]'L]%FUWNW;M]NAK^CL:W;[O52P1E_8L?>^LO])FXM8X"=HG:'6.=M5GT MVBPV?G$!I/D"3_WY)C&UL:Q@AK0&M'D-$K4U<7[4/7W&M_Z9^T .9#=-C72Z MW<_]Y_\ X&F#K3EY >P-:*:B'ATR2[(W-V[6N;L5IE;6;MOYSBXSXE0LK(?; M;.CV-;']4O=_Z,0M3__1]0<]IO:R?FDIUDED/Z+AFJUOI5 MAQVN])A+ =KC6QOH[7M5ZMEM=VUA K;6UK*!HQH&@75[V;/["C?9;938&6>@6.#38P;B""W0-LJ>UV[=^ZDIL M,^E9_6_[ZU198QUKR#PT3.G#GM/*DP.&XNB7&8&O8#^"I]2Z?CY37/MK87-: M VUS&O>T3+MH?7=]/^JDIO2.)U3K,/2,0V%IHI]/TP&T[&;6D.N,AY+Y;L$5?FC4^\.]/^ M@^"";+;'X]C'[&ND^F!H^1^>7U;Z]G_6U9K:6L:T\@:I*8TN!#B#^<5.1,3J M.RSLKI6)=D-LMHJ>7O.XN8UQ?[=&V/=6]S=K6?2W(=W2<9[+G.94'[]S;/28 M37.QY:QKJ7-LW?O;4E.LDLZKIF/3ENMHIJJ?L.W8QHVEQ.^QMGI?2=^YN5FE M]K:JFN=ZI>-+'2"[3=+FMK:UB2FPH6_S;O@@-LMJ;:^Q_J //(/M!B*V[*_> MUL_23Q[Z>W_ ,#24WL^G"S?2:_+?0YKOT;J+O3)+PX- M;[3^DW;';&JJW Z2:V5GJ-KG-B6V?S MC;MGN_PG_!I*;^!]AQ*;&,S'7M]0ESK[=[FNGTW,W/\ HM]1GT?WUYK1[T-_Y^S_@E>Z8, MJ6&AV&,.2;6XVIDMT:'U[:O9^A_,_FDE.JF) $G0!.DDI!]OP9 ^T52= -[? M#=XJGFX>%F7AYS;Z+"!5MHN-8.USVP6-]N_U/4K2;_S:VC;]BVQI'I1"MN^P M;V;O2]3>?3^C.^7;MO\ PF[>DIS?L'2SLCJ-S;6UMKWMR2USF ^NPO&[:Y^R MS^[Z3[/8Y!R?V!Z=OK_9HVCU?H M[HCV_0_2?U$S_P#F]OLW?9Y_1^K]';,N]+=^9O\ I_V/YS]&DIO59./<2VFU MEA: 7!C@Z Z=A]O[VU%57$_9GJ6?8O0]3_"^CMGEW\YZ?\OU/I*TDI2';?13 M'JV-KGCY]HS[Z!=8;"&9+F@O.RSVMSGW>G.S_KFQ#N_8,#U_LVWWQOV;9]GK_2]F M[^;WI*;3T.!.O'?R1E1K_8?JL]+[+ZV[V;?3W;OY,>[ S@ #(! M @ 4 [ &F'! ! $ "P! ( @ " ( ,#&+0 0)P P,8M M ! G !!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C Y.C$W M(#$S.C Q.C X , : # $ #__P J $ $ !H!P Z $ $ #? M @ !@ # 0, 0 8 : 04 0 'H! ; 04 0 ((! M H 0, 0 ( ! @0 0 (H! " @0 0 2 M $ !( 0 #A"24T#_0 " ! _^$!C$E)*@ ( M#@ 0, 0 ,<( ! 0, 0 -P# " 0, ! +8 # 0, 0 M 4 & 0, 0 4 2 0, 0 5 0, 0 0 : 04 M 0 +X ; 04 0 ,8 < 0, 0 $ H 0, 0 ( Q M 0( '@ ,X R 0( % .P !IAP0 0 ! L 0 " ( @ M" # P 0 , # ! 061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W MG)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O M8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q M(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @ M/')D9CI21$8@>&UL;G,Z&UL;G,Z9&,](FAT=' Z+R]P=7)L M+F]R9R]D8R]E;&5M96YT&UL M.FQA;F<](G@M9&5F875L="(^4')I;G0\+W)D9CIL:3X*(" @(" @(" @(" @ M/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" \+W)D9CI$ M97-C&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C Q."TP M.2TQ-U0Q,SHP,3HP."TP-SHP,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @ M(" @/'AM<#I-;V1I9GE$871E/C(P,3@M,#DM,3=4,3,Z,#$Z,#@M,#&UP.D-R96%T941A=&4^,C Q M."TP.2TQ,U0R,#HT-CHP-2TP-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @ M(" @(#QX;7 Z0W)E871O7!E+U)E&UL;G,Z&%P+S$N,"]S M5'EP92]297-O=7)C945V96YT(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC M94E$/GAM<"YI:60Z,T4S049#,C)"-$)!13@Q,3@S-D1%.3&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@ M(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA&UP+FEI9#HS1#-!1D,R,D(T0D%%.#$Q.#,V1$4Y-S(U M,T1%-#=#.#PO&UP34TZ2&ES=&]R>3X* M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@ M7!E/2)297-O=7)C92(^"B @(" @ M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^&UP+FEI M9#HQ.3=A,&-E9BTW.3DQ+35A-&0M8C7!E/2)297-O=7)C92(^"B @(" @(" @(" @ M(" @(" @(#QS=$5V=#IA8W1I;VX^&UP+FEI9#HX,C4V M-C0Y04(P0D%%.#$Q.#,V1$4Y-S(U,T1%-#=#.#PO7!E/2)297-O=7)C92(^"B @(" @(" @(" @ M(" @(" @(#QS=$5V=#IA8W1I;VX^&UP+FEI9#HS1#-! M1D,R,D(T0D%%.#$Q.#,V1$4Y-S(U,T1%-#=#.#PO&%P+S$N,"]R:6=H=',O M(CX*(" @(" @(" @/'AM<%)I9VAT#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\ $0@ ZP)? P$1 (1 0,1 M ?_$ !X 0 " @,! 0$ '" 4& P0) @$*_\0 5A 00" 0(" M PP&!@8&!PD ! (#!08!!P ($1(3%"'4"146%S$V-U=V=Y:W(D%6E;6V(S(X M47-X87%T=;2X&"0E,S2S&3529Y&DL28G0U-4=A;>W-K;I\U-6SY!R&KA.R-IR9 $&=;YIE@HF+JT0,%(RLJZ& M*0<7@1F,$2PZ=@T7)/3IL&M1V4$Z-$$EQ&I@"P%R=H$D::T%KWGJTVYC$29( M %]))N;P 3!, Q_=.MH#IQF[VGJ.V)I:TU2FBZLBS'M$C2TCM*OWK8]R8HZ8 M.Y:01=+_ '2-A$S$S4$PL^ X<]*+LN!B(@!4>EV09KQ=GX:,,"Q%X'5"BR$R!(V. #DL MNJ-:USW2&L:]Q)%OW=)M:HT'0N8QP+F@S,M$N! T*3W%@ !-1S6MN!.9YIM- MX@.>(&V() !E:3'>ZX='$M4R;I&3FPCH,:+Z?9K*AM=3SIS\;U.R9\)J)\2- M1C)I3DU-QQ$2<&RRHZ)+RTHL9(KF">;)@@;7/;3;_,YU+G@!L_AWDP)MJLEI M:W,Z W(:DDQT0\L/DX&VX2K;Z:ZFM1[RU1-[DJ,V5&T^I3%]KE[1;@':W,T" MQZODY&(O\%<8XM2O>D^L%Q9:SE8?("<"PS(A%E $CDN3,W(*D] LYR?Y8))( MU!$&01/=HF1V?FXZ>;+&\DP(.AF1!4/="_6?$]9E,VI*KJ9VNKSI_=FP-477 M7TP\TY,PHD5+.2>O)HO#;KR5)MFNY*N2S[[*E 9G\6 &-=?#CVWEULN8UY@$ MYFN:+Y*C'%KV$[2PB"1;J*(9:G#VZ33PHV-S/7&ZV=F*<'E9I$'#X;Q%5:-.B";!)ELCKG(< M5DDQ&9)>U@VM>XN-P&L F!(EQD0) B238 [#1D<\GJEK0-"7/S$7@@ !IG4R M6@"Y(T^=Z\J=I0V4CMWW77>PUR.YJAH_7F>F"/FMBVV7OMPK]FF *A==50<_ M>;92+:\=4IZ'CHW)LR')*#&)3(#%'OQ$3,UIB;NRY;AP:T&U^L>D(-AEU,A, MEQ%K#-GM!+HW7:+&>_2RXG_=3>DD,BU#24Y>8=VG0VT39=J:H4W$%?"71^L: MMN'E ME_ +40[LRPR4MLC7NI(6$@==RQTQ,W[:VG/CWU]!@"9=:2K%CUSWDT2!#H\; M%F)7'SA<60A>$Z)B=;<[/"C'.'@)D;QHLN:6P'$"2P"3MJ1EOIJ0.)6N]4_N MA\70/<]4=>G38Q7MFUB3,UB[7 ;=&60!B5B[WM"OZPEA"P 2(R=B;!6I.:*R M4 ZR0YB2A"X=8^%$(,'CB6NI#45'L;(!)(J-ECFZ3,M,'4'85NG3S\X"8+&. M?LU80"#LWB=)@W"DSH/ZM;-U6P>_%VRNUR"EM']0UZTDT9 9FH1ZU1=5&B"@ M+1-ZRN2L;%U1*'YDGQW*C>6&Y-;03QZ0F/#3,.B[5I5\.593A$X1.$3A$X1.$3A$X1.$ M3A$X1.$3A$X1.$3A$X1.$3A%YO3?6E9;/U<=0'3)KI_6&NH'I1U/1MA[MV_N MI$H7 >_FTH]V:I=8@HV-M5)%BX$&OL.2ULO4W8WF@GW6H@&MDY2[)8R"2*CK M ,BT=42"2[9E@G>4#(+ESP7$-'5:+;KN,9HT#8O)MQQ7NENEJ MXJN5#:Y9#VQ6=+PN\=FS6D8&P;BT=1M>%F6J)G=B%;6J(TO"AZXKDW3)Z-D[ M#-.@$#+9'6^ C)&4-3-#27@MR@%]K#H9[:S.C0)+G6$ID+B P@YG$-O$P[+M MB(!!), #6]EW@/=2^DZ0%@5)F+N++V&ZU"A"UMW9()!# M@X45?=5AD6. DUF*'9>9(@9[,+8@SHH8ZHUDAUBUM=S@1=HPP:ZL#WM#FFT@ MR()6Z="I5M[EC@9 @B\2%A _=;.CDU^HY3/7]B&M]4 MT7>F[65KR=8JM=IO4;/$535-CM\PK&6Z['S5K8Q7#$F-^F1)SS91PK4.V7)C M;%W!FTN#!WO=3YUK1O)8"1&XC8N4<+,+];Y6N:UQ\"YL\1O"W7:W5?>E=:-% MZ&M)Q%,%V#)Z+FNI+8.P]F!STQ5ZOKB.N(U AX2N52M2];DK3;[#9B%Y>65: M8")KT,(LY>9HLEN.:@ESGQ&6FUI<=IK05_1*6D.6!I1YTE6'HZ/M)"-Q@J,-DB8U[],3/ F!(@Q<3,';!VB=# D;!HH8!Z)D;"1!TVC M8=]R-Q(N9!Y5$X1.$3A$X1.$3A$X11)=-[ZAUW.?!N[WV$K4S@6(.<$DU$M( M&"G79IF,,,+0,L((5Y5=F%.D%DLLA,A^D'+&8(%9(%MI U(6 M@UQ@QK,:7C6/UL,=4QWZ7N/66PY0^$IENCYV7BLR2)..':.8* ?A28\.:"+: M-$&4/)0Q$O$-S$8YX9"+]]XI9XP[2A! !/UA(TN)B8UB M=NU29PHG")PB<(G")PB<(G"*']Y:&U7U'Z_,UEN&K,VFJD2&>,OS&O-6*02P]")+3HYC@YCA8M< 0 M' [X)&X@D$$$A:#BW,!HYN5P(D.:2#!'$ [P0""" 55^S>YK].EW.V;/W4K9 MEJNNX9S24[L*^2EV4S99YWIUE!IS4 /E149&UP &J300DFO,=7Q#YXAC#=C. MEA7'AW8&@.#@((J\\>]XIFF"1I 88RV$P8E"\D08(R&F! LPN+R!MNXF29-U MOMNZ$>FV\[MS5+#L/7-)L^N*%?YN!96ALNTU2CW M"6F2V:K!3J. T!>QH:2-V80XE MQHJ/&4M.4MRPX6<,C\[1.MG$D<8-H HQM'W&C4T?J5VB=,DK5TR.2T MIL6^V^VQ[5 Z9MD*OU1K,#A]F5+A#0!GCJ["D@I8%''.]\9-F3/%\95@YZ3I MM3JMJ.FY=EHOHB#$3#AJ(MIL4<[.U[2 6.8T 6&9^:X)NT2;3N&\KT"KW1Y MI^IZ/L>@JVFSQ%-NMOLE]OP1+ MD:W"'5Y>:MB-:KFC9,Q)<3J\$$Z1 MF$'+$!LB1;221!@CLZSZ0M,Z?WKM/J$US&RU5N>YH.K0&P82'D&(V@3 ])": MCZL>FE1P(D.+.1 :21V9QAM,F^Q(GL%DD,.MM,FC*' 3#W9S/:@-D;NB (%C MJ9==1Q+LL_5;E!B\277.V[B9-Q8 @"%9_E43A$X1.$3A$X1.$3A$X1.$4%S7 M4OHJNGSL9,['A03JU),PTT.MF4=4'+D-EO#1:5CQ[K9<@4Q'2KX@82R""AX: M,CSF8TLV-4ZMALLJ&B+&$E*G6FO-8D*]/P<[& MF,X<#DH:7C9,!\@(P=]QN[Q/@>[9X[+Z%0B/Z$$6,&XM8@@[B"-0MTX43A$X M1.$3A$X1.$3A%"6[>GO5_4#'T\;8D.8[+:XN<7L;6EO@90VOW'7E\A4/M1MI MJD_'.-D!FML$D"&@EH-@YH!]Z-G8J3CW7!50BX=HYLP1$P>LTS(+71TFD$& M8D B@D C4'4'21,'N<),$01)$P2#7L?W.;IR:E!;&0W?)&W)ZGZ[UB2UL-N# M^9>R;ZJD$16(&T3(PH0L"W' 5\I^+^#,+"P]?(:7D@J/?.Q@K$:QK8RB '5' M1)(+JI+GDS)N7.@3 FP$"*YSG3F,DM8V;3EI@-8-U@UNR3 DF\\T][F_TF6B M][!OL_03I(W92]S'S\$[9)AJL"6;J&U_7M6[JND!%C$,.PMLV%0ZO$P$M)B& M8;#1F5/@Q8J5GYXZ2R:3"US8LYKV=X;4>VH]K3L!J-#]\BQB0M"J\%I!NTM( M,#5@+6SP:2V-"-;W57[C[DA1X4W2"] 7.U4UJD]3&I=\;'E[G>+!9[5.!:BT ME:=%UT"G2I\;+M0\V-5)V(2QZ9,%::]S<\&[P0X[P3F<-W2(O;N$*5M'=-.J>GLK9[V>=DK);;Y;.CF6P8J&A1(J"BQ\.8 MC&'""7'J+ -V N('>XR3.M_Z"RP3)G@+6L-+?HG:I]X1.$3A$X1.$3A$X1.$ M3A%U3C@XL(R2D2F H^/%?-.,*<2R,((*TIX@DAY><(:99:0MQQQ6<)0A.59S MC&.0D $DP!J50"XAK0220 )))T "@9SJKZ>FD-..[0@6TOPS=A9PIB72MR$ M>/&AV9)#68WS,C.SYHE7:5X.[EM)8J2$JLCJ(O-%W,:+NJ/--@&KWM)!:WM. MEKK"9RNB0TQ1C) ?Q^24&4WAQEU*7$H=;SE*NRVG6VWF5X4T\VVZA:$OF 1P(D'@09&\+ M.TC<2#Q!@CP-EEN$3A$X1.$3A$X1.$3A%4W:_1=I3;-RNVQ#1[/3+SL_5YNE M=I677T]FOE[,U:D1RMAP#L#?%R .P->;&:N[.QK+'W]4QJG5KVDJ!'*L\62"4 MW US5!)-+% ';8=>&*+FRRB+463/.QS&OG,))Y[,="[GVAM;-&NEH^9EP% M;;8EQN[G&5&'3*64G4@;1) <8DD;2"5S-\L?Y;V.EH,A[V.@$R0(8)B"9V 7 M]!-H]+>K]I;,I>["56JD[IH$!,4^M;4UW8B:S;44JP$-FS-*FL9:.@;55#)% MEB5:AK3"3(T9+-8E(?$<>MXAR1!+A8D971M:)(!G<3((@@Z$+68QEU ,B;Y3 MM(W2+$:&TBP4WUBN U*"CZ]&D3!8<X1.$3A$X1.$3A$X1 M.$4+6CIST5=;6;>;3JJES5ODVH@>6L14,/B4F1H)!+,2+-DLX:5,BB,%NBX& ME/2V'A$#"$-NC!!M,-^R8F#$QIIN(!'>&G5HBR;7T! F\ W($Z3>>)[1G+US M26J:D]-$5^CPL>_8Q9<2?=\M\M4TU8' W; Y)Y-?)]-+GUQT9[^GD>8=,HBX MMN2(*;C04#I,DS=Q#CQ @'CP0DD!IN ( M8&\<+FVERM+@M2:O>O%\">U_47 M1 1ZDH,9R!CE,"J* D%DY8:RQE#67UMH4]E&,>8I"S<9W]IWQ'W3(SLM^$>R?$OJ3ZMJ5^'8SV;C._M.^(^Z9&=EOPCV3XE] M2?5M2OP[&>S<9W]IWQ'W3(SLM^$>R?$OJ3ZMJ5^'8SV;C._M.^(^Z9&=EOPC MV3XE]2?5M2OP[&>S<9W]IWQ'W3(SLM^$>R?$OJ3ZMJ5^'8SV;C._M.^(^Z9& M=EOPCV3XE]2?5M2OP[&>S<9W]IWQ'W3(SLM^$>R?$OJ3ZMJ5^'8SV;C._M.^ M(^Z9&=EOPCV3XE]2?5M2OP[&>S<9W]IWQ'W3(SLM^$>R?$OJ3ZMJ5^'8SV;C M._M.^(^Z9&=EOPCV3XE]2?5M2OP[&>S<9W]IWQ'W3(SLM^$>R?$OJ3ZMJ5^' M8SV;C._M.^(^Z9&=EOPCV3XE]2?5M2OP[&>S<9W]IWQ'W3(SLM^$>R?$OJ3Z MMJ5^'8SV;C._M.^(^Z9&=EOPCV3XE]2?5M2OP[&>S<9W]IWQ'W3(SLM^$>R? M$OJ3ZMJ5^'8SV;C._M.^(^Z9&=EOPCV3XE]2?5M2OP[&>S<9W]IWQ'W3(SLM M^$>R?$OJ3ZMJ5^'8SV;C._M.^(^Z9&=EOPCV3XE]2?5M2OP[&>S<9W]IWQ'W M3(SLM^$>RTK8>K]4F6&WTM3 M4LDR0 WZH:Y@&P->\U'-CR,$ *PUH$B()D" 9,QIKKI;@LGI:@$;H$7,Z::DGC?5:+0]2ZQD8 M0]\^@U(U]JY[% ;=*@H]]QL&*V!9HR-$0MQA2DC 1P@H(;.,X;'$&8':2AII M"<;)*Q,F$]CLZ) M(1QS3X9@SN/4XP0RXTO']9.>0@$01(_1_ W"H)!D&#^A^(L5"+/2ETZC"" C M:DJ8P($. BQ$7'1%C8@ &P M"VZU:XH::+B*S4H)P"F5F4'JHY #)/O"VS&X\O,L35=/:J)K M%<)(UW3GR"(&'??>=K\:XZ\\['CN.NN+4/E2W'%J4M:U9RI2LYSG.S/H5E_5/AZA2/S*TG")PB<(M!UM\WY+[? M;4_,ZW\T[4?99^1JRW0_:?\ GBV/D53A$X1 M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%'2?I:?\ NZ$_F4SFOJ?> M^2S]?[OS4B\RM)PBCRO?2#L;_9J5_#I/FCU6^/JL#KOX,_W*0^96TX1.$3A$ MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X11QMKZ/YS_%A/Y@BN:9UAX^A M67]4^'J%(_,K2<(G")PBT'6WS?DOM]M3\SK?S3M1]EGY&K+=#]I_YW+?N96D MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X11CL#YR:9^\XS\J=H MF^\;;L>\4@MM$VG?9=J*M%9G75,0=B@YEY R#%,Q4L!(.I$<=6P@I38A M#RTCK>;<92]G&&U.H6WA7C3G&&_NL>XD2 =TB_!2"-1$S'?&OEM6LU[Z0=C? M[-2OX=)\T>JWQ]5@==_!G^Y2'S*VG")PB<(G")PB<(G")PB<(G")PB<(G")P MB<(G")PB<(G"*.-M?1_.?XL)_,$5S3.L/'T*R_JGP]0I'YE:3A%IF-CZ\R@M MS%\IN4 .FL'+Q9X3*0GHT_WKD&2U8.[#.@2?_9QC;V4*&._ZH]A#_P#1\=^S M7PDB?,$<01JKE,Q!F8B#,Q,<8OPNMBC9>)F6GWXB4CI5D4IX$EV--&.:'-'P MC+X;[@SKJ6BF,.-Y='!7)3OFC5O MLY"?PP7@ZGB?5!H. ]%L?(JG"+Y6M#:%..*2A"$J6M:U82A"$XRI2E*5G&$I M3C&$+0O+:_+^2S]?[OS4=;4Z7M7[GG53VP$6&4>4B'$]"%F(894 %$.D2+AJ;N/:<''B!&GK[0%'',&@@ - M:6B)'1)F)F;;#KWE;5184*!NNQ@ %R*Q_!3G^\I,S$Z3YCD9()5C!LX?(FX: M[(3X6,$88;SXE-MI4M>5:/5;X]VWN7)HASP-(;M)UG?=2QS*Z*&.GC8DUMC2 M]!V)8AXT2;M$2^=(#Q#) \:T\U)GA)P(R64:0VWEH5M64NE/*\>5YPK"H4C\RM)PBJ?;>C34-XDIV8LI%Q/E+')QTY*%HG1A$JFX= MJ<%B900(2*9CHYT&.M-H!]$CPQHL_-ADY>6 D+$L>9'D6C9DXN?P+RX MR6QW029T'D&8;U@ZX)ZH :-= -L "84E:YT-K[5M3EZ74F9X2#FI:,EBD_ M".7&D&E0=5JM'@0A)6+)C9$<&(J5)K$&PE).231XS)4P5)R1TB:9J28)N8 G M?%K[-+:;-]UEP#K$0+F 2(DEQO,W))UVQI 6>U2&S'U,D$?)"F!+QM$=G)9A M<@3EMK9EN2G+YQ[Y)I3O;&/&^40\^YG])QQ2LYSROU^ZS\K5EEFQN<[\Q4@D MDC!#O%F$,""CMK>())=;8'89;QE2W7GG5(;:;0G&5+6M24IQC.[2$!@SN513NA#0A[B7'!K> MWY5=15!DHL[[V1H%FS 7H4+#Q@Q112QM@Q@-X0=(/F2#TRQB/,*)JSCM=_K,52Z?)1T,D:SV",>6TQ%JQYDFJ&D8UJ5<=6.E MU:3F7AT+$46[R^A3H?\Y[KPBGWA%B6IV&?G#Z MRS)ANV"*B8B=DH=#Z%2 4-/F3FK?1Z%'6A4BDF0$\A:/$:-Z&CR$/>)C/C5YB%>KA%+W" M*.D_2T_]W0G\RF5[Z0=C?[-2OX=)\T>JWQ]5@ M==_!G^Y2'S*VJM]%/]EK3OV=,_C\QPBM)PBQ@[J(Y&.-D,ML$KEJR R^LADIM8+A32&FWG M&R&9MCN/R]T4L\J+0MG[%@=2T.Q[$L[4D_ U@5@N1:B!V"I);1!PL>W@46UD6]\(G")PB< M(HLTY?C]E4PRS20(D<2-L3<=,2,$IY3"@]:[?O.N(TQ67UK<])D8ZJ"R!J<* M\I)I1"6$H8PVA)%W-M?1_.?XL)_,$5S3.L/'T*R_JGP]0I'YE:3A$X1.$6@Z MV^;\E]OMJ?F=;^:=J/LL_(U9;H?M/_.Y0IUR?V.>IO[DMB?RV?S*TK4\(G") MPB<(G")PBZSYH8KH0Y)8P[\D0L..9??:9=/+;$*D'!0FW%I640V "::MAA+C MJ1!"B5)PR.ZM!%V>$3A$X1.$3A$X185BQ0A-AE*F/)BNV2%A8&Q2L.A>,J(LUPB<(G"+#6.PPE1KT]:[ M+)"PU1AQIQ.?UI6A25)S^O&<<(HVV!\Y-,_><9^5. MT.:;H_[(_.U0ZCC\BI.YE5.$3A%K]L^:MF^S\S_#B>4:CB/50Z'@?1?%.^:- M6^SD)_#!>#J>)]4&@X#T45;?^?\ TM_?Q/?\L_43R*J>.$46[R^A3<'W6[ _ ME.7X1;52/F74/LO ?PD3A%M'"* NG7YJ7S[_ 'J'_.>Z\(I]X15[KW]JS;W^ M7OIR_,?JFX5V#B?0*PG"BKOU#_\ =:3_ ,Q&J_\ C9'A%8CA$X1.$3A%">HO MG)O[[['?RIU3PBFSA$X1.$57.J#^KT\_YH]1?^9.\(K1\(HZ3]+3_P!W0G\R MF^D'8W^S4K^'2?-'JM\?58'7?P9_N7=V1L M6FZCH5NV;L*::KM(HL#(66SS3S!12(Z(C&%$%/I$ 8*.,>\*? .&$,066^ML M<9AU]Q#:OHP6#Q/*.+PV!P=(UL5BZS*%"D"UI?5J.#6C,\M8T2;N]Q!.5K1), $FVP DZ $JH/N;&YM:[GZ3: ?K>SCV- MFH+E:A9VVQ3@2X2QBR!$JY&'AR(HA+3JXR5C9!AS#2F"!#67675XRK"?LY9Y M#Y4^C^*&"Y6PKL)B'4FUV--2E5:^D\N:'LJ4'U*;AF:YIAY+7-&N%B")%P00KZ<\E?0JT:=^G#JY^\?6/Y":TX5 M.@X?,JR_"BKGN#Z8>D[[U-@?\OFW>3:.!]0BL9RHJI];_P#95W%_N.*_FB"X M16LX1.$58>C'^S!I_P"SI?\ '9;A%9[A$X1.$4 [0^F'IF^VFQ/R?NO"*?N$ M3A$X1.$5;^E/Z)Y7[]NJO_FDW'PBDG;7T?SG^+"?S!%QV-L44*[C13T*R;.76$Q'OE(-<;73;M8J6Z1DAM@=*D MGNU]9[;>&L98;*0.I3JFLNK(I*X1.$3A%5[?7TO=$O\ F/NO_)[U3<9^5.T.:;H_[(_.U0ZCC\ MBI.YE5.$3A%K]L^:MF^S\S_#B>4:CB/50Z'@?1?%.^:-6^SD)_#!>#J>)]4& M@X#T45;?^?\ TM_?Q/?\L_43R*J>.$46[RSVTIN#OZO_ +K=@?RG+<(MJH^? M_L54,_J^"]?SW_\ ZD3A%I%YWOJR@!SJY:W14A-0,7(2C].KI;%@NI:(\-\U M8P=7BW"999#S;"D-*>'8&0K.%DD,,X6ZCT<+R5C\6ZD*>'J,I5:C*8Q-9KJ. M%:7N#0Y]>H!3 !-X<7'ZK28"Y/KTF!Q+P2UI<6-(<\@ DPP7)@>Z\WO=5$!M>&?@5:OL$?MZWV*&C;'9(PIJV";8MELNX4?7RE,1>3YRO-.K"G(H5 M@AQIMR.D&7'&#\MC_JOI?]!<;]%784C$CE.CB*-2I4JT,-4I_LII%C7<\W/5 MRTG%_P"ZK.

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end GRAPHIC 28 g582934g68o80.jpg GRAPHIC begin 644 g582934g68o80.jpg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end GRAPHIC 29 g582934snap1.jpg GRAPHIC begin 644 g582934snap1.jpg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end

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

  • 3*M3K&4-25J.1=-N#9%T^L&)='YS3(Y'\J:BHB5 M-/4HJP#YDS1EW1UTZ@-.K=TS&&:Z-(C\A^-5%0 M94-%I#/A9+*JI+:?98;Y95/'!7:=,!8OQOG1$Q1;Y8L-JBDT[56H?Y<&HN+S M4/F90(XU):A-/@;O::Q-8&G-@/+4F52)GUL.&"5.4;I:TSNYYZ.W+'S?-LDZ M:4&:@J,QNQ;=R?DN7(@IG_D(9K(I<%WKY=0H1I.Q1<)).ZE2CHK,8\(%0.Z] MNZ9+;8Z732HBQ*'$^FO0!,CYA$] 5CF4K.?41J6D")7T3R4'&;L]8W15B-V\ MEOK)L C'':S3RHBD!U-/Q)+6"N%6BI?\J2C&Q)+M:VH\>!^H&AS% * 4!^?G M5UI0F+4[W8>-SC'?N<4M6'-*VF*4%*0K82A=P$1VIJYF-P.-K1ADU7NU(^R< ML@-I'"8SYM)".^DH)A.(88%LBG+$!K#::5%Q48QA9"Q*+BFY1BH0-.8:F;NB M6E:""@D4J:Y*R1)46]U@D1@P>KP>2/#PX^H1UDA69SD35E(*%'_(RJZT"27L M\P&.XE44HYBJ.E(#-2L+X7-FA?\ %V_\.-LDJ48N4^/!1BCUOKNANLE!CC54 MLQ-K27YE9$4.31H-&TV./1ZG1NZI 2Y#:>I-;FV/V"FXP2I1^=>IIP,1C)J& MN/AI)#(#%2Q8HLYVM(KE+NPR"HT914'.*3C9"$>,W%6RMG!HV(1=<_="73W0 MQM14%R2/8[49;B-$;\#R?'RLB+3ZTY.*,FH['[+!T9OP*[UDM(!013>!DLLD MI\:<6L=W-*\7O5J9*. JNHR<2D"X5,JQK#W19-%&C]S:22,N%')J#DV?,Y,?@CP(&)'55I2$: M)3CJ-\4I,NK.!1 W&$DNG'$WBH04 H M#H6[L+IGE;5OJ T$PG%[B),D9RM_67SE(*V'*F:+'AP!AQ7=OO@ET4OB/%+I M :QS(PMQJ&N.4-N"N8B'@L)RJF?=1$N!71##LC5",@RJ">[G7'R]>9#LIF"-W6W3!E[,!HHA01!4D MUDEE49Q<^8JYA1"+D!?\6E'A1=CL_P Z4H=^+N(HT.Z%:[5Q"<5T[5L=4'>8 MT%/R990)2+HJ5HY:>D_5>-0,,Z]]4+2B>5'H,XI&[J)$Y$KI'-:\0:9V?-$O!SV*VQ1V:5BYEI:XYPQD5V);?:1]D<9YI#@"D!&+EAJ M"=&C'E:C%2:=)I0MG+,[I9IS$EC57IS@DMGF*VXK 4]7,N!A99=X$R;(IV/] M.S45\,;\-@G))JLZY50\[6M;G;3AEB(+8.]RYH8X-]E[[0Q.J37(NP"K=U7T MO,U-<4L-[4$E2=I_>CXFI3&EH['40QTS%80ZB:;(B1VDB#MD=VZK%!V%4V6L MUW,9HID?GU!:=BSB? ;R(7&J+_Q=D(.4HMN$W/\ 536-DVS]&U# H!0"@/R( MR5I$G=RE^[;ZJP'DJ-YK-\GW2*+4..D,K+)A^33=S0!Y5Q,N89-P 3\!THM*I&]3E!*MTS<;(&QCBU.:]8*#.L]/TNM=><,'P_+FE]VR&N)Z?'B&UEEG*:&%-;8:<6IT M@.YLNX=C)3WO=[&UM8NGJA8()S2X."C:TU[1<%=!6F-0YW076^J/W0X&Z95= M$AM>5I^U&Q@YV@A:9PHXD65&V@ZC7-'L0R.X49U1;DCLB+T^/TM+47^G(+Z8 MTIQLG',WZY"$@(@1@J7!JC_E>E1XJ"<%%8N,5VA(NO4@WDFIS99"#WJ V"434PN2R<: N-*296EA\K.:: MEOEJN8=LX*EC(E)45&$;9635]N32AP/@BE08H_=M[.&%D.5 3JVS]3S#U2-M M=(SJE.ELO="46>I-*4I/6GVINZ*W9IYV$1MZ76['0S&!033J.KJ8 MI9L M^E-\)U)PM4+.Z4+'??# _1#0P* 4 H!0"@% * UPUC&%,GI%U4&T4<\562NG M"<#"292Q3 "F74P(R;K5[R)%#':&J6;EL=OH^F=)<,FRF_K3F_7$ MYT%\Z>5(!&>BZ@1DI($5R(?5 8V1&YBYG6BF2D3CQ4<)G2"=)UI*$G%7RSG) MSX\#:UX=TRU!$M34DL6*]5+'E"[$E;0HTH'TZ :=;*#FUAL.?8>T_.V7G@6D MA!$)69PB,0D-VR86%1D\N0C@N3#L]P!VJH(A,"DJJ";5M&DXQA!IM)6<8)0M M>!\L3]TN[H\Z9RU#HX+*CAZK\=M#6BO#Z/Q$JR;)$?B0FG._Q?04TNBI^#\5 MSLCN1&9"&L&WYK7DA'6C M22NGV,O$\7RA$&0H-Z2%,ZC/JV)(1))S4/\ &E:TYU7!_>-EA]<7=TO[I Z) MJU')1=G1N\'%'+)UJN 72(.CV(R+'1B$TQX7T]X)Y)$(!/U;-R(Y49D(BR.[ M5G)(DM,?PKDB4-++)1C+1W,:='C/>O:3':NZH".J MI/\ $!@6QQXMR(5*%VRTGJ>F:55AU1P(VT MG7B,X&VHFS(C25%2@ZUZT;PKIA?>HC(YI^3S>)P!4)9/==AW1^(V$=-R 24EX,8F((.8P4 M)]^SZ6>\5M*C*R25!J]TDDZ6K:@IPX29L0NZH9Z9,]S_ *CM.L?*CCD$"AD MVIC#TS!54FX34;)0?\D?"*;FIUJ,Q&E%IM1H/J1 M929(D2N1UOR,F4WTU/;4'.J2FZ[RK;-HB856F28?C<4CT8HKH2)<*$1E@*M& M,.,''@DXJ]R4.+C?"!D9'4MJ;@A[:D\%W4R+ \*2UW2W4(ENC4O)$ C/TA J M:UM-T)O>-V 3;!Y1YG1<9<4G"&TBIIR_^$I1N-5HDCA6>K]L*6!I.$HNJI1M MC&+?3#J\.;5>Z"]TI7&D!+.*DU8I!BO25HSGY\1&IP&;.9R^Y9IU42A#KE!" M..16 >$9MMW18TT6006UA8^[FF:6D0GFJ$L"BQSL$**E?2I*,;$DFHV<7#$R M-B]T7U]NK5_.L:J"K"[*2V0O:NDL]"K_ &\>P5XCC.(&Z\[PU-APLU$8]*#C M).!21F.[W"I&C9]GR6S'@J$8I3D]=(I80H.C1A%1C+NW"*72>-\CLY[E#J4D MC51I&2I&EMS9/:0$J0'TQW$]"34;;::#I--L^6RP58Z4&B<&;[W8E@3X9!&> MI-,;!M1')'TQ<:R,X$=5 R&:2A2:7WJ=E-#(H!0"@% * 4 H!0&F/=!6%/FA;TM1 OZ8X. MC=(8*SJ4*:A,E>8&6])+5)(>I<0!UN:[>";Y-<5G.30TM2*H^9#QE!_M5M%4=X3.O-YS24 M3@!LX8)E!$QFMA"0P@TLL1 % 3@QS 0QT01Q6DXNH6)Y,M1,W+6'QXW>KCV=P% MA;X_JX]@0^'_ -MJTTDX0>?P93;48K+Y,CYIE;;9G;B*/;.I*YYK8L[UD]QS M3*VVS.W$4>V=)7/-;"=ZR>XYIE;;9G;B*/;.DKGFMA.]9/<LGN.:96VV9VXBCVSI*YYK83O63W'-,K;;,[<11[9TE<\UL)WK)[C MFF5MMF=N(H]LZ2N>:V$[UD]QS3*VVS.W$4>V=)7/-;"=ZR>XYIE;;9G;B*/; M.DKGFMA.]9/V=A;8=ZQXG'RL%",[86J[H2+C"5D;'?U,CYIE;;9G;B*/;.I*YYK8 ML[UD]QS3*VVS.W$4>V=)7/-;"=ZR>XYIE;;9G;B*/;.DKGFMA.]9/<LGN.:96VV9VXBCVSI*YYK83O63W'-,K;;,[<11[9TE<\U ML)WK)[CFF5MMF=N(H]LZ2N>:V$[UD]QS3*VVS.W$4>V=)7/-;"=ZR>YC8IN5 M0W<2:GA6S[Y'&XI.#EW@6HVL'9.4DM.N4Y/X77OE<6ZG8;OW?\;86!OAWK/O MG'PLH1@^'%<8X8"=D5ETQQ,DYIE;;9G;B*/;.I*YYK83O63W'-,K;;,[<11[ M9TE<\UL)WK)[CFF5MMF=N(H]LZ2N>:V$[UD]QS3*VVS.W$4>V=)7/-;"=ZR> MXYIE;;9G;B*/;.DKGFMA.]9/<LGN.:96VV9VXBC MVSI*YYK83O63W'-,K;;,[<11[9TE<\UL)WK)[CFF5MMF=N(H]LZ2N>:V$[UD M]QS3*VVS.W$4>V=)7/-;"=ZR>YC;=-RJX,G!CBZV>5YA56MWF_?+X<3A[[EQOLK24+9I.U<>Q%%\5D^$KS).:96VV9V MXBCVSJ2N>:V+.]9/<LGN.:96VV9VXBCVSI*YYK8 M3O63W'-,K;;,[<11[9TE<\UL)WK)[CFF5MMF=N(H]LZ2N>:V$[UD]QS3*VVS M.W$4>V=)7/-;"=ZR>XYIE;;9G;B*/;.DKGFMA.]9/<LGN.:96VV9VXBCVSI*YYK83O63W,;;1N57$$L"XNMGE.:'(N-Z^-V6HC] M_P D4[F3N;M>SN"[W8QQ>^6!X,[A:V+.]9/<LGN.:96VV9VXBCVS MI*YYK83O63W'-,K;;,[<11[9TE<\UL)WK)[CFF5MMF=N(H]LZ2N>:V$[UD]Q MS3*VVS.W$4>V=)7/-;"=ZR>XYIE;;9G;B*/;.DKGFMA.]9/<LGN.:96VV9VXBCVSI*YYK83O63W,;$-RJ&[R;4\*V??(VVU)PV/ M>!:C;$/%.4TI-N4Y/X77OE<:ZI8:PW?L;86 OAWK/OG'PLH1@[;UCA@)WK)[ MF2:V$[UD]QS3*VVS.W$ M4>V=)7/-;"=ZR>XYIE;;9G;B*/;.DKGFMA.]9/< MLGN.:96VV9VXBCVSI*YYK83O63W'-,K;;,[<11[9TE<\UL)WK)[CFF5MMF=N M(H]LZ2N>:V$[UD]QS3*VVS.W$4>V=)7/-;"=ZR>XYIE;;9G;B*/;.DKGFMA. M]9/<LGN.:96VV9VXBCVSI*YYK83O63W'-,K;;,[ M<11[9TE<\UL)WK)[CFF5MMF=N(H]LZ2N>:V$[UD]QS3*VVS.W$4>V=)7/-;" M=ZR>XYIE;;9G;B*/;.DKGFMA.]9/<LGN.:96VV9 MVXBCVSI*YYK83O63W'-,K;;,[<11[9TE<\UL)WK)[CFF5MMF=N(H]LZ2N>:V M$[UD]QS3*VVS.W$4>V=)7/-;"=ZR>XYIE;;9G;B*/;.DKGFMA.]9/<LGN.:96VV9VXBCVSI*YYK83O63W)1+3ZE*+$A+51%MHK= ME)2R3[ 8-103[@WQ+"F>^W$R$6A^*[^64FLFA0"@% * 4 H!0"@)L!Y7U3V;( M7YH<=:_3^WL9_?\ K[E)K)H4 H!0"@% * 4!-3/E@1?9NY?S,U:O!]5X9.*Z M/RCYEJ;XC;JH=1%V0FNE*Z:-,3!OK29W\V!IZ=/E8KT M;]'L/&)@WUI,[^; T].GRL5Z-^CV'C$P;ZTF=_-@:>G3Y6*]&_1[#QB8-]:3 M._FP-/3I\K%>C?H]AXQ,&^M)G?S8&GIT^5BO1OT>P\8F#?6DSOYL#3TZ?*Q7 MHWZ/8^U-GB&E<^32TV2FB;4% P$4)%0U5JLFB:QQ^TD+VE.+^U2:U2_7_5$5G=^64J MLE% * 4 H!0"@% * FL9_NCR]I3Z_&A:KM[+PB*SN_+*54** 4 H!0"@% * M4!-3/EA1O9JYOS0TZO!]5X8*54 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 MH!0"@% * U+U=?P@U_O()^&&ZW0M[>Z,4[._LRUP]Y+F+]W$_P#IU*?Y/MX1 M:'XKOY92:R:% * 4 H!0"@% * FP'E?5/9LA?FAQUK]/[>QG]_Z^Y2:R:% * M X%(=+8< AI!<:"ME05 5(%,I"NGJ0 2J!^V3!!B9@8/!0!_P#RDLLK&0__ M %A6H#E.7D>_"E^6%>4 8B9#@. @8P6>&5\1,+W Y6@% 34SY8$7V;N7\S-6KP?5>&3BNC\HZ7=3'EYD M[[R"?VA6O9_'^%'H<7:^K\D+K9!0"@% * 4 H#S:][7M>U[VO:_#:]OLO:]O MU7M?_*]J [2=*>JRRS9.C*35&UEBU@B35=1T7@LKVMP!ET5:,"7^Q5M^B$GJ M N7_ (I^B5-9TIQ?VJ37.E^O M^J-JSN_+*562B@% * 4 H!0"@% 36,_W1Y>TI]?C0M5V]EX1%9W?EE*J%% * M 4 H!0"@% * FIGRPHWLU_\ CSM>U\UZ _@4T6 $ "', BFA,@BH8HH88AD7'#(3(,##/*V0P MF(>&0F6 =LLK88Y9WMQ;7O8#VWSPM;AOGC:W#E;AOE:UN''C<:W#P\'#CQ]A,+XY8Y<;#AQXN6-^'@O:@/ P MX)?&V8XP0&&0H(&.8PF >.0QD; N7!MEG?&UQ3!@4( $.U^.*,)@%A;+//'& MX'@0R7!$#"%, A"BXB9A!B"AX""8 W#Q%S#PRRMEGB%D,%83+&U[87%#ME>U M\\>$#R","8P[Z *$.'QA,.^ B8"8<<$3((7#CX7RQXP0N&80F/#PX"89896M MEC>U@/[QRQSQQSPRQSPSQMECGC>V6.6.5N&V6.5N&U\;V^VU[7O:]OMM0']4 M!_.>> >-\Q,\0\,>#ASSRMAC;AO:UN'+*]K6X;WM:W#?[;WM;]=Z \WO:UKW MO>UK6MPWO?[+6M;]=[W_ ,K6H#Y@SI,;DW>3947EH.1@GWL<+/E9?"P>68Y; MBYW[^#CB,%ED*%Q\,;"AWOE:V>/"![,C)?"X-LAP<;F1+@E[9"X6N8%Q#$%R M"!M?*UQ1+! BB7P#XV5@PA,[VXN&5[ >Z@% :EZNOX0:_P!Y!/PPW6Z%O;W1 MBG9W]F6N'O)-&B8C=5<$=1TW93)3I&+H0'I#.*@ MY(=F21D%V1;'[G1%DZX453;34P'*KZ>@M4VX48PZ3AD6.,>[XQC:N/W#B\=, M$ZN XS7N><[HC"17I"^J5Q3<=8!Z)7%?&6YL7]/)]HQ$.HR,S'> N-QB,R/< M8O;SO04=%R,-R+D0TIJJ<*IEBYL(JZZ$8R2Z0MM9AS(T[2 1,IR"1B M:. MN'PH^7E%9H&T^-\N[:PX[3.W.AD4!-3/E@1?9NY?S,U:O!]5X9.*Z/RCI=U, M>7F3OO()_:%:]G\?X4>AQ=KZOR0NMD% * 4 H!0"@% 98R64Y9!-K6QMD)D&'G&U1478$HR M1W?Z?D-5;327&^N+(KA6$=X*:>I+8W?;B*1LLFHP0QG+(?,0?/C98WMB*/GD M.+C:P@U^^Y9UXZ;3::4$TH*ZT[4;,_++K6#0H#\ND'Z$>Z5, ]IW73.#@!;X M3K[E:V]046N24VBJ@%&MIO;$*."3)89BBG/%0+6<[$>C1D%A2 @!GAL);:SN MLL(P#A,-%O\ .T5BC; VZ2_[0>+C)X0AT?5FX_CB3I12FBW04 P&B+JR9/,UX/VRJGXJK M1!Q9Z:=SHIM-R::_*3G[J\TD^%&])1K5WB')4U1DS7J080 MN@T].RX[4[2MK+?VH^\*KG)H+;82 MSPL*,[+/^4%_E12QC",815F)FP2%WCA7@*#%US\ MX!1*CMUOERZ)J#4YS;*,6/H"4K H2(F8AX'V_P PK"D,N$H73MMB[\(&YE"" M@)K&?[H\O:4^OQH6J[>R\(BL[ORRE5"B@% * 4 H!0"@% 34SY84;V:N;\T- M.KP?5>&"E5 =3T1]S]5(T9T'!I[@>"$ZTZ-$TC*7@:O,N-0TUWH$/GVRADDD MW$C98HBMD&\UHT:6G@H&EQW/ NB-Y,>KI<+/30$*XL9W]8M:^YSBG'VL53"2 M;S:#9'"73-]W][79A$K'UAEIK9KBD155$UE!)[:&6D3?! M*HR:<,KK>4S14 J22W6V! ":\DB?9_?B\Q(>-);="(;O*,1KDM$XKCR0%F-8 MH>#W;9HU(+FDB57"9CUC/M[J"UFWCJ]%,/LEILM].!257JC.E,1K-!H)ZFTH/)NR0X$_,J[ER'\F7@L!'U8V1Q>Q@LN6#NEK[V1E%0XV. M2X=*E3I]1Q$!.W'#%/+ Q8U$&IAN&9E2?S@%]3"603WTJQFPFN$7L5",&VJO&+G$%7 0 MEQQ-UU(K;5<4]PW2S08/>1QDRTLP)J4H@>J(33W:D&3$YQ.Z8J;$JO=$?S]: M,_W[KF M1)RZ8)^<9 FSUY>=CP:YF#VIBMK3AE$]D\>G$VXF$=D,9)=1)63W*VT%4+LD MLHW16F>16.$:,JA)'1R:FMI+ M+66V-*K<:,:M.$1)UNXI0;;^9@:X04'4\G0Q!G$9+K9-JNI1%)++<1$QQ,9< M25Y04Q):<9SAPNG9/8XJ+8,U61PNZ?6N4<+@*1^PV'!*$9#"=!YR(C?*-M'Q MQFQMO ROS26&"@FM96$B25 D5--M@DT5^-@T4PJ !%0LG.[;27&\[1HHY&20+'(()N"AD)G-8\FJ,DKI,F[TZ=Q 7 MJ.X\].JB?LG%N,:DU2:^><4#A*6NOMB8(?@C4>]W"Y@)M61P;)$SJ:6B.!]N]++F54N;&L0MDUV\V032T M]XPTN=W&-R8B!+"]$,[!2PW%:9PBIAV13'48'U<)LBRRQXD5W*WD-<>)QT1K*(D0K!9QLS])AMC,HJPSKF.. MA)0RF9S<3=9)(,(^$ MLE"_[F=EE""@-2]77\(-?[R"?AANMT+>WNC%.SO[,M2YB_=Q/_IU*?Y/M MX1:'XKOY92:R:% * 4 H!0"@% * FP'E?5/9LA?FAQUK]/[>QG]_Z^Y2:R:% M * 4 H!0"@% 34SY8$7V;N7\S-6KP?5>&3BNC\HZJ=0,,RPX)FD)91([=ZJD MJ"\(.142*&>,DS8-RQ;&PH X8.6 H=\L-C>]N&U[?Y5ZJ%.@J%%.DHP.3 M3BY.U\".] $V^JM];N*7T*UZE#F1(.YY,= $V^JM];N*7T*>I0YD(.YY,= $ MV^JM];N*7T*>I0YD(.YY,= $V^JM];N*7T*>I0YD(.YY,= $V^JM];N*7T*> MI0YD(.YY,= $V^JM];N*7T*>I0YD(.YY,= $V^JM];N*7T*>I0YD(.YY,^Y, MTXS@J*)).#C1V$\SID$M8VII)M.3BW?<[8W,'3ID/ L6"M>X@PN>7Z.&-^+ MCGGQ<E-TJ806;E]BQ?AMF/GPFS7&&RQQ"\M.FZ;PX+[Q.M&C#J9=''[20O:4XO[5)J4OU M_P!456=WY92JR44 H!0"@% * 4 H":QG^Z/+VE/K\:%JNWLO"(K.[\LI50HH M!0"@% * 4 H!0$U,^6%&]FKF_-#3J\'U7A@I50"@% * 4 H!0"@% * 4 H!0 M"@% * 4 H!0"@% * 4 H#4O5U_"#7^\@GX8;K="WM[HQ3L[^S+7#WDN8OW<3 M_P"G4I_D^WA%H?BN_EE)K)HZ^]:NJ&9M-S_TKIK":,7.1A35)3T8\A*#R5W: M1=;:(,6&I(GU64V>GH2<9254R88,/O=*(%E@\1PS=R@U@1\P$<9642 TDFJ4 M>"CJE/,F2?W6F&U(FQ58M ^J/P?=Q33><<#BNS(QS1XH"U=R"386G3"2Q 9@ M%-$C$D JJ&]@RK3*.\PTFBOHH3\":[P/AM&P57AQX\JB\968\(J9AHW=J-.) M-D.-_*<.ZFT5#1TU@N-&$7&A%J, \V3(,E/6)"4@)*\I3&6:#69B&^X_<*.O M*TJ.2.\\>,B&44JM@.1!S4)'[9AQ^Z"J[UK;=9X/3J%[KRQ8M8>HA3:L-RZ& MO14EZHVO'+\D%N-9B^.Z[P%'8CX.N.*=1@K%9(.I<(O+24 MR60/'#]7=(*.X#\_-QAF#::>.YFHV$9T.),/8MM65$8@?62 MH57*R<.U:QO[8*2GGD]O20YB9Y%<[7F]LGQ3B1FNFP!W>R"F18F,"^<&J#HP48K@U",TXX<& MCM#H9% 38#ROJGLV0OS0XZU^G]O8S^_]?TI]?C0M5V]EX1%9W?EE*J%% * M4 H!0"@% * FIGRPHWLU\ES%^[B?\ MTZE/\GV\(M#\5W\LI-9-$ODF&(QE\9FF)(:9-TC1\MK[C9PAHVJ%+H:TZ(^> M45KQ\"R:>)6'$48_D%XML0,Y8R $67!S1<(%1+DCA8+\;?/E'6VR&#W++4<& M)*B4R^;VWI4-1C&)20GH'.D(1@(5TY/4^3B(X2<3M/,:/)R1HM?C26$=I/4V M8?F""IDU)*#5@"JWD"JC4:2E?%NSBIQA9+@9DO0%W-=UI3XC)SM1(;C)C2/( MN8JZOJ+^DV,V H1O(JH^)#8S6092+/1MHSU05Q3=;R'6D])#<@C<<=C M2:?*I=P3I1QG*"MXROQ@<6T.YV]SW2'[+;>=(#,D>0IT6YT6C3%<$B'BQE&: M,ZMC!-?;<8T8([P*)*#QHQ4\&J._VXVDU^#QZ?!2C;FYA&! N%:E)V0A/H^+ MZKI%7F2N/1_W,%Y#RK,;@0HA5$QP#R:TY3RL"%DK#HPN+H;4*141$N"3Y*$7:1$=-P* MC'50<^$7"'#_ -W9>*$% 1593%Q2EHW@AN45MB!1TBY#C!)2"K_ /6F;W/;/T:1H\NK$*7-HAX*O_UIF]SVS]&D M:/+JQ"ES:(>"K_\ 6F;W/;/T:1H\NK$*7-HAX*O_ -:9O<]L_1I&CRZL0I"K_]:9O<]L_1I&CRZL0I13.1[)AKXX:EX+M^V010-P-P,4C8I8+ MD^>(XP@(]S&5KC!W+V#PO; 42D5#\>*E%W/Q[B#C^7!S@KUY]C/O!5_^M,WN M>V?HTC1Y=6(4N;1#P5?_ *TS>Y[9^C2-'EU8A2YM$/!5_P#K3-[GMGZ-(T>7 M5B%+FT0\%7_ZTS>Y[9^C2-'EU8A2YM$/!5_^M,WN>V?HTC1Y=6(4N;1#P5?_ M *TS>Y[9^C2-'EU8A2YM$/!5_P#K3-[GMGZ-(T>75B%+FT0\%7_ZTS>Y[9^C M2-'EU8A2YM$/!5_^M,WN>V?HTC1Y=6(4N;1#P5?_ *TS>Y[9^C2-'EU8A2YM M$8"Q&X]1Q'OR613)*X+^70#5\6NWS'+3>!9,N*>R[\%?O&0ULL,;EP> $/O= MKX6X"K_]:9O<]L_1K,:/+JQ"ES:(>"K_ M /6F;W/;/T:1H\NK$*7-HAX*O_UIF]SVS]&D:/+JQ"ES:(>"K_\ 6F;W/;/T M:1H\NK$*7-HAX*O_ -:9O<]L_1I&CRZL0I"K_]:9O<]L_1I&CRZL0I"K_P#6 MF;W/;/T:1H\NK$*7-HC 8_;CU'+.JY213)'$)_/ ?'%KM\QRHV$K"8F#U[C MA7N#D;$X1;EP^ $'AX@5K8VJMT>7@N+N1$J7-";X*_WM,^\%7_ZTS>Y[9^C4 MC1Y=66%+FT0\%7_ZTS>Y[9^C2-'EU8A2YM$/!5_^M,WN>V?HTC1Y=6(4N;1# MP5?_ *TS>Y[9^C2-'EU8A2YM$/!5_P#K3-[GMGZ-(T>75B%+FT0\%7_ZTS>Y M[9^C2-'EU8A2YM$/!5_^M,WN>V?HTC1Y=6(4N;1#P5?_ *TS>Y[9^C2-'EU8 MA2YM$/!5_P#K3-[GMGZ-(T>75B%+FT1@([<>MI12BUY%,Y'LF"OCAJ7@NW[9 M!% W"V@Q2-BE@N3YXCC" F+F,K=^#N7L'A>P8HEKV-&'X\5*+Q\>XA2YM$9] MX*O_ -:9O<]L_1J1H\NK$*7-HAX*O_UIF]SVS]&D:/+JQ"ES:(>"K_\ 6F;W M/;/T:1H\NK$*7-HAX*O_ -:9O<]L_1I&CRZL0I"K_]:9O<]L_1I&CRZL0I"K M_P#6F;W/;/T:1H\NK$*7-HAX*O\ ]:9O<]L_1I&CRZL0I"K_ /6F;W/;/T:1H\NK$*7-HAX*O_UIF]SVS]&D:/+JQ"ES:(>"K_\ M6F;W/;/T:1H\NK$*7-HAX*O_ -:9O<]L_1I&CRZL0I"K_]:9O<]L_1I&CRZL0I"K_P#6F;W/;/T:1H\NK$*7-HAX*O\ ]:9O<]L_1I&CRZL0ISP!+"H:2E6+B\WF\ES%^[B?_ $ZS3_)]O"-4/Q7? MRRDUDT* Z0S7#;:^D VQ&=(+JD)X/1((J8SU, M2$WQU9P.3P;YO)MU0#=!G#PDL"IM9/5QC9>ED<<[.Y#N][0''\3JTC:9FPXH M>DB/'DR%2'-,#YA!I/I*CN)7M#Z>5G5,CK4LE/=XN7-*?*@Y4)?:D@LDJSW M6L4*I"R@*2FFF!*W5IJ<6GQ3=JP7!SF=L.FV%4C3C D1P2A& #:5%3$;[,*F M2=G*&G#KH,H23R-&LMGP2(0^0C<6W>X_ M8)+1="VT(* FP'E?5/9LA?FAQUK]/[>QG]_Z^Y2:R:% * 4 H!0"@% 34SY8 M$7V;N7\S-6KP?5>&3BNC\HR0T]6:0,C$SSM;),V6$R",%32\E%S( N/^(,8 M8W@*$)C_ .K#/''*W^=J0=SR$5>LSY^D!A[;-'>1&Z[2#N>3$5>LT.D!A[;- M'>1&Z[2#N>3$5>LT.D!A[;-'>1&Z[2#N>3$5>LT.D!A[;-'>1&Z[2#N>3$5> MLT.D!A[;-'>1&Z[2#N>3$5>LT.D!A[;-'>1&Z[2#N>3$5>LT.D!A[;-'>1&Z M[2#N>3$5>LT?42>304C0)%.=3;/G3%\L0"9)<3#1H?+'#(3+$$N :$%$OCAA MEGE;##*]L,7M*?7XT+5=O9>$16=WY92JA10"@% * 4 H! M0"@)J9\L*-[-7-^:&G5X/JO#!2J@% * 4 H!0"@% * 4 H!0"@% * 4 H!0" M@% * 4 H!0&I>KK^$&O]Y!/PPW6Z%O;W1BG9W]F6N'O)#ZKPR<5T?E'2EJ,\N]3_ ._&O9_' M^%'H<7:^K\D6K9!0"@% * 4 H#ZB)XXF'"JBG&C!$^1, FR1TH,(7-%#1<3$ M4 P7'"RQ$!&!$QQS#$PRQSPSQMEC>U[4!W&:7]3Q.520#.>)@N1D4@7X A;] M[+EG<5+A\.9TEA;BAA*X(>-Q%)-#MCB)C;-03P[%K&BR?Y/Y/XZKBOQ>F&QU MHTXR=ODV CC]I(7M*<7]JDUBE^O^J-*SN_+*562B@% * 4 H!0"@% 36,_W1 MY>TI]?C0M5V]EX1%9W?EE*J%% * 4 H!0"@% * FIGRPHWLU\ES%^[B?\ TZE/\GV\(M#\5W\LI-9-"@% * 4 H!0" M@% 38#ROJGLV0OS0XZU^G]O8S^_]?=V\WH<4E14I+)R6L]-D$-V%FBBMEB2!&8EXF<^G)25Y^C);*.- MM,M9;:DJD$YR("\&5<3/DN14^-FB&88+Q2F@BNV0BY97$;0L;W&?67'XSN.) M6X.U/JQ$R[T-3Q93^E'3KJ+=4KE%=L6?^($D2BKQV<9D/)YDD]FP3**D=LE# M3(N0G(4Y<544MB J>1; P;'$,!*?&:APOZVW'R,V)%,DZRET:#'.FL\G@\D-%80)S-SYG 3* M<9)#"%7M*?7XT+ M5=O9>$16=WY92JA10"@% * 4 H!0"@)J9\L*-[-7-^:&G5X/JO#!2J@.IB(M M($W,)G04<*O]S,5Y7C4CTD$(T1V,@)#;>"-#Y],+YGD9VC28B.*070]UK'&1 MY$ Q,>&PK3;=A2B4F%3.2@+&-OV/UYF1*9G7.I I(@YF8&L\E T^9 M_>W6_,HE$UKGYI9JC))QU-R/!T]M&%UC&VY$SF;Y-OC0,D"+!9?DI!7VPM"R M 2G@15 /GVTQN1G<2G>DQJD6"H +26*X8:WY6?\ L3-(V:#F*:A)O=2'%;EC ML$NA.]%;KH=1I//I4YN9><*6Y\WL^%M.=*RX#"*TE /!EPJVSJ07.,6.\7D M4,$4MPM]IMX3+A[_ %]B:FVM,;P9[#RD]H:@90;R&\VDKSK%K\O 1$N[R^4? M2$EKA!H(S /MY-?[/;5,&T94)62F:)(TFI#7E*,G M.B+"G%;00W0&B$&PY#>8S59BZM+#210UQO\ #GQX\3@)3@;4@/'2FB(UC#B: M($CZK323%*602R:Z S74RM023'>(KO4WY@17DE;&<34(HS:-IB?9*R74?%1& M(@M\V/@$HJ&&<)\-RIY14_E"'M7C>C1B/B%&N_HF44"&8S-KC/"7"$D9LMZD MW$YV8FD'&\FG'#7>8RDPD--;/+T4$JXFTZW@9;R&;= RVL!=Q[2^=M.!4VAJ MQ1W$F.(RM2"Y$XPY9=1GFNH"+ F4JH$2E9A/%XP3(T&-MA,31A5MF)+-9E%+%9'+,M+(!'!:[\#TM^.]3+LA+5D3>^4AI\AR'%3U:T:J2N M>BH@_#MR+HU!%(\)GL&1RF-DARCL57C0HLGTPF23,C!_(Q@: 4"YDR3%E+K/ MI+Y^2S1]AJ-+S+8JZ#L@GVN Y)(+N85PE8C#B02-@!#H<.J$?&FT1)R<-)A\ MN&V1WB"OW\'PSX\K\N)IY#"( *&?OW[=.TUURCG6+T4O5-OF=$%-8OIE(,/7 M;4"VCL1DJ&D18-)9T5)LV>(;.*.IX8BG# *:R(F7+V$)&D/%GGE4R<%4):VR MGMU.218[U-,%;0%L M$D'##6Y1QA=UM-F,V9J47L=+RD,\ T!YM^/'>%+[I6V6WSA85Q*Z&RL"Y5:8 MK8D.S= 73JB241# [5(Y8B'TZ6HVD!C9H1Q](YM.41=( MND%D.(V<42*@8.2A'I:8BTA%#PQ0^>S.*J6$NM8$ZL99CEE(,=%G9(9U1##>%CPUMXQX\,(6QO+Q(T#2^M,^90 MBJ0WG6]%5T0HY4-'=J827XDEUW),6MR/'$+*C3P 9XFN) MPK.17"B(3M-H2>TUP$U+I.%MK^/$3>N.6H98<>L1CG7 INTXS&:UVH;=2WF( M(LN8RW40BD#N!6$%'-"B*:R*3S4C^8IDP)D:,BY9CC97N)D,F94 H!0"@-2] M77\(-?[R"?AANMT+>WNC%.SO[,M2YB_=Q/_IU*?Y/MX1:'XKOY92:R:% M* 4 H!0"@% * FP'E?5/9LA?FAQUK]/[>QG]_P"ON4FLFA0"@% * 4 H!0$U M,^6!%]F[E_,S5J\'U7ADXKH_*.HZ>XKDY7F62%-)CE]J::>=*B8)*">T5\X2 M-@9YXWP'*FBZ>( .#G;[<1 A,\,K?JRO7JH4Z"H44Z2C Y-.+D[7P)'T-2_Z MJY'W(I0YD(.YY,=#4O\ JKD?I0YD(.YY,=#4O^JN1]R'-_ME/4H-7H1&4309;$ZLMI:2$HI;._Z1@^I'R()4H5!PMD(*()GPWQQX@6 M HV086;U*',A5=SR.XZ"8);4(MJQ A8-2R\(BL[ORRE5"B@ M% * 4 H!0"@% 34SY84;V:N;\T-.KP?5>&"E5 * 4 H!0"@% * 4 H!0"@% M* 4 H!0"@% * 4 H!0"@-2]77\(-?[R"?AANMT+>WNC%.SO[,M2YB_=Q/ M_IU*?Y/MX1:'XKOY92:R:% * 4 H!0"@% * FP'E?5/9LA?FAQUK]/[>QG]_ MZ^Y2:R:% * 4 H!0"@% 34SY8$7V;N7\S-6KP?5>&3BNC\HI50HH!0"@% * M4 H!0"@)K''[20O:4XO[5)K5+]?]416=WY92JR44 H!0"@% * 4 H":QG^Z/ M+VE/K\:%JNWLO"(K.[\LI50HH!0"@% * 4 H!0$U,^6%&]FKF_-#3J\'U7A@ MI50"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#4O5U_"#7^\@GX8 M;K="WM[HQ3L[^S,NBXW)N$>,_%*0V.83L4(E8D,?YQ=CJR:'+9=V=CS>YQ=CJ < MMEW9V/-[G%V.H!RV7=G8\WN<78Z@'+9=V=CS>YQ=CJ YQ=CJ 1BX^ A>Y3$' ' (3$QGF)F$'K]?[>QG] ML:OO]S,]Y;+NSL>;W.+L=630Y;+NSL>;W.+L=0#ELN[.QYO;W.+L=0#ELN[.QYO; MW.+L=0& F#RK9AK^(1>SF7+D,B%W W+F!A#5VM8? W@8L6P!+ MXE,P1 ;W.+L M=0#ELN[.QYO;W.+L=0#ELN[.QYO;W.+L=0#ELN[.QYO\#"7RS MMF7#MCC?+5+]?]41<>K\F>\MEW9V/-[G%V.K)1RV7=G8\WN<78Z@'+9=V=CS M>YQ=CJ YQ=CJ YQ=CJ P)@&Y-Q+.KFY#8XV.3]>&1NYQ MS+A?(-0R5A+G 2]@6L9L*4"&X<2Q@2X(PP?!F(7!ROQ+5\.BCEL1<>KAGN9[ MRV7=G8\WN<78ZH4YQ=CJ < MMEW9V/-[G%V.H!RV7=G8\WN<78Z@'+9=V=CS>YQ=CJ 2&Q[*MF"OXA%[.986 0MX/JO#'@SWELN[.QYO;W.+L=0#ELN[.QYO;W.+L=0#ELN[.QYO;W.+L=0# MELN[.QYO;W.+L=0#ELN[.QYO;W.+L=0#ELN[.QYO;W.+L=0#ELN[.QYO;W.+L=0#ELN[ M.QYOPS8;MG0EM@@5LO9W+"(2TJ*@^9CF\ MS:^ P1]"2@PP>]\;*PF HN?'MCCWOBWOE;="WM[HQ3L[^S-EH>\ES%^[B?\ MTZE/\GV\(M#\5W\LI-9-"@% * 4 H!0"@% 38#ROJGLV0OS0XZU^G]O8S^_] M?*B"9Y?^W## M6^65_P#]8VO>@.2H":QQ^TD+VE.+^U2:U2_7_5$5G=^64JLE% * 4 H!0"@% M * FL9_NCR]I3Z_&A:KM[+PB*SN_+*54** 4 H!0"@% * 4!-3/EA1O9JYOS M0TZO!]5X8*54 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * U+U=? MP@U_O()^&&ZW0M[>Z,4[._LRUP]Y+F+]W$_^G4I_D^WA%H?BN_EE)K)H4 H! M0"@% * 4 H"; >5]4]FR%^:''6OT_M[&?W_K[E)K)H4 H!0"@% * 4!-3/E@ M1?9NY?S,U:O!]5X9.*Z/RCI+U!^6^4_OLN_W@E>S^/\ "CT.+M?5^2.UL@H! M0"@% * 4!]),X;3S98^0,F"1XD8!-$SA480N9*F2XF(H!@N.%EB(",")CB($ M*'ECGAGC;+&]KVM>C2:@YI@[A=+VJ$I*)0LRGJ9+DI#)%^*5-9=[+EG>6+A\ M.9DMA;BA@K8(>-Q%!/#MC@8PQS/D,+ V-%2/C_D_C=!Q4Z+TP9UHTHR=ODV( MCC]I(7M*<7]JDUFE^O\ JC2L[ORRE5DHH!0"@% * 4 H!0$UC/\ ='E[2GU^ M-"U7;V7A$5G=^64JH44 H!0"@% * 4 H":F?+"C>S5S?FAIU>#ZKPP4JH"0W MU P/;%"SO-,46P="N;;[:SO(32MBX%P@<34XZD(V5U;@4U$JH+2*1'*$[C#A MG%I'*Y86'52&!@#E%B9H@;R5@NKTJ1RC(HA-*40U94>K;(IPI!=.GDY#.A'# M*D&7%*K*@EJ9%*,!B9!*)Q./EBF0PQ,Q@&!P)_4AIY2@3QA3G:'2 "9=N641 MSDELPN"0N\&YD\6IRP459Q#+>$C/PS=J%W[+#G5KX9.$EWY'QN0X@=C1?O@$UD'5UIZC8L?,+DFM0_FE@RIDHDV^X4!8/D3T+- Z^)&1#9 M4!5QS++K<02 HA]*'[V:)F2*HYX[/\*DR3 MA,'RJ";-2BR"Y9:,I9T@FJ0*6.,N8!GQ$]15DH@=Q+9"W*G51-*C<0<^4#&$ M@[CZC&HW3Z4(MY3-SG$!1.=N"B(USYJ2&>7)N+!(5\V^JYHID98P!4L4Q?#S M05"Y3,6Q-;QNDF.]J'_+T$#(EB7HG;SQ3H[7Y.CY$?ZQBFY)3(5GDW4YW*6* MT8-$T;(BW#:B"KFL5;*7P0'28:+A?6>"F8LY"Q M< !KME14[ %A#BNH8BIH",E*9E3) C!!_>L/)S4@:B(3C+!ZA.^362GKD?L MMP/]S,^SH020UO,F L N ZVU8<@GYYF3IIO M+:RDJ^H""<2[6-Y3/%6)5\&C MI%FF,I :F(+J.IRU@VE$HWQ+JML%MR4L,T%=1U=/4&.Z5 MQSMU-7DLZGGC."@1#5FFI%CQHOCD4)Y#)N(ACCG@L* P9K:NM/3U3&DK-B4F M*J$W60.K0EL'TQ"QQK-M/;3R=!IS.M..N@L?3T0$FQ7 7&,$BRD8+C%#1TR5 M 0T=Q*Z,!F#8U 0Z^%XF@L60FF^,C2*]ULPL,]Q(CD;Z.''HL;XN9-7E=(43 M99'6BI:5V4IAI1VX9K))4[*(F();(OF8%AQZ:QV/@8VI6")#(QL9;WNC%.SO[,M2YB_=Q/\ Z=2G M^3[>$6A^*[^64FLFCIKU!:>-4TM=U!:\CQK)T@Q7$<+Z9(7=>(Y<:6L&+)+^ M#E74W9RQ8G$TJ0&Q""DHN)%R8 4H7D)F2.O)+.':)MO%&P=&3EK,:356R+;= MTI*<;>UCXFB[IU$=T[D]F1C*J1$6H1-?$)16HJ-T8YIO?3.,J.K5%[E;K>,R MN7.L4VU2&?-EU;4$ VY$DZ.&6U%K300CQMOXL:[G2LZFH_D)5? M"'R+!(;:3JUQ0],9!1+*J8V38W+6DYEP[(9H-231(47A%)VV.O5:_P#G_*%O M&PX-%G/NI+_()C:83AF8HTCCV=P934#(FA<:,)).%4+24^Y*56DM0D]6\2+- M]NIFH9":4:LM_GFXG /81R&VHB*#T4$TDZ%H6%&<<()4HIS7%3LBWAC9A+YU M>]U>L.34$U@S6W9 /H[8.EH3;&B%W.V,<60I:(#$F'9"49Q,MU9+I$DVU7Y& M(R/1 I+A5PH@::FMDPR!,S0SK502HSC8N,9MUKN,KH2B^FX<-S)KHSU=1;I8 M?;F*NIOJ,+Q=J^E.5%%CLQLN!JL=69[LCEUZZ@4&90CU5O&*<S9"_-#CK7Z? MV]C/[_U]S0^894U5(K]E%"89>1U1I%I+C4KF[$V,W 238^C-48L@"JX,>8Y: M79177P[\Y,;K(2G8O(C>U)M,HTWISOWB*;EC@R%DW*"OG;Q>=W2SB9$W7SK@ M'3V$2LUB:^9=[#57X,XE!#P:X" :C<1W8%F$[ '(WV2JH[DG>ZC!>!!*8CY5RBN!DH M2BN0'"!(RPP#11'* Y%#,N&6[;*PYJ6G<$K%A"PC]WWU>W4A2K,VJD@FCGD) MS:F'25*1XSG2ZR"GI$4F#M(6QY:-"RNNO[N3]UTM,H;$E:@U"=HW2ULS+J<$N3 M;*+>D>-KP*-T)M6$4>,I@5XK>25-^3% Q\('0M(&9XKH_*.DO4'Y;Y3^^R[_> M"5[/X_PH]#B[7U?DCM;(* 4 H!0"@% * YQLD7"I.%&(M,%1,.4PHE<4,-(N M+BI!U;%-1K&Q,+A!@A97N+P]\S!"#!S$MGF#AB'EC: MWCIPBH604.AWHV3MB_++I6"B@% * 4 H!0"@% 36,_W1Y>TI]?C0M5V]EX1% M9W?EE*J%% * 4 H!0"@% * FIGRPHWLU+'$H$%E&;;,0U5$/MEFH0PAD^-8)'(B-I2$>[ MGRLV0 +LLLRQ8O'YOZZF9*&E6"I 4G;FSWMF8=H4O7FT(7$\C/(BS%-E\GP Z(8ER( MV;C2?!LFYF:Y2*P;-8)# 4,TL=6A*,XE/%%=G)K?26VG&5YMQFUWDG&":,CY MD'!Q^0%Q&0=4FBIA'[W;\LR^6--S$7VJGQRG2L:B4MXN+VA!1+II&-LC*E!@ M2:VD1QJ2:B+[=%0V^,S>4(85UU$0R[12 W*&07VV=#':5D,(SCC'CO'WQ,?P MTSQ+(F$M-$"83#HP"ARLX2K-4Q Y M#CD=% (D#IUL$1$FR$ JO$NZ18SB9(@:4D@JNH3G=\@NY[KC=!;**1.#$VVT["L]E MQU-T;MQ!-!,M(0^]'L"$^OM<55](S231E?S3,T D8A'[EL<,\-&;5= M^+K1!7V\TY@NHPXUT1G@8HA\PGO)RP@?T_FETN\%E-474<)%V0H#* "2J*)X MP(Z. P:6!VS_ .5*$*2[8%+JCK37\R'PYX[>I-.?"$:62V*>\BAU"D8PS#CH M+A(;Y 7DE*/!GV UE) '3"Y=*33I 7!00UI+/'DLP!/U?1\W7 =+EUM^.M19 MB-(;CE9KLW--:0(".^7L^\Y >1\ZMED$)774M46#[E (()T;!.32;N6,3&"H M,ELL5I@920TY>#0V/)+H::@_CY<1_$,$=GKA)<22#J<+P3$U,LNH1Z[? M,DU)W.PD(I 8F^7I+A.8'28RN0;ZTBBQ^]DM($)*Z"D]HC,P>-W^,A&6*YFP M,TE!1:3)/*;89C=,J:I9"NHCMDXHNLV?.W;Z2I#*AY+L?;R$4.=_*/T,5[G! M.,6;,1' Z)$BJN+Q)PKKA6W0E7*N(ZKAI!<,^KG90ER7EU< )I"<0+D!%9WS M,Z;XD <;E"*452"8-A!P#1PX!'SFAR.#[8+M<9T/,($JII"N75"N;>Q5 %! MB%[1"C&,;FT$ZG&+)Q%[G7*$24DY02S*Z1*EU)//H)A32#PL6FW?O$HD:Z=P MV-)2_+BX_P!P/=\.@P\S*N.<1VP@(N%WFV-/33,%DU+04LL8!*IB9IQ:6:?D MI*:LH9&EIPW.*)HK='*I01E#[QW,80-)""V06FAI3]=F#(0\H-4E]IF"+8,7 M=KHT\$FB3CIP&'"(C<^(N F3#9AESHJ.9 250=M$KI@"#BK/&SI"/OD_O_IM MQ0@H!0"@-2]77\(-?[R"?AANMT+>WNC%.SO[,M2YB_=Q/_IU*?Y/MX1:' MXKOY92:R:% * 4 H!0'$ET!")K*HXRB*DE7"MDTI.6ETNG$P%E73T+-1$1"* MHJ! XGCY-'$6%;-**FQQ0$_-44S9"_-#CK7Z? MV]C/[_U]RDUDT* 4 H!0"@% * FIGRP(OLW&!%#R."7QS#%# RPSPRM]MLLLT!X)NK9EP?R91ZM2*O6: \$W5LRX/Y,H]6I%7K- >";JV9<'\F4 M>K4BKUF@/!-U;,N#^3*/5J15ZS0/M3F$]E8^33$YI.(T>4#()0H7P1SV-Q3 M^=@P\..(!@$'C?+*W&$%SP"#QX1!,\,,5N&V%K\%E!0M;$4^+CQ<>(4P##OY/Y/Y'3<% M*BM<6=:-&$W;X*]''[20O:4XO[5)K-+]?]4:5G=^64JLE% * 4 H!0"@% * MFL9_NCR]I3Z_&A:KM[+PB*SN_+*54** 4 H!0"@% * 4!-3/EA1O9JYOS0TZ MO!]5X8*54!UJD-$\@)[92Q 'XE6D[%:8@2Z^LEAV#'S[":^E!H0RJL:A>5KM_#$!%,J?%=1P#PO&,YY"Q[PLSC]MN/8%HO=#:4PQ$!*B9V, M !95U0:#%Y0763&RZ:6)-U,O8%<4\4!F.8C@M-PC,C)R2@#;174PTL-4)PF#)P>9L B0F$>+M/HD1W$ M>SLD"*9P4'!@D.L2SU:F3S:#S-V'+EU #4'T-AWEI M047TWHF0W*_'8I&8XTUR5#B@XR,E2:S7,Z7F\R4,E"3I7UUC+S?57&E#9QPM M'7&2+[3\$_@XYG_DSO*BX-N\=]!N.;><#3@SI4G] MPX/5=7T>!TEY/Z*Y8T\G04)]O XS&?#CR7C3_C\O=,;P0>,K_L[+.MVD;3(X7JFRX$DO,=HN9ZSHTY08+\;Z MNKI;JC8@'!D:0 ]EA-& +"$3SV&8R1)A=ME58HK->YMRHIQ7+YYE!@RPAM@V MFZC-!N(#2;A$-+;S714INH*8#F*($G(R(1 3$LB$(.(*/F&4(E@"^&8PH@N6 M(=LA!,\[WRN!S5 * 4 H!0"@% * 4 H!0"@% * 4!J7JZ_A!K_>03\,-UNA; MV]T8IV=_9EKA[R7,7[N)_P#3J4_R?;PBT/Q7?RRDUDT* 4 H!0"@% * 4!-@ M/*^J>S9"_-#CK7Z?V]C/[_U]RDUDT* 4 H!0"@% * FIGRP(OLWS5S?FAIU>#ZKPP4JH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H! M0"@% * 4!J7JZ_A!K_>03\,-UNA;V]T8IV=_9F)L;4VV6JT&ZW#3=73)E&2R MQ 8P7$3[ #" 8\7+,*PAC$2V&7Z[-TT=EG'\5,ZU2H\-=AZF M&OP/&Z:.RSC^*F=:I4>&NP]3#7X'C=-'99Q_%3.M4J/#78>IAK\#QNFCLLX_ MBIG6J5'AKL/4PU^!XW31V6-TT=EG'\5,ZU2H\-=AZF&OP8H'J;;.#X-NF[=7;E3#53D#$M81/Y1B8 M)*ZHHYCY7Y1WOO.89\,/&ULN/Q\,^'&V/%O>U'5A*V.A*\XPX0MQZ&5^-TT= MEG'\5,ZU4J/#78OJ8:_ \;IH[+./XJ9UJE1X:[#U,-?@>-TT=EG'\5,ZU2H\ M-=AZF&OP/&Z:.RSC^*F=:I4>&NP]3#7X'C=-'99Q_%3.M4J/#78>IAK\#QNF MCLLX_BIG6J5'AKL/4PU^!XW31V60PTT0 M/.U\K9WS$POC:^-LKVM1PA*U>^&(K\87ZPV,K\;IH[+./XJ9UJI4>&NP]3#7 MX'C=-'99Q_%3.M4J/#78>IAK\#QNFCLLX_BIG6J5'AKL/4PU^!XW31V6-TT=EG'\5,ZU2H\-=AZF& MOP/&Z:.RSC^*F=:I4>&NP]3#7X'C=-'99Q_%3.M4J/#78>IAK\#QNFCLLX_B MIG6J5'AKL/4PU^!XW31V6IAK\#QNFCLLX_BIG6J5'AKL/4PU^!XW31V6-TT=EG'\5,ZU2H\-=AZF&O MP/&Z:.RSC^*F=:I4>&NP]3#7X'C=-'99Q_%3.M4J/#78>IAK\#QNFCLLX_BI MG6J5'AKL/4PU^!XW31V6'"_C>VS M*_&Z:.RSC^*F=:J5'AKL/4PU^!XW31V6-TT=EG'\5,ZU2H\-=AZF&OP/&Z:.RSC^*F=:I4>&NP]3# M7X'C=-'99Q_%3.M4J/#78>IAK\#QNFCLLX_BIG6J5'AKL/4PU^!XW31V6_'OF)A?&W%ME>UJ.$(JU:1W'J8 M:_!E?C=-'99Q_%3.M5*CPUV'J8:_ \;IH[+./XJ9UJE1X:[#U,-?@>-TT=EG M'\5,ZU2H\-=AZF&OP/&Z:.RSC^*F=:I4>&NP]3#7X'C=-'99Q_%3.M4J/#78 M>IAK\#QNFCLLX_BIG6J5'AKL/4PU^!XW31V6-TT=EG'\5,ZU2H\-=AZF&OP/&Z:.RSC^*F=:I4>&N MP]3#7X'C=-'99Q_%3.M4J/#78>IAK\#QNFCLLX_BIG6J5'AKL/4PU^!XW31V M6-TT=EG'\5,ZU2H\- M=AZF&OP/&Z:.RSC^*F=:I4>&NP]3#7X'C=-'99Q_%3.M4J/#78>IAK\#QNFC MLLX_BIG6J5'AKL/4PU^!XW31V6-TT=EG'\5,ZU2H\-=AZF&OP/&Z:.RSC^*F=:I4>&NP]3#7X'C=- M'99Q_%3.M4J/#78>IAK\#QNFCLLX_BIG6J5'AKL/4PU^"+39-J)*"(CI:6CJ MB:*G*N2@(*?S*9!B!Y%!B_$PL7&$RX_&%ME^E:V/%M?[>&M4:+3BX6$I4JRA %"$]S_]D! end GRAPHIC 15 g582934g07v70.jpg GRAPHIC begin 644 g582934g07v70.jpg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end GRAPHIC 16 g582934g12w52.jpg GRAPHIC begin 644 g582934g12w52.jpg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�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end GRAPHIC 17 g582934g28r56.jpg GRAPHIC begin 644 g582934g28r56.jpg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